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Preface 
Bladder cancer is an malignant disease affecting many patients worldwide. This book 
includes chapters related to tumor biology, epidemiology, biomarkers, prognostic
factors, clinical presentation and diagnosis of bladder cancer, treatment of bladder
cancer including surgery, chemotherapy, radiation therapy, and immunotherapy. I
would like to thank all the authors and co-authors who have contributed to this book, 
as well as the InTech Open Access Publisher team, and particularly Ms.Tajana Jevtic, 
who has been very helpful as a process manager during the preparation of the book.
Hopefully this book will be beneficial and useful for colleagues who are interested in 
bladder cancer.
Dr. Abdullah Erdem Canda
Associate Professor of Urology
Ankara Atatürk Training and Research Hospital 
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Tumor Biology and Bladder Cancer 
Part 1 
Tumor Biology and Bladder Cancer 
 1 
Bladder Cancer Biology 
Susanne Fuessel, Doreen Kunze and Manfred P. Wirth 
Department of Urology, Technical University of Dresden 
Germany 
1. Introduction 
At present, bladder cancer (BCa) is worldwide the 9th most common tumor; in men it 
represents the 7th and in women 17th most common malignancy (Ploeg et al., 2009). In the 
European Union approximately 104,400 newly diagnosed BCa and 36,500 BCa-related 
deaths were estimated for the year 2006 (Ferlay et al., 2007). In the United States, 
approximately 70,530 new cases and 14,680 BCa-related deaths were expected for 2010 
(Jemal et al., 2010). Men are three to four times more frequently affected than women (Ferlay 
et al., 2007; Jemal et al., 2010). 
Detection of BCa is hampered due to lately emerging symptoms, such as hematuria, and the 
lack of specific tumor markers. Treatment options, particularly for the advanced disease, 
appear currently insufficient, leading together with the BCa-inherent high recurrence and 
progression rates to the relatively high BCa-related mortality (Ferlay et al., 2007). For the 
development of more specific and efficient diagnostic tools and therapeutic approaches a 
profound understanding of the onset and course of this disease is indispensable. 
Molecular alterations that presumably lead to malignant transformation of the bladder 
urothelium belong to specified pathways involved in regulation of cellular homeostasis. As 
consequence of genetic and epigenetic alterations as well as of changes in subsequent 
regulatory mechanisms several major cellular processes are influenced in a manner that 
results in tumor development and progression. Regulation of the cell cycle, cell death and 
cell growth belong to these processes as well as the control of signal transduction and gene 
regulation. Particularly important for tumor cell spread and metastasis are changes in the 
regulation of interactions with stromal cells and extracellular components, of tumor cell 
migration and invasion and of angiogenesis (Mitra & Cote, 2009). 
Interestingly, numerous associations between risk factors for the development of BCa and 
the affected cellular processes were identified (Mitra & Cote, 2009). For tobacco smoking or 
the occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and 
aniline dyes − the major environmental risk factors that contribute to BCa genesis − strong 
associations with alterations in cell cycle regulation have been reported (Bosetti et al., 2007; 
Golka et al., 2004; Mitra & Cote, 2009; Strope & Montie, 2008). Other factors such as use of 
hair dyes, several noxious substances and drugs, dietary components and urological 
pathologies influence with more or less evidence the control of cell cycle and the regulation 
of gene expression or signal transduction (Golka et al., 2004; Kelsh et al., 2008; Michaud, 
2007; Mitra & Cote, 2009; Shiff et al., 2009). 
 1 
Bladder Cancer Biology 
Susanne Fuessel, Doreen Kunze and Manfred P. Wirth 
Department of Urology, Technical University of Dresden 
Germany 
1. Introduction 
At present, bladder cancer (BCa) is worldwide the 9th most common tumor; in men it 
represents the 7th and in women 17th most common malignancy (Ploeg et al., 2009). In the 
European Union approximately 104,400 newly diagnosed BCa and 36,500 BCa-related 
deaths were estimated for the year 2006 (Ferlay et al., 2007). In the United States, 
approximately 70,530 new cases and 14,680 BCa-related deaths were expected for 2010 
(Jemal et al., 2010). Men are three to four times more frequently affected than women (Ferlay 
et al., 2007; Jemal et al., 2010). 
Detection of BCa is hampered due to lately emerging symptoms, such as hematuria, and the 
lack of specific tumor markers. Treatment options, particularly for the advanced disease, 
appear currently insufficient, leading together with the BCa-inherent high recurrence and 
progression rates to the relatively high BCa-related mortality (Ferlay et al., 2007). For the 
development of more specific and efficient diagnostic tools and therapeutic approaches a 
profound understanding of the onset and course of this disease is indispensable. 
Molecular alterations that presumably lead to malignant transformation of the bladder 
urothelium belong to specified pathways involved in regulation of cellular homeostasis. As 
consequence of genetic and epigenetic alterations as well as of changes in subsequent 
regulatory mechanisms several major cellular processes are influenced in a manner that 
results in tumor development and progression. Regulation of the cell cycle, cell death and 
cell growth belong to these processes as well as the control of signal transduction and gene 
regulation. Particularly important for tumor cell spread and metastasis are changes in the 
regulation of interactions with stromal cells and extracellular components, of tumor cell 
migration and invasion and of angiogenesis (Mitra & Cote, 2009). 
Interestingly, numerous associations between risk factors for the development of BCa and 
the affected cellular processes were identified (Mitra & Cote, 2009). For tobacco smoking or 
the occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and 
aniline dyes − the major environmental risk factors that contribute to BCa genesis − strong 
associations with alterations in cell cycle regulation have been reported (Bosetti et al., 2007; 
Golka et al., 2004; Mitra & Cote, 2009; Strope & Montie, 2008). Other factors such as use of 
hair dyes, several noxious substances and drugs, dietary components and urological 
pathologies influence with more or less evidence the control of cell cycle and the regulation 
of gene expression or signal transduction (Golka et al., 2004; Kelsh et al., 2008; Michaud, 
2007; Mitra & Cote, 2009; Shiff et al., 2009). 
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
4 
Not only environmental risk factors determine the risk of BCa development, but also strong 
correlations with a genetic predisposition or polymorphisms in detoxification or repair 
genes leading to alterations in gene expression and regulation have been described 
(Bellmunt et al., 2007; Dong et al., 2008; Franekova et al., 2008; Garcia-Closas et al., 2006; 
Horikawa et al., 2008a; Kellen et al., 2007; Mitra & Cote, 2009; Sanderson et al., 2007). 
Several genome-wide association studies revealed the association of different single 
nucleotide polymorphisms (SNPs) with an altered risk of BCa. Strong associations of SNPs 
on the chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3 with the risk of BCa development 
were observed (Kiemeney et al., 2008, 2010; Rothman et al., 2010; X. Wu et al., 2009). 
Rothman et al. identified also new chromosomal regions on 2q37.1, 19q12 and 22q13.1, 
which are related to the susceptibility for BCa (Rothman et al., 2010). 
2. Different clinical behavior due to varying genetic & molecular pathways 
Clinical behavior and outcome of superficial, non muscle-invasive BCa doubtless differ from 
muscle-invasive BCa what is the result of varying molecular pathways characteristic for 
each subtype [Fig.1]. The more frequently diagnosed non muscle-invasive BCa comprise 
papillary Ta tumors confined to the mucosa and T1 tumors spread into submucosal layers of 
the bladder. In dependence on tumor grade, stage and size, the presence of concomitant 
carcinoma in situ (CIS), the occurrence of multifocal lesions and the prior recurrence rate the 
risk of recurrence of non muscle-invasive Ta/T1 BCa and the risk of progression to muscle-
invasive BCa differ considerably (Babjuk et al., 2011; Sylvester et al., 2006). In principle, flat 
CIS lesions also belong to the group of non muscle-invasive BCa but are associated with a 
higher aggressiveness due to a completely different tumor biological behavior rather 
resembling muscle-invasive BCa (Kitamura & Tsukamoto, 2006; Pashos et al., 2002). 
It appears meaningful to regard the different types of non muscle-invasive BCa separately 
due to dissimilar phenotype-specific alterations in molecular and cellular pathways, which 
are also reflected by the varying clinical behavior. Ta tumors, which account for 
approximately 70% of non muscle-invasive BCa, bear a relatively high risk of local 
recurrence but rarely become muscle-invasive BCa (Kitamura & Tsukamoto, 2006; Pashos et 
al., 2002; Van Rhijn et al., 2009; Wu, 2005). The remaining non-muscle invasive BCa consist 
of 20% T1 tumors and about 10% primary CIS (Kitamura & Tsukamoto, 2006; Van Rhijn et 
al., 2009). Particularly, high grade T1 tumors (previously T1G3) have an increased 
propensity to progress compared to low grade T1 and Ta tumors (Emiliozzi et al., 2008; 
Kitamura & Tsukamoto, 2006). In contrast, CIS lesions are rather characterized by molecular 
alterations that are also observed in muscle-invasive BCa. Therefore, a high risk of 
progression of these CIS tumors seems to be implicated and leads to a poor outcome similar 
to that of muscle-invasive BCa (Knowles, 2008; Wu, 2005). 
In low-grade papillary tumors a constitutively activated receptor tyrosine kinase/RAS 
pathway in consequence of activating mutations in the genes FGFR3 (fibroblast growth factor 
receptor 3) or HRAS (Harvey rat sarcoma viral oncogene homolog) was described (Jebar et al., 
2005; Knowles, 2008; Wu, 2005). The rate of FGFR3 mutations of about 70% in Ta and in low-
grade tumors is much higher than in invasive BCa with a rate of 10-20% (Bakkar et al., 2003; 
Billerey et al., 2001; Rieger-Christ et al., 2003; Serizawa et al., 2011). 
Activating HRAS mutations are detected with an estimated overall frequency of 10-15% 
without a clear association with tumor grade or stage (Jebar et al., 2005; Knowles, 2008; 
Kompier et al., 2010a; Oxford & Theodorescu, 2003; Serizawa et al., 2011). Interestingly, 
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mutations in FGFR3 and in RAS genes are mutually exclusive events and therefore 
suggested to represent alternative means to activate the MAPK (mitogen-activated protein 
kinase) pathway resulting in the same phenotype (Jebar et al., 2005; Kompier et al., 2010a).  
Furthermore, deletions of chromosome 9 belong to the most common genetic alterations in 
Ta tumors with a frequency of 36-66% (Knowles, 2008). Several putative tumor suppressor 
genes (TSG) located on this chromosome are affected by such deletions in combination with 
loss of heterozygosity (LOH) events, mutations or promoter hypermethylation (Knowles, 
2008). Amongst others, the CDKN2A locus on 9p21 encoding the TSG p16INK4A and p14ARF is 
altered as well as PTCH1 (9q22.3), DBC1 (9q32-33) and TSC1 (9q34) located on the long arm 
of chromosome 9 (Aboulkassim et al., 2003; Berggren et al., 2003; Cairns et al., 1995; 
Chapman et al., 2005; Knowles, 2003, 2008; Lopez-Beltran et al., 2008; S.V. Williams et al., 
2002; Williamson et al., 1995). LOH events in these chromosomal regions are associated with 
a high tumor grade and an elevated risk of recurrence of Ta and T1 tumors (Simoneau et al., 
2000). 
In principle, T1 tumors belong to the group of non-muscle-invasive BCa but obviously differ in 
their clinical behavior from Ta tumors since they show a higher potential for invasive growth 
and risk to progression. Nevertheless, dedifferentiation reflected by the tumor grade is a 
crucial factor for the determination of the phenotype resulting from differing molecular 
alterations (Kitamura & Tsukamoto, 2006). High-grade Ta tumors (TaG3) display a FGFR3 
mutation frequency of 34% ranging between that of TaG1 (58-82%) and T1G3 tumors (17%) 
paralleling the phenotype and clinical behavior (Hernandez et al., 2005; Herr, 2000; Junker et 
al., 2008; Kitamura & Tsukamoto, 2006; Van Oers et al., 2007). Additionally, a high rate of 
homozygous deletions of the CDKN2A/INK4A gene, which was associated with an increased 
relative risk of recurrence, was observed in high-grade Ta tumors (Orlow et al., 1999). 
Deletions or promoter hypermethylation of the CDKN2A/INK4A gene affect the 
expression of its gene products p14ARF and p16INK4A finally leading to deregulation in the 
p53 and RB1 (retinoblastoma 1) pathways. Alterations in these pathways are in fact 
molecular characteristics for CIS lesions and muscle-invasive BCa but can also be found in 
papillary tumors progressed to an invasive stage (Kitamura & Tsukamoto, 2006; Mitra & 
Cote, 2009; Orlow et al., 1999). Inactivation of p53 in muscle-invasive BCa is 
predominantly the consequence of allelic loss and mutations in this gene or of the 
homozygous deletion of its regulator p14ARF (Mitra & Cote, 2009). Disturbed expression or 
uninhibited hyperphosphorylation of the tumor suppressor RB1 result in its inactivation 
(Mitra & Cote, 2009). Simultaneous dysfunction of p53 and RB1, the two central regulators 
of the cell cycle and apoptosis, is observed in more than 50% of high grade T1 tumors and 
in the majority of muscle-invasive BCa (Kitamura & Tsukamoto, 2006; Knowles, 2008). 
Furthermore, two other alterations affecting the p53 pathway are characteristic for 
muscle-invasive BCa: the lack of p21Waf1, the cyclin-dependent kinase inhibitor 1A 
(CDKN1A), and overexpression of the p53-regulator MDM2 (Mdm2 p53 binding protein 
homolog (mouse)) (Mitra & Cote, 2009).  
Muscle-invasive BCa display a high number and variety of chromosomal alterations such as 
loss of 5q, 6q, 8p, 9p, 9q, 10q, 11p, 11q, 17p and Y or gains of 1q, 3q, 5p, 6p, 7p, 8q, 17q, 20p 
and 20q (Blaveri et al., 2005; Heidenblad et al., 2008; Knowles, 2008; Richter et al., 1998; 
Simon et al., 2000). 
The frequency of specific genomic alterations increases with tumor stage and is associated 
with a worse outcome (Blaveri et al., 2005; Richter et al., 1998). Several genes putatively 
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mutations in FGFR3 and in RAS genes are mutually exclusive events and therefore 
suggested to represent alternative means to activate the MAPK (mitogen-activated protein 
kinase) pathway resulting in the same phenotype (Jebar et al., 2005; Kompier et al., 2010a).  
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2008). Amongst others, the CDKN2A locus on 9p21 encoding the TSG p16INK4A and p14ARF is 
altered as well as PTCH1 (9q22.3), DBC1 (9q32-33) and TSC1 (9q34) located on the long arm 
of chromosome 9 (Aboulkassim et al., 2003; Berggren et al., 2003; Cairns et al., 1995; 
Chapman et al., 2005; Knowles, 2003, 2008; Lopez-Beltran et al., 2008; S.V. Williams et al., 
2002; Williamson et al., 1995). LOH events in these chromosomal regions are associated with 
a high tumor grade and an elevated risk of recurrence of Ta and T1 tumors (Simoneau et al., 
2000). 
In principle, T1 tumors belong to the group of non-muscle-invasive BCa but obviously differ in 
their clinical behavior from Ta tumors since they show a higher potential for invasive growth 
and risk to progression. Nevertheless, dedifferentiation reflected by the tumor grade is a 
crucial factor for the determination of the phenotype resulting from differing molecular 
alterations (Kitamura & Tsukamoto, 2006). High-grade Ta tumors (TaG3) display a FGFR3 
mutation frequency of 34% ranging between that of TaG1 (58-82%) and T1G3 tumors (17%) 
paralleling the phenotype and clinical behavior (Hernandez et al., 2005; Herr, 2000; Junker et 
al., 2008; Kitamura & Tsukamoto, 2006; Van Oers et al., 2007). Additionally, a high rate of 
homozygous deletions of the CDKN2A/INK4A gene, which was associated with an increased 
relative risk of recurrence, was observed in high-grade Ta tumors (Orlow et al., 1999). 
Deletions or promoter hypermethylation of the CDKN2A/INK4A gene affect the 
expression of its gene products p14ARF and p16INK4A finally leading to deregulation in the 
p53 and RB1 (retinoblastoma 1) pathways. Alterations in these pathways are in fact 
molecular characteristics for CIS lesions and muscle-invasive BCa but can also be found in 
papillary tumors progressed to an invasive stage (Kitamura & Tsukamoto, 2006; Mitra & 
Cote, 2009; Orlow et al., 1999). Inactivation of p53 in muscle-invasive BCa is 
predominantly the consequence of allelic loss and mutations in this gene or of the 
homozygous deletion of its regulator p14ARF (Mitra & Cote, 2009). Disturbed expression or 
uninhibited hyperphosphorylation of the tumor suppressor RB1 result in its inactivation 
(Mitra & Cote, 2009). Simultaneous dysfunction of p53 and RB1, the two central regulators 
of the cell cycle and apoptosis, is observed in more than 50% of high grade T1 tumors and 
in the majority of muscle-invasive BCa (Kitamura & Tsukamoto, 2006; Knowles, 2008). 
Furthermore, two other alterations affecting the p53 pathway are characteristic for 
muscle-invasive BCa: the lack of p21Waf1, the cyclin-dependent kinase inhibitor 1A 
(CDKN1A), and overexpression of the p53-regulator MDM2 (Mdm2 p53 binding protein 
homolog (mouse)) (Mitra & Cote, 2009).  
Muscle-invasive BCa display a high number and variety of chromosomal alterations such as 
loss of 5q, 6q, 8p, 9p, 9q, 10q, 11p, 11q, 17p and Y or gains of 1q, 3q, 5p, 6p, 7p, 8q, 17q, 20p 
and 20q (Blaveri et al., 2005; Heidenblad et al., 2008; Knowles, 2008; Richter et al., 1998; 
Simon et al., 2000). 
The frequency of specific genomic alterations increases with tumor stage and is associated 
with a worse outcome (Blaveri et al., 2005; Richter et al., 1998). Several genes putatively 
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relevant for tumor proliferation and progression are located in these altered chromosomal 
regions such as the transcription factors E2F3 and SOX4 on 6p22 or the supposed oncogene 
YWHAZ (14-3-3-zeta) on 8q22 (Heidenblad et al., 2008). Interestingly, amplification of 6p22 
containing E2F3, which is involved in cell cycle regulation, and the frequently occurring 
homozygous deletions of CDKN2A and CDKN2B on 9p21 exist mutually exclusive 
indicating that they possibly play complementary roles (Feber et al., 2004; Heidenblad et al., 
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Fig. 1. Molecular pathways of BCa development and progression 
Non-muscle invasive and muscle-invasive BCa fundamentally differ in their geno- and 
phenotypes. Varying genetic aberrations as well as the occurrence of p53 mutations in the 
normal urothelium are of crucial importance, which route of tumor progression will be 
followed. Carcinoma in situ (CIS) or muscle-invasive BCa, which may emerge from dysplasia 
of the urothelium, possess generally a high risk of progression. Papillary, non-muscle 
invasive Ta tumors, which are characterized by a high risk of recurrence and a lower risk of 
progression, rather develop from hyperplasia of the urothelium. 
Abbreviations: 9p- / 9q- – loss of the short / long arm of chromosome 9, BCa – bladder 
cancer, CIS – Carcinoma in situ, ECM – extracellular matrix, HG-Ta – high grade Ta tumor, 
LG-Ta – low grade Ta tumor, T1 to T4 – tumor stages 1 to 4. 
During progression and metastasis profound changes of regulatory networks involving the 
extracellular matrix (ECM), cell adhesion and migration, attraction of blood vessels and 
neovascularization occur, which characterize advanced tumor stages (Mitra & Cote, 2009). 
These processes comprise alterations in the regulation of cadherins, which are responsible 
for epithelial cell-cell adhesion, and matrix metalloproteinases (MMPs), which play an 
important role in the ECM-degradation as prerequisite for tumor cell migration (Mitra & 
Cote, 2009; Slaton et al., 2004; Wallard et al., 2006). Angiogenesis is driven by angiogenic 
factors such as the vascular endothelial growth factor (VEGF), one of the key factors responsible 
for tumor progression (Crew, 1999a). 
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3. Alterations in cell cycle regulation 
Correct course of cell cycle is controlled by the p53 and RB1 pathways that are tightly linked 
with each other and influence regulation of apoptosis, signal transduction and gene 
expression [Fig.2]. The TSG p53, the central regulator of these processes, is located on 
chromosome 17p13.1, a region that is affected by allelic loss more frequently in BCa of 
higher stage and grade (Knowles, 2008; Olumi et al., 1990). Parallel to the loss of one 17p 
allele, frequently occurring mutations lead to the inactivation of the tumor suppressor p53 
(Cordon-Cardo et al., 1994; Dalbagni et al., 1993; Sidransky et al., 1991). Mutated p53 
becomes resistant to degradation and due to this longer stability detectable in the nucleus by 
immunohistochemistry (Dalbagni et al., 1993; Esrig et al., 1993). Such mutations were 
observed with a high frequency in BCa of higher stage and grade (Dalbagni et al., 1993; 
Esrig et al., 1993; Fujimoto et al., 1992; Puzio-Kuter et al., 2009; Serizawa et al., 2011; 
Sidransky et al., 1991). Therefore, the assessment of the nuclear immunoreactivity of altered 
p53 facilitates prognostic conclusions (Esrig et al., 1993; Kuczyk et al., 1995; Sarkis et al., 
1993, 1995; Serth et al., 1995). Particularly for invasive, but still organ-confined BCa without 
metastasis (T1-2b N0 M0) and also for advanced BCa p53 is of prognostic importance with 
regard to the prediction of recurrence and cancer-specific mortality after radical cystectomy 
(Shariat et al., 2009a, 2009b). Nevertheless, nuclear accumulation and mutations of p53 
provide differing contribution to the prediction of the outcome. Mutations and altered 
protein stability of p53 lead to worst prognosis compared to patients with one of these 
events and to patients with wild-type p53 and unchanged protein stability, who showed a 
more favorable outcome (George et al., 2007). 
Interestingly, a study on BCa patients without evidence of distant metastases suggested that 
tumors harboring p53 mutations are more susceptible to adjuvant chemotherapy containing 
DNA-damaging agents such as e.g. cisplatin and doxorubicin (Cote et al., 1997). Possibly, 
these chemotherapeutics induce apoptosis in p53-mutated cells by uncoupling of the S and 
M cell cycle phases (Waldman et al., 1996). These observations built the basis for a large 
international multicenter clinical trial dealing with the assessment of response rates of high-
risk patients with organ-confined invasive BCa to a chemotherapy containing DNA-
damaging agents (Mitra et al., 2007). However, first data analysis did not confirm the 
predictive value of p53 immunohistochemistry (Stadler, 2009). 
Wild-type p53 controls cell cycle progression at G1-S transition by transcriptional activation 
of p21WAF1 (CDKN1A), a cyclin-dependent kinase inhibitor (CDKI) that additionally can be 
regulated by p53-independent mechanisms (El-Deiry et al., 1993; Michieli et al., 1994; Parker 
et al., 1995; Stein et al., 1998). As potent CDKI, p21Waf1 inhibits the activity of cyclin-CDK2 or 
-CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1 (Mitra et 
al., 2007). Loss or under-expression of p21Waf1 appears to have impact on tumor progression 
and consequently on the outcome of the patients (Stein et al., 1998). Patients with wild-type 
p53 and p21Waf1 positivity had the best prognosis whereas patients with altered p53 and 
maintained p21Waf1 expression displayed worse outcome and patients with altered p53 and 
lack of p21Waf1 showed the highest rate of recurrence and worst survival (Stein et al., 1998). 
MDM2, located on chromosome 12q14.3-q15, is another component involved in the 
regulatory network of p53 and an indispensable factor for the feedback control of p53 
stability. Transcription of MDM2 is induced by p53. In the form of an autoregulatory loop, 
MDM2 can build a complex with p53 and transports it to the proteasome for degradation 
(Mitra & Cote, 2009; Wu et al., 1993, 2005). 
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important role in the ECM-degradation as prerequisite for tumor cell migration (Mitra & 
Cote, 2009; Slaton et al., 2004; Wallard et al., 2006). Angiogenesis is driven by angiogenic 
factors such as the vascular endothelial growth factor (VEGF), one of the key factors responsible 
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3. Alterations in cell cycle regulation 
Correct course of cell cycle is controlled by the p53 and RB1 pathways that are tightly linked 
with each other and influence regulation of apoptosis, signal transduction and gene 
expression [Fig.2]. The TSG p53, the central regulator of these processes, is located on 
chromosome 17p13.1, a region that is affected by allelic loss more frequently in BCa of 
higher stage and grade (Knowles, 2008; Olumi et al., 1990). Parallel to the loss of one 17p 
allele, frequently occurring mutations lead to the inactivation of the tumor suppressor p53 
(Cordon-Cardo et al., 1994; Dalbagni et al., 1993; Sidransky et al., 1991). Mutated p53 
becomes resistant to degradation and due to this longer stability detectable in the nucleus by 
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Sidransky et al., 1991). Therefore, the assessment of the nuclear immunoreactivity of altered 
p53 facilitates prognostic conclusions (Esrig et al., 1993; Kuczyk et al., 1995; Sarkis et al., 
1993, 1995; Serth et al., 1995). Particularly for invasive, but still organ-confined BCa without 
metastasis (T1-2b N0 M0) and also for advanced BCa p53 is of prognostic importance with 
regard to the prediction of recurrence and cancer-specific mortality after radical cystectomy 
(Shariat et al., 2009a, 2009b). Nevertheless, nuclear accumulation and mutations of p53 
provide differing contribution to the prediction of the outcome. Mutations and altered 
protein stability of p53 lead to worst prognosis compared to patients with one of these 
events and to patients with wild-type p53 and unchanged protein stability, who showed a 
more favorable outcome (George et al., 2007). 
Interestingly, a study on BCa patients without evidence of distant metastases suggested that 
tumors harboring p53 mutations are more susceptible to adjuvant chemotherapy containing 
DNA-damaging agents such as e.g. cisplatin and doxorubicin (Cote et al., 1997). Possibly, 
these chemotherapeutics induce apoptosis in p53-mutated cells by uncoupling of the S and 
M cell cycle phases (Waldman et al., 1996). These observations built the basis for a large 
international multicenter clinical trial dealing with the assessment of response rates of high-
risk patients with organ-confined invasive BCa to a chemotherapy containing DNA-
damaging agents (Mitra et al., 2007). However, first data analysis did not confirm the 
predictive value of p53 immunohistochemistry (Stadler, 2009). 
Wild-type p53 controls cell cycle progression at G1-S transition by transcriptional activation 
of p21WAF1 (CDKN1A), a cyclin-dependent kinase inhibitor (CDKI) that additionally can be 
regulated by p53-independent mechanisms (El-Deiry et al., 1993; Michieli et al., 1994; Parker 
et al., 1995; Stein et al., 1998). As potent CDKI, p21Waf1 inhibits the activity of cyclin-CDK2 or 
-CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1 (Mitra et 
al., 2007). Loss or under-expression of p21Waf1 appears to have impact on tumor progression 
and consequently on the outcome of the patients (Stein et al., 1998). Patients with wild-type 
p53 and p21Waf1 positivity had the best prognosis whereas patients with altered p53 and 
maintained p21Waf1 expression displayed worse outcome and patients with altered p53 and 
lack of p21Waf1 showed the highest rate of recurrence and worst survival (Stein et al., 1998). 
MDM2, located on chromosome 12q14.3-q15, is another component involved in the 
regulatory network of p53 and an indispensable factor for the feedback control of p53 
stability. Transcription of MDM2 is induced by p53. In the form of an autoregulatory loop, 
MDM2 can build a complex with p53 and transports it to the proteasome for degradation 
(Mitra & Cote, 2009; Wu et al., 1993, 2005). 
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Degraded p53 in turn causes reduction in MDM2 levels, but this can be bypassed by MDM2 
gene amplification, which is observed approximately in 5% of the BCa with an increased 
frequency in tumors of higher stage and grade (Simon et al., 2002). Additionally, MDM2 
overexpression is a common event in BCa in strong association with p53 nuclear 
immunoreactivity (Lianes et al., 1994; Lu et al., 2002; Pfister et al., 1999, 2000). A combined 
assessment of alterations of p53, p21Waf1 and MDM2 revealed that patients with mutant p53 
and/or p53 nuclear overexpression, loss of p21Waf1 and MDM2 nuclear overexpression 
exhibited the worst outcome (Lu et al., 2002). Furthermore, a specific SNP at nucleotide 
position 309 in the MDM2 promoter region was evaluated for prognostic and predictive 
purposes. It can predict a poor outcome particularly in conjunction with the mutation and 
SNP status of p53 (Horikawa et al., 2008b; Sanchez-Carbayo et al., 2007; Shinohara et al., 
2009). 
The chromosomal region 9q21, which is frequently lost in non-muscle invasive and in 
muscle-invasive BCa, harbors the gene locus CDKN2A (cyclin-dependent kinase inhibitor 2A) 
whose transcription results in two different splice variants, p14ARF and p16INK4A (Knowles, 
2008; Quelle et al., 1995; S.G. Williams & Stein, 2004). Normally, p14ARF is induced by the 
transcription factor E2F and can inhibit transcription of MDM2 thereby blocking the MDM2-
induced p53 degradation (S.G. Williams & Stein, 2004). Thus, p14ARF builds a link between 
the p53 and the RB1 pathways. The expression of the splice variant p14ARF is predominantly 
reduced by homozygous deletions and also by promoter hypermethylation in BCa (Chang 
et al., 2003; Dominguez et al., 2003; Kawamoto et al., 2006; W.J. Kim & Quan, 2005). 
The gene product of the other splice variant, p16INK4A, normally functions as CDKI by 
blocking the cyclin D-CDK4/6-mediated phosphorylation of the RB1 protein thereby 
maintaining it in its active hypophosphorylated state and preventing exit from the G1 phase 
(Quelle et al., 1995; Serrano et al., 1993). In a study on BCa of all stages and grades 
homozygous deletion of p16INK4A was observed in a lower frequency than of p14ARF (Chang 
et al., 2003). In another study on non-muscle invasive BCa a higher risk of recurrence was 
found for homozygous deletion of the CDKN2A gene where loss of both splice variants 
p14ARF and p16INK4A correlated with clinicopathological parameters of a worse prognosis 
due to the potential deregulation of both the p53 and RB1 pathways (Orlow et al., 1999). 
Additionally, hypermethylation in the promoter region of p16INK4A was reported for BCa in 
a range of 6-60% (Chang et al., 2003; Chapman et al., 2005; Dominguez et al., 2003; 
Kawamoto et al., 2006; W.J. Kim & Quan, 2005; Orlow et al., 1999). Loss of p16INK4A protein 
expression in T1 tumors correlated significantly with a reduced progression-free survival 
and was an independent predictor of tumor progression (Kruger et al., 2005). In another 
study, aberrant p16INK4A protein expression was found to be an adverse prognostic factor 
only in T3-T4 tumors whereas abnormal immunoreactivity of p53 and p16INK4A was 
identified as an independent predictor of reduced survival for all muscle-invasive BCa 
(Korkolopoulou et al., 2001). 
Concluding data on BCa, homozygous deletions in the CDKN2A gene were not associated 
with tumor stage or grade supporting the hypothesis that chromosomal alteration of 9p21 is 
an early event in bladder carcinogenesis (Berggren et al., 2003). Nevertheless, aberrant 
methylation of p14ARF and p16INK4A occurs more frequently in muscle-invasive than in non-
muscle invasive BCa and seems to be associated with adverse clincopathological parameters 
as well as with a poor outcome (Dominguez et al., 2003; Kawamoto et al., 2006). 
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The CDKN2B gene located adjacent to CDKN2A on 9p21 encodes the CDKI p15INK4B, which 
inhibits cyclin D1-CDK4/6 complexes similar to p16INK4A (Orlow et al., 1995). In contrast to 
p16INK4A no association was observed between the expression and promoter methylation 
status of p15INK4B whereas the rate of chromosomal alterations was comparable (M.W. Chan 
et al., 2002; Gonzalez-Zulueta et al., 1995; Le Frere-Belda et al., 2004; Orlow et al., 1995). 
Decreased p15INK4B mRNA expression was only observed in non-muscle invasive BCa; in 
muscle invasive BCa p15INK4B expression varied widely (Le Frere-Belda et al., 2001). The 
authors concluded that decreased p15INK4B expression might be an important step in early 
neoplastic transformation of the urothelium and could be caused by other mechanisms than 
deletion or promoter hypermethylation (Le Frere-Belda et al., 2001). 
The potential TSG p27Kip1 (CDKN1B) is located on chromosome 12p13.1-p12 and belongs to 
the Kip1 family of CDKIs. It inhibits cyclin D-CDK4/6 and cyclin E/A-CDK2 complexes 
consequently preventing RB1 hyperphosphorylation (Coats et al., 1996; Polyak et al., 1994). 
The prognostic value of p27Kip1 was analyzed in several immunohistochemistry studies on 
non-muscle and muscle-invasive BCa which revealed that this factor is preferentially 
expressed in early stage BCa (Franke et al., 2000; Korkolopoulou et al., 2000; Rabbani et al., 
2007). In non-muscle invasive BCa expression of p27Kip1 decreased significantly with 
increasing grade and a significant correlation between low p27Kip1 expression and shorter 
disease-free survival and overall survival was observed, facts that support the hypothesis 
that loss of p27Kip1 confers a selective growth advantage to tumor cells (Kamai et al., 2001; 
Korkolopoulou et al., 2000; Migaldi et al., 2000; Sgambato et al., 1999). However, some 
studies on non-muscle invasive and/or muscle-invasive BCa did not reveal a significant 
association between the loss of p27Kip1 and outcome (Doganay et al., 2003; Franke et al., 2000; 
Kuczyk et al., 1999), whereas other reports showed that a decreased expression of p27Kip1 
significantly correlated with worse prognosis (Kamai et al., 2001; Rabbani & Cordon-Cardo, 
2000). 
Another central pathway influencing cell cycle progression is the regulatory network 
around the nuclear phosphoprotein RB1, a TSG located on chromosome 13q14 (Cairns et al., 
1991; Mitra et al., 2007; Takahashi et al., 1991; S.G. Williams & Stein, 2004). RB1 in its 
physiological active, hypophosphorylated form inhibits cell cycle progression at the G1-S 
checkpoint by sequestering transcription factors of the E2F family (Chellappan et al., 1991; 
Fung et al., 1987; Hiebert et al., 1992; Mihara et al., 1989). Hyperphosphorylation of RB1 
abolishes its cell cycle-inhibitory activity by the release of E2F transcription factors leading 
to transcription of genes involved in DNA synthesis and progression through mitosis 
(Degregori et al., 1995; Hernando et al., 2004; Mitra et al., 2007). RB1 becomes 
hyperphosphorylated by different cyclin-CDK complexes, such as cyclin D1-CDK4/6 and 
cyclin E-CDK2, which in turn can be inhibited by specific CDKIs, such as p16INK4A, p21Waf1 
and p27Kip1. The phosphorylation-mediated inactivation of RB1 can be the consequence of 
the already described loss of different CDKIs (Mitra et al., 2007). 
In addition, mutations and LOH events in the RB1 gene can also lead to loss of RB1 
expression and consequently to unregulated cellular proliferation (Miyamoto et al., 1995; 
Wada et al., 2000; Xu et al., 1993). Therefore, both aberrant RB1 down-regulation and 
dominance of the hyperphosphorylated inactive RB1 can be associated with tumor 
progression (Cote et al., 1998). For BCa, the proportion of RB1 alterations due to loss or 
inactivation was reported to increase with tumor stage and grade (Cairns et al., 1991; 
Ishikawa et al., 1991; Wada et al., 2000; Xu et al., 1993). 
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The CDKN2B gene located adjacent to CDKN2A on 9p21 encodes the CDKI p15INK4B, which 
inhibits cyclin D1-CDK4/6 complexes similar to p16INK4A (Orlow et al., 1995). In contrast to 
p16INK4A no association was observed between the expression and promoter methylation 
status of p15INK4B whereas the rate of chromosomal alterations was comparable (M.W. Chan 
et al., 2002; Gonzalez-Zulueta et al., 1995; Le Frere-Belda et al., 2004; Orlow et al., 1995). 
Decreased p15INK4B mRNA expression was only observed in non-muscle invasive BCa; in 
muscle invasive BCa p15INK4B expression varied widely (Le Frere-Belda et al., 2001). The 
authors concluded that decreased p15INK4B expression might be an important step in early 
neoplastic transformation of the urothelium and could be caused by other mechanisms than 
deletion or promoter hypermethylation (Le Frere-Belda et al., 2001). 
The potential TSG p27Kip1 (CDKN1B) is located on chromosome 12p13.1-p12 and belongs to 
the Kip1 family of CDKIs. It inhibits cyclin D-CDK4/6 and cyclin E/A-CDK2 complexes 
consequently preventing RB1 hyperphosphorylation (Coats et al., 1996; Polyak et al., 1994). 
The prognostic value of p27Kip1 was analyzed in several immunohistochemistry studies on 
non-muscle and muscle-invasive BCa which revealed that this factor is preferentially 
expressed in early stage BCa (Franke et al., 2000; Korkolopoulou et al., 2000; Rabbani et al., 
2007). In non-muscle invasive BCa expression of p27Kip1 decreased significantly with 
increasing grade and a significant correlation between low p27Kip1 expression and shorter 
disease-free survival and overall survival was observed, facts that support the hypothesis 
that loss of p27Kip1 confers a selective growth advantage to tumor cells (Kamai et al., 2001; 
Korkolopoulou et al., 2000; Migaldi et al., 2000; Sgambato et al., 1999). However, some 
studies on non-muscle invasive and/or muscle-invasive BCa did not reveal a significant 
association between the loss of p27Kip1 and outcome (Doganay et al., 2003; Franke et al., 2000; 
Kuczyk et al., 1999), whereas other reports showed that a decreased expression of p27Kip1 
significantly correlated with worse prognosis (Kamai et al., 2001; Rabbani & Cordon-Cardo, 
2000). 
Another central pathway influencing cell cycle progression is the regulatory network 
around the nuclear phosphoprotein RB1, a TSG located on chromosome 13q14 (Cairns et al., 
1991; Mitra et al., 2007; Takahashi et al., 1991; S.G. Williams & Stein, 2004). RB1 in its 
physiological active, hypophosphorylated form inhibits cell cycle progression at the G1-S 
checkpoint by sequestering transcription factors of the E2F family (Chellappan et al., 1991; 
Fung et al., 1987; Hiebert et al., 1992; Mihara et al., 1989). Hyperphosphorylation of RB1 
abolishes its cell cycle-inhibitory activity by the release of E2F transcription factors leading 
to transcription of genes involved in DNA synthesis and progression through mitosis 
(Degregori et al., 1995; Hernando et al., 2004; Mitra et al., 2007). RB1 becomes 
hyperphosphorylated by different cyclin-CDK complexes, such as cyclin D1-CDK4/6 and 
cyclin E-CDK2, which in turn can be inhibited by specific CDKIs, such as p16INK4A, p21Waf1 
and p27Kip1. The phosphorylation-mediated inactivation of RB1 can be the consequence of 
the already described loss of different CDKIs (Mitra et al., 2007). 
In addition, mutations and LOH events in the RB1 gene can also lead to loss of RB1 
expression and consequently to unregulated cellular proliferation (Miyamoto et al., 1995; 
Wada et al., 2000; Xu et al., 1993). Therefore, both aberrant RB1 down-regulation and 
dominance of the hyperphosphorylated inactive RB1 can be associated with tumor 
progression (Cote et al., 1998). For BCa, the proportion of RB1 alterations due to loss or 
inactivation was reported to increase with tumor stage and grade (Cairns et al., 1991; 
Ishikawa et al., 1991; Wada et al., 2000; Xu et al., 1993). 
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Particularly muscle-invasive, advanced BCa with an altered RB1 expression had a more 
aggressive behavior reflected by significantly decreased survival (Cordon-Cardo et al., 1992; 
Cote et al., 1998; Logothetis et al., 1992). 
Regarding both p53 and RB1 − the key players of cell cycle regulation − as well as the other 
components of this regulatory network, a combined analysis of multiple factors seems to be 
reasonable. Therefore, a multitude of comprehensive immunohistochemical analyses of 
different cell cycle regulators such as p53, RB1, MDM2, cyclin D1 and E, p14ARF, p16INK4A, 
p21Waf1, p27Kip1, Ki67 and PCNA (proliferating cell nuclear antigen) were performed on tissue 
specimens originating from non-muscle invasive and muscle-invasive BCa (Brunner et al., 
2008; Cordon-Cardo et al., 1997; Cote et al., 1998; Grossman et al., 1998; Hitchings et al., 
2004; Kamai et al., 2001; Korkolopoulou et al., 2000; Lu et al., 2002; Migaldi et al., 2000; 
Niehans et al., 1999; Pfister et al., 1999, 2000; Sarkar et al., 2000; Shariat et al., 2004, 2006, 
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Fig. 2. Simplified illustration of the interactive network between the p53 & RB1 pathways 
Transcription of MDM2 is induced by p53. In the form of an autoregulatory loop, MDM2 
conveys p53 by ubiquitination to proteasomal degradation. Degraded p53 in turn causes 
reduction in MDM2 levels. Wild-type p53 can induce transcription of the CDKI p21WAF1, 
which inhibits the activity of cyclin-CDK2 or -CDK4 complexes similar to the CDKI p15INK4B, 
p16INK4A and p27Kip1. When RB1 gets hyperphosphorylated by different cyclin-CDK 
complexes bound E2F transcription factors are released leading to the induction of cell 
cycle-promoting genes, but also to transcription of p14ARF, which can inhibit MDM2. 
Abbreviations: CDK – cyclin-dependent kinase, CDKI – cyclin-dependent kinase inhibitor, 
E2F – E2F transcription factors, MDM2 – Mdm2 p53 binding protein homolog (mouse), p14ARF 
and p16 INK4A – splice variants of the cyclin-dependent kinase inhibitor 2A gene, p15INK4B – 
cyclin-dependent kinase inhibitor 2B, p27Kip1 – cyclin-dependent kinase inhibitor 1B, RB1 – 
retinoblastoma 1. 
The bottom line of most of these studies is that changes in gene expression, which can be 
caused by chromosomal alterations, promoter hypermethylation or altered regulation of 
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transcriptional induction, as well as alterations of stability, modification and activity of the 
different involved factors contribute to deregulation of the complex processes during cell 
cycle progression. The number of altered components correlates with the severity of 
dysfunction and deregulation finally leading to increased aggressiveness of the tumor and 
to worse prognosis. Most promising candidates, when analyzed in parallel with regard to 
prediction of the outcome of BCa patients, seem to be p53, RB1, p16INK4A, p21Waf1, p27Kip1 
and the proliferation marker Ki67. This prognostic information can support the stratification 
of the tumors according to their aggressiveness and the selection of adapted treatment 
options (Grossman et al., 1998). 
4. Deregulation of cell death pathways 
Course of development, cell differentiation and homeostasis is normally regulated by the 
tight control of cell death pathways [Fig.3]. This programmed cell death, the apoptosis, is 
usually induced by a variety of extra- and intracellular stimuli and is mediated by a complex 
arrangement of sensors, regulators and effectors whose interactions are frequently 
perturbed in tumor cells. Failure of apoptosis permits mutated cells to continue progression 
through the cell cycle, to accumulate mutations and to increase molecular deregulations. 
The resulting unrestricted propagation of active oncogenes and defective TSG finally leads 
to the uncontrolled proliferation and spread of these abnormal cells (Bryan et al., 2005a; 
Duggan et al., 2001; Mcknight et al., 2005). Defects and deregulation in the extrinsic and in 
the intrinsic apoptotic pathways contribute to development and progression of many 
tumors including BCa and are also the main reason for therapeutic failure. Particularly, 
defective p53 fails as detector of DNA damage and main inductor of apoptosis, when DNA 
repair was not achieved (Duggan et al., 2001). 
The extrinsic apoptotic pathway is induced through the stimulation of cell surface death 
receptors by their corresponding ligands while the intrinsic pathway is switched on by the 
disruption of mitochondrial membranes. There is a cross-talk between both routes that 
finally lead to the cleavage of cellular proteins by caspases and subsequently to the 
degradation of the cells by gradual destruction of cellular components (Mcknight et al., 
2005). 
Transmembrane death receptors, such as FAS (CD95, APO-1), TNFR1, TRAILR1 or 
TRAILR2, belong to the tumor necrosis factor (TNF) receptor superfamily and contain an 
intracellular death domain. After binding of the respective ligands, such as FAS ligand, 
TNF or TRAIL, extracellular death signals are transmitted via these domains by formation 
of a death-inducing signaling complex that activates the initiator caspases 8 and 10 
(Mcknight et al., 2005; Mitra & Cote, 2009). Impairment of this processes was reported in 
BCa e.g. for FAS-mediated apoptosis that might be caused by mutation or decreased 
expression of FAS, which is associated with disease progression and poor outcome (Lee et 
al., 1999; Mcknight et al., 2005; Yamana et al., 2005). An alternative splice variant of FAS 
results in circulating soluble FAS that can capture the respective ligands and consequently 
prevent the normal death signal transduction. Soluble FAS, which was detected in serum 
and also in urine samples from BCa patients, could serve as predictor of recurrence and 
progression of BCa (Mizutani et al., 2001; Svatek et al., 2006). 
The intrinsic or mitochondrial induced apoptotic pathway can be initiated by DNA damage 
or different cellular stress signals (Mcknight et al., 2005). The BCL2 (B-cell CLL/lymphoma 2) 
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transcriptional induction, as well as alterations of stability, modification and activity of the 
different involved factors contribute to deregulation of the complex processes during cell 
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to worse prognosis. Most promising candidates, when analyzed in parallel with regard to 
prediction of the outcome of BCa patients, seem to be p53, RB1, p16INK4A, p21Waf1, p27Kip1 
and the proliferation marker Ki67. This prognostic information can support the stratification 
of the tumors according to their aggressiveness and the selection of adapted treatment 
options (Grossman et al., 1998). 
4. Deregulation of cell death pathways 
Course of development, cell differentiation and homeostasis is normally regulated by the 
tight control of cell death pathways [Fig.3]. This programmed cell death, the apoptosis, is 
usually induced by a variety of extra- and intracellular stimuli and is mediated by a complex 
arrangement of sensors, regulators and effectors whose interactions are frequently 
perturbed in tumor cells. Failure of apoptosis permits mutated cells to continue progression 
through the cell cycle, to accumulate mutations and to increase molecular deregulations. 
The resulting unrestricted propagation of active oncogenes and defective TSG finally leads 
to the uncontrolled proliferation and spread of these abnormal cells (Bryan et al., 2005a; 
Duggan et al., 2001; Mcknight et al., 2005). Defects and deregulation in the extrinsic and in 
the intrinsic apoptotic pathways contribute to development and progression of many 
tumors including BCa and are also the main reason for therapeutic failure. Particularly, 
defective p53 fails as detector of DNA damage and main inductor of apoptosis, when DNA 
repair was not achieved (Duggan et al., 2001). 
The extrinsic apoptotic pathway is induced through the stimulation of cell surface death 
receptors by their corresponding ligands while the intrinsic pathway is switched on by the 
disruption of mitochondrial membranes. There is a cross-talk between both routes that 
finally lead to the cleavage of cellular proteins by caspases and subsequently to the 
degradation of the cells by gradual destruction of cellular components (Mcknight et al., 
2005). 
Transmembrane death receptors, such as FAS (CD95, APO-1), TNFR1, TRAILR1 or 
TRAILR2, belong to the tumor necrosis factor (TNF) receptor superfamily and contain an 
intracellular death domain. After binding of the respective ligands, such as FAS ligand, 
TNF or TRAIL, extracellular death signals are transmitted via these domains by formation 
of a death-inducing signaling complex that activates the initiator caspases 8 and 10 
(Mcknight et al., 2005; Mitra & Cote, 2009). Impairment of this processes was reported in 
BCa e.g. for FAS-mediated apoptosis that might be caused by mutation or decreased 
expression of FAS, which is associated with disease progression and poor outcome (Lee et 
al., 1999; Mcknight et al., 2005; Yamana et al., 2005). An alternative splice variant of FAS 
results in circulating soluble FAS that can capture the respective ligands and consequently 
prevent the normal death signal transduction. Soluble FAS, which was detected in serum 
and also in urine samples from BCa patients, could serve as predictor of recurrence and 
progression of BCa (Mizutani et al., 2001; Svatek et al., 2006). 
The intrinsic or mitochondrial induced apoptotic pathway can be initiated by DNA damage 
or different cellular stress signals (Mcknight et al., 2005). The BCL2 (B-cell CLL/lymphoma 2) 
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family, which plays a crucial role in the intrinsic apoptotic pathway, consists of anti-
apoptotic members, such as BCL2 and BCLXL (BCL2-like 1), as well as of pro-apoptotic 
members, such as BAX (BCL2-associated X protein), BID (BH3 interacting domain death agonist) 
and BAD (BCL2-associated agonist of cell death). BCL2 is an integral protein of the outer 
mitochondrial membrane that is involved in the control of ion channels, inhibition of 
cytochrome c release from the mitochondria or modulation of caspase activation (Mcknight 
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Fig. 3. Simplified illustration of the apoptotic cell death pathways 
The extrinsic apoptotic pathway is induced through stimulation of cell surface death 
receptors by their corresponding ligands. The intrinsic mitochondrial route of apoptosis is 
initiated by DNA damage and cellular stress signals. Both pathways are interconnected and 
lead to the caspase-mediated cleavage of cellular proteins and consequently to the gradual 
degradation of further cellular components and cellular destruction. 
Abbreviations: AIF – apoptosis-inducing factor, APAF1 – apoptotic peptidase activating factor 1, 
ATP – adenosine-5'-triphosphate, BAD – BCL2-associated agonist of cell death, BAX – BCL2-
associated X protein, BCL2 – B-cell CLL/lymphoma 2, BCLXL – BCL2-like 1, BID – BH3 
interacting domain death agonist, CASP – caspase, Cyto C – cytochrome c, DNA – 
deoxyribonucleic acid, FADD – Fas-associated via death domain, FAS – Fas (TNF receptor 
superfamily, member 6), FASLG – Fas ligand, FLIP – FLICE-inhibitory protein, IAP – inhibitors of 
apoptosis, RIP1 – receptor interacting protein 1, SMAC – second mitochondria-derived activator of 
caspase, TNFR – tumor necrosis factor receptor, TRADD – TNFR1-associated death domain protein, 
TRAF2 – TNF receptor-associated factor 2, TRAIL – TNF-related apoptosis inducing ligand. 
 
Bladder Cancer Biology 
 
13 
The export of cytochrome c into the cytoplasm and its binding to APAF1 (apoptotic peptidase 
activating factor 1) together with ATP induces the formation of apoptosomes that can cleave 
and activate pro-caspase 9. Subsequently, caspase 9 activates the effector caspases 3 and 7, 
which can be alternatively activated in the extrinsic pathway by the initiator caspases 8 and 
10 as mentioned above. This caspase cascade finally commits the cell to apoptosis by 
gradual degradation of cellular proteins (Mcknight et al., 2005; Mitra & Cote, 2009). 
BCL2 can block the apoptotic death and thereby trigger tumor recurrence and progression 
as well as mediate resistance to chemotherapy and radiation (Duggan et al., 2001). Different 
studies on non-muscle invasive and muscle-invasive BCa showed, that BCL2 was up-
regulated in a varying number of the analyzed cases ranging from 41 to 63% (Cooke et al., 
2000; Korkolopoulou et al., 2002; Liukkonen et al., 1997; Maluf et al., 2006; Ong et al., 2001). 
This BCL2 up-regulation correlated only partially with tumor stage and grade, but was 
frequently indicative for patients with poor prognosis after chemo- and/or radiotherapy 
(Cooke et al., 2000; Hussain et al., 2003; Ong et al., 2001; Pollack et al., 1997). Expression 
analyses of BCL2 together with other prognostic markers such as p53 and MDM2 revealed 
their usefulness as complementary predictors of survival of patients with non-muscle 
invasive and muscle-invasive BCa (Gonzalez-Campora et al., 2007; Maluf et al., 2006; Ong et 
al., 2001; Wolf et al., 2001). 
Furthermore, the ratio between the anti-apoptotic factor BCL2 and the pro-apoptotic factor 
BAX seems to act as a cellular rheostat that might be predictive for a cell’s response toward 
life or death after an apoptotic stimulus (Gazzaniga et al., 1996). BAX can be activated by 
BID that in turn can be induced by the initiator caspase 8. BAX forms a heterodimer with 
BCL2 and functions as an apoptotic activator by increasing the opening of the mitochondrial 
voltage-dependent anion channel (VDAC), which leads to the loss in membrane potential and 
the release of cytochrome c. The predominant expression of BCL2 over that of BAX 
correlated with a worse outcome and shorter time to relapse in low grade and non-muscle 
invasive BCa (Gazzaniga et al., 1996, 2003). 
Apoptotic cell death can also be hampered by members of the IAP (inhibitor of apoptosis 
proteins) family that are also known as baculoviral IAP repeat-containing (BIRC) proteins. 
With regard to BCa, survivin (BIRC5) is the most interesting IAP since it can serve as 
diagnostic, prognostic and predictive marker (Margulis et al., 2008). Survivin inhibits 
apoptosis, promotes cell proliferation and enhances angiogenesis leading to its prominent 
role for tumor onset and progression in general and in particular for BCa (Margulis et al., 
2008). For this tumor entity, high survivin expression at mRNA and protein levels is 
associated with advanced tumor grade and stage as well as with affection of lymph nodes 
(Karam et al., 2007a; I.J. Schultz et al., 2003; Shariat et al., 2007a; Swana et al., 1999; Weikert 
et al., 2005a). Survivin may serve either alone or together with other markers, such as p53, 
BCL2 and caspase 3, as a significant predictor of disease recurrence, progression and/or 
mortality after transurethral resection or radical cystectomy (Gonzalez et al., 2008; Karam et 
al., 2007a; 2007b; Ku et al., 2004; Shariat et al., 2007a). Response to chemo- and radiotherapy 
could also be estimated by the use of survivin as a predictive marker in BCa patients 
(Hausladen et al., 2003; Weiss et al., 2009). 
For XIAP (X-linked inhibitor of apoptosis / BIRC4), which can directly inhibit the action of 
caspase 3, 7 and 9 and also interfere with the TNFR-associated cell death signaling, an up-
regulation and association with an earlier recurrence was described in non-muscle invasive 
BCa (Dubrez-Daloz et al., 2008; Li et al., 2007). 
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The export of cytochrome c into the cytoplasm and its binding to APAF1 (apoptotic peptidase 
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which can be alternatively activated in the extrinsic pathway by the initiator caspases 8 and 
10 as mentioned above. This caspase cascade finally commits the cell to apoptosis by 
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This BCL2 up-regulation correlated only partially with tumor stage and grade, but was 
frequently indicative for patients with poor prognosis after chemo- and/or radiotherapy 
(Cooke et al., 2000; Hussain et al., 2003; Ong et al., 2001; Pollack et al., 1997). Expression 
analyses of BCL2 together with other prognostic markers such as p53 and MDM2 revealed 
their usefulness as complementary predictors of survival of patients with non-muscle 
invasive and muscle-invasive BCa (Gonzalez-Campora et al., 2007; Maluf et al., 2006; Ong et 
al., 2001; Wolf et al., 2001). 
Furthermore, the ratio between the anti-apoptotic factor BCL2 and the pro-apoptotic factor 
BAX seems to act as a cellular rheostat that might be predictive for a cell’s response toward 
life or death after an apoptotic stimulus (Gazzaniga et al., 1996). BAX can be activated by 
BID that in turn can be induced by the initiator caspase 8. BAX forms a heterodimer with 
BCL2 and functions as an apoptotic activator by increasing the opening of the mitochondrial 
voltage-dependent anion channel (VDAC), which leads to the loss in membrane potential and 
the release of cytochrome c. The predominant expression of BCL2 over that of BAX 
correlated with a worse outcome and shorter time to relapse in low grade and non-muscle 
invasive BCa (Gazzaniga et al., 1996, 2003). 
Apoptotic cell death can also be hampered by members of the IAP (inhibitor of apoptosis 
proteins) family that are also known as baculoviral IAP repeat-containing (BIRC) proteins. 
With regard to BCa, survivin (BIRC5) is the most interesting IAP since it can serve as 
diagnostic, prognostic and predictive marker (Margulis et al., 2008). Survivin inhibits 
apoptosis, promotes cell proliferation and enhances angiogenesis leading to its prominent 
role for tumor onset and progression in general and in particular for BCa (Margulis et al., 
2008). For this tumor entity, high survivin expression at mRNA and protein levels is 
associated with advanced tumor grade and stage as well as with affection of lymph nodes 
(Karam et al., 2007a; I.J. Schultz et al., 2003; Shariat et al., 2007a; Swana et al., 1999; Weikert 
et al., 2005a). Survivin may serve either alone or together with other markers, such as p53, 
BCL2 and caspase 3, as a significant predictor of disease recurrence, progression and/or 
mortality after transurethral resection or radical cystectomy (Gonzalez et al., 2008; Karam et 
al., 2007a; 2007b; Ku et al., 2004; Shariat et al., 2007a). Response to chemo- and radiotherapy 
could also be estimated by the use of survivin as a predictive marker in BCa patients 
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For XIAP (X-linked inhibitor of apoptosis / BIRC4), which can directly inhibit the action of 
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Another IAP – cIAP2 (BIRC3) – that regulates apoptosis by binding to the TNFR-associated 
factors TRAF1 and TRAF2, has been shown to provoke chemoresistance when overexpressed 
in BCa cell lines (Jonsson et al., 2003). In expression analyses of livin (BIRC7) in tissue 
specimens from non-muscle invasive BCa only its anti-apoptotic isoform was detected 
which was significantly associated with BCa relapse (Gazzaniga et al., 2003; Liu et al., 2009). 
5. Immortalization of tumor cells – importance of the human telomerase 
Activation of the human telomerase represents a very early event during the development 
of malignant tumors that leads to immortalization and as a consequence to the capability for 
unlimited division of tumor cells (Hiyama & Hiyama, 2002). Telomeres, the ends of 
eukaryotic chromosomes, normally get truncated during each cell division until they reach a 
critical length. This results in a severe impairment of the division capability leading to 
senescence of the cells (Harley, 1991). This senescence and the consequential cell death can 
be bypassed through activation of the telomerase ribonucleoprotein complex, since its 
catalytic subunit TERT (telomerase reverse transcriptase) supports the continuous prolongation 
of telomeres (Blackburn, 2005). Most of the differentiated somatic cells do not possess 
telomerase activity, whereas germline and stem cells as well as tumor cells frequently are 
telomerase-positive (Hiyama & Hiyama, 2002; N.W. Kim et al., 1994). 
Several studies proved that TERT as well as the telomerase RNA component (TERC) represent 
essential subunits of the telomerase complex, but only TERT is specifically induced in cancer 
and functions as limiting factor of the enzymatic telomerase activity (Ito et al., 1998; 
Meyerson et al., 1997). Nevertheless, TERT protects the chromosomal ends also 
independently from its catalytic activity through its so-called capping function thereby 
providing tumor cells with further survival benefit (Blackburn, 2005; Blasco, 2002; S.W. 
Chan & Blackburn, 2002). 
For most tumors it remains unclear whether TERT expression originates from telomerase-
positive tumor stem cells or from the activation of the gene during tumorigenesis. A number 
of transcription factors, tumor suppressors, cell cycle inhibitors, hormones, cytokines and 
oncogenes have been implicated in the control of TERT expression but without providing a 
clear explanation for the tumor-specific TERT activity so far (Ducrest et al., 2002; Kyo et al., 
2008). 
Definitely, a tumor-specific activation of the telomerase complex is detectable in the majority 
of BCa. In contrast to telomerase-negative normal urothelium cells, > 90% of the analyzed 
BCa tissue specimens displayed a high expression and activity of telomerase (de Kok et al., 
2000a; Heine et al., 1998; Hiyama & Hiyama, 2002; Ito et al., 1998; Lin et al., 1996; Muller, 
2002). Therefore, the detection of TERT expression or the determination of telomerase 
activity in tissue or urine samples from patients suspected of having BCa is very useful for 
tumor detection (Alvarez & Lokeshwar, 2007; Glas et al., 2003; Muller, 2002; Weikert et al., 
2005b). Possibly, quantitative determination of the TERT transcript levels in urine or bladder 
washings can support the prediction of recurrent BCa (Brems-Eskildsen et al., 2010; de Kok 
et al., 2000b). 
6. Alterations in cell growth signaling 
Cell growth signaling is transduced from the cell surface to the nucleus by different 
signaling cascades which can be altered and disturbed in tumor cells at different levels 
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leading to uncontrolled cell growth and proliferation [Fig.4]. In principle, peptide growth 
factors bind to their corresponding growth factor receptors on the cell surface leading to 
receptor activation and via several signal transduction events to the activation of 
downstream factors (RAS and RAF1). Through the subsequent activation of the MAPK 
pathway several transcription factors, such as MYC (v-myc myelocytomatosis viral oncogene 
homolog (avian)) or ELK1 (ETS-like transcription factor 1), are induced, which finally regulate 
the expression of growth-promoting genes. Transmission of extracellular growth signals can 
be altered in tumor cells at different levels of these cascades, e.g. by an abnormally increased 
supply of growth factors or by amplification, mutation or alternative up-regulation of the 
growth factor receptors leading to their constitutive, excessive and uncontrolled activity 
(Hanahan & Weinberg, 2000). Mutations or other regulatory alterations affecting 
downstream targets, such as members of the RAS family, can additionally provide tumor 
cells with an increased growth potential (Jebar et al., 2005; Knowles, 2008).  
FGFR3, one of the four members of the FGFR family, is constitutively activated by different 
mutations, which are found in approximately 70% of low-grade Ta and to a much lower 
extent of 10-20% in muscle-invasive BCa (Bakkar et al., 2003; Billerey et al., 2001; Hernandez 
et al., 2006; Jebar et al., 2005; Junker et al., 2008; Knowles, 2008; Kompier et al., 2010a; Rieger-
Christ et al., 2003; Van Oers et al., 2007; Van Rhijn et al., 2004). The most frequent mutations 
lead to amino acid substitutions to cysteine residues which can build covalent disulfide 
bonds mimicking dimerization and thereby activation of the receptor (Kompier et al., 
2010b). Mutated FGFR3 correlates with favorable disease parameters and improved survival 
(Kompier et al., 2010b; Van Oers et al., 2007, 2009; Van Rhijn et al., 2001, 2004, 2010). In a 
recent multicenter study, the so called molecular grade, a combination of the FGFR3 
mutation status and the proliferation marker Ki67, could improve the predictive accuracy of 
the EORTC (European Organisation for Research and Treatment of Cancer) risk scores for 
progression (Van Rhijn et al., 2010). 
Mutated FGFR3 leads to the activation of the RAS-MAPK-pathway and consequently to an 
augmented transduction of growth signals. RAS mutations are found in BCa with an overall 
frequency of approximately 10-15% and do not depend on tumor grade or stage, (Jebar et 
al., 2005; Knowles, 2008; Kompier et al., 2010a; Oxford & Theodorescu, 2003; Serizawa et al., 
2011). Such mutations occur in all three RAS genes (HRAS, NRAS and KRAS) whereby 
HRAS is affected most frequently (Jebar et al., 2005). Interestingly, simultaneous mutations 
in FGFR3 and RAS, both resulting in the activation of the same pathway, are very 
uncommon and rather occur mutually exclusive (Jebar et al., 2005). Thus, low grade and Ta 
tumors harbor mutations either of FGFR3 or HRAS in more than 80% of the cases reflecting 
the necessity of constitutive activation of the MAPK pathway for non muscle-invasive BCa 
(Jebar et al., 2005; Knowles, 2008). 
Additionally, the up-regulation of FGFs can contribute to the pathogenesis of cancer (Bryan 
et al., 2005a). Levels of FGF1 (acidic FGF) in urine samples correlated with tumor stage 
(Chopin et al., 1993). An association with an increased tumor stage and early local 
recurrence was shown for the expression of FGF2 (basic FGF) (Bryan et al., 2005a; Gazzaniga 
et al., 1999). 
The epidermal growth factor (EGF) receptor family comprising EGFR (ERBB1), ERBB2 
(HER-2/neu), ERBB3 (HER3) and ERBB4 (HER4) represents another tyrosine kinase 
receptor family involved in growth signaling in BCa cells that can also transduce 
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Another IAP – cIAP2 (BIRC3) – that regulates apoptosis by binding to the TNFR-associated 
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extracelluar growth signals via the RAS-MAPK pathway or alternatively via the 
phosphatidylinositol 3-kinase (PIK3)-Akt pathway (Bryan et al., 2005a; Mitra & Cote, 2009). 
Expression at mRNA and protein level of all members of the EGFR family was observed in 
BCa specimens but with varying patterns of coexpression and differing prognostic impact, 
possibly depending on the size and composition of the patients cohorts and the detection 
techniques used in the different studies (Amsellem-Ouazana et al., 2006; Chow et al., 2001; 
Chow et al., 1997b; Forster et al., 2011; Junttila et al., 2003; Kassouf et al., 2008; Memon et al., 
2006; Rotterud et al., 2005). Increased expression of EGFR and ERBB2 has been observed in a 
number of studies (Black & Dinney, 2008; Mitra & Cote, 2009). Many of these analyses 
revealed a correlation between increased levels of these two receptors and parameters of 
high risk tumors or of a poor prognosis for BCa patients (Black & Dinney, 2008; Mitra & 
Cote, 2009). 
Several studies analyzed the BCa-related impact of growth factors activating EGFR, which 
comprise EGF, TGF(transforming growth factor alpha), HB-EGF (heparin-binding EGF-like 
growth factor), epiregulin and others. Levels of TGF in tissue samples and urine specimens 
from BCa patients correlated strongly with poor prognosis (Gazzaniga et al., 1998; Ravery et 
al., 1997; Thogersen et al., 2001; Turkeri et al., 1998). An association with tumor recurrence 
was also observed for EGF in BCa tissues, but not for urinary EGF (Chow et al., 1997a; 
Turkeri et al., 1998). Further studies revealed also an inverse correlation between the 
expression of epiregulin or nuclear HB-EGF and the survival of BCa patients (Adam et al., 
2003; Kramer et al., 2007; Thogersen et al., 2001). 
Another growth signaling pathway profoundly altered in many tumor entities including 
BCa is that of VEGF. This pathway is predominantly involved in the regulation of 
angiogenesis through the attraction and direction of blood vessels to the tumor by VEGF, 
which is secreted by tumor cells (Sato et al., 1998). Additionally, an autocrine function of 
VEGF in direct activation of the tumor cells themselves is assumed due to the observed up-
regulation of different VEGF receptors such as FLT1 (VEGFR1) and KDR (VEGFR2 = FLK1) 
in BCa (Black & Dinney, 2008; Sato et al., 1998; Xia et al., 2006). An increased expression of 
KDR in BCa patients correlated with higher disease stage, muscle invasion and lymph node 
metastasis (Mitra et al., 2006; Xia et al., 2006). 
PIK3CA (phosphoinositide-3-kinase catalytic subunit alpha) is part of the Akt signaling pathway 
and in this way also involved in the transformation of extracellular growth signals into an 
increased potential of cell proliferation and survival. PIK3CA mutations with an overall 
frequency of 13-25% seem to be a common event that occurs early in bladder carcinogenesis 
(Kompier et al., 2010a; Lopez-Knowles et al., 2006; Platt et al., 2009; Serizawa et al., 2011). A 
correlation with low stage and grade was observed in several studies (Lopez-Knowles et al., 
2006; Serizawa et al., 2011). Interestingly, PIK3CA mutations were shown to be strongly 
associated with FGFR3 mutations possibly indicating cooperative oncogenic effects 
(Castillo-Martin et al., 2010; Kompier et al., 2010a; Lopez-Knowles et al., 2006; Serizawa et 
al., 2011). However, PIK3CA mutations showed no correlation with progression or disease-
specific survival (Kompier et al., 2010a). 
PTEN (phosphatase and tensin homolog), which is a phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase and as such a negative regulator of the PIK3/Akt signaling pathway, acts by 
this way as a TSG. The PTEN gene located on 10q23.3 is frequently inactivated by 
chromosomal loss and mutations in a number of malignant tumors including BCa (Aveyard 
et al., 1999; Cairns et al., 1998; Knowles et al., 2009; Platt et al., 2009; Teng et al., 1997). The rate 
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of LOH events and allelic imbalances in a chromosomal region including the PTEN gene is 
with 23-32% in muscle-invasive BCa notably higher than in non-muscle invasive BCa 
(Aveyard et al., 1999; Cappellen et al., 1997; Knowles et al., 2009). Nevertheless, mutations in 
the retained PTEN allele or homozygous deletions do not occur very frequently indicating the 
existence of further mechanisms of PTEN inactivation (Aveyard et al., 1999; Cairns et al., 1998; 
Platt et al., 2009). A reduction in PTEN protein levels in BCa tissue specimens was observed in 
several studies and correlated with higher grade and/or higher stage (Harris et al., 2008; Platt 
et al., 2009; Puzio-Kuter et al., 2009; L. Schultz et al., 2010; Sun et al., 2011; Tsuruta et al., 2006). 
Interestingly, a reduced PTEN expression was related to poor outcome in BCa patients, 

































Fig. 4. Simplified illustration of the principles of growth factor signaling 
Growth factors bind to their corresponding receptors at the cell surface thereby starting 
signaling cascades which transduce the signal through cytoplasmatic factors into the 
nucleus. There, genes supporting survival, proliferation and migration of the tumor cells are 
induced as final consequence. For BCa, the RAS/RAF/MEK/ERK- and the PIK3/AKT-
pathways are of particular importance. 
Abbreviations: Akt – v-akt murine thymoma viral oncogene homolog 1, DNA – deoxyribonucleic 
acid, EGF – epidermal growth factor, ELK – member of ETS oncogene family, ERBB – EGF 
receptor family member, ERK = MAPK1 – mitogen-activated protein kinase 1, FGF – fibroblast 
growth factor, FGFR – FGF receptor family member, GF – growth factor, GFR – growth factor 
receptor, GRB2 – growth factor receptor-bound protein 2, MEK – mitogen-activated protein kinase 
kinase, MYC – v-myc myelocytomatosis viral oncogene homolog, PIK3 – phosphoinositide-3-kinase, 
PKC – protein kinase C, PLC – phospholipase C gamma,  
PTEN – phosphatase and tensin homolog, RAF-1 – v-raf-1 murine leukemia viral oncogene 
homolog 1, RAS – rat sarcoma viral oncogene homolog, SOS – son of sevenless homolog,  
TF – transcription factor, VEGF – vascular endothelial growth factor, VEGFR – VEGF receptor 
family member. 
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extracelluar growth signals via the RAS-MAPK pathway or alternatively via the 
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high risk tumors or of a poor prognosis for BCa patients (Black & Dinney, 2008; Mitra & 
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2003; Kramer et al., 2007; Thogersen et al., 2001). 
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KDR in BCa patients correlated with higher disease stage, muscle invasion and lymph node 
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The activation of the PIK3 pathway leads to transmission of extracellular growth signals via 
the phosphorylation of the serine-threonine protein kinase Akt (v-akt murine thymoma viral 
oncogene homolog 1) to the activation of several downstream signaling routes resulting in an 
increased proliferation, survival or migration of tumor cells (Wu et al., 2004). Elevated levels 
of phosphorylated Akt (pAkt) compared to normal bladder tissue were observed in 
different immunohistochemical studies on BCa tissue specimens (L. Schultz et al., 2010; Wu 
et al., 2004). Increased detection rates of pAkt correlated significantly with high-grade and 
advanced stage BCa as well as with a poor clinical outcome and survival (Sun et al., 2011). 
Furthermore, Askham et al. reported the detection of a transforming Akt mutation (G49A / 
E17K) in 2.7% of 184 analyzed BCa samples (Askham et al., 2010).  
7. Tumor angiogenesis and metastasis 
Angiogenesis comprises the recruitment and accelerated formation of new blood vessels 
from the surrounding vasculature. After proteolytic degradation of the adjacent ECM 
activated endothelial cells become able to migrate and invade as well as to maturate to 
coalescent, water-tight blood tubules (S.G. Williams & Stein, 2004). This essential 
physiologic process that occurs during development, reproduction and repair is tightly 
controlled by stimulatory and inhibitory regulators. During tumor genesis and progression 
this balance is disturbed by the up-regulation of angiogenic inducers and/or loss of anti-
angiogenic factors which can be secreted by the tumor cells themselves, by neighboring 
tumor-associated stromal cells or by tumor-infiltrating inflammatory cells (S.G. Williams & 
Stein, 2004). Newly formed blood vessels provide the tumor cells with oxygen and nutrients, 
which is an essential prerequisite for rapid tumor growth and also for tumor cell spread 
during metastasis (Mitra & Cote, 2009). A high microvessel density (MVD) in the tumor as 
reflector of angiogenic processes is a strong predictor of a poor outcome of BCa patients 
(Bochner et al., 1995; Canoglu et al., 2004; Chaudhary et al., 1999; Dickinson et al., 1994; 
Hawke et al., 1998; Jaeger et al., 1995; Philp et al., 1996). 
Hypoxia, which is frequently occurring in growing tumors, results in elevated levels of the 
hypoxia-inducible transcription factors HIF-1 and HIF-2. Stability of the HIF-1 subunit  is 
regulated by the cellular oxygen concentration via the inhibition of its oxygen-dependent 
degradation. HIF-1 (HIF1A) can induce transcription of VEGF which in turn stimulates 
tumor vascularization (Mitra & Cote, 2009). In BCa specimens, a significant positive 
correlation between HIF-1, VEGF and MVD was observed (Chai et al., 2008; 
Theodoropoulos et al., 2004). Similar to MVD and VEGF, HIF-1 can serve as indicator of a 
high recurrence rate and short survival of patients with non-muscle invasive and muscle-
invasive BCa (Chai et al., 2008; Palit et al., 2005; Theodoropoulos et al., 2004). Focused on 
non-muscle invasive BCa, HIF-1 overexpression combined with aberrant nuclear p53 
accumulation seemed to indicate an aggressive phenotype with a high risk of progression 
(Theodoropoulos et al., 2005). 
High mRNA expression of VEGF in non-muscle invasive BCa correlated with high 
recurrence and progression rates, particularly in combination with aberrant p53 staining 
(Crew et al., 1997). Elevated VEGF protein levels in urine samples from patients with non-
muscle invasive BCa showed a significant association with tumor recurrence (Crew et al., 
1999b). 
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Elevated VEGF serum levels were observed in BCa patients with high tumor grade and 
stage, with vascular invasion, CIS tumors or distant metastases and correlated with a shorter 
disease-free survival (Bernardini et al., 2001). Furthermore, VEGF expression and MVD in 
biopsy specimens taken prior to therapy were significant predictors of recurrence of muscle-
invasive BCa after neoadjuvant chemotherapy and radical cystectomy (Inoue et al., 2000). 
Increased VEGF levels in tissue samples from patients with locally advanced BCa treated by 
radical cystectomy and chemotherapy (MVAC) were strongly related to poor disease-
specific survival (Slaton et al., 2004). 
Thrombospondin-1 (TSP-1) is an ECM component glycoprotein that functions as potent 
inhibitor of angiogenesis. Expression analyses of this putative tumor suppressor in tissue 
specimens from patients with muscle-invasive BCa who underwent radical cystectomy 
revealed a significant association between low TSP-1 levels and increased recurrence rates as 
well as with a decreased overall survival (Grossfeld et al., 1997). In non-muscle invasive BCa 
a reduced perivascular TSP-1 staining served as independent predictor of progression to 
muscle-invasive or metastatic disease (Goddard et al., 2002). Furthermore, expression of 
angiopoietin 2 (ANG-2), an angiogenic modulator that potentiates angiogenesis in presence of 
VEGF, was identified as a strong and independent predictor of tumor recurrence of non-
muscle invasive BCa (Szarvas et al., 2008).  
The scaffolding ECM serves to maintain endothelial cell function and its degradation is 
mediated amongst others by MMPs. Additionally, MMPs activate the basic and acidic FGF 
(FGF1 and FGF2) as well as the scatter factor (SF; identical to HGF = hepatocyte growth factor) – 
all regulators which promote migration and invasion of endothelial cells as well as of tumor 
cells thereby supporting angiogenesis and metastasis (Mitra & Cote, 2009). These factors are 
also stimulated by plasmin that is proteolytically generated by the urokinase-type plasminogen 
activator (uPA = PLAU = plasminogen activator, urokinase). uPA, which can be induced by VEGF, 
as well as its receptor uPAR (PLAUR= plasminogen activator, urokinase receptor) are also 
involved in ECM degradation, adhesion and migration of tumor cells (Mitra & Cote, 2009). 
Determination of the FGF1 and FGF2 levels in urine samples of patients with BCa revealed 
their prognostic value as indicators of increased disease stage and high rates of local 
recurrence (Chopin et al., 1993; Gazzaniga et al., 1999; Gravas et al., 2004; Nguyen et al., 
1993). SF/HGF levels in urine and serum samples were elevated in BCa patients and related 
particularly to higher tumor stages as well as to metastasis and worse survival (Gohji et al., 
2000; Joseph et al., 1995; Rosen et al., 1997; Wang et al., 2007). The receptor of SF/HFG, the 
met proto-oncogene (MET), was also detected in BCa tissue specimens. Its up-regulation 
correlated with disease progression and poor long-term survival (Cheng et al., 2002, 2005; 
Joseph et al., 1995; Miyata et al., 2009). 
A significant association between the expression of uPA and uPAR was observed in BCa 
tissues; both factors were higher in muscle-invasive than in non-muscle invasive BCa and 
correlated with a worse outcome (Champelovier et al., 2002; Hasui et al., 1994; 
Seddighzadeh et al., 2002). Elevated levels of uPA and uPAR were also detected in urine 
and plasma samples from BCa patients compared to controls without BCa (Casella et al., 
2002; Shariat et al., 2003). Furthermore, increased preoperative uPA plasma levels in BCa 
patients were shown to be indicators of a poor outcome after radical cystectomy (Shariat et 
al., 2003).  
Metastasis is initiated by the ability of the tumor to degrade the ECM and to invade the 
basement membrane followed by the invasion of tumor cells into blood and lymphatic 
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The activation of the PIK3 pathway leads to transmission of extracellular growth signals via 
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stage, with vascular invasion, CIS tumors or distant metastases and correlated with a shorter 
disease-free survival (Bernardini et al., 2001). Furthermore, VEGF expression and MVD in 
biopsy specimens taken prior to therapy were significant predictors of recurrence of muscle-
invasive BCa after neoadjuvant chemotherapy and radical cystectomy (Inoue et al., 2000). 
Increased VEGF levels in tissue samples from patients with locally advanced BCa treated by 
radical cystectomy and chemotherapy (MVAC) were strongly related to poor disease-
specific survival (Slaton et al., 2004). 
Thrombospondin-1 (TSP-1) is an ECM component glycoprotein that functions as potent 
inhibitor of angiogenesis. Expression analyses of this putative tumor suppressor in tissue 
specimens from patients with muscle-invasive BCa who underwent radical cystectomy 
revealed a significant association between low TSP-1 levels and increased recurrence rates as 
well as with a decreased overall survival (Grossfeld et al., 1997). In non-muscle invasive BCa 
a reduced perivascular TSP-1 staining served as independent predictor of progression to 
muscle-invasive or metastatic disease (Goddard et al., 2002). Furthermore, expression of 
angiopoietin 2 (ANG-2), an angiogenic modulator that potentiates angiogenesis in presence of 
VEGF, was identified as a strong and independent predictor of tumor recurrence of non-
muscle invasive BCa (Szarvas et al., 2008).  
The scaffolding ECM serves to maintain endothelial cell function and its degradation is 
mediated amongst others by MMPs. Additionally, MMPs activate the basic and acidic FGF 
(FGF1 and FGF2) as well as the scatter factor (SF; identical to HGF = hepatocyte growth factor) – 
all regulators which promote migration and invasion of endothelial cells as well as of tumor 
cells thereby supporting angiogenesis and metastasis (Mitra & Cote, 2009). These factors are 
also stimulated by plasmin that is proteolytically generated by the urokinase-type plasminogen 
activator (uPA = PLAU = plasminogen activator, urokinase). uPA, which can be induced by VEGF, 
as well as its receptor uPAR (PLAUR= plasminogen activator, urokinase receptor) are also 
involved in ECM degradation, adhesion and migration of tumor cells (Mitra & Cote, 2009). 
Determination of the FGF1 and FGF2 levels in urine samples of patients with BCa revealed 
their prognostic value as indicators of increased disease stage and high rates of local 
recurrence (Chopin et al., 1993; Gazzaniga et al., 1999; Gravas et al., 2004; Nguyen et al., 
1993). SF/HGF levels in urine and serum samples were elevated in BCa patients and related 
particularly to higher tumor stages as well as to metastasis and worse survival (Gohji et al., 
2000; Joseph et al., 1995; Rosen et al., 1997; Wang et al., 2007). The receptor of SF/HFG, the 
met proto-oncogene (MET), was also detected in BCa tissue specimens. Its up-regulation 
correlated with disease progression and poor long-term survival (Cheng et al., 2002, 2005; 
Joseph et al., 1995; Miyata et al., 2009). 
A significant association between the expression of uPA and uPAR was observed in BCa 
tissues; both factors were higher in muscle-invasive than in non-muscle invasive BCa and 
correlated with a worse outcome (Champelovier et al., 2002; Hasui et al., 1994; 
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vessels, the path for tumor cell to spread into regional lymph nodes and secondary organs 
(Gontero et al., 2004; Mitra & Cote, 2009). Several key mediators are involved in metastatic 
spread such as cadherins which are located at adherens junctions and desmosomes between 
neighboring cells. Particularly, E-cadherin plays an important role in epithelial cell-cell 
contacts which is mediated by homodimerization and anchoring to the actin cytoskeleton 
via binding to catenins (Bryan et al., 2005b). In BCa patients, a reduced expression of 
E-cadherin was associated with an increased aggressiveness and a higher risk of tumor 
recurrence and progression as well as with a shorter survival (Bringuier et al., 1993; Byrne et 
al., 2001; Mahnken et al., 2005; Mhawech-Fauceglia et al., 2006; Nakopoulou et al., 2000; 
Popov et al., 2000). Immunohistochemical analyses of E-cadherin, - and -catenin revealed 
that loss of these factors can indicate a poor survival of BCa patients (Clairotte et al., 2006; 
Garcia Del Muro et al., 2000; Kashibuchi et al., 2007; Mialhe et al., 1997; Shimazui et al., 
1996). 
In addition, integrins are involved in the regulation of processes linked to tumor cell 
invasion and migration consequently leading to metastasis. Integrins are heterodimeric 
transmembrane glycoproteins on the surface of tumor cells that function as receptors of 
ECM proteins such as laminin and collagen. Thereby, integrins serve as molecular links 
between the ECM and the intracellular actin cytoskeleton and are in this way involved in the 
maintenance of normal tissue architecture (Gontero et al., 2004). Among the numerous 
members of the integrin family 64 integrin, which closely interacts with collagen VII and 
laminin thereby restricting cell migration, is one of the best studied integrins in BCa patients 
(Gontero et al., 2004). Altered expression of 64 integrin was observed in superficial BCa; 
in muscle-invasive BCa loss of 64 integrin and/or collagen VII or lack of their co-
localization was reported (Liebert et al., 1994). BCa patients with weak 64 integrin 
immunoreactivity showed a better outcome than those with either no or strong expression 
(Grossman et al., 2000). 
MMPs and members of the uPA system are proteases involved not only in invasion 
processes of endothelial cells, they are also key factors triggering the invasion of tumor cells 
by degradation of ECM and the basement membrane (Gontero et al., 2004). MMPs are 
frequently overexpressed and secreted in human tumors (Bryan et al., 2005b; Wallard et al., 
2006). Additionally, members of the ADAM (a disintegrin and metalloproteinase domain) family 
have been implicated in cancer progression (Frohlich et al., 2006). An imbalance between 
MMPs and their natural counterparts, the tissue inhibitors of metalloproteases (TIMPs), which 
is frequently observed in tumors, is also assumed to support tumor cell invasion and 
metastasis (Gontero et al., 2004). TIMPs might be paradoxically up-regulated in response to 
the elevation of MMPs levels (Gontero et al., 2004). 
For BCa, MMP-2 and MMP-9 are of particular prognostic importance since increase in their 
tissue levels correlated with higher tumor grade and/or stage (Davies et al., 1993; 
Kanayama et al., 1998; Papathoma et al., 2000). Overexpression of MMP-2 and MMP-9 in 
BCa tissues was associated with disease progression and poor survival (Durkan et al., 2003; 
Vasala et al., 2003). The ratio of the MMP-9 to E-cadherin levels in BCa tissue specimens was 
also useful for prediction of the disease-specific survival of patients with locally advanced 
BCa (Slaton et al., 2004). 
Additionally, poor outcome was reported for BCa patients with high levels of TIMP-2 in 
tumor and/or stromal cells and for patients with increased tissue expression of MMP-2 and 
TIMP-2 or MMP-9 and TIMP-2 (Gakiopoulou et al., 2003; Grignon et al., 1996; Hara et al., 
2001; Kanayama et al., 1998). 
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Higher recurrence rates and poor prognosis were observed in BCa patients with high serum 
levels of MMP-2, MMP-3 or with high ratios of the serum levels of MMP-2 to TIMP-2 (Gohji 
et al., 1996a, 1996b, 1998). MMP-1, MMP-2, MMP-9 and TIMP-1 were also detectable in urine 
samples from BCa patients and correlated with increasing grade and/or stage (Durkan et 
al., 2003; Durkan et al., 2001; Gerhards et al., 2001; Nutt et al., 1998, 2003; Sier et al., 2000). 
Urinary MMP-1 was associated with higher rates of disease progression and death from 
cancer (Durkan et al., 2001). 
ADAM12, a disintegrin and metalloproteinase, that was shown to be up-regulated in BCa 
tissues in association with disease stage, could also be detected in urine samples, where it 
might serve as biomarker reflecting presence of BCa (Frohlich et al., 2006). 
8. Conclusion 
On the basis of specific genetic and molecular patterns two clearly distinguishable types of 
BCa can be defined, which differ in their phenotype and clinical behavior. They mainly 
diverge in the genetic stability and in the presence of alterations in the genes p53 and 
FGFR3. The knowledge of BCa-related genetic and molecular processes provides the basis 
for the development of new diagnostic and therapeutic approaches. Molecular-diagnostic 
assays can be designed for BCa subtypes, e.g. for low grade and low stage tumors, which are 
poorly detectable by the currently used techniques. Furthermore, new BCa subtype-selective 
therapeutics will provide more specific and effective treatment options leading to the 
reduction of tumor recurrence and progression. After successful implementation, both 
aspects will improve clinical outcome of BCa patients and save costs for diagnosis and 
therapy for this tumor type, which are huge compared to other tumor entities. 
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1. Introduction 
The diagnosis of bladder cancer is generally made by cystoscopy and biopsy. Moreover, 
bladder cancer has a very high frequency of recurrence and therefore requires follow-up 
cystoscopy, along with urine cytology, as periodic surveillance to identify recurrence early. 
Cystoscopy is invasive and apt with complications like urine infection which sometimes 
lead to septicaemia with serious consequencies. Patient experience is most times not 
pleasant. Therefore, there needs to be a better way of surveillance for bladder cancer which 
is non-invasive and more acceptable to the patient experience. Consequently, urine 
biomarkers might be used to either supplement or supplant these tests. 
Urinary bladder carcinoma, the fourth most common cancer in men and ninth most 
common in women results in significant morbidity and mortality. 
Bladder cancer (urothelial carcinoma) typically presents as a tumour confined to the 
superficial mucosa of the bladder. The most common symptom of early bladder cancer is 
haematuria; however, urinary tract symptoms (i.e., urinary frequency, urgency and 
dysuria) may also occur. Most urologists follow the American Urological Association 
(AUA) guidelines for haematuria which recommend cystoscopic evaluation of all adults 
greater than 40 years old with microscopic haematuria and for those less than 40 years old 
with risk factors for developing bladder cancer. Confirmatory diagnosis of bladder cancer 
must by made by cystoscopic examination and biopsy which is considered to be the “gold 
standard.” 
At initial diagnosis, about 70 percent of patients have cancers confined to the epithelium or 
sub-epithelial connective tissue. Non-muscle invasive disease is usually treated with 
transurethral resection with or without intravesical therapy, depending on depth of 
invasion and tumour grade. However, there is a 75 percent incidence of recurrence in these 
patients with 10-15 percent progressing to muscle invasion over a five year period. Current 
follow-up protocols include flexible cystoscopy and urine cytology every three months for 
one to three years, every six months for an additional two to three years, and then annually, 
assuming no recurrence. 
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While urine cytology is a specific test (from 90 percent–100 percent), its sensitivity is lower, 
ranging from 50 percent–60 percent overall and is considered even lower for low-grade 
tumours. Therefore, there has been interest in identifying tumour markers in voided urine 
that would provide a more sensitive and objective test for tumour recurrence. 
2. Background 
Bladder cancer is very common, ranking second only to prostate cancer for cancers of the 
urinary tract. Approximately 54 000 new cases of bladder cancer are diagnosed and ~12 000 
people die from this disease every year in the United States alone. Most patients are 
diagnosed with superficial tumours, which can be completely resected. However, two-thirds 
of these patients will experience recurrence within 5 years, and almost 90% will have a 
recurrence by 15 years. Early diagnosis leads to better clinical outcomes, underscoring the 
importance of finding new ways for screening the general population. Currently, potential 
bladder tumour markers can be used in various clinical scenarios, including (14): 
 Serial testing for earlier detection of recurrence;  
 Complementary testing to urine cytology to improve the detection rate;  
 Providing a less expensive and more objective alternative to the urine cytology test; and  
 Directing the cytoscopic evaluation of patient follow-up.  
The gold standard for the detection of urothelial neoplasia is cytologic examination of 
urothelial cells from voided urine, urinary bladder washings, and urinary tract brushing 
specimens in combination with cystoscopic examination 12,13. Because cystoscopy is an 
invasive procedure and urinary cytology suffers from low sensitivity and specificity, 
particularly for lower grade tumours, it is desirable to identify novel biomarkers for this 
cancer. Biochemical testing of urine is a non-invasive and less expensive procedure for 
diagnosing and monitoring this disease. Because none of the markers mentioned above has 




Fig. 1. Cystoscopic appearance of bladder tumour  
Biomarkers of Bladder Cancer in Urine: Evaluation of Diagnostic  




Fig. 2. Relationship between sensitivity and specificity  
 
 
Fig. 3. Ca 19-9 levels in urine (Adapted from ClinChem.org) 
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Fig. 4. Mechanism of cancer marker production and appearance in urine (Adapted from 
flipper.diff.org) 
Kageyama et al. propose proteomic analysis of urine as a new way to identify bladder cancer 
biomarkers. Previously, Celis et al. utilised two-dimensional gel electrophoresis and 
developed a comprehensive database for bladder cancer profiles of both transitional and 
squamous cell carcinomas.  
Biochemical testing of urine should be able to diagnose early bladder carcinoma because 
candidate informative molecules could be excreted into the urine during cancer 
development. Proteomic profiling of urine has been suggested as a diagnostic test for 
bladder carcinoma 11. In addition, many other biochemical molecules or genetic markers 
have been discovered that could be used to diagnose bladder carcinoma with fair sensitivity 
and specificity. Such molecules (or methods) include, but are not limited to, the following 
(the approximate diagnostic sensitivities and specificities are in parentheses): BTA stat (68%; 
66%); BTA-TRAK (71%; 62%); NMP22 (64%; 71%); telomerase (74%; 89%); HA-HAase (91%; 
86%); Immunocyt (68%; 79%); F/FDP (68%; 86%); multicolor fluorescence in situ 
hybridization assays (84%; 90%); cytokeratins (76%; 84%); metalloproteinases (60%; 80%); 
and p53 mutation (32%; 100%). The most common noninvasive test, however, is voided 
urine cytology (VUC), which has a sensitivity of 50%and a specificity of 97% 12. This test 
has higher sensitivity for higher grade tumors. 
Through their studies, Kageyama et al. were able to identify a potential tumour marker, 
calreticulin, which is found in the urine of patients with bladder carcinoma. The authors 
used a differential display method of bladder cancer vs healthy urothelial tissue and mass 
spectrometry to identify proteins that are increased in cancer tissue. In addition to 
calreticulin, an endoplasmic reticulum chaperone, they found nine other candidate proteins 
that could constitute new biomarkers for bladder carcinoma. The authors confirmed their 
data with quantitative Western blot analysis, immunoprecipitation, and 
immunohistochemistry. Their reported sensitivity and specificity were 73% and 86%, 
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respectively, similar to the values reported for other biochemical bladder markers (see 
above). However, the diagnostic accuracy of their test was vulnerable to urinary tract 
infections. 
The main question surrounding bladder cancer and urinary biomarkers is how these 
molecules can be used in clinical practice. Clearly, these tests are not useful for population 
screening because of their low sensitivity and specificity. In addition, none of the available 
tests is sufficiently accurate to replace cystoscopy in the investigation of a patient with a 
possible bladder tumour. VUC has relatively low sensitivity, especially for low-grade 
tumours, but it is currently the most specific test for bladder carcinoma. Consequently, when 
VUC is positive, it indicates a high-risk tumour that requires definitive treatment. VUC is 
currently used for monitoring of patients with known high-risk disease, and positive 
cytology with negative cystoscopy may indicate malignancy of the prostate or upper urinary 
tract. 
Current guidelines suggest that low-risk patients should be surveyed once a year with 
cystoscopy and high-risk patients at 3-month intervals. Currently, cystoscopy is always 
combined with VUC. Because, as mentioned earlier, new urinary bladder tests such as BTA 
or NMP22 could detect lower-grade disease recurrence with higher sensitivity than VUC, it 
could be worthwhile to consider including one or more of these tests in the routine follow-
up of patients with bladder carcinoma. However, large prospective studies will be necessary 
to test the clinical utility of these assays against cytology. Such trials could show the value of 
these new tests in reducing the frequency of cystoscopy and in contributing to the earlier 
and more sensitive detection of disease recurrence, leading to earlier therapeutic 
interventions and, fortunately, to improved clinical outcomes. 
In conclusion, bladder cancer biomarkers have proliferated more than any other class of 
cancer markers over the last 10 years. We now have at hand a multitude of molecules that 
can be measured with automated, inexpensive, quantitative assays in urine. These markers 
may aid in the monitoring of patients with bladder carcinoma and have the potential to 
reduce the number of follow-up cystoscopy, thus reducing healthcare costs and patient 
discomfort and, at the same time, detecting relapsing disease more effectively than VUC. It is 
time to test these new possibilities with prospective clinical trials. 
3. Evaluation of individual markers 
Urine-based marker tests are being developed to fill some of the remaining needs. These 
newer tests are more accurate in detecting low-grade bladder cancer, so they are especially 
useful in monitoring for recurrence, may significantly improve and simplify workup, 
diagnosis, and follow-up, and hopefully allow for detection of disease at an earlier stage, 
thus improving the chances of curative therapy.  
The urine marker assays discussed here have shown enhanced sensitivity in detecting 
bladder cancers. However, each still requires further validation and testing in clinical trials 
to determine how best to apply these tools for in individual patients. In recent years several 
of the newer tests are being used by urologists as another weapon in the arsenal. Although 
immunological markers are superior to standard urine cytology, at the present time urine 
bound tests are not specific enough to completely replace cystoscopy as a definite diagnostic 
tool. 
In order to understand what these tests are about it's helpful to have an understanding of 
Sensitivity vs. Specificity: 
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A diagnostic test is one that predicts the presence of a disease. An ideal diagnostic test 
would always give the right answer, with a positive result in everyone with the disease and 
a negative result in everyone else - and would be quick, safe, simple, painless, reliable, and 
inexpensive, as well. Since no current diagnostic test is ideal, we need to evaluate each of 
them for their clinical usefulness. In practice, for any diagnostic test there is a trade-off 
between sensitivity and specificity. In cancer diagnosis, the need for this trade-off is rooted 
in the fact that cancer arises from our own tissues. It is not completely "foreign" to our 
systems like a virus or bacterium is. 
It's important to remember that there are four possible results when a diagnostic test is run: 
True positive - when the test is positive and the patient does have the disease 
False positive - when the test is positive but the patient does not have the disease 
True negative - when the test is negative and the patient does not have the disease 
False negative - when the test is negative but the patient does have the disease 




The disease being tested for is 
present 
The disease being tested for is not 
present 
"Positive" True positive False positive 
"Negative" False negative True negative 
 
Calculating the disease sensitivity and specificity are ways of evaluating diagnostic tests, 
using the four possible results. 
Sensitivity - is the ability of a test to correctly identify a positive specimen, and it tells you 
how good the test is at identifying the disease. Statistically, it's the proportion of patients 
with the disease who have a positive result, that is, the number of "true positives" out of all 
the situations where the disease is present. 
For example, 100 patients with cancer are tested using a test that detects tumours. There are 
80 positive results and 20 negative results. This means the test has a sensitivity of 80% - it 
correctly identified 80 of the 100 cancers - and it gave 20 false negative results. 
Specificity - is the ability of a test to correctly identify a negative specimen, and it tells you 
how good the test is at identifying when the disease is absent. The statistical way of looking 
at this is the proportion of patients without the disease who have a negative test, that is, the 
number of "true negatives" out of all the situations where the disease is not present. 
For example, 100 normal, healthy individuals are tested using a test that detects tumours. 
There are 80 positives and 20 negatives. This means the test has a specificity of 20% - it 
correctly identified 20 of the 100 negative specimens - and it gave 80 false positive results. 
Both sensitivity and specificity are very important, and they can both be influenced by 
various factors, such as the characteristics of the population tested or the value used as a 
cut-off for the test (above which the test is positive and below which it is negative). A test 
with low sensitivity and many false negative results will fail to detect the tumour in a large 
portion of the patients being tested, while a test with low specificity with many false 
positive results may lead to unnecessary invasive or expensive procedures and cause undue 
alarm. 
Many, but not all, patients report they would rather be "scared for nothing" than miss a 
tumour, and are therefore most interested in tests with high sensitivity.1 
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4. BTA stat test and the BTA TRAK assay 
The original Bard BTA Test, which continues to be referred to in the literature from time to 
time, was a latex agglutination test detecting bladder tumour-associated antigen and is no 
longer distributed in the US. It is important to note that it has been replaced by two newer 
tests based on significantly improved technology with much better sensitivity and 
specificity. 
Both of the new tests detect a human complement factor H-related protein (hCFHrp) which 
has been shown to be produced by several human bladder cancer cell lines, and by human 
bladder cancers, but not by other epithelial cell lines (Kinders, Clin Cancer Res 4:2511, 1998). 
It is thought that factor H acts to protect the tumor cell from the body's natural immune 
system (Corey, J Biol Chem 275:12917, 2000). Both the BTA stat and BTA TRAK tests can 
provide valuable but slightly different information for the bladder cancer patient and her 
doctor. 
The BTA stat Test is a qualitative (positive or negative) test provided in a disposable format 
similar to a home pregnancy test. It uses five drops of urine and can be read in five minutes 
by the appearance of a coloured line in the patient window, while a coloured line appears in 
a "check" window to indicate the test is working properly. This test is cleared in the US for 
use by clinical laboratories, the physician or his staff right in the office, or even by the 
bladder cancer patient at home (with a physician's prescription). To date, it is the only 
tumour marker in the United States with this status. Besides being highly sensitive, fast, and 
easy to use, with a unique availability to be run by the physician and/or the patient, this test 
is significantly less costly than other diagnostic tests or cytology. 
The BTA TRAK Assay is a quantitative immunoassay test and provides a numerical result 
of the hCFHrp level. Like the NMP22 test, urine must be sent to a reference laboratory 
where the test is performed by professional technologists. In addition to knowledge of the 
specific level, an advantage of the BTA TRAK test is the ability to monitor the rise or fall 
of hCFHrp. 
Numerous clinical studies have been conducted with the new BTA tests. Most reports state 
findings in terms of "sensitivity" and "specificity." Briefly, sensitivity is the ability of the test 
to correctly identify a positive specimen, and specificity is the ability of the test to correctly 
identify a negative specimen. 
4.1 BTA stat test studies  
In the most recent study (June 2000) and the largest of its kind to date, Raitanen reported the 
overall sensitivity of BTA stat as 82%, and cytology as 30% . In another study, Pode reported 
100% BTA stat sensitivity in tumors of stage T2 or higher, grade III, and all tumors greater 
than 2cm (Pode, J Urol 161:443, 1999). Specificity of the BTA stat Test has been reported as 
72-95% (Sarosdy, Urology 50:349, 1997) and 98% in healthy individuals (Raitanen, Scand J 
Urol Nephrol 33:234, 1999). 
4.2 BTA TRAK assay studies  
In one study, the overall sensitivity of the BTA TRAK Assay was reported as 72% with a 
specificity of 75-97% (Ellis, Urology 50:882, 1997). Heicappell again reported an overall 
sensitivity of 72%, with 97% specificity in healthy individuals. He also reported that BTA 
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A diagnostic test is one that predicts the presence of a disease. An ideal diagnostic test 
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inexpensive, as well. Since no current diagnostic test is ideal, we need to evaluate each of 
them for their clinical usefulness. In practice, for any diagnostic test there is a trade-off 
between sensitivity and specificity. In cancer diagnosis, the need for this trade-off is rooted 
in the fact that cancer arises from our own tissues. It is not completely "foreign" to our 
systems like a virus or bacterium is. 
It's important to remember that there are four possible results when a diagnostic test is run: 
True positive - when the test is positive and the patient does have the disease 
False positive - when the test is positive but the patient does not have the disease 
True negative - when the test is negative and the patient does not have the disease 
False negative - when the test is negative but the patient does have the disease 




The disease being tested for is 
present 
The disease being tested for is not 
present 
"Positive" True positive False positive 
"Negative" False negative True negative 
 
Calculating the disease sensitivity and specificity are ways of evaluating diagnostic tests, 
using the four possible results. 
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with the disease who have a positive result, that is, the number of "true positives" out of all 
the situations where the disease is present. 
For example, 100 patients with cancer are tested using a test that detects tumours. There are 
80 positive results and 20 negative results. This means the test has a sensitivity of 80% - it 
correctly identified 80 of the 100 cancers - and it gave 20 false negative results. 
Specificity - is the ability of a test to correctly identify a negative specimen, and it tells you 
how good the test is at identifying when the disease is absent. The statistical way of looking 
at this is the proportion of patients without the disease who have a negative test, that is, the 
number of "true negatives" out of all the situations where the disease is not present. 
For example, 100 normal, healthy individuals are tested using a test that detects tumours. 
There are 80 positives and 20 negatives. This means the test has a specificity of 20% - it 
correctly identified 20 of the 100 negative specimens - and it gave 80 false positive results. 
Both sensitivity and specificity are very important, and they can both be influenced by 
various factors, such as the characteristics of the population tested or the value used as a 
cut-off for the test (above which the test is positive and below which it is negative). A test 
with low sensitivity and many false negative results will fail to detect the tumour in a large 
portion of the patients being tested, while a test with low specificity with many false 
positive results may lead to unnecessary invasive or expensive procedures and cause undue 
alarm. 
Many, but not all, patients report they would rather be "scared for nothing" than miss a 
tumour, and are therefore most interested in tests with high sensitivity.1 
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overall sensitivity of BTA stat as 82%, and cytology as 30% . In another study, Pode reported 
100% BTA stat sensitivity in tumors of stage T2 or higher, grade III, and all tumors greater 
than 2cm (Pode, J Urol 161:443, 1999). Specificity of the BTA stat Test has been reported as 
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TRAK levels reflect tumour stage and grade, with levels in superficial bladder cancer at high 
risk of tumour progression significantly higher compared to low and intermediate grade 
superficial cancers (Heicappell, Eur Urol 35:81, 1999). 
4.3 Comparison studies 
In a study conducted at the Mayo Clinic, several urine tumour markers were evaluated, 
including urine cytology, BTA stat, NMP22, fibrin/fibrinogen degradation products (FDP), 
telomerase, chemiluminescent hemoglobin and hemoglobin dipstick. The telomerase test 
presented the highest combination of sensitivity and specificity for screening. However, 
other researchers have had difficulty reproducing the telomerase results of this study, 
possibly due to the technical difficulties of running the test. It's also important to note that 
telomerase is a "Research Use Only" test, and has not received FDA clearance for marketing 
in the US. In the same study, the BTA stat Test was shown to have the best overall 
sensitivity (74%), and the best sensitivity for T1-T3 and primary tumour detection 
(Ramakumar, J Urol 161:388, 1999). 
Another comparison study (Giannopoulos, Urology 55:871, 2000) showed that the BTA stat 
Test was more sensitive than cytology in all stages and grades except G3, while NMP22 was 
more sensitive than cytology only in stage Ta and Grade 1 and 2. The BTA stat Test also had 
higher sensitivity than NMP22 in all stages and grades. 
It is also important to note that in both of the BTA tests, and with NMP22 as well, results can 
be compromised if there is a urinary tract infection, inflammation, or kidney stones present, 
if there has been recent trauma to the bladder, or if the specimen is collected by catheter. The 
paper by Sharma, for example, shows the dramatic increase in specificity when these 
conditions are excluded from testing (Sharma, J Urol 162:53, 1999). As with any test, for the 
results to be most useful they should be interpreted in light of all the medical and clinical 
information available. 
5. NMP22 'Bladder check'  
In a study comparing cystoscopy, cytology, and Bladder Check; the NMP22/Bladderchek 
test had a considerably higher detection rate than cytology (67% vs. 20%). Cystoscopy 
detected 86% of bladder cancers. 
More cost effective than cytology, the Bladder check test could also be a good adjunct to 
cystoscopy. The test costs in the range of $20 to $25, which Medicare reimburses for both 
bladder cancer monitoring and detection. It is a waived test under the Clinical Laboratory 
Improvement Amendments (CLIA).  
While the test showed a high negative predictive value, it produced a false-positive result in 
19 of the 194 patients without bladder cancer. Dr. Tomera advised that such patients need to 
be watched closely. Earlier data by Mark Soloway, MD, has shown that bladder cancer will 
be found in 70% of these individuals during the following 3 to 6 months (J Urol 1996; 
156:363-7). 
NMP22's core technology is based on the level of nuclear matrix proteins (NMPs) that are 
detected in body fluids. These levels are correlated to the presence of early-stage cancerous 
abnormalities, which have been validated in multiple clinical studies. The technology was 
discovered at the Massachusetts Institute of Technology and licensed to Matritech. 
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6. FISH  
Florescence in situ hybridization (FISH) is an assay which uses a mixture of fluorescent 
labeled probes to assess urinary cells for chromosomal abnormalities associated with 
malignancy.  
In a study at the Mayo clinic, researchers found that urine cytology detected cancerous cells 
in only 57 percent of the patients with bladder cancer while the FISH test picked up more 
than 95 percent of the high grade cancers, which are the most dangerous and important 
group of bladder cancers because they have a high probability of progressing to potentially 
incurable muscle-invasive bladder cancer. Cancers the test missed were low-grade tumours, 
which are less dangerous and have only a 3 to 5 percent chance of progressing to a higher 
stage tumour over five years. The FISH test also detected recurrence of the cancer three to 
six months earlier than by the cytology. This earlier detection capability should allow 
treatment to be initiated earlier and possibly give the patient a greater chance for survival, 
he said. 
Fluorescence-in-situ-hybridization (FISH) for multiple centromeric probes has previously 
been shown to be a very sensitive test for diagnosing UC, however the test was limited by 
the requirement of multiple cytospins to evaluate 4 or more probe sets. Recently a new 
commercial test (VYSIS) for evaluating urinary cytology became available in which 4 probes 
are simultaneously evaluated on a per cell basis on a single cytospin. We performed a pilot 
study to test the efficacy of the new FISH test compared to standard urine cytology. This 
study showed that the multi-colour FISH probe test was more sensitive than cytology, easily 
performed and yielded a high number of cells with numerical chromosomal aberrations. 
7. DiagnoCure’s ImmunoCyt™ bladder cancer monitoring test 
ImmunoCyt™ is a 510(k) cleared, by the FDA, qualitative direct immuno-cytofluorescence 
assay, intended for use in conjunction with cytology to increase the overall sensitivity for the 
detection of tumor cells exfoliated in the urine of patients previously diagnosed with 
bladder cancer. 
ImmunoCyt™ contains a cocktail of three monoclonal antibodies labeled with fluorescent 
markers. The cocktail of antibodies have been shown to react with a mucin glycoprotein as 
well as to be specific to a glycoform of CEA. The test detects cellular markers specific for 
bladder cancer in exfoliated cells isolated from urine sample. This non-invasive test, when 
coupled with urine cytology proves to be more sensitive than urine cytology alone or other 
currently available tumour markers. 
The current standard method for non-invasive detection of bladder cancer is urinary 
cytology, which consists of identifying the presence of cancer cells in urine. Urinary 
cytology has high specificity but poor sensitivity, typically no greater than 30% to 45%. This 
sensitivity varies according to the stage and grade of the tumor. 
ImmunoCytT™is carried out in parallel with cytology to improve cytology's sensitivity at 
detecting tumour cells in the urine of patients, especially those with low stage, low grade 
tumors. The concomitant use of classical cytology and ImmunoCytTM can substantially 
improve the detection of bladder cancer. As shown in the ImmunoCytTM performance 
analysis (cumulative data from eleven publications and presentations from 3,203 cases), a 
sensitivity of 88% has been obtained when both cytology and ImmunoCyt™ were used 
together. 
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TRAK levels reflect tumour stage and grade, with levels in superficial bladder cancer at high 
risk of tumour progression significantly higher compared to low and intermediate grade 
superficial cancers (Heicappell, Eur Urol 35:81, 1999). 
4.3 Comparison studies 
In a study conducted at the Mayo Clinic, several urine tumour markers were evaluated, 
including urine cytology, BTA stat, NMP22, fibrin/fibrinogen degradation products (FDP), 
telomerase, chemiluminescent hemoglobin and hemoglobin dipstick. The telomerase test 
presented the highest combination of sensitivity and specificity for screening. However, 
other researchers have had difficulty reproducing the telomerase results of this study, 
possibly due to the technical difficulties of running the test. It's also important to note that 
telomerase is a "Research Use Only" test, and has not received FDA clearance for marketing 
in the US. In the same study, the BTA stat Test was shown to have the best overall 
sensitivity (74%), and the best sensitivity for T1-T3 and primary tumour detection 
(Ramakumar, J Urol 161:388, 1999). 
Another comparison study (Giannopoulos, Urology 55:871, 2000) showed that the BTA stat 
Test was more sensitive than cytology in all stages and grades except G3, while NMP22 was 
more sensitive than cytology only in stage Ta and Grade 1 and 2. The BTA stat Test also had 
higher sensitivity than NMP22 in all stages and grades. 
It is also important to note that in both of the BTA tests, and with NMP22 as well, results can 
be compromised if there is a urinary tract infection, inflammation, or kidney stones present, 
if there has been recent trauma to the bladder, or if the specimen is collected by catheter. The 
paper by Sharma, for example, shows the dramatic increase in specificity when these 
conditions are excluded from testing (Sharma, J Urol 162:53, 1999). As with any test, for the 
results to be most useful they should be interpreted in light of all the medical and clinical 
information available. 
5. NMP22 'Bladder check'  
In a study comparing cystoscopy, cytology, and Bladder Check; the NMP22/Bladderchek 
test had a considerably higher detection rate than cytology (67% vs. 20%). Cystoscopy 
detected 86% of bladder cancers. 
More cost effective than cytology, the Bladder check test could also be a good adjunct to 
cystoscopy. The test costs in the range of $20 to $25, which Medicare reimburses for both 
bladder cancer monitoring and detection. It is a waived test under the Clinical Laboratory 
Improvement Amendments (CLIA).  
While the test showed a high negative predictive value, it produced a false-positive result in 
19 of the 194 patients without bladder cancer. Dr. Tomera advised that such patients need to 
be watched closely. Earlier data by Mark Soloway, MD, has shown that bladder cancer will 
be found in 70% of these individuals during the following 3 to 6 months (J Urol 1996; 
156:363-7). 
NMP22's core technology is based on the level of nuclear matrix proteins (NMPs) that are 
detected in body fluids. These levels are correlated to the presence of early-stage cancerous 
abnormalities, which have been validated in multiple clinical studies. The technology was 
discovered at the Massachusetts Institute of Technology and licensed to Matritech. 
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Florescence in situ hybridization (FISH) is an assay which uses a mixture of fluorescent 
labeled probes to assess urinary cells for chromosomal abnormalities associated with 
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in only 57 percent of the patients with bladder cancer while the FISH test picked up more 
than 95 percent of the high grade cancers, which are the most dangerous and important 
group of bladder cancers because they have a high probability of progressing to potentially 
incurable muscle-invasive bladder cancer. Cancers the test missed were low-grade tumours, 
which are less dangerous and have only a 3 to 5 percent chance of progressing to a higher 
stage tumour over five years. The FISH test also detected recurrence of the cancer three to 
six months earlier than by the cytology. This earlier detection capability should allow 
treatment to be initiated earlier and possibly give the patient a greater chance for survival, 
he said. 
Fluorescence-in-situ-hybridization (FISH) for multiple centromeric probes has previously 
been shown to be a very sensitive test for diagnosing UC, however the test was limited by 
the requirement of multiple cytospins to evaluate 4 or more probe sets. Recently a new 
commercial test (VYSIS) for evaluating urinary cytology became available in which 4 probes 
are simultaneously evaluated on a per cell basis on a single cytospin. We performed a pilot 
study to test the efficacy of the new FISH test compared to standard urine cytology. This 
study showed that the multi-colour FISH probe test was more sensitive than cytology, easily 
performed and yielded a high number of cells with numerical chromosomal aberrations. 
7. DiagnoCure’s ImmunoCyt™ bladder cancer monitoring test 
ImmunoCyt™ is a 510(k) cleared, by the FDA, qualitative direct immuno-cytofluorescence 
assay, intended for use in conjunction with cytology to increase the overall sensitivity for the 
detection of tumor cells exfoliated in the urine of patients previously diagnosed with 
bladder cancer. 
ImmunoCyt™ contains a cocktail of three monoclonal antibodies labeled with fluorescent 
markers. The cocktail of antibodies have been shown to react with a mucin glycoprotein as 
well as to be specific to a glycoform of CEA. The test detects cellular markers specific for 
bladder cancer in exfoliated cells isolated from urine sample. This non-invasive test, when 
coupled with urine cytology proves to be more sensitive than urine cytology alone or other 
currently available tumour markers. 
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cytology, which consists of identifying the presence of cancer cells in urine. Urinary 
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A multi-centre study in the United States, published in the Journal of Urology, concluded: 
ImmunoCyt™ enhances the sensitivity of cytology, which is a specific but not a sensitive 
method for detecting bladder cancer. The ability of this immuno-cytochemical test to detect 
low grade, superficial, small tumours makes it the most suitable available marker to test for 
monitoring strategies in patients with low risk bladder cancer. Performance of urine test in 
patients monitored for recurrence of bladder cancer: a multi-centre study in the United 
States.  
8. FDP-Fibrin/Fibrinogen Degradation Products 
FDP has shown high sensitivity even for low-grade and non-invasive tumours, and its 
diagnostic ability could be superior to NMP22 according to a recent study  
The FDP test detects the presence of fibrin and fibrinogen degradation products in urine. It 
is a simple test that can be performed in the office, and results are available in about 10 
minutes. Fibrin and fibrinogen degradation products are protein fragments generated by the 
action of the fibrinolytic system on fibrin and fibrinogen. Plasma proteins leak from blood 
vessels in tumours into the surrounding tissue. Clotting factors rapidly convert the 
fibrinogen in the plasma into an extravascular fibrin clot, which is degraded by plasmin and 
activated by urokinase. The FDP test can detect these degradation products and is positive 
in two thirds of patients with bladder cancer. The FDP assay is more accurate than urine 
cytology and has high specificity (negative in 96% of healthy subjects). The FDP test was 
found to be superior to the BTA test in at least one study*. 
Telomerase is another substance currently being assessed for its potential usefulness in 
diagnosing transitional cell cancer (TCC) and in monitoring for recurrence. It will soon be 
made available to doctors and patients. Telomerase is a ribonucleoprotein enzyme 
responsible for production of telomeres, which are DNA sequences that occupy the ends of 
chromosomes and protect their integrity during DNA replication and may be involved in 
the immortalization of a cancer cell 3 
9. Comparison of screening methods in the detection of bladder cancer  
In a study done in ’99, researchers prospectively evaluated and compared the sensitivity and 
specificity of urine cytology, BTA stat, NMP22, fibrin/fibrinogen degradation products (FDP), 
telomerase, chemiluminescent hemoglobin and hemoglobin dipstick to detect bladder cancer ; 
within each tumour grade and stage telomerase had the strongest association with bladder 
cancer among all tests (69% overall concordance). Telomerase was positive in 91% of the 
patients (10 of 11) with carcinoma in situ. The combination of sensitivity and specificity (70 
and 99%, respectively) was the highest for bladder cancer screening in these patients. 
Telomerase outperformed cytology, BTA stat, NMP22, FDP, chemiluminescent hemoglobin 
and hemoglobin dipstick in the prediction of bladder cancer. 4 
Telomerase - According to a study published in JAMA (2005; 294:2052-6) Italian 
researchers reported the assay showed 90% sensitivity and 88% specificity. Specificity 
increased to 94% for those aged 75 years or younger. The same predictive capacity of 
activity levels was observed for patients with low-grade tumours or with negative 
cytology results. In particular, sensitivity was 93%, 87%, and 89% for tumour grades 1, 2, 
and 3, respectively. 
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Although the test is proven to identify low-grade tumours, it is not recommended for use in 
routine screening programs because of the low incidence of bladder cancer and should be 
aimed at high-risk subgroups, noted the authors, from Morgagni-Pierantoni Hospital, Forli. 
Theoretically, urine telomerase appears more promising than do non-invasive tests for 
bladder cancer to date. The main advantages of the test, are that it is non-invasive, can be 
performed under local anaesthetic, and is significantly less expensive, at $20, than the 
approximately $100 for cystoscopy or $50 for urinary cytology. It could be a good marker for 
high-risk screening groups. Furthermore, it shows a high sensitivity for the diagnosis of 
low-grade tumours that can escape detection during cytological examination. Results are 
usually available in 2 to 3 days.  
10. Hyaluronidase and hyaluronic acid 
Hyaluronidase seems to be directly involved in tumour growth and progression, and recent 
reports have shown this marker has high accuracy in detecting bladder cancer and 
evaluating its grade, Hyaluronidase and hyaluronic acid are associated with induction of 
angiogenesis. It has been shown that Hyaluronic acid (HA), the urinary HAase levels of 
intermediate (G2) to high- grade (G3) bladder cancer patients are five- to seven-fold elevated 
as compared to those of normal individuals and patients with other genitourinary 
conditions or low-grade (G1) bladder cancer. The increase in urinary HAase levels is due to 
the secretion of a tumour-derived HAase which is elevated eight-fold in G2/G3 tumour 
tissues. The HAase in bladder tumour tissues is secreted by tumour epithelial cells and is 
associated with the invasive/ metastatic potential of the tumour cells.5 
Researchers from Brazil investigated the usefulness of HA for the detection of residual 
tumours that may remain after incomplete TUR. 10 The authors concluded that HA- in 
addition to being one of the best markers for the initial evaluation of bladder carcinoma- can 
be used to determine the presence of a residual tumour. This is associated with poor 
prognosis. Furthermore, haematuria does not seem to influence the content of urinary HA. 
Other tumor markers such as FISH (Fluorescence in Situ Hybridization) and NMP22 might 
be affected by instrumentation and therefore could not be evaluated this early. 
11. Low values of urinary HA after TUR indicate a favourable prognosis and 
could probably avoid the second procedure 
The researchers suggest that after more experience and follow-up using this assay in the 
clinical setting, it might be possible to predict not only the cases with residual tumour, but 
also those who require early radical surgery or those in whom this can be delayed. 
In addition to being a good marker in the initial evaluation of bladder carcinoma thanks to 
its excellent sensitivity (83.1%) and specificity (90.1%), HA potential uses include follow-up, 
prognostic evaluation, preventing unnecessary interventions and/or to indicate cases where 
early radical intervention is necessary.10 
12. BLCA-4 
Robert H. Getzenberg and colleagues at the University of Pittsburgh, USA have identified 
several components of the nuclear matrix, one of which is called BLCA-4, that differentiate 
human bladder tumour cells from normal bladder cells. Normal samples from unaffected 
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
56
A multi-centre study in the United States, published in the Journal of Urology, concluded: 
ImmunoCyt™ enhances the sensitivity of cytology, which is a specific but not a sensitive 
method for detecting bladder cancer. The ability of this immuno-cytochemical test to detect 
low grade, superficial, small tumours makes it the most suitable available marker to test for 
monitoring strategies in patients with low risk bladder cancer. Performance of urine test in 
patients monitored for recurrence of bladder cancer: a multi-centre study in the United 
States.  
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FDP has shown high sensitivity even for low-grade and non-invasive tumours, and its 
diagnostic ability could be superior to NMP22 according to a recent study  
The FDP test detects the presence of fibrin and fibrinogen degradation products in urine. It 
is a simple test that can be performed in the office, and results are available in about 10 
minutes. Fibrin and fibrinogen degradation products are protein fragments generated by the 
action of the fibrinolytic system on fibrin and fibrinogen. Plasma proteins leak from blood 
vessels in tumours into the surrounding tissue. Clotting factors rapidly convert the 
fibrinogen in the plasma into an extravascular fibrin clot, which is degraded by plasmin and 
activated by urokinase. The FDP test can detect these degradation products and is positive 
in two thirds of patients with bladder cancer. The FDP assay is more accurate than urine 
cytology and has high specificity (negative in 96% of healthy subjects). The FDP test was 
found to be superior to the BTA test in at least one study*. 
Telomerase is another substance currently being assessed for its potential usefulness in 
diagnosing transitional cell cancer (TCC) and in monitoring for recurrence. It will soon be 
made available to doctors and patients. Telomerase is a ribonucleoprotein enzyme 
responsible for production of telomeres, which are DNA sequences that occupy the ends of 
chromosomes and protect their integrity during DNA replication and may be involved in 
the immortalization of a cancer cell 3 
9. Comparison of screening methods in the detection of bladder cancer  
In a study done in ’99, researchers prospectively evaluated and compared the sensitivity and 
specificity of urine cytology, BTA stat, NMP22, fibrin/fibrinogen degradation products (FDP), 
telomerase, chemiluminescent hemoglobin and hemoglobin dipstick to detect bladder cancer ; 
within each tumour grade and stage telomerase had the strongest association with bladder 
cancer among all tests (69% overall concordance). Telomerase was positive in 91% of the 
patients (10 of 11) with carcinoma in situ. The combination of sensitivity and specificity (70 
and 99%, respectively) was the highest for bladder cancer screening in these patients. 
Telomerase outperformed cytology, BTA stat, NMP22, FDP, chemiluminescent hemoglobin 
and hemoglobin dipstick in the prediction of bladder cancer. 4 
Telomerase - According to a study published in JAMA (2005; 294:2052-6) Italian 
researchers reported the assay showed 90% sensitivity and 88% specificity. Specificity 
increased to 94% for those aged 75 years or younger. The same predictive capacity of 
activity levels was observed for patients with low-grade tumours or with negative 
cytology results. In particular, sensitivity was 93%, 87%, and 89% for tumour grades 1, 2, 
and 3, respectively. 
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Although the test is proven to identify low-grade tumours, it is not recommended for use in 
routine screening programs because of the low incidence of bladder cancer and should be 
aimed at high-risk subgroups, noted the authors, from Morgagni-Pierantoni Hospital, Forli. 
Theoretically, urine telomerase appears more promising than do non-invasive tests for 
bladder cancer to date. The main advantages of the test, are that it is non-invasive, can be 
performed under local anaesthetic, and is significantly less expensive, at $20, than the 
approximately $100 for cystoscopy or $50 for urinary cytology. It could be a good marker for 
high-risk screening groups. Furthermore, it shows a high sensitivity for the diagnosis of 
low-grade tumours that can escape detection during cytological examination. Results are 
usually available in 2 to 3 days.  
10. Hyaluronidase and hyaluronic acid 
Hyaluronidase seems to be directly involved in tumour growth and progression, and recent 
reports have shown this marker has high accuracy in detecting bladder cancer and 
evaluating its grade, Hyaluronidase and hyaluronic acid are associated with induction of 
angiogenesis. It has been shown that Hyaluronic acid (HA), the urinary HAase levels of 
intermediate (G2) to high- grade (G3) bladder cancer patients are five- to seven-fold elevated 
as compared to those of normal individuals and patients with other genitourinary 
conditions or low-grade (G1) bladder cancer. The increase in urinary HAase levels is due to 
the secretion of a tumour-derived HAase which is elevated eight-fold in G2/G3 tumour 
tissues. The HAase in bladder tumour tissues is secreted by tumour epithelial cells and is 
associated with the invasive/ metastatic potential of the tumour cells.5 
Researchers from Brazil investigated the usefulness of HA for the detection of residual 
tumours that may remain after incomplete TUR. 10 The authors concluded that HA- in 
addition to being one of the best markers for the initial evaluation of bladder carcinoma- can 
be used to determine the presence of a residual tumour. This is associated with poor 
prognosis. Furthermore, haematuria does not seem to influence the content of urinary HA. 
Other tumor markers such as FISH (Fluorescence in Situ Hybridization) and NMP22 might 
be affected by instrumentation and therefore could not be evaluated this early. 
11. Low values of urinary HA after TUR indicate a favourable prognosis and 
could probably avoid the second procedure 
The researchers suggest that after more experience and follow-up using this assay in the 
clinical setting, it might be possible to predict not only the cases with residual tumour, but 
also those who require early radical surgery or those in whom this can be delayed. 
In addition to being a good marker in the initial evaluation of bladder carcinoma thanks to 
its excellent sensitivity (83.1%) and specificity (90.1%), HA potential uses include follow-up, 
prognostic evaluation, preventing unnecessary interventions and/or to indicate cases where 
early radical intervention is necessary.10 
12. BLCA-4 
Robert H. Getzenberg and colleagues at the University of Pittsburgh, USA have identified 
several components of the nuclear matrix, one of which is called BLCA-4, that differentiate 
human bladder tumour cells from normal bladder cells. Normal samples from unaffected 
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individuals did not react with the antibody, and importantly, BLCA-4 appears to be present 
throughout the bladder (i.e., in both normal and tumour areas) in bladder cancer patients. 
This "field effect" permitted development of a urine immunoassay for BLCA-4 that detects 
the presence of tumour anywhere in the bladder, regardless of stage or grade. The BLCA-4-
urine immunoassay has a specificity of 100% and a sensitivity of 95%. According to Dr. 
Getzenberg, the assay is currently being tested by the Pittsburgh researchers in a clinical 
trial of individuals at high risk for bladder cancer. 6 
Using a prospectively determined cut-off, 67 of the 75 samples from patients with bladder 
cancer were positive for BLCA-4, resulting in an assay sensitivity of 89%. Also, 62 of the 65 
samples from individuals without bladder cancer were negative for BLCA-4, resulting in an 
assay specificity of 95%. The authors concluded that the high sensitivity and specificity of 
the sandwich BLCA-4 immunoassay may allow for earlier detection and treatment of 
disease, thus greatly improving patient care. 7 
BLCA-4, appears to be associated with a "field effect" of the disease, and in clinical trials is 
able to separate individuals with bladder cancer from those without the disease with high 
sensitivity and specificity. BLCA-4 is a bladder cancer marker that is highly specific and 
occurs early in the development of the disease. It appears to be a transcription factor that 
may play a role in the regulation of the gene expression in bladder cancer. BLCA-4 is a 
marker with significant clinical utility that may have an active role in the disease. 
13. Other proposed markers  
DD 23 monoclonal antibody recognizes a 185 kDa antigen expressed by bladder cancer cells 
and has been proposed as an adjunct to cytology for the detection of bladder cancer. Urine 
fibronectin and chorionic gonadotropin (protein and mRNA transcript) may also be markers 
for transitional cell carcinoma of the bladder .  
14. Role of urine markers in early detection of bladder cancer  
Almost all cases of bladder cancer are found during the work-up of patients who present 
with haematuria (71), but most cases of haematuria are not caused by bladder cancer. 
Urologic disease is detected in 10% of subjects who present with haematuria, and bladder 
cancer is detected in fewer than half of these subjects (72,73,74). The work-up of patients 
with haematuria is costly and often requires cytology, cystoscopy, intravenous urography or 
computed tomography (75). Thus, tumor markers could be useful in identifying the patients 
in this high-risk group, which requires more intensive clinical work-up for bladder cancer. 
Zippe et al reported on the value of the urine NMP22 test in the evaluation of 330 patients 
with haematuria (76). The NMP22 test when used with a cut-off value of 10.0 u/ml detected 
all 18 cases of bladder cancer with 45 false positive cases (sensitivity, 100%; specificity, 85%). 
In this study, 267 unnecessary cystoscopy could have been avoided if cystoscopy had been 
directed by the NMP22 test. In a clinical trial submitted to the Food and Drug 
Administration (as Pre-Market Approval Data), the NMP22 test was elevated in 69.6% of 56 
bladder cancer that were detected in the high risk group. In this report, the specificity was 
67.7% (77). The NMP22 test has been cleared by the FDA for use as an aid to diagnose 
bladder cancer in individuals with risk factors or who have symptoms of bladder cancer. It 
is highly likely that other urine markers (e.g. BTA, UroVysion and Immunocyt) may also 
have value for cancer detection in subjects who present with haematuria. The high false 
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positive rate is the major criticism of the urine-based tests when they are used to assess 
patients who present with haematuria or are used in patient surveillance. The low false 
negative rate of these tests is their strength, leading to a high negative predictive value that 
effectively rules out disease in a significant proportion of patients, thereby eliminating 
unnecessary clinical work-ups for bladder cancer.  
15. Role of tissue markers for prognosis  
Considerable research effort continues to be directed towards the identification of markers 
that predict the aggressive potential of superficial bladder tumors. Such information could 
lead to more effective surveillance protocols and permit more aggressive treatment of those 
patients with tumors most likely to progress to invasive or metastatic disease. Stein et al 
have performed an exhaustive review of a variety of biological markers reported to have 
prognostic value. More recently, p53 and other cell cycle control genes, chorionic 
gonadotropin beta gene transcripts, various cell matrix and adhesion proteins and 
differentially expressed NACB. 
16. Role of urine markers for patient surveillance  
Many reports have established the value of urine tumor marker tests in the early detection 
of recurrent bladder tumors, but as yet these urine tests cannot replace routine cystoscopy 
and cytology in the management of bladder cancer patients. Instead, they may be used as 
complementary adjuncts that direct more effective utilization of clinical procedures, thus 
reducing the cost of patient surveillance. Patients with superficial lesions of low grade (Ta, 
Grade 1 and II) are at lower risk for recurrence than patients with Ta Grade III and T1 
tumors, and these lower-risk patients may need less intensive follow-up .  
The urine markers used in patient surveillance have on occasion been criticized for their low 
sensitivity in detecting disease, but in most studies they have significantly improved the 
detection of bladder cancer when used in conjunction with cytology and cystoscopy. Voided 
urine cytology has its own limitations in detecting carcinoma in situ (cis) and low-grade 
bladder tumors. It appears that urine markers can assist in the early detection of recurrence 
in patients with carcinoma in situ and low-grade superficial tumors.  
17. Conclusion 
The availability of many new markers for bladder cancer raises the possibility of improving 
the rate of cancer detection by combined use of selected markers, measured either 
simultaneously or sequentially. The objective of such panel testing should be to improve 
both the sensitivity and the specificity for bladder cancer detection. Prospective clinical trials 
are undoubtedly necessary to prove their clinical value, before such panels could be 
implemented in routine patient care. It should also be noted that the stability of these 
tumour marker antigens must be better defined in order to minimize false negative test 
results. Improved definition of the disease conditions which can produce false positive test 
results for urine based markers could lead to more effective use of these tests for cancer 
detection. It seems a long way before these markers replace invasive testing, but at least it 
can help define those group of patients who need cystoscopic surveillance while sparing the 
majority of patients who do not need the procedure. This will bring enormous cost saving to 
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individuals did not react with the antibody, and importantly, BLCA-4 appears to be present 
throughout the bladder (i.e., in both normal and tumour areas) in bladder cancer patients. 
This "field effect" permitted development of a urine immunoassay for BLCA-4 that detects 
the presence of tumour anywhere in the bladder, regardless of stage or grade. The BLCA-4-
urine immunoassay has a specificity of 100% and a sensitivity of 95%. According to Dr. 
Getzenberg, the assay is currently being tested by the Pittsburgh researchers in a clinical 
trial of individuals at high risk for bladder cancer. 6 
Using a prospectively determined cut-off, 67 of the 75 samples from patients with bladder 
cancer were positive for BLCA-4, resulting in an assay sensitivity of 89%. Also, 62 of the 65 
samples from individuals without bladder cancer were negative for BLCA-4, resulting in an 
assay specificity of 95%. The authors concluded that the high sensitivity and specificity of 
the sandwich BLCA-4 immunoassay may allow for earlier detection and treatment of 
disease, thus greatly improving patient care. 7 
BLCA-4, appears to be associated with a "field effect" of the disease, and in clinical trials is 
able to separate individuals with bladder cancer from those without the disease with high 
sensitivity and specificity. BLCA-4 is a bladder cancer marker that is highly specific and 
occurs early in the development of the disease. It appears to be a transcription factor that 
may play a role in the regulation of the gene expression in bladder cancer. BLCA-4 is a 
marker with significant clinical utility that may have an active role in the disease. 
13. Other proposed markers  
DD 23 monoclonal antibody recognizes a 185 kDa antigen expressed by bladder cancer cells 
and has been proposed as an adjunct to cytology for the detection of bladder cancer. Urine 
fibronectin and chorionic gonadotropin (protein and mRNA transcript) may also be markers 
for transitional cell carcinoma of the bladder .  
14. Role of urine markers in early detection of bladder cancer  
Almost all cases of bladder cancer are found during the work-up of patients who present 
with haematuria (71), but most cases of haematuria are not caused by bladder cancer. 
Urologic disease is detected in 10% of subjects who present with haematuria, and bladder 
cancer is detected in fewer than half of these subjects (72,73,74). The work-up of patients 
with haematuria is costly and often requires cytology, cystoscopy, intravenous urography or 
computed tomography (75). Thus, tumor markers could be useful in identifying the patients 
in this high-risk group, which requires more intensive clinical work-up for bladder cancer. 
Zippe et al reported on the value of the urine NMP22 test in the evaluation of 330 patients 
with haematuria (76). The NMP22 test when used with a cut-off value of 10.0 u/ml detected 
all 18 cases of bladder cancer with 45 false positive cases (sensitivity, 100%; specificity, 85%). 
In this study, 267 unnecessary cystoscopy could have been avoided if cystoscopy had been 
directed by the NMP22 test. In a clinical trial submitted to the Food and Drug 
Administration (as Pre-Market Approval Data), the NMP22 test was elevated in 69.6% of 56 
bladder cancer that were detected in the high risk group. In this report, the specificity was 
67.7% (77). The NMP22 test has been cleared by the FDA for use as an aid to diagnose 
bladder cancer in individuals with risk factors or who have symptoms of bladder cancer. It 
is highly likely that other urine markers (e.g. BTA, UroVysion and Immunocyt) may also 
have value for cancer detection in subjects who present with haematuria. The high false 
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positive rate is the major criticism of the urine-based tests when they are used to assess 
patients who present with haematuria or are used in patient surveillance. The low false 
negative rate of these tests is their strength, leading to a high negative predictive value that 
effectively rules out disease in a significant proportion of patients, thereby eliminating 
unnecessary clinical work-ups for bladder cancer.  
15. Role of tissue markers for prognosis  
Considerable research effort continues to be directed towards the identification of markers 
that predict the aggressive potential of superficial bladder tumors. Such information could 
lead to more effective surveillance protocols and permit more aggressive treatment of those 
patients with tumors most likely to progress to invasive or metastatic disease. Stein et al 
have performed an exhaustive review of a variety of biological markers reported to have 
prognostic value. More recently, p53 and other cell cycle control genes, chorionic 
gonadotropin beta gene transcripts, various cell matrix and adhesion proteins and 
differentially expressed NACB. 
16. Role of urine markers for patient surveillance  
Many reports have established the value of urine tumor marker tests in the early detection 
of recurrent bladder tumors, but as yet these urine tests cannot replace routine cystoscopy 
and cytology in the management of bladder cancer patients. Instead, they may be used as 
complementary adjuncts that direct more effective utilization of clinical procedures, thus 
reducing the cost of patient surveillance. Patients with superficial lesions of low grade (Ta, 
Grade 1 and II) are at lower risk for recurrence than patients with Ta Grade III and T1 
tumors, and these lower-risk patients may need less intensive follow-up .  
The urine markers used in patient surveillance have on occasion been criticized for their low 
sensitivity in detecting disease, but in most studies they have significantly improved the 
detection of bladder cancer when used in conjunction with cytology and cystoscopy. Voided 
urine cytology has its own limitations in detecting carcinoma in situ (cis) and low-grade 
bladder tumors. It appears that urine markers can assist in the early detection of recurrence 
in patients with carcinoma in situ and low-grade superficial tumors.  
17. Conclusion 
The availability of many new markers for bladder cancer raises the possibility of improving 
the rate of cancer detection by combined use of selected markers, measured either 
simultaneously or sequentially. The objective of such panel testing should be to improve 
both the sensitivity and the specificity for bladder cancer detection. Prospective clinical trials 
are undoubtedly necessary to prove their clinical value, before such panels could be 
implemented in routine patient care. It should also be noted that the stability of these 
tumour marker antigens must be better defined in order to minimize false negative test 
results. Improved definition of the disease conditions which can produce false positive test 
results for urine based markers could lead to more effective use of these tests for cancer 
detection. It seems a long way before these markers replace invasive testing, but at least it 
can help define those group of patients who need cystoscopic surveillance while sparing the 
majority of patients who do not need the procedure. This will bring enormous cost saving to 
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the increasing health care cost we face in the presence of dwinding health care budget 
allocations from other competing needs. 
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1. Introduction 
1.1 Epigenetics and cancer: An overview 
Genetic and epigenetic alterations are hallmarks of human cancer. In the last few decades, it 
has been well established that epigenetic changes are important events in human cancer 
development and progression in addition to genetic alterations (such as chromosomal 
rearrangements, aneuploidies and point mutations). Epigenetics refers to the study of 
changes in gene expression that are determined by mechanisms other than changes in the 
DNA sequence. Epigenetic phenomena include X-chromosome inactivation, genomic 
imprinting, cellular differentiation and the maintenance of cell identity. These events are 
mediated by several molecular mechanisms, including DNA methylation, post-translational 
histone modifications and various RNA-mediated processes. Many studies in the field of 
epigenetics have focused on the effects of histone modifications and DNA methylation in 
the transcription process because these mechanisms are often linked and interdependent 
(Ballestar, 2011). A variety of methods are currently being applied to detect epigenetic 
changes, and the past two decades have shown an exponential increase in novel approaches 
aimed at elucidating the molecular basis of epigenetic inheritance. 
DNA methylation is the most well studied epigenetic modification in human diseases 
(Fernandez et al., 2011). It involves the addition of a methyl group to the 5 carbon of a 
cytosine that is immediately followed by one guanine; i.e., DNA methylation typically 
occurs in a CpG dinucleotide context. CpG dinucleotides are generally underrepresented in 
the genome due to the increased mutation frequencies of the methylcytosines that are 
spontaneously converted to thymines. However, within the regions that are known as CpG 
islands, these dinucleotides are found at higher frequencies than is expected. It is believed 
that the human genome is comprised of approximately 38,000 CpG islands, and a large 
proportion of them (~37%) are located in the 5’ gene regulatory regions (promoters). The 
aberrant content of DNA methylation (global genome hypomethylation) and patterns of 
cytosine methylation, especially hypermethylation in promoter-associated CpG islands, are 
known to be associated with cancer. Gene-specific promoter hypermethylation causes the 
breakdown of normal cell physiology by silencing tumor suppressor genes, while DNA 
hypomethylation can reactivate oncogenes and repetitive sequences of the genome and lead 
to chromosomal instability (Sawan et al., 2008).  
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Histones (H2A, H2B, H3 and H4) are the main protein components of chromatin that 
package and order DNA into structural units that are called nucleosomes. The histone code 
consists of post-translational covalent changes of specific amino acid residues that are 
located at histone tails (NH2 terminal regions). These modifications include methylation, 
acetylation, phosphorylation, poly-ADP ribosylation, ubiquitinylation, sumoylation, 
carbonylation and glycosylation (Kouzarides, 2007). The histone code and DNA methylation 
interact to promote the regulation of specific gene activity and mediate chromatin 
accessibility and compaction by changing the local chromatin structure, as has been 
reported to occur during the silencing of tumor suppressor genes. In cancer cells, the 
hypermethylation of CpG islands in the promoter regions of tumor suppressor genes was 
associated with a specific profile of histone markers such as the loss of acetylation of 
histones H3 and H4, loss of H3K4 trimethylation, and gains of methylation  in lysine 
residues of histone H3 (such as H3K9 and H3K27) (Portela & Esteller, 2010). 
The most recently discovered epigenetic modification is mediated by a small class of RNAs 
that are also known as microRNAs (miRNAs). These molecules promote the silencing of 
target genes by associating with the 3’ untranslated region of messenger RNA (mRNA), 
which culminates in endonucleolytic cleavage, mRNA degradation by deadenylation or the 
inhibition of mRNA translation (Valeri et al., 2009). It is estimated that at least 30% of all 
human genes are regulated by miRNAs. Similar to the protein-coding genes, the down-
regulation of miRNAs in cancer cells has been correlated with the presence of DNA 
hypermethylation in the regulatory regions. In addition, these molecules (named epi-
miRNAs) were recently found to regulate epigenetic enzymes, such as DNA 
methyltransferases and histone deacetylases. Thus, it is possible that epi-miRNAs could 
indirectly affect the expression of cancer-related genes (Fabbri & Callin, 2010).  
In summary, epigenetics is one of the most promising fields in biomedical research. Novel 
strategies for risk assessment, early detection and new therapeutic targets may be revealed 
by epigenetic studies (Boumber & Issa, 2011). This chapter will summarize the common 
epigenetic aberrations that are detected in bladder cancer, their translational implications 
and possible epigenetic therapies. 
2. Translational implications of epigenetic changes in bladder cancer 
Bladder cancer is the fifth most commonly diagnosed non-cutaneous solid tumor and the 
second most common in the urological tract. Although many tumors that originate in this 
organ are superficial, with low risks of metastasis, bladder cancer has a high recurrence risk; 
the 4-year recurrence rate for patients with superficial tumors is 50%. Currently, the 
diagnosis of bladder cancer is based on histological, pathological and morphological 
parameters and provides only a generalized outcome for patients (Tanaka & Sonpadvde, 
2011). The gold standard for detecting bladder cancer is cystoscopic examination, but this 
analysis is costly, causes discomfort to the patient (invasive method) and has variable 
sensitivity, providing only a generalized outcome to patients. In addition, the sensitivity of 
the cytological analysis is questionable, especially in cases of low-grade carcinoma (Kim & 
Kim, 2009). With the advent of targeted therapy, molecular biomarkers are becoming 
increasingly important in both clinical research and practice. These markers are being 
identified with the purpose of reducing the need for invasive follow-up examinations and 
also to anticipate the prognosis of individual patients. Furthermore, the early diagnosis of 
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bladder cancer by non-invasive methods could allow for more effective treatment and 
optimize the success of surgical therapy.  
The DNA methylation of CpG islands that are mapped to promoter regions of specific 
genes, such as tumor suppressor genes, has been extensively reported in many cancer types. 
In bladder cancer, this epigenetic event has been related to tumor development, staging, 
recurrence, progression and clinical outcome. More specifically, DNA methylation has been 
strongly associated with higher stages, high rates of tumor progression and high mortality 
in patients with this cancer. As was demonstrated by Wolff et al. (2010), the analysis of 
epigenetic backgrounds can allow for the differentiation between noninvasive and invasive 
tumors by the identification of the different epigenetic characteristics that are present, such 
as the extensive DNA hypomethylation that is observed in noninvasive tumors compared to 
the high rates of DNA hypermethylation in invasive urothelial cancer. This may explain 
why ~15% of tumors will progress to invasive disease and have poor prognosis, while 
others will remain with low rates of generate metastasis.   
Currently, some histone modifications and the aberrant expression of miRNAs have been 
linked to tumorigenesis and have also been identified to be reliable and strong biomarkers 
for bladder cancer. MicroRNAs are specifically interesting because they are very stable in 
body fluids due to their small sizes and thus are resistant to degradation by nucleases, 
which are present in large quantities in urine (Tilki et al., 2011).     
2.1 Candidate epigenetic biomarkers in the diagnosis of bladder cancer 
Because DNA methylation is chemically and biologically stable and can be detected early in 
the carcinogenesis process, this epigenetic change has been considered to be a valuable 
potential diagnostic marker that is feasible to assess in clinical routine analysis through the 
investigation of exfoliated cells in the urine or blood of patients with bladder cancer and 
appears to be more sensitive than conventional cytology. A number of genes have been 
identified as being hypermethylated in the urine or tissue samples of cancer patients 
compared to healthy tissues, indicating that the down-regulation of these genes has some 
clinical relevance to the origin and development of the disease (Table 1).  
One example is the RUNX3 (runt-related transcription factor 3) gene, which has been 
mapped to 1p36 and is thought to be a tumor suppressor gene that is frequently deleted or 
transcriptionally silenced in patients with cancer. In a study that analyzed 124 tumor tissue 
samples, 73% were found to have a methylation-positive pattern compared to the 
methylation-free pattern that was exhibited by the normal bladder mucosa. Moreover, the 
methylation of this gene was found to confer a significant increase (100-fold) in the risk of 
tumor development (Kim et al., 2005), suggesting that it may have potential as a potent 
bladder cancer detection marker. 
Our group also contributed to the literature surrounding epigenetic markers in bladder 
cancer. We discovered high rates of DNA methylation in exfoliated urinary cells, in which 
the RARB gene had a sensitivity of 95% and specificity of 71% for detecting the presence of 
cancer (Negraes et al., 2008). These results are concordant with the increased methylation 
frequencies that have been previously described (Chan et al., 2002; Hoque et al., 2006) and 
suggest that this gene could be considered as a diagnostic biomarker. It encodes a member 
of the thyroid-steroid hormone receptor superfamily of nuclear transcriptional regulators 
that binds retinoic acid (the biologically active form of vitamin A) and also mediates cellular 
signaling during embryonic morphogenesis and cell growth and differentiation. It is 
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thought that this protein limits the growth of many cell types by regulating gene expression 
(Soprano et al., 2004).  
In the study conducted by Renard et al. (2010), it was demonstrated that 2 genes (TWIST1 
and NID2) were frequently methylated in urine samples collected from bladder cancer 
patients, including those with early-stage and low-grade diseases, with a specificity of 93% 
and sensitivity of 90%, which was an improvement from the cytological method of detection 
(48%). 
Besides the identification of DNA hypermethylation at a single locus, some authors have 
demonstrated that several genes may be analyzed together to generate a profile of 
hypermethylated genes.  These profiles may be able to allow for a more sensitive and 
reliable marker for the detection of bladder cancer (Table 1). Based on this, Chan et al. (2002) 
discovered that the sensitivity of the methylation analysis (90.9%) of four genes (DAPK1, 
RARB, CDH1 and CDKN2A) was higher than that of urine cytology (45.5%) for cancer 
detection and was more striking in low-grade cases (100% versus 11.1%).  
Similarly, Urakami et al. (2006) found that the identification of the increased methylation of 
six Wnt-antagonist genes (SFRP1, SFRP2, SFRP4, SFRP5, WIF1 and DKK3) could predict 
bladder tumors with a sensitivity of 77.2% and specificity of 66.7%. These genes are known 
to inhibit Wnt signaling by binding to specific molecules that act in this pathway. The DNA 
methylation and consequent functional loss of these genes may result in the activation of the 
Wnt signaling pathway and promote the dysregulation of cell proliferation and 
differentiation. The authors also discovered that two of these genes (SFRP2 and DKK3) were 
able to act as independent predictors of bladder tumors (P < 0.05 and P < 0.01, respectively). 
Friedrich et al. (2004) also suggested that the presence of a combination of DNA methylation 
at the 5’ regions of three apoptosis-associated genes (DAPK1, BCL2 and TERT) in urine 
sediment could be diagnostic of bladder cancer with a sensitivity of 78%, suggesting that 
this combined methylation analysis was a highly sensitive method for the noninvasive 
detection of bladder cancer.      
In addition, Hoque et al. (2006) proposed a two-stage predictor for the classification of 
bladder cancer that was based on an investigation of a panel composed of nine genes 
(APC, ARF, CDH1, GSTP1, MGMT, CDKN2A, RARB, RASSF1A and TIMP3) in urine 
sediment. In the first stage, patients who presented with DNA methylation in the 
promoters of at least one of four specific genes (CDKN2A, ARF, MGMT and GSTP1) were 
classified as having cancer (100% specificity). Moreover, patients with no methylation in 
these genes were subjected to a second stage of investigation with a logistic prediction of 
risk scores based on the promoter methylation of the five remaining genes (sensitivity of 
82% and specificity of 96%). 
Three of these genes had previously been investigated by Dulaimi et al. (2004), who 
demonstrated the feasibility of obtaining reproducible highly sensitive (87%) and 100% 
positive identifications of hypermethylation in a panel composed of the APC, RASSF1A and 
CDKN2A tumor suppressor genes in urine in cases of early-stage disease. In addition to 
RASSF1A (a tumor suppressor gene that is frequently inactivated in several cancer types), 
the other two genes chosen were involved in the p53/p14ARF tumor suppressor gene pathway 
(CDKN2A gene) (Sherr & McCormick, 2002) and the Wnt signaling pathway (APC gene) 
(Taipale & Beachy, 2001). The evaluation of this panel yielded superior results compared to 
those of cytology in the detection of bladder cancer. Yates et al. (2006) also investigated the 
APC, RASSF1A and CDH1 genes in urine. This panel generated a lower sensitivity (69%) 
and specificity (60%) than the former; however, the diagnostic accuracy was 86%. 
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Many of the genes that have been chosen to be investigated in combined analyses to 
generate panels have frequently been suggested to be individually methylated in bladder 
cancer, such as RASSF1A. The DNA methylation of this gene had previously been reported 
to be able to detect bladder cancer in urine samples with 100% sensitivity by Chan et al. 
(2003). The authors advocated that the detection of gene methylation using multiple markers 
could increase both the sensitivity and specificity of cancer detection, and the addition of 
RASSF1A to this panel could improve the diagnostic accuracy even further. 
Yu et al. (2007) discovered that the methylation of a panel composed by 11 genes (SALL3, 
CFTR, ABCC6, HPSE, RASSF1A, MT1A, ALX4, CDH13, RPRM, APBA1 and BRCA1) in urine 
sediments showed positive correlations with  diagnosis in 121 out of 132 bladder cancer 
cases with a sensitivity of 91.7% and accuracy of 87%. Remarkably, this approach was able 
to detect more than 75% of tumors at stage 0a and 88% of stage I tumors, indicating the 
value of this panel in the early diagnosis of bladder cancer.   
Likewise, a three-gene (GDF15, TMEFF2 and VIM) panel was able to detect bladder cancer 
in urine samples with a sensitivity of 94% and specificity of 100% (Costa et al., 2010), 
exceeding the detection rates that are normally obtained using conventional cytopathology 
and cytology. This panel of genes was selected based on stringent criteria after a screening 
test that employed a genome-wide approach and was distinctive because it was able to 
detect bladder cancer by noninvasive methods even when patients with kidney or prostate 
cancer were used as controls. These three genes are biologically relevant to carcinogenesis 
because TMEFF2 (mapped at 2q32.3) and VIM (mapped at 10p13) were previously found to 
be silenced by promoter methylation in esophageal, colorectal (Shirahata et al., 2009; 
Tsunoda et al., 2009) and bladder cancer (Hellwinkel et al., 2008). GDF15 (mapped to 
19p13.11) is a member of the transforming growth factor (TGF)-β superfamily and may act 
as a tumor suppressor gene in early-stage cancers (Eling et al., 2006). 
Another biomarker of interest for the detection of urothelial cancer, according to Ellinger et 
al. (2008), is cell-free serum DNA methylation. The authors detected that the diagnostic 
accuracy of this marker increased when hypermethylation at multiple gene sites was 
assessed simultaneously, particularly at the GSTP1, RARRES1 or APC genes (80% sensitivity 
and 93% specificity).  
The list of aberrant epigenetically regulated genes continues to grow. Is important to note 
that the same genes have been investigated by different groups, and the methylation rates 
found may vary from one report to another. Results may reflect the distinct methodologies 
employed, the numbers and types of samples (urine, surgical tissue and/or serum) as well 
as disease classifications. Nevertheless, the reports above highlight the high potential of 
DNA methylation markers for the effective early detection of bladder cancer using 
noninvasive urine tests. 
The measurement of global cytosine methylation rates (%5-mC) concomitantly with the 
DNA methylation of specific genes could be a useful biomarker to assess a patient’s 
susceptibility to bladder cancer. In a large case-control study conducted by Moore et al. 
(2008), the DNA hypomethylation of leukocytes was strongly associated with an increased 
bladder cancer risk, and this association was independent of smoking and other assessed 
risk factors.  
Recently, evidence has emerged that circulating miRNAs are present in human body fluids 
(as urine) in concentrations that are subject to variation during cancer pathogenesis or 
development (Iguchi et al., 2010), as was reported by Dudziec et al. (2011). The authors 
discovered that the combined low expression levels of miR-152, -328 and -1224-3p allowed 
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thought that this protein limits the growth of many cell types by regulating gene expression 
(Soprano et al., 2004).  
In the study conducted by Renard et al. (2010), it was demonstrated that 2 genes (TWIST1 
and NID2) were frequently methylated in urine samples collected from bladder cancer 
patients, including those with early-stage and low-grade diseases, with a specificity of 93% 
and sensitivity of 90%, which was an improvement from the cytological method of detection 
(48%). 
Besides the identification of DNA hypermethylation at a single locus, some authors have 
demonstrated that several genes may be analyzed together to generate a profile of 
hypermethylated genes.  These profiles may be able to allow for a more sensitive and 
reliable marker for the detection of bladder cancer (Table 1). Based on this, Chan et al. (2002) 
discovered that the sensitivity of the methylation analysis (90.9%) of four genes (DAPK1, 
RARB, CDH1 and CDKN2A) was higher than that of urine cytology (45.5%) for cancer 
detection and was more striking in low-grade cases (100% versus 11.1%).  
Similarly, Urakami et al. (2006) found that the identification of the increased methylation of 
six Wnt-antagonist genes (SFRP1, SFRP2, SFRP4, SFRP5, WIF1 and DKK3) could predict 
bladder tumors with a sensitivity of 77.2% and specificity of 66.7%. These genes are known 
to inhibit Wnt signaling by binding to specific molecules that act in this pathway. The DNA 
methylation and consequent functional loss of these genes may result in the activation of the 
Wnt signaling pathway and promote the dysregulation of cell proliferation and 
differentiation. The authors also discovered that two of these genes (SFRP2 and DKK3) were 
able to act as independent predictors of bladder tumors (P < 0.05 and P < 0.01, respectively). 
Friedrich et al. (2004) also suggested that the presence of a combination of DNA methylation 
at the 5’ regions of three apoptosis-associated genes (DAPK1, BCL2 and TERT) in urine 
sediment could be diagnostic of bladder cancer with a sensitivity of 78%, suggesting that 
this combined methylation analysis was a highly sensitive method for the noninvasive 
detection of bladder cancer.      
In addition, Hoque et al. (2006) proposed a two-stage predictor for the classification of 
bladder cancer that was based on an investigation of a panel composed of nine genes 
(APC, ARF, CDH1, GSTP1, MGMT, CDKN2A, RARB, RASSF1A and TIMP3) in urine 
sediment. In the first stage, patients who presented with DNA methylation in the 
promoters of at least one of four specific genes (CDKN2A, ARF, MGMT and GSTP1) were 
classified as having cancer (100% specificity). Moreover, patients with no methylation in 
these genes were subjected to a second stage of investigation with a logistic prediction of 
risk scores based on the promoter methylation of the five remaining genes (sensitivity of 
82% and specificity of 96%). 
Three of these genes had previously been investigated by Dulaimi et al. (2004), who 
demonstrated the feasibility of obtaining reproducible highly sensitive (87%) and 100% 
positive identifications of hypermethylation in a panel composed of the APC, RASSF1A and 
CDKN2A tumor suppressor genes in urine in cases of early-stage disease. In addition to 
RASSF1A (a tumor suppressor gene that is frequently inactivated in several cancer types), 
the other two genes chosen were involved in the p53/p14ARF tumor suppressor gene pathway 
(CDKN2A gene) (Sherr & McCormick, 2002) and the Wnt signaling pathway (APC gene) 
(Taipale & Beachy, 2001). The evaluation of this panel yielded superior results compared to 
those of cytology in the detection of bladder cancer. Yates et al. (2006) also investigated the 
APC, RASSF1A and CDH1 genes in urine. This panel generated a lower sensitivity (69%) 
and specificity (60%) than the former; however, the diagnostic accuracy was 86%. 
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Many of the genes that have been chosen to be investigated in combined analyses to 
generate panels have frequently been suggested to be individually methylated in bladder 
cancer, such as RASSF1A. The DNA methylation of this gene had previously been reported 
to be able to detect bladder cancer in urine samples with 100% sensitivity by Chan et al. 
(2003). The authors advocated that the detection of gene methylation using multiple markers 
could increase both the sensitivity and specificity of cancer detection, and the addition of 
RASSF1A to this panel could improve the diagnostic accuracy even further. 
Yu et al. (2007) discovered that the methylation of a panel composed by 11 genes (SALL3, 
CFTR, ABCC6, HPSE, RASSF1A, MT1A, ALX4, CDH13, RPRM, APBA1 and BRCA1) in urine 
sediments showed positive correlations with  diagnosis in 121 out of 132 bladder cancer 
cases with a sensitivity of 91.7% and accuracy of 87%. Remarkably, this approach was able 
to detect more than 75% of tumors at stage 0a and 88% of stage I tumors, indicating the 
value of this panel in the early diagnosis of bladder cancer.   
Likewise, a three-gene (GDF15, TMEFF2 and VIM) panel was able to detect bladder cancer 
in urine samples with a sensitivity of 94% and specificity of 100% (Costa et al., 2010), 
exceeding the detection rates that are normally obtained using conventional cytopathology 
and cytology. This panel of genes was selected based on stringent criteria after a screening 
test that employed a genome-wide approach and was distinctive because it was able to 
detect bladder cancer by noninvasive methods even when patients with kidney or prostate 
cancer were used as controls. These three genes are biologically relevant to carcinogenesis 
because TMEFF2 (mapped at 2q32.3) and VIM (mapped at 10p13) were previously found to 
be silenced by promoter methylation in esophageal, colorectal (Shirahata et al., 2009; 
Tsunoda et al., 2009) and bladder cancer (Hellwinkel et al., 2008). GDF15 (mapped to 
19p13.11) is a member of the transforming growth factor (TGF)-β superfamily and may act 
as a tumor suppressor gene in early-stage cancers (Eling et al., 2006). 
Another biomarker of interest for the detection of urothelial cancer, according to Ellinger et 
al. (2008), is cell-free serum DNA methylation. The authors detected that the diagnostic 
accuracy of this marker increased when hypermethylation at multiple gene sites was 
assessed simultaneously, particularly at the GSTP1, RARRES1 or APC genes (80% sensitivity 
and 93% specificity).  
The list of aberrant epigenetically regulated genes continues to grow. Is important to note 
that the same genes have been investigated by different groups, and the methylation rates 
found may vary from one report to another. Results may reflect the distinct methodologies 
employed, the numbers and types of samples (urine, surgical tissue and/or serum) as well 
as disease classifications. Nevertheless, the reports above highlight the high potential of 
DNA methylation markers for the effective early detection of bladder cancer using 
noninvasive urine tests. 
The measurement of global cytosine methylation rates (%5-mC) concomitantly with the 
DNA methylation of specific genes could be a useful biomarker to assess a patient’s 
susceptibility to bladder cancer. In a large case-control study conducted by Moore et al. 
(2008), the DNA hypomethylation of leukocytes was strongly associated with an increased 
bladder cancer risk, and this association was independent of smoking and other assessed 
risk factors.  
Recently, evidence has emerged that circulating miRNAs are present in human body fluids 
(as urine) in concentrations that are subject to variation during cancer pathogenesis or 
development (Iguchi et al., 2010), as was reported by Dudziec et al. (2011). The authors 
discovered that the combined low expression levels of miR-152, -328 and -1224-3p allowed 
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for accurate diagnosis with 81% sensitivity and 75% specificity. These miRNAs were found 
to be epigenetically regulated by DNA methylation at CpG islands and the shores (regions 
of less dense CpG dinucleotides) that surrounded them following a genome-wide screening. 
In addition, Hanke et al. (2010) found that the ratio of miR-126:miR-152 enabled the 
detection of bladder cancer from urine samples with a specificity of 82% and a sensitivity of 
72%; thus, they may be used as a tumor markers for this disease.  
In addition, Yamada et al. (2011) identified one microRNA (miR-96) that may be a useful 
diagnostic marker with high sensitivity and specificity (71.0% and 89.2%, respectively) when 
assessed in combination with urinary cytology (80% diagnostic accuracy). This molecule, 
which has been mapped to 7q32, is a putative onco-miRNA that has been demonstrated to 
be able to down-regulate tumor suppressor genes. It was found to be up-regulated in a 
previous study conducted by the same group (Ichimi et al., 2009), in which the microRNA 
expression signatures that are specific to bladder cancer were determined, and a subset of 7 
microRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) 
that are significantly down-regulated in bladder cancer were validated. These microRNAs 
were sufficiently sensitive (>70%) and specific (>75%) to distinguish bladder cancer from 
normal epithelium.  
As mentioned above, not only the DNA methylation but also the expression profile of the 
miRNA molecules have been closely associated with the diagnosis of bladder cancer. 
 




RASSF1A Urine Sensitivity: 100% Chan et al., 2003 
RUNX3 Tissue OR 107.55 (95% CI, 6.33-1827.39) 









Negraes et al., 
2008 
TWIST1 and NID2 Urine Sensitivity/specificity: 90%/93% 
Renard et a., 
2010 
DAPK1, RARB, CDH1
and CDKN2A Urine 
Sensitivity/specificity: 
90.9%/76.4% 
Chan et al.,  
2002 




Dulaimi et al., 
2004 
DAPK1, BCL2 and 
TERT Urine Sensitivity: 78% 
Friedrich et al., 
2004 
APC, ARF, CDH1, 
GSTP1, MGMT, 
CDKN2A, RARB, 
RASSF1A and TIMP3 
Urine 
1st stage 
  sensitivity: 100% 
2nd stage 
  Sensitivity/specificity: 
82%/96% 
Hoque et al., 
2006 
SFRP1, SFRP2, SFRP4, 
SFRP5, WIF1, DKK3  Tissue 
Sensitivity/specificity: 
77.2%/66.7% 
Urakami et al., 
2006 
APC, RASSF1A and Urine Sensitivity/specificity: Yates et al., 2006 
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Epigenetic biomarker Samples Sensitivity/ specificity/ OR 
Supporting 
literature 
CDH1 69%/60%  
SALL3, CFTR, ABCC6, 
HPSE, RASSF1A, 
MT1A, ALX4, CDH13, 
RPRM, APBA1 and 
BRCA1 
Urine Sensitivity/especificity: 91.7%/87% 
Yu et al.,  
2007 
GSTP1, RARRES1, APC Cell-free serum DNA 
Sensitivity/specificity: 
80%/93% 
Ellinger et al., 
2008 




Costa et al.,  
2010 
%5-mC of leukocytes Blood cells OR 1.38 (95% CI:1.05–1.08, p=0.02) 





miR-195, miR-125b and 
miR-199a* 
Tissue Sensitivity/specificity: >70%/>75% 
Ichimi et al.,  
2009 




Hanke et al., 
2010 
miR-152, -328 and -1224 Urine Sensitivity/specificity: 81%/75% 
Dudziec et al., 
2011 
miR-96 Urine Sensitivity/specificity: 71%/89.2% 
Yamada et al., 
2011 
Table 1. Epigenetic diagnostic markers in bladder cancer. The genes were described as 
official symbols according recommendations of Guidelines for Human Gene Nomenclature. 
More information about specific genes can be achieved at 
http://www.genenames.org/guidelines.html. 
2.2 Candidate epigenetic biomarkers in the prognosis of bladder cancer 
The knowledge of prognostic factors is of great importance for the determination of 
therapeutic strategies and to enable the application of different modalities of therapy in 
cancer treatment. In cases of bladder cancer, patients are monitored for recurrence or 
progression by periodic cystoscopy and urine cytological analysis, the frequencies of which 
vary depending on the risk factors that are associated with the disease. Thus, the discovery 
of more sensitive and non-invasive tumor markers that can help to predict tumor 
recurrence, progression and metastasis are required, and epigenetic alterations may be 
promising new potential prognostic markers for bladder cancer. 
Bladder tumors may be superficial, with low risks of metastasis, but may have high 
recurrence risks (McConkey et al., 2010). Several genes that are related to the progression 
and prognosis of bladder cancer have been identified in bladder washes, urine and tumor 
tissues using various molecular and epigenetic approaches (Mitra et al., 2006) and are 
considered to be potential markers (Table 2).  
Maruyama et al. (2001) determined the methylation statuses of 10 genes in 98 fresh bladder 
tumor tissues and found that multiple genes are methylated during the process of bladder 
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for accurate diagnosis with 81% sensitivity and 75% specificity. These miRNAs were found 
to be epigenetically regulated by DNA methylation at CpG islands and the shores (regions 
of less dense CpG dinucleotides) that surrounded them following a genome-wide screening. 
In addition, Hanke et al. (2010) found that the ratio of miR-126:miR-152 enabled the 
detection of bladder cancer from urine samples with a specificity of 82% and a sensitivity of 
72%; thus, they may be used as a tumor markers for this disease.  
In addition, Yamada et al. (2011) identified one microRNA (miR-96) that may be a useful 
diagnostic marker with high sensitivity and specificity (71.0% and 89.2%, respectively) when 
assessed in combination with urinary cytology (80% diagnostic accuracy). This molecule, 
which has been mapped to 7q32, is a putative onco-miRNA that has been demonstrated to 
be able to down-regulate tumor suppressor genes. It was found to be up-regulated in a 
previous study conducted by the same group (Ichimi et al., 2009), in which the microRNA 
expression signatures that are specific to bladder cancer were determined, and a subset of 7 
microRNAs (miR-145, miR-30a-3p, miR-133a, miR-133b, miR-195, miR-125b and miR-199a*) 
that are significantly down-regulated in bladder cancer were validated. These microRNAs 
were sufficiently sensitive (>70%) and specific (>75%) to distinguish bladder cancer from 
normal epithelium.  
As mentioned above, not only the DNA methylation but also the expression profile of the 
miRNA molecules have been closely associated with the diagnosis of bladder cancer. 
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90.9%/76.4% 
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GSTP1, MGMT, 
CDKN2A, RARB, 
RASSF1A and TIMP3 
Urine 
1st stage 
  sensitivity: 100% 
2nd stage 
  Sensitivity/specificity: 
82%/96% 
Hoque et al., 
2006 
SFRP1, SFRP2, SFRP4, 
SFRP5, WIF1, DKK3  Tissue 
Sensitivity/specificity: 
77.2%/66.7% 
Urakami et al., 
2006 
APC, RASSF1A and Urine Sensitivity/specificity: Yates et al., 2006 
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Epigenetic biomarker Samples Sensitivity/ specificity/ OR 
Supporting 
literature 
CDH1 69%/60%  
SALL3, CFTR, ABCC6, 
HPSE, RASSF1A, 
MT1A, ALX4, CDH13, 
RPRM, APBA1 and 
BRCA1 
Urine Sensitivity/especificity: 91.7%/87% 
Yu et al.,  
2007 
GSTP1, RARRES1, APC Cell-free serum DNA 
Sensitivity/specificity: 
80%/93% 
Ellinger et al., 
2008 




Costa et al.,  
2010 
%5-mC of leukocytes Blood cells OR 1.38 (95% CI:1.05–1.08, p=0.02) 





miR-195, miR-125b and 
miR-199a* 
Tissue Sensitivity/specificity: >70%/>75% 
Ichimi et al.,  
2009 




Hanke et al., 
2010 
miR-152, -328 and -1224 Urine Sensitivity/specificity: 81%/75% 
Dudziec et al., 
2011 
miR-96 Urine Sensitivity/specificity: 71%/89.2% 
Yamada et al., 
2011 
Table 1. Epigenetic diagnostic markers in bladder cancer. The genes were described as 
official symbols according recommendations of Guidelines for Human Gene Nomenclature. 
More information about specific genes can be achieved at 
http://www.genenames.org/guidelines.html. 
2.2 Candidate epigenetic biomarkers in the prognosis of bladder cancer 
The knowledge of prognostic factors is of great importance for the determination of 
therapeutic strategies and to enable the application of different modalities of therapy in 
cancer treatment. In cases of bladder cancer, patients are monitored for recurrence or 
progression by periodic cystoscopy and urine cytological analysis, the frequencies of which 
vary depending on the risk factors that are associated with the disease. Thus, the discovery 
of more sensitive and non-invasive tumor markers that can help to predict tumor 
recurrence, progression and metastasis are required, and epigenetic alterations may be 
promising new potential prognostic markers for bladder cancer. 
Bladder tumors may be superficial, with low risks of metastasis, but may have high 
recurrence risks (McConkey et al., 2010). Several genes that are related to the progression 
and prognosis of bladder cancer have been identified in bladder washes, urine and tumor 
tissues using various molecular and epigenetic approaches (Mitra et al., 2006) and are 
considered to be potential markers (Table 2).  
Maruyama et al. (2001) determined the methylation statuses of 10 genes in 98 fresh bladder 
tumor tissues and found that multiple genes are methylated during the process of bladder 
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cancer development. Their results also indicated that the frequent methylation of four genes 
(CDH1, CDH13, RASSF1A and APC) together with high MIs (median methylation index) 
were correlated with poor prognosis (tumors showed high grade, nonpapillary growth 
patterns, muscle invasions, advanced tumor stages and aneuploidies). In addition, the 
methylation of CDH1, FHIT and high MIs were associated with reduced patient survival 
rates. 
In a study performed by Catto et al. (2005) that employed a large cohort of urothelial 
carcinomas, CpG hypermethylation at DAPK was associated with higher progression rates 
(log-rank P = .014) in all of the transitional-cell carcinoma (TCC) samples that were 
investigated compared to unmethylated samples at this locus. 
In another study, Christoph et al. (2006) selected related genes as targets of p53 in the 
apoptotic cycle to perform a quantitative analysis of 110 tumor samples. The authors found 
that APAF1 methylation levels were correlated with tumor stages and grades. In addition, 
the methylation levels of the APAF1 and IGFBP3 genes enabled tumors with higher 
recurrence risks to be distinguished from low-risk tumors in non-muscle-invasive and 
muscle-invasive tumors. The epigenetic inactivation of pro-apoptotic genes may be 
important events that are related to the progression and increased aggressiveness of tumors 
that are hypermethylated in these loci. 
In addition, the hypermethylation of the promoter region of the TIMP3 gene detected in 
urine sediments was found to be associated with an increased risk of death (Hoque et al., 
2008). Other genes also have been found to undergo aberrant promoter methylation and 
were associated with poor prognosis in bladder cancer, including the hypermethylation of 
the RUNX3 promoter, which was correlated with the development of invasive tumors, 
tumor progression and cancer specific-survival in patients with TCC (Kim et al., 2008).  The 
methylation of this gene was also shown to be related to an increased risk of developing 
bladder cancer (Kim et al., 2005), suggesting that this gene not only suppresses the 
aggressiveness of tumors but also inhibits the tumor development. 
Beyond to the tumor size and grade parameters, response to treatment is also an important 
prognostic factor because multidrug resistance to chemotherapy is a major obstacle in the 
treatment of cancer patients. Tada et al. (2000) showed that the overexpression of the ABCB1 
gene may be a prognostic factor indicating recurrence in bladder cancer, and the 
hypomethylation of the promoter of this gene may be necessary for the development of 
increased ABCB1 mRNA levels and multidrug resistance. 
Global DNA hypomethylation is also a common phenomenon that has been reported in 
bladder cancer (Seifert et al., 2007). The loss of DNA methylation in repetitive sequences 
may account for a majority of the global hypomethylation that characterizes a large 
percentage of human cancers. Neuhausen et al. (2006) found that the hypomethylation of 
LINE-1 retrotransposons was present in 90% of the urothelial carcinoma specimens that 
were studied, and the absence of this epigenetic change was indicative of a better clinical 
prognosis. In a high-throughput DNA methylation analysis, a distinct hypomethylation 
pattern was found in non-invasive (Ta-T1) urothelial tumors compared to both normal 
urothelium and invasive tumors (Wolff et al., 2010). These researchers found a substantial 
number of probes to be hypomethylated in non-invasive tumors only, suggesting that lower 
levels of DNA methylation may be related to a less malignant phenotype. 
A particularly interesting example of epigenetic regulation is genomic imprinting, in which 
one copy of a gene is silenced in a manner determined by its parental origin. Thus, 
imprinted genes show parental-specific monoallelic expression. The loss of allele-specific 
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expression pattern is termed as loss of imprinting (LOI), an event described in several types 





Epigenetic biomarker Supporting literature 
Grade 
DNA methylation 
CDKN2A, BCL2, TERT, 
EDNRB, CDH1, RASSF1A, 
APC, CDH13 
Maruyama et al., 2001; 
Domínguez et al.,  2002; 
Friedrich et al., 2004 
Stage 
DNA methylation 
TIMP3, CDKN2A, RASSF1A, 




Maruyama et al., 2001; 
Domínguez et al.,  2002; 
Friedrich et al., 2004; Hoque et 
al., 2008; Schneider et al. 2011; 
Duarte-Pereira et al., 2011 
Recurrence DNA methylation DAPK1, H19, TIMP3 
Ariel et al., 2000; Tada et al., 
2002; Friedrich et al., 2005 
Survival 
DNA methylation 




Maruyama et al., 2001; Kim et 
al., 2008; Hoque et al., 2008; 
Schneider et al. 2011; Duarte-














Maruyama et al., 2001; 
Domínguez et al.,  2002; Veerla 
et al., 2009 
Tumor progression 
DNA methylation
RASSF1A, CDH1, TNFRSF25, 





Set of miR-21, miR-510, miR-
492, miR-20a, miR-198 and set 
of miR-455-5p, miR-143, miR-
145, miR-125b, miR-503 
Catto et al., 2005; Yates et al., 
2007; Dyrskjøt et al., 2009; 
Schneider et al. 2011 
Table 2. Epigenetic prognostic markers in bladder cancer. The genes were described as 
official symbols according recommendations of Guidelines for Human Gene Nomenclature. 
More information about specific genes can be achieved at 
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cancer development. Their results also indicated that the frequent methylation of four genes 
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imprinted genes show parental-specific monoallelic expression. The loss of allele-specific 
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expression pattern is termed as loss of imprinting (LOI), an event described in several types 
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epimarker of cancer development. The IGF2 and H19 imprinted genes have been well 
documented in the literature. Some studies showed that the H19 gene is involved in the 
development of bladder cancer (Ariel et al., 1995; Elkin et al., 1995) and is associated with 
high recurrence risks for this tumor type (Ariel et al., 2000). Furthermore, insulin-like 
growth factor-II (IGF-II) loss of imprinting (LOI) in a series of paired tumoral and normal 
adjacent bladder tissues and E-cadherin (CDH1) immunolocalization suggested a possible 
mechanism underlying E-cadherin relocalization to the cytoplasm, that is, the presence of 
aberrant levels of IGF-II due in some cases to IGF2 LOI (Gallagher et al., 2008). Furthermore, 
the finding of LOI in the tumoral adjacent normal samples holds promise of IGF2 LOI as a 
predictor of tumor development.  
Others epigenetic mechanisms in cancer patients remain less comprehensively understood. 
One of these epigenetic changes involves the histone modifications, which include changes 
in their levels and distribution at gene promoters, gene coding regions, repetitive DNA 
sequences and other genomic elements (Kurdistani, 2011). In a recent study, Schneider et al. 
(2011) found that global levels of H3K4me1, H4K20me1, H4K20me2 and H4K20me3 were 
decreased compared to normal urothelium. The distribution of these histone modifications 
were associated with the risk of metastasis in muscle-invasive compared to non-muscle-
invasive bladder cancers. The authors also showed that H4K20me1 levels were increased in 
patients with non-muscle-invasive bladder cancer with advanced pT stages and less 
differentiated bladder cancer, and H4K20me3 levels were signicantly correlated with 
mortality after radical cystectomy in patients with muscle-invasive cancer.  
Recently, several groups have questioned whether the miRNA expression proles or even 
single miRNAs could act as useful biomarkers not only for cancer diagnosis but also for 
prognosis and treatment optimization (Lu et al., 2005; Calin & Croce, 2006). Dyrskjøt et al. 
(2009) identified the aberrant expression of several miRNAs in 106 samples from patients 
with different stages of bladder cancer and associated their profiles with disease 
progression. Among the miRNAs that were differentially expressed in normal bladder 
tissue compared to that of bladder cancer, two subsets [(miR-21, miR-510, miR-492, miR-20a, 
miR-198) and (miR-455-5p, miR-143, miR-145, miR-125b, miR-503)] were up- and down-
regulated by two-fold, respectively. In another large-scale study that evaluated miRNA 
expression, high expression levels of miR-222 and miR-125b were observed in muscle-
invasive tumors, and miR-452 and miR-452* were shown to be over-expressed in node-
positive tumors (Veerla et al., 2009).  
Moreover, aberrant DNA methylation has been implicated in the deregulation of several 
miRNAs in different types of cancer (Lujambio et al., 2007). Wiklund et al. (2011) studied 
this relationship and found that the miR-200 family and miR-205 are concurrently silenced 
and that DNA hypermethylation would be associated with the silencing of these 
microRNAs in invasive bladder tumors. They also found that the loss of miR-200c 
expression was associated with disease progression of muscle-invasive cancers and with 
poor prognosis. 
3. The promise of epigenetic therapy 
The knowledge of epigenetic alterations that are associated with human cancers and their 
potential reversibility has prompted the development of drugs that target epigenetic 
enzymes. Either natural or synthetic modulators can be utilized to restore normal epigenetic 
and gene expression patterns; for example, by restoring the expression of the frequently 
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silenced RUNX3 gene, which is considered to be good target for this new therapeutic 
modality since the loss of its function in cancer cells due to genetic mutations is a rare event 
(Kim et al., 2005). The epigenetic therapy can be used alone or in combination with other 
therapeutic modalities, such as chemotherapy, immunotherapy or radiotherapy. This 
approach will eventually lead to targeted therapies that are suited for specific molecular 
defects, thereby significantly decreasing the morbidity associated with bladder cancer in 
addition to other cancers (Balmain, 2002; Kim & Kim, 2009; Mund & Lyko, 2010). 
Two principal classes of epigenetic drugs have been demonstrated to be clinically relevant: 
DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors 
(Esteller, 2005) (Table 3). Novel epigenetic compounds that are of potential interest as 
clinical therapeutic drugs include the histone acetyltransferase inhibitors, such as anacardic 
acid, curcumin and peptide CoA conjugates. In addition, histone methyltransferase 
inhibitors and HDACis  that are specific for SIRT1 (class III HDAC), such as nicotinamide 
and splitomycin, are now under intense analysis (Ballestar & Esteller, 2008; Greiner et al., 
2005). 
3.1 DNMTs inhibitors 
Genes that are silenced by DNA hypermethylation may be reactivated by small molecules 
that are called DNMT inhibitors. These agents may be structural analogues of the nucleoside 
deoxycytidine or non-nucleoside analogues. The analogues, after being phosphorylated by 
kinases that convert the nucleosides into nucleotides, can be incorporated into DNA and 
subsequently inhibit DNMT activity by forming a covalent bond with the cysteine residue in 
the active DNMT site. However, it has also been shown that such incorporation may lead to 
instabilities in DNA structure and even DNA damage (Bouchard & Momparler, 1983; Goffin 
& Eisenhauer, 2002). 
Two prominent examples are the cytosine analogs 5-azacytidine (azacytidine, Vidaza) and 
2’-deoxy-5-azacytidine (decitabine, Dacogen), which are potent inhibitors of DNMTs (Table 
3) and have been approved by the FDA (Food and Drug Administration) for the treatment 
of myelodysplastic syndrome, a pre-leukemic bone marrow disorder (Lübbert, 2000). 
Various additional molecules has been found to possess better stability and less toxicity and 
are currently being investigated as DNMT inhibitors in preclinical experiments, such as 
dihydro-5-azacytidine, arabinofuranosyl-5-azacytosine (fazarabine) and zebularine (Cheng 
et al., 2003).  
Azacytidine and decitabine have been widely used in cell culture systems to reverse DNA 
hypermethylation and restore silenced gene expression. However, results from in vivo 
studies are not satisfactory, especially with solid tumors in which limited efficacy has been 
encountered. In general, both agents are unstable in aqueous solutions, have short half-lives 
and need to be freshly prepared before administration. In addition, both drugs have 
relatively poor bioavailabilities and high cytotoxic effects with potential risks, such as 
myelotoxicity, mutagenesis, and tumorigenesis, which have limited their clinical 
applications (Jackson-Grusby et al., 2007). 
Despite this discouraging data, the orally administered zebularine shows some promise. It 
was shown to suppress the growth of TCC in bladder xenografts in nude mice and was less 
toxic than other nucleoside analogues. In addition, when zebularine was given at a lower 
dose after an initial dose of decitabine, a profound demethylation of the CDKN2A gene 
promoter was observed. These results provide a rationale for the strategy of combining an 
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
72
epimarker of cancer development. The IGF2 and H19 imprinted genes have been well 
documented in the literature. Some studies showed that the H19 gene is involved in the 
development of bladder cancer (Ariel et al., 1995; Elkin et al., 1995) and is associated with 
high recurrence risks for this tumor type (Ariel et al., 2000). Furthermore, insulin-like 
growth factor-II (IGF-II) loss of imprinting (LOI) in a series of paired tumoral and normal 
adjacent bladder tissues and E-cadherin (CDH1) immunolocalization suggested a possible 
mechanism underlying E-cadherin relocalization to the cytoplasm, that is, the presence of 
aberrant levels of IGF-II due in some cases to IGF2 LOI (Gallagher et al., 2008). Furthermore, 
the finding of LOI in the tumoral adjacent normal samples holds promise of IGF2 LOI as a 
predictor of tumor development.  
Others epigenetic mechanisms in cancer patients remain less comprehensively understood. 
One of these epigenetic changes involves the histone modifications, which include changes 
in their levels and distribution at gene promoters, gene coding regions, repetitive DNA 
sequences and other genomic elements (Kurdistani, 2011). In a recent study, Schneider et al. 
(2011) found that global levels of H3K4me1, H4K20me1, H4K20me2 and H4K20me3 were 
decreased compared to normal urothelium. The distribution of these histone modifications 
were associated with the risk of metastasis in muscle-invasive compared to non-muscle-
invasive bladder cancers. The authors also showed that H4K20me1 levels were increased in 
patients with non-muscle-invasive bladder cancer with advanced pT stages and less 
differentiated bladder cancer, and H4K20me3 levels were signicantly correlated with 
mortality after radical cystectomy in patients with muscle-invasive cancer.  
Recently, several groups have questioned whether the miRNA expression proles or even 
single miRNAs could act as useful biomarkers not only for cancer diagnosis but also for 
prognosis and treatment optimization (Lu et al., 2005; Calin & Croce, 2006). Dyrskjøt et al. 
(2009) identified the aberrant expression of several miRNAs in 106 samples from patients 
with different stages of bladder cancer and associated their profiles with disease 
progression. Among the miRNAs that were differentially expressed in normal bladder 
tissue compared to that of bladder cancer, two subsets [(miR-21, miR-510, miR-492, miR-20a, 
miR-198) and (miR-455-5p, miR-143, miR-145, miR-125b, miR-503)] were up- and down-
regulated by two-fold, respectively. In another large-scale study that evaluated miRNA 
expression, high expression levels of miR-222 and miR-125b were observed in muscle-
invasive tumors, and miR-452 and miR-452* were shown to be over-expressed in node-
positive tumors (Veerla et al., 2009).  
Moreover, aberrant DNA methylation has been implicated in the deregulation of several 
miRNAs in different types of cancer (Lujambio et al., 2007). Wiklund et al. (2011) studied 
this relationship and found that the miR-200 family and miR-205 are concurrently silenced 
and that DNA hypermethylation would be associated with the silencing of these 
microRNAs in invasive bladder tumors. They also found that the loss of miR-200c 
expression was associated with disease progression of muscle-invasive cancers and with 
poor prognosis. 
3. The promise of epigenetic therapy 
The knowledge of epigenetic alterations that are associated with human cancers and their 
potential reversibility has prompted the development of drugs that target epigenetic 
enzymes. Either natural or synthetic modulators can be utilized to restore normal epigenetic 
and gene expression patterns; for example, by restoring the expression of the frequently 
 
Epigenetic Biomarkers in Bladder Cancer 
 
73 
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modality since the loss of its function in cancer cells due to genetic mutations is a rare event 
(Kim et al., 2005). The epigenetic therapy can be used alone or in combination with other 
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approach will eventually lead to targeted therapies that are suited for specific molecular 
defects, thereby significantly decreasing the morbidity associated with bladder cancer in 
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initial administration of a parenteral DNMT inhibitor with a subsequent low dose of oral 
zebularine (Cheng et al., 2004; Zhang et al., 2006).  
Another group of compounds are called non-nucleoside analogues. These small molecules 
inhibit DNA methylation by binding directly to the catalytic site of the DNMT enzyme 
without being incorporated into the DNA. The local anesthetic procaine and its derivative 
procainamide, which is an approved antiarrhythmic drug, have exhibited demethylating 
activities. For example, Lin et al. (2001) reported that procainamide was able to restore 
GSTP1 gene expression by reversing the hypermethylation of the promoter CpG islands of 
androgen-sensitive human prostate adenocarcinoma (LNCaP) cells in vitro and in vivo. 
Because these agents do not incorporate into DNA, it is expected that they may have less 
genotoxicity than nucleoside DNMT inhibitors. In addition, (-)-epigallocatechin-3-gallate 
(EGCG), the main polyphenol compound in green tea, also acts as DNMT inhibitor . Cancer 
cells treated with micromolar concentrations of EGCG showed reduced DNA methylation 
and the increased transcription of tumor suppressor genes. However, it is still unknown 
whether EGCG has a direct inhibitory effect on DNMTs (Fang et al., 2003; Villar-Garea et al., 
2003). 
3.2 HDAC inhibitors 
A variety of structurally distinct groups of compounds have been identified as histone 
deacetylase inhibitors (HDACi) (Table 3). These compounds inhibit histone deacetylase 
activity by binding to the catalytic site of the enzyme and chelating zinc ions because they 
share similar structures with the substrates (Finnin et al., 1999). Similar to their effects on 
gene expression and differentiation, HDACi have also been shown to be efficient inducers of 
apoptosis in several cellular systems. The precise mechanism of this effect is under 
investigation, and it has been suggested that they may affect cellular oxidative stress and 
DNA damage induction. They have shown impressive activities in preclinical studies as 
well as selectivity for neoplastic cells.  Many HDACi are being tested in clinical trials for 
various malignancies (Bolden et al., 2006; Xu et al., 2007).  
The class of the HDAC inhibitors is divided into four groups: hydroxamic acids, cyclic 
tetrapeptides, short-chain fatty acids and benzamides. The hydroxamate compounds are 
more potent and have higher inhibitory effects. Trichostatin A from Streptomyces 
hygroscopicus is active at nanomolar concentrations, while the synthetic compounds, such 
as suberoylanilide hydroxamic acid (SAHA), can function in low micromolar or 
nanomolar ranges. Cyclic tetrapeptides are very potent compounds and can inhibit 
histone deacetylase at nanomolar concentrations. Short-chain fatty acid compounds 
usually require millimolar concentrations to inhibit histone deacetylase activities in vivo; 
therefore, their clinical applicability could be limited. The fourth class is the benzamides, 
such as MS-275 and CI-994, which are effective at micromolar concentrations (Rosato et 
al., 2003; Zhang et al., 2006). 
The clinical potentials of histone deacetylase inhibitors have been suggested by several 
promising in vivo studies. For example, SAHA was FDA approved in Oct. 2006 for the 
treatment of cutaneous T cell lymphoma (CTCL), and it is under a phase I clinical trial for 
use in patients with TCC (Mann et al., 2007). Preliminary reports have indicated that 2 out of 
6 patients with metastatic TCC disease have had objective tumor regression and tumor-
related symptom relief (Kelly et al., 2003). The induction of CDKN1A messenger RNA and 
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(Richon et al., 2000). Other researchers have reported similar inhibitory effects on bladder 
tumor growth using trichostatin A and pyroxamide on T24 cells. Additionally, trichostatin 
A is able to suppress 70% of tumor growth with no detectable toxicity in EJ and UM-UC-3 
xenograft models (Canes et al., 2005).  
3.3 Combination therapy 
The emerging concept of gene silencing involves the interaction of multiple factors that may 
act in a sequential manner. It is also known that a single agent may not be able to eradicate a 
tumor mass that is derived from a very heterogeneous population of cells. Moreover, the 
adverse toxic effects that are caused by single-agent treatments, especially at high doses, call 
for a rationalized therapeutic approach with low-dosage drug combinations. Accumulating 
evidence has shown that the combination of histone deacetylase inhibitors and DNMT 
inhibitors is very effective (and synergistic) in inducing apoptosis, differentiation and/or 
cell growth arrest in various human cancer cell lines (Gottlicher et al., 2001; Mei et al., 2004; 
Stirzaker et al., 2004).  
In urologic cancers, Cameron et al. (1999) showed that the combination of decitabine and 
trichostatin A stimulated a synergistic reactivation of several tumor suppressor genes. Dunn 
et al. (2005) reported that the combination of DNMT inhibitors and histone deacetylase 
inhibitors was able to reactivate the sensitivities of LNCaP cells to interferon treatment by 
the re-expression of JAK1 kinase, which is a key mediator of both interferon-gamma and 
interferon-alpha/beta receptor-elicited effects. Another strategy is to combine either histone 
deacetylase inhibitors or DNMT inhibitors with conventional therapies, as was 
demonstrated by Zhang et al. (2007), who indicated that the combination of FK228 (a HDAC 
inhibitor) and docetaxel (chemotherapeutic drug) caused a synergistic growth inhibition in 
androgen-independent prostate cancer cell lines. Moreover, single treatments with SAHA or 
MS-275 show enhanced radiation-induced cytotoxicity in DU-145 cells both in vitro and in 
vivo (Chinnaiyan et al., 2005). 
4. Future 
There is a great deal of evidence that demonstrates the connections between epigenetic 
modification enzymes and cancer. Epigenetic alterations contribute to tumorigenesis by the 
activation of oncogenes or inactivation of tumor suppressor genes. The identification of 
molecules that can modulate epigenetic enzymes could lead to the prevention of oncogene 
transcription and activation of tumor repressors, and thus it is an important topic to 
research (Zheng, 2008). 
A major impediment to the use of such drugs is that they are nonspecific and may reactivate 
genes non-discriminately. However, this does not seem to be a problem in the present case 
because DNA methylation inhibitors only act on dividing cells and leave normal, non-
dividing cells unaffected. Also, it seems that the drugs preferentially activate genes that 
have become abnormally silenced in cancer. Further studies are required to establish an 
unambiguous proof of concept for epigenetic cancer therapies (Jones & Baylin, 2007; Liang 
et al., 2002; Mund & Lyko, 2010).  
For future clinical applications, researchers should focus on several aspects, including the 
biomarkers that predict drug responses. Researchers should also focus on the screening of 
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new, more effective and less toxic agents. The psammaplin, for example, a family of 
bromotyrosine derivatives that have been extracted from the marine sponge Pseudoceratina 
purpurea, appear to be a novel class of compounds with the ability to inhibit both DNMT 
and histone deacetylase activities (Pina et al., 2003).  
In addition, exploring the silencing of specific genes by RNA interference for key epigenetic 
regulatory complexes could enhance therapeutic indices. For example, DNMT-specific 
siRNA (single-interfering RNA) is able to elicit the demethylation of several epigenetically 
silenced genes. Additionally, the treatment of cultured cells in vivo with demethylating 
agents, either alone or in combination with HDACi, has been shown to re-activate the 
expression of tumor-suppressor miRNAs, such as miR-124a and miR-127, causing the 
corresponding repression of their oncogenic targets. Although the successful delivery of 
siRNAs to solid tumors has yet to be achieved, designing small-molecule siRNAs to mimic 
tumor-suppressor miRNAs could be a potential method to selectively repress the expression 
of oncogenes (Leu et al., 2003; Saito et al., 2006). 
In the next decade, with the availability of gene profiling databases of epigenetic modifiers, 
it is expected that epigenetic therapy will be translated from the bench to the clinical arena 
and become a real alternative to conventional cancer treatments (Rodríguez-Paredes & 
Esteller, 2011; Zhang et al., 2006). 
In summary, the field of epigenetic biomarker studies is still new but shows promise in the 
clinical management of cancer. Valuable progress has been made on this end, and the 
combination of existing and newly discovered biomarkers will likely allow for more 
accurate diagnosis. Thus, patients will be able to benefit from this new era of personalized 
medicine, in which biomarkers will allow for direct treatments with more effective 
therapeutic agents. 
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Bladder cancer is the second most common tumor of the urogenital tract. Urothelial 
carcinoma is the most frequent histologic type, being unique among epithelial carcinomas in 
its divergent pathways of tumorigenesis. Surgery continues to have a predominant role in 
the management of urothelial bladder cancer (Kaufman et al., 2009). However, the debate 
about the best treatment approach for T1G3 and muscle invasive tumors continually 
challenges all urologic surgeons and oncologists. This debate involves several aspects. First, 
a significant number of T1G3 tumors recurs and progresses rapidly after transurethral 
resection and BCG treatment (Wiesner et al., 2005). Second, half of patients with invasive 
tumors have a dismal outcome despite an effective treatment by radical cystectomy 
(Sternberg et al., 2007). Third, the extension of lymphadenectomy remains an issue of 
controversy, although clinical evidence suggests that an extended lymph node dissection 
may not only provide prognostic information, but also a significant therapeutic benefit for 
both lymph node-positive and lymph node-negative patients undergoing radical cystectomy 
(May et al., 2011). In muscle invasive bladder cancer, the presence of tumor foci in lymph 
nodes is an early event in progression, and the lymphatic vessels within or in the proximity 
to the primary tumor serve as the primary conduits for tumor dissemination (Youssef et al., 
2011). Fourth, although urothelial bladder cancer is a chemo-sensitive tumor (Kaufman et 
al., 2000; von der Maase et al., 2000), adjuvant systemic chemotherapy does not reveal 
benefits (Walz et al., 2008), and neoadjuvant chemotherapy is not yet accepted as the best 
approach in invasive bladder cancer (Clark, 2009). Therefore, in order to solve the 
aforementioned problems, it is crucial to improve the knowledge about tumor 
microenvironment, regulation of cancer metabolism and neovascularization. 
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Blood and lymphatic neovascularization are essential for tumor progression and metastasis, 
by promoting oxygenation and fluid drainage, and establishing potential routes of 
dissemination (Adams and Alitalo, 2007). Therefore, the inhibition of tumor-induced 
neovascularization represents a powerful option for target therapy, in order to restrain the 
most efficient pathway of cancer spread.   
2. Angiogenesis and lymphangiogenesis: Molecular regulation of vasculature 
development 
During embryogenesis, the formation of the blood vascular system initiates by 
vasculogenesis: haemangioblasts proliferate, migrate and differentiate into endothelial cells, 
which in turn will organize a primitive vascular plexus. In parallel, angiogenesis promotes 
the remodeling and expansion of the primary capillary network, originating a hierarchical 
structure of different sized vessels that will mature into functional capillaries, veins and 
arteries (Risau, 1997). The lymphatic vascular system develops latter, when a group of blood 
endothelial cells differentiates into a lymphatic endothelium that subsequently sprouts to 
form the primary lymph sacs. By lymphangiogenesis, the lymphatic endothelial cells from 
the lymph sacs will further sprout, originating the peripheral lymphatic system (Sabin, 1902, 
as cited by Oliver & Detmar, 2002). 
During postnatal life, blood and lymphatic vascular systems are, normally, in a quiescent 
state. Physiological angiogenesis and/or lymphangiogenesis occur to maintain or restore the 
integrity of tissues, namely during wound healing and the ovarian cycle. Conversely, the 
neovascularization machinery may be activated in pathological processes such as cancer and 
inflammatory diseases (reviewed in Lohela et al., 2009).  
Similarly to physiological neovascularization, tumor-induced angiogenesis and/or 
lymphangiogenesis occur to satisfy the metabolic demands of a new tissue ― the 
malignant tissue. Therefore, the molecular factors involved in the formation of the 
vascular systems during embryogenesis are newly recruited by the growing tumor 
(Papetti & Herman, 2002). 
2.1 From angiogenesis to lymphangiogenesis in the embryo 
The proliferation, sprouting and migration of endothelial cells during vasculogenesis and 
angiogenesis is mainly guided by the vascular endothelial growth factor (VEGF) signaling 
through VEGF receptor-2 (VEGFR-2) (Risau, 1997). 
VEGF (or VEGF-A), initially termed as vascular permeability factor (VPF) (Senger et al., 
1983), is a specific mitogen and pro-survival factor for blood endothelial cells, also 
stimulating vascular permeability. It binds and activates two tyrosine kinase receptors 
primarily found on the blood endothelium: VEGFR-1 (or Flt-1, fms-like tyrosine kinase 1) 
and VEGFR-2 (or KDR/Flk-1, human kinase insert domain receptor/mouse foetal liver 
kinase 1) (reviewed in Carmeliet, 2005). Interaction of VEGF with VEGFR-1 negatively 
regulates vasculogenesis and angiogenesis during early embryogenesis (Fong et al., 1999). 
On the contrary, VEGFR-2 is the earliest marker for endothelial cell development: mouse 
embryos lacking VEGFR-2 die at embryonic day 8.5-9.5 due to no development of blood 
vessels as well as very low hematopoiesis (Shalaby et al., 1995). Regarding the ligand, 
even heterozygote mice for Vegf deficiency die at embryonic day 11-12: blood islands, 
endothelial cells and vessel-like tubes fail to develop (Carmeliet et al., 1996; Ferrara et al., 
1996). 
Angiogenesis, Lymphangiogenesis and Lymphovascular  
Invasion: Prognostic Impact for Bladder Cancer Patients 
 
89 
In humans, five weeks after fertilization, certain blood endothelial cells become responsive 
to lymphatic inducing-signals. The lymphatic vessel endothelial hyaluronan receptor-1 
(LYVE-1), a CD44 homologous transmembrane protein, is the first marker of lymphatic 
endothelial commitment.  Initially, it is evenly expressed by the blood endothelium of the 
cardinal vein, which causes the blood endothelium to acquire the ability to differentiate in 
lymphatic endothelium (Banerji et al., 1999). The polarized expression of the prospero 
related homeobox gene-1 (Prox-1) transcription factor in a subpopulation of blood 
endothelial cells determines the establishment of the lymphatic identity and initiates the 
formation of the lymphatic vascular system. In mice, Prox-1 expressing cells are first 
observed at embryonic day 10 in the jugular vein (Wigle & Oliver, 1999). Prox1 deletion 
leads to a complete absence of the lymphatic vasculature (Wigle et al., 2002). The expression 
of the transcription factor Sox18 [SRY (sex determining region Y) box 18] acts as a molecular 
switch to induce differentiation of lymphatic endothelial cells: it activates Prox-1 
transcription by binding to its proximal promoter. Sox18-null embryos show a complete 
blockade of lymphatic endothelial cell differentiation (François et al., 2008). Later, the 
sprouting, migration and survival of the newly formed lymphatic endothelial cells depends 
on the expression of VEGF-C by the mesenchymal cells surrounding the cardinal veins 
(Karkkainen et al., 2004) (Fig. 1).  
VEGF-C, like VEGF, is a member of the VEGF family of growth factors and a mitogen for 
lymphatic endothelial cells. VEGF-D is also a pro-lymphangiogenic factor, although its 
deletion does not affect the development of the primitive lymphatic vessels (Baldwin et al. 
2001). Conversely, in Vegfc-/- mice, Prox-1 positive cells appear in the cardinal veins, but fail 
to migrate and proliferate to form primary lymph sacs (Karkkainen et al., 2004). VEGF-C 
and VEGF-D interact with VEGFR-3 (of Flt-4, fms-like tyrosine kinase 4). Their affinity to 
VEGFR-3 is increased by proteolytic cleavage; the fully processed forms can also bind to 
VEGFR-2 (reviewed in Lohela et al., 2009). 
VEGFR-3 is widely expressed at the early stages of embryonic blood vasculature, becoming 
virtually restricted to lymphatic endothelium in the later stages of embryonic development, 
(after the lymphatic commitment mediated by Prox-1 expression), and during adult life 
(Kaipainen et al., 1995). In mice, inhibition of VEGFR-3 expression at embryonic day 15 
induces regression of the developing lymphatic vasculature by apoptosis of lymphatic 
endothelial cells (Makinen et al., 2001). 
The subsequent development of the lymphatic vasculature involves the separation of the 
blood and lymphatic vascular systems, the maturation of lymphatic vessels and the 
formation of secondary lymphoid organs. The molecular regulation of these processes 
involves the coordinated expression of distinct genes from those involved in the early 
events of lymphangiogenesis (reviewed in Alitalo et al., 2005) (Fig. 1). Moreover, several 
other growth factors, namely cyclooxygenase-2 (COX-2) fibroblast growth factor-2 (FGF-
2), hepatocyte growth factor (HGF), insulin-like growth factors (IGFs) and platelet-
derived growth factor-B (PDGF-B) have been shown to induce lymphangiogenesis and/or 
angiogenesis in experimental models (reviewed in Cao, 2005). These are mainly protein 
tyrosine kinases, which play central roles in signal transduction networks and regulation 
of cell behavior. In the lymphatic endothelium, these tyrosine kinases are collectively 
involved in processes such as the maintenance of existing lymphatic vessels, growth and 
maturation of new vessels and modulation of their identity and function (Williams et al., 
2010). 
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
88
Blood and lymphatic neovascularization are essential for tumor progression and metastasis, 
by promoting oxygenation and fluid drainage, and establishing potential routes of 
dissemination (Adams and Alitalo, 2007). Therefore, the inhibition of tumor-induced 
neovascularization represents a powerful option for target therapy, in order to restrain the 
most efficient pathway of cancer spread.   
2. Angiogenesis and lymphangiogenesis: Molecular regulation of vasculature 
development 
During embryogenesis, the formation of the blood vascular system initiates by 
vasculogenesis: haemangioblasts proliferate, migrate and differentiate into endothelial cells, 
which in turn will organize a primitive vascular plexus. In parallel, angiogenesis promotes 
the remodeling and expansion of the primary capillary network, originating a hierarchical 
structure of different sized vessels that will mature into functional capillaries, veins and 
arteries (Risau, 1997). The lymphatic vascular system develops latter, when a group of blood 
endothelial cells differentiates into a lymphatic endothelium that subsequently sprouts to 
form the primary lymph sacs. By lymphangiogenesis, the lymphatic endothelial cells from 
the lymph sacs will further sprout, originating the peripheral lymphatic system (Sabin, 1902, 
as cited by Oliver & Detmar, 2002). 
During postnatal life, blood and lymphatic vascular systems are, normally, in a quiescent 
state. Physiological angiogenesis and/or lymphangiogenesis occur to maintain or restore the 
integrity of tissues, namely during wound healing and the ovarian cycle. Conversely, the 
neovascularization machinery may be activated in pathological processes such as cancer and 
inflammatory diseases (reviewed in Lohela et al., 2009).  
Similarly to physiological neovascularization, tumor-induced angiogenesis and/or 
lymphangiogenesis occur to satisfy the metabolic demands of a new tissue ― the 
malignant tissue. Therefore, the molecular factors involved in the formation of the 
vascular systems during embryogenesis are newly recruited by the growing tumor 
(Papetti & Herman, 2002). 
2.1 From angiogenesis to lymphangiogenesis in the embryo 
The proliferation, sprouting and migration of endothelial cells during vasculogenesis and 
angiogenesis is mainly guided by the vascular endothelial growth factor (VEGF) signaling 
through VEGF receptor-2 (VEGFR-2) (Risau, 1997). 
VEGF (or VEGF-A), initially termed as vascular permeability factor (VPF) (Senger et al., 
1983), is a specific mitogen and pro-survival factor for blood endothelial cells, also 
stimulating vascular permeability. It binds and activates two tyrosine kinase receptors 
primarily found on the blood endothelium: VEGFR-1 (or Flt-1, fms-like tyrosine kinase 1) 
and VEGFR-2 (or KDR/Flk-1, human kinase insert domain receptor/mouse foetal liver 
kinase 1) (reviewed in Carmeliet, 2005). Interaction of VEGF with VEGFR-1 negatively 
regulates vasculogenesis and angiogenesis during early embryogenesis (Fong et al., 1999). 
On the contrary, VEGFR-2 is the earliest marker for endothelial cell development: mouse 
embryos lacking VEGFR-2 die at embryonic day 8.5-9.5 due to no development of blood 
vessels as well as very low hematopoiesis (Shalaby et al., 1995). Regarding the ligand, 
even heterozygote mice for Vegf deficiency die at embryonic day 11-12: blood islands, 
endothelial cells and vessel-like tubes fail to develop (Carmeliet et al., 1996; Ferrara et al., 
1996). 
Angiogenesis, Lymphangiogenesis and Lymphovascular  
Invasion: Prognostic Impact for Bladder Cancer Patients 
 
89 
In humans, five weeks after fertilization, certain blood endothelial cells become responsive 
to lymphatic inducing-signals. The lymphatic vessel endothelial hyaluronan receptor-1 
(LYVE-1), a CD44 homologous transmembrane protein, is the first marker of lymphatic 
endothelial commitment.  Initially, it is evenly expressed by the blood endothelium of the 
cardinal vein, which causes the blood endothelium to acquire the ability to differentiate in 
lymphatic endothelium (Banerji et al., 1999). The polarized expression of the prospero 
related homeobox gene-1 (Prox-1) transcription factor in a subpopulation of blood 
endothelial cells determines the establishment of the lymphatic identity and initiates the 
formation of the lymphatic vascular system. In mice, Prox-1 expressing cells are first 
observed at embryonic day 10 in the jugular vein (Wigle & Oliver, 1999). Prox1 deletion 
leads to a complete absence of the lymphatic vasculature (Wigle et al., 2002). The expression 
of the transcription factor Sox18 [SRY (sex determining region Y) box 18] acts as a molecular 
switch to induce differentiation of lymphatic endothelial cells: it activates Prox-1 
transcription by binding to its proximal promoter. Sox18-null embryos show a complete 
blockade of lymphatic endothelial cell differentiation (François et al., 2008). Later, the 
sprouting, migration and survival of the newly formed lymphatic endothelial cells depends 
on the expression of VEGF-C by the mesenchymal cells surrounding the cardinal veins 
(Karkkainen et al., 2004) (Fig. 1).  
VEGF-C, like VEGF, is a member of the VEGF family of growth factors and a mitogen for 
lymphatic endothelial cells. VEGF-D is also a pro-lymphangiogenic factor, although its 
deletion does not affect the development of the primitive lymphatic vessels (Baldwin et al. 
2001). Conversely, in Vegfc-/- mice, Prox-1 positive cells appear in the cardinal veins, but fail 
to migrate and proliferate to form primary lymph sacs (Karkkainen et al., 2004). VEGF-C 
and VEGF-D interact with VEGFR-3 (of Flt-4, fms-like tyrosine kinase 4). Their affinity to 
VEGFR-3 is increased by proteolytic cleavage; the fully processed forms can also bind to 
VEGFR-2 (reviewed in Lohela et al., 2009). 
VEGFR-3 is widely expressed at the early stages of embryonic blood vasculature, becoming 
virtually restricted to lymphatic endothelium in the later stages of embryonic development, 
(after the lymphatic commitment mediated by Prox-1 expression), and during adult life 
(Kaipainen et al., 1995). In mice, inhibition of VEGFR-3 expression at embryonic day 15 
induces regression of the developing lymphatic vasculature by apoptosis of lymphatic 
endothelial cells (Makinen et al., 2001). 
The subsequent development of the lymphatic vasculature involves the separation of the 
blood and lymphatic vascular systems, the maturation of lymphatic vessels and the 
formation of secondary lymphoid organs. The molecular regulation of these processes 
involves the coordinated expression of distinct genes from those involved in the early 
events of lymphangiogenesis (reviewed in Alitalo et al., 2005) (Fig. 1). Moreover, several 
other growth factors, namely cyclooxygenase-2 (COX-2) fibroblast growth factor-2 (FGF-
2), hepatocyte growth factor (HGF), insulin-like growth factors (IGFs) and platelet-
derived growth factor-B (PDGF-B) have been shown to induce lymphangiogenesis and/or 
angiogenesis in experimental models (reviewed in Cao, 2005). These are mainly protein 
tyrosine kinases, which play central roles in signal transduction networks and regulation 
of cell behavior. In the lymphatic endothelium, these tyrosine kinases are collectively 
involved in processes such as the maintenance of existing lymphatic vessels, growth and 
maturation of new vessels and modulation of their identity and function (Williams et al., 
2010). 
 




Fig. 1. Model for the development of mouse lymphatic vasculature (E- embryonic day; Syk- 
protein-tyrosine kinase SYK; Slp76- SH2 domain-containing leucocyte protein, 76-kDa; 
Ang2- angiopoietin 2; Foxc2- Forkhead Box C2) (adapted by permission from © 2005 Nature 
Publishing Group. Originally published in Nature. 438: 946-953) 
2.2 Promotion of angiogenesis and lymphangiogenesis in the malignancy context 
The major cause of cancer mortality is the metastatic spread of tumor cells that can occur via 
multiple routes, including blood and lymphatic vasculatures. For metastasis to occur, 
selected clones of malignant cells must be able to invade the newly formed vessels and 
disseminate. Induction of angiogenesis and/or lymphangiogenesis is, therefore, one of the 
first steps of the metastatic cascade (Alitalo & Carmeliet, 2002; Tobler & Detmar, 2006). 
During the pre-vascular phase, the malignant tumor remains small (up to 1 or 2 mm3); the 
preexistent surrounding blood vessels ensure the supply of oxygen and nutrients necessary 
for its survival. However, the expansion of the tumor mass is angiogenesis-dependent. As a 
compensatory response to hypoxia, proangiogenic factors such as VEGF are released by the 
malignant cells and infiltrating immune cells, namely monocytes. As a result, angiogenesis 
occurs and the tumor acquires its own blood supply. Neoplastic growth is thus promoted, as 
well as the potential for invasion and haematogenic metastasis (Kerbel, 2000). 
Vegf is upregulated in hypoxia via the oxygen sensor hypoxia-inducible factor (HIF)-1 (Pugh 
& Ratcliffe, 2003). Another recently described VEGF activation mechanism is the induction of 
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the transcriptional coactivator peroxisoma proliferator-activated receptor-gamma coactivator-
1 (PGC-1) in response to the lack of nutrients and oxygen (Arany et al., 2008). Additionally, 
VEGF gene expression can be upregulated by oncogene signaling, several growth factors, 
inflammatory cytokines and hormones (reviewed in Ferrara, 2004). Tumor cells secrete VEGF 
mainly in a paracrine manner, although it can also act in an autocrine manner to promote a 
protective/survival effect to endothelial cells, among other cell types (Brusselmans et al., 2005). 
The mechanisms underlying tumor lymphangiogenesis are not clearly defined. Inflammation 
seems to promote lymphatic neovascularization: inflammatory cells that infiltrate in the 
growing tumor produce lymphangiogenic growth factors. Another lymphangiogenesis trigger 
mechanism may be the high interstitial pressure generated inside the tumors due to the 
excessive production of interstitial fluid (reviewed in Cao, 2005). On the other hand, the 
extracellular matrix is of central importance for the generation of new lymphatic vessels as a 
response to the pathological stimulus. Integrins, a superfamily of cell adhesion molecules, are 
able to influence cell migration: integrin 91 is a target gene for Prox1, and its direct binding 
to VEGF-C and VEGF-D stimulates cell migration (reviewed in Wiig, 2010). 
VEGF-C and VEGF-D, via signaling through VEGFR-3, appear to be essential for tumor-
associated lymphangiogenesis, leading to lymphatic vessel invasion, lymph node 
involvement and distant metastasis (reviewed in Achen & Stacker, 2008). Moreover, VEGF 
interaction with VEGFR-2 may also promote lymphatic neovascularization, namely inside 
the regional draining lymph nodes, even before lymph node metastasis occurrence. This 
probably corresponds to a pathophysiologic strategy of “soil” preparation by the primary 
tumor to ensure the success of its future dissemination (Hirakawa et al., 2005). In fact, 
sentinel lymph node metastasis is the first step in the spreading of many cancer types. 
Preexisting blood and lymphatic vessels in the vicinity of the malignant mass may 
contribute to tumor spread. However, de novo formed vessels by tumor-induced 
angiogenesis and lymphangiogenesis seem to be the preferential routes for dissemination 
(reviewed in Cao, 2005). This is a consequence of the ultra-structure of the tumor-associated 
blood and lymphatic vessels. 
2.3 Ultra-structure of tumor-associated blood and lymphatic vessels 
Blood vessels present in malignant tissues show remarkable differences with vessels present 
in normal tissues. Tumor blood vessels are highly disorganized: they are tortuous, 
excessively branched and dilated. The basement membrane and the muscular coverage are 
incomplete or absent. The endothelial cells, abnormal in shape, overlap and are projected 
into the lumen rather than organizing a pavement layer below the basement membrane. 
Blood vessel invasion is facilitated by this aberrant structure, but the extravasation rate is 
high, and blood flow is variable. As a result, interstitial tumor hypertension occurs, and 
delivery of therapeutic agents into tumors is compromised (Jain & Carmeliet, 2001; 
reviewed in Cao, 2005). The intratumoral edema is pernicious to malignant cells; therefore, 
homeostasis needs to be re-established. The formation of a tumoral lymphatic vasculature 
could potentially resolve this problem. 
The key function of lymphatic vessels is to collect the excessive amount of interstitial fluid 
back to the blood circulation for immune surveillance in lymph nodes. Unlike normal blood 
capillaries, lymphatic capillaries have a discontinuous or fenestrated basement membrane and 
are not ensheathed by pericytes or smooth muscle cells; the endothelial cells are arranged in a 
slightly overlapping pattern and lack tight interendothelial junctions. Specialized anchoring 
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filaments of elastic fibers connect the endothelial cells to the extracellular matrix, which causes 
the vessels to dilate rather than to collapse when hydrostatic pressure rises (Alitalo et al., 2005; 
Tobler & Detmar, 2006). This structure facilitates the collection of interstitial fluid and is ideal 
for malignant cells’ entry into the lymphatic flow. 
A highly debated question is whether there are functional lymphatic vessels inside tumors 
(reviewed in Alitalo & Carmeliet, 2002; reviewed in Detmar & Hirakawa, 2002). On one 
hand, the elevated interstitial pressure generated by the proliferation of the malignant cells 
and by the high extravasion rate compromises the infiltration of new lymphatic vessels in 
the tumor stroma. Although intratumoral lymphangiogenesis may occur, the newly formed 
vessels are compressed and nonfunctional (Jain & Fenton, 2002). To compensate the lack of 
an intratumoral draining mechanism, the peritumoral lymphatic vessels enlarge due to an 
excess of pro-lymphangiogenic factors in that area. Therefore, in this model, the peritumoral 
lymphatic vessels passively collect interstitial fluid and, eventually, malignant cells 
(Carmeliet & Jain, 2000) (Fig. 2, A). However, some studies have demonstrated a 
relationship between the existence of functional intratumoral lymphatics, with cycling 
lymphatic endothelial cells and tumor emboli, and lymph node involvement (reviewed in 
Da et al., 2008). Additionally, peritumoral lymphangiogenesis occurs, and the new vessels 
actively contribute to metastatic spread (Padera et al., 2002) (Fig. 2, B). Probably, there are 
some organ-specific determinants that influence the occurrence of peritumoral and/or 
intratumoral lymphangiogenesis, as well as the function of the newly formed vessels. 
2.4 Lymphovascular invasion and metastasis   
Tumor metastasis involves a coordinated series of complex events that include promotion of 
angiogenesis and lymphangiogenesis, detachment of malignant cells from the primary 
tumor, microinvasion of the surrounding stroma, blood and/or lymphatic vessel invasion, 
survival of the malignant cells in the blood and/or lymphatic flow, and extravasion and 
growth in secondary sites. Because the large lymphatic vessels reenter the blood vascular 
system, malignant cells spread via the lymphatic system to the regional lymph nodes and, 
from this point, to distant organs (Alitalo & Carmeliet, 2002; Tobler & Detmar, 2006) (Fig. 3). 
Follow-up data have shown that 80% of the tumors, mainly those of epithelial origin, 
disseminate through the lymphatic vasculature; the remaining 20% use the blood circulation 
to colonize secondary organs (reviewed in Saharinen et al., 2004; reviewed in Wilting et al., 
2005). 
The blood vessels are not the best route for the success of malignant dissemination. 
Although their disorganized structure may contribute to the intravasion of malignant cells 
or emboli, in the bloodstream these cells experience serum toxicity, high shear stresses and 
mechanical deformation. Consequently, the viability of the tumor cells is seriously 
compromised (reviewed in Swartz, 2001). Conversely, the success rate of lymphogenous 
spread is high. As previously referred, the structure and function of the lymphatic 
capillaries facilitates intravasion of tumor cells or emboli. On the other hand, the 
composition of the lymph is similar to interstitial fluid, which provides an optimal medium 
for the survival of malignant cells. In collecting lymphatic vessels, muscle fibers assure 
lymph propulsion, that flows slowly, and valves prevent its backflow. Lymph nodes are 
areas of flow stagnation that represent ideal “incubators” for malignant cells’ growth. Some 
cells exit the lymph node through the efferent channels or high endothelial venules.  
Other cells may remain mechanically entrapped for long periods of time, originating 
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Fig. 2. (A) Traditional model of tumor metastasis via lymphatic and blood vessels. (B) Active 
lymphangiogenesis model of tumor metastasis (reprinted by permission from © 2002 




Fig. 3. Pathways of dissemination of malignant cells (reprinted by permission from © 2008 
John Wiley & Sons, Inc. Originally published in Ann. N. Y. Acad. Sci. 1131: 225-234) 
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micrometastases (Swartz, 2001; Van Trapen & Pepper, 2002). Martens and colleagues 
described the expression of a gene signature of scavenger and lectin-like receptors in the 
lymph node sinus, which are known mediators of tumour cell adhesion and, therefore, can 
contribute to selective metastasis in an organ-specific context (Martens et al., 2006). Probably, 
tumor-cell-specific characteristics, microenvironmental factors and crosstalk between tumor 
and host cells have a pivotal role in determining survival and growth of micrometastasis. 
Moreover, lymph node lymphangiogenesis may provide an additional mechanism to facilitate 
further metastatic spread throughout the lymphatic system (Ji, 2009). The occurrence of 
lymphangiogenesis prior to arrival of tumor cells indicates that signals derived from the 
primary tumor are transported to the draining lymph nodes (Hirakawa et al., 2005). 
Different tumors metastasize preferentially to different organs, suggesting that tumor 
spread is a guided process. It has been reported that malignant cells may use chemokine 
receptor ligand interactions to guide the colonization of target organs (reviewed in 
Saharinen et al., 2004; reviewed in Achen & Stacker, 2008). Chemokines are a family of 
chemoattractant cytokines that bind to G protein-coupled receptors expressed on target 
cells, namely malignant cells (Laurence, 2006). For instance, breast cancer cells, that 
normally choose regional lymph nodes, bone marrow, lung and liver as their first sites of 
destination, overexpress CCR7 (chemokine, CC motif, receptor 7) and CXCR4 (chemokine, 
CXC motif, receptor 4). Their ligands, SLC/CCL2 (secondary lymphoid chemokine / CC-
type chemokine ligand 21) and SDF-1 CXCL12/ (stromal cell-derived factor 1 / chemokine, 
CXC motif, ligand 12) are expressed at high levels by isolated lymphatic endothelial cells 
and lymphatic endothelium from vessels present in the preferred sites of metastasis (Muller 
et al., 2001). This guides chemoattraction and migration of tumor cells, and characterizes 
lymphatic vessel invasion as an active event. 
3. Angiogenesis, lymphangiogenesis and lymphovascular invasion in 
urothelial bladder cancer  
The metastatic profile of urothelial bladder carcinoma implies, as in most malignant tumors, 
the dissemination of tumor cells through the lymphatic vasculature, and the colonization of 
regional lymph nodes is an early event in progression. Smith & Whitmore reported the 
involvement of the internal iliac and obturator groups of lymph nodes in about 74% of patients 
who underwent radical cystectomy; the external iliac nodes were involved in 65% of the 
patients, and the common iliac nodes were involved in 20% of the cases (Smith & Whitmore, 
1981). As already referred, controversy exists regarding the optimal extent of 
lymphadenectomy and the number of lymph nodes to be retrieved at radical cystectomy. An 
extended pelvic lymph node dissection (encompassing the external iliac vessels, the obturator 
fossa, the lateral and medial aspects of the internal iliac vessels, and at least the distal half of 
the common iliac vessels together with its bifurcation) has been suggested as potentially 
curative in patients with metastasis or micrometastasis to a few nodes (Karl et al., 2009; Abol-
Enein et al., 2011). Wright and colleagues observed that an increased number of lymph nodes 
removed at the time of radical cystectomy associates with improved survival in patients with 
lymph node-positive bladder cancer (Wright et al., 2008). The recommendation from the 
Bladder Cancer Collaboration Group is that ten to fourteen lymph nodes should be removed 
at the time of radical cystectomy (Herr et al., 2004). The concept of lymph node density (the 
number of positive lymph nodes divided by the total number of lymph nodes) was introduced 
by Stein and colleagues and helps to select lymph node-positive patients after radical 
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cystectomy for adjuvant treatment (Stein et al., 2003). However, the lymph node density 
threshold is a debatable question (Gilbert, 2008). In large series, the median number of total 
lymph nodes removed was nine, with high lymph node density (25%), which can lead to 
misleading N0 staging (Wright et al., 2008). Therefore, in this subgroup of patients (lymph 
nodes removed ≤ 9 and N0), another prognostic factor is needed to better select patients for 
adjuvant treatment. Moreover, according to Malmström, extending the boundaries of surgery 
will not drastically improve survival. The focus should be on exploring biomarkers that 
predict extravesical dissemination and improving on the systemic treatment concept 
(Malmström, 2011). In this line of investigation, angiogenesis, lymphangiogenesis and 
lymphovascular invasion occurrence have been implicated in bladder cancer progression, 
invasion and metastasis, and represent potential targets for guided therapy. 
Several studies reported a significant association between VEGF overexpression ― both in 
tumor tissue (Crew et al., 1997; O’Brien et al., 1995) and urine (Crew et al., 1999; Jeon et al., 
2001) ―, high blood vessel density (Goddard et al., 2003; Santos et al., 2003) and the 
occurrence of recurrence and progression in patients with non-muscle invasive bladder 
cancer. In this group of patients, it has been observed that angiotensin II type 1 receptor 
(AT1R) expression associates with high blood vessel density and is related to early 
intravesical recurrence (Shirotake et al., 2011). AT1R supports tumor-associated macrophage 
infiltration, which results in enhanced tissue VEGF protein levels (Egami et al., 2009). These 
results suggest that AT1R is involved in bladder tumor angiogenesis and may become a new 
molecular target and a prognostic factor for urothelial bladder cancer patients  
In the subset of invasive urothelial bladder cancer, most studies also reported the 
association between angiogenesis occurrence and unfavorable prognosis. High blood vessel 
density was identified as an independent prognostic factor by several authors (Bochner et 
al., 1995; Chaudhary et al., 1999; Dickinson et al., 1994; Jaeger et al., 1995). Moreover, 
overexpression of VEGF associates with high blood vessel density (Sato et al., 1998; Yang et 
al., 2004). Analysis of serum levels of VEGF has demonstrated its optimal sensitivity and 
specificity for predicting metastatic disease (Bernardini et al., 2001). Inoue and colleagues 
reported the importance of measuring blood vessel density and VEGF immunoexpression in 
identifying patients with invasive tumors who are at high risk of recurrence and 
development of metastasis after radical cystectomy and neoadjuvant systemic 
chemotherapy. The author highlighted the role of VEGF as a cell survival factor, not only by 
protecting the malignant cells in situations of hypoxia, but also during the occurrence of 
chemotherapy-induced apoptosis (Inoue et al., 2000). 
Beyond VEGF signaling, other angiogenesis-related molecules have been implicated in 
bladder cancer recurrence, progression and metastasis, namely several proangiogenic 
factors ― matrix metalloproteinases, fibroblast growth factors, platelet derived-growth 
factors, cyclooxygenases, integrins, angiopoietins, Notch signaling ― and several 
antiangiogenic factors ― thrombospondin-1, angiostatin-endostatin, platelet factor-4 
(Chikazawa et al., 2008; Durkan et al., 2001; Grossfeld et al., 1997;  Patel et al., 2006; reviewed 
in Pinto et al., 2010; Shariat et al., 2010). 
The relevance of lymphangiogenesis in bladder cancer setting has gained recent attention. A 
few articles suggest that lymphangiogenesis occurrence, detected using specific lymphatic 
markers, is associated with poor prognosis (Fernández et al., 2008; Ma et al., 2010; Miyata et 
al., 2006; Zhou et al., 2011; Zu et al., 2006). VEGF-C, VEGF-D and VEGFR-3 are 
overexpressed in bladder cancer and promote tumor-induced lymphangiogenesis. This 
correlates with tumor upstaging and lymph node involvement, and results in a worse 
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prognosis (Afonso et al., 2009; Miyata et al., 2006; Suzuki et al., 2005; Herrmann et al., 2007; 
Zhou et al., 2011; Zu et al., 2006). Interestingly, VEGF-C overexpression also associates with 
angiogenic events, probably by interaction of the fully processed form with VEGFR-2 
(Afonso et al., 2009; Miyata et al., 2006). On the other hand, tumor associated macrophages 
play an important role in promoting lymphangiogenesis by producing VEGF-C and VEGF-
D, mainly in peritumoral areas (Schoppmann et al., 2002). The blockade of VEGF-C/D with 
a soluble VEGF receptor-3 markedly inhibited lymphangiogenesis and lymphatic metastasis 
in an orthotopic urinary bladder cancer model. In addition, the depletion of tumor 
associated macrophages exerted similar effects (Yang et al. 2011). 
Lymphovascular invasion has been identified as an independent prognostic factor for bladder 
cancer patients in several studies (Cho et al., 2009; Leissner et al., 2003; Lotan et al., 2005; Quek 
et al., 2005). In patients with newly diagnosed T1 urothelial bladder cancer, lymphovascular 
invasion in transurethral resection of bladder tumor specimens predicts disease progression 
and metastasis (Cho et al., 2009). Lotan and colleagues observed that blood and lymphatic 
vessel invasion (accessed by Haematoxylin-eosin stain) is an independent predictor of 
recurrence and low overall survival in patients who undergo radical cystectomy for invasive 
urothelial bladder cancer and are lymph node negative. They emphasized that these patients 
represent a high risk group that may benefit from neoadjuvant or adjuvant treatments. 
However, in this study, the mean number of lymph nodes removed per patient at the time of 
radical cystectomy was 20,1±10,2 (Lotan et al., 2005). 
The prognostic impact of lymphovascular invasion in patients with lymph node-negative 
urothelial bladder cancer treated by radical cystectomy has been recently validated in large 
multicentre trials (Bolenz et al., 2010; Shariat et al, 2010). May and colleagues emphasized that, 
besides the importance of performing extended lymphadenectomies, the information resulting 
from an assessment of lymphovascular invasion is critical for stratification of risk groups and 
identification of patients who might benefit from adjuvant treatments (May, 2011). Algaba 
underlined that, in this field, it would be necessary to reach a consensus on strict diagnostic 
criteria as soon as possible, to be able to incorporate this prognostic factor in clinical practice 
(Algaba, 2006). Leissner and colleagues endorsed that blood and lymphatic vessel invasion 
should be commented on separately in the pathology report (Leissner et al., 2003). 
Afonso and colleagues reported the prognostic contribution of molecular markers of blood 
vessels (like CD31) (Fig. 4, A) and lymphatic vessels (like D2-40) (Fig. 4, B) to accurately 
assess the occurrence of blood and/or lymphatic vessel invasion. The use of endothelial 
markers is encouraged because immunohistochemistry antibodies are significantly more 
sensitive in detecting invasive events than the standard Haematoxylin-eosin staining 
method and, additionally, facilitate the discrimination between blood and lymphatic vessel 
invasion. This is particularly important in identifying isolated malignant cells invading 
lymphatic vessels, because their viability is more probable in the lymphatic flow than in the 
blood circulation. Conversely, emboli of malignant cells are better suited to survive in the 
bloodstream, and are more easily identified, even by the traditional Haematoxylin-eosin 
staining method. This advocates the use of lymphatic markers for purposes of counting 
invaded lymphatic vessels. In this study, blood vessel invasion by malignant emboli 
assessed by CD31 staining (Fig. 5, A), and lymphatic vessel invasion by isolated malignant 
cells assessed by D2-40 staining (Fig. 5, B) significantly affected patients’ prognosis; blood 
vessel invasion remained as an independent prognostic factor (Afonso et al., 2009). When 
included in a model of bladder cancer aggressiveness, these parameters contributed to a 
clear separation between low and high aggressiveness groups (Afonso et al., 2011).  
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Fig. 4. Intratumoral blood vessels highlighted by CD31 (A), and intratumoral lymphatic 
vessels highlighted by D2-40 (B), in invasive urothelial bladder carcinoma. Evidence of 
internal negative control in A (D2-40 negative blood vessel ) (original magnification x100) 
(reprinted by permission from © 2009 John Wiley & Sons, Inc. Originally published in 
Histopathol. 55: 514-524) 
Both peritumoral and intratumoral lymphatic vessels seem to be functional for urothelial 
cells’ dissemination. Some articles reported the existence of intratumoral lymphatic 
vessels in bladder tumors, and their possible participation in metastatic events. No 
intratumoral edema has been observed, which is consistent with the occurrence of 
efficient lymphatic neovascularization (Afonso et al., 2009; Fernández et al., 2008; Ma et 
al., 2010; Miyata et al. 2006). Lymphatic vessel invasion occurrence correlates with high 
lymphatic vessel density values, mainly in the intratumoral areas. Although most of the 
invaded lymphatic vessels were distorted and collapsed, single malignant cells were 
significantly observed in the well-preserved intratumoral lymphatic vessels (Fig. 5, B). 
Moreover, the absence of intratumoral edema is a surrogate marker of an efficient 
lymphatic flow (Afonso et al., 2009). 
 
  
Fig. 5. Intratumoral blood vessel highlighted by CD31 invaded by a small malignant 
embolus (A), and intratumoral lymphatic vessel highlighted by D2-40 invaded by an 
isolated malignant cell (B), in invasive urothelial bladder carcinoma (original magnification 
x100) (reprinted by permission from © 2009 John Wiley & Sons, Inc. Originally published in 
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prognosis (Afonso et al., 2009; Miyata et al., 2006; Suzuki et al., 2005; Herrmann et al., 2007; 
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Fig. 5. Intratumoral blood vessel highlighted by CD31 invaded by a small malignant 
embolus (A), and intratumoral lymphatic vessel highlighted by D2-40 invaded by an 
isolated malignant cell (B), in invasive urothelial bladder carcinoma (original magnification 
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4. Angiogenesis and Lymphangiogenesis as therapeutic targets in urothelial 
bladder cancer  
Our current understanding of the importance of tumor-induced angiogenesis and 
lymphangiogenesis for the occurrence of haematogenous and lymphogenous metastasis 
suggests that, by blocking the activity of key molecules involved in these processes, it 
should be possible to suppress the onset of metastasis following diagnosis of cancer and its 
subsequent therapy. Moreover, prophylactic suppression of metastasis would be useful for 
patients who are at risk of recurrence (Thiele & Sleeman, 2006). Therefore, clinical trials 
evaluating novel agents and combinations including chemotherapeutic drugs, as well as 
targeted inhibitors, are desperately needed (Iyer et al., 2010). 
Two types of neovascularization inhibitors have been described. The direct inhibitors refer 
to compounds that function directly on endothelial cells by blocking a common pathway of 
vessel growth. Indirect inhibitors are molecules that neutralize the functions of angiogenic 
and lymphangiogenic growth factors; due to their mode of action, these are preferred over 
the direct inhibitors (Cao, 2005; Folkman, 2003). The main strategies that have been tested 
focus on modulating the signaling of VEGF family of growth factors and receptors, and are 
based on the use of monoclonal antibodies or soluble versions of receptors to neutralize the 
ligand-receptor interaction, and the inhibition of the kinase activity of the receptors (Achen 
et al., 2006; Thiele & Sleeman, 2006).  
In 2004, the U.S. Food and Drug Administration (FDA) has approved bevacizumab 
(Avastin®), a humanized monoclonal antibody that binds to VEGF-A, as the first drug 
developed solely for antiangiogenesis anticancer use in humans. Antiangiogenic drugs are 
presently approved in a wide number of tumor types, namely in breast, colorectal, lung, 
liver, glioblastoma and kidney cancer. Other compounds are currently in preclinical 
development, with many of them now entering the clinic and/or achieving approval 
(reviewed in Boere et al., 2010; reviewed in Cook & Figg, 2010; reviewed in Pinto et al., 
2010).  
In anticancer therapy, an angiogenesis inhibitor may prevent the growth of new blood 
vessels. This should decrease the delivery of oxygen and nutrients – the “starving therapy” – 
which are indispensable elements for the support of uncontrolled cell division and tumor 
expansion. Angiogenesis inhibitors are predicted to be cytostatic, stabilizing tumors and 
perhaps preventing metastasis, rather than being curative (Zhi-chao & Jie, 2008). Therefore, 
there is the need to administrate this type of therapy for long periods of time. As a 
consequence, problems with bleeding, blood clotting, heart function and depletion of the 
immune system are common (Cohen et al., 2007). Nevertheless, inhibition of circulating 
VEGF reduces vascular permeability and thus tumoral interstitial pressure, permitting 
easier penetration of the tumor by conventional chemotherapeutic targets (Ferrara, 2005). 
A second concern of anti-angiogenesis therapy is the approach to objectify the response to 
anti-angiogenic drugs. Chan and colleagues found that targeted contrast enhanced micro-
ultrasound imaging enables investigators to detect and monitor vascular changes in 
orthotopic bladder tumors. Therefore, this technique may be useful for direct, noninvasive 
and in vivo evaluation of angiogenesis inhibitors (Chan et al., 2011). Lassau and colleagues 
demonstrated that dynamic ultrasound can be used to quantify dynamic changes in tumor 
vascularity as early as three days after the administration of the anti-angiogenic drug. These 
changes may be potential surrogate measures of the effectiveness of antiangiogenic therapy, 
namely by predicting progression-free survival and overall survival (Lassau et al., 2011). 
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Regarding antilymphangiogenic strategies, numerous compounds that could be used to 
block lymphangiogenesis already exist, although there is some delay in the translation to the 
clinic. These act mainly by targeting lymphangiogenic protein tyrosine kinases (Williams et 
al., 2010) (Table 1) or other indirect regulators of lymphangiogenic events. For instance, 
rapamycin (sirolimus), a classical immunosuppressant drug used to prevent rejection in 
organ transplantation, and a known inhibitor of the mTOR (mammalian target of 
rapamycin) signaling, has demonstrated potent antilymphangiogenic properties (Huber et 
al., 2007), and may suppress lymphatic metastasis (Kobayashi et al., 2007). mTOR is a 
member of the phosphoinositide-3-kinase-related kinase family, and is centrally involved in 
growth regulation, proliferation control and cancer cell metabolism (Rosner et al., 2008). Its 
inhibition impairs downstream signaling of VEGF-A as well as VEGF-C via mTOR to the 
ribosomal p70S6 kinase (a regulator of protein translation, and a major substrate of mTOR) 
in lymphatic endothelial cells (Huber et al., 2007). Other derivative compounds of 
rapamycin, like everolimus (RAD001) and temsirolimus (Torisel), have also demonstrated 
anti-tumor properties, namely by inhibiting tumor neovascularization (reviewed in Garcia & 
Danielpour, 2008). Recently, in patients with lymphangioleiomyomatosis (LAM, a 
progressive, cystic lung disease in women, which is associated with inappropriate activation 
of mTOR) sirolimus stabilized lung function, reduced serum VEGF-D levels, and was 
associated with a reduction in symptoms and improvement in the quality of life 
(McCormack et al., 2011).  
Inhibition of lymphangiogenesis has been shown to block lymphatic metastasis by 50-70% in 
preclinical animal models, with good safety profiles, which suggests that anti-
lymphangiogenic therapy could possibly be used safely in cancer patients, without 
disrupting normal lymphatic function (reviewed in Holopainen et al., 2011). Optimally, the 
gold-standard strategy would be the one that could inhibit both angiogenic and 
lymphangiogenic cascades, in order to compromise the success of haematogenous and 
lymphogenous dissemination. Some potential compounds are being investigated (reviewed 
in Boere et al., 2010; reviewed in Cook & Figg, 2010; reviewed in Pinto et al., 2010; reviewed 
in Stacker & Achen, 2008). 
Urothelial bladder carcinoma has experienced very few therapeutic successes, regarding 
antineovascularization therapy, in the last years. Compounds like bevacizumab (Avastin®), 
aflibercept (VEGF-Trap, AVE0005), sunitinib malate (Sutent, SU11248), sorafenib (BAY 43-
9006), vandetanib (Zactima, ZD6474) and pazopanib (Votrient, GW786034) are being tested 
in preclinical and clinical trials (reviewed in Pinto et al., 2010) (Table 2). 
Bevacizumab, as has been already referred, is a monoclonal antibody that binds and 
neutralizes VEGF in the serum. Aflibercept is a soluble fusion protein of the human 
extracellular domains of VEGFR-1 and VEGFR-2, and the Fc portion of human 
immunoglobulin G. It binds, with a higher affinity than other monoclonal antibodies, to 
VEGF and additional VEGF-family members, namely VEGF-B and placental growth factor 
(PlGF). Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor, with activity 
against VEGF receptors and PDGF receptors, among others. Sorafenib is a small, oral 
molecule that inhibits various targets along the EGFR/MAPK (epidermal growth factor 
receptor / mitogen-activated protein kinase) signal transduction pathway, and also through 
VEGFR and PDGFR families. Vandetanib is a tyrosine kinase inhibitor, antagonist of VEGFR 
and EGFR. Pazopanib is a multitargeted tyrosine kinase inhibitor against VEGF receptors, c-
kit, and PDGF receptors (Cook & Figg, 2010). 
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4. Angiogenesis and Lymphangiogenesis as therapeutic targets in urothelial 
bladder cancer  
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Regarding antilymphangiogenic strategies, numerous compounds that could be used to 
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9006), vandetanib (Zactima, ZD6474) and pazopanib (Votrient, GW786034) are being tested 
in preclinical and clinical trials (reviewed in Pinto et al., 2010) (Table 2). 
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neutralizes VEGF in the serum. Aflibercept is a soluble fusion protein of the human 
extracellular domains of VEGFR-1 and VEGFR-2, and the Fc portion of human 
immunoglobulin G. It binds, with a higher affinity than other monoclonal antibodies, to 
VEGF and additional VEGF-family members, namely VEGF-B and placental growth factor 
(PlGF). Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor, with activity 
against VEGF receptors and PDGF receptors, among others. Sorafenib is a small, oral 
molecule that inhibits various targets along the EGFR/MAPK (epidermal growth factor 
receptor / mitogen-activated protein kinase) signal transduction pathway, and also through 
VEGFR and PDGFR families. Vandetanib is a tyrosine kinase inhibitor, antagonist of VEGFR 
and EGFR. Pazopanib is a multitargeted tyrosine kinase inhibitor against VEGF receptors, c-
kit, and PDGF receptors (Cook & Figg, 2010). 
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Gene Role in lymphatic vessels Inhibitorsavailable Effect of pathway inhibition 
VEGFR-2 
Receptor for the VEGF family 
of ligands. Can also 
heterodimerize with VEGFR-3.
Yes 
Secreted VEGFR-2 is a naturally 
occurring inhibitor of lymphatic 
vessel growth; however, Sorafenib† 
did not block VEGF-C/D induced 
tumor lymphangiogenesis. 
VEGFR-3 
Predominant receptor for 
VEGF-C and VEGF-D. 
Transduces survival, 
proliferation and migration 
signals. 
Yes 
Cediranib‡ blocks VEGFR-3 activity 
and inhibits lymphangiogenesis. 
Anti-VEGFR-3 antibody prevented 
tumor lymphangiogenesis with no 
effect on preexisting vessels. 
Tie1 
Not critical for lymphatic cell 
commitment during 
development, and no ligand 
has been shown. 
None 
reported. 
Tie1 knockout mouse has lymphatic 
vascular 




Receptor for Ang-1 and Ang-2. 
Appears to control vessel 
maturation. 
Yes 
Tie2-/- mice are embryonic lethal 
due to vascular defects. Inhibition 
of Ang-2 leads to tumor blood 
vessel normalization. 
EphB4 
Expressed on lymphatic 
capillary vessels. Involved in 
vascular patterning. Binds to 
the ephrinB2 ligand. 
Yes 
Mice expressing a mutant form of 
ephrinB2 lacking the PDZ binding 
domain show major lymphatic 
defects in capillary vessels and 
collecting vessel valve formation. 
FGFR3 
The ligands FGF-1 and FGF-2 
promote proliferation, 
migration, and survival of 
cultured lymphatic endothelial 
cells. FGFR3 is a direct  
transcriptional target  
of Prox1. 
Yes 
Knockdown of FGFR3 reduced 
lymphatic endothelial cells’ 
proliferation. 
IGF1R 
Both of the IGF1R ligands,  
IGF-1 and IGF-2, significantly 
stimulated proliferation  
and migration of  
primary lymphatic  
endothelial cells. 
Yes None reported. 
PDGFR 
The ligand PDGF-BB 
stimulated MAP kinase 
activity and cell motility of 
isolated lymphatic endothelial 
cells. 
Yes None reported. 
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Gene Role in lymphatic vessels Inhibitorsavailable Effect of pathway inhibition 
MET 
The ligand for c-Met, 
hepatocyte growth factor, has 
lymphangiogenic effect, but it 
is unclear if c-Met is expressed 
on lymphatic endothelial cells.
Yes May be indirect effect. 
†Sorafenib inhibits B-Raf, PDGFRb, VEGFR-2 and c-Kit. ‡Cediranib inhibits VEGFR-1, -2, -3, PDGFRb 
and c-Kit. 
Table 1. Protein tyrosine kinases involved in lymphatic biology, and available inhibitors 
(Tie- tyrosine kinase with immunoglobulin and EGF homology domain; EphB4- ephrin 
type-B receptor 4) (reprinted by permission from © 2010 BioMed Central Ltd. Originally 
published in J. Ang. Res. 2: 1-13) 
 
Principal investigator / 
organization Regimen Patient population Phase 
Siefker-Radtke/MDACC 
Methotrexate + vinblastine + 





Gemcitabine + cisplatin + 
bevacizumab → cystectomy → 
paclitaxel + bevacizumab 
Neoadjuvant/adjuvant  
(muscle-invasive) II 
Hahn/HOG Gemcitabine + cisplatin + bevacizumab First-line metastatic II 
Bajorin/MSKCC Gemcitabine + carboplatin + bevacizumab 
First-line metastatic  
(cisplatin-ineligible) II 
Rosenberg/CALGB Gemcitabine + cisplatin ± bevacizumab First-line metastatic III 
Garcia/Cleveland Clinic Sunitinib Neoadjuvant  (muscle-invasive) II 
Sonpavde/HOG Gemcitabine + cisplatin + sunitinib 
Neoadjuvant  
(muscle-invasive) II 
Bellmunt Sunitinib First-line metastatic (cisplatin-ineligible) II 
Galsky/US Oncology Gemcitabine + cisplatin + sunitinib First-line metastatic II 
Hussain/University of 
Michigan Sunitinib versus placebo 
Maintenance after first-
line chemotherapy II 
Gallagher/MSKCC Sunitinib Second-line metastatic II 
Milowsky/MSKCC Gemcitabine + cisplatin + sorafenib First-line metastatic II 
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Mice expressing a mutant form of 
ephrinB2 lacking the PDZ binding 
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lymphatic endothelial cells’ 
proliferation. 
IGF1R 
Both of the IGF1R ligands,  
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The ligand PDGF-BB 
stimulated MAP kinase 
activity and cell motility of 
isolated lymphatic endothelial 
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Yes None reported. 
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Gene Role in lymphatic vessels Inhibitorsavailable Effect of pathway inhibition 
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The ligand for c-Met, 
hepatocyte growth factor, has 
lymphangiogenic effect, but it 
is unclear if c-Met is expressed 
on lymphatic endothelial cells.
Yes May be indirect effect. 
†Sorafenib inhibits B-Raf, PDGFRb, VEGFR-2 and c-Kit. ‡Cediranib inhibits VEGFR-1, -2, -3, PDGFRb 
and c-Kit. 
Table 1. Protein tyrosine kinases involved in lymphatic biology, and available inhibitors 
(Tie- tyrosine kinase with immunoglobulin and EGF homology domain; EphB4- ephrin 
type-B receptor 4) (reprinted by permission from © 2010 BioMed Central Ltd. Originally 
published in J. Ang. Res. 2: 1-13) 
 
Principal investigator / 
organization Regimen Patient population Phase 
Siefker-Radtke/MDACC 
Methotrexate + vinblastine + 





Gemcitabine + cisplatin + 
bevacizumab → cystectomy → 
paclitaxel + bevacizumab 
Neoadjuvant/adjuvant  
(muscle-invasive) II 
Hahn/HOG Gemcitabine + cisplatin + bevacizumab First-line metastatic II 
Bajorin/MSKCC Gemcitabine + carboplatin + bevacizumab 
First-line metastatic  
(cisplatin-ineligible) II 
Rosenberg/CALGB Gemcitabine + cisplatin ± bevacizumab First-line metastatic III 
Garcia/Cleveland Clinic Sunitinib Neoadjuvant  (muscle-invasive) II 
Sonpavde/HOG Gemcitabine + cisplatin + sunitinib 
Neoadjuvant  
(muscle-invasive) II 
Bellmunt Sunitinib First-line metastatic (cisplatin-ineligible) II 
Galsky/US Oncology Gemcitabine + cisplatin + sunitinib First-line metastatic II 
Hussain/University of 
Michigan Sunitinib versus placebo 
Maintenance after first-
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Gallagher/MSKCC Sunitinib Second-line metastatic II 
Milowsky/MSKCC Gemcitabine + cisplatin + sorafenib First-line metastatic II 
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Principal investigator / 
organization Regimen Patient population Phase 
Sternberg/EORTC Gemcitabine + carboplatin ± sorafenib First-line metastatic II 
Dreicer/ECOG Sorafenib Second-line metastatic II 
Choueiri/DFCI Docetaxel ± vandetanib Second-line metastatic II 
Vaishampayan/Mayo 
Clinic Pazopanib Second-line metastatic II 
MDACC = MD Anderson Cancer Center; MUSC = Medical University of South Carolina; HOG = 
Hoosier Oncology Group; MSKCC = Memorial Sloan-Kettering Cancer Center; CALGB = Cancer and 
Leukemia Group B; EORTC = European Organization for Research and Treatment of Cancer; ECOG = 
Eastern Cooperative Oncology Group; DFCI = Dana-Farber Cancer Institute 
Table 2. Selected ongoing or recently completed trials exploring antiangiogenic therapies in 
urothelial bladder carcinoma (reprinted by permission from © 2010 Elsevier. Originally 
published in Commun. Oncol. 7: 500-504) 
4.1 Preclinical studies 
In the preclinical scenario, Videira and colleagues studied the effect of bevacizumab on 
autocrine VEGF stimulation in bladder cancer cell lines, and concluded that, at clinical 
bevacizumab concentrations, cancer cells compensate the VEGF blockade, by improving the 
expression of VEGF and related genes. This highlights the need to follow the patient’s 
adaptation response to bevacizumab treatment (Videira et al., 2011). The antiangiogenic 
treatment of tumours may restore vascular communication and, thereby, normalize flow 
distribution in tumour vasculature. The use of antiangiogenic drugs leads to improved 
tumour oxygenation and chemotherapy drug delivery (Pries et al., 2010). However, these 
mechanisms may be also the cause of malignant dissemination, because tumours elicit 
evasive resistance. Caution is recommended, due to the divergent effects that VEGF 
inhibitors can induce on primary tumor growth and metastasis (Loges et al., 2009).  
Yoon and colleagues, when exposing six human bladder cancer cell lines to an escalating 
dose of sunitinib alone or in combination with cisplatin/gemcitabine, demonstrated that 
sunitinib malate has a potent antitumor effect and may synergistically enhance the known 
antitumor effect of gemcitabine (Yoon et al, 2011).  
The first study with vandetanib in bladder cancer cell lines demonstrated its potential to 
sensitize tumor cells to cisplatin. At vandetanib concentrations of ≤2microM, the 
combination with cisplatin was synergistic, especially when given sequentially after 
cisplatin , and additive with vandetanib followed by cisplatin (Flaig et al., 2009). 
Li and colleagues studied the efficacy of pazopanib, both alone and in combination with 
docetaxel, in bladder cancer cell lines. They demonstrated that single-agent pazopanib has 
modest activity, but when given in combination with docetaxel, acted synergistically in 
docetaxel-resistant bladder cancer cells, with the potential of improved toxicity (Li et al., 2001). 
Urothelial bladder carcinoma expresses mTOR signaling molecules, providing a rationale 
for clinical trials evaluating agents targeting this pathway (Tickoo et al., 2011). In fact, some 
studies using bladder cancer cell lines have demonstrated that sirolimus and related drugs 
inhibit the growth of cancer cells and decrease their viability (Fechner et al., 2009; Hansel et 
al., 2010; Pinto-Leite et al., 2009; Schedel et al., 2011). Similar results were obtained when 
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treating bladder cancer animal models with sirolimus or everolimus (Chiong et al., 2011; 
Oliveira et al., 2011; Parada et al., 2011; Seager et al., 2009; Vasconcelos-Nóbrega et al., 2011). 
4.2 Phase II studies 
The results of a phase II trial of cisplatin, gemcitabine, and bevacizumab  (CGB) as first-line 
therapy for metastatic urothelial carcinoma revealed that CGB may improve overall survival 
― with a median follow-up of 27.2 months, overall survival time was 19.1 months. However, 
the rate of side effects was high, namely neutropenia, thrombocytopenia, anemia, and deep 
vein thrombosis/pulmonary embolism (Hahn et al., 2011).  
In a phase II trial of gemcitabine, carboplatin, and bevacizumab in patients with 
advanced/metastatic urothelial carcinoma, Balar and colleagues concluded that addition of 
bevacizumab does not improve the response rate. However, bevacizumab can be safely 
added to gemcitabine and carboplatin, because the rate of venous thromboembolisms is 
similar to the one observed with gemcitabine and carboplatin alone (Balar et al., 2011). 
Moreover, in a pooled analysis of cancer patients in randomized phase II and III studies, the 
addition of bevacizumab to chemotherapy did not statistically significantly increase the risk 
of venous thromboembolisms versus chemotherapy alone. Probably, the risk for venous 
thromboembolisms is driven predominantly by tumor and host factors (Hurwitz et al., 
2011). This type of side effect is primarily prevented by using anticoagulants simultaneously 
with cytotoxic chemotherapy (Riess et al., 2010). However, anticoagulant use during 
bevacizumab therapy may increase the risk of serious hemorrhage, although it is generally 
well tolerated (Bartolomeo et al., 2010). This controversial issue is still under scrutiny and 
more data are needed to clarify the optimal regime to reduce venous thromboembolisms in 
bladder cancer patients, particularly in those who are being treated with antiangiogenic 
drugs.   
Patients with recurrent or metastatic urothelial carcinoma who had received a prior 
platinum-containing regimen were entered in a phase II trial with aflibercept as a second-
line therapy. Aflibercept was well tolerated, but it had limited single agent activity in 
platinum-pretreated bladder cancer patients (Twardowski et al., 2009). 
In a phase II study of sunitinib in patients with metastatic urothelial cancer designed to assess 
the efficacy and tolerability of this drug in patients with advanced, previously treated 
urothelial cancer, anti-tumour responses were observed. However, sunitinib did not achieve 
the predetermined threshold of 20% activity defined by the Response Evaluation Criteria in 
Solid Tumors, and side effects such as embolic events were reported (Gallagher et al., 2010).  
In a multicenter phase II trial with sunitinib as first-line treatment in patients with 
metastatic urothelial cancer ineligible for cisplatin, on intention-to-treat analysis revealed 
that 38% of the patients showed partial responses (PRs), and 50% presented with stable 
disease (SD), the majority more than 3 months. Clinical benefit (PR + SD) was 58%. Median 
time to progression was 4.8 months and median overall survival 8.1 months (Bellmunt et al., 
2011).  
In a multicentre phase II trial of sorafenib as second-line therapy in patients with metastatic 
urothelial carcinoma, there were no objective responses to therapy. The 4-month 
progression-free survival rate was 9.5%, and the overall survival was 6.8 months (Dreicer et 
al., 2009). 
Choueiri and colleagues conducted a double-blind randomized trial in which patients with 
metastatic bladder cancer and as many as three previous chemotherapy regimens received 
intravenous docetaxel with or without vandetanib. The results demonstrated that the 
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Principal investigator / 
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tumour oxygenation and chemotherapy drug delivery (Pries et al., 2010). However, these 
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combination with cisplatin was synergistic, especially when given sequentially after 
cisplatin , and additive with vandetanib followed by cisplatin (Flaig et al., 2009). 
Li and colleagues studied the efficacy of pazopanib, both alone and in combination with 
docetaxel, in bladder cancer cell lines. They demonstrated that single-agent pazopanib has 
modest activity, but when given in combination with docetaxel, acted synergistically in 
docetaxel-resistant bladder cancer cells, with the potential of improved toxicity (Li et al., 2001). 
Urothelial bladder carcinoma expresses mTOR signaling molecules, providing a rationale 
for clinical trials evaluating agents targeting this pathway (Tickoo et al., 2011). In fact, some 
studies using bladder cancer cell lines have demonstrated that sirolimus and related drugs 
inhibit the growth of cancer cells and decrease their viability (Fechner et al., 2009; Hansel et 
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treating bladder cancer animal models with sirolimus or everolimus (Chiong et al., 2011; 
Oliveira et al., 2011; Parada et al., 2011; Seager et al., 2009; Vasconcelos-Nóbrega et al., 2011). 
4.2 Phase II studies 
The results of a phase II trial of cisplatin, gemcitabine, and bevacizumab  (CGB) as first-line 
therapy for metastatic urothelial carcinoma revealed that CGB may improve overall survival 
― with a median follow-up of 27.2 months, overall survival time was 19.1 months. However, 
the rate of side effects was high, namely neutropenia, thrombocytopenia, anemia, and deep 
vein thrombosis/pulmonary embolism (Hahn et al., 2011).  
In a phase II trial of gemcitabine, carboplatin, and bevacizumab in patients with 
advanced/metastatic urothelial carcinoma, Balar and colleagues concluded that addition of 
bevacizumab does not improve the response rate. However, bevacizumab can be safely 
added to gemcitabine and carboplatin, because the rate of venous thromboembolisms is 
similar to the one observed with gemcitabine and carboplatin alone (Balar et al., 2011). 
Moreover, in a pooled analysis of cancer patients in randomized phase II and III studies, the 
addition of bevacizumab to chemotherapy did not statistically significantly increase the risk 
of venous thromboembolisms versus chemotherapy alone. Probably, the risk for venous 
thromboembolisms is driven predominantly by tumor and host factors (Hurwitz et al., 
2011). This type of side effect is primarily prevented by using anticoagulants simultaneously 
with cytotoxic chemotherapy (Riess et al., 2010). However, anticoagulant use during 
bevacizumab therapy may increase the risk of serious hemorrhage, although it is generally 
well tolerated (Bartolomeo et al., 2010). This controversial issue is still under scrutiny and 
more data are needed to clarify the optimal regime to reduce venous thromboembolisms in 
bladder cancer patients, particularly in those who are being treated with antiangiogenic 
drugs.   
Patients with recurrent or metastatic urothelial carcinoma who had received a prior 
platinum-containing regimen were entered in a phase II trial with aflibercept as a second-
line therapy. Aflibercept was well tolerated, but it had limited single agent activity in 
platinum-pretreated bladder cancer patients (Twardowski et al., 2009). 
In a phase II study of sunitinib in patients with metastatic urothelial cancer designed to assess 
the efficacy and tolerability of this drug in patients with advanced, previously treated 
urothelial cancer, anti-tumour responses were observed. However, sunitinib did not achieve 
the predetermined threshold of 20% activity defined by the Response Evaluation Criteria in 
Solid Tumors, and side effects such as embolic events were reported (Gallagher et al., 2010).  
In a multicenter phase II trial with sunitinib as first-line treatment in patients with 
metastatic urothelial cancer ineligible for cisplatin, on intention-to-treat analysis revealed 
that 38% of the patients showed partial responses (PRs), and 50% presented with stable 
disease (SD), the majority more than 3 months. Clinical benefit (PR + SD) was 58%. Median 
time to progression was 4.8 months and median overall survival 8.1 months (Bellmunt et al., 
2011).  
In a multicentre phase II trial of sorafenib as second-line therapy in patients with metastatic 
urothelial carcinoma, there were no objective responses to therapy. The 4-month 
progression-free survival rate was 9.5%, and the overall survival was 6.8 months (Dreicer et 
al., 2009). 
Choueiri and colleagues conducted a double-blind randomized trial in which patients with 
metastatic bladder cancer and as many as three previous chemotherapy regimens received 
intravenous docetaxel with or without vandetanib. The results demonstrated that the 
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addition of vandetanib to second-line docetaxel did not result in significant improvements 
in progression-free survival, overall survival or response rates (Choueiri et al., 2011). 
The final results of a phase II study of everolimus in metastatic urothelial cell carcinoma 
have been presented at 2011 ASCO (American Society of Clinical Oncology) Annual 
Meeting. It was demonstrated that everolimus has clinical activity in patients with advanced 
urothelial bladder cancer.  For the thirty-seven evaluable patients, the median progression-
free survival was 3.3 months, and the median overall-survival was 10.5 months. Some side 
effects possibly related to everolimus were observed, namely anemia, infection, 
hyperglycemia, lymphopenia, hypophosphatemia and fatigue (Milowsky et al., 2011). 
Dovitinib (TKI258) is an oral investigational drug that inhibits angiogenic factors, including 
FGFR and VEGFR. A multicenter, open-label phase II trial of dovitinib in advanced 
urothelial carcinoma patients with either mutated or wild-type FGFR3 is currently 
underway (Milowsky et al., 2011). 
4.3 Phase III studies 
A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and 
bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced urothelial 
carcinoma is open to enrollment. The primary end point is to compare the overall survival of 
patients with advanced urothelial carcinoma treated with gemcitabine hydrochloride, 
cisplatin, and bevacizumab versus gemcitabine hydrochloride, cisplatin, and placebo. The 
secondary end points are to compare the progression-free survival, the objective response 
rate and the grade 3 and greater toxicities of these regimens in the patients (Cancer and 
Leukemia Group B, 2011). 
5. Conclusion 
Bladder cancer represents a significant health problem, and the costliest type of cancer to 
treat. Although the majority of cases present as non-muscle invasive disease, the recurrence 
and progression rates are high, which demands for long-term follow-up and repeated 
interventions. Moreover, patients with advanced tumors treated by neoadjuvant or adjuvant 
regiments frequently progress and may develop chemotherapy resistance. Therefore, 
biomarkers of tumour aggressiveness and response to therapy are urgently needed, since 
the classical formulae based on stage and grade classification are insufficient to characterize 
bladder cancer. In this sense, angiogenesis, lymphangiogenesis and lymphovascular 
invasion have been described as surrogate markers of bladder cancer progression, invasion 
and metastasis, and represent potential fields of intervention. On one hand, the combined 
analysis of these biological parameters in tumor samples with the classical 
clinicopathological parameters may improve the individual characterization of bladder 
cancer, in what concerns to its clinical and prognostic course, and should allow therapeutic 
adequacy. On the other hand, the knowledge and modulating of biological phenomena 
related with bladder cancer progression may represent a significant improvement in the 
development of new drugs and in the pathological response to therapy, which ultimately 
will lead to an increase in disease-free survival and overall survival rates. 
Targeted therapy has caused dramatic changes in the treatment of other types of tumors. 
However, in bladder cancer setting, clinical trials with molecularly targeted agents have 
been few in number and largely unsuccessful. Regarding antiangiogenic and 
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antilymphangiogenic agents, these are still considered an investigational option for 
urothelial bladder cancer patients, and more results are needed to establish their roles in the 
treatment armamentarium. Research studies with anti-neovascularization drugs should not 
only provide effective agents to treat bladder cancer patients, but also predictive biomarkers 
for response to anti-neovascularization therapy, in order to implement the concept of 
personalized therapy. 
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1. Introduction 
In cancer patients, the majority of deaths occur as a consequence of metastatic diseases. In 
addition, metastasis is a marker for poor prognosis and low quality of life in many 
malignancies. Several groups have investigated the mechanism of tumor metastasis. 
Metastatic lesions are formed through a multi-step complex process and then spread either 
locally at the site of the primary tumor, or into distant organs through the blood or 
lymphatic vessels. 
Another important feature of cancers is the chaotic behavior of tumor growth and cancer 
cell cycle progression. To maintain such activities, abundant supply of oxygen and nutrients 
are necessary. Angiogenesis refers to the formation of new blood vessels and development 
of new branching vessels from the existing tumor tissue vasculature and this pathological 
process is important to secure adequate blood supply including oxygen and nutrients to the 
rapidly dividing malignant cells. In fact, there is a good correlation between tumor 
growth/cancer cell proliferation and the extent of angiogenesis in almost of all cancers.  
While there is abundant information on the mechanisms that are involved in the initiation, 
regulation and maintenance of angiogenesis in cancer tissue, little is known about the 
mechanisms involved in the formation of new lymphatic vessels (lymphangiogenesis) in 
cancers. Furthermore, the current knowledge about cancer dissemination through the 
lymphatics lacks details about the mode of transport of cancer cells within the lymphatic 
vessels and the mechanisms involved in their exit and seeding into the distant organs. 
In this paper, we review the clinical and pathological significance of angiogenesis and 
lymphangiogenesis in bladder cancer. In addition, the mechanisms that regulate the 
formation of new vessels in bladder cancer are discussed. Specifically, we focus on the 
factors that co-regulate these two different vessels and their potential use as predictive 
marker of outcome in patients with bladder cancer. In addition, we also discuss the 
limitation of quantification of these vessels in human tissues.  
2. Angiogenesis and lymphangiogenesis  
2.1 Angiogenesis in cancer tissues 
Angiogenesis is defined as the formation of new blood vessels from pre-existing 
vasculature, and it is an integrated process of tumor growth, maintenance, and progression 
in solid tumors (Folkmann, 1992). Angiogenesis is a multistep processes involving changes 
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in the extracellular matrix, cell proliferation, cell migration, and tube formation. Blood 
vessel density (BVD), a surrogate marker for angiogenesis, correlates with the malignant 
potential and poor prognosis of patients with various types of cancers. In addition, anti-
angiogenic therapy that targets the tumor vascular supply and pathways of cancer cell 
dissemination was first introduced in 1971 (Folkman, 1971). Since then, numerous 
investigators have focused on the mechanisms of angiogenesis, including molecular 
mechanisms. At present, there is a general agreement that the regulation of tumor 
angiogenesis depends on a complex mechanism that dynamically balances angiogenic and 
anti-angiogenic factors. In this regard, these factors are secreted by both tumor cells and 
stromal cells in complicated systems. To complicate the issue, the mechanisms and 
pathological roles of these factors vary according to the type of cancer, its malignant 
potential, and systemic condition. 
2.2 Lymphangiogenesis in cancer tissues 
In addition to angiogenesis, many investigators have examined the process of 
lymphangiogenesis, i.e., the formation of new lymphatic vessels, due to its importance in 
lymph node metastasis and distant metastasis. Lymph node metastasis occurs in various 
types of malignancies and its presence is considered a strong predictor of recurrence and 
poor survival of patients with bladder cancer. However, the clinical role and prognostic 
value of lymphangiogenesis in cancer patients remain unclear, largely due to the lack of 
specific endothelial markers for lymphatic vessels as well as the lack of proper imaging 
procedures for lymphatic vessels in human tissues (Pepper, 2001). In recent years, various 
specific antibodies for lymphatic endothelial cells have been developed and used to 
investigate the clinical and pathological significance of lymphangiogenesis in cancer 
patients. Similar to angiogenesis, evidence suggests that lymphangiogenesis is also 
regulated by complex mechanisms that include a variety of factors. While various common 
mechanisms regulate the processes of angiogenesis and lymphangiogenesis, other 
mechanisms vary according to these processes. For example, in contrast to angiogenesis, no 
intrinsic anti-lymphangiogenic molecules have yet been isolated.  
Thus, to discuss the pathological roles, predictive values, and potential therapeutic targets 
of angiogenesis and lymphangiogenesis, it is important to understand the various complex 
mechanisms and cooperative functions involved in these two processes.  
2.3 Angiogenesis and lymphangiogenesis in bladder cancer 
BVD is often used in the analysis of human cancer tissues as a surrogate and semi-
quantitative marker of angiogenesis. Previous studies suggested that BVD provides 
significant information on prognosis and survival in patients with bladder cancer (Streeter & 
Harris, 2002; Goddard, 2003). However, other investigators were less supportive for the 
prognostic value of BVD, especially in patients with non-muscle-invasive bladder cancer 
(NMIBC) (Korkolopoulou, et al., 2001; Ioachim, et al., 2006; Miyata, et al., 2006). Table 1 
provides a summary of the currently held opposing views on BVD.  
Such discrepancy could be attributed to differences in methodology, such as methods used 
for counting, size of the field of view, definition of microvessel, and antibodies used in 
different assays. For example, measurement at periphery or growth from of the tumor 
(Stavropoulos et al., 2004) or at highest vascularity “hot spots” (Korkolopoulou et al., 2001). 
Furthermore, the diameter of the microvessel was no mentioned in some studies; though 
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other provided descriptive terms (the lumen diameter was smaller than approximately eight 
red blood cells) (Stavropoulos, 2004). More detailed problems are described in the following 
section.  
 
Patients Findings Reference 
109 NMIBC Predictor of muscle invasion in G3 patients, 
though not an independent factor. 
Starvropoulos 
66 NMIBC Independent predictor of recurrence-free 
survival, particularly in T1G2 tumors 
Santos 
35 NMIBC + 80 
MIBC 
Independent predictor for overall survival in 
MIBC. No significant role in NMIBC 
Korkolopoulou 
87 NMIBC + MIBC Independent predictor of lymph node metastasis. Susuki 
104 NMIBC + 22 
MIBC 
Not significant for recurrence-free, metastasis-
free, or cause-specific survival. 
Miyata 
NMIBC: non-muscle-invasive bladder cancer, MIBC: muscle-invasive bladder cancer 
Table 1. Predictive value of blood vessel density (BVD) for progression and survival. 
In addition to semi-quantitative measures of BVD, vascular invasion by tumor cells (blood 
vessel invasion, BVI) has also been identified as a prognostic factor in bladder cancer 
(Harada et al., 2005). Furthermore, vascular area and various parameters related to the 
shape, relapse, and/or complexity of the vessels have been suggested as important for more 
detailed discussion on the relationship between angiogenesis and pathological role, 
prognosis, and survival. In this regard, several investigators paid special attention to the 
morphological variability in the vascular pattern (Korkolopoulou et al., 2001; Sharma et al., 
2005), and one study reported that the vascular area was an independent predictor of overall 
survival in patients with T1 disease whereas BVD was not (Korkolopoulou et al., 2001).  
In contrast to angiogenesis, there is little or no information on the clinical and pathological 
significance and predictive value of lymphangiogenesis in patients with bladder cancer. 
Several studies reported that higher LVD correlates significantly with malignant behavior, 
cancer cell progression, and prognosis (Fernández et al., 2008; Miyata et al., 2006). In 
addition, one report indicated that the pathological role of lymphangiogenesis was 
depended on the location of lymphatic vessels, such as intra-tumoral and peri-tumoral area. 
In other words, intra-tumoral LVD correlated with histological differentiation, and peri-
tumoral LVD correlated with lymph node metastasis (Fernández, et al., 2008). Similar to 
BVI, of lymphatic vessel invasion (LVI) by tumor cells was also identified as a prognostic 
factor in bladder cancer (Algaba, 2006). In general, however, information on 
lymphangiogenesis in human bladder cancer is to a large extent scarce, compared to that on 
angiogenesis.  
2.4 Regulation of angiogenesis and/or lymphangiogenesis 
Members of the vascular endothelial growth factor (VEGF) family are the most important 
molecules involved in the processes of angiogenesis and lymphangiogenesis. This family 
consists of 7 members, including VEGF-A, -B, -C, -D, and -E, svVEGF, and placental growth 
factor. In addition, three types of receptors have so far been identified: VEGFR-1, -2, and -3 
(Takahashi et al., 2005). The angiopoietin (Ang) family also encompasses several pro-
angiogenic factors. This family consists of Ang-1 and -2 and Tie2 tyrosine kinase receptors, 
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and the system is influenced by VEGF family. In addition, several factors, for example, 
fibroblast growth factor (FGF)-2, hepatocyte growth factor (HGF), and insulin-like growth 
factor (IGF), are also reported to be involved in the regulation of both angiogenesis and 
lymphangiogenesis.  
Angiostatin and endostatin, which are both produced by proteolytic cleavage of 
plasminogen and collagen XVIII, respectively, are well characterized anti-angiogenic factors. 
(O’Reilly, et al., 1994, 1997). In addition, thrombospondins (TSPs) also inhibits angiogenesis 
(Lawler, 2000). Another report indicated that down-regulation of TSP-1 secretion in bladder 
cancer tissues was a key event in the change from an anti-angiogenic to an angiogenic 
phenotype during carcinogenesis (Campbell, et al., 1998). On the other hand, there are 
conflicting results on the relationship between TSP-1 expression and BVD in human bladder 
cancer. Specifically, TSP-1 staining correlated negatively with BVD (Grossdfeld et al., 1997), 
whereas other investigators reported that TSP-1 expression correlated positively with BVD 
(Ioachim et al., 2006).  
We review here in detail two representative pro-angiogenic factors; VEGF family and Ang 
family. Their selection was based on the finding that they are potential therapeutic targets in 
various cancers. Actually, targeted therapies based on these factors have been tested already 
in patients with bladder cancer. Unfortunately, however, anti-angiogenic factor-targeted 
therapy is still in its infancy and there is little possibility to use such drugs for treatment of 
bladder cancer in the near future.  
2.5 VEGF family 
Among the VEGF family members, VEGF-A is a major regulator of angiogenesis. On the 
other hand, both VEGF-C and VEGF-D have been found to play major roles in 
lymphangiogenesis. Furthermore, VEGFR-2 and VEGFR-3 are reported to be the major 
mediators of angiogenic response in blood endothelial cells and lymphangiogenic response 
in lymphatic endothelial cells, respectively. In other words, VEGF-A signaling through 
VEGFR-2 is the major pathway that activates angiogenesis by stimulating cell proliferation, 
survival, and migration of endothelial cells (Shibuya & Claesson-Welsh, 2006). Furthermore, 
the VEGF-C/D-VEGFR-3 signaling pathway is important for the growth of lymphatic 
endothelial cells (Skobe et al. 2001; Stacker et al., 2001; Lin, et al., 2005). In support of this 
notion, blocking the VEGF-C/D-VEGFR-3 signaling pathway was reported to inhibit tumor 
lymphangiogenesis and lymph node metastasis in several xenograft and transgenic tumor 
models (He et al., 2002; Lin et al., 2005; Roberts et al., 2006).  
In contrast to the above studies, several groups reported that VEGF-A could stimulate 
lymphangiogenesis in vivo (Nagy et al., 2002; Cursiefen et al., 2004). In addition, in an 
animal model of chemically-induced skin cancer, VEGF-A induced lymphangiogenesis and 
promoted lymphatic metastasis (Hirakawa et al., 2005). Conversely, VEGF-C and VEGF-D 
were reported to play important roles in angiogenesis under various physiological and 
pathological conditions (Cao 1998, Jussila & Alitalo, 2002).  
VEGFR-1 has a high affinity for VEGF-A, VEGF-B, and PIGF. However, its tyrosine kinase 
activity is comparatively weak (Autiero, et al., 2003; Shibutya & Claesson-Welsh, 2006). 
VEGFR-1 is expressed in endothelial cells. In addition, it is also expressed in 
monocytes/macrophages, hemopoietic cells, and pericytes. Its tyrosine kinase activity is 
required for stimulation of hemopoietic cell migration towards VEGFs and PIGFs (Barleon, 
et al., 1996; Clauss, et al. 1996). Based on these results, VEGF-B, PIGF, and VEGFR-1 are 
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thought to play minimal roles in angiogenesis. In fact, they do not activate angiogenesis 
during development. However, they have been reported to exhibit angiogenic activity 
under a variety of pathological conditions (Fisher et al., 2008). For examples, in animal 
experiments, PIGF was associated with angiogenesis in various pathological conditions 
including ischemia, inflammation, and tumor growth (Carmeliet, et al., 2001; Luttun, et al., 
2002).  
The role of VEGFR-2 in lymphangiogenesis is still controversial. VEHGR-2 is expressed at 
low levels in lymph vessels, and VEGF-VEGFR-2 signaling can induce lymphatic vessel 
formation (Hong et al., 2004). On the other hand, evidence suggests that lymphangiogenesis 
induced by such system involves the recruitment of immune cells producing VEGF-C and –
D (Crusiefen, et al., 2004). 
The following schematic diagram illustrates the relationship between VEGFs and VEGFRs 
and angiogenesis and lymphangiogenesis: 
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expression of VEGF-C in bladder cancer was a significant and independent predictor of 
pelvic lymph node metastasis. Thus, these reports have demonstrated that VEGF-C plays 
important role in the malignant aggressiveness and its overexpression is associated with 
poor prognosis of patients with bladder cancer. On the other hand, controversy exists 
regarding the prognostic value of VEGF-C expression in bladder cancer (Mylona, et al., 
2006).  
The fact that VEGF-C binds to and stimulates phosphorylation of tyrosine kinase receptor 
VEGFR-3 is well-known. In addition to VEGFR-3, VEGF-C also binds and activates VEGFR-
2, but not VEGFR-1 (Roberts, et al., 2006). Because VEGFR-2 is the major pathway of 
angiogenesis, it is possible that VEGF-C also correlates with angiogenesis in bladder cancer. 
One study of 45 patients with bladder cancer reported that VEGF-C expression did not 
correlate with microvessel density (Zu, et al., 2006). On the other hand, we found that 
VEGF-C expression correlated positively with both MVD and LVD in 126 patients with 
bladder cancer. Another group reported that VEGF-C expression correlated with intra-
tumoral BVD, but not with overall BVD. They also showed that VEGF-C expression 
correlated significantly with both intra-tumoral and peri-tumoral LVD (Afonso, et al., 2009). 
The reasons for these discrepancies are probably related to differences in antibodies used to 
measure MVD and also differences in sample size.  
VEGF-D expression is also reported to be significantly associated with pathological features 
and prognosis of patients with bladder cancer (Miyata et al, 2006; Herrmann, et al., 2007). In 
addition, several studies demonstrated that VEGF-D expression also correlated with tumor 
growth, metastasis, and survival of patients with bladder cancer (Miyata, et al., 2006; 
Herrmann, et al, 2007). However, in comparison with VEGF-C, information regarding 
pathological significance and predictive value of VEGF-D in patients with bladder cancer is 
very limited.  
Similarly, there is a little information on VEGF-B expression in bladder cancer. To our 
knowledge, there is only one study on VEGF-B m-RNA expression in bladder cancer tissues 
(Fauconett, et al., 2009). These authors used Northern blot analysis and reported the lack of 
VEGF-B mRNA expression in 37 bladder cancer specimens.  
2.7 Ang family in cancers including bladder cancer 
Angiopoietin (Ang)-1 and -2 have angiogenic function acting on Tie2 tyrosine kinase 
receptors (Maisonpierre, et al., 1997; Papapetropoulos, et al., 1999). Ang-1 is known as 
stabilizing factor because it helps to maintain and stabilize mature vessels by promoting 
interactions between endothelial cells and neighboring cells including pericytes and smooth 
muscle cells (Maisonpierre, et al., 1997; Papapetropoulos, et al., 1999, 2000). In contrast, Ang-
2 is known as an antagonist to Ang-1 because it is expressed at sites of vascular remodeling 
and acts to destabilize vessels (Maisonpierre, et al., 1997). Interestingly, Ang-2 is reported to 
potentiate angiogenesis in the presence of VEGF, but causes regression of this process in the 
absence of VEGF (Maisonpierre, et al., 1997; Holash, et al., 1999). Thus, the angiopoietin-Tie2 
system, comprising Ang-1, Ang-2, Tie2, and VEGF, seems to be regulated by complex 
mechanisms.  
In bladder cancer, there are conflicting results on the clinical and pathological significance of 
angiopoietin-Tie2 system. One study demonstrated a significant correlation between Ang-2 
protein expression and high stage, high grade tumors, and poor prognosis, whereas Ang-1 
protein expression did not show the same trend (Oka, et al., 2005). It also showed that Ang-2 
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expression was an independent predictor of overall survival in patients with bladder cancer. 
On the other hand, Ang-2 mRNA expression in early stage superficial carcinomas and low 
grade tumors was reported to be significantly higher than in advanced stage muscle 
invasive carcinomas and high grade tumors (Quentin, et al., 2004). In comparison, the same 
study also reported that Ang-1 mRNA was expressed at significantly low levels in low 
grade and early stage tumors compared to high grade or advanced stage tumors. Other 
studies on Ang-1 and Ang-2 demonstrated the presence of significantly higher serum levels 
of Ang-1 in patients with bladder cancer relative to the control; and conversely, Ang-2 and 
Tie2 levels were significantly lower. (Szarvas, et al., 2009). The same study also showed that 
high Tie2 serum level was an independent prognostic factor for metastasis in multivariate 
analysis model that included tumor grade and stage.  
2.8 Limitation of quantification of angiogenesis and lymphangiogenesis 
BVD is often used as a quantitative marker of angiogenesis. The method used for 
quantification was first described after antibodies to factor VIII-related antigen became 
commercially availability; these antibodies were used to immunohistochemically stain blood 
vessels. Since then, various immunohistochemical pan-endothelial markers, such as CD31, 
CD34, von-Willebrand factor, have been used to stain and study blood vessels. CD31, also 
known as PECAM-1 (Platelet Endothelial Cell Adhesion Molecule-1), is a 130 KDa integral 
membrane protein, and is expressed constitutively on the surface of adult and embryonic 
endothelial cells. The CD34 protein is a member of a family of single-pass transmembrane 
proteins expressed on blood vessel endothelial cells (Nielsen & McNagny, 2008). However, 
these markers cannot distinguish between small and large blood vessels (Hassan, et al., 
2002). On the other hand, CD105, also known as endoglin, is a disulphide-linked, 
proliferation-associated, hypoxia-inducible homodynamic cell membrane glycoprotein, and 
is known to be over-expressed in proliferating endothelial cells and is strongly up-regulated 
in endothelial cells of neoplastic tissues compared with normal cells (Fonasanti, et al., 2002; 
Minhajat, et al., 2006). Based on these properties, many recent studies have recommended 
the use of CD105 for evaluation of angiogenesis in tumor tissues because it reflects the 
dynamic status of tumor-related angiogenesis compared to other pan-endothelial markers 
(Sharma, et al., 2005). In fact, so far, CD105 antibody was demonstrated to have a greater 
specificity for tumor vasculature than other pan-endothelial markers, such as CD31, CD34, 
and Factor VIII in a clinical study of colorectal cancer (Saadi, et al., 2004). 
In bladder cancer tissues, several antibodies have been used to evaluate angiogenesis. These 
include factor VIII (Lianes, et al., 1998; Shirotake, et al., 2011), CD31 (Korkolopoulos, et al., 
2001; Afonso, et al., 2009), and CD34 (Shirotake, et al., 2011; Stavropoulos, et al., 2004; 
Ioachim, et al., 2006); whereas CD105 has rarely been used in bladder cancer tissues.  
It is suggested that CD31, CD34, and CD105 are more useful because they efficiently 
recognize small-caliber vessels that are associated with angiogenesis in bladder cancer than 
factor VIII (Santos, et al., 2003). However, this study did not discuss the difference between 
these markers. Thus, to date, there is no ideal antibody to truly reflect the clinical and 
pathological significance of angiogenesis in bladder cancer. To this effect, some investigators 
have doubted the pathological significance and predictive value of BVD in patients with 
bladder cancer (Table 2).  
Similar to angiogenesis, there is no ideal antibody that reflects the significance of 
lymphangiogenesis. In general, three different antibodies such as anti-lymphatic vessel 
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endothelial hyaluronan receptor (LYVE)-1 (Yang, et al., 2011), anti-VEGFR-3 (Zhou et al., 
2011) and anti-D2-40 (Miyata, et al., 2006; Afonso, et al., 2009,) have been used to detect 
lymphatic vessels. However, detailed information on the differences and characteristics of 
each of these factors is not available. Further studies are necessary to discuss the methods of 
quantification and evaluation of lymphangiogenesis in bladder cancer tissues.  
 
 n Antibody Progression Survival Reference year 
NMIBC 35 CD31 No No Korkolopoulou 2001 
NMIBC 66 CD31+CD34+FVIII Yes* – Santos 2003 
NMIBC 109 CD34 Yes** – Stavropoulos 2004 
MIBC 109 FVIII No No Linanes 1998 
MIBC 80 CD31 Yes No Korkolpoulou 2001 
Both 113 CD31+CD34 No Yes Bochener 1995 
Both 148 CD34 No No Ioachim 2006 
Both 42 CD31+FVIII – – Gehani 2011 
NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; 
FVIII, factor VIII. * In T1/grade 2 patients. ** In grade 3 patients. 
Table 2. Prognostic significance of blood vessel density (BVD)  
3. Conclusion 
Angiogenesis and lymphangiogensis play important roles for tumor growth and 
progression in bladder cancer. VEGF family and Ang family are well known to be associated 
with these phenomenon in bladder cancer. However, other factors and molecules are also 
speculated to regulate them by complex mechanism. So, detailed mechanism of their 
regulations is still fully understood. In addition, further studies are necessary to discuss the 
methods of quantification and evaluation of angiogenesis and lymphangiogenesis in 
bladder cancer tissues.  
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lymphatic vessels. However, detailed information on the differences and characteristics of 
each of these factors is not available. Further studies are necessary to discuss the methods of 
quantification and evaluation of lymphangiogenesis in bladder cancer tissues.  
 
 n Antibody Progression Survival Reference year 
NMIBC 35 CD31 No No Korkolopoulou 2001 
NMIBC 66 CD31+CD34+FVIII Yes* – Santos 2003 
NMIBC 109 CD34 Yes** – Stavropoulos 2004 
MIBC 109 FVIII No No Linanes 1998 
MIBC 80 CD31 Yes No Korkolpoulou 2001 
Both 113 CD31+CD34 No Yes Bochener 1995 
Both 148 CD34 No No Ioachim 2006 
Both 42 CD31+FVIII – – Gehani 2011 
NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; 
FVIII, factor VIII. * In T1/grade 2 patients. ** In grade 3 patients. 
Table 2. Prognostic significance of blood vessel density (BVD)  
3. Conclusion 
Angiogenesis and lymphangiogensis play important roles for tumor growth and 
progression in bladder cancer. VEGF family and Ang family are well known to be associated 
with these phenomenon in bladder cancer. However, other factors and molecules are also 
speculated to regulate them by complex mechanism. So, detailed mechanism of their 
regulations is still fully understood. In addition, further studies are necessary to discuss the 
methods of quantification and evaluation of angiogenesis and lymphangiogenesis in 
bladder cancer tissues.  
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Japan 
1. Introduction 
Bladder cancer is the second most common cancer of the urinary system. An estimated 
386,300 new cases and 150,200 deaths from bladder cancer occurred in 2008 worldwide 
(Jemal et al., 2011). The highest rates of bladder cancer incidence are found in industrially 
developed countries, particularly in North America and Western Europe (Parkin et al., 
2005). Bladder cancer is more common in males. The cancer is the 7th most common cancer 
in males worldwide and 4th most common cancer in males in industrially developed 
countries, while the cancer is not ranked in the top 10 most common cancers in females even 
in industrially developed countries (Jemal et al., 2011). In industrially developed countries, 
approximately 90% of the cancers are transitional cell carcinomas (TCCs), while the 
remaining 10% are squamous cell carcinomas and adenocarcinomas (Stein et al., 2001).  
There are several potential biomarkers for diagnosis and prognosis for bladder cancer, 
including Nuclear matrix protein-22 (NMP-22), human complement factor H related 
protein, telomerase, fibrin degradation product, and hyaluronic acid (Dey, 2004). Among 
these, only two biomarkers, NMP-22 and human complement factor H related protein, are 
in clinical use in Japan. Although these two markers are in clinical use, sensitivity and 
specificity of these markers are not perfect (van Rhijn et al., 2005); NMP-22 staining shows 
false positivity reactions in patients with hematuria, and the BTA (bladder tumour antigen) 
stat/BTA TRAK assay, which detects human complement factor H related protein, shows 
false positivity reactions in patients with urinary tract inflammation, recent genitourinary 
tumours and in cases of bladder stone (Dey, 2004). Cytology is still the most accurate 
diagnosis method, although sensitivity is not enough high (van Rhijn et al., 2005). Thus, 
discovery of a novel biomarker, which is sensitive and specific for bladder cancer, is an 
urgent subject. 
2. UHRF1 is a potential molecular marker for diagnosis and prognosis of 
bladder cancer 
UHRF1 (ubiquitin-like with PHD and ring finger domains 1), also known as ICBP90 
(Inverted CCAAT box-binding protein of 90 kDa), was identified as a protein, whose 
expression is only detectable in proliferating cells, not in quiescent cells (Hopfner et al., 
2000; Unoki et al., 2004). UHRF1 plays a central role in transferring DNA methylation status 
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1. Introduction 
Bladder cancer is the second most common cancer of the urinary system. An estimated 
386,300 new cases and 150,200 deaths from bladder cancer occurred in 2008 worldwide 
(Jemal et al., 2011). The highest rates of bladder cancer incidence are found in industrially 
developed countries, particularly in North America and Western Europe (Parkin et al., 
2005). Bladder cancer is more common in males. The cancer is the 7th most common cancer 
in males worldwide and 4th most common cancer in males in industrially developed 
countries, while the cancer is not ranked in the top 10 most common cancers in females even 
in industrially developed countries (Jemal et al., 2011). In industrially developed countries, 
approximately 90% of the cancers are transitional cell carcinomas (TCCs), while the 
remaining 10% are squamous cell carcinomas and adenocarcinomas (Stein et al., 2001).  
There are several potential biomarkers for diagnosis and prognosis for bladder cancer, 
including Nuclear matrix protein-22 (NMP-22), human complement factor H related 
protein, telomerase, fibrin degradation product, and hyaluronic acid (Dey, 2004). Among 
these, only two biomarkers, NMP-22 and human complement factor H related protein, are 
in clinical use in Japan. Although these two markers are in clinical use, sensitivity and 
specificity of these markers are not perfect (van Rhijn et al., 2005); NMP-22 staining shows 
false positivity reactions in patients with hematuria, and the BTA (bladder tumour antigen) 
stat/BTA TRAK assay, which detects human complement factor H related protein, shows 
false positivity reactions in patients with urinary tract inflammation, recent genitourinary 
tumours and in cases of bladder stone (Dey, 2004). Cytology is still the most accurate 
diagnosis method, although sensitivity is not enough high (van Rhijn et al., 2005). Thus, 
discovery of a novel biomarker, which is sensitive and specific for bladder cancer, is an 
urgent subject. 
2. UHRF1 is a potential molecular marker for diagnosis and prognosis of 
bladder cancer 
UHRF1 (ubiquitin-like with PHD and ring finger domains 1), also known as ICBP90 
(Inverted CCAAT box-binding protein of 90 kDa), was identified as a protein, whose 
expression is only detectable in proliferating cells, not in quiescent cells (Hopfner et al., 
2000; Unoki et al., 2004). UHRF1 plays a central role in transferring DNA methylation status 
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from mother cells to daughter cells. Its SET and RING finger-associated (SRA) domain 
recognizes hemi-methylated DNA that appears in newly synthesized daughter DNA 
strands during duplication of DNA strands through the S phase (Arita et al., 2008; 
Avvakumov et al., 2008; Hashimoto et al., 2008). UHRF1 recruits DNA methyltransferase 1 
(DNMT1) to the site with proliferating cell nuclear antigen (PCNA) and methylates the 
newly synthesized strands (Achour et al., 2008; Sharif et al., 2007). UHRF1 also recognizes 
tri/di-methylated H3K9, and recruits the H3K9 methyltransferase G9a, the histone 
deacetylase 1 (HDAC1), and the histone acetylase Tip60 (Achour et al., 2009; Hashimoto et 
al., 2009; Karagianni et al., 2008; Kim et al., 2009; Unoki et al., 2004), indicating that UHRF1 
links DNA methylation and histone modification status (Fig. 1).  
 
 
Fig. 1. Proposed mechanism of heterochromatin formation through UHRF1 at DNA 
replication fork or DNA repair site. 1) UHRF1 binds to PCNA and the SRA domain of 
UHRF1 recognizes hemi-methylated CpG on newly synthesized DNA. Then histones are 
reassembled. 2) UHRF1 recruits DNMT1 to methylate both DNA strands to transfer 
methylation status. UHRF1 also recruits G9a to methylate histone H3K9. Methylated histone 
H3K9 interacts with the Tudor-PHD domain of UHRF1. 3) UHRF1 recruits HDAC1 to the 
site and deacetylates histones. Then, histones become charged positively and bind to 
negatively charged DNA tightly, causing heterochromatin formation. This figure is cited 
from our article (Unoki et al., 2009a). 
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UHRF1 promotes G1/S transition (Arima et al., 2004; Jeanblanc et al., 2005) and is a direct 
target of E2F transcription factor 1 (E2F1) (Abbady et al., 2005; Mousli et al., 2003; Unoki et 
al., 2004). The tumour suppressor p53, which is deficient in 50% of all human cancers 
(Hussain & Harris, 2000), indirectly down-regulates UHRF1 through up-regulation of 
p21/WAF1 and subsequent deactivation of E2F1 (Arima et al., 2004) (Fig. 2). 
 
 
Fig. 2. Proposed p53-UHRF1 pathway model. 
Expression of UHRF1 is up-regulated in various cancers, including breast cancer (Fig. 3), 
lung cancer (Fig. 4), prostate cancer, astrocytoma, pancreatic cancer, cervical cancer, and 
poorly differentiated thyroid carcinoma (Crnogorac-Jurcevic et al., 2005; Jenkins et al., 
2005; Lorenzato et al., 2005; Mousli et al., 2003; Oba-Shinjo et al., 2005; Pita et al., 2009; 
Unoki et al., 2010; Unoki et al., 2004). Overexpression of UHRF1 in these cancers could be 
partially due to the inactivation of p53, although there could be several pathways, which 
regulate expression of UHRF1. Knock down of UHRF1 expression in cancer cells suppressed 
cell growth, indicating that UHRF1 is essential for progression of cancers and thus could be 
an anticancer drug target (Tien et al., 2011; Unoki, 2011; Unoki et al., 2009a; Unoki et al., 
2004; Yan et al., 2011). Moreover, knockdown or inactivation of UHRF1 is reported to 
enhance sensitivity against current chemotherapies and radiation therapy in vitro (Alhosin 
et al., 2010; Jenkins et al., 2005; Jin et al., 2010; Li, X. et al., 2011; Li, X. L. et al., 2009; Muto 
et al., 2002). Therefore, UHRF1 is also an attractive target of cancer combination therapies 
(Bronner et al., 2007; Unoki, 2011; Unoki et al., 2009a). 
 
 
Fig. 3. Expression of UHRF1 in breast cancer clinical samples detected by semi-quantitative 
RT-PCR. This figure is cited from our article (Unoki et al., 2004). 
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Fig. 4. Expression of UHRF1 in lung cancer clinical samples detected by 
immunohistochemistry. Representative data of UHRF1 staining in small cell lung carcinoma 
(SCLC), fibrosarcoma, and non-adenocarcinoma (ADC) histological types of non-small-cell 
lung carcinoma including squamous cell carcinoma (SCC), large cell carcinoma, and 
adenosquamous carcinoma (x 200). This figure is cited from our article (Unoki et al., 2010). 
2.1 UHRF1 is overexpressed in bladder cancer 
Considering these features of UHRF1, we thought that UHRF1 could be also important for 
bladder carcinogenesis, and examined expression of UHRF1 in bladder cancer specimens 
obtained from 124 UK cases (Table 1) and 36 Japanese cases (Unoki et al., 2009b). As a 
result, we found that UHRF1 was significantly overexpressed in bladder cancers at the 
mRNA and protein level (Fig. 5 and Fig. 6).   
Because overexpression of UHRF1 in the cancer was detected both in UK cases and also in 
Japanese cases, the overexpression of UHRF1 could be common worldwide. Recently, 
another group showed that UHRF1 is also overexpressed in superficial, non-muscle-
invasive bladder cancer of Chinese cases (Yang et al., 2011). Their result supports our 
observation. We also examined correlation between expression of UHRF1, p53, and 
p21/WAF1, and observed accumulation of stabilized p53 protein, which is probably mutated, 
in cancer tissues at grade II-III. However, we did not observe any accumulation of p53 in 
cancer tissues at grade I, although overexpression of UHRF1 was observed in this grade 
(Fig. 7). There was no relationship between expression levels of UHRF1 and p21 mRNA. 
Therefore, UHRF1 seems to be superior to p53 as a potential diagnostic marker of bladder 
cancer. This result is concordant with the fact that p53 is mutated only in 10-30 % of bladder 
cancer cases (Berggren et al., 2001; Lorenzo Romero et al., 2004). 
 













Fig. 5. Expression levels of UHRF1 mRNA in urinary system tumours and normal tissues 
detected by TaqMan qRT-PCR. Expression of UHRF1 in 12 different normal tissues,  
21 normal kidneys, 6 oncocytomas, 71 kidney tumours, 21 normal bladders, and 124 bladder 
tumours, including 112 bladder located transitional cell carcinomas (TCCs) and 12 TCCs 
occurred in upper tract, were compared. Expression of UHRF1 differed among the seven 
groups (p<0.0001, Kruskal-Wallis’ test). Expression of UHRF1 in the kidney cancers was 
higher than that in the normal kidneys and also in the oncocytomas significantly (p<0.0001, 
and p=0.0206, respectively, Mann-Whiteney’s U-test), but expression levels of UHRF1 in the 
bladder cancers were much higher than those in the kidney cancers (p<0.0001, Mann-
Whiteney’s U-test). Among the bladder cancers, expression of UHRF1 was significantly high 
in upper tract TCCs (n=12) compared with the bladder-origin bladder tumours (n=112) 
(Mann-Whiteney’s U-test; p=0.0042). 2-microgloblin was used for normalization. Asterisk 
indicates statistically significant p-values. This figure is cited from our article  
(Unoki et al., 2009b). 
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Characteristics an (%)  Characteristics n (%) 
Total numbers of patients 124 Sex
Anatomic site   Male 75 (72%) 
   Bladder 112 (90%)     Female 29 (28%) 
   Upper tract 12 (10%) Numbers of tumours
Type   <4 53 (85%) 
   TCC 122 (>99%)     >4 9 (15%) 
   Others 1 (<1%) Tumour size
Invasiveness   <5 38 (66%) 
   Superficial 71 (63%)   >5 20 (34%) 
   Invasive 41 (37%) Growth pattern
T-category   cCIS 1 (2%) 
   Ta 40 (35%)   Papillary 32 (52%) 
   T1 32 (28%)   Solid 19 (31%) 
   T2 24 (21%)   Solid/Papillary 9 (15%) 
   T3 14 (12%) Recurrence
   T4 4 (4%)   No 19 (29%) 
WHO grading   Yes 46 (71%) 
   Grade 1 9 (8%) 5-years survival
   Grade 2 59 (51%)   Alive 46 (49%) 
   Grade 3 47 (41%)   Dead 48 (51%) 
Risk after bTURBT Smoking
   Low 7 (13%)   Non-smoker 22 (35%) 
   Intermediate 26 (46%)   Smoker 40 (65%) 
   High 23 (41%)
aTotal numbers of the patients are not always 124, because not all patients have all the clinical 
information; bTURBT, transurethral resection of the bladder tumour; cCIS, carcinoma in situ.  
Table 1. Base line characteristics of bladder cancer patients used for our analyses (Unoki et 
al., 2009b). 
We also examined expression of UHRF1 in kidney cancer, another urinary system tumour, 
together with the bladder cancer by immunohistochemistry. Although overexpression of 
UHRF1 is significant at mRNA level (Fig. 5), expression of UHRF1 in kidney cancer was not 
detected at protein level (Fig. 8A).  Therefore, immunohistochemical staining of UHRF1 in 
the cancer seems not to be useful.  However, overexpression of UHRF1 at the mRNA level 
was associated with several characteristics of kidney cancer patients including 5-year 
survival rates, pathological staging and histological grade (Fig. 8B-D). Thus, detection of 
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UHRF1 mRNA overexpression in surgical specimen might be useful as a prognosis tool in 




     
Fig. 6. Immunohistochemical staining of UHRF1 in 13 bladder tumour cases. A. 
Expression of UHRF1 in 11 transitional cell carcinomas and two adenocarcinomas with 
the different stage and grade. High expression of UHRF1 was detected only in nucleus of 
cancer cells, not in stromal cells. B. Expression of UHRF1 in normal tissues including 
bladder, lung, liver, heart, and kidney. No expression was observed in these normal 
tissues. Original magnifications, x 200 (top), and x 400 (bottom). C. Representative images 
of normal IgG staining as a negative control (Case 11 used for Fig. 6A). Original 
magnifications, x 200 (top), and x 400 (bottom). This figure is cited from our article  
(Unoki et al., 2009b). 
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Fig. 7. Expression of p53 and UHRF1 in bladder cancers detected by immunohistochemistry. 
This figure is cited from our article (Unoki et al., 2009b). 
 




Fig. 8. Expression of UHRF1 in kidney cancer. A. UHRF1 expression in kidney cancers 
examined by immunohistochemistry. Magnification level is x400. B. Expression levels of 
UHRF1 correlate with 5-years’ survival rate of kidney tumours detected by TaqMan qRT-
PCR. Patients were categorized into two groups by expression levels of UHRF1. The UHRF1 
high expression group is a group, which expresses UHRF1 eight or more (≥8) and the low 
expression group is a group, which expresses UHRF1 less than eight fold (<8) compared 
with average of UHRF1 expression level in normal kidney from 21 individuals as 1.0. In the 
result of Kaplan-Meier survival analysis, the UHRF1 high expression group showed 
significantly poor survival rate compared with the UHRF1 low expression group (p=0.0096: 
Logrank test). 2-microgloblin was used for normalization. C. Expression levels of UHRF1 
correlated with histological grade of kidney tumours detected by TaqMan qRT-PCR. 
Patients were categorized into four groups by histological grade (I to IV). High expression of 
UHRF1 correlated with advanced grade (p=0.0093: Kruskal-Wallis’s test). 2-microgloblin 
was used for normalization. D. Expression levels of UHRF1 correlated with pathological 
staging and histological grade of renal cancers detected by TaqMan qRT-PCR. Patients were 
categorized into three groups with pathological stages, pT1 to pT3. High expression of 
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UHRF1 correlated with advanced stage (p=0.0005: Kruskal-Wallis’s test). 2-microgloblin was 
used for normalization. This figure is cited from our article (Unoki et al., 2009b). 
2.2 Expression level of UHRF1 correlates with malignancy of bladder cancer 
We examined correlations between UHRF1 expression in bladder cancer and various clinical 
features of the patients (Table 1). Among these features, the expression of UHRF1 correlated 
with the T-category and the WHO histological grading significantly (Fig. 9A and 9B). 
Expression level of UHRF1 in superficial bladder cancers (T-category: Ta and T1) and 
invasive bladder cancers (T-category classification: T2, T3 and T4) was both significantly 
higher than that in normal bladders. This result is concordant with data from the another 
group (Yang et al., 2011). In addition, expression of UHRF1 in invasive bladder cancers was 
higher than that in superficial cancers, when we compared the three groups, normal 
bladders, invasive bladder cancers (pTa, pT1), and superficial bladder cancers (pT2-4), by 
Kruskal-Wallis’s test (Fig. 9A). In addition, expression level of UHRF1 in cancers with 
grade-II and -III was up-regulated compared with that in normal bladders (Fig. 9B). 
Therefore, up-regulation level of UHRF1 reflects progression level of bladder cancer.  
 
 
Fig. 9. Expression of UHRF1 correlated with the stage, and grade. A. Expression of UHRF1 
in 21 normal bladders, 71 superficial bladder tumours (T-category is pTa and pT1), and 41 
invasive bladder tumours (T-category is pT2, pT3, and pT4) detected by TaqMan qRT-PCR. 
Expression levels of UHRF1 in superficial bladder tumours and in invasive tumours were 
significantly higher compared with those in normal bladders by Mann-Whiteney’s U-test 
(p=0.0063 and p=0.0034, respectively). Although its expression in superficial tumours and 
invasive tumours did not differ (p=0.2442, Mann-Whiteney’s U-test), it differed among the 
three different groups (p=0.0058, Kruskal-Wallis’ test). 2-microgloblin was used for 
normalization. B. Expression of UHRF1 differed among four groups with the different grade 
(p=0.0156, Kruskal-Wallis’ test) detected by TaqMan qRT-PCR. Expression of UHRF1 in 
grade II, and III tumour was higher than that in the normal bladders (p=0.0033 and 
p=0.0041). 2-microgloblin was used for normalization.  
In our result, expression of UHRF1 was not associated with difference of gender, numbers of 
tumour, tumour size, growth pattern (papillary or solid), incidence of recurrence, survival 
status after five years from surgery, and smoking history (Fig. 10), although the another 
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group showed an association between UHRF1 expression levels and tumour recurrence in 
superficial bladder cancer of Chinese cases (Yang et al., 2011). Therefore, UHRF1 could be a 




Fig. 10. Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of 
patients were compared by Mann-Whiteney’s U-test. A. Expression levels of UHRF1 in female 
patients (n=29) and male patients (n=75). Gender was not associated with expression levels of 
UHRF1 (p=0.2162). B. Expression levels of UHRF1 in patients with tumours four and less 
(n=53) and more than four (n=9) were not different (p=0.2896). C. Expression levels of UHRF1 
in patients with ≤ 5cm tumours (n=38) and with >5 cm tumours (n=20) were not different 
(p=0.4567). D. Expression levels of UHRF1 in patients with papillary type tumours (n=32) and 
with solid or solid/papillary tumours (n=28) were not different (p=0.4567). E. Expression 
levels of UHRF1 in patients who did not have a recurrence (n=19) and have a recurrence 
(n=46) were not different (p=0.6239). F. Expression levels of UHRF1 in patients who survived 5 
years after surgery (n=45) and died within 5 years (n=48) were not different (p=0.4151). G. 
Expression levels of UHRF1 in non-smoker patients (n=22) and smoker patients including 4 ex-
smokers (n=40) was not different (p=0.0750). 2-microgloblin was used for normalization. 
2.3 Expression UHRF1 can be used for predicting recurrence risk after TURBT 
Over 75% bladder cancer patients have one or more superficial bladder cancers, and two 
thirds of them will develop recurrent disease (Lutzeyer et al., 1982), with 10–20% 
progressing to an invasive phenotype (Torti & Lum, 1984). The outcome of patients with 
invasive tumours remains still poor, with distant metastasis occurring in over 50% within 2 
years and an average 5-year survival of only 50% (Raghavan et al., 1990). Currently, 
superficial bladder cancers are resected by a procedure called TURBT (TransUrethral 
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UHRF1 correlated with advanced stage (p=0.0005: Kruskal-Wallis’s test). 2-microgloblin was 
used for normalization. This figure is cited from our article (Unoki et al., 2009b). 
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grade-II and -III was up-regulated compared with that in normal bladders (Fig. 9B). 
Therefore, up-regulation level of UHRF1 reflects progression level of bladder cancer.  
 
 
Fig. 9. Expression of UHRF1 correlated with the stage, and grade. A. Expression of UHRF1 
in 21 normal bladders, 71 superficial bladder tumours (T-category is pTa and pT1), and 41 
invasive bladder tumours (T-category is pT2, pT3, and pT4) detected by TaqMan qRT-PCR. 
Expression levels of UHRF1 in superficial bladder tumours and in invasive tumours were 
significantly higher compared with those in normal bladders by Mann-Whiteney’s U-test 
(p=0.0063 and p=0.0034, respectively). Although its expression in superficial tumours and 
invasive tumours did not differ (p=0.2442, Mann-Whiteney’s U-test), it differed among the 
three different groups (p=0.0058, Kruskal-Wallis’ test). 2-microgloblin was used for 
normalization. B. Expression of UHRF1 differed among four groups with the different grade 
(p=0.0156, Kruskal-Wallis’ test) detected by TaqMan qRT-PCR. Expression of UHRF1 in 
grade II, and III tumour was higher than that in the normal bladders (p=0.0033 and 
p=0.0041). 2-microgloblin was used for normalization.  
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group showed an association between UHRF1 expression levels and tumour recurrence in 
superficial bladder cancer of Chinese cases (Yang et al., 2011). Therefore, UHRF1 could be a 




Fig. 10. Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of 
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in patients with ≤ 5cm tumours (n=38) and with >5 cm tumours (n=20) were not different 
(p=0.4567). D. Expression levels of UHRF1 in patients with papillary type tumours (n=32) and 
with solid or solid/papillary tumours (n=28) were not different (p=0.4567). E. Expression 
levels of UHRF1 in patients who did not have a recurrence (n=19) and have a recurrence 
(n=46) were not different (p=0.6239). F. Expression levels of UHRF1 in patients who survived 5 
years after surgery (n=45) and died within 5 years (n=48) were not different (p=0.4151). G. 
Expression levels of UHRF1 in non-smoker patients (n=22) and smoker patients including 4 ex-
smokers (n=40) was not different (p=0.0750). 2-microgloblin was used for normalization. 
2.3 Expression UHRF1 can be used for predicting recurrence risk after TURBT 
Over 75% bladder cancer patients have one or more superficial bladder cancers, and two 
thirds of them will develop recurrent disease (Lutzeyer et al., 1982), with 10–20% 
progressing to an invasive phenotype (Torti & Lum, 1984). The outcome of patients with 
invasive tumours remains still poor, with distant metastasis occurring in over 50% within 2 
years and an average 5-year survival of only 50% (Raghavan et al., 1990). Currently, 
superficial bladder cancers are resected by a procedure called TURBT (TransUrethral 
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Resection of Bladder Tumour), and patients are treated differently based on estimated 
recurrence risk after TURBT. Thus, diagnosis of bladder cancer at non-advanced stage and 
also precise estimation of the risk after the TURBT, are very important for prognosis of 
patients. Currently, the risk after the surgery is estimated by a scoring system and risk tables 
developed by European Organization for Research and Treatment of Cancer (EORTC). The 
EORTC scoring system was developed based on the six most significant clinical and 
pathological factors, which are tumour stage, tumour grade, numbers of tumour, tumour 
size, prior recurrence rate, and presence of carcinoma in situ (CIS). Bladder cancer patients 
with pTaG1 tumours (50% of all patients) are at very low risk, and those with CIS or with 
pT1G3 tumours are at the highest risk (15% of all patients). Intermediate risk patients are 
those with pTa/pT1 G1/G2 disease who develop multiple recurrent cancers (35% of all 
patients). Our TaqMan qRT-PCR result showed that high expression of UHRF1 was 
associated with high risk after TURBT (Fig. 11), probably because reflecting the association 
between high expression of UHRF1 and stage, and/or grade (Fig. 9A and 9B). Based on 
these results, detection of UHRF1 in tissue samples after TURBT will be a prognostic marker 




Fig. 11. Expression of UHRF1 correlated with the recurrence risk after TURBT. Significant 
high expression of UHRF1 in the high risk group after TURBT (n=23) was observed 
compared with that in the low risk group (n=7) by Mann-Whiteney’s U-test (p=0.0350). 
Asterisk indicates statistically significant p-values. 2-microgloblin was used for 
normalization. This figure is cited from our article (Unoki et al., 2009b). 
2.4 UHRF1 is a possible marker of bladder cancers and upper tract TCCs  
Because UHRF1 was significantly overexpressed in bladder cancers and upper tract TCCs 
(Fig. 5), UHRF1 might be a useful diagnostic marker especially for upper tract TCCs. 
Upper tract TCCs are often very malignant when it is diagnosed, partially because it is 
relatively difficult to find at an early stage. If the cancer is found at an early stage, the 
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prognosis of patients is improved. The development of a sensitive urine based detection 
marker is still being sought. Examination of voided urine or bladder barbotage for 
exfoliated cancer cells is useful for diagnosis of urothelial tumours anywhere in the 
urinary tract, from the calyx, through the ureters, into bladder and urethra. However, 
cytological interpretation can be problematic; low cellular yields, atypia, degenerative 
changes, urinary tract infections, stones and intravesical instillations hamper a correct 
diagnosis. Because the current two biomarker tests in clinical use, NMP-22 detection and 
BTA stat/BTA TRAK assay, can be hampered by existence of bleeding, inflammation, 
recent genitourinary tumours, and bladder stone (Dey, 2004), these markers have not 
improved the traditional cytology-based bladder cancer diagnosis largely. Thus, cytology 
is still the mainstay for diagnosing bladder cancer. Because the expression of UHRF1 in 
peripheral blood mononuclear cells (PBMCs) was under detection limit of qRT-PCR (Fig. 
12), the presence of these cells in urine would not impede the diagnosis. Additionally, 
expression of UHRF1 was not detected in adjacent normal bladder tissues by 
immunohistochemistry (Fig. 6A and 6B). Thus, contamination of these stromal cells also 
would not disturb the diagnosis, either. Therefore, an immunohistochemistry or Enzyme-
Linked ImmunoSorbent Assay (ELISA)-based UHRF1 detection in urine sediment can be a 
sensitive and cancer-specific diagnostic method, and may greatly improve the current 






Fig. 12. Relative expression levels of UHRF1 in peripheral blood mononuclear cells (PBMCs) 
were examined by TaqMan qRT-PCR. Almost no expression of UHRF1 was detected in 
PBMCs.  
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prognosis of patients is improved. The development of a sensitive urine based detection 
marker is still being sought. Examination of voided urine or bladder barbotage for 
exfoliated cancer cells is useful for diagnosis of urothelial tumours anywhere in the 
urinary tract, from the calyx, through the ureters, into bladder and urethra. However, 
cytological interpretation can be problematic; low cellular yields, atypia, degenerative 
changes, urinary tract infections, stones and intravesical instillations hamper a correct 
diagnosis. Because the current two biomarker tests in clinical use, NMP-22 detection and 
BTA stat/BTA TRAK assay, can be hampered by existence of bleeding, inflammation, 
recent genitourinary tumours, and bladder stone (Dey, 2004), these markers have not 
improved the traditional cytology-based bladder cancer diagnosis largely. Thus, cytology 
is still the mainstay for diagnosing bladder cancer. Because the expression of UHRF1 in 
peripheral blood mononuclear cells (PBMCs) was under detection limit of qRT-PCR (Fig. 
12), the presence of these cells in urine would not impede the diagnosis. Additionally, 
expression of UHRF1 was not detected in adjacent normal bladder tissues by 
immunohistochemistry (Fig. 6A and 6B). Thus, contamination of these stromal cells also 
would not disturb the diagnosis, either. Therefore, an immunohistochemistry or Enzyme-
Linked ImmunoSorbent Assay (ELISA)-based UHRF1 detection in urine sediment can be a 
sensitive and cancer-specific diagnostic method, and may greatly improve the current 






Fig. 12. Relative expression levels of UHRF1 in peripheral blood mononuclear cells (PBMCs) 
were examined by TaqMan qRT-PCR. Almost no expression of UHRF1 was detected in 
PBMCs.  
 




Although UHRF1 expression in muscle invasive cancer was greater than in non-invasive 
(pTa) or superficially invasive (pT1) cancers, UHRF1 could still be detected by 
immunohistochemistry in the early stage bladder cancers. In addition, overexpression of 
UHRF1 was associated with increased risk of progression after TURBT. Therefore, our 
result indicates that detection of UHRF1 may be a useful marker for early stage bladder 
cancers, and also for estimation of risk after TURBT, although it should be tested in larger 
series to determine if it can improve current strategies for diagnosis and prognosis of 
bladder cancer. 
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Bladder cancer (BC) is the fourth most common cancer in men and the eighth most common 
in women being the responsible for annual deaths of 150,000 and is the seventh most 
prevalent type of cancer worldwide (Parkin, et al., 2005; Jemal, et al., 2009; Altayli, et al., 
2009; Covolo, et al., 2008; Marmot, et al., 2007). In Ecuador the incidence rates of BC are 5.4% 
in males and 1.6% in females taking into account all cases of cancer diagnosed (Cueva & 
Yepez, 2009). In Argentina, it was reported as the fourth and the fourteenth most commonly 
diagnosed malignancy in men and women, respectively, with age-standardized incidence 
rate per 100,000 people around 15.1 (men) and 2.6 (women) in the period 1998 - 2002 (Pou, et 
al., 2011). The estimated downward trend in bladder cancer mortality over the last decades 
has been previously reported in countries of the European Union (Bosetti, et al., 2008) as 
well as South and North America (Bosetti, et al., 2005). 
Susceptibility to BC is considered to depend on interaction between genetic factors and 
environmental chemical carcinogens. Bladder cancer involves a heterogeneous cell 
population, and numerous factors are likely to be involved in tumorigenesis (Hirao, et al., 
2009). These factors result in uncontrolled growth of the cell population, decreased cell 
death, invasion and metastasis, and may influence the patient´s prognosis. Identification of 
the aggressive features of the cancer in patients with BC is very important for adequate 
management of this disease (Ha, et al., 2011). 
Many studies have investigated the effects of gene polymorphism on the risk of cancer in 
humans (Paz-y-Miño, at al., 2010; Wacholder, et al., 2004; Marchini, et al., 2004). Single 
nucleotide polymorphisms (SNPs) are the most common type of gene polymorphism. 
Several millions of SNP variants have been identified. The risk of cancer associated with this 
type of polymorphism probably is not high, and the proportion of malignant tumors 
associated with a distinct polymorphism depends on the frequency of occurrence of this 
variant in the human population (Zaridze, 2008). Genetic polymorphisms that alter the 
activity of enzymes of biotransformation pathways have been reported to be associated with 
cancer development and progression (Franekova, et al., 2008).  
In the other hand, molecular epidemiology of cancer studies, molecular markers of 
distribution of malignant tumors in the populations and their effects on individual are 
important to understand the risk of developing a disease. For an epidemiological study is 
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very important not only the source of the biological material, but also the individual 
information, that could be the factors influencing the risk of developing cancer. Among 
these can mention lifestyle factors as smoking, alcohol consumption, nutrition/diet, physical 
activity, environmental factors as occupation and exposure to carcinogens at workplace, 
familial and individual medical history, and many other variables (Zaridze, 2008). Many 
epidemiological studies have been conducted to investigate the putative association 
between polymorphic genes for biometabolism, environmental carcinogens, and the 
development of urinary tract cancer (Souto Grando, et al., 2009). 
The association between cigarette smoking and cancer of the urinary tract has been 
extensively investigated in epidemilogy (Zeegers, et al., 2000). Cigarette smoking is the main 
bladder cancer risk factor for both men (60%) and women (25%) (Paz-y-Miño, et al., 2010); 
approximately half of male urinary tract cancers and one third of female urinary tract 
cancers may be attributable to cigarette smoking (Hecht, 2003). Over 60 carcinogens have 
been identified in cigarette smoke. Among these are polycyclic aromatic hydrocarbons 
(PAHs) such as benzo[a]pyrene and aromatic amines, such as 2-naphtylamine and 4-
aminobiphenyl, the organic benzene derivatives found in cigarettes and the reactive oxygen 
species (ROS) such molecular oxygen, hydrogen peroxide, and hydroxyl radicals (Ichimura, 
et al., 2004) increase the risk of developing this neoplasm by 25% (Paz-y-Miño, et al., 2010; 
Hecht, 2003; Luch, 2005). Molecular markers can be detected in tissues and biological liquids 
and characterize individual exposure to carcinogens, biological effect of the exposure, 
genetic susceptibility to the development of disease, and final result of carcinogenesis, i.e. 
tumor (Zaridze, 2008).  
Many studies have indicated the relationship between different genetic polymorphisms and 
bladder cancer among the may appoint enzymes that perform a detoxifying function 
deactivate compounds and anions that are dangerous for the cell (Paz-y-Miño, et al., 2010). 
Cells are protected against metabolic ROS by several enzymatic and non-enzymatic defense 
systems, including superoxide dismutase (SOD), glutathione peroxidase (GPX) and reduced 
glutathione (Heistad, 2003). Three isoforms of SOD are present: Cu,Zn-SOD (SOD1 gene, 
cytosolic protein), Mn-SOD (SOD2 gene, mitochondrial protein) and EC-SOD (SOD3 gene, 
extracellular SOD) (Faraci & Didion, 2004). Manganese superoxide dismutase (MnSOD) has 
been the subject of particular interest as it is located in mitochondria and can be induced by 
several cytokines and by superoxide anion; it also appears to be involved in other processes, 
including tumor suppression and cellular differentiation (Charniot, et al., 2011). 
In regards to GPX1, this is a major intracellular enzyme that catalyzes the degradation of 
peroxides by oxidizing glutathione with the formation of its conjugates, thereby preventing 
cellular injury (Deng, et al., 2008; Trošt, et al., 2010). Mutation in gene GPX1, which locates 
at chromosome 3p21, is one of the major factors regulating GPX1 activity. And among these, 
a genetic polymorphism at codon 198, resulting in either a proline (Pro) or leucine (Leu) at 
the corresponding position of the encoded peptide, have drawn increasing attention in the 
etiology of several cancers (Raaschou-Nielsen, et al., 2007; Ezzikouri, et al., 2010). In 
humans, the selenium-dependent activation of GPX 198Leu mutant enzyme is lower than 
for the GPX 198Pro wild-type enzyme (Hu, et al., 2010). And associations between low level 
of GPX1 activity in the circulation and increased risk of cancer were found in several cancer 
types including breast cancer (Arsova-Sarafinovska, et al., 2009; Hansen, et al., 2009); it is 
presumed that GPX1 Pro198Leu (C[T) polymorphism affecting GPX1 activity may be 
important for cancer development (Hu, et al., 2010). 
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The glutathione S-transferases (GSTs) are conjugation enzymes, which detoxify reactive 
chemical species, for example polycyclic aromatic hydrocarbons. Moreover these enzymes 
belong to a group of dimeric isozymes with various catalytic activities, which 
predominantly conjugate with electrophiles of glutathione conjugation and exert other 
noncatalytic functions. This isozyme is expressed in many tissues, including urinary 
bladder, and frequently overexpressed in carcinomas. The respiratory, urinary, and 
digestive tract epithelia express high levels of GSTP1 activity (Altayli, et al., 2009; Kopps, et 
al., 2008; Fishbain, et al., 2004) 
There are five subclasses of the GST enzymes in humans: alpha, pi, mu, theta and zeta 
(Strange, et al., 2001). GSTM1, GSTT1, and GSTP1 are phase II enzymes (Rodriguez-Antona 
& Ingelman-Sundberg, 2006).  
Altered substrate affinity has been shown in a polymorphism at exon 5 of the GSTP1 gene. 
Some studies have reported higher susceptibility to cancer in individuals carrying the 
variant GSTP1 allele, although contradictory results have also been obtained (Srivastava, et., 
2005; Hu, et al., 1997). 
A prevalent genetic polymorphism of the GSTP1 gene was reported differing only in a 
single A to G transition at nucleotide position 1578 corresponding to codon 105, resulting in 
an amino acid change from isoleucine to valine (Zimniak, et al., 1994; Harries, et al., 1997). 
The polymorphic forms were designated GSTP1a (Ile105, wild type) and b (Val105, mutant). 
Homozygosity for GSTP1 (Ile105Val) was found to be associated with a considerably higher 
risk for bladder cancer in patients in the United Kingdom (Harries, et al., 1997). In contrast, 
another study on Chinese benzidine workers diagnosed with bladder cancer indicated that 
GSTP1 Ile/Val and Val/Val polymorphism was a factor in disease occurrence (Ma, et al., 
2003).  
Association between oxidative stress and DNA damage has been well known and many 
studies have focused on the association between DNA damage and the development of 
certain diseases (Paz-y-Miño, et al., 2010; Padma, et al., 2011). DNA repair enzymes 
continuously monitor chromosomes to correct damaged nucleotide residues generated by 
exposure to cytotoxic compounds or carcinogens (Wood, et al., 2001). Recently, it has been 
hypothesized in many studies that polymorphisms in DNA repair genes reduce their 
capacity to repair DNA damage and thereby lead to enhanced cancer or other age-related 
disease susceptibility (Liu, et al., 2007; Povey, et al., 2007).  
To date more than 100 DNA repair genes have been identified and their polymorphisms 
have been reported to be related with some diseases. Among them, polymorphisms of 
xeroderma pigmentosum complementation group D (XPD) and X-ray complementing 
group I (XRCC1) have been studied extensively (Clarkson & Wood, 2005; Paz-y-Miño, et al., 
2011).  
The human XRCC1 (X-ray repair cross-complementing group 1) gene is involved in single 
strand breaks and base excision repair (BER), it is located on chromosome 19q13.2, encodes 
for a 633 amino acids protein that plays an important role in BER and single-strand breaks 
repair (SSBR), following exposure to endogenous ROS or alkylating agents (Padma, et al., 
2011; Vidal, et al., 2003; Marsin, et al., 2003). The XRCC1 is a scaffold protein that interacts 
with other many components of BER as DNA polymerase β, APE1, hOGG1, poly-(ADP-
ribose) polymerase and DNA ligase III in the NH2-terminal, central, and COOH-terminal 
regions, respectively (Sterpone & Cozzi, 2010). In 1998 Shen et al., described three 
polymorphisms of XRCC1 gene, which resulted in non-conservative aminoacid changes at 
evolutionary conserved regions: C → T substitution in codon 194 of exon 6 (Arg to Trp);  
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very important not only the source of the biological material, but also the individual 
information, that could be the factors influencing the risk of developing cancer. Among 
these can mention lifestyle factors as smoking, alcohol consumption, nutrition/diet, physical 
activity, environmental factors as occupation and exposure to carcinogens at workplace, 
familial and individual medical history, and many other variables (Zaridze, 2008). Many 
epidemiological studies have been conducted to investigate the putative association 
between polymorphic genes for biometabolism, environmental carcinogens, and the 
development of urinary tract cancer (Souto Grando, et al., 2009). 
The association between cigarette smoking and cancer of the urinary tract has been 
extensively investigated in epidemilogy (Zeegers, et al., 2000). Cigarette smoking is the main 
bladder cancer risk factor for both men (60%) and women (25%) (Paz-y-Miño, et al., 2010); 
approximately half of male urinary tract cancers and one third of female urinary tract 
cancers may be attributable to cigarette smoking (Hecht, 2003). Over 60 carcinogens have 
been identified in cigarette smoke. Among these are polycyclic aromatic hydrocarbons 
(PAHs) such as benzo[a]pyrene and aromatic amines, such as 2-naphtylamine and 4-
aminobiphenyl, the organic benzene derivatives found in cigarettes and the reactive oxygen 
species (ROS) such molecular oxygen, hydrogen peroxide, and hydroxyl radicals (Ichimura, 
et al., 2004) increase the risk of developing this neoplasm by 25% (Paz-y-Miño, et al., 2010; 
Hecht, 2003; Luch, 2005). Molecular markers can be detected in tissues and biological liquids 
and characterize individual exposure to carcinogens, biological effect of the exposure, 
genetic susceptibility to the development of disease, and final result of carcinogenesis, i.e. 
tumor (Zaridze, 2008).  
Many studies have indicated the relationship between different genetic polymorphisms and 
bladder cancer among the may appoint enzymes that perform a detoxifying function 
deactivate compounds and anions that are dangerous for the cell (Paz-y-Miño, et al., 2010). 
Cells are protected against metabolic ROS by several enzymatic and non-enzymatic defense 
systems, including superoxide dismutase (SOD), glutathione peroxidase (GPX) and reduced 
glutathione (Heistad, 2003). Three isoforms of SOD are present: Cu,Zn-SOD (SOD1 gene, 
cytosolic protein), Mn-SOD (SOD2 gene, mitochondrial protein) and EC-SOD (SOD3 gene, 
extracellular SOD) (Faraci & Didion, 2004). Manganese superoxide dismutase (MnSOD) has 
been the subject of particular interest as it is located in mitochondria and can be induced by 
several cytokines and by superoxide anion; it also appears to be involved in other processes, 
including tumor suppression and cellular differentiation (Charniot, et al., 2011). 
In regards to GPX1, this is a major intracellular enzyme that catalyzes the degradation of 
peroxides by oxidizing glutathione with the formation of its conjugates, thereby preventing 
cellular injury (Deng, et al., 2008; Trošt, et al., 2010). Mutation in gene GPX1, which locates 
at chromosome 3p21, is one of the major factors regulating GPX1 activity. And among these, 
a genetic polymorphism at codon 198, resulting in either a proline (Pro) or leucine (Leu) at 
the corresponding position of the encoded peptide, have drawn increasing attention in the 
etiology of several cancers (Raaschou-Nielsen, et al., 2007; Ezzikouri, et al., 2010). In 
humans, the selenium-dependent activation of GPX 198Leu mutant enzyme is lower than 
for the GPX 198Pro wild-type enzyme (Hu, et al., 2010). And associations between low level 
of GPX1 activity in the circulation and increased risk of cancer were found in several cancer 
types including breast cancer (Arsova-Sarafinovska, et al., 2009; Hansen, et al., 2009); it is 
presumed that GPX1 Pro198Leu (C[T) polymorphism affecting GPX1 activity may be 
important for cancer development (Hu, et al., 2010). 
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The glutathione S-transferases (GSTs) are conjugation enzymes, which detoxify reactive 
chemical species, for example polycyclic aromatic hydrocarbons. Moreover these enzymes 
belong to a group of dimeric isozymes with various catalytic activities, which 
predominantly conjugate with electrophiles of glutathione conjugation and exert other 
noncatalytic functions. This isozyme is expressed in many tissues, including urinary 
bladder, and frequently overexpressed in carcinomas. The respiratory, urinary, and 
digestive tract epithelia express high levels of GSTP1 activity (Altayli, et al., 2009; Kopps, et 
al., 2008; Fishbain, et al., 2004) 
There are five subclasses of the GST enzymes in humans: alpha, pi, mu, theta and zeta 
(Strange, et al., 2001). GSTM1, GSTT1, and GSTP1 are phase II enzymes (Rodriguez-Antona 
& Ingelman-Sundberg, 2006).  
Altered substrate affinity has been shown in a polymorphism at exon 5 of the GSTP1 gene. 
Some studies have reported higher susceptibility to cancer in individuals carrying the 
variant GSTP1 allele, although contradictory results have also been obtained (Srivastava, et., 
2005; Hu, et al., 1997). 
A prevalent genetic polymorphism of the GSTP1 gene was reported differing only in a 
single A to G transition at nucleotide position 1578 corresponding to codon 105, resulting in 
an amino acid change from isoleucine to valine (Zimniak, et al., 1994; Harries, et al., 1997). 
The polymorphic forms were designated GSTP1a (Ile105, wild type) and b (Val105, mutant). 
Homozygosity for GSTP1 (Ile105Val) was found to be associated with a considerably higher 
risk for bladder cancer in patients in the United Kingdom (Harries, et al., 1997). In contrast, 
another study on Chinese benzidine workers diagnosed with bladder cancer indicated that 
GSTP1 Ile/Val and Val/Val polymorphism was a factor in disease occurrence (Ma, et al., 
2003).  
Association between oxidative stress and DNA damage has been well known and many 
studies have focused on the association between DNA damage and the development of 
certain diseases (Paz-y-Miño, et al., 2010; Padma, et al., 2011). DNA repair enzymes 
continuously monitor chromosomes to correct damaged nucleotide residues generated by 
exposure to cytotoxic compounds or carcinogens (Wood, et al., 2001). Recently, it has been 
hypothesized in many studies that polymorphisms in DNA repair genes reduce their 
capacity to repair DNA damage and thereby lead to enhanced cancer or other age-related 
disease susceptibility (Liu, et al., 2007; Povey, et al., 2007).  
To date more than 100 DNA repair genes have been identified and their polymorphisms 
have been reported to be related with some diseases. Among them, polymorphisms of 
xeroderma pigmentosum complementation group D (XPD) and X-ray complementing 
group I (XRCC1) have been studied extensively (Clarkson & Wood, 2005; Paz-y-Miño, et al., 
2011).  
The human XRCC1 (X-ray repair cross-complementing group 1) gene is involved in single 
strand breaks and base excision repair (BER), it is located on chromosome 19q13.2, encodes 
for a 633 amino acids protein that plays an important role in BER and single-strand breaks 
repair (SSBR), following exposure to endogenous ROS or alkylating agents (Padma, et al., 
2011; Vidal, et al., 2003; Marsin, et al., 2003). The XRCC1 is a scaffold protein that interacts 
with other many components of BER as DNA polymerase β, APE1, hOGG1, poly-(ADP-
ribose) polymerase and DNA ligase III in the NH2-terminal, central, and COOH-terminal 
regions, respectively (Sterpone & Cozzi, 2010). In 1998 Shen et al., described three 
polymorphisms of XRCC1 gene, which resulted in non-conservative aminoacid changes at 
evolutionary conserved regions: C → T substitution in codon 194 of exon 6 (Arg to Trp);  
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G → A substitution in codon 280 of exon 9 (Arg to His) and G → A substitution in codon 399 
of exon 10 (Arg to Gln). All these single nucleotide polymorphisms (SNPs) could alter the 
XRCC1 function and impair DNA repair efficiency or accuracy (Shen, et al., 1998). 
Given the large number of polymorphic variants and due to the existence of substantial 
differences in bladder cancer incidence in different ethnic groups, it is very important 
determine the frequencies of polymorphisms of many genes in Ecuadorian population 
affected with bladder cancer. These analyses are of great interest since it allows determining 
the genetic constitution of the population. 
2. Materials and methods 
2.1 Biological samples and data collection  
A total of 97 formalin-fixed, paraffin-embedded (FFPE) bladder cancer samples were obtained 
from males and females individuals affected with bladder cancer. These samples were 
collected from the Department of Urology of Carlos Andrade Marín Hospital in Quito and the 
Department of Pathology of the Solón Espinoza Ayala Oncologic Hospital of Ecuador 
(SOLCA). One hundred twenty peripheral blood samples from male and female individuals 
with a medical history without malignancy served as control. In both cases, all the individuals 
signed informed consent after receiving information about the study. The study protocol and 
consent forms were approved by the University Institutional Bioethics Committee. 
The distribution of selected characteristics between cases and control groups is summarized 
in Table 1. As for gender, the group of healthy individuals consisted of 33% of women and 
67% of men, while de group of affected individuals consisted of 43% of women and 57% of 
men. In regard to histological subtype, transitional cell carcinoma accounted for 89%, of 
total cancer cases; 1% cases consisted of adenocarcinoma, 6% presented urothelial papillary 
carcinoma and 4% of affected individuals presented squamous cell carcinoma. 
 
Characteristic Cases Number 
Control 
Number Odds Ratio 
Gender 5.3, 95% CI 2.9-9.5, p<0.001 
Women 42 37
Men 55 83
Age 71 (>68) 41 (>66) 0.6, 95% CI 0.334-1.020, p<0.05 
 26 (<68) 76 (<66)
Age (X + SD) 68 + 5.5 66 + 4.5




Transitional cell carcinoma 47 (55%) 39 (45%)
Adenocarcinoma 1 (100%) 0 (0%)
Urothelial papillary carcinoma 4 (67%) 2 (33%)
Squamus cell carcinoma 3 (75%) 1 (25%)
X + SD medium + standard deviation 
CI confidence interval 
Table 1. Clinical-Pathological characteristic of bladder cancer and control individuals 
 
Epidemiology and Polymorphisms Related to Bladder Cancer in Ecuadorian Individuals 
 
151 
Concerning cigarette consumption as a risk factor to develop bladder cancer, 74% and 56% 
of affected individuals and healthy individuals respectively used to smoke, whereas 26% of 
affected and 44% of controls never smoked. 
2.2 Genotyping 
The DNA of affected individuals was obtained using the Purelink Genomic DNA extraction 
kit (Invitrogen, Carlsbad, CA), while, DNA from peripheral venous blood samples was 
isolated by a “salting out” method (Sambrook, et al., 1989), stored in the nucleic acid data 
bank of the Biomedical Research Institute at the Universidad de las Américas. The mean 
concentration of the DNA samples was 80ng/mL measured in a Qubit® Fluorometer 
(Invitrogen, Carlsbad, CA). We proceeded to study single nucleotide polymorphisms (SNPs) 
in the GSTP1 (Ile105Val), GPX-1 (Pro198Leu), MnSOD (Ile58Thr) and XRCC1 (Arg399Gln) 
genes. Genotyping was performed through the polymerase chain reaction–restriction 
fragment length polymorphism technique (PCR-RFLP).  
For GPX-1, MnSOD, GSTP-1 and XRCC1 genes amplification, a PCR final volume of 50µl 
was prepared, containing 4µl of DNA template, 34µl H2O Milli-Q, 0,4µM of forward and 
reverse primers, (Table 2) 1.5mM MgCl 2,5µl 10 × buffer (200 mM Tris-HCl pH 8.4, 500 mM 
KCl), 0,2µm each deoxynucleotide triphosphate (dNTPs), and 2.5 U Taq DNA polymerase 
(Invitrogen). For a 191-bp fragment amplification and the analysis of the Pro198Leu 
polymorphism found in chromosome 3, we used the initial denaturation step lasted 10 min 
at 95oC, then 35 cycles of 30 s at 56oC, 30 s at 56oC, 45 s at 72oC and 3 min at 72oC were 
needed. Digestion of PCR product was carried out during 2h at 37oC with the ApaI 
(Promega, Madison, USA) restriction enzyme. The PCR-RFLP test revealed homozygous 
individuals (Pro/Pro), (Leu/Leu) or heterozygous (Pro/Leu) (Paz-y-Miño, et al., 2010; 
Ichimura, et al., 2004). For the amplification of the 145-bp fragment of the Ile58Thr found in 
chromosome 6, for the PCR reaction, samples were placed in a thermo cycler MJ Research 
PTC 200® (MJ-Research Inc., Watertown, MA) for the amplification. The initial denaturation 
step lasted 10 min at 95oC, followed by 35 cycles of 30 s at 95oC, 30 s at 55oC, 1 min at 72oC, 
and 10 min at 72oC. For the 177-bp fragment amplification and the analysis of the Ile105Val 
polymorphism found in chromosome 11, codon 105, exon 5, once the PCR reaction was 
obtained, the samples were placed in the MultiGene Thermal Cycler TC9600-G for 
amplification (Labnet, Edison, NJ, USA). The initial denaturation lasted 5 min at 95oC, 
followed by 35 cycles of 45 s at 94oC, 30 s at 62oC, 30 s at 72oC, and 1 min at 72oC. Digestion 
of the amplified fragment was performed during 2 h at 37oC with 5 U of the Alw26I 
 
Genes Primers 
GPX-1 Forward, 5′-AAGGTGTTCCTCCCTCGTAGGT-3′ 
 Reverse, 5′-CTACGCAGGTACAGCCGCCGCT-3′ 
MnSOD Forward, 5′-ACTTCAGTGCAGGCTGAACAGC-3′ 
 Reverse, 5′-CTGGTCCCATTATCTAATAGCTT-3′ 
GSTP-1 Forward, 5′-ACCCCAGGGCTCTATGGGAA-3′ 
 Reverse, 5′-TGAGGGCACAAGAAGCCCCT-3′ 
XRCC1 Forward, 5′-CCCCAAGTACAGCCAGGTC-3′ 
 Reverse, 5′-TGCCCCGCTCCTCTCAGTAG-3′ 
Table 2. Sequences of the PCR primers 
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G → A substitution in codon 280 of exon 9 (Arg to His) and G → A substitution in codon 399 
of exon 10 (Arg to Gln). All these single nucleotide polymorphisms (SNPs) could alter the 
XRCC1 function and impair DNA repair efficiency or accuracy (Shen, et al., 1998). 
Given the large number of polymorphic variants and due to the existence of substantial 
differences in bladder cancer incidence in different ethnic groups, it is very important 
determine the frequencies of polymorphisms of many genes in Ecuadorian population 
affected with bladder cancer. These analyses are of great interest since it allows determining 
the genetic constitution of the population. 
2. Materials and methods 
2.1 Biological samples and data collection  
A total of 97 formalin-fixed, paraffin-embedded (FFPE) bladder cancer samples were obtained 
from males and females individuals affected with bladder cancer. These samples were 
collected from the Department of Urology of Carlos Andrade Marín Hospital in Quito and the 
Department of Pathology of the Solón Espinoza Ayala Oncologic Hospital of Ecuador 
(SOLCA). One hundred twenty peripheral blood samples from male and female individuals 
with a medical history without malignancy served as control. In both cases, all the individuals 
signed informed consent after receiving information about the study. The study protocol and 
consent forms were approved by the University Institutional Bioethics Committee. 
The distribution of selected characteristics between cases and control groups is summarized 
in Table 1. As for gender, the group of healthy individuals consisted of 33% of women and 
67% of men, while de group of affected individuals consisted of 43% of women and 57% of 
men. In regard to histological subtype, transitional cell carcinoma accounted for 89%, of 
total cancer cases; 1% cases consisted of adenocarcinoma, 6% presented urothelial papillary 
carcinoma and 4% of affected individuals presented squamous cell carcinoma. 
 
Characteristic Cases Number 
Control 
Number Odds Ratio 
Gender 5.3, 95% CI 2.9-9.5, p<0.001 
Women 42 37
Men 55 83
Age 71 (>68) 41 (>66) 0.6, 95% CI 0.334-1.020, p<0.05 
 26 (<68) 76 (<66)
Age (X + SD) 68 + 5.5 66 + 4.5




Transitional cell carcinoma 47 (55%) 39 (45%)
Adenocarcinoma 1 (100%) 0 (0%)
Urothelial papillary carcinoma 4 (67%) 2 (33%)
Squamus cell carcinoma 3 (75%) 1 (25%)
X + SD medium + standard deviation 
CI confidence interval 
Table 1. Clinical-Pathological characteristic of bladder cancer and control individuals 
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Concerning cigarette consumption as a risk factor to develop bladder cancer, 74% and 56% 
of affected individuals and healthy individuals respectively used to smoke, whereas 26% of 
affected and 44% of controls never smoked. 
2.2 Genotyping 
The DNA of affected individuals was obtained using the Purelink Genomic DNA extraction 
kit (Invitrogen, Carlsbad, CA), while, DNA from peripheral venous blood samples was 
isolated by a “salting out” method (Sambrook, et al., 1989), stored in the nucleic acid data 
bank of the Biomedical Research Institute at the Universidad de las Américas. The mean 
concentration of the DNA samples was 80ng/mL measured in a Qubit® Fluorometer 
(Invitrogen, Carlsbad, CA). We proceeded to study single nucleotide polymorphisms (SNPs) 
in the GSTP1 (Ile105Val), GPX-1 (Pro198Leu), MnSOD (Ile58Thr) and XRCC1 (Arg399Gln) 
genes. Genotyping was performed through the polymerase chain reaction–restriction 
fragment length polymorphism technique (PCR-RFLP).  
For GPX-1, MnSOD, GSTP-1 and XRCC1 genes amplification, a PCR final volume of 50µl 
was prepared, containing 4µl of DNA template, 34µl H2O Milli-Q, 0,4µM of forward and 
reverse primers, (Table 2) 1.5mM MgCl 2,5µl 10 × buffer (200 mM Tris-HCl pH 8.4, 500 mM 
KCl), 0,2µm each deoxynucleotide triphosphate (dNTPs), and 2.5 U Taq DNA polymerase 
(Invitrogen). For a 191-bp fragment amplification and the analysis of the Pro198Leu 
polymorphism found in chromosome 3, we used the initial denaturation step lasted 10 min 
at 95oC, then 35 cycles of 30 s at 56oC, 30 s at 56oC, 45 s at 72oC and 3 min at 72oC were 
needed. Digestion of PCR product was carried out during 2h at 37oC with the ApaI 
(Promega, Madison, USA) restriction enzyme. The PCR-RFLP test revealed homozygous 
individuals (Pro/Pro), (Leu/Leu) or heterozygous (Pro/Leu) (Paz-y-Miño, et al., 2010; 
Ichimura, et al., 2004). For the amplification of the 145-bp fragment of the Ile58Thr found in 
chromosome 6, for the PCR reaction, samples were placed in a thermo cycler MJ Research 
PTC 200® (MJ-Research Inc., Watertown, MA) for the amplification. The initial denaturation 
step lasted 10 min at 95oC, followed by 35 cycles of 30 s at 95oC, 30 s at 55oC, 1 min at 72oC, 
and 10 min at 72oC. For the 177-bp fragment amplification and the analysis of the Ile105Val 
polymorphism found in chromosome 11, codon 105, exon 5, once the PCR reaction was 
obtained, the samples were placed in the MultiGene Thermal Cycler TC9600-G for 
amplification (Labnet, Edison, NJ, USA). The initial denaturation lasted 5 min at 95oC, 
followed by 35 cycles of 45 s at 94oC, 30 s at 62oC, 30 s at 72oC, and 1 min at 72oC. Digestion 
of the amplified fragment was performed during 2 h at 37oC with 5 U of the Alw26I 
 
Genes Primers 
GPX-1 Forward, 5′-AAGGTGTTCCTCCCTCGTAGGT-3′ 
 Reverse, 5′-CTACGCAGGTACAGCCGCCGCT-3′ 
MnSOD Forward, 5′-ACTTCAGTGCAGGCTGAACAGC-3′ 
 Reverse, 5′-CTGGTCCCATTATCTAATAGCTT-3′ 
GSTP-1 Forward, 5′-ACCCCAGGGCTCTATGGGAA-3′ 
 Reverse, 5′-TGAGGGCACAAGAAGCCCCT-3′ 
XRCC1 Forward, 5′-CCCCAAGTACAGCCAGGTC-3′ 
 Reverse, 5′-TGCCCCGCTCCTCTCAGTAG-3′ 
Table 2. Sequences of the PCR primers 
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(Promega, Madison, WI, USA) restriction enzyme. Electrophoresis analysis revealed 
homozygous individuals (Ile/Ile), (Val/Val) or heterozygous (Ile/Val) (Paz-y-Miño, et al., 
2011); whereas for a 242-bp fragment amplification and the analysis of the Arg399Gln 
polymorphism found in chromosome 19, codon 399, exon 10, the initial denaturation step 
lasted 5 min at 95oC, then 35 cycles of 45 s at 94oC, 1 min at 59oC, 30 s at 72oC and 3 min at 
72oC. Digestion of amplicon was performed during 2 hours at 37oC with the MspI (Promega) 
restriction enzyme. The analysis revealed homozygote individuals (Arg/Arg), (Gln/Gln) or 
heterozygote individuals (Arg/Gln) (Wong, et al., 2008).  
All the polymorphisms were genotyped using a PCR-RFLP assay. After amplification, PCR 
products were cleaved by 5U of the corresponding enzyme. After digestion, the fragments 
were separated by electrophoresis on a 3.0% agarose gel and visualized using ethidium 
bromide in a transilluminator under ultraviolet light. 
2.3 Statistical analysis 
All information obtained from the studied individuals was kept in a database and statistical 
analyses were performed using PASW Statistics 17 for Windows (SPSS, Chicago, IL). The 
allelic and genotypic frequencies of each single nucleotide polymorphism were calculated 
from the information provided by the genotypes; and the Hardy-Weinberg equilibrium was 
determined by using software available on the Internet 
(http://www.genes.org.uk/software/hardy-weinberg.shtml). Chi-square (Χ) analysis was 
performed to determine significant differences between the presence of Ile105Val, 
Pro198Leu, and Arg399Gln polymorphisms of the studied population. The risk of 
developing disease in the presence of the studied polymorphisms between affected and 
control groups was determined using the odds ratio test (OR). Data were analyzed using a 
2x2 contingency table. 
Table 3 shows the Hardy-Weinberg equilibrium and the genotypic and allelic frequency of 
the studied polymorphisms. For the GPX1 and MnSOD genes, the genotypic frequencies 
 





 Affected Pro/Pro 28 (29%) 0.29 0.39 
 (n = 97) Pro/Leu 19 (19%) 0.19  
  Leu/Leu 50 (52%) 0.52 061 
GPX-1      
 Control Pro/Pro 73 (61%) 0.61 0.79 
 (n = 120) Pro/Leu 42 (35%) 0.35  
  Leu/Leu 5 (4%) 0.04 0.21 
      
 Affected Ile/Ile 43 (44%) 0.44 0.68 
 (n = 97) Ile/Thr 47 (49%) 0.48  
  Thr/Thr 7 (7%) 0.07 0.32 
MnSOD      
 Control Ile/Ile 75 (62%) 0.63 0.82 
 (n = 120) Ile/Thr 45 (38%) 0.37  
  Thr/Thr 0  (0%) 0.0 0.18 
Table 3. Genotype Distribution and Allele Frequency of the pro198leu and ile58thr 
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observed in both groups were in Hardy–Weinberg equilibrium (GPX1 cases, Χ = 0.36, 
p<0.05; controls, Χ = 0, p<0.05 and MnSOD; cases, Χ = 0.02; p<0.05; controls, Χ = 0.05; 
p<0.05), confirming that the study samples were obtained from a population in equilibrium. 
Regarding the GSTP1 Ile105Val polymorphism, we observed that the frequency of the Val 
allele in control individuals was 0.28 (Table 4). Concerning to the XRCC1 Arg399Gln 
polymorphism, we observed that the frequency of the Gln allele in control individuals was 
(0.98) (Table 4). The frequencies of both alleles for the individuals affected with bladder 
cancer are not shown but according to information reported in other studies could be 
correlated with the results obtained from the Ecuadorian population. 
 
Genes Genotype Genotypic frequency Control 
Allele frequency 
Control 
 Ile/Ile 0.54 0.72 
GSTP1 Ile105Val Ile/Val 0.36  
 Val/val 0.10 0.28 
    
XRCC1 Arg399Gln Arg/Arg 0.01 0.02 
 Arg/Gln 0.01  
 Gln/Gln 0.98 0.98 
Table 4. Genotypic distribution and allelic frequency of GSTP1 Ile105Val and XRCC1 
Arg399Gln polymorphisms 
3. Conclusion 
Bladder cancer is an important cause of death worldwide, there are many known risk factors 
for this cancer including age, male sex, smoking habit, and exposure to carcinogens (Pou, et 
al., 2011). The results obtained from the analysis of four genes using PCR-RFLP technique to 
determine the presence of the polymorphisms pro198leu in the GPX-1 gene, ile58thr in the 
MnSOD gene, Ile105Val in the GSTP1 gene and Arg399Gln in the XRCC1 gene in 
Ecuadorian individuals affected with bladder cancer, although small, support other 
evidence that genetic polymorphisms of the detoxification enzymes can modify bladder 
cancer risk. 
GSTP1 participates in the detoxification of polycyclic aromatic hydrocarbon in promoting 
the conjugation of carcinogenic electrophiles with glutathione, thus enhancing excretion in 
the urine. This gene has been reported to possess two variant alleles. A single base 
substitution at position 313 of exon 5, guanine for adenine, results in the presence of valine 
(Val), where originally isoleucine (Ile) was present (Cao,  et al., 2005). The prevalence rates 
of these isoforms are entirely dependent on which ethnic group is being considered 
(Shimada, 2006). Some have suggested that GSTP1 genes have an increased risk for tobacco-
related cancers, including bladder cancer (Souto Grando, et al., 2009). Regarding genetics, 
the GSTP1 gene encodes proteins that are believed to function in xenobiotic metabolism and 
play the role as regulator of apoptosis (Moyer, et al., 2008). We found an association 
between the polymorphism and bladder cancer (data not shown), these findings could be 
suggesting that the presence of the Val/Val variant could be associated with an increased 
risk of acquiring detoxification problems, whereas the combination of the Ile/Val and 
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(Promega, Madison, WI, USA) restriction enzyme. Electrophoresis analysis revealed 
homozygous individuals (Ile/Ile), (Val/Val) or heterozygous (Ile/Val) (Paz-y-Miño, et al., 
2011); whereas for a 242-bp fragment amplification and the analysis of the Arg399Gln 
polymorphism found in chromosome 19, codon 399, exon 10, the initial denaturation step 
lasted 5 min at 95oC, then 35 cycles of 45 s at 94oC, 1 min at 59oC, 30 s at 72oC and 3 min at 
72oC. Digestion of amplicon was performed during 2 hours at 37oC with the MspI (Promega) 
restriction enzyme. The analysis revealed homozygote individuals (Arg/Arg), (Gln/Gln) or 
heterozygote individuals (Arg/Gln) (Wong, et al., 2008).  
All the polymorphisms were genotyped using a PCR-RFLP assay. After amplification, PCR 
products were cleaved by 5U of the corresponding enzyme. After digestion, the fragments 
were separated by electrophoresis on a 3.0% agarose gel and visualized using ethidium 
bromide in a transilluminator under ultraviolet light. 
2.3 Statistical analysis 
All information obtained from the studied individuals was kept in a database and statistical 
analyses were performed using PASW Statistics 17 for Windows (SPSS, Chicago, IL). The 
allelic and genotypic frequencies of each single nucleotide polymorphism were calculated 
from the information provided by the genotypes; and the Hardy-Weinberg equilibrium was 
determined by using software available on the Internet 
(http://www.genes.org.uk/software/hardy-weinberg.shtml). Chi-square (Χ) analysis was 
performed to determine significant differences between the presence of Ile105Val, 
Pro198Leu, and Arg399Gln polymorphisms of the studied population. The risk of 
developing disease in the presence of the studied polymorphisms between affected and 
control groups was determined using the odds ratio test (OR). Data were analyzed using a 
2x2 contingency table. 
Table 3 shows the Hardy-Weinberg equilibrium and the genotypic and allelic frequency of 
the studied polymorphisms. For the GPX1 and MnSOD genes, the genotypic frequencies 
 





 Affected Pro/Pro 28 (29%) 0.29 0.39 
 (n = 97) Pro/Leu 19 (19%) 0.19  
  Leu/Leu 50 (52%) 0.52 061 
GPX-1      
 Control Pro/Pro 73 (61%) 0.61 0.79 
 (n = 120) Pro/Leu 42 (35%) 0.35  
  Leu/Leu 5 (4%) 0.04 0.21 
      
 Affected Ile/Ile 43 (44%) 0.44 0.68 
 (n = 97) Ile/Thr 47 (49%) 0.48  
  Thr/Thr 7 (7%) 0.07 0.32 
MnSOD      
 Control Ile/Ile 75 (62%) 0.63 0.82 
 (n = 120) Ile/Thr 45 (38%) 0.37  
  Thr/Thr 0  (0%) 0.0 0.18 
Table 3. Genotype Distribution and Allele Frequency of the pro198leu and ile58thr 
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observed in both groups were in Hardy–Weinberg equilibrium (GPX1 cases, Χ = 0.36, 
p<0.05; controls, Χ = 0, p<0.05 and MnSOD; cases, Χ = 0.02; p<0.05; controls, Χ = 0.05; 
p<0.05), confirming that the study samples were obtained from a population in equilibrium. 
Regarding the GSTP1 Ile105Val polymorphism, we observed that the frequency of the Val 
allele in control individuals was 0.28 (Table 4). Concerning to the XRCC1 Arg399Gln 
polymorphism, we observed that the frequency of the Gln allele in control individuals was 
(0.98) (Table 4). The frequencies of both alleles for the individuals affected with bladder 
cancer are not shown but according to information reported in other studies could be 
correlated with the results obtained from the Ecuadorian population. 
 
Genes Genotype Genotypic frequency Control 
Allele frequency 
Control 
 Ile/Ile 0.54 0.72 
GSTP1 Ile105Val Ile/Val 0.36  
 Val/val 0.10 0.28 
    
XRCC1 Arg399Gln Arg/Arg 0.01 0.02 
 Arg/Gln 0.01  
 Gln/Gln 0.98 0.98 
Table 4. Genotypic distribution and allelic frequency of GSTP1 Ile105Val and XRCC1 
Arg399Gln polymorphisms 
3. Conclusion 
Bladder cancer is an important cause of death worldwide, there are many known risk factors 
for this cancer including age, male sex, smoking habit, and exposure to carcinogens (Pou, et 
al., 2011). The results obtained from the analysis of four genes using PCR-RFLP technique to 
determine the presence of the polymorphisms pro198leu in the GPX-1 gene, ile58thr in the 
MnSOD gene, Ile105Val in the GSTP1 gene and Arg399Gln in the XRCC1 gene in 
Ecuadorian individuals affected with bladder cancer, although small, support other 
evidence that genetic polymorphisms of the detoxification enzymes can modify bladder 
cancer risk. 
GSTP1 participates in the detoxification of polycyclic aromatic hydrocarbon in promoting 
the conjugation of carcinogenic electrophiles with glutathione, thus enhancing excretion in 
the urine. This gene has been reported to possess two variant alleles. A single base 
substitution at position 313 of exon 5, guanine for adenine, results in the presence of valine 
(Val), where originally isoleucine (Ile) was present (Cao,  et al., 2005). The prevalence rates 
of these isoforms are entirely dependent on which ethnic group is being considered 
(Shimada, 2006). Some have suggested that GSTP1 genes have an increased risk for tobacco-
related cancers, including bladder cancer (Souto Grando, et al., 2009). Regarding genetics, 
the GSTP1 gene encodes proteins that are believed to function in xenobiotic metabolism and 
play the role as regulator of apoptosis (Moyer, et al., 2008). We found an association 
between the polymorphism and bladder cancer (data not shown), these findings could be 
suggesting that the presence of the Val/Val variant could be associated with an increased 
risk of acquiring detoxification problems, whereas the combination of the Ile/Val and 
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Val/Val alleles could be associated with the risk of presenting a GSTP1 gene dysfunction. 
Those individuals presenting the GSTP1 Val/Val and GPX-1 Leu/Leu variables may have a 
higher risk of acquiring problems in the detoxification (Paz-y-Miño, et al., 2011; Cao, et al., 
2005). 
Altayli, et al., had reported that smokers with GSTP1 Val105Leu heterozygous genotype had 
a reduced risk of bladder cancer. Some other authors reported a statistically significant 
association between the Leu/Leu and Val/Leu genotypes and bladder cancer risk. There are 
other authors that reported no association between the Ile105Val polymorphism of the 
GSTP1 gene and laryngeal squamous cell cancer, gastric cancer, and colorectal cancer (Unal, 
et al., 2004; Cao, et al., 2005). 
The GSTP1 Ile105Val polymorphisms appear to be associated with a modest increase in the 
risk of bladder cancer. Some studies conducted in Asiatic population shows higher risk of 
developing bladder cancer when GSTP1 Ile/Val and Val/Val versus genotype Ile/Ile were 
compared, whereas the Chinese population did not have a significant influence on the 
unadjusted summary odds ratio for GSTP1 Ile/Val and Val/Val compared with GSTP1 
Ile/Ile (Ma, et al., 2003). In conclusion, the GSTP1 polymorphisms Ile/Val and Val/Val 
compared with Ile/Ile seem to be associated with a modest increase in the risk of bladder 
cancer (data not published).  
Our results indicate that the Ile105 allele was associated with an increased risk of bladder 
cancer. In previous articles, several types of carcinoma have been studied, in which there 
appeared to be an approximately threefold increase in risk between those with the GSTP1 
(Val/Val) allele and those with GSTP1 (Ile/Ile) variant for bladder carcinoma (Harries, et al., 
1997).  
Successful repair of damaged DNA relies on the coordinated action of many repair enzyme 
systems. Age dependent decline or imbalance of the activities of the DNA repair enzymes 
will result in the compromise of the overall capacity of repair for the damaged DNA 
molecules. Common polymorphisms in DNA repair enzymes have been hypothesized to 
result in reduced capability to repair DNA damage. XRCC1 is a DNA repair gene that is 
emerging as an essential element in the repair of both damaged bases and SSBs (Padma, et 
al., 2011). Additionally, XRCC1 is important in BER, the major repair pathway for nonbulky 
damaged bases, abasic sites, and DNA single-stranded breaks after treatment with ionizing 
radiation. Some reports in human populations suggested the 399Gln variant of XRCC1 was 
associated with greater DNA and chromosomal damage (Yoon, et al., 2011). 
It has been suggested that changes in the XRCC1 protein, mainly in amino acid 399, increase 
the susceptibility for tumor development via genomic instability (Meza-Espinoza, et al., 
2009). Nevertheless, another study did not find any effect of the Arg399Gln polymorphisms 
with regard to DNA damage (Pastorelli et al., 2002), even though it is not well known 
whether these polymorphisms produce a functional change in the protein. In any case, the 
risk of cancer depends on the involvement of several factors, and not only on the presence 
or combination of certain common genetic polymorphisms (Naccarati et al., 2007).  
Earlier investigators reported that reduced DNA repair capacity resulting from genetic 
polymorphism was associated with increased risk for various cancers (Mittal, et al., 2008). In 
our study the Arg allele was found mainly in the population affected with bladder cancer. In 
our study, the results obtained show that the XRCC1 Arg399Gln polymorphism, the 
frequency of the Gln allele was higher in affected individuals when compared to the control 
group (data not show). Among the polymorphisms of the XRCC1 gene the Arg399Gln 
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amino acid change alters the phenotype of XRCC1 protein and thereby result in deficient 
DNA repair. According to our data in case of codon 399 our study exhibited no risk for 
bladder cancer which was in accord with the Northern Italian population (Shen, et al., 2003). 
Kelsey et al., 2004 indicated a 40% reduction in risk for bladder cancer among patients with 
homozygous variant XRCC1 399 (AA) compared with those with wild-type allele carriers. 
However, Stern et al., 2001 observed contrasting results by showing low risk for AA 
genotype in bladder cancer patients (OR = 0.7), but with not significant p value. One of the 
most interesting findings was the obtained by Mittal, et al., 2008 in which XRCC1 codon 399 
where AA genotype exhibited 5.27 folds increased recurrence risk (HR=5.27, p=0.04).  
On the one hand, GPX1 is suggested to play an important role in moderating H2O2 under 
pathological conditions (Ardanaz, et al., 2010). Over-expression of GPX-1 is associated with 
a wide range of effects, including the prevention of apoptosis, the protection against toxicity 
and the reduction of DNA damage (Zhuo, et al., 2009). Given human epidemiological data 
indicating significant associations between polymorphisms in GPx-1 and the risk of several 
cancer types due to the important biological activities of the essential trace element selenium 
are mediated through the function of selenoenzymes (Ichimura, et al., 2004; Hu & Diamond, 
2003; Mak, et al., 2006; Choi, et al., 2007; Peters, et al., 2008). In this article we show the 
relationship between the presence of the Pro198Leu variant of the GPX-1 gene and its 
association with the risk of developing bladder cancer. 
Among the ninety-seven patients analyzed for the GPX1 gene, 28.87% harbored the P/P 
homozygous genotype, 19,58% were P/L heterozygous and 51.55% were L/L homozygous. 
Of the 120 controls analyzed for the GPX-1 gene, 60.83% were P/P homozygous, 35% were 
P/L heterozygous and 4.17% were L/L homozygous (Table 3). For the MnSOD gene in the 
affected population, 44.33% were I/I homozygous, 48.45% I/T heterozygous, and 7.22% T/T 
homozygous. For controls 62.5% I/I homozygous, 39.17% I/T heterozygous and 0% T/T 
homozygous. The allelic frequency of the (I/I) allele was 0.68 for the group of affected 
individuals and 0.32 for control group (Table 3). The frequencies of the GPX-1 and MnSOD 
null genotypes were, respectively 39 and 82% in the patients and 79 and 18% in the control 
group. 
When comparing control subjects and those affected with bladder cancer, we found that the 
presence of the Pro198Leu polymorphism has a relationship with the risk of developing 
bladder cancer (OR = 3.8; 95% CI 2.1-6.8; p<0.001), therefore the presence of the allelic 
variant (L/L) decreases the unique redox characteristics of the glutathione peroxidase, 
which can reduce reactive oxygen species and thereby prevent damage of important 
biomolecules, including DNA, RNA, lipids, proteins, and membranes; reactive oxygen 
species–induced DNA damage is known to promote tumor progression (Peters, et al., 2008), 
thereby conferring risk of developing bladder cancer in the Ecuadorian population. Previous 
studies demonstrate that the carriers of the variant L/L have a four times greater risk of 
developing bladder cancer than the individuals with the P/P variant (Ichimura, et al., 2004; 
Hu & Diamond, 2003). 
Table 5 shows the respective OR values of the GPX1 and MnSOD genotypes. We found an 
increased risk of bladder cancer associated with the genotypes for the GPX1 (P/L or L/L) 
OR = 3.8; 95% CI=2.1-6.8; p<0.001), while the MnSOD was not statistically significant (OR = 
2.1; 95% CI=1.3-3.5; p>0.05). Possible modification of associations between genetic 
polymorphisms and bladder cancer risk was also achieved by stratifying cases based on old 
age (OR = 5.3; 95% CI 2.9-9.5; p<0.001), sex (OR = 0.6; 95% CI 0.33-1.02; p<0.05), and 
smoking history (OR = 2.3; 95% CI 1.28-4.07; p<0.05). 
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Val/Val alleles could be associated with the risk of presenting a GSTP1 gene dysfunction. 
Those individuals presenting the GSTP1 Val/Val and GPX-1 Leu/Leu variables may have a 
higher risk of acquiring problems in the detoxification (Paz-y-Miño, et al., 2011; Cao, et al., 
2005). 
Altayli, et al., had reported that smokers with GSTP1 Val105Leu heterozygous genotype had 
a reduced risk of bladder cancer. Some other authors reported a statistically significant 
association between the Leu/Leu and Val/Leu genotypes and bladder cancer risk. There are 
other authors that reported no association between the Ile105Val polymorphism of the 
GSTP1 gene and laryngeal squamous cell cancer, gastric cancer, and colorectal cancer (Unal, 
et al., 2004; Cao, et al., 2005). 
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compared, whereas the Chinese population did not have a significant influence on the 
unadjusted summary odds ratio for GSTP1 Ile/Val and Val/Val compared with GSTP1 
Ile/Ile (Ma, et al., 2003). In conclusion, the GSTP1 polymorphisms Ile/Val and Val/Val 
compared with Ile/Ile seem to be associated with a modest increase in the risk of bladder 
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Our results indicate that the Ile105 allele was associated with an increased risk of bladder 
cancer. In previous articles, several types of carcinoma have been studied, in which there 
appeared to be an approximately threefold increase in risk between those with the GSTP1 
(Val/Val) allele and those with GSTP1 (Ile/Ile) variant for bladder carcinoma (Harries, et al., 
1997).  
Successful repair of damaged DNA relies on the coordinated action of many repair enzyme 
systems. Age dependent decline or imbalance of the activities of the DNA repair enzymes 
will result in the compromise of the overall capacity of repair for the damaged DNA 
molecules. Common polymorphisms in DNA repair enzymes have been hypothesized to 
result in reduced capability to repair DNA damage. XRCC1 is a DNA repair gene that is 
emerging as an essential element in the repair of both damaged bases and SSBs (Padma, et 
al., 2011). Additionally, XRCC1 is important in BER, the major repair pathway for nonbulky 
damaged bases, abasic sites, and DNA single-stranded breaks after treatment with ionizing 
radiation. Some reports in human populations suggested the 399Gln variant of XRCC1 was 
associated with greater DNA and chromosomal damage (Yoon, et al., 2011). 
It has been suggested that changes in the XRCC1 protein, mainly in amino acid 399, increase 
the susceptibility for tumor development via genomic instability (Meza-Espinoza, et al., 
2009). Nevertheless, another study did not find any effect of the Arg399Gln polymorphisms 
with regard to DNA damage (Pastorelli et al., 2002), even though it is not well known 
whether these polymorphisms produce a functional change in the protein. In any case, the 
risk of cancer depends on the involvement of several factors, and not only on the presence 
or combination of certain common genetic polymorphisms (Naccarati et al., 2007).  
Earlier investigators reported that reduced DNA repair capacity resulting from genetic 
polymorphism was associated with increased risk for various cancers (Mittal, et al., 2008). In 
our study the Arg allele was found mainly in the population affected with bladder cancer. In 
our study, the results obtained show that the XRCC1 Arg399Gln polymorphism, the 
frequency of the Gln allele was higher in affected individuals when compared to the control 
group (data not show). Among the polymorphisms of the XRCC1 gene the Arg399Gln 
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amino acid change alters the phenotype of XRCC1 protein and thereby result in deficient 
DNA repair. According to our data in case of codon 399 our study exhibited no risk for 
bladder cancer which was in accord with the Northern Italian population (Shen, et al., 2003). 
Kelsey et al., 2004 indicated a 40% reduction in risk for bladder cancer among patients with 
homozygous variant XRCC1 399 (AA) compared with those with wild-type allele carriers. 
However, Stern et al., 2001 observed contrasting results by showing low risk for AA 
genotype in bladder cancer patients (OR = 0.7), but with not significant p value. One of the 
most interesting findings was the obtained by Mittal, et al., 2008 in which XRCC1 codon 399 
where AA genotype exhibited 5.27 folds increased recurrence risk (HR=5.27, p=0.04).  
On the one hand, GPX1 is suggested to play an important role in moderating H2O2 under 
pathological conditions (Ardanaz, et al., 2010). Over-expression of GPX-1 is associated with 
a wide range of effects, including the prevention of apoptosis, the protection against toxicity 
and the reduction of DNA damage (Zhuo, et al., 2009). Given human epidemiological data 
indicating significant associations between polymorphisms in GPx-1 and the risk of several 
cancer types due to the important biological activities of the essential trace element selenium 
are mediated through the function of selenoenzymes (Ichimura, et al., 2004; Hu & Diamond, 
2003; Mak, et al., 2006; Choi, et al., 2007; Peters, et al., 2008). In this article we show the 
relationship between the presence of the Pro198Leu variant of the GPX-1 gene and its 
association with the risk of developing bladder cancer. 
Among the ninety-seven patients analyzed for the GPX1 gene, 28.87% harbored the P/P 
homozygous genotype, 19,58% were P/L heterozygous and 51.55% were L/L homozygous. 
Of the 120 controls analyzed for the GPX-1 gene, 60.83% were P/P homozygous, 35% were 
P/L heterozygous and 4.17% were L/L homozygous (Table 3). For the MnSOD gene in the 
affected population, 44.33% were I/I homozygous, 48.45% I/T heterozygous, and 7.22% T/T 
homozygous. For controls 62.5% I/I homozygous, 39.17% I/T heterozygous and 0% T/T 
homozygous. The allelic frequency of the (I/I) allele was 0.68 for the group of affected 
individuals and 0.32 for control group (Table 3). The frequencies of the GPX-1 and MnSOD 
null genotypes were, respectively 39 and 82% in the patients and 79 and 18% in the control 
group. 
When comparing control subjects and those affected with bladder cancer, we found that the 
presence of the Pro198Leu polymorphism has a relationship with the risk of developing 
bladder cancer (OR = 3.8; 95% CI 2.1-6.8; p<0.001), therefore the presence of the allelic 
variant (L/L) decreases the unique redox characteristics of the glutathione peroxidase, 
which can reduce reactive oxygen species and thereby prevent damage of important 
biomolecules, including DNA, RNA, lipids, proteins, and membranes; reactive oxygen 
species–induced DNA damage is known to promote tumor progression (Peters, et al., 2008), 
thereby conferring risk of developing bladder cancer in the Ecuadorian population. Previous 
studies demonstrate that the carriers of the variant L/L have a four times greater risk of 
developing bladder cancer than the individuals with the P/P variant (Ichimura, et al., 2004; 
Hu & Diamond, 2003). 
Table 5 shows the respective OR values of the GPX1 and MnSOD genotypes. We found an 
increased risk of bladder cancer associated with the genotypes for the GPX1 (P/L or L/L) 
OR = 3.8; 95% CI=2.1-6.8; p<0.001), while the MnSOD was not statistically significant (OR = 
2.1; 95% CI=1.3-3.5; p>0.05). Possible modification of associations between genetic 
polymorphisms and bladder cancer risk was also achieved by stratifying cases based on old 
age (OR = 5.3; 95% CI 2.9-9.5; p<0.001), sex (OR = 0.6; 95% CI 0.33-1.02; p<0.05), and 
smoking history (OR = 2.3; 95% CI 1.28-4.07; p<0.05). 
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Pro198Leu Pro/Pro Pro/Leu Leu/Leu Chi-Square Odds Ratio 
Affected 29% 19% 52% 69.9, p> 0.001 
3.8, 95% CI 2.1-6.8, 
p<0.001 
Control 61% 35% 4%   
Ile58Thr Ile/Ile Ile/Thr Thr/Thr Chi-square Odds Ratio 
Affected 44% 49% 7% 0.25, p > 0.05 2.1, 85% CI 1.3-3.5, p>0.05 
Control 62% 38% 0%   
Table 5. Statistical Analysis 
Several studies in different populations worldwide have reported, and an association 
between these variants with the risk of developing different types of cancer (Raaschou-
Nielsen, et al., 2007; Ezzikouri, et al., 2010; Hu, et al., 2010; Arsova-Sarafinovska, et al., 2009; 
Hansen, et al., 2009). The incidence of these polymorphisms according to the population 
analyzed, for example: the allelic frequency of L/L in the Japanese population is 0.05, and in 
the Caucasian population it is 0.36 (Ichimura, et al., 2004; Hu & Diamond, 2003). 
Furthermore, it has been determined that variants in different populations increases 2.6 
times of developing bladder cancer and 1.43 times of developing breast cancer (Ratnasinghe, 
et al., 2000). 
About the age of individuals under study, it has been determined that the risk of acquire 
bladder cancer is increased in old aged individuals (OR = 0.6; 95% CI 0.334-1.020; p<0.05), 
and can be considered as a risk factor for developing this disease. Furthermore, it was 
determined that men are at five times more risk to develop this type of cancer than women 
(OR = 5.3; 95% CI 2.9-9.5; p<0.001).  
Current scientific evidence considers tobacco as a carcinogenic in human, with a causal 
relationship also to urinary bladder cancer (Lagiou, et al., 2005), being one of the most 
important risk factors, responsible for almost one-third of bladder cancer deaths (Parkin, 
2008). It has been determined that individuals who used to smoke are at two times more risk 
to develop bladder cancer than individuals that never smoke (OR = 2.3; 95% CI 1.28-4.07; 
p<0.05). These findings are supported because it has previously been reported that smoking 
results in lower GPX activity (Ravn-Haren, et al., 2006). 
As a result of the ethnic differences, the distribution of the polymorphisms is affected; some 
studies have found that the risk of developing bladder cancer when a significant incidence 
of the L/L allelic variant exists, with the proportion of homozygous individuals for the L/L 
allele being low for the Asian population and high for the Caucasian population (Ichimura, 
et al., 2004; Hu & Diamond, 2003). These findings have been corroborated for the 
Ecuadorian population, due to the L/L genotype being present in a high proportion of 
individuals diagnosed with bladder cancer (n = 51; 51%). 
Free radicals, which are produced naturally in the body, can cause oxidative damage of 
DNA, lipids, proteins and other cell constituents, contributing to the onset of cancer and 
other chronic diseases (Evans, et al., 2004). Several enzymes, including MnSOD, GSTP, are 
involved in the scavenging of free radicals and prevention of oxidative damage. MnSOD 
catalyzes the dismutation of superoxide radicals in mitochondria by converting anion 
superoxide into hydrogen peroxide and oxygen, being a primary source of defense against 
cellular oxidants, regulating mitochondrial transport. It plays a key role in protecting cells 
from oxidative stress, especially in people with a low intake of natural antioxidants (Vineis, 
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et al., 2007) because low levels of MnSOD gene activity may cause oxidative stress, leading 
to the development of cancer, diabetes, and neurodegenerative diseases like Parkinson´s 
and Alzheimer´s (Paz-y-Miño, et al., 2010). Although low expression of MnSOD has often 
been suggested for different types of cancer, it has been demonstrated that overexpression 
of this protein inhibited cancerous growth implying it as a tumor suppressor gene (Tamimi, 
et al., 2004). In addition, MnSOD may exert its effect as a tumor suppressor, by altering 
pathways involving in cellular apoptosis and proliferation (Canan, et al., 2011). 
It has been reported that the frequency of the ile58thr variant of the MnSOD gene does not 
have a high significance (Hu & Diamond 2003). However there are other reports that have 
found an association between genetic polymorphisms in MnSOD and myeloid leukemia 
(Vineis, et al., 2007) indicating that oxidative stress can play a role in cancer.  When we 
compare the values reported with the values obtained in the study we performed, we 
confirmed that the incidence of the T/T allele maintains a low level within the Ecuadorian 
population. We have shown statistically that there is no significant difference between the 
bladder cancer group and the control group (Paz-y-Miño, et al., 2010).  
In the same way when we calculate the related risk of this two polymorphism (Pro/Leu and 
Ile/Thr), a negative relationship between the tendency to develop bladder cancer was found 
(OR = 2.1; 95% CI 1.2-3.6; p>0.05), concluding that the individuals who present the 
pro198leu variant have an increased risk of developing bladder cancer; contrary to what we 
found for ile58thr polymorphism and being different from that reported by other authors 
(Clemente, et al., 2007). It is well known that the ile58thr polymorphism of the MnSOD gene 
varies within different populations, with an incidence of 11% in Japanese populations and 
30% in Chinese populations, compared to the Caucasian populations, which has a 62% of 
incidence (Hori, et al., 2000; Ambrosone, et al. 1999).  
Some authors have reported that the expression level of the manganese superoxide 
dismutase enzyme, varies within tissues and shows an increment in individuals with brain, 
skin, lung tumors, breast, bladder cancer and myeloid leukemia (Vineis, et al., 2007; 
Ichimura, et al., 2004; Clemente, et al., 2007; Ambrosone, et al., 1999), for this reason the 
present study is important because it allows a characterization of the Ecuadorian population 
with bladder cancer. Various ethnic groups exhibit significant differences in the distribution 
of alleles throughout the population, which may influence the interpretation of 
epidemiological and association studies, these region-specific epidemiological studies 
provide important information on the frequency of polymorphic allelic variants in various 
ethnic groups (Souto Grando, et al., 2009). 
The very different findings in other populations might be caused by some confounding 
factors such as ethnicity, selection of control groups and characterization of cases, sample 
sizes, and gene–gene and gene–environment interactions. In conclusion, these results shown 
an association with increased risk of bladder cancer in the population studied. In addition, 
the results suggest that the genotypes of the polymorphisms may be associated with 
increased risk of bladder cancer. 
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Several studies in different populations worldwide have reported, and an association 
between these variants with the risk of developing different types of cancer (Raaschou-
Nielsen, et al., 2007; Ezzikouri, et al., 2010; Hu, et al., 2010; Arsova-Sarafinovska, et al., 2009; 
Hansen, et al., 2009). The incidence of these polymorphisms according to the population 
analyzed, for example: the allelic frequency of L/L in the Japanese population is 0.05, and in 
the Caucasian population it is 0.36 (Ichimura, et al., 2004; Hu & Diamond, 2003). 
Furthermore, it has been determined that variants in different populations increases 2.6 
times of developing bladder cancer and 1.43 times of developing breast cancer (Ratnasinghe, 
et al., 2000). 
About the age of individuals under study, it has been determined that the risk of acquire 
bladder cancer is increased in old aged individuals (OR = 0.6; 95% CI 0.334-1.020; p<0.05), 
and can be considered as a risk factor for developing this disease. Furthermore, it was 
determined that men are at five times more risk to develop this type of cancer than women 
(OR = 5.3; 95% CI 2.9-9.5; p<0.001).  
Current scientific evidence considers tobacco as a carcinogenic in human, with a causal 
relationship also to urinary bladder cancer (Lagiou, et al., 2005), being one of the most 
important risk factors, responsible for almost one-third of bladder cancer deaths (Parkin, 
2008). It has been determined that individuals who used to smoke are at two times more risk 
to develop bladder cancer than individuals that never smoke (OR = 2.3; 95% CI 1.28-4.07; 
p<0.05). These findings are supported because it has previously been reported that smoking 
results in lower GPX activity (Ravn-Haren, et al., 2006). 
As a result of the ethnic differences, the distribution of the polymorphisms is affected; some 
studies have found that the risk of developing bladder cancer when a significant incidence 
of the L/L allelic variant exists, with the proportion of homozygous individuals for the L/L 
allele being low for the Asian population and high for the Caucasian population (Ichimura, 
et al., 2004; Hu & Diamond, 2003). These findings have been corroborated for the 
Ecuadorian population, due to the L/L genotype being present in a high proportion of 
individuals diagnosed with bladder cancer (n = 51; 51%). 
Free radicals, which are produced naturally in the body, can cause oxidative damage of 
DNA, lipids, proteins and other cell constituents, contributing to the onset of cancer and 
other chronic diseases (Evans, et al., 2004). Several enzymes, including MnSOD, GSTP, are 
involved in the scavenging of free radicals and prevention of oxidative damage. MnSOD 
catalyzes the dismutation of superoxide radicals in mitochondria by converting anion 
superoxide into hydrogen peroxide and oxygen, being a primary source of defense against 
cellular oxidants, regulating mitochondrial transport. It plays a key role in protecting cells 
from oxidative stress, especially in people with a low intake of natural antioxidants (Vineis, 
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et al., 2007) because low levels of MnSOD gene activity may cause oxidative stress, leading 
to the development of cancer, diabetes, and neurodegenerative diseases like Parkinson´s 
and Alzheimer´s (Paz-y-Miño, et al., 2010). Although low expression of MnSOD has often 
been suggested for different types of cancer, it has been demonstrated that overexpression 
of this protein inhibited cancerous growth implying it as a tumor suppressor gene (Tamimi, 
et al., 2004). In addition, MnSOD may exert its effect as a tumor suppressor, by altering 
pathways involving in cellular apoptosis and proliferation (Canan, et al., 2011). 
It has been reported that the frequency of the ile58thr variant of the MnSOD gene does not 
have a high significance (Hu & Diamond 2003). However there are other reports that have 
found an association between genetic polymorphisms in MnSOD and myeloid leukemia 
(Vineis, et al., 2007) indicating that oxidative stress can play a role in cancer.  When we 
compare the values reported with the values obtained in the study we performed, we 
confirmed that the incidence of the T/T allele maintains a low level within the Ecuadorian 
population. We have shown statistically that there is no significant difference between the 
bladder cancer group and the control group (Paz-y-Miño, et al., 2010).  
In the same way when we calculate the related risk of this two polymorphism (Pro/Leu and 
Ile/Thr), a negative relationship between the tendency to develop bladder cancer was found 
(OR = 2.1; 95% CI 1.2-3.6; p>0.05), concluding that the individuals who present the 
pro198leu variant have an increased risk of developing bladder cancer; contrary to what we 
found for ile58thr polymorphism and being different from that reported by other authors 
(Clemente, et al., 2007). It is well known that the ile58thr polymorphism of the MnSOD gene 
varies within different populations, with an incidence of 11% in Japanese populations and 
30% in Chinese populations, compared to the Caucasian populations, which has a 62% of 
incidence (Hori, et al., 2000; Ambrosone, et al. 1999).  
Some authors have reported that the expression level of the manganese superoxide 
dismutase enzyme, varies within tissues and shows an increment in individuals with brain, 
skin, lung tumors, breast, bladder cancer and myeloid leukemia (Vineis, et al., 2007; 
Ichimura, et al., 2004; Clemente, et al., 2007; Ambrosone, et al., 1999), for this reason the 
present study is important because it allows a characterization of the Ecuadorian population 
with bladder cancer. Various ethnic groups exhibit significant differences in the distribution 
of alleles throughout the population, which may influence the interpretation of 
epidemiological and association studies, these region-specific epidemiological studies 
provide important information on the frequency of polymorphic allelic variants in various 
ethnic groups (Souto Grando, et al., 2009). 
The very different findings in other populations might be caused by some confounding 
factors such as ethnicity, selection of control groups and characterization of cases, sample 
sizes, and gene–gene and gene–environment interactions. In conclusion, these results shown 
an association with increased risk of bladder cancer in the population studied. In addition, 
the results suggest that the genotypes of the polymorphisms may be associated with 
increased risk of bladder cancer. 
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1. Introduction 
Bladder cancer can occur at any age. However, it is known to be a disease of the middle-
aged or elderly patient. The incidence is variable in different countries and the risk factors 
includes male sex, increasing age, smoking, occupational exposure to carcinogens, chronic 
inflammation, drugs such as phenacitin and cyclophosphamide, and pelvic radiation. In this 
chapter, we will discuss the different symptoms and signs that the bladder cancer patient 
could present with, keeping in mind that non of these presenting features are unique for 
bladder cancer. 
2. Haematuria 
Haematuria is the presenting symptom in up to 80% of patients with bladder 
cancer(Cummings et al., 1992).  It could be Visible (previously called gross or frank 
haematuria), or Non Visible (previously called Dipstick or Microscopic haematuria). It is 
usually intermittent rather than constant, therefore, if a second urine specimen is free of any 
haematuria after a previous positive sample, investigations are still warranted in a bladder 
cancer age range patient. It may be initial or terminal if the lesion is at the bladder neck or in 
the prostatic urethra. The history of smoking or occupational exposure to certain chemicals 
is relevant. The Renal Association and British Association of Urological Surgeons joint 
consensus statement uses the abbreviations VH and NVH to refer to visible and non visible 
haematuria respectively (Kelly et al., 2009). They also define significant haematuria as the 
one that is visible (VH), Symptomatic non visible (sNVH)ie: associated with lower urinary 
tract symptoms, and persistent asymptomatic (aNVH)ie: without association with any 
urinary tract symptoms. Persistence was defined as 2 out of 3 positive urine samples. 
Microscopic or non visible haematuria (NVH) is defined as more than 3 Red blood cells 
(RBCs) per high-powered field(HPF) on a spun specimen by the American Urological 
Association. However, Campbell-Walsh definition is more than 5 RBCs per HPF for spun 
urine and more than 2 RBCs per HPF for unspun urine. The degree of haematuria does not 
correlate with the stage or the grade of the bladder cancer but cancer pick up rate is 
different. Cancer diagnosis is about 20-25% for the VH and 5-10% for the NVH (Khadra et 
al.,2000; Edwards et al.,2006). Majority of cancers discovered when investigating haematuria 
are bladder ones and the rarity relate to the upper urinary tract. Haematuria is an alarming 
presentation especially when asymptomatic. It requires extensive examination and 
investigations to rule out underlying pathologies and in particular bladder or upper urinary 
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Fig. 1. Diagram showing the common and uncommon presenting symptoms and signs of 
bladder cancer.  
and some evidence is existent that it could well reduce the time to cancer diagnosis and 
treatment (Katmawi-Sabbagh et al., 2010). Patients will require full history and examination 
including detailed information abouthaematuria, its duration and any associated symptoms. 
Smoking, occupation and exposure to chemicals and drugs should be documented. 
Abdominal, genital, and rectal examinations will be required in men. Vaginal examination is 





of required investigations will be discussed at different chapter of this book. Common 
causes of haematuria are listed below in Table 1: 
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Table 1. Common causes of Haematuria based on the anatomical location and the causative 
factors.  
3. Lower urinary tract symptoms  
Frequency, nocturia, urgency, and urge incontinence are symptoms of vesical irritability. 
These could be seen in association with haematuria in bladder cancer patients (with or 
without the presence of dysuria or suprapubic pain). These symptoms were previously 
named as irritative symptoms and they have association with diffuse carcinoma in situ (CIS) 
as well as invasive cancer (Farrow et al., 1977).  
4. Flank pain  
Flank pain can be a symptom of advanced bladder cancer representing ureteric obstruction 
due to invasion of bladder muscular wall or the ureter. Tumours cause hydronephrosis as 
they become invasive (Figure 2). This is usually seen with high grade TCC rather than low 
grade (Table 2).   
Alternatively hydronephrosis with or without pain could happen when there is 
involvement of the ureteric orifice (Leibovitch et al., 1993).  
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1973 World Health Organisation (WHO) grading 
Grade 1: Well differentiated
Grade 2: Moderately differentiated 
Grade 3: Poorly differentiated 
 
2004 WHO grading – Flat lesions:
Hyperplasia (flat lesion without atypia or papillary)
Reactive Atypia (flat lesion with atypia) 
Atypia of unknown significance 
Urothelial dysplasia 
Urothelial Carcinoma in situ (CIS) 
 
2004 WHO grading – Papillary lesions:
Urothelial Papilloma (wich is a completely benign lesion)
Papillary urothelial neoplasm of low malignant potential 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
 
Table 2. WHO grading in 1973 and in 2004 (Sauter el al.,2004) 
 
Fig. 2. An Intravenous urography (I.V.U) of a 76 year old man presented with haematuria 
and left sided loin pain. It shows left sided hydroureteronephrosis and large filling defect in 
the bladder. Cystoscopy confirmed a bladder tumour and histology revealed invasive G3 





Pyelonephritis may result if obstruction is complicated with infection.  Flank pain and 
hydronephrosis could also be seen in cases of retroperitoneal metastasis. Flank pain caused 
by a bladder tumour is rarely encountered as the obstruction arises gradually. It should be 
distinguished from the one caused by a urinary stone which could also be associated with a 
degree of haematuria, but the colicky pain caused by a stone is normally of sudden onset 
and of higher intensity than that caused by a gradually occurring obstruction. Another 
differential diagnosis is the flank pain caused by a clot colic related to a bleeding from upper 
urinary tract transitional cell carcinoma or renal cell carcinoma. 
5. Recurrent urinary tract infections (UTI’s) 
Recurrent urinary tract infections (UTI’s) can be the first presentation of patients with 
necrotic infected bladder tumours. Therefore, it is always recommended to investigate 
recurrent UTI’s with cystoscopic examination to rule out associated bladder tumour. It is 
also believed that bladder stones, long term catheters, and ova of Schistosoma haematobium 
(bilharziasis) are all implicated in the development of squamous cell carcinoma of the 
bladder via the mechanism of chronic inflammation of bladder mucosa.   
6. Rare presentation symptoms and signs / symptoms and signs of advanced 
or complicated disease 
The natural history of bladder cancer can be classified as follows: 
- No further recurrence following initial presentation, diagnosis and treatment.  
- Local recurrence, which can occur on a single occasion or on multiple occasions. The 
recurrent tumours are usually of the same stage and grade as the primary tumour. 
Clinically patient may be asymptomatic or represent with haematuria or any other local 
symptoms.  
- Local Progresssion, which represent an increase in the local staging with time, the 
appearance of distant metastases and subsequent death. It is rare to encounter the 
symptoms and signs of advanced disease in the first presentation but patients with local 
recurrence and progression do represent with some of these symptoms and signs that 
are discussed below.  
6.1 Anaemia, Anorexia, weight loss and abdominal mass:  
Patients with large volume disease, muscle invasive tumours, or metastatic disease do 
sometimes present with these symptoms. The mass is properly assessed during 
bimanual examination under general anaesthesia and if it is immobile, this suggests 
that it is fixed to adjacent structures. Palpable masses that remain after local resection 
are likely to be extensive (non organ confined or T3 disease). The Tumour, Node, 
Metastasis(TNM) classification approved by the Union Internationale Contre le Cancer, 
which was updated in 2009 is shown in the table 3 (Sobin et al 2009): 
 
T Primary tumour.
TX primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Ta Noninvasive papillary carcinoma. 
Tis carcinoma in situ:`Flat tumour` 
T1 Tumour invades subepithelial connective tissue. 
T2 Tumour invades muscle
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     T2a Tumour invades superficial muscle (inner half)
     T2b Tumour invades Deep muscle (outer half) 
T3 Tumour invades perivesical tissue: 
     T3a Microscopically 
     T3b Macroscopically (extravesical mass) 
T4 Tumour invades any of the following: Prostate, Uterus, Vagina, Pelvic Wall, 
abdominal wall. 
      T4a Tumour invades prostate, uterus, or vagina. 
      T4b Tumour invades pelvic wall or abdominal wall.
N Lymph Nodes
Nx Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis 
N1 Metastasis in a single lymph node in the true pelvis (hypogastric, Obturator, external 
iliac, or presacral). 
N2 Metastasis in multiple lymph nodes in the true pelvis (hypogastric, Obturator, 
external iliac , or presacral). 
N3 Metastasis in a common iliac lymph node(s).
M Distant metastasis
Mx Distant metastasis cannot be assessed. 
M0 No distant metastasis. 
M1 Distant metastasis. 
Table 3. 2009 TNM classification of urinary bladder cancer 
6.2 Lower limb swelling and lymphedema:  
This is normally caused by occlusive pelvic lymphadenopathy or venous obstruction in 
the context of advanced disease. 
6.3 Hepatomegaly and supraclavicular lymphadenopathy:  
both are signs of metastatic disease.  
6.4 Pneumaturia:  
uncommon presentation of bladder cancer after enterovesical fistula formation. These 
type of fistulas are commoner with benign causes such as diverticular and crohn’s 
disease. (Dawam et al.,2004). Nevertheless, pneumaturia warrants further 
investigations with urine cytology and cystoscopy with bladder biopsy if any neoplastic 
lesions could be seen.  
6.5 Small bowel obstruction:  
uncommon and unusual presentation caused by large and advanced disease (Aigen et 
al.,1983).  
6.6 Renal failure:  
caused be blocked ureters due to extensive muscle invasive disease or unilateral 
blockage in case of malfunctioning or absent contralateral kidney. This could also be 
related to retroperitoneal metastasis.  
6.7 Painful cutaneous nodules and ulcerations:  
very unusual and rare site of metastasis (Fujita et al., 1994;Block et al.,2006).  
6.8 Urachal discharge (mucus or bloody):  
a very rare presentation of adenocarcinoma, which is a rare histological subtype of 
bladder cancer. The tumour could be in the urachus itself or at the dome of the urinary 
bladder. It could also present with mucosuria.  






Fig. 3. An isotope bone scan of 38 year-old smoker female patient known to have G3pT2a 
bladder transitional cell carcinoma. She presented 2 years after radical radiation therapy 
with left sided hip pain. The bone scan shows wide spread metastasis ( Spine, Pelvis, left 
forearm, left tibia, right femur and tibia ).  
7. Clinical conditions that could predispose to delayed presentation 
7.1 Spina bifida patients 
Patients with spinal bifida and bladder cancer present at a young age with variable tumour 
histology and advanced stage and they also have poor survival. These patients have 
neuropathic bladder dysfunction in addition to the fact that bladder augmentation is a 
significant risk factor for developing bladder cancer. Presenting symptoms are often 
atypical. 
Although there has been suggestion of a role for annual serial bladder biopsies (Game et al., 
1999) but it is not clear yet if screening would be beneficial for earlier detection and 
improved outcome. However, bladder cancer should be a consideration in this patient 
population, even in young adults (Austin et al. 2007).            
7.2 Blind and colour blind patients 
In a study of 200 bladder cancer patients, we found that those who had colour blindness (21 
patients) did present with higher grade and stage disease compared to non colour blind 
population. The hypothesis is that these patients do not promptly notice the red colour of 
their urine at earlier stage, However, this is not proven. There is not sufficient evidence for 
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screening of colour blind patients for bladder cancer. However, it is advisable to keep these 
findings in mind when assessing colour blind patients as they may help in case finding and 
early diagnosis of bladder cancer in this group of patients (Katmawi-Sabbagh et al., 2009).  
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1. Introduction 
Human papillomaviruses (HPV) of the so-called high risk types (HR-HPV) cause cervical 
cancer (CC). Carcinomas in other organs such as vagina, vulva, penis, oropharynx and 
rectum are known to be aetiologically heterogeneous with respect to HPV (zur Hauzen, 
2000, 2008; Gillison & Shah, 2003; International Agency for Research on Cancer [IARC], 
2008). HPV-positive cancer in those organs including cervix uteri differs from HPV-negative 
one in molecular-genetic profile, morphology as well as in clinical peculiarities (Morrison et 
al., 2001; Gillison & Shah, 2003). 
Carcinogenicity of the HR-HPV is determined by two viral genes, E6 and E7. Their 
expression is recognized as a necessary condition for conversion of virus-infected cell from 
normal to malignant state. Viral oncoproteins E6 and E7 can interact with various cellular 
proteins and thus preclude their normal functioning. Among numerous activities of viral 
oncoproteins the following two are usually regarded as principal ones. E7 is capable of 
binding to retinoblastoma protein pRb, and E6 can interact with p53. Therefore both above 
mentioned tumor suppressors become inactivated and then degraded. Cellular functions 
such as proliferation, apoptosis, DNA repair etc., controlled by pRb and p53, become 
disturbed (zur Hauzen, 2000, 2008; IARC, 2008).  
Since CC is a frequent female malignancy many research groups were occupied in search of 
early diagnostic markers for this cancer type. Experience thus obtained extends usually to 
HPV-associated carcinomas of other organs after necessary validation. Attempts to detect 
HR-HPV DNA by PCR did not leads in those studies to designing of a reliable diagnostic 
test because cancer in situ and invasive CC developed in a small proportion of women with 
HR-HPV-positive dysplasia (zur Hauzen, 2000). So specificity of the given approach turned 
out to be low despite the known very high PCR sensitivity. Current attempts to improve 
early diagnostics of CC and some other HPV-associated cancers are mostly focused on 
search of genes in virus-infected host cell whose expression becomes unconvertably altered 
under the influence of viral oncoproteins (Santin et al., 2005). 
One of these genes is INK4a encoding p16INK4a protein, an inhibitor of cyclin D-dependent 
kinases Cdk 4/6 (Serrano et al., 1993). INK4a transcription in displastic and cancer cells 
becomes much more active in comparison with its level in normal epithelium being 
triggered by HR-HPV oncoprotein E7; the content of p16INK4a in a cell increases 
correspondingly (Li et al., 1994; Khleif et al., 1996; Sano et al., 1998; Kaneko et al., 1999; Klaes 
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et al., 2001). This phenomenon formed experimental grounds for the immunohistochemical 
test which is currently widely applied in early CC diagnostics (Klaes et al., 2001, 2002; 
Milde-Langosch et al., 2001; Volgareva et al., 2002, 2004, 2006). This test is becoming popular 
in diagnostics of HR-HPV-associated carcinomas of other localizations (Begum et al., 2007; 
Kim et al., 2007). 
Bladder cancer (BC) takes 7-th place in the global cancer incidence making up ~ 2-5% of all 
neoplasms. BC is 2.5-6 times more frequent in men than in women: 260000 new BC cases are 
registered annually among men and only 76000 among women. Bladder tumors are rare in 
people under 35 years old; however BC has become younger recently (Parkin et al., 2003). It 
seems reasonable to mention in this connection the data of Scandinavian investigators 
(Litlekalsoy et al., 2007) concerning dynamics of the BC molecular markers. They reported 
that significant shift in the BC molecular profile occurred during 70 years. This shift possibly 
reflects some alterations in the set of BC causative factors which might have taken place 
during these years. 
In Russia BC makes up ~ 3 % of all malignant tumors; the trend has been registered for the 
steady elevation of new cases number (Chissov et al., 2010). Mortality among male BC 
patients in Russia is higher (> 7 in many regions) than the highest indices for countries from 
the WHO mortality list; as to female BC patiens, mortality figures do not differ in this group 
from those in other European countries (Zaridze, 2009). 
BC development is a multistage process with unpredictable course. Several risk factors for 
BC are known (Zaridze et al., 1992; Dinney et al., 2004). Among these factors are: geographic 
region (BC morbidity may vary worldwide up to tenfold); professional occupation (there are 
about 40 professions at high risk); smoking; nutritional habits and drinking water quality; 
use of certain medicines; parasitic diseases caused by some Trematoda (Schistosomas). 
Possible significance of some other factors is still under discussion including irradiation, 
hereditary predisposition, some other. 
Association of some biological agents with BC development might be suggested from 
results of one study in ~ 6000 patients cohort (Adami et al., 2003). Various organs had been 
transplanted to those patients with consequent immunosuppressor treatment. BC incidence 
in this group turned out to be 2-4 times higher as compared with corresponding index for 
the population as a whole. Carcinomas with proven causative role of HPV occurred in this 
group of patients even more frequently. Thus prevalence of vulvar and vaginal cancer was 
20 times higher than expected one, and that for rectal and oropharyngeal cancer – 10 and 5 
times higher, respectively. 
The problem of HPV involvement in urinary bladder carcinogenesis is not novel. 
Historically one of the first indications to the possible linkage between these viruses and BC 
was the fact that secondary BC occurrence in women with primary CC was significantly 
higher (five to six-fold) than its occurrence in general population (Bailar, 1963; Newell et al., 
1974, 1975). The interpretation of that data in favor of real HPV involvement in urothelial 
carcinogenesis became possible later after the discovery of HR-HPV carcinogenicity for 
cervical epithelium by H. zur Hausen and co-authors (Durst et al., 1983, zur Hauzen, 2000, 
2008). However definitive commentary on those results as proving HPV carcinogenicity for 
urinary bladder is still difficult due to the known fact that both CC and BC are more 
frequent among smoking women. 
One more evidence in favour of HPV involvement into BC development was obtained in 
observations carried out on immunodeficient patients with benign or malignant bladder 
 
Role of HPV in Urothelial Carcinogenesis: Current State of the Problem 
 
179 
neoplasms where HPV DNA was found (Del Mistro et al., 1988; Kitamura et al, 1988; Querci 
della Rovere et al., 1988; Maloney et al., 1994). 
The International Expert Group on HPV selected over twenty studies dedicated to HPV role 
in BC which had been published in 1991-2001 worldwide. The authors had detected HPV 
DNA in BC specimens by PCR, in situ hybridization and/or Southern blot hybridization. 
Percentage of HPV-positive cases in these communications varied from 0 up to 82.6 %. 
Therefore the experts included BC into the category of cancers for which aetiological role of 
HPV remains unclear – “inadequate evidence” (IARC, 2008). 
2. The recent data warn against HPV underestimation as a risk factor in 
urinary bladder carcinogenesis  
Several researchers have published recently some data proving topicality of the HPV 
problem in BC aetiology (Barghi et al., 2005; Yang et al., 2005; Helal Tel et al., 2006; Moonen 
et al., 2007; Badawi et al., 2008).  
Thus ~ 36 % of transitional-cell BC specimens from Iran (21 out of 59 studied) harboured 
HPV DNA (Barghi et al., 2005). HPV 18 predominated over other types of the viruses (it was 
found in 17 patients out of 21, - 81 %); - viruses of the given type are second most frequent 
causative agents for CC (the first place belongs to HPV16). Urinary bladder tissues from 20 
non-oncological patients were taken for control in this study and HPV18 DNA was detected 
in 1 patient with heavy cystitis. Possibility of precancerous alterations in the latter case 
could not be ruled out. The authors concluded that HPV may play role of a causative BC 
factor.  
Similar was the opinion by the researchers from the Netherlands who carried out study of 
BC specimens from 107 patients and found DNA of various HPV types in ~ 15 %; HR-HPV 
DNA was detected in ~ 8 % (Moonen et al., 2007). Percentage of HR-HPV DNA-positive 
specimens increased with progression of clinical stage of BC (Ta, T1 and T2-T4), making 0, 
12.5 and 18.2 % respectively 
Group of investigators from Egypt and USA presented data on HPV-positivity of 27 
Schistosoma-associated BC cases (Yang et al., 2005). All of them harboured HPV16. Highly 
sensitive variety of PCR was used in the study. The results reported by another group from 
Egypt (Helal Tel et al., 2006) differ dramatically from the data of H. Yang et al. These 
authors found HPV 16/18 DNA in a single Schistosoma-associated BC specimen 
(squamous cancer in situ) out of 64 studied. Much lower sensitivity of in situ hybridization 
used in the last study for HPV DNA detection in comparison with the method used by H. 
Yang  et al. may be responsible for such a sharp data discrepancy. The total sum of BC 
specimens examined by A. Helal Tel et al. was 114 including 67 transitional-cell, 32 
squamous and 15 other. The above mentioned case was the only HPV-positive BC in this 
study. The results obtained enabled the authors to conclude that HPV do not play any 
significant role in pathogenesis of urinary bladder in Egypt. 
The data reported by these two research groups, H. Yang et al. and A. Helal Tel et al. and 
mutually exclusive inferences made by the investigators warn against underestimation of 
HPV as a risk factor in BC genesis. Essential in this connection is the fact that results 
reported by H. Yang et al. were confirmed recently by another research group from Egypt 
(Badawi et al., 2008). The authors using PCR detected HR-HPV DNA (belonging to types 
16,18 and 52) more frequently in BC specimens than in urothelial biopsies from cystitis 
patients. The PCR data were compared with the data on antibody to HPV16 protein L1 
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detection in blood serum of the HPV16-positive BC patients; perfect coincidence of these 
results took place. The association was observed in this study between HPV-positivity of BC 
and its propensity for relapse. The authors concluded that HPV participates in BC genesis in 
combination with other risk factors, including Schistosomas which were commonly found in 
the group of patients examined. The authors recommend detection of antibodies to HPV L1 
to optimize the treatment of BC patients and their further follow-up . 
3. Aspects of the problem to be addressed 
Thus a glimpse into the problem of HPV role in BC gives idea of its complexity. Therefore 
we rise the following questions:  
1. What reasons may be the for conflicting data communicated by different research 
groups? Are there any ways to optimize the methodology of the study and get uniform 
data? 
2. What is the incidence of HPV-positivity among urothelial dysplasia and BC specimens 
obtained from Russian patients keeping in mind ethno-geographic BC heterogeneity?  
3. Have there been any attempts to investigate the role of papillomaviruses in urothelial 
carcinogenesis in experimental models?  
4. What benefits may it bring to practical oncourology provided that a certain role of HPV 
in BC is accepted by medical community?  
4. What reasons may be for conflicting data communicated by different 
research groups? Are there any ways to optimize the methodology of the 
study and get uniform data? 
The authors usually explain the conflicting data character by different research groups by 
either of the following factors: 
1. objective ethno-geographic heterogeneity of BC and 
2. technical peculiarities of studies. 
Concerning the first factor, a relationship seems to be evident between the state of the 
excretory organ lining, on the one hand, and environmental factors such as drinking water 
quality, regional and ethnic specificity of food, endemic urinary bladder parasitic diseases, 
etc., on the other hand. Each of these factors may influence the HPV-BC association rate. 
This statement could be verified by comparison of HPV-positivity in BC from different 
regions worldwide done by the same research group with unified technical approaches. 
Such studies have never been carried out as far as we know . 
The second group of factors includes small numbers of specimens tested in some works; 
application of a single test for viral DNA detection (most commonly PCR or in situ 
hybridization, wherein both techniques have benefits and limitations); detection of only one 
or two HPV types, usually HPV16 and HPV18, which are most frequent in CC, while other 
HPV types might be involved in carcinogenesis in urinary bladder. The data by C. De 
Gaetani et al. prove the latter point (De Gaetani et al., 1999). Using in situ hybridization with 
probe to 31/33/35 viral types the authors detected HPV DNA positivity in 60 % of BC 
specimens, while the index turned out to be 24 % with probe to the types 16/18 . 
In addition, a predominant majority of groups which publish data on high incidence of HR-
HPV DNA in BC made no attempts to confirm viral genome expression and in particular E6/ 
E7 expression.  
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Contamination should be mentioned also besides the above-listed factors. It may be either 
laboratory (admixing of products of viral genome amplification to the samples under study) 
or patient related. The former is a well-known source of false-positivity of PCR data. 
Possibility of the latter is to be kept in mind in studies of BC specimens particularly. If any 
adjacent organ (vulva, penis, urethra) is HPV-infected, casual bladder contamination with 
HPV-harbouring cell(s) might occur through blood during surgical operation or by 
endoscope during cystoscopy. False HPV-positivity data may occur both in PCR done to 
screen materials for viral DNA presence and in reverse-transcription PCR (RT-PCR) study of 
viral genome expression as well. 
Thereby complex approach seems to be reasonable to study possible HPV role in urothelial 
carcinogenesis. Techniques are reasonable which enable to detect DNA not only of HPV16 
and HPV18 but of other types of viruses as well. To check up whether viral oncogenes E6 
and E7 are expressed in DNA-HPV-positive specimens methods seem to be appropriate of 
both viral mRNA E6/E7 detection (by RT-PCR) and viral oncoproteins E6 and E7 revelation 
(by immunohistochemistry). In female BC cases it may be reasonable to examine patient's 
cervical epithelium for HPV infection.  
5. What is the incidence of HPV-positivity among urothelial dysplasia and BC 
specimens obtained from Russian patients?  
The given section presents data of two independent studies of Russian patients with urinary 
bladder oncological conditions including results of our own complex approach to HPV 
detection in BC specimens. 
5.1 Attempts to determine occurrence of HPV-positivity in bladder urothelium 
DNA of HPV16 and HPV18 was found in ~ 50 % of urinary bladder dysplasia and 
carcinoma in situ specimens by in situ hybridization; an attempt to detect HPV of other 
types (6, 11, 31, 33 and 51) gave negative results (Frank et al., 2002).  
We have screened 130 transitional BC specimens (1-3 grade) obtained by transurethral 
resections for HPV DNA using several PCR versions with primers to L1, E6 and E7 genes of 
the viral genome (Volgareva et al., 2007, 2008, 2009; Trofimova et al., 2009). Our tests 
included application of literary primers My09/11 and GP5-GP6 to L1 enabling one to detect 
HPV of various types; these primer sets are commonly used in similar studies (Resnik et al., 
1990; van den Brule et al., 1990). HPV16 genetic material was found in ~ 40% of the 
specimens tested, DNA of other HPV types was not found. Viral genome expression was 
confirmed at the level of mRNA by RT-PCR in some of the specimens (Volgareva et al., 2009; 
Trofimova et al., 2009). Viral oncoprotein E7 was spotted by immunohistochemistry in ~30% 
of DNA HPV16-positive cases (Cheng et al., 2009; Volgareva et al., 2009 a,b). BC specimens 
stained positively with polyclonal anti-E7 HPV16 serum (done by Fiedler et al., 2004) turned 
out to be positive also when stained by monoclonal antibodies to HPV16 E6 and E7 from 
Neodiagnostic (Cheng et al., 2009). Five examples of BC specimens’ screening for HPV are 
presented in Table 1 and Figure 1. 
The fact that HPV16 oncoprotein E7 is detected in ~30% of BC specimens means that HPV16 
plays some role in urothelial carcinogenesis in Russian patients. However in case of urothelial 
malignization some deviations there seem to exist from the known role of these viruses in 
cervical carcinogenesis. Signs testifying to the truth of the given assumption are as follows. 
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2. What is the incidence of HPV-positivity among urothelial dysplasia and BC specimens 
obtained from Russian patients keeping in mind ethno-geographic BC heterogeneity?  
3. Have there been any attempts to investigate the role of papillomaviruses in urothelial 
carcinogenesis in experimental models?  
4. What benefits may it bring to practical oncourology provided that a certain role of HPV 
in BC is accepted by medical community?  
4. What reasons may be for conflicting data communicated by different 
research groups? Are there any ways to optimize the methodology of the 
study and get uniform data? 
The authors usually explain the conflicting data character by different research groups by 
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Such studies have never been carried out as far as we know . 
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application of a single test for viral DNA detection (most commonly PCR or in situ 
hybridization, wherein both techniques have benefits and limitations); detection of only one 
or two HPV types, usually HPV16 and HPV18, which are most frequent in CC, while other 
HPV types might be involved in carcinogenesis in urinary bladder. The data by C. De 
Gaetani et al. prove the latter point (De Gaetani et al., 1999). Using in situ hybridization with 
probe to 31/33/35 viral types the authors detected HPV DNA positivity in 60 % of BC 
specimens, while the index turned out to be 24 % with probe to the types 16/18 . 
In addition, a predominant majority of groups which publish data on high incidence of HR-
HPV DNA in BC made no attempts to confirm viral genome expression and in particular E6/ 
E7 expression.  
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Contamination should be mentioned also besides the above-listed factors. It may be either 
laboratory (admixing of products of viral genome amplification to the samples under study) 
or patient related. The former is a well-known source of false-positivity of PCR data. 
Possibility of the latter is to be kept in mind in studies of BC specimens particularly. If any 
adjacent organ (vulva, penis, urethra) is HPV-infected, casual bladder contamination with 
HPV-harbouring cell(s) might occur through blood during surgical operation or by 
endoscope during cystoscopy. False HPV-positivity data may occur both in PCR done to 
screen materials for viral DNA presence and in reverse-transcription PCR (RT-PCR) study of 
viral genome expression as well. 
Thereby complex approach seems to be reasonable to study possible HPV role in urothelial 
carcinogenesis. Techniques are reasonable which enable to detect DNA not only of HPV16 
and HPV18 but of other types of viruses as well. To check up whether viral oncogenes E6 
and E7 are expressed in DNA-HPV-positive specimens methods seem to be appropriate of 
both viral mRNA E6/E7 detection (by RT-PCR) and viral oncoproteins E6 and E7 revelation 
(by immunohistochemistry). In female BC cases it may be reasonable to examine patient's 
cervical epithelium for HPV infection.  
5. What is the incidence of HPV-positivity among urothelial dysplasia and BC 
specimens obtained from Russian patients?  
The given section presents data of two independent studies of Russian patients with urinary 
bladder oncological conditions including results of our own complex approach to HPV 
detection in BC specimens. 
5.1 Attempts to determine occurrence of HPV-positivity in bladder urothelium 
DNA of HPV16 and HPV18 was found in ~ 50 % of urinary bladder dysplasia and 
carcinoma in situ specimens by in situ hybridization; an attempt to detect HPV of other 
types (6, 11, 31, 33 and 51) gave negative results (Frank et al., 2002).  
We have screened 130 transitional BC specimens (1-3 grade) obtained by transurethral 
resections for HPV DNA using several PCR versions with primers to L1, E6 and E7 genes of 
the viral genome (Volgareva et al., 2007, 2008, 2009; Trofimova et al., 2009). Our tests 
included application of literary primers My09/11 and GP5-GP6 to L1 enabling one to detect 
HPV of various types; these primer sets are commonly used in similar studies (Resnik et al., 
1990; van den Brule et al., 1990). HPV16 genetic material was found in ~ 40% of the 
specimens tested, DNA of other HPV types was not found. Viral genome expression was 
confirmed at the level of mRNA by RT-PCR in some of the specimens (Volgareva et al., 2009; 
Trofimova et al., 2009). Viral oncoprotein E7 was spotted by immunohistochemistry in ~30% 
of DNA HPV16-positive cases (Cheng et al., 2009; Volgareva et al., 2009 a,b). BC specimens 
stained positively with polyclonal anti-E7 HPV16 serum (done by Fiedler et al., 2004) turned 
out to be positive also when stained by monoclonal antibodies to HPV16 E6 and E7 from 
Neodiagnostic (Cheng et al., 2009). Five examples of BC specimens’ screening for HPV are 
presented in Table 1 and Figure 1. 
The fact that HPV16 oncoprotein E7 is detected in ~30% of BC specimens means that HPV16 
plays some role in urothelial carcinogenesis in Russian patients. However in case of urothelial 
malignization some deviations there seem to exist from the known role of these viruses in 
cervical carcinogenesis. Signs testifying to the truth of the given assumption are as follows. 
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Case No DNA* RNA** Protein E7
*** 

























* HPV DNA was detected by PCR, viral typing carried out either by PCR with type-specific primers or 
by restriction fragment length polymorphism test (Astori et al.,1997). Specimens 2-5 appeared to 
harbour DNA of HPV16.  
** reverse-transcription PCR was carried out with primers to E6/E7 HPV16. 
*** immunohistochemical staining was performed with polyclonal serum to HPV16 oncoprotein E7 
(Fiedler et al., 2004). The type of staining was either diffuse (over 25% of stained cells in a cancer tissue) 
or focal (less than 25% of stained cancer cells). 
Table 1. Data of the complex approach to HPV detection in five BC specimens. Case 1: 
Transitional BC relapse, focuses of squamous metaplasia, 3-d grade, muscle-invasive.  
Case 2: Transitional BC, 3-d grade, muscle-invasive.  Case 3: Transitional BC, 2-d grade, 
submucosal invasion, no muscle cells on the slide.  Case 4: Transitional BC, focuses of 
squamous metaplasia, 2-3-d grade, growth within mucous layer, no invasion into muscle. 
Case 5. Transitional BC, 3-d grade, submucosal invasion, no muscle cells on the slide. 
Firstly, along with BC specimens expressing viral oncoprotein E7 in a predominant majority of 
cancer cells throughout cancer tissue (as was usually the case with CC in our previous studies, 
- the so-called “diffuse staining”; - Volgareva et al., 2006) we observed some BC cases in which 
E7 was registered only in certain groups of cancer cells or in separate cells, - the so-called 
“focal staining” (Table 1, cases 4 and 5; Fig. 1d,e). It should be underlined in this connection 
that we confirmed HPV16 genome expression at the level of mRNA by RT-PCR for some of 
such BC specimens. However it was not in every BC specimen studied that the results of RT-
PCR and immunohistochemistry coincided: cases 4 and 5 in Table 1 serve as examples of the 
lack of the data homogeneity. Focal character of HPV16 genome expression registered 
immunohistochemically may perhaps be responsible for this discrepancy: HPV16-harbouring 
cells detected by staining in a certain section of a BC specimen might not occur in another 
section of the same specimen from which mRNA was obtained. It is also important that in all 
such specimens HPV16 E7-expressing cells were found in the internal layers of cancer tissue 
but not at its brims (Fig. 1d,e). This observation enables one to rule out the above-mentioned 
possibility of the urinary bladder intrapatient contamination with cells of some adjacent HPV-
infected organ. Focal HPV16 E7 expression in some BC specimens in our study is in a good 
agreement with the data by C. De Gaetani et al. on HPV DNA detection in BC by in situ 
hybridization (De Gaetani et al., 1999). These investigators had at their disposal several biopsy 
samples for each of ten patients under study. It was from only one out of ten patients that the 
test results were permanently positive in all biopsies, while in the rest nine cases only a quota 
of samples was DNA HPV-positive. 
Secondly, in some cases of focal E7 expression BC cells contain this viral oncoprotein only in 
a cytoplasm (Fig 1e). Its ability to get bound to the nuclear pRb remains under question in 
such cases. 
 




Fig. 1. Results of the HPV16 E7 immunohistochemical detection in BC specimens. 
Specimens’ numbers match to those in Table 1. a  Negative reaction with E7-specific serum 
in specimen N1. b, c  Diffuse staining of specimens NN 2 and 3, respectively.  d, e  Focal 
staining of specimens NN 4 and 5, respectively. Uncoloured nuclei of three cells expressing 
E7 in a cytoplasm are indicated with arrows in “e”. 
Thirdly, the results of our repeated examination of the female patient with relapsing BC 
turned out to be quite unexpected. In her original tumor removed surgically in 2004 we 
detected HPV16 DNA, E7 mRNA as well as protein E7 (the latter spotted independently in 
two laboratories with different antibodies) (Volgareva et al., 2009 b; Cheng et al., 2009). The 
patient is a hard smoker. For more than 20 years she had worked at a chemical factory and 
had been exposed with solvents and aniline dyes. Three BC relapses took place in 2005-2008. 
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During this period the patient undervent surgery, chemotherapy and BCG treatment. At the 
next relapse in 2009 we performed repeated study. Neither HPV DNA nor protein E7 were 
found in BC cells. Colposcopy study was also performed and HPV DNA tested in cervical 
cells by PCR; the results of both analyses proved absence of HPV in cervical epithelium of 
the patient (Volgareva et al., 2010a). Could there occur a total clearance from virus-
harbouring cells due to surgical and other treatments in this patient? Further observations 
on similar cases are desirable to answer in the affirmative. 
5.2. Study of INK4a expression in DNA HPV16-positive bladder cancer specimens 
To verify the fact of HPV16 genome expression in 50 DNA HPV16-positive BC specimens 
we studied cellular INK4a expression at the levels of mRNA (Fig. 2) and respective protein 
p16INK4a (Fig. 3) (Volgareva et al., 2010b). The above mentioned phenomenon of the INK4a 
overexpression indicating to HR-HPV E7 activity in cervical cells served as a rationale. In 12 
BC specimens under study the HPV16 E7 expression had been detected at the mRNA 
and/or protein level. Five conditionally normal urothelial specimens obtained from the 
same BC patients were studied as well. In some BC cases associated with HPV16 DNA we 
detected INK4a overexpression at the both levels (Fig. 2, patients A,B and E; Fig. 3c). 
 
 
Fig. 2. Analysis of expression of INK4a by RT-PCR in BC specimens obtained from five 
patients (A, B, C, D and E); t - urinary bladder carcinoma, n – morphologically normal tissue 
adjacent to tumour.  
The top-panel electrophoregram developed  after Southern blot hybridization with the 
INK4a-specific radio-active probe according to Nguyen and co-authors  
(Nguyen et al., 2000).  
The bottom panel: results with GAPDH-specific primers as a control for stability and 
concentration of RNA; amplification products visualized by staining with ethidium 
bromide.  
Incidence of p16INK4a- overexpressing BC specimens was ~ 10% (Fig. 3c), however as 
opposed to CC in BC it did not correlate with HPV16 E7 expression in any case (Figures 2c 
and 3d present lack of such correlation for one and the same BC specimen). 
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We don't regard this result as evidence disproving the role of HPV in urinary bladder 
carcinogenesis. The point is, according to literature data, that factors determining INK4a 
expression in HPV-associated BC may differ in essence from those in HPV-positive CC. 
Thus in BC, in contrast to CC, INK4a undergoes frequent deletions, point mutations or 
promoter methylations (Ruas, Peters, 1998; Aveyard, Knowles, 2004; Gallucci et al., 2007). 
Due to any of these events its expression at the level of protein p16INK4a may become partly 
or fully lost. For example, homozygous INK4a deletions depriving cell of p16INK4a synthesis 
were found in ~ 30-50 % of BC specimens (Aveyard, Knowles, 2004; Gallucci et al., 2007). 




Fig. 3. Results of the immunohistochemical p16INK4a detection in BC specimens. 
a. Positive control: HPV16 – harbouring cervical cancer, diffuse staining.  
b. Negative control: cells of HCT line (smear), negative reaction with p16INK4a-specific 
antibodies. 
c. BC, diffuse staining. 
d. BC specimen represented as N3 in Table 1 and “c” in Fig. 1, negative reaction with 
p16INK4a-specific antibodies. 
5.3 Summary 
The results obtained in two independent samplings of urothelial dysplasia and BC from 
Russian patients show as a whole that HR-HPV DNA-positivity reaches up to ~ 40-50 %. 
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Presence of viral DNA in cancer cells is frequently accompanied by expression of viral 
oncogenes. These results are in agreement with the notion that HR-HPV may take part in BC 
initiation either solely or in combination with other factors, in particular chemical 
carcinogens. There are certain reasons still to assume some difference in the action of these 
viruses in urothelium in comparison with their manifestation in cervical epithelium. 
6. Have there been any attempts to investigate the role of papillomaviruses in 
urothelial carcinogenesis in experimental models? 
Urinary bladder similarly to other parts of urinary system (renal pelvis, ureter, etc.) is lined 
with epithelium of a special kind, the so-called transitional epithelium (Henle epithelium). 
The question is of particular interest in this connection  whether HPV can cause oncogenesis 
in urinary bladder lining. 
M. Campo and co-authors addressed this problem in vivo in cattle (Campo et al., 1992; 
Campo, 2002). The investigators demonstrated that bovine papillomavirus BPV-2 takes part 
in BC development under both spontaneous and experimental infection. An important 
peculiarity of their model is that BPV-associated BC develops commonly in animals being 
fed with a certain kind of plant, namely bracken fern. Besides BC these animals are affected 
often with carcinomas in various segments of gastrointestinal tract. When studied 
particularly bracken fern appeared to contain a number of ingredients which possess 
mutagenic, carcinogenic and immunosuppressive activities. 
The thesis of a species-specific character of papillomavirus infection is well-known (IARC, 
2008). In view of this point an exact extrapolation of the data by M. Campo et al. to human 
papillomaviruses and their possible role in human urothelial oncogenesis seems not quite 
correct. There are yet some indirect evidences that such extrapolation is not fully 
groundless. They are as follows. First of all, these researchers found among various 
histological BC types substantial quota of transitional carcinomas, the type of BC 
predominating among human patients in many countries including Russia. Secondly, 
bracken fern similarly to cattle promotes in a human organism carcinogenesis just in 
gastrointestinal tract. In the regions where it is consumed as food (Brazil in particular) 
HPV16 is commonly found in dysplasia and carcinoma specimens of esophagus (Campo et 
al., 1999, as cited in Campo, 2002). Thirdly, transactivation of HPV16 promoter was achieved 
in experimental model by quercetine, one of the mutagenic ingredients of bracken fern; in 
such a way it was demonstrated that some types of human cancer in which HPV are being 
regularly detected may be aetiologically similar to corresponding cancer types of cattle 
(Campo et al., 1999, as cited in Campo, 2002). 
C. Reznikoff and co-authors carried out study on HPV oncogenicity in human urothelial 
cells in vitro (Reznikoff et al., 1994). The authors transformed isogenic mucosal cells of 
ureteral uroepithelium obtained from a healthy donor by HPV16 E6 and/or E7 gene(s). 
Cellular immortalization occurred after the integration of either of these viral oncogenes into 
host chromosomes. Simultaneous integration of both of them led to similar effect. 
Phenotypic and genotypic alterations were more prominent in cells immortalized by E6 
alone or in combination with E7 than in cells harbouring sole E7. Neither of the transformed 
cell clones formed tumors when inoculated into nude mice. Some chromosomal alterations 
found in the transformed cells were identical to karyotype abnormalities found by other 
researchers in clinical specimens from BC patients. The authors inferred that the phenomena 
taking place in vitro may correspond to initial stages of urothelial oncogenesis in vivo. 
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Thus the results obtained in experimental models show that there is no good cause to 
eliminate papillomaviruses from the list of potential carcinogens in urinary bladder 
urothelium of Homo sapiens. 
7. What benefits may it bring to practical oncourology provided that a certain 
role of HPV in BC is accepted by medical community?  
If this notion is accepted new prospects for BC prevention may come to light. Keeping in 
mind that efficient vaccines were designed for CC prevention, on the one hand, and that BC 
is a predominantly male type of cancer, on the other hand, both girls and boys vaccination 
might become one of such prospects. It is noteworthy in this connection that when the item 
of reasonability of boys’ vaccination is being discussed it is usually being done for the sake 
of CC prevention in their wives-to-be. Resolution is usually made in the negative in 
resource-constrained countries. As to the female BC, possibility to prevent women from 
urothelial carcinogenesis might become an additional convincing argument in favour of 
their vaccination. 
Possible ways of HPV ingress into human urinary bladder lining should be thought over by 
both clinicians and experimenters. The idea of HPV-associated BC may form grounds for 
adding of some tests (aimed to detect anogenital HPV) to the currently accepted ways of 
preoperative check-up of BC patients. This idea may also become the reason to reconsider 
safety of cystoscope and catheter in treatment of BC patients infected with HPV in 
anogenital region. 
Despite that HPV role in urothelial carcinogenesis is still open-ended question several 
research groups tried to find an answer to the related one: whether clinical course of BC is 
affected by HPV presence in urothelial cells. 
Y. Andreeva and co-authors studied if papillomaviruses influence relapse incidence in BC 
patients (Andreeva et al., 2008). The authors preselected 44 BC specimens taken from 
patients with superficial tumors (stages Ta and T1) on the basis that there occurred 
koilocytes in these specimens (an indirect morphological sign of viral infection). The 
specimens were then subdivided into 3 groups: (1) 16 ones from patients with high relapse 
incidence, (2) 13 - from patients with moderate and (3) 15 - from patients with low relapse 
incidence. DNA of HPV16 and HPV18 was found by in situ hybridization in specimens from 
patients of the first and second groups only. Seven out of 16 specimens (44%) harboured 
HPV16 DNA in the first group. Three specimens (23%) were HPV18-positive while HPV16 
genetic material was found in neither case in the second group. The authors concluded that 
HPV occurrence in urothelial cells increases the risk of a superficial BC relapse.  
A. Lopes-Beltran and co-authors studied whether HPV DNA presence in cancer cells may 
influence BC patient survival (Lopes-Beltran et al., 1996). The group of 76 BC patients with 
transitional BC was formed without any preselection. In materials obtained at transurethral 
resections the authors detected DNA of HPV6, HPV11, HPV16 and HPV18 using PCR. 
Follow-up lasted for 5 years. The resultant survival among HPV-positive patients was found 
to be ~ 29 % (2 out of 7), while among negative ones - 75 % (52 out of 69). The authors 
concluded that HPV-DNA-positivity serves as a negative predictor of BC patient survival. 
The results reported by C. De Gaetani and co-authors (De Gaetani et al., 1999) are in good 
agreement with those data. The authors found by in situ hybridization with the probes to 
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Phenotypic and genotypic alterations were more prominent in cells immortalized by E6 
alone or in combination with E7 than in cells harbouring sole E7. Neither of the transformed 
cell clones formed tumors when inoculated into nude mice. Some chromosomal alterations 
found in the transformed cells were identical to karyotype abnormalities found by other 
researchers in clinical specimens from BC patients. The authors inferred that the phenomena 
taking place in vitro may correspond to initial stages of urothelial oncogenesis in vivo. 
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Thus the results obtained in experimental models show that there is no good cause to 
eliminate papillomaviruses from the list of potential carcinogens in urinary bladder 
urothelium of Homo sapiens. 
7. What benefits may it bring to practical oncourology provided that a certain 
role of HPV in BC is accepted by medical community?  
If this notion is accepted new prospects for BC prevention may come to light. Keeping in 
mind that efficient vaccines were designed for CC prevention, on the one hand, and that BC 
is a predominantly male type of cancer, on the other hand, both girls and boys vaccination 
might become one of such prospects. It is noteworthy in this connection that when the item 
of reasonability of boys’ vaccination is being discussed it is usually being done for the sake 
of CC prevention in their wives-to-be. Resolution is usually made in the negative in 
resource-constrained countries. As to the female BC, possibility to prevent women from 
urothelial carcinogenesis might become an additional convincing argument in favour of 
their vaccination. 
Possible ways of HPV ingress into human urinary bladder lining should be thought over by 
both clinicians and experimenters. The idea of HPV-associated BC may form grounds for 
adding of some tests (aimed to detect anogenital HPV) to the currently accepted ways of 
preoperative check-up of BC patients. This idea may also become the reason to reconsider 
safety of cystoscope and catheter in treatment of BC patients infected with HPV in 
anogenital region. 
Despite that HPV role in urothelial carcinogenesis is still open-ended question several 
research groups tried to find an answer to the related one: whether clinical course of BC is 
affected by HPV presence in urothelial cells. 
Y. Andreeva and co-authors studied if papillomaviruses influence relapse incidence in BC 
patients (Andreeva et al., 2008). The authors preselected 44 BC specimens taken from 
patients with superficial tumors (stages Ta and T1) on the basis that there occurred 
koilocytes in these specimens (an indirect morphological sign of viral infection). The 
specimens were then subdivided into 3 groups: (1) 16 ones from patients with high relapse 
incidence, (2) 13 - from patients with moderate and (3) 15 - from patients with low relapse 
incidence. DNA of HPV16 and HPV18 was found by in situ hybridization in specimens from 
patients of the first and second groups only. Seven out of 16 specimens (44%) harboured 
HPV16 DNA in the first group. Three specimens (23%) were HPV18-positive while HPV16 
genetic material was found in neither case in the second group. The authors concluded that 
HPV occurrence in urothelial cells increases the risk of a superficial BC relapse.  
A. Lopes-Beltran and co-authors studied whether HPV DNA presence in cancer cells may 
influence BC patient survival (Lopes-Beltran et al., 1996). The group of 76 BC patients with 
transitional BC was formed without any preselection. In materials obtained at transurethral 
resections the authors detected DNA of HPV6, HPV11, HPV16 and HPV18 using PCR. 
Follow-up lasted for 5 years. The resultant survival among HPV-positive patients was found 
to be ~ 29 % (2 out of 7), while among negative ones - 75 % (52 out of 69). The authors 
concluded that HPV-DNA-positivity serves as a negative predictor of BC patient survival. 
The results reported by C. De Gaetani and co-authors (De Gaetani et al., 1999) are in good 
agreement with those data. The authors found by in situ hybridization with the probes to 
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viral types 16/18 and 31/33/35 HPV DNA in 17 out of 43 BC specimens. Follow-up lasted 
for 72 months. During this time 10 HPV-positive patients died (~59%). Meanwhile 5 out of 
26 HPV-negative patients died (~20%). 
If HPV contribution to urinary bladder carcinogenesis gains recognition current therapeutic 
methods might be supplemented in the near future with the administration to the bladder of 
HPV-positive BC patients of low molecular weight chemical substances inhibiting HPV 
oncogenes expression. Results of successful studies of such substances in experimental 
models were presented at the 25-th International papillomavirus conference (Hellner et al., 
2009). 
8. Conclusion 
The problem of HPV involvement in urinary bladder carcinogenesis is still open. In a 
complex study performed on clinical specimens of dysplasia and carcinoma of urinary 
bladder from Russian patients with the use of several methods of HPV DNA detection (in 
situ hybridization, PCR with several types of primers) we registered up to 40-50 % of DNA 
HPV-positive cases. In many cases DNA HPV-positivity was accompanied with expression 
of viral oncogenes E6 and E7 at the levels of mRNA and/or protein. Thus we detected 
oncoprotein E7 HPV16 known for its ability to interfere with the normal pRb functioning 
(which leads to unchecked transition of a cell from G1 to S stage of the cell cycle) in every 
third BC specimen harbouring HPV16 DNA. Results reported by other research groups 
obtained both in clinical materials and in experimental models in vivo and in vitro confirm 
the idea of HPV as a possible causative agent of BC. There are certain signs that role of HPV 
in urinary bladder carcinogenesis may be somewhat different from their role in CC 
origination. Their most probable role in urothelial carcinogenesis seems to be partnership in 
initiation of the process jointly with other agents (such as parasitic helminths, components 
of cigarette smoke, chemical pollutants of industrial origin, etc.). The notion that HPV in 
some cases takes part in urinary bladder carcinogenesis may be helpful for BC prevention, 
prediction of its clinical course and, in prospect, for treatment of HPV-associated BC. 
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1. Introduction 
Bladder cancer represents a significant worldwide health problem with an estimated 386,300 
new cases and 150,200 deaths in 2008 worldwide. The majority of bladder cancer occurs in 
males and there is a 14-fold variation in incidence internationally. The highest incidence 
rates are found in the countries of Europe, North America, and Northern Africa (Jemal et 
al.2011). Smoking and occupational exposures are the major risk factors in Western 
countries, whereas chronic infection with Schistosoma hematobium (SH) in developing 
countries, particularly in Africa and the Middle East, accounts for about 50% of the total 
burden. The majority of bladder cancers associated with schistosomiasis are squamous cell 
carcinoma (Figure 1). 
Although the majority of bladder cancers, present with disease confined to the superficial 
layer of the bladder wall, approximately 20–40% of the patients will present with or 
subsequently develop invasive cancer. Bladder cancer is morphologically heterogeneous; 
more than 90 % of bladder cancer cases are urothelial (UC, transitional cell, TCC) carcinoma, 
whereas primary squamous  cell carcinoma (SCC), adenocarcinoma, small cell carcinoma 
and other rare tumors are less common (Lopez-Beltran and Cheng, 2006). Urothelial cell 
carcinoma can present mixed with other malignant components (figure 2). These mixed 
forms of bladder histologies include squamous differentiation (present in 20 - 60% of 
bladder cancer cases), adenocarcinoma or glandular differentiation (10%), sarcomatoid (7%), 
micropapillary (3.7%) and lymphoepìtelioma-like carcinoma. About 1 in 25 Western men 
and 1 in 80 women will be diagnosed with bladder cancer (BC) sometime in their life. In 
many developing countries, life expectancy is much lower than Westerns, which is one of 
the reasons why overall BC incidence (not age-specific incidence) is lower in these 
developing countries (Albertson and Pinkel, 2003). It is associated with substantial 
morbidity and mortality. History of Tobacco smoking not only increases the incidence of 
BC, but also it can increase the tumor grade, its  size and the number of tumor lesions 
(Muscheck et al, 2000). Chronic schistosomal cystitis was related for a long period to the 
development of BC in areas endemic for schistosomiasis like Egypt. In these areas, risk 
factors are many, including exposure to schistosomiasis, increased smoking rate and 
exposure to carcinogenic chemicals (Kallioniemi et al, 1992). 
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Fig. 1. Squamous cell carcinoma. Groups of malignant squamous cells show central keratin 
nests formation. Aggregates of calcified bilharzias eggs are seen between groups of 
malignant cells. 
Although smoking is still recognized as a major risk factor of cancers including bladder 
cancer, the increasing incidence of bladder cancer, despite the reduction in smoking in the 
United States, suggests that other environmental factors may be playing an increasing role 
in the development of bladder cancer. Unlike the common belief, risk factors such as 
positive family history, parent’s consanguinity, exposure to pesticides and chronic cystitis 
seem to play now more important roles than bilharziasis and smoking in the development 
of this disease in Egypt, yet reports on larger numbers of patients are needed to support this 
conclusion (Zarzour et al, 2008). 
2. Bladder cancer formation 
Urothelial tumor is characterized by its multifocality. There have been two theories 
proposed to explain the frequency of this Urothelial tumor multifocality.  One theory, the 
monoclonal theory, suggests that multiple tumors arise from a single transformed cell that 
proliferates and spreads throughout the urothelium. The second theory, the field-effect 
theory, explains tumor multifocality as a development secondary to the field cancerization 
effect. In the last scenario, carcinogens cause independent transforming genetic alterations at 
different sites in the urothelial lining leading to multiple genetically defective tumors 
 




Fig. 2. Invasive urothelial cell carcinoma. Small groups of cells with glandular differentiation 
on the right are seen infiltrating muscle layer (arrow). Bilharzial granulomas are seen on the 
left. 
(Cheng et al, 2010). That may highlight the existence of different histopathologies in the 
same specimen. A recent study suggests that both field cancerization and monoclonal tumor 
spread may coexist in the same patient (Jones et al, 2005). In this study, molecular evidence 
supported an oligoclonal origin for multifocal Urothelial carcinoma. Field cancerization, 
which is an important cause of multicenteric squamous cell carcinoma (SCC) of head and 
neck postulates that multifocal Urothelial carcinoma arises in the same way. The 
independent transformations are a consequence of external cancer-causing influences. 
Premalignant changes, such as dysplasia or carcinoma in situ (CIS) are often found in 
Urothelial mucosa distant from an invasive bladder cancer. Furthermore, various theories 
have been proposed to combine the two mechanisms. Early or preneoplastic lesions may 
arise independently with specific clone and pseudomonoclonality (Hafner et al, 2002). The 
modern carcinogenesis model suggests that malignancy represents clonal expansion of one 
or a few cancer stem cells that proliferate through asymmetric differentiation and can 
diversify into heterogeneous cancer cell lineages. Asymmetric differentiation means that 
following cell division, one daughter cell retains the capacity to divide again and the other 
daughter cell possesses genetic plasticity, allowing phenotypic variation in the offspring. 
When tumors arise from Chromosomal Somatic Changes (CSC) of progenitor cells, a specific 
set of genomics, epigenomic and/ or microenvironment niche alterations is essential for 
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continued clonal expansion. Therefore, each CSC and its pro/zaxgency possess a unique set 
of genetic, epigenetic and phenotypic features. Genetic alterations of stromal somatic cells 
assist CSCs in the niche to promote cancer development and progression (Cheng and  
Zhang, 2008). Since the sixties of the last century, meaningful chromosomal changes were 
subsequently reported in human cancer. With the establishment of different new methods, 
detection of these changes became more apparent and allowed better understanding of the 
process of evolving of different kinds of cancer. Each new method widened the recognition 
of karyotypic changes, increasing the resolution of cytogenetic details until the limit of 
microscopic visualization were almost reached. The evolution of cytogenetics encompasses 
also molecular approaches such as fluorescent in situ hybridization (FISH) and comparative 
genomic hybridization (CGH) whether metaphasic or array. These techniques have revealed 
novel and otherwise cryptic rearrangements, as well as providing chromosomal information 
for cases in which conventional cytogenetic analysis is not possible (Sendberg and Meloni-
Ehrg, 2010). 
A meta-analysis examining urine markers for surveillance showed that Fluorescence In Situ 
Hybridization (FISH) test had a median sensitivity of 79% and median specificity of 70% in 
detecting genetic abnormalities in cells present in urine using FISH (Van Rhijin et al, 2005). 
The main disadvantages of FISH are the lack of standardization of the criterion for a positive 
test, the low sensitivity of detecting low-grade tumors, its expense, and the need for 
specially trained laboratory personnel to perform the test (Degtyar et al, 2004 & Lokeshwar 
et al, 2005). Combined testing with other assays may improve the effectiveness of this 
biomarker. Several markers have shown promise as noninvasive biomarkers of bladder 
cancer, and some may be useful as therapeutic targets. To date, however, none have found a 
strong niche in clinical care because of the lack of evidence demonstrating that outcomes are 
altered on a practical basis. In addition, at this time, none of these markers can supplant 
cystoscopy, and most add little advantage to the combination of cystoscopy and cytology. 
3. Schistosomiasis  
Schistosomiasis  infect 200 million people according to the World Health Organization and 
is endemic in as much as 76 tropical developing countries. S. hematobium (SH) is associated 
with bladder cancer. Schistosomes are dioecious parasitic blood flukes, which have a 
mammalian host and an intermediate invertebrate host: fresh water snails (Kuper et al, 
2000). There are four human schistosomes :S. haematobium, S. mansoni, S. japonicum, S. 
mekonji. The S. haematobium, like other schistosomes  is dioecious and the adult female 
lives in-copulo in the gynecophoral canal of the male; this species of schistosome lives in the 
venules of the human urinary bladder. Eggs laid in the urinary bladder produce irritation 
and eventual fibrosis, contributing to the events that lead to human carcinogenicity (Fried et 
al, 2011). 
All schistosoma infections follow direct contact with fresh water that harbors free-
swimming larval forms of the parasite known as cercariae. Cercariae penetrate the skin. The 
cercariae shed their bifurcated tails, and the resulting schistosomula enter capillaries and 
lymphatic vessels en route to the lungs. After several days, the worms migrate to the portal 
venous system, where they mature and unite. Pairs of worms then migrate to the vesical 
plexus and veins draining the ureters. Egg production commences four to six weeks after 
infection and continues for the life of the worm, usually three to five years. Eggs pass from 
the lumen of blood vessels into adjacent tissues, and many then pass through the bladder 
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mucosa and are shed in the urine. The life cycle is completed when the eggs hatch, releasing 
miracidia that, in turn, infect specific freshwater snails (Bulinus species).After two 
generations - primary and then daughter sporocysts — within the snail, cercariae are 
released (Ross et al, 2002).  
4. Schistosoma-Associated Bladder Cancer (SA-BC) 
Schistosomiasis was first linked to urinary bladder cancer in Egypt in 1911 (Ferguson et al, 
1911). The incidence of urinary bladder cancer in the Middle East and Africa is greater in 
areas with high rather than low SH prevalence; the aforementioned study noted that 60% of 
the Egyptian population was at risk of infection with SH, with rural school children at 
particular risk because of their proximity to contaminated water. The overall prevalence of 
SH infection in Egypt was 37–48% that decreased due to the antibilharzial campaign to 3 % 
(Ministry of Health and Population, 2004). The urinary bladder cancer accounted for about 
31% of the total incidence of cancers in Egypt that subsequently decreased to 12% in recent 
years. However still, it is the most common type of cancer in males and the second most 
prevalent, after breast cancer, in females (Gouda et al, 2007). In Egypt, Iraq, Zambia, 
Zimbabwe, Malawi and Sudan, the incidence of SA-BC peaks at 40–49 years of age; the male 
to female ratio for bladder cancer is 5:1 in endemic and 3:1 in non-endemic areas. This 
relates to the fact that it is agricultural workers, mainly men, who have daily exposure to 
water infected with SH cercariae. (Makhyoun  et al, 1971). Mechanicaly, there are several 
factors that may contribute to the oncological potential of schistosomia infection. 
Schistosoma ova deposited in the bladder provoke an intense inflammatory reaction, 
associated with the production of oxygen-derived free radicals, which may induce genetic 
mutations or promote the production of carcinogenic compounds (such as N-nitrosamines 
and polycyclic aromatic hydrocarbons) (Marletta 1988 & Rosin et al, 1994) ,leading to 
malignant transformation. Shokeir (2004) showed that schistosomiasis is often accompanied 
by chronic bacterial super-infection, which may in itself predispose to squamous cell (SC) 
neoplasia. Bacteria found to accompany schistosomiasis can promote the formation of N-
nitrosation of amines, adding to those from other sources such as the diet. A 54–81% 
incidence of SCC was found in all cases of bladder cancers in endemic areas, opposed to 3–
10% in Western countries. The higher incidence of SCC is probably due to exposure to 
carcinogens such as N-nitroso compounds that are abundantly present in the urine of 
patients with SH (Tricker et al,1989). International Agency for Research on Cancer (IARC) 
found that the intensity of infection was determined by urinary egg counts and confounded 
by smoking, a recognized cause of bladder cancer in non-endemic countries, and the 
combination was strongly considered. Positive association between bladder cancer and SH 
infection was detected, with odd ratios ranging from 2 to 14. The more heavily infected 
individuals were with this schistosome, the more likely they were to develop bladder 
cancer, and at a younger age (IARC, 1994). 
Most of the pathological findings of schistosomiasis are due to an inflammatory and 
immunological response to egg deposition. Granulomatous areas form around the eggs and 
induce an exudative cellular response consisting of lymphocytes, polymorphonuclear 
leukocytes and eosinophil. The early stage of SH infection is characterized by egg deposition 
in the lower ureters and urinary bladder. Resultant perioval granulomas, fibrosis and 
muscular hypertrophy are seen histologically. In the ureter, lesions can cause stenosis, 
leading to hydronephrosis. In the urinary bladder, masses of large granulomatous 
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inflammatory polyps containing eggs are found at the bladder apex, dome, trigone and 
posterior wall. Polyps may ulcerate and slough, producing haematuria. Hyperplasia of the 
urothelium occurred in 38% of the autopsied SH cases as opposed to 21% in non-infected 
cases; also, metaplasia in 31.6% versus 11.5% and dysplasia in 27.2% versus 8.5% cases were 
found. Late-stage infections were characterized by schistosomal bladder ulcers and sandy 
patches, and irregularly thickened or atrophic mucosa in the posterior bladder or trigone 
area. Histologically, fibrosis with some round cell infiltration was seen; old granulomas 
containing calcified or disintegrating eggs were also seen (Smith and Christie, 1986). The 
inflammatory and fibrotic response to egg deposition could lead to calcification of the 
urinary bladder, infection and stone disease and these changes are frequently associated 
with urinary bladder cancer (EL-Bolkainy et al, 1981). These lesions may be at least partially 
responsible to the reported clinical picture of SA-BC. Furthermore, the following sequence 
of events in SH-induced carcinogenesis has been suggested: chronic infection leads to 
schistosoma eggs being trapped in the bladder wall. Proliferation of cells in the bladder 
mucosa results from constant irritation and inflammation. Clones of neoplastic cells develop, 
stimulated by N-nitrosamines and other environmental carcinogens such as cigarette smoke 
and pesticides (Abdel et al, 2000).  The importance of urinary retention, whether from 
fibrosis and obstruction of the urinary bladder neck or from voluntary causes such as pain 
on urination, in prolonging the exposure of the bladder mucosa to various exogenous and 
endogenous carcinogens was documented. Schistosome-induced urinary stasis allows 
increased absorption of carcinogens and therefore plays an integral role in carcinogenesis. 
Recurrent bacterial urinary tract infections are associated with squamous cell carcinoma of 
the urinary bladder, even in the absence of SH infection (Genile et al, 1985). Carcinogenesis 
of SH involving an initiating and promoting effect has been described. First, the damage 
occurs to the DNA template which, unless repaired, leads to irreversible changes in the 
complementary strand of DNA produced during the S-phase of the cell cycle. Somatic 
mutation results when the altered strand is used as a template. The promotion phase 
followed by stimulation of cell proliferation. Different cancer-associated genes, notably 
protoncogenes/oncogenes and tumor suppressor genes, were known to be associated with 
numerous human cancers; recent efforts have been made to study the specific genes 
involved in the induction of SA-BC. Cell exposed to SH cell total antigen (warm exttract) 
was found to divide faster than those not exposed to the parasite and died 
much less. This was probably due to increased level of bcl2, a protein involved in cancer 
apoptosis that may lead to SH carcinogenic ability in bladder urothelium (Botelho et al, 
2009). The urothelium of mice exposed to SH total antigen showed dysplasia, low grade 
intra-urothelial neoplasm, non-invasive malignant flat lesions in 70 % of the tested mice 
after 40 weeks of exposure. Carcinoma of the bladder frequently harbors gene mutations 
that constitutively activate the receptors tyrosine kinase Ras pathway (Wu, 2005). The Ras 
gene product is a monometric membrane-localized G protein of 21 Kd that functions as a 
molecular switch linking receptors and non-receptors tyrosine kinase activation to 
downstream cytoplasmic or nuclear events. Each mammalian cell contains at least three 
distinct Ras proto-oncogenes encoding closely related but distinct protein, Kras, Hras and 
Nras. Activating mutation in these Ras protein, result in constitutive signaling. Thereby 
stimulating cell proliferation and inhibiting apoptosis. Oncogenic mutations in the Ras gene 
are present in approximately 30% of all human cancer (Adjer, 2001). Botelho et al (2010) 
used the dysplastic bladders induced by SH in mice and screened them by sequencing for 
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mutations in Kras codon hotspots gene. They concluded that the parasite abstract has 
carcinogenic ability possibly through oncogenic mutation of Kras gene. 
5. Genetic changes in SA-BC 
Among the most common genetic changes in bladder cancer is the loss of heterozygosity 
(LOH) on chromosomes 9p and 9q, which is found regardless of tumor grade and stage 
(Jacobs et al,2010 & McConkey et al, 2010). A prospective study stated that there was no 
evident line of demarcation between schistosomiasis-associated and non schistosomiasis-
associated bladder cancer in terms of LOH of microsatellite markers on chromosome 9. This 
suggests that data obtained from schistosoma-associated bladder cancer can be extrapolated 
to bladder cancer induced by a schistosomiasis independent mechanism (Abdel Wahab et al, 
2005). DNA microsatellites are highly polymorphic repeats found throughout the genome, 
and microsatellite markers can detect cancer-associated alterations in genetic material, 
including microsatellite instability and LOH (Nielsen et al, 2006). A more recent analytical 
tool that has been developed to detect genomic instability in urinary DNA uses small 
nucleotide polymorphisms (SNPs). SNP chips have a potential advantage over microsatellite 
analysis in that they can screen more than 300 genetic loci at once compared with 13-20 loci, 
which leads to a greater sensitivity of the detection of molecular changes (Hoque et al, 2003). 
6. Cytogenetics for understanding carcinogenesis 
Carcinogenesis is a complex process in which normal cell growth is modified as a result of 
the interaction of multiple factors, including xenobiotics and endogenous constituents. 
Carcinogenic process results from the accumulation of both genetic and epigenetic changes 
that are driven by instability of cellular genome and alterations in inter- or intra-cellular 
communication, which disrupt the cell proliferation regulation process (Loeb and loeb, 
2000). Cytogenetics is concerned with the task of finding recurrent (repeated) or specific 
abnormalities associated with cancer, and continues to provide crucial diagnostic and 
prognostic information. In current practice, cytogenetic data often serve as a guide in other 
studies, ranging from the exploration of cytogenetic findings with various methodologies, 
singly or in combination, including fluorescence in situ hybridization (FISH), polymerase 
chain reaction (PCR), or microarray-based technologies such as comparative genomic 
hybridization (CGH), both metaphasic (mCGH) and array (aCGH), to the use of 
immunohistochemical techniques by the pathologist. Cytogenetic data also provide key 
background information for the recognition and identification of genes (and their networks) 
involved in cancer.  Progress in understanding the cytogenetic and molecular basis of 
neoplastic transformation has strengthened the conception of cancer as a genetic disease. 
Thus, the finding of apparently normal karyotypes in abnormal cells presents an enigma. It 
can be assumed that cryptic genetic changes are involved in such cases. Newer technologies 
highlight the more complicated and perplexing aspects of cancer that have eluded more 
traditional cytogenetic studies. For example, molecular studies have demonstrated fusion 
genes associated with many tumors like prostate and lung cancers that are not discernible 
cytogenetically. These findings raise the strong possibility that more epithelial carcinomas, 
which are usually associated with numerous or complex karyotypic alterations, will be 
shown to have cryptic primary genetic alterations (Sandberg et al,2010) 
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mutations in Kras codon hotspots gene. They concluded that the parasite abstract has 
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7. Requirements and limitations of cancer cytogenetic studies 
Cytogenetic techniques require the presence of dividing cells (preferably in the metaphase 
stage) for the visualization of chromosomes. Thus, fresh specimens are necessary for 
establishing either short-term or long-term cultures (Sandberg, 1990, Brigge and Sandberg, 
2000, Sandberg and Chen, 2001& Gersen and Keagle, 2005). Nevertheless, useful genetic 
information can be obtained from fixed specimens with appropriate FISH or other molecular 
techniques (Gersen and Keagle, 2005). Cytogenetic changes represent genetic mechanisms 
that are thought to be responsible for the biology of the respective clinical conditions, and 
have become important components of diagnostic and prognostic criteria. There are two 
different classes of genetic alterations associated with cancer: activation of oncogenes and 
inactivation of tumor suppressor genes. Rearrangements are a common source of activating 
mutations. Another scenario is exemplified by chromosome translocations, inversions, or 
insertions that lead to formation of fusion oncogenes. The oncogene fusion mechanism has 
received increased attention, because many of these fusions lead to activation of protein 
tyrosine kinases (PTKs) in various types of cancer. Most of the cytogenetic changes involve 
activation of receptor proteins, especially PTKs. Receptor PTKs are a highly regulated family 
of proteins in normal cells, but may undergo activating mutations or structural alterations to 
become oncoproteins in human malignancies. As already noted, oncogenic activation of 
PTKs can result from genetic lesions such as point mutations, deletions, or overexpression 
by gene amplification. Alternatively, chromosomal rearrangements such as translocations, 
inversions, and insertions that lead to formation of an oncogenic gene fusion can involve 
receptor PTK or other PTK encoding genes as fusion partners. Another type of gene 
rearrangement involves tumor suppressor genes, whose products normally serve as brakes 
on cell growth and runaway cell proliferation. Inactivation of tumor suppressor genes leads 
to uncontrolled cell proliferation and downregulation of apoptosis (programmed cell 
death)(Jones and Baylin, 2002 & Feinberg and Tycko, 2004). The activation of oncogenes 
sometimes results from complex genetic rearrangements. In each of the fusion genes the 
kinase domain of the neural-associated receptor tyrosine kinase gene is fused to an 
activating domain of another gene. The same genes may be altered in a number of different 
tumors, but apparently at varying chronologies in tumor development and associated with 
different genetic changes. In many tumors, a specific translocation may be the only 
alteration present. Many cases, however, display additional structural or numeric 
karyotypic changes that may be responsible for, or at least are associated with, disease 
progression(Sandberg, 1990). The relevance of additional abnormalities is also reflected by 
alterations in the expression of a number of genes apart from those involved in the 
translocations. The exact cause or causes of these additional alterations is unknown, and it 
remains uncertain whether the primary translocation per se is responsible for the basic 
genetic process underlying the tumor genesis. These additional changes usually vary from 
tumor to tumor, even among tumors with the same diagnosis. Tumors with specific 
translocations may exhibit a variety of anomalies, with or without additional chromosome 
changes, at the molecular level. Carcinomas being diagnosed relatively late in their 
development, thus allow for the genesis of chromosomal rearrangements in addition to the 
primary genetic event. Although some of the chromosomal changes have been related to 
prognosis and tumor biology yet, few recurrent or repeated chromosomal anomalies have 
been identified as characterizing these tumors (Teixeira et al, 2006). 
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MicroRNAs (miRNAs) constitute a rapidly developing field of study at many levels. The 
miRNAs are short segments of RNA (~22 bases in length) that affect mRNA functions, most 
often by suppressing translation of the protein product or by promoting degradation of 
them. An important value of miRNAs is that they can be detected and quantified in a 
variety of samples, including plasma and formalin-fixed, paraffin-embedded tissues. This 
makes them a valuable testing tool, particularly in the clinical arena(Wijnhoven et al, 2007, 
Grady and Tewari, 2010 & Ferracin et al, 2010) 
In cancer, the combination of cytogenetic and molecular studies (FISH, SKY, PCR, CGH, and 
related methodologies) can more clearly define pathogenetic pathways and the biologic 
functions of molecular markers than either approach alone. Such a dual approach should 
lead to less empiric and more biologically oriented approaches to tumor classification and, 
ultimately, to more efficient clinical use of biomarkers (Wang,2002 & Balsara et al, 2002). 
Findings based on the combination of cytogenetic and molecular approaches have improved 
the criteria for diagnosis of cancer. The hypothesis that specific clones of spontaneously 
evolving aneuploidies or karyotypes, rather than specific mutations, generate the 
individuality of cancers (Fabarius et al, 2008), may apply to at least some of, if not all, the 
conditions .Cancer development not only depends on genetic alterations but also on 
epigenetic changes (Jones and Baylin, 2007).  These changes modify gene expression through 
DNA methylation, histone modifications, chromatin remodeling, and/or the expression of 
noncoding RNA(Esteller, 2007 & Zaratiegui et al, 2007). 
Epigenetic gene silencing in cancer was thought to be restricted to focal events that silenced 
isolated genes (Smith and Costello, 2006). However, recent findings have indicated that 
epigenetic silencing can extend to a whole chromosomal region and has been reported to 
involve DNA methylation and/or histone modification in various cancers (bladder, breast, 
colorectal, and prostate cancer) (Coolen et al, 2010). 
The development of cancer is often a multistage process where the disruption of specific 
subsets of genes can result in cells expressing a malignant phenotype. However, the series of 
mutations leading to malignancy has only been elucidated for a small number of human 
cancers (e.g., polyposis of the colon, retinoblastoma). There has been no entirely specific 
cytogenetic aberration identified for bladder cancer, but various nonrandom deletions, gains 
of chromosomes, polyploidisation, and formation of isochromosomes have been observed 
(Gibas and Gibas, 1997). 
8. Bladder cancer cytogenetics and epigenetics 
Chromosome 1 has been reported as being the most frequently involved chromosome in 
rearrangements; other chromosomes commonly reported in bladder cancer include 
chromosomes 3,5,7, and 9 (Heim and Mitelman, 1995). Yunis and Soreng (1984) suggested 
that there was a relationship between chromosomal fragile sites and oncogenesis. It is 
believed that fragile sites provide regions of the genome that are more susceptible to 
damage and that this contributes to the carcinogenic process because of subsequent changes 
to gene function or dosage.  Bladder cancer is a very heterogenous disease cytogenetically, 
which suggests that the pathogenesis of the disease may not be consistent for every case. A 
possible scenario of pathogenesis could be the disruption of a nonconsistent set of cell 
regulatory genes compounded with disruption to genes that have a phenotypic effect on the 
bladder. Sustained disruptions to fragile regions as a result of prolonged exposure to 
clastogens in vivo are likely to lead to enduring chromosomal rearrangements and 
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associated gene alterations. The heterogeneity of cytogenetic findings in bladder cancer 
hints that there might be different “fingerprints” or accumulations of genetic changes that 
individually lead to bladder cancer and that fragile sites may be providing a gateway for 
oncogenesis for some cases. Different combinations of these damaged sites could result in 
varying cancer phenotypes, depending upon which particular genes were located at the 
sites susceptible to the mutagens. 
Protoncogenes encode proteins that ultimately enhance cell proliferation. Events that 
convert  protoncogenes to oncogenes can lead to uncontrolled cell proliferation and 
carcinogenesis (Badawi et al, 1995).  The RAS oncogene and its potential association with 
urinary bladder cancer was studied, though still not totally clear. The RAS oncogene 
encodes a 21-kDa protein that affects signal transmission between the nucleus and tyrosine 
kinase receptors. H-RAS activation was estimated in bladder cancer to range between 7% 
and 17%, with its expression being similar with or without concurrent schistosomal 
infection. The TP53 tumor suppressor gene, located on the short arm of chromosome 17, 
encodes a protein that regulates DNA damage repair and controls aspects of the cell cycle 
involving cellular apoptosis and senescence. TP53 mutation results in a reduction of DNA 
damage surveillance leading to instability of the genome and malignant transformation 
(Strohmeyer and Slamon, 1994). The overexpression of the BCL-2 gene in SA-BC patients 
was found to be up-regulated in squamous but not transitional cell cancers of the urinary 
bladder. Therefore, this BCL-2 overexpression is consistent with the predominance of SCC 
in SA-BC. Upregulation  of this gene overrides programmed cell apoptosis increasing the 
risk of genomic instability and may interact with various proto-oncogenes facilitating 
tumorigenesis. Mutations of TP53 were found in 73% of tumors, BCL-2 expression in 32% 
and abnormalities of both TP53 and BCL-2 in 13%. Loss of the normal reciprocal control 
mechanism for apoptosis was suggested in the subset of patients with overexpression of 
both TP53 and BCL-2 (Chaudhary et al, 1997). 
Furthermore, cyclooxygenase-2 is overexpressed in SA-BC. The quantitative relationship 
between cyclooxygenase-2 expression and tumor grade was statistically significant. The 
cyclooxygenase-2 role in the complex multi-stage process of SA-BC carcinogenesis was 
proposed: pro-inflammatory cytokines such as interleukin-1, tumor growth factor-β and 
tumor necrosis factor-alpha, are generated by activated macrophages in the inflammatory 
lesions. These cytokines and growth factors are potent inducers of cyclooxygenase-2 
production. By-products of uncontrolled cyclooxygenase activity together with endogenous 
genotoxins produce oxidative and nitrosative stress creating lipid peroxidation by-products. 
Additional mutations are induced: TP53, H-RAS, deletion of p16 and p15, increased 
epidermal growth factor receptor, c-erb-2 and tumor necrosis factor-alpha. Increased 
prostaglandin production up-regulates cyclooxygenase-2, decreases killer T-cell activity, 
increases BCL-2 and glutathione-S-transferase. These changes increase tumorgenicity by 
decreasing cell apoptosis, creating immunosupression. Prostaglandin products of 
cyclooxygenase-2 cause tumor progression and eventual metastasis by down-regulating 
adhesion molecules, increasing the degradation of extracellular matrix and increasing 
angiogenesis (El-Sheikh et al, 2001). 
9. Natural history of SA-BC 
The association between SA-BC and SH was established through case-controlled studies and 
through the close correlation of the incidence of bladder cancer with the prevalence of SH 
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within different geographic areas. Moreover, the association was based on the frequent 
association of tumors with the presence of parasitic eggs and egg-induced granulomatous 
pathology involving bladder tissues  (Figure 2). Despite that linkage between SH and 
bladder cancer, only limited data are available on cytopathologic findings in SA-BC. The 
cellular mechanisms linking SH infestation with bladder cancer formation are not yet 
defined. In some cases, severe metaplasia in bladder urothelium may represent a 
precancerous transformation, whereas in others it may merely serve as a marker of 
prolonged inflammation, which is associated with high cancer risk (Hodder et al, 2000). 
Keratinizing or adenomatous metaplasia per se has a strong association with cancer 
formation in patients with chronic irritation due to bladder stones, chronic infection, or 
prolonged catheterization. 
SA-BC was defined by characteristic pathology (i.e., squamous carcinoma, transitional cell 
carcinoma, or adenocarcinoma, rather than mainly transitional) and cellular and molecular 
biology that differ from non-Schistosoma-associated bladder cancer (NSA-BC). Few studies 
have analysed the cytogenetic and molecular genetic abnormalities in SA-BC and some 
compared DNA copy number changes in SA-BC and NSA-BC (Kallioniemi et al, 
1992,Tsutumi et al, 1998, Muscheck et al,2000,  Fadl-Elmula et al, 2002 & Albertson and 
Pinkel, 2003). Further future studies are needed to characterize the genetic alterations in 
schistosomal bladder tumors and their role in bladder cancer induction. 
These studies used metaphase CGH to obtain overview of chromosomal alterations in SA-
BC. The value of pooled DNA in aCGH was shown to be advantageous in detecting 
recurrent changes associated with specific histopathologic or clinical features (Kendziorski 
et al, 2005).    Two more recent studies used aCGH, rather than metaphase CGH (Armengol 
et al, 2007 & Vauhkonen et al, 2007). Array CGH provides higher density region-specific 
coverage and direct mapping of aberrations to the genome sequence, as well as higher 
throughput (Albertson and Pinkel, 2003).  This ensures greater accuracy in comparing two 
groups of tumors (e.g., SA-BC and NSA-BC). Muscheck et al. (2000) demonstrated deletion 
similarities in Schistosoma-associated transitional cell carcinoma (SA-TCC) and 
Schistosoma-associated squamous cell carcinoma (SA-SCC), compared to what has been 
previously reported by Kallioniemi et al. (1992) on NSA-TCC and Tsutsumi et al. (1998) on 
NSA-SCC. The previous investigators (Kallioniemi et al,1992,Tsutsumi et al,1998, Muscheck 
et al, 2000, Fadl-Elmula et al, 2002 &  Albertson and Pinkel, 2003) used the technique of CGH 
on individual tumor tissues, not pooled tissues of similar pathologies. Armengol et al. (2007) 
used an excellent technique of combining similar pathological types into pools of tissue 
arising from patients having similar pathological subtypes. These pooled DNAs revealed 
recurrent primary changes covering secondary changes that vary from case to case. The 
pooled specimens of SA-BC tumors showed no schistosomiasis specific changes, compared 
with pools of NSA tumors. The comparison between SA-TCC and NSA-TCC and that 
between SA-SCC and NSA-SCC gave similar results. DNA copy number profiles of urinary 
bladder SA adenocarcinoma revealed similarities to that of SA-TCC and SA-SCC reported 
by Vauhkonen et al. (2007). The results in these two publications showed that the detailed 
analysis of individual genes revealed a set of genes with the same copy number changes in 
all bladder carcinomas, including both SA and NSA tumors. Armengol et al. (2007) 
concluded that there are no major cytogenetic differences among different urinary bladder 
epithelial tumors, regardless of the suspected carcinogen. All the detected imbalances in SA-
BC have been repeatedly reported in NSA-BC that suggested that cytogenetic profiles of 
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with pools of NSA tumors. The comparison between SA-TCC and NSA-TCC and that 
between SA-SCC and NSA-SCC gave similar results. DNA copy number profiles of urinary 
bladder SA adenocarcinoma revealed similarities to that of SA-TCC and SA-SCC reported 
by Vauhkonen et al. (2007). The results in these two publications showed that the detailed 
analysis of individual genes revealed a set of genes with the same copy number changes in 
all bladder carcinomas, including both SA and NSA tumors. Armengol et al. (2007) 
concluded that there are no major cytogenetic differences among different urinary bladder 
epithelial tumors, regardless of the suspected carcinogen. All the detected imbalances in SA-
BC have been repeatedly reported in NSA-BC that suggested that cytogenetic profiles of 
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chemical- and Schistosoma-induced carcinoma are largely similar in the reports of 
Muscheck et al. (2000) and Fadl-Elmula et al. (2002). Patients having SA-BC usually present 
late with more advanced stage, due to the repeated SH infestations having similar 
symptoms. The decreased intensity of schistosomal infestation in Egypt led to a changing 
pattern of the clinicoepidemiologic features of SA-BC. A decreased SCC/TCC ratio (increase 
in the percentage of TCC and decrease in that of SCC), lowering of the tumor stage and 
increase in the mean age incidence and percentage of pelvic nodal involvement have been 
reported. The reported clinicoepidemiologic differences between SA-BC and SNA-BC are 
now continuously decreasing and the features of SA-BC is slowly approaching that of NSA-
BC as reported by Koraitim et al. (1995) and Zaghloul et al. (2008). These changing features 
were attributed to the decreased intensity of schistosomal infestation in the urinary bladder, 
as a higher degree of schistosomal infestation and egg deposition was found more 
frequently with SCC and a lower with TCC (Zaghloul et al, 2008 & Zaghloul, 2010). 
Furthermore, these changes are repeatedly evident with the predominance of TCC over the 
SCC type, and a decrease of male predominance. If these changes continue with the same 
rate, bladder cancer in Egypt is expected to become identical in features to that of Western 
countries in the near future (Gouda et al, 2007). 
10. Clinical presentation  
Clinical presentations in SA-BC and SNA-BC are similar with few minor differences. 
Hematuria, dysuria and necroturia are the main symptoms in both situations. However, SA-
BC patients usually had experienced these symptoms beforehand as a result of simple 
schistosomal cystitis. This may be the reason of their relatively late presentation. Table (1) 
showed the postcystectomy pathological staging in SA-BC and SNA-BC large studies. The 
early stages (Pa, Pis, P1) were fewer in SA-BC than that in SNA-BC in both the Urothelial 
and non-urothelial pathology. The pelvic nodal involvement was nearly similar in SA-BC 
(range: 16.7% - 25.5%) , Urothelial SNA-BC (range: 16.3% - 45%) and non-urothelial SNA-BC 
(21.8% - 23%). The clincopathologic differences between SA-BC and SNA-BC were 
previously summarized as late presentation, with younger median age and a higher 
percentage of squamous cell carcinoma category (Zaghloul, 1994). 
11. Treatment of non-muscle invasive (superficial) bladder cancer 
Treatment of superficial bladder cancer remains to be transurethral resection and bladder 
biopsy (TURBT) with and without intravesical BCG or chemotherapy instillation. Although 
this treatment type is very popular in Urothelial cancer, it is less popular in non-urothelial 
SNA-BC and SA-BC, probably due to the rarity of the non-invasive stages and the presence 
of many lesions either precancerous or cancerous in the bladder mucosa. 
12. Treatment of muscle-invasive bladder cancer 
Radical cystectomy  
Muscle-invasive bladder cancer is mostly treated with radical cystectomy in many parts of 
the world. Radical cystectomy procedure includes removal of the bladder, seminal vesicles 
and prostate together with perivesical fat and peritoneal coverage, in addition to bilateral 
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Pure Urothelial Carcinoma (SNA-BC) 
Bassi  
et al (1999) 338 32.8 19.8 42.0 19.8 NM 
Stein  
et al, (2001) 1057 39.9 23.5 23.5 13 23.3 
Cheng  
et al, (2003) 303 36.1 28.6 25.5 9.9 16.3 
Shariat  
et al, (2006) 958 22 35 31 12 23 
Urothelial & Non-urothelial (SNA-BC) 
Rogers  
et al, (2006) 955 21 33 32 14 23 
Lughezzani  
et al, (2010) 12003 13.4 38.9 28.1 19.6 21.8 
Scosyrev  
et al,(2009) 1422 14.8 29 29.3 26.8 
Urothelial & Non-urothelial (SA-BC) 
El Said  
et al, (1997) 420 1 3.8 70.7 24.5 16.7 
Zaghloul, 
(1996) 357 0 33.3 47.9 18.8 24.4 
El Makresh  
et al,(1998) 185 7 25 64 7 16 
Zaghloul  
et al, (2006) 192 3.6 28.1 51.6 16.7 25.5 
Ghoneim  
et, (2008) 2720 10.5 63.9 16.6 9.0 20.4 
Zaghloul  
et al, (2008) 5071 1.9 30.1 54.9 13.1 21.9 
Khaled  
et al, (2005) 180 1.2 5.8 14.1 11.5 16.6 
Ali-El-Dein, 
(2009) 180 10.0 62.8 25.0 2.2 18.3 
Table 1. Postcystectomy pathological stages and nodal involvement in pure Urothelial and 
mixed Urothelial and non-urothelial schistosoma-non associated and schistosoma associated 
bladder cancer in large series. 
endopelvic lymphadenectomy (with varying level of dissection) in male patients. In females, 
it includes removal of the bladder, its perivesical fat and peritoneal coverage, urethra, uterus, 
ovary and anterior wall of the vagina (anterior pelvic excentration) (Ghoneim et al, 1997 & 
Stein et al, 2001). A review of recent literature of treatment results of different types of 
bladder cancer showed that applying the same treatment yielded nearly the same level of 
results if comparing the same pathological stage (Zaghloul, 2006 & Zaghloul et al, 2006). 
Similar 5-year overall survival rates were found in SA-BC, pure Urothelial and combined 
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endopelvic lymphadenectomy (with varying level of dissection) in male patients. In females, 
it includes removal of the bladder, its perivesical fat and peritoneal coverage, urethra, uterus, 
ovary and anterior wall of the vagina (anterior pelvic excentration) (Ghoneim et al, 1997 & 
Stein et al, 2001). A review of recent literature of treatment results of different types of 
bladder cancer showed that applying the same treatment yielded nearly the same level of 
results if comparing the same pathological stage (Zaghloul, 2006 & Zaghloul et al, 2006). 
Similar 5-year overall survival rates were found in SA-BC, pure Urothelial and combined 
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Urothelial and non-urothelial SNA-BC types (Table 2). The results were slightly higher in 
Stein et al. (2001) (NSA-BC) and Zaghloul et al.(2006) (SA-BC) as both studies reported 
neoadjuvant or adjuvant radiotherapy and /or chemotherapy as a part of treatment in more 
than one third of their patients. Furthermore, this conclusion applies for comparison of 
disease-free survival, overall survival, or local control rates for radical cystectomy or even in 
adjuvant and neoadjuvant radiotherapy types of treatment for SA-BC and NSA-BC 
(Zaghloul, 2006 & 2010). The treatment end-results of radical cystectomy was not affected by  
 
Author Patients # PT1 PT2 PT3 PT4 Nodal involvement 
Pure Urothelial Carcinoma (SNA-BC) 
Cheng  
et al, (2003) 218 --- 50 28 17 11 
Stein et al, (2001) 1054 74 81/68* 47 44 35 
Medersbacher  
et al, (2003) 507 76 62 40 49 26 
Takahashi  
et al, (2004) 466 81 74 47 38 50 
Dhar et al, (2006) 385 --- 63 19 NM 9 
Ho et al, (2009) 148 77 68 65 11 37 
Manoharan  
et al, (2009) 432 79 60 43 17 22 
Urothelial & Non-urothelial (SNA-BC) 
Nishiyama  
et al, (2004) 1113 82 84/69* 59 43 35 
Niu et al, (2008) 356 --- 73/44* 22 0 8 
Gupta  
et al, (2008) 502 90 78 70/58* 46 NM 
Urothelial & Non-urothelial (SA-BC) 
Ghoneim  
et al, (1997) 1026 73 66 47/31* 19 23 
El Mekresh  
et al, (1985) 185 83 41 21 
Khaled  
et al, (2005) 180 55 12 6 
Zaghloul  
et al, (2006) 192 100 100/47 40 44 31 
Zaghloul  
et al, (2007) 216 100 51 40 30 31 
Ghoneim  
et al, (2008) 2720 82 75/53 40 30 27 
*= a/b, NM = not mentioned 
Table 2. The 5-y survival of each pathological stage in Schistosoma-non associated and 
schistosoma associated bladder cancer patients in large radical cystectomy patients. 
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the association with schistosomiasis, nor tumor cell type (Urothelial or non-urothelial) in 
most of the recently published literatures (Ghoneim et al, 1997, Stein et al, 2001, Zaghloul et 
al, 2006) (Table 2). Favorable end-results were reported for patients with pathologically 
organ confined disease. These results were constant for both SA-BC (ranged from 47% to 
83%), and SNA-BC (ranged from 50% to84%). However, the results were significantly worse 
when reporting upon locally advanced tumors (PT3N0M0, PT4aN0M0 or Any N). Again, 
these worse results were experienced by both SA-BC and SNA-BC patients (Ghoneim et al, 
1997 & 2008,Stein et al, 2001,Gschwend et al, 2002, Chang et al, 2003, Medersbacher et al, 
2003, Nishiyama et al, 2004, Takahashi et al, 2004, Rogers et al, 2006 & Lughezzani et al, 
2010). Regardless of the old belief that aberrant differentiation leads to worse results, yet 
many authors reported similar results of these aberrant variants to UC when comparing 
stage to stage. Rogers et al (2006) reported a 5-year progression-free survival rate of 60±2% 
after radical cystectomy for UC and 55±11% for SCC. This difference was statistically 
insignificant. Patients with UC or SCC had statistically significant higher progression-free 
survival rates than non-UC non-SCC patients including those having adenocarcinoma. 
Another study containing considerable number of adenocarcinoma patients was conducted 
using 17 Surveillance, Epidemiology and End Results (SEER) and it showed a difference of 
statistical significance in adenocarcinoma patients who underwent RC at a more advanced 
disease stage than their UC counterparts. Another recent study using a similar SEER 
database demonstrated that SCC was more aggressive than Urothelial cancer after adjusting 
for common prognostic factors, such as stage and grade (Scosyrev et al, 2009). Scosyrev et al 
(2009) concluded that SCC was an independent predictor of mortality among patients with 
stage III and IV disease, and among patients with stage I and II disease who did not 
undergo cystectomy as part of their treatment. Therefore, squamous histology was not 
associated with increased mortality among patients with stage I and II disease when treated 
with cystectomy. Moreover, Ploeg et al (2010) studied all invasive bladder cancer cases 
treated in The Netherlands during a 12 year period of (1995-2006). They concluded that the 
relative survival of muscle-invasive adenocarcinoma patients were equal to that of UC 
patients. For stage II and III disease, adenocarcinoma patients had even better outcome. 
Muscle-invasive SCC patients showed worse survival regardless of stage. In SA-BC, 
Ghoneim et al (2008) demonstrated that SCC (1345 patients) had 10 year overall survival rate 
(OS) of 53.05% (95% CI: 51-57) compared to 48.49% (44-53 for pure UC (705 patients) and 
51.18 % (CI: 45-58) for adenocarcinoma (262 patients). Those patients who had UC with 
squamous or adenomatous metaplasia (286 patients) showed a lower 10-year OS of 42.78% 
(CI: 36-49). The lowest 10-year OS was experienced by those patients who had 
undifferentiated pathology (122 patients) having 10-year OS of 34.23 (CI: 24-45). It is clear 
from this large-number single institution study that the OS of SCC, UC and adenocarcinoma 
were similar and having the same profile. They demonstrated that although the univariate 
analysis was significant (Undifferentiated carcinoma had much lower OS), the multivariate 
analysis proved that tumor cell type is not an independent working factor determining the 
OS. The only significant prognostic factors were stage, grade and pelvic nodal involvement. 
Many authors cautiously concluded that RC treatment end-results were not affected by 
tumor histology or etiology but affected by other prognostic factors like stage, grade, nodal 
involvement, lymphovascular invasion, angiogenesis, P53, P21, Retinoblastoma genes (Rb) 
and other biological factors. These prognostic and predictor factors were shown in many 
SA-BC and SNA-BC studies to have varying weight effect (Ghoneim et al, 2008,Scosyrev et 
al, 2009,Ploeg et al, 2010 & Zaghloul, 2010). 
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survival rates than non-UC non-SCC patients including those having adenocarcinoma. 
Another study containing considerable number of adenocarcinoma patients was conducted 
using 17 Surveillance, Epidemiology and End Results (SEER) and it showed a difference of 
statistical significance in adenocarcinoma patients who underwent RC at a more advanced 
disease stage than their UC counterparts. Another recent study using a similar SEER 
database demonstrated that SCC was more aggressive than Urothelial cancer after adjusting 
for common prognostic factors, such as stage and grade (Scosyrev et al, 2009). Scosyrev et al 
(2009) concluded that SCC was an independent predictor of mortality among patients with 
stage III and IV disease, and among patients with stage I and II disease who did not 
undergo cystectomy as part of their treatment. Therefore, squamous histology was not 
associated with increased mortality among patients with stage I and II disease when treated 
with cystectomy. Moreover, Ploeg et al (2010) studied all invasive bladder cancer cases 
treated in The Netherlands during a 12 year period of (1995-2006). They concluded that the 
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patients. For stage II and III disease, adenocarcinoma patients had even better outcome. 
Muscle-invasive SCC patients showed worse survival regardless of stage. In SA-BC, 
Ghoneim et al (2008) demonstrated that SCC (1345 patients) had 10 year overall survival rate 
(OS) of 53.05% (95% CI: 51-57) compared to 48.49% (44-53 for pure UC (705 patients) and 
51.18 % (CI: 45-58) for adenocarcinoma (262 patients). Those patients who had UC with 
squamous or adenomatous metaplasia (286 patients) showed a lower 10-year OS of 42.78% 
(CI: 36-49). The lowest 10-year OS was experienced by those patients who had 
undifferentiated pathology (122 patients) having 10-year OS of 34.23 (CI: 24-45). It is clear 
from this large-number single institution study that the OS of SCC, UC and adenocarcinoma 
were similar and having the same profile. They demonstrated that although the univariate 
analysis was significant (Undifferentiated carcinoma had much lower OS), the multivariate 
analysis proved that tumor cell type is not an independent working factor determining the 
OS. The only significant prognostic factors were stage, grade and pelvic nodal involvement. 
Many authors cautiously concluded that RC treatment end-results were not affected by 
tumor histology or etiology but affected by other prognostic factors like stage, grade, nodal 
involvement, lymphovascular invasion, angiogenesis, P53, P21, Retinoblastoma genes (Rb) 
and other biological factors. These prognostic and predictor factors were shown in many 
SA-BC and SNA-BC studies to have varying weight effect (Ghoneim et al, 2008,Scosyrev et 
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13. Preoperative and postoperative radiotherapy 
The rationale of preoperative radiotherapy is to prevent intraoperative seeding of tumor 
cells in the operative field and to sterilize microscopic extensions in the perivesical tissues. 
In the English literature, there are 6 randomized trials addressing the issue of adding 
preoperative radiotherapy to RC. Two of these 6 studies were on SABC (Awwad et al, 1979 
& Ghoneim et al, 1985). Only one (Awwad et al, 1979) showed the benefit of adding 
preoperative radiotherapy. Most of the other 5 studies showed this effect on high stage and 
high grade tumors. On the other hand, there were no differences in statistical values in 
earlier cases. Meta-analysis of these randomized studies showed a corrected odd ratio of 
0.94 (95% CI: 0.57-1.55), indicating no benefit for adding preoperative radiotherapy in BC 
(Huncharek et al,1998). 
Postoperative radiotherapy (PORT) has the advantage of dealing with microscopic cells that 
are easier to sterilize. It allows better identification of the group of patients that may benefit 
from this adjuvant therapy. One large prospective randomized trial proved the benefit of 
PORT in locally advanced SA-BC. The 5-year disease-free survival (DFS) rate was 49 and 44 
% for hyperfractionated (HF) and conventional fractionation (CF) PORT, respectively 
compared with 25% for cystectomy alone patients (Zaghloul et al,1992). This effect was 
constant across all tumor cell type, all muscle-invasive stages and grades in SA-BC. These 
results were replicated in a non-randomized prospective controlled Radiation Therapy 
Oncology Group (RTOG) trial on SNA-BC (Reisinger et al,1992). The results ot the 2 studies 
were nearly identical when compared stage by stage (Zaghloul, 1994). The only difference 
was the high GIT late complication rate reported by Reisinger et al study. They reported 
37% (15 out of 40 patients) developed intestinal obstruction after PORT. Nine out of these 15 
patients required surgery and 3 died. On the contrary, Zaghloul et al (1992) reported 5% and 
18% all grades of late GIT complications for the HF and CF respectively. Only 4% and 5% 
out of the HF and CF group respectively necessitated surgical interference. Similar low 
levels of late GIT complications were experienced by other retrospective studies reported on 
SA-BC and SNA-BC (Cozzarini et al,1999, Zaghloul et al,2002, Zaghloul et al, 2006). 
Abdel Moneim et al (2011) compared, in a prospective randomized trial, preoperative and 
postoperative radiotherapy in SA-BC. They administered the same dose of 50 Gy in 5 weeks 
to both groups. The study reported both similar treatment end-results and late complication 
rates for the two randomized pre- and postoperative groups. 
14. Neoadjuvant and adjuvant chemotherapy 
Neoadjuvant and adjuvant chemotherapy have been utilized in bladder cancer, in an 
attempt to improve the outcome for patients with high risk muscle-invasive disease. At least 
50% of these patients developed distant metastasis after radical cystectomy. Several meta-
analysis of prospective, randomized trials indicated that patients undergoing neoadjuvant 
chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) prior to 
cystectomy have an approximate 5.0 – 6.5 % survival advantage over those who underwent 
surgery alone (Winquist et al, 2004 & Vaughn et al, 2005). However, some investigators still 
argue that this neoadjuvant advantage is small and chemotherapy might be better targeted 
to those at highest risk of relapse after surgery. Furthermore, many elderly patients or who 
have comorbidities will not tolerate MVAC chemotherapy. Therefore, many investigators 
tried adjuvant chemotherapy in a supposed more favorable situation. In reality, adjuvant 
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chemotherapy yielded a modest, statistically significant improvement in survival over 
cystectomy alone (Vale, 2006 & Ruggeri et al, 2006). 
The Egyptian bladder cancer cooperative group compared Neoadjuvant chemotherapy 
using gemcitabine-cisplatin regimen to cystectomy alone in 109 SA-BC patients,  in a 
prospective controlled randomized study. The one-year survival rate was 54% for the 
cystectomy alone patients compared to 69% for the neoadjuvant chemotherapy patients 
(Khaled et al, 2003). 
15. Bladder preservation trimodality treatment 
Since the late 1980s, many centers investigated the bladder preservation strategy as an 
alternative to radical cystectomy. The rationale of this strategy depends on 3 goals: first, 
eradication of the local disease, second, elimination of potential micrometastasis and third, 
maintenance of the best possible quality of life (QoL) through organ preservation (Rodel, 
2004). Several treatment protocols were carried out by different investigators. However, 
they all characterized 3 main and essential procedures with varying timing and varying 
minute details. The first main procedure is maximal TURBT. This is to be followed by 
neoadjuvant chemotherapy or radiochemotherapy (second procedure) and then after 
cystoscopic assessment, followed by either radical radiotherapy or consolidation 
radiochemotherapy for the complete responders (third procedure). There was another 
group treated with radiochemotherapy after TURBT. Cystoscopic assessment will segregate 
the complete responder (CR) for bladder-conserving management and those showing less 
than CR to undergo salvage cystectomy (Zaghloul and Mousa,2010).  The 5-year OS rates 
ranged between 39% and 58% and the 5-year survival with native bladder preservation 
ranged from 36% to 43% (Tester et al, 1993,Kachnic et al, 1997, Shipley et al, 1998, Sauer et al, 
1998  & Arias et al, 2000). Saba et al (2010) reported similar results for UC (SA-BC and SNA-
BC) in Egypt using a trimodality treatment. Complete remission was achieved in 79% of 
cases after initial radiochemotherapy using gemcitabine- cisplatin regimen. The 5-year OS 
rate for patients with initial CR was 68% which is comparable to the results in SNA-BC in 
the western countries treated with trimodality therapy. Moreover, Sabba et al (2010) found 
that the association with schistosomiasis had no significant impact on the results of therapy 
for their patients. 
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13. Preoperative and postoperative radiotherapy 
The rationale of preoperative radiotherapy is to prevent intraoperative seeding of tumor 
cells in the operative field and to sterilize microscopic extensions in the perivesical tissues. 
In the English literature, there are 6 randomized trials addressing the issue of adding 
preoperative radiotherapy to RC. Two of these 6 studies were on SABC (Awwad et al, 1979 
& Ghoneim et al, 1985). Only one (Awwad et al, 1979) showed the benefit of adding 
preoperative radiotherapy. Most of the other 5 studies showed this effect on high stage and 
high grade tumors. On the other hand, there were no differences in statistical values in 
earlier cases. Meta-analysis of these randomized studies showed a corrected odd ratio of 
0.94 (95% CI: 0.57-1.55), indicating no benefit for adding preoperative radiotherapy in BC 
(Huncharek et al,1998). 
Postoperative radiotherapy (PORT) has the advantage of dealing with microscopic cells that 
are easier to sterilize. It allows better identification of the group of patients that may benefit 
from this adjuvant therapy. One large prospective randomized trial proved the benefit of 
PORT in locally advanced SA-BC. The 5-year disease-free survival (DFS) rate was 49 and 44 
% for hyperfractionated (HF) and conventional fractionation (CF) PORT, respectively 
compared with 25% for cystectomy alone patients (Zaghloul et al,1992). This effect was 
constant across all tumor cell type, all muscle-invasive stages and grades in SA-BC. These 
results were replicated in a non-randomized prospective controlled Radiation Therapy 
Oncology Group (RTOG) trial on SNA-BC (Reisinger et al,1992). The results ot the 2 studies 
were nearly identical when compared stage by stage (Zaghloul, 1994). The only difference 
was the high GIT late complication rate reported by Reisinger et al study. They reported 
37% (15 out of 40 patients) developed intestinal obstruction after PORT. Nine out of these 15 
patients required surgery and 3 died. On the contrary, Zaghloul et al (1992) reported 5% and 
18% all grades of late GIT complications for the HF and CF respectively. Only 4% and 5% 
out of the HF and CF group respectively necessitated surgical interference. Similar low 
levels of late GIT complications were experienced by other retrospective studies reported on 
SA-BC and SNA-BC (Cozzarini et al,1999, Zaghloul et al,2002, Zaghloul et al, 2006). 
Abdel Moneim et al (2011) compared, in a prospective randomized trial, preoperative and 
postoperative radiotherapy in SA-BC. They administered the same dose of 50 Gy in 5 weeks 
to both groups. The study reported both similar treatment end-results and late complication 
rates for the two randomized pre- and postoperative groups. 
14. Neoadjuvant and adjuvant chemotherapy 
Neoadjuvant and adjuvant chemotherapy have been utilized in bladder cancer, in an 
attempt to improve the outcome for patients with high risk muscle-invasive disease. At least 
50% of these patients developed distant metastasis after radical cystectomy. Several meta-
analysis of prospective, randomized trials indicated that patients undergoing neoadjuvant 
chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) prior to 
cystectomy have an approximate 5.0 – 6.5 % survival advantage over those who underwent 
surgery alone (Winquist et al, 2004 & Vaughn et al, 2005). However, some investigators still 
argue that this neoadjuvant advantage is small and chemotherapy might be better targeted 
to those at highest risk of relapse after surgery. Furthermore, many elderly patients or who 
have comorbidities will not tolerate MVAC chemotherapy. Therefore, many investigators 
tried adjuvant chemotherapy in a supposed more favorable situation. In reality, adjuvant 
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chemotherapy yielded a modest, statistically significant improvement in survival over 
cystectomy alone (Vale, 2006 & Ruggeri et al, 2006). 
The Egyptian bladder cancer cooperative group compared Neoadjuvant chemotherapy 
using gemcitabine-cisplatin regimen to cystectomy alone in 109 SA-BC patients,  in a 
prospective controlled randomized study. The one-year survival rate was 54% for the 
cystectomy alone patients compared to 69% for the neoadjuvant chemotherapy patients 
(Khaled et al, 2003). 
15. Bladder preservation trimodality treatment 
Since the late 1980s, many centers investigated the bladder preservation strategy as an 
alternative to radical cystectomy. The rationale of this strategy depends on 3 goals: first, 
eradication of the local disease, second, elimination of potential micrometastasis and third, 
maintenance of the best possible quality of life (QoL) through organ preservation (Rodel, 
2004). Several treatment protocols were carried out by different investigators. However, 
they all characterized 3 main and essential procedures with varying timing and varying 
minute details. The first main procedure is maximal TURBT. This is to be followed by 
neoadjuvant chemotherapy or radiochemotherapy (second procedure) and then after 
cystoscopic assessment, followed by either radical radiotherapy or consolidation 
radiochemotherapy for the complete responders (third procedure). There was another 
group treated with radiochemotherapy after TURBT. Cystoscopic assessment will segregate 
the complete responder (CR) for bladder-conserving management and those showing less 
than CR to undergo salvage cystectomy (Zaghloul and Mousa,2010).  The 5-year OS rates 
ranged between 39% and 58% and the 5-year survival with native bladder preservation 
ranged from 36% to 43% (Tester et al, 1993,Kachnic et al, 1997, Shipley et al, 1998, Sauer et al, 
1998  & Arias et al, 2000). Saba et al (2010) reported similar results for UC (SA-BC and SNA-
BC) in Egypt using a trimodality treatment. Complete remission was achieved in 79% of 
cases after initial radiochemotherapy using gemcitabine- cisplatin regimen. The 5-year OS 
rate for patients with initial CR was 68% which is comparable to the results in SNA-BC in 
the western countries treated with trimodality therapy. Moreover, Sabba et al (2010) found 
that the association with schistosomiasis had no significant impact on the results of therapy 
for their patients. 
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Chemo- and immunotherapeutic approaches have been used to prevent recurrence of 
transitional cell carcinoma (TCC), the most common type of superficial bladder cancer 
(SBC). The bacillus Calmette-Guérin (BCG) vaccine for tuberculosis, which consists of an 
attenuated form of Mycobacterium bovis, is the most commonly used immunotherapeutic 
agent (Morales et al., 1976). Despite the successful results achieved with BCG, its serious 
side effects have led researchers to investigate other immunostimulatory substances. In the 
early 1970s, Olsson and collaborators reported that subcutaneous stimulation with keyhole 
limpet hemocyanin (KLH) from the Californian marine gastropod Megathura crenulata 
significantly reduced SBC recurrence frequency in TCC patients without any toxic side 
effects, making it ideal for long-term repetitive treatments (Olsson et al., 1974). These results 
provided promising support for the use of mollusk hemocyanins as alternative agents in 
SBC immunotherapy.  
Hemocyanins, blue respiratory glycoproteins that were discovered in 1878 by Léon 
Fredericq (Ghiretti-Magaldi & Ghiretti, 1992), are found freely dissolved in the blood of 
some mollusks and arthropods. These proteins are giant structures with molecular weights 
between 4 and 8 MDa, and they exhibit some of the most complex and sophisticated 
quaternary structures known. Hemocyanins are part of the type-3 group of copper proteins 
that includes phenoloxidases and tyrosinases (Decker & Tuczek, 2000). These proteins 
contain active copper-containing sites in which the Cu(I,I) state is oxidized to the Cu(II,II) 
state, thus accounting for their distinctive deep blue color. Because of these properties, the 
biochemistry of hemocyanins has been intensively studied (van Holde & Miller, 1995). The 
pioneering work of Weigle in the 1960s on the immunochemical properties of KLH 
demonstrated its remarkable immunostimulatory properties in an experimental animal 
model (Weigle, 1964). These results were quickly incorporated into clinical studies to 
evaluate its immunological effects.  
Because the primary amino acid sequences of mollusk hemocyanins are highly divergent 
from mammalian sequences, they are strongly recognized by the immune system, resulting 
in potent immunogenicity; these proteins can be used therapeutically as non-specific 
immunostimulants with beneficial clinical outcomes. Moreover, hemocyanins have been 
extensively used as carriers to generate antibodies against diverse hapten molecules and 
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in potent immunogenicity; these proteins can be used therapeutically as non-specific 
immunostimulants with beneficial clinical outcomes. Moreover, hemocyanins have been 
extensively used as carriers to generate antibodies against diverse hapten molecules and 
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peptides and to induce antigen-specific CD8+ and CD4+ T cell responses (Harris & Markl, 
1999). Currently, hemocyanins are used as carrier-adjuvants for several tumor-associated 
antigens (TAAs), such as glycolipid and glycoprotein (mucin-like) antigens, in experimental 
therapeutic vaccines against certain cancers, including melanomas, sarcomas, breast, 
prostate, ovary and lung (Musselli et al., 2001; Schumacher, 2001; Zhu et al., 2009; Del 
Campo et al., 2011). Other therapeutic strategies that use hemocyanins include dendritic cell 
(DC) vaccines pulsed with tumor lysates to enhance interferon gammaIFN- production 
by tumor-reactive T cells (Timmerman & Levy, 2000; Shimizu et al., 2001; Millard et al., 
2003; Lopez et al., 2009; Jacobs et al., 2010; Lesterhuis et al., 2011) and anti-idiotype vaccines 
for some types of B cell malignancies (Leitch & Connors, 2005; Kafi et al., 2009). KLH has 
been the gold standard for these applications for over 40 years simply because it was used in 
earlier studies instead of other hemocyanins (Harris & Markl, 1999). The first studies used a 
research-grade KLH (non-GMP) containing different levels of endotoxin (Vandenbark et al., 
1981); since then, several companies have produced clinical-grade KLH. 
The versatile properties of KLH in biomedical and biotechnological applications have led to 
increasing commercial demand and growing interest in finding new, alternative 
hemocyanins with similar or more potent immunomodulatory properties. Although the 
KLH gene has been cloned, and its amino acid sequence is known, it has not been possible 
to express a heterologous protein, mainly because of its complex structure (Lieb et al., 2001; 
Markl et al., 2001; Altenhein et al., 2002). Therefore, this protein can be obtained only from 
its natural source. Several hemocyanins from other species of mollusks have been studied 
biochemically and immunologically, including Haliotis tuberculata (HtH, Abalon) (Markl et 
al., 2001); Helix vulgarix (HpH, Vineyard snail), Rapana venosa (RvH, Asian rapa whelk), and 
Rapana thomasiana (RtH, Black sea murex) (Dolashka-Angelova et al., 2003; 2008; 2010); and 
Concholepas concholepas (CCH, Loco), which is found on the pacific Chilean coast (De Ioannes 
et al., 2004). Only CCH has been pre-clinically evaluated in a murine experimental model of 
SBC and may be considered a safe alternative therapy (Moltedo et al., 2006; Atala, 2006). 
Although KLH and CCH have different origins and structure they have similar 
immunostimulatory capacities, suggesting that a conserved pattern common to both 
hemocyanins induces an ancient immunological mechanism (Moltedo et al., 2006). 
Interestingly, we have described a new hemocyanin from Fissuerella latimarginata (FLH) that 
exhibits higher immunogenicity than either CCH or KLH, opening a new avenue for 
research on the use of hemocyanins (Espinoza et al., 2006; Arancibia et al., 2010). 
Notwithstanding the biomedical interest in mollusk hemocyanins, the molecular and 
cellular bases of their adjuvant/immunostimulatory capacity in SBC remain poorly 
understood. Currently, we know that hemocyanins are able to drive the differentiation of T 
helper (Th) cells toward a Th1 phenotype, characterized by increased secretion of IFN-γ and 
the production of IgG2a isotype antibodies (Moltedo et al., 2006).  
In this chapter, we will review what is currently known about the experimental and clinical 
uses of mollusk hemocyanins as non-specific immunostimulants to prevent SBC recurrence, 
including the details of their intricate structure and the immunologic mechanisms that have 
been proposed to explain their antitumor activity. 
2. Structure of the mollusk hemocyanins  
Because of their enormous size, mollusk hemocyanins are easily observed by transmission 
electron microscopy (TEM) using negative staining. These molecules have a cylindrical form 
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with an external diameter of approximately 350 nm and length of approximately 400 nm. 
Fig. 1 shows the characteristic appearance of gastropod hemocyanins under TEM. 
 
 
Fig. 1. Electron microscopy of negatively stained C. concholepas hemocyanin molecules. A. 
Low magnification micrographs of a preparation of the protein showing their characteristic 
hollow cylinder form. The images show the top (circles) and lateral (rectangles) views of the 
molecule. The arrow shows a decamer. B. High magnification images of hemocyanin 
molecules showing their intricate structure. The side views show the proteins’ characteristic 
didecameric form with subunits arranged in layers. 
Many experimental studies on hemocyanins, using different dissociation and association 
conditions and physicochemical and biochemical methods, have helped to elucidate their 
hierarchically organized structure (van Holde & Miller, 1995; Harris & Markl, 1999). As 
shown in Fig. 2, the basic structure of hemocyanins is composed of ten subunits that are self-
assembled into a hollow cylinder, a structure known as a decamer, with a lumen that is 
narrowed by a complex collar (Harris et al., 1993; Cuff et al., 1998; Decker et al., 2007). In 
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gastropods, the decamers can self-associate face-to-face to form stable dimers or didecamers, 
which display an intricate internal arrangement and result in the formation of extremely 
large structures with approximate D5 symmetry (Orlova et al., 1997). Hemocyanin subunits 
have a molecular weight ranging from 350 to 450 kDa and are composed of a string of seven 
or eight globular domains called functional units (FUs), each with a molecular weight 
between 35 and 50 kDa. These FUs are connected by a short flexible linker peptide strand of 
10 to 15 amino acid residues. Each FU has two well-separated copper atoms that reversibly 
capture O2 molecules; one is called the A site, which is located towards the N-terminus, and 




Fig. 2. Model of the structure of mollusk hemocyanin. The basic structure of a mollusk 
hemocyanin is a decamer, which is formed by the association of 10 polypeptides or subunits. 
In hemocyanins from some species of mollusk, such as gastropods, including KLH and 
CCH, the decamers are associated in pairs to form very large molecules called didecamers.  
The subunit consists of seven or eight globular domains linked by a peptide spacer 
consisting of 10 to 15 amino acid residues, similar to a pearl necklace. Each of these globular 
domains has a pair of copper atoms that reversibly bind one oxygen molecule, which is why 
they are called functional units. 
Knowledge of the carbohydrate moieties present in mollusk hemocyanins has been essential 
for understanding their organization, antigenicity and biomedical properties (Paccagnella et 
al., 2004; Siddiqui et al., 2007). In fact, several authors have reported that hemocyanin 
carbohydrates may play a role in their immunostimulatory effects. The high carbohydrate 
content of hemocyanins, up to 9% (w/w), has been measured by different methods, including 
the use of lectins and high-pressure liquid chromatography–tandem mass spectrometry 
(HPLC-MS/MS). The presence of numerous N-glycosylation sites and a reduced number of O-
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glycosylation sites has been established (Dolashka-Angelova et al., 2003; Gielens et al., 2004; 
Idakieva et al., 2004; Gatsogiannis & Markl, 2009; Dolashka et al., 2010). Mollusk hemocyanins 
contain diverse sugar moieties, including mannose, D-galactose, fucose, N-acetyl-D-
galactosamine and N-acetyl-glucosamine residues, with mannose being the most abundant 
(Harris & Markl, 1999). Hemocyanins also contain monosaccharides that are not usually found 
in animal proteins, such as xylose (Lommerse et al., 1997). 
2.1 KLH and CCH 
Although KLH and CCH each have two subunits that constitute the basic structure known 
as a decamer, closer analysis revealed unique differences. Native gel electrophoresis has 
shown that KLH is made up of two different non-covalently linked subunits called KLH1 
(350 KDa) and KLH2 (350 KDa) that do not display shared epitopes (Swerdlow et al., 1996). 
Using the same approach, it was demonstrated that CCH is also made up of two different 
subunits, CCHA (405 kDa) and CCHB (350 kDa), that contain common and specific epitopes 
(Oliva et al., 2002; De Ioannes et al., 2004). In KLH, the subunits form homodidecamers (i.e., 
the molecules are formed from either KLH1 or KLH2 subunits). However, in CCH the 
subunits form heterodidecamers (i.e., the molecules are formed by pairing the two different 
subunits). In addition, purified KLH requires divalent cations in storage buffers to maintain 
the stability of its quaternary structure, whereas CCH does not (De Ioannes et al., 2004); this 
is probably a consequence of the higher hydrophobicity of CCH (Leyton et al., 2005). 
Despite these differences, the immunogenic properties of CCH and KLH are similar. CCH 
has been successfully used as a carrier protein to generate antibodies against hapten 
molecules and peptides (Becker et al., 1998; Torres et al., 1999; Mura et al., 2002; Duvillie et 
al., 2003; Manosalva et al., 2004; Cancino et al., 2007; Gravotta et al., 2007; Matus et al., 2007; 
Grenegard et al., 2008); as a carrier in vaccines (Miller et al., 2006; Mauldin & Miller, 2007; 
Pilon et al., 2007) and as an experimental antigen (Becker et al., 2007; Moltedo et al., 2009). 
Several studies have demonstrated that KLH contains approximately 3.2% (w/w) 
carbohydrate residues, displaying specific structural motifs on N-glycans, such as 
Fuc(alpha1-3)GalNAc, Gal-(beta1-6)Man-, Gal(beta1-4)Fuc-, and Gal(beta1-4)Gal(beta(1-
4)Fuc-, which are thought to contribute to its non-specific immunostimulatory capacities in 
SBC (Wuhrer et al., 2004). Our knowledge of the corresponding oligosaccharide composition 
of CCH is very limited. However, we have demonstrated using selective glycosidase 
treatments and electrophoretic analysis that sugar moieties account for 3.1% (w/w) of the 
mass of CCH. A comparative analysis using lectin staining indicated that mannose is the 
only exposed carbohydrate common to CCH and KLH (Becker et al., 2009). It is important to 
note that, despite the differences in carbohydrate composition between KLH and CCH, both 
proteins have similar immunogenicity and immunotherapeutic capacity in SBC, suggesting 
that other factors are responsible for this effect. We assume that the primary structure of 
these proteins contains the determining factor because they share regions of high sequence 
homology (van Holde et al., 2001; Manubens et al., 2010). These regions were confirmed in 
antibody cross-reactivity experiments that revealed the presence of common or mimetic 
epitopes in CCH and KLH (Oliva et al., 2002).  
3. Use of hemocyanins in experimental SBC 
Rats and various strains of mice have been used as in vivo SBC models to evaluate 
therapeutic agents because bladder tumors in these rodents have similarities with human 
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tumors. In addition, tumor cells can be established subcutaneously (heterotopically) or in 
the bladder (orthotopically) by either transplantation or chemical induction, allowing the 
investigation of clinical aspects such as pharmacokinetics and toxicity (Gunther et al., 1999; 
Linn et al., 2000; Arentsen et al., 2009).  
The first controlled study of a hemocyanin as immunotherapy in the treatment of superficial 
bladder cancer was published in the 1980s by the Lamm group (Lamm et al., 1981). They 
developed the mouse bladder tumor-2 cell (MBT-2) transplantable murine model of SBC 
and demonstrated that pre-immunization with 200 µg of KLH three weeks prior to 
subcutaneous injection with MBT-2, followed by intralesional immunotherapy with 50 µg 
one and seven days after inoculation, resulted in a significant reduction in tumor growth 
and a prolongation of animal survival. Later, other studies by the same researchers 
evaluated non-specific immunotherapeutic regimens (Lamm et al., 1982). Animals received 
an intradermal MBT-2 inoculation, and the immunotherapy was administered 
intralesionally one day after tumor transplantation. Tumors were excised at a volume of 400 
mm3, and the animals were re-challenged with tumor cells, treated again, and followed for 
tumor incidence, growth rate and survival. This study demonstrated that KLH had a weak 
antitumor effect compared with the response to BCG. In 1986, Lau and collaborators studied 
the same response, this time comparing intraperitoneal and intralesional administration of 
the agents. C3H/He mice were injected subcutaneously with 5 x 104 tumor cells. After that, 
the mice received either intraperitoneal or intralesional treatments (50 μg KLH); these 
experiments demonstrated that the intralesional route was more effective than 
intraperitoneal administration for tumor growth inhibition (Lau et al., 1986).  
Lamm´s group also evaluated the possible additive and/or synergistic effects of KLH 
immunotherapy in the MBT-2 model in conjunction with other treatments, such as IFN-α. 
Tumor cells were transplanted subcutaneously without prior immunization. Treatment was 
given intraperitoneally twice weekly for three weeks, except for BCG, which was 
administered once a week. Significant reductions in tumor incidence relative to the controls 
were observed in groups receiving KLH (42%), IFN-α (42%) and KLH + IFN-α (17%) (Riggs 
et al., 1992). The following year, the same group compared two alternative immunotherapies 
in the MBT-2 model: crude KLH and Immucothel, a clinical-grade KLH from Biosyn 
Arzneimittel GmbH. Mice were sensitized with 50 or 100 μg KLH, and 21 days later, 103 
tumor cells were injected. Intralesional treatment with 50 or 100 μg KLH was performed on 
days 1, 7 and 13 or 14. Crude KLH required either immunization before tumor transplant or 
frequent therapy after transplantation to be effective. In addition, Immucothel required pre-
immunization to be effective, even with an increased frequency and dosage of the post-
transplant immunizations. In a subsequent study, the endotoxin contamination of KLH was 
demonstrated to be partly responsible for the antitumor activity because treatment with 
endotoxin alone resulted in a significant reduction of tumor growth and mortality (50% 
survival) (Lamm et al., 1993). Moreover, KLH + 100 Endotoxin Units (EU) resulted in 
complete inhibition of tumor growth and 100% survival. KLH + 1000 EU appeared to reduce 
the antitumor response (50% survival), suggesting that endotoxin may interfere with the 
response to purified KLH. Finally, endotoxin-free KLH induced antitumor responses (50% 
survival). However, pre-immunization was required for KLH to exert a significant (75% 
survival) antitumor effect (Lamm et al., 1993). 
Walsh and collaborators studied KLH immunotherapy in two different models with no 
promising results. First, they transplanted 2.5 x 106 MBT-2 tumor cells subcutaneously after 
pre-immunization 20 days prior. Treatment was given on days 1, 8 and 18 in the form of 
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subcutaneous or intralesional injection of 50 µg KLH. The results showed no difference 
between the control and treated groups in terms of either tumor growth or animal survival. 
Alternatively, they transplanted 2.1 x 106 MBT-2 tumor cells into the bladder of C3H/He 
mice. The bladder was irrigated with 1.5 mg N-methyl-N-nitrosourea 48 hours prior. The 
treatment group was injected with 50 µg KLH on day 1, and the bladders were instilled with 
200 µg KLH on days 14 and 21. There was no significant difference from the control group 
(Walsh et al., 1983). Using a similar model, Marsh and collaborators demonstrated that 
intravesical immunotherapy with Corynebacterium parvum and Allium sativum was more 
effective than KLH and slightly more effective than BCG. MBT-2 cells were delivered into 
the bladder transurethrally using a small catheter, and the immunotherapy was 
administered directly into the bladder via this catheter on day 1 or day 6, or both. The 
authors associated the lack of a significant effect with inappropriate dosage or insufficient 
stimulation of the immune system (Marsh et al., 1987). Later, the antitumor activity and 
potential toxicity of a clinical grade KLH preparation named KLH-Immune Activator (KLH-
IA) was examined. Mice were immunized subcutaneously with KLH-IA two weeks prior to 
intravesical implantation with 2 x 104 MB-49 tumor cells. Treatment consisted of intravesical 
KLH-IA (10 or 100 µg) 1, 4, 7, 14 and 21 days after implantation. By four weeks after 
implantation, tumor outgrowth in the treated groups was significantly decreased. Prior 
subcutaneous immunization was required to elicit the antitumor activity of KLH-IA. 
Animals treated with a dissociated form of KLH showed decreased tumor outgrowth, but 
this was not significant. A separate toxicity study in which KLH-IA was given 
subcutaneously (4 mg/kg), intraperitoneally (40 mg/kg) or intravesically (40 mg/kg) 
reported no significant gross or histopathological abnormalities, except for mild to moderate 
papillary hyperplasia in all catheterized animals (Swerdlow et al., 1994). 
A third model developed by Recker and collaborators also showed the effectiveness of KLH. 
Bladder carcinoma was induced in Wistar rats using N-butyl-N-(4-hydroxybutyl) 
nitrosamine (BBN). Stimulation of the rats with 12.5 mg of KLH administered intravesically 
and 0.5 mg administered subcutaneously twice weekly after sensitization with 1 mg 
subcutaneous KLH resulted in a reduction in BBN-induced bladder tumors. These results 
confirmed that effective induction of an immune response is important for the control of 
tumor development because immune-suppressed rats treated with cyclosporine A (CsA) 
showed enhanced bladder tumor expansion compared with rats treated with 0.05% BBN 
alone (Recker & Rubben, 1989). A subsequent study distinguished between intravesical and 
subcutaneous application to determine the most effective treatment regime. Five weeks after 
the completion of tumor induction with 0.05% BBN solution, exophytic bladder tumors 
appeared in all control animals. In group 2, which was given KLH via intravesical 
instillation, tumors developed in 73.5% of cases. In group 1, with subcutaneous 
administration, tumors developed in only 50% of cases. The tumor growth was significantly 
slower in group 1 than group 2 (Linn et al., 2000). 
The results described above demonstrated promising potential for the use of KLH in SBC 
therapy. More recently, preclinical studies have proven hemocyanin from Concholepas 
concholepas (CCH) to be a reliable alternative to KLH (Moltedo et al., 2006). C3H/He mice 
were primed with CCH before subcutaneous implantation of MBT-2 cells. Treatment 
consisted of a subcutaneous dose of CCH (1 mg or 100 µg) at different intervals after 
implantation. The results demonstrated a significant antitumor effect, as indicated by 
decreased tumor growth and incidence, prolonged survival and a lack of toxic effects. These 
results were similar to those achieved with KLH.  
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subcutaneous injection with MBT-2, followed by intralesional immunotherapy with 50 µg 
one and seven days after inoculation, resulted in a significant reduction in tumor growth 
and a prolongation of animal survival. Later, other studies by the same researchers 
evaluated non-specific immunotherapeutic regimens (Lamm et al., 1982). Animals received 
an intradermal MBT-2 inoculation, and the immunotherapy was administered 
intralesionally one day after tumor transplantation. Tumors were excised at a volume of 400 
mm3, and the animals were re-challenged with tumor cells, treated again, and followed for 
tumor incidence, growth rate and survival. This study demonstrated that KLH had a weak 
antitumor effect compared with the response to BCG. In 1986, Lau and collaborators studied 
the same response, this time comparing intraperitoneal and intralesional administration of 
the agents. C3H/He mice were injected subcutaneously with 5 x 104 tumor cells. After that, 
the mice received either intraperitoneal or intralesional treatments (50 μg KLH); these 
experiments demonstrated that the intralesional route was more effective than 
intraperitoneal administration for tumor growth inhibition (Lau et al., 1986).  
Lamm´s group also evaluated the possible additive and/or synergistic effects of KLH 
immunotherapy in the MBT-2 model in conjunction with other treatments, such as IFN-α. 
Tumor cells were transplanted subcutaneously without prior immunization. Treatment was 
given intraperitoneally twice weekly for three weeks, except for BCG, which was 
administered once a week. Significant reductions in tumor incidence relative to the controls 
were observed in groups receiving KLH (42%), IFN-α (42%) and KLH + IFN-α (17%) (Riggs 
et al., 1992). The following year, the same group compared two alternative immunotherapies 
in the MBT-2 model: crude KLH and Immucothel, a clinical-grade KLH from Biosyn 
Arzneimittel GmbH. Mice were sensitized with 50 or 100 μg KLH, and 21 days later, 103 
tumor cells were injected. Intralesional treatment with 50 or 100 μg KLH was performed on 
days 1, 7 and 13 or 14. Crude KLH required either immunization before tumor transplant or 
frequent therapy after transplantation to be effective. In addition, Immucothel required pre-
immunization to be effective, even with an increased frequency and dosage of the post-
transplant immunizations. In a subsequent study, the endotoxin contamination of KLH was 
demonstrated to be partly responsible for the antitumor activity because treatment with 
endotoxin alone resulted in a significant reduction of tumor growth and mortality (50% 
survival) (Lamm et al., 1993). Moreover, KLH + 100 Endotoxin Units (EU) resulted in 
complete inhibition of tumor growth and 100% survival. KLH + 1000 EU appeared to reduce 
the antitumor response (50% survival), suggesting that endotoxin may interfere with the 
response to purified KLH. Finally, endotoxin-free KLH induced antitumor responses (50% 
survival). However, pre-immunization was required for KLH to exert a significant (75% 
survival) antitumor effect (Lamm et al., 1993). 
Walsh and collaborators studied KLH immunotherapy in two different models with no 
promising results. First, they transplanted 2.5 x 106 MBT-2 tumor cells subcutaneously after 
pre-immunization 20 days prior. Treatment was given on days 1, 8 and 18 in the form of 
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subcutaneous or intralesional injection of 50 µg KLH. The results showed no difference 
between the control and treated groups in terms of either tumor growth or animal survival. 
Alternatively, they transplanted 2.1 x 106 MBT-2 tumor cells into the bladder of C3H/He 
mice. The bladder was irrigated with 1.5 mg N-methyl-N-nitrosourea 48 hours prior. The 
treatment group was injected with 50 µg KLH on day 1, and the bladders were instilled with 
200 µg KLH on days 14 and 21. There was no significant difference from the control group 
(Walsh et al., 1983). Using a similar model, Marsh and collaborators demonstrated that 
intravesical immunotherapy with Corynebacterium parvum and Allium sativum was more 
effective than KLH and slightly more effective than BCG. MBT-2 cells were delivered into 
the bladder transurethrally using a small catheter, and the immunotherapy was 
administered directly into the bladder via this catheter on day 1 or day 6, or both. The 
authors associated the lack of a significant effect with inappropriate dosage or insufficient 
stimulation of the immune system (Marsh et al., 1987). Later, the antitumor activity and 
potential toxicity of a clinical grade KLH preparation named KLH-Immune Activator (KLH-
IA) was examined. Mice were immunized subcutaneously with KLH-IA two weeks prior to 
intravesical implantation with 2 x 104 MB-49 tumor cells. Treatment consisted of intravesical 
KLH-IA (10 or 100 µg) 1, 4, 7, 14 and 21 days after implantation. By four weeks after 
implantation, tumor outgrowth in the treated groups was significantly decreased. Prior 
subcutaneous immunization was required to elicit the antitumor activity of KLH-IA. 
Animals treated with a dissociated form of KLH showed decreased tumor outgrowth, but 
this was not significant. A separate toxicity study in which KLH-IA was given 
subcutaneously (4 mg/kg), intraperitoneally (40 mg/kg) or intravesically (40 mg/kg) 
reported no significant gross or histopathological abnormalities, except for mild to moderate 
papillary hyperplasia in all catheterized animals (Swerdlow et al., 1994). 
A third model developed by Recker and collaborators also showed the effectiveness of KLH. 
Bladder carcinoma was induced in Wistar rats using N-butyl-N-(4-hydroxybutyl) 
nitrosamine (BBN). Stimulation of the rats with 12.5 mg of KLH administered intravesically 
and 0.5 mg administered subcutaneously twice weekly after sensitization with 1 mg 
subcutaneous KLH resulted in a reduction in BBN-induced bladder tumors. These results 
confirmed that effective induction of an immune response is important for the control of 
tumor development because immune-suppressed rats treated with cyclosporine A (CsA) 
showed enhanced bladder tumor expansion compared with rats treated with 0.05% BBN 
alone (Recker & Rubben, 1989). A subsequent study distinguished between intravesical and 
subcutaneous application to determine the most effective treatment regime. Five weeks after 
the completion of tumor induction with 0.05% BBN solution, exophytic bladder tumors 
appeared in all control animals. In group 2, which was given KLH via intravesical 
instillation, tumors developed in 73.5% of cases. In group 1, with subcutaneous 
administration, tumors developed in only 50% of cases. The tumor growth was significantly 
slower in group 1 than group 2 (Linn et al., 2000). 
The results described above demonstrated promising potential for the use of KLH in SBC 
therapy. More recently, preclinical studies have proven hemocyanin from Concholepas 
concholepas (CCH) to be a reliable alternative to KLH (Moltedo et al., 2006). C3H/He mice 
were primed with CCH before subcutaneous implantation of MBT-2 cells. Treatment 
consisted of a subcutaneous dose of CCH (1 mg or 100 µg) at different intervals after 
implantation. The results demonstrated a significant antitumor effect, as indicated by 
decreased tumor growth and incidence, prolonged survival and a lack of toxic effects. These 
results were similar to those achieved with KLH.  
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Mouse, MBT-2 Yes  
200 µg 
Intralesional 50 µg 
Days: 1 and 7. 
Significant reduction of 
tumor growth and 
survival with KLH. 
Lamm  
et al.1981 
 No Intralesional Day: 1 KLH presented a minor 
antitumor effect 
compared with BCG. 
Lamm  





50 or 200 μg 
Days: 1, 8 and 18 
or 1, 14 and 21. 
KLH do not show 
difference with controls 
in tumor growth or 
animal survival.  
Walsh  
et al. 1983 




Intralesional route of 
inoculation of KLH was 
more effective. 
Lau  
et al. 1986 
 No Intravesical 50 µg 
Days: 1 or 6,  
or both. 
Immunotherapy with C. 
parvum and A. sativum 




 No Intraperitoneal 50 µg 
Twice weekly for 
3 weeks. 
Better response in the 
animals treated with 
KLH more INF-α. 
Riggs  
et al. 1992 
 Yes 
50 or 100 μg 
Intralesional 50 or 100 μg 
Days: 1, 7 and  
13 or 14. 
Required pre-
immunization of KLH 
and Immucothel to be 
effective. 
Lamm  
et al. 1993a 
 Yes 
50 or 100 μg 
Intralesional 50 or 100 μg 
Days: 1, 7 and  
13 or 14. 
Endotoxin 
contamination of KLH 
was responsible in  
part for the antitumor  
activity. 
Lamm  
et al. 1993b 
 Yes 
200 to 400 µg 
Subcutaneous 1 mg  
Days: 1 to 6 or  
100 µg 
Days: 1, 3, 5,  
7 and 9. 
Significant reduction of 
tumor growth and 
survival with CCH. 
Moltedo  
et al. 2006 
 Yes  
200 µg 
Subcutaneous 100 µg 
Days: 1, 3, 5,  
7 and 9. 
Better antitumor effect 
with  
CCHA subunit than 
CCHB subunit. 
Becker  
et al. 2009 
Mouse, MB-49 Yes 
100 µg 
Intravesical 10 or 100 µg 
Days: 1, 4, 7,  
14 and 21. 
Prior immunization of 
KLH-IA was required to 
elicit antitumor  
activity. 
Swerdlow  








12.5 mg and 500 
µg 
Twice weekly. 
Reduction of bladder 









Twice weekly for 
8 weeks. 
Subcutaneous route of 
KLH was more effective 
than intravesical route. 
Linn  
et al. 2000 
1 Priming: Usually, around two weeks prior to tumor challenge. 2 Immunotherapy after tumor 
transplantation. 3 BNN: N-butyl-N-(4-hydroxybutyl) nitrosamine 
Table 1. Preclinical studies in different animal models of SBC with KLH or CCH as an 
immunotherapeutic agent. 
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Later, the individual contributions of the CCHA and CCHB subunits of CCH as 
immunotherapeutic agents in the same bladder cancer model were studied. C3He/He mice 
were subcutaneously primed with CCHA or CCHB; whole CCH and PBS were used as 
positive and negative controls, respectively. After day 15, mice were challenged with a 
subcutaneous injection of 2 x 105 MBT-2 cells, and the antitumor treatment was started; 
treatment consisted of a subcutaneous dose of either subunit or a control on alternate days 
for 9 days. Surprisingly, either subunit alone showed an antitumor effect in the MBT-2 
model. However, the tumor incidence was lower in animals treated with CCHA (44% 
incidence) than with CCHB (60% incidence) or whole CCH (62.5% incidence). Moreover, the 
survival probability increased in mice under immunotherapy with CCHA (69.5%) compared 
with CCHB- (64%), CCH- (60%) and PBS-treated (46.5%) mice. In conclusion, this study 
indicated that the CCHA subunit accounts for the most important immunogenic effects of 
CCH (Becker et al., 2009). Together, these preclinical studies (summarized in Table 1) 
demonstrated that hemocyanins have beneficial effects in animal models of SBC that 
resemble human disease without the negative side effects of BCG (Schenkman & Lamm, 
2004). 
4. Use of hemocyanins in clinical studies of SBC 
Surgical procedures such as transurethral resection (TUR) are commonly used as the first 
option to treat SBC. However, there are some tumors that must be treated by other 
strategies, due to the difficulties of fully removing them and the high risk of recurrence. 
Thus, intravesical administration of chemotherapeutic and biological agents has been 
demonstrated to be an effective method in the early stages of the disease, either to treat an 
existing tumor or to prevent recurrence and tumor progression after TUR (Perabo & Muller, 
2004). BCG is one biological therapy that is used as a non-specific immunostimulant to treat 
several malignant tumors (Edwards & Whitwell, 1974; Milas & Withers, 1976), including 
SBC (Morales et al., 1976). BCG has become the first-line treatment and the most effective 
intravesical immunotherapy, lowering the risk of recurrence to an average of 27% of cases 
(Nseyo & Lamm, 1997). Despite these successful results, BCG therapy causes numerous side 
effects, such as dysuria, urinary frequency, cystitis (90% of cases), hematuria and, in rare 
cases, sepsis, indicating the need for new approaches that provide the same or a better 
response without toxic effects (Lamm, 2003).  
In a 1974 delayed-type hypersensitivity (DTH) experiment to measure the immune 
competence of patients with TCC, Olson and collaborators reported the unexpected result 
that patients subcutaneously primed with 5 mg of KLH and then subcutaneous immunized 
with 200 µg of KLH had a significantly diminished tumor recurrence rate over a study 
period of two years. Those patients that were DTH positive to KLH, and therefore immune 
competent, had almost no recurrences (Olsson et al., 1974). This outstanding effect was 
confirmed many years later in a controlled study of patients in stages Ta and T1 who had 
previously been subject to TUR. In this study, the ability of KLH to prevent tumor 
recurrence was compared to mitomycin C (MMC). The patients were subcutaneously 
immunized with 1 mg of KLH and then received monthly intravesical administrations of 10 
mg of KLH. Only 14% of the patients treated with KLH had recurrences, in contrast to the 
MMC patients, 39% of whom reported recurrences, demonstrating that KLH was 
significantly more effective than MMC (Jurincic et al., 1988).  
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Moltedo  
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with  
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Linn  
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1 Priming: Usually, around two weeks prior to tumor challenge. 2 Immunotherapy after tumor 
transplantation. 3 BNN: N-butyl-N-(4-hydroxybutyl) nitrosamine 
Table 1. Preclinical studies in different animal models of SBC with KLH or CCH as an 
immunotherapeutic agent. 
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Later, the individual contributions of the CCHA and CCHB subunits of CCH as 
immunotherapeutic agents in the same bladder cancer model were studied. C3He/He mice 
were subcutaneously primed with CCHA or CCHB; whole CCH and PBS were used as 
positive and negative controls, respectively. After day 15, mice were challenged with a 
subcutaneous injection of 2 x 105 MBT-2 cells, and the antitumor treatment was started; 
treatment consisted of a subcutaneous dose of either subunit or a control on alternate days 
for 9 days. Surprisingly, either subunit alone showed an antitumor effect in the MBT-2 
model. However, the tumor incidence was lower in animals treated with CCHA (44% 
incidence) than with CCHB (60% incidence) or whole CCH (62.5% incidence). Moreover, the 
survival probability increased in mice under immunotherapy with CCHA (69.5%) compared 
with CCHB- (64%), CCH- (60%) and PBS-treated (46.5%) mice. In conclusion, this study 
indicated that the CCHA subunit accounts for the most important immunogenic effects of 
CCH (Becker et al., 2009). Together, these preclinical studies (summarized in Table 1) 
demonstrated that hemocyanins have beneficial effects in animal models of SBC that 
resemble human disease without the negative side effects of BCG (Schenkman & Lamm, 
2004). 
4. Use of hemocyanins in clinical studies of SBC 
Surgical procedures such as transurethral resection (TUR) are commonly used as the first 
option to treat SBC. However, there are some tumors that must be treated by other 
strategies, due to the difficulties of fully removing them and the high risk of recurrence. 
Thus, intravesical administration of chemotherapeutic and biological agents has been 
demonstrated to be an effective method in the early stages of the disease, either to treat an 
existing tumor or to prevent recurrence and tumor progression after TUR (Perabo & Muller, 
2004). BCG is one biological therapy that is used as a non-specific immunostimulant to treat 
several malignant tumors (Edwards & Whitwell, 1974; Milas & Withers, 1976), including 
SBC (Morales et al., 1976). BCG has become the first-line treatment and the most effective 
intravesical immunotherapy, lowering the risk of recurrence to an average of 27% of cases 
(Nseyo & Lamm, 1997). Despite these successful results, BCG therapy causes numerous side 
effects, such as dysuria, urinary frequency, cystitis (90% of cases), hematuria and, in rare 
cases, sepsis, indicating the need for new approaches that provide the same or a better 
response without toxic effects (Lamm, 2003).  
In a 1974 delayed-type hypersensitivity (DTH) experiment to measure the immune 
competence of patients with TCC, Olson and collaborators reported the unexpected result 
that patients subcutaneously primed with 5 mg of KLH and then subcutaneous immunized 
with 200 µg of KLH had a significantly diminished tumor recurrence rate over a study 
period of two years. Those patients that were DTH positive to KLH, and therefore immune 
competent, had almost no recurrences (Olsson et al., 1974). This outstanding effect was 
confirmed many years later in a controlled study of patients in stages Ta and T1 who had 
previously been subject to TUR. In this study, the ability of KLH to prevent tumor 
recurrence was compared to mitomycin C (MMC). The patients were subcutaneously 
immunized with 1 mg of KLH and then received monthly intravesical administrations of 10 
mg of KLH. Only 14% of the patients treated with KLH had recurrences, in contrast to the 
MMC patients, 39% of whom reported recurrences, demonstrating that KLH was 
significantly more effective than MMC (Jurincic et al., 1988).  
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
230 
A prospective randomized trial compared the effects of ethoglucid and KLH in patients who 
were unresponsive to the chemotherapeutic treatments, doxorubicin or MMC. The 
recurrence rate and the tumor progression rate for the two therapies showed no statistical 
differences (Flamm et al., 1990). Wishahi et al., reported that the incidence of recurrence in 
patients with TCC associated with urinary schistosomiasis was 15% after KLH treatment 
compared with 77% before therapy (Wishahi et al., 1995). This result was similar to the 
results obtained by Olson et al., (1974) and Jurincic et al., (1998) confirming the outstanding 
immunotherapeutic properties of KLH (Olsson et al., 1974; Jurincic et al., 1988). The efficacy 
of this treatment in patients with carcinoma in situ (CIS) grade 3 was studied in a long-term 
follow-up. The patients received an intravesical instillation of KLH weekly for 6 weeks, 
monthly for 1 year and bimonthly for the following 2 years. Patients who were 
unresponsive to KLH were treated with BCG. CIS long-term remission was observed only in 
a limited number of cases, and most cases progressed over time, indicating the 
aggressiveness of this disease (Jurincic-Winkler et al., 1995a). In Table 2, we summarize the 
clinical studies previously described. 
Currently, Immucothel, a clinical-grade KLH preparation, is being evaluated in a Phase III 
clinical trial in Germany for its efficacy in SBC treatment (Biosyn). The Food and Drug 
Administration (FDA) has also authorized another Phase III trial to evaluate the efficacy and 
safety of KLH BCI-Immune Activator (Intracell, USA) versus doxorubicin in BCG refractory 
or intolerant patients with carcinoma in situ, with or without resected SBC. However, this 
study has been suspended. 
The mechanism associated with the immunotherapeutic effect of KLH in this disease is still 
poorly understood. However, there are immunohistological studies on biopsies of TCC 
patients treated with KLH that show strong cellular activation characterized by the 
infiltration of large numbers of mononuclear cells and CD4+ lymphocytes, and to a lesser 
extent, CD8+ T cells and granulocytes, nine months after the beginning of therapy (Jurincic-
Winkler et al., 1995b). This result suggests that the effect of KLH might be strongly related to 
a non-specific immunostimulation of the immune system leading to the development of an 
antitumor response.  
5. Immunologic mechanisms involved in the immunotherapy of SBC with 
hemocyanins 
Although hemocyanins are widely used as thymus-dependent model antigens, the 
relationship between the structure of hemocyanins and the molecular and cellular basis of 
their immunostimulatory capacity is still largely unknown. Investigations into the antitumor 
effect of hemocyanins in human and murine models of SBC have demonstrated a systemic 
activation of the immune response. In these experiments, priming with hemocyanins is 
crucial for the induction of antitumor activity (Lamm et al., 2000; Moltedo et al., 2006). This 
could partially explain why hemocyanins stimulate the immune system. In patients with 
TCC under intravesical KLH therapy, DTH reactions occur. As mentioned previously, 
studies on biopsies of TCC patients treated with KLH showed a higher increase in CD4+ cell 
infiltration than CD8+ T lymphocytes in the submucosa and urothelial cells (Jurincic-
Winkler et al., 1995b). Currently, we know that such responses are characteristic of Th1 type 
responses, which mediate inflammatory functions critical for the development of cell-
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mediated immune responses (Szabo et al., 2003). Other investigations demonstrated that 
during immunization with KLH, the T CD4+ lymphocyte response showed a mixed profile 
of IL-4 and IFN- with an increase in T CD8+ cells in the lymphatic nodules (Doyle et al., 
1998). 
 
Patients  Control    
Group 
Priming Therapeutic              
Dosage and 
Schedule 
Recurrence                 
Rate 
Reference 
19 10 5 mg  
subcutaneous 
200 µg  
Subcutaneous 
11% Olsson  
et al. 1974 
44 23 1 mg 
subcutaneous 
10 mg  
Intravesical, 
monthly for 21 
months, 
approximately. 
14% Jurincic  
et al. 1988 




weekly for six 
weeks and then 
monthly for one 
year. 
55% Flamm  
et al. 1990 




for five days 
until DTH 
10 mg  
Intravesical, for 
seven days. 
15% Wishashi  
et al. 1995 
21 Own 
controls 
No 20 mg  
Intravesical, 
weekly for six 
weeks and then 
monthly for one 
year or bimonthly 
for two years. 
43% of patients 
presented long-
term remission 
57% had to be 
cystectomized 




et al. 1995a 
Table 2. Clinical studies using KLH as an immunotherapeutic agent in SBC patients. 
The fact that the non-specific immunotherapeutic effects of hemocyanins are not due to 
any super-antigen-like activity, but rather rely on adequate priming, strongly suggests 
that their therapeutic properties could be attributable to a bystander effect on the tumor 
due to either a loss of tolerance toward tumor antigens or an enhancement of the immune 
response to the tumor. This kind of response would favor a milieu that augments the 
antigen-specific activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cell 
responses. These hypotheses are supported by the observation that IFN- and IL-2 are 
secreted in the regional lymph nodes in response to hemocyanin treatment (Gilliet et al., 
2003; Verdijk et al., 2009). NK cells are strongly stimulated by IL-2 secreted by T 
lymphocytes, leading to their differentiation into lymphokine-activated killer cells (LAK) 
and increasing the destructive elements acting on tumor cells. It has been reported that 
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A prospective randomized trial compared the effects of ethoglucid and KLH in patients who 
were unresponsive to the chemotherapeutic treatments, doxorubicin or MMC. The 
recurrence rate and the tumor progression rate for the two therapies showed no statistical 
differences (Flamm et al., 1990). Wishahi et al., reported that the incidence of recurrence in 
patients with TCC associated with urinary schistosomiasis was 15% after KLH treatment 
compared with 77% before therapy (Wishahi et al., 1995). This result was similar to the 
results obtained by Olson et al., (1974) and Jurincic et al., (1998) confirming the outstanding 
immunotherapeutic properties of KLH (Olsson et al., 1974; Jurincic et al., 1988). The efficacy 
of this treatment in patients with carcinoma in situ (CIS) grade 3 was studied in a long-term 
follow-up. The patients received an intravesical instillation of KLH weekly for 6 weeks, 
monthly for 1 year and bimonthly for the following 2 years. Patients who were 
unresponsive to KLH were treated with BCG. CIS long-term remission was observed only in 
a limited number of cases, and most cases progressed over time, indicating the 
aggressiveness of this disease (Jurincic-Winkler et al., 1995a). In Table 2, we summarize the 
clinical studies previously described. 
Currently, Immucothel, a clinical-grade KLH preparation, is being evaluated in a Phase III 
clinical trial in Germany for its efficacy in SBC treatment (Biosyn). The Food and Drug 
Administration (FDA) has also authorized another Phase III trial to evaluate the efficacy and 
safety of KLH BCI-Immune Activator (Intracell, USA) versus doxorubicin in BCG refractory 
or intolerant patients with carcinoma in situ, with or without resected SBC. However, this 
study has been suspended. 
The mechanism associated with the immunotherapeutic effect of KLH in this disease is still 
poorly understood. However, there are immunohistological studies on biopsies of TCC 
patients treated with KLH that show strong cellular activation characterized by the 
infiltration of large numbers of mononuclear cells and CD4+ lymphocytes, and to a lesser 
extent, CD8+ T cells and granulocytes, nine months after the beginning of therapy (Jurincic-
Winkler et al., 1995b). This result suggests that the effect of KLH might be strongly related to 
a non-specific immunostimulation of the immune system leading to the development of an 
antitumor response.  
5. Immunologic mechanisms involved in the immunotherapy of SBC with 
hemocyanins 
Although hemocyanins are widely used as thymus-dependent model antigens, the 
relationship between the structure of hemocyanins and the molecular and cellular basis of 
their immunostimulatory capacity is still largely unknown. Investigations into the antitumor 
effect of hemocyanins in human and murine models of SBC have demonstrated a systemic 
activation of the immune response. In these experiments, priming with hemocyanins is 
crucial for the induction of antitumor activity (Lamm et al., 2000; Moltedo et al., 2006). This 
could partially explain why hemocyanins stimulate the immune system. In patients with 
TCC under intravesical KLH therapy, DTH reactions occur. As mentioned previously, 
studies on biopsies of TCC patients treated with KLH showed a higher increase in CD4+ cell 
infiltration than CD8+ T lymphocytes in the submucosa and urothelial cells (Jurincic-
Winkler et al., 1995b). Currently, we know that such responses are characteristic of Th1 type 
responses, which mediate inflammatory functions critical for the development of cell-
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mediated immune responses (Szabo et al., 2003). Other investigations demonstrated that 
during immunization with KLH, the T CD4+ lymphocyte response showed a mixed profile 
of IL-4 and IFN- with an increase in T CD8+ cells in the lymphatic nodules (Doyle et al., 
1998). 
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Table 2. Clinical studies using KLH as an immunotherapeutic agent in SBC patients. 
The fact that the non-specific immunotherapeutic effects of hemocyanins are not due to 
any super-antigen-like activity, but rather rely on adequate priming, strongly suggests 
that their therapeutic properties could be attributable to a bystander effect on the tumor 
due to either a loss of tolerance toward tumor antigens or an enhancement of the immune 
response to the tumor. This kind of response would favor a milieu that augments the 
antigen-specific activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cell 
responses. These hypotheses are supported by the observation that IFN- and IL-2 are 
secreted in the regional lymph nodes in response to hemocyanin treatment (Gilliet et al., 
2003; Verdijk et al., 2009). NK cells are strongly stimulated by IL-2 secreted by T 
lymphocytes, leading to their differentiation into lymphokine-activated killer cells (LAK) 
and increasing the destructive elements acting on tumor cells. It has been reported that 
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MBT-2 cells do not grow when they are injected into the bladders of mice treated with a 
combination of IL-2 and the cytotoxic agent cyclophosphamide (Ikemoto et al., 1997). 
Moreover, KLH has been shown to enhance NK cell activity and stimulate IFN- secretion 
in SBC patients (Molto et al., 1991). Our later results confirm these observations; mice 
treated with KLH or CCH increase NK cell activity and serum levels of IFN- (Moltedo et 
al., 2006). This is a very important result because, in primary tumors, IFN- is a tumor 
suppressor cytokine that coordinates T and NK cell activities (Kaplan et al., 1998). Indeed, 
it has been demonstrated that the depletion of NK cells abolishes the immunotherapeutic 
effect of BCG on bladder cancer in mice, confirming that these cells play a key role in the 
destruction of primary tumors (Brandau & Bohle, 2001).  
In addition to the antitumor effect provided by the secretion of IFN-, NK cells can delay 
tumor growth by means of antibody-dependent cell-mediated cytotoxicity (ADCC), which 
induces effector cells to kill bladder tumor target cells. We have observed that, in the MBT-2 
model, intralesional CCH or KLH induce an increase in the humoral immune response 
against cell surface tumor antigens in addition to the CCH or KLH antibody response. 
Biopsies taken from the surrounding bladder tissues in SBC patients treated with KLH 
showed an increase in the B lymphocyte population in the lymph follicles, suggesting that 
humoral mechanism are also involved in the immune response induced by hemocyanins 
(Jurincic-Winkler et al., 1995b). 
Finally, the fact that the immunotherapeutic effects of KLH and CCH on bladder cancer do 
not require an adjuvant raises intriguing questions regarding the means by which 
hemocyanins initiate the non-specific anti-tumor immune response and which cells are 
involved. It is possible that hemocyanins interact with a putative receptor on the cell surface 
of antigen presenting cells, leading to their internalization and processing. A promising 
candidate was the mannose receptor because of the high levels of this sugar residue in KLH 
and CCH and the fact that this receptor is highly expressed in antigen presenting cells. 
However, experiments on endocytosis inhibition performed in human DCs cultured in vitro 
with an anti-mannose receptor antibody and KLH showed that while KLH incorporation by 
DCs was partially inhibited, KLH still promoted the activation and maturation of DCs as 
assessed by the up-regulation of the cell surface expression of Major Histocompatibility 
Complex (MHC) class II and co-stimulatory molecules (Presicce et al., 2008). In contrast, 
Teitz-Tennenbaum and collaborators (2008) demonstrated that murine DCs pulsed with 
KLH for 18 hours in vitro did not undergo DC maturation, a result that is consistent with in 
vivo experiments (Teitz-Tennenbaum et al., 2008; Moltedo et al., 2009) and our current 
results. We observed that DCs internalized (Fig. 3) but did not mature within 72 hours of 
culture in vitro with this protein  
It is not known whether hemocyanins might be processed and presented by bladder tumor 
cells themselves, leading to the stimulation of the cytotoxic killer cell antitumor activity. 
Murine bladder tumor cells have been shown to be able to present BCG antigens to specific 
CD4+ T lymphocytes in a classic MHC Class II (Ia)-dependent fashion (Lattime et al., 1992). 
Experiments performed in our laboratory demonstrated that primary cultures of mouse 
bladder epithelial cells and MBT-2 cells cultured in vitro incorporate hemocyanin; however, we 
did not observe any changes in the expression pattern of MHC I and MHC II antigens (Del 
Campo et al., 2007). In addition, in vitro anti-cancer effects of KLH against breast, esophageal, 
prostate and pancreas cancer has been reported (Riggs et al., 2002), also in melanoma 
(Somasundar et al., 2005), however if this effect have an in vivo implication is unknown. 
 





Fig. 3. Incorporation of Concholepas hemocyanin by mouse myeloid dendritic cells cultured 
in vitro, analyzed by transmission electron microscopy. Mouse myeloid DCs of 5th day of 
culture in vitro as described (Inaba et al., 1992), previously isolated by positive selection with 
immunomagnetic beads, and later culture with CCH during different times. A. Dendritic 
cell cultured during 30 minutes with CCH. The photograph shows its characteristic 
superficial membrane process, the nucleus (n), and hemocyanin molecules inside a clear 
vacuole (arrow) that resemble a primary lysosome. B. Because of the large size of CCH, and 
because of its peculiar structure as a hollow cylinder, we were able to identify the presence 
of whole hemocyanin molecules inside secondary lysosome like vesicles (arrows) containing 
membrane debris (Del Campo et al., 2007). 
Macrophages are another potential cell type through which hemocyanins could initiate anti-
tumor immune responses. Indeed, IL-1, a pro-inflammatory cytokine produced by 
activated macrophages, has been shown to be increased in the urine after intravesical 
instillation with KLH in patients with SBC (Jurincic-Winkler et al., 1995c). Similarly, this 
cytokine, in addition to other pro-inflammatory cytokines, has been detected in the urine 
after BCG instillation along with an influx of mononuclear cells into the bladder (Teppema 
et al., 1992; Brandau & Bohle, 2001; Brandau et al., 2001).  
In summary, considering that BCG is a whole organism, whereas KLH or CCH are single 
molecules, it is amazing that it induces a similar response. In both cases, however, it is not 
clear which cytokines and cells contribute directly to the anti-tumor activity and which 
represent a secondary phenomenon. 
6. Conclusions 
Hemocyanins have proven to be safe and useful in the immunotherapy and prophylaxis of 
patients with superficial bladder cancer who have failed or are intolerant to the current BCG 
therapy. Moreover, KLH has been shown to produce a more predictable reaction than BCG, 
eliminating the risk of further infections. Despite the fact that biomedical interest in mollusk 
hemocyanins goes back more than 40 years, the precise molecular and cellular mechanisms 
underlying the non-specific immunostimulatory capacities of KLH and, more recently, 
CCH, are poorly understood. The current evidence shows that these huge proteins can 
induce an inflammatory milieu and activate innate immunity, driving a vigorous antitumor 
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patients with superficial bladder cancer who have failed or are intolerant to the current BCG 
therapy. Moreover, KLH has been shown to produce a more predictable reaction than BCG, 
eliminating the risk of further infections. Despite the fact that biomedical interest in mollusk 
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underlying the non-specific immunostimulatory capacities of KLH and, more recently, 
CCH, are poorly understood. The current evidence shows that these huge proteins can 
induce an inflammatory milieu and activate innate immunity, driving a vigorous antitumor 
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adaptive immune response characterized by long-lasting HLA-DR+ cell infiltration into the 
bladder and the secretion of a Th1-type cytokine profile. 
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1. Introduction 
1.1 Epidemiology and bladder carcinogenesis 
Cancer represents phenotypic manifestations of abnormal gene expression. Genetic 
mutations, dysregulation, and gene losses can influence cell proliferation and 
differentiation, and eventually lead to formation of cancer. Risk factors and etiologic agents 
involved in the genetic abnormalities influence the distribution of cancer worldwide. This 
chapter aims at highlighting the epidemiologic significance of urothelial bladder cancer; 
reviewing its natural history, the roles of industrial and environmental carcinogens and life 
style factors in urothelial carcinogenesis; and framing possible strategies for 
chemoprevention in the management of human urothelial cancer of the urinary bladder. 
Bladder cancer remains a serious public health problem worldwide, and accounts for 5-10% 
of all malignancies annually in western countries (Cancer Treatment of America). Though the 
age-adjusted incidence varies in the different parts of the world, the highest rates are found 
in men from North America (23.3/100,000), North Africa (23.3/100,000) and Southern 
Europe (22.0/100,000), while the corresponding rates are 5.4, 4.8, and 3.2 per 100000 for 
women (Cancer Treatment of America). These high rates may be influenced by increased 
industrialization, cigarette smoking, and infection of schistosomiasis (primarily of concern 
in North Africa). The lowest rates for both sexes have been reported for the Melanesia 
region of South Pacific and Middle Africa (Cancer Treatment of America; Prout, Barton et al. 
1992; Grasso 2008; American Cancer Society 2010). 
Bladder cancer, which is immensely impacted by environmental carcinogens and tobacco 
smokes, remains a common disease in the United States, and it is estimated that 70, 530 
persons (52,760 men and 17,770 women) were diagnosed with cancer of the urinary bladder 
in 2010, (Cancer Treatment of America; American Cancer Society 2010) and an estimated 14, 680 
died of the disease accounting for 3% and 2% of all cancer deaths in men and women, 
respectively (Cancer Treatment of America; American Cancer Society 2010). Estimates of new 
cancer cases classify urothelial bladder cancer (UBC) as the fourth most common in men and 
the eighth most common in women. The prevalence of UBC in the US is estimated at about 
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1. Introduction 
1.1 Epidemiology and bladder carcinogenesis 
Cancer represents phenotypic manifestations of abnormal gene expression. Genetic 
mutations, dysregulation, and gene losses can influence cell proliferation and 
differentiation, and eventually lead to formation of cancer. Risk factors and etiologic agents 
involved in the genetic abnormalities influence the distribution of cancer worldwide. This 
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reviewing its natural history, the roles of industrial and environmental carcinogens and life 
style factors in urothelial carcinogenesis; and framing possible strategies for 
chemoprevention in the management of human urothelial cancer of the urinary bladder. 
Bladder cancer remains a serious public health problem worldwide, and accounts for 5-10% 
of all malignancies annually in western countries (Cancer Treatment of America). Though the 
age-adjusted incidence varies in the different parts of the world, the highest rates are found 
in men from North America (23.3/100,000), North Africa (23.3/100,000) and Southern 
Europe (22.0/100,000), while the corresponding rates are 5.4, 4.8, and 3.2 per 100000 for 
women (Cancer Treatment of America). These high rates may be influenced by increased 
industrialization, cigarette smoking, and infection of schistosomiasis (primarily of concern 
in North Africa). The lowest rates for both sexes have been reported for the Melanesia 
region of South Pacific and Middle Africa (Cancer Treatment of America; Prout, Barton et al. 
1992; Grasso 2008; American Cancer Society 2010). 
Bladder cancer, which is immensely impacted by environmental carcinogens and tobacco 
smokes, remains a common disease in the United States, and it is estimated that 70, 530 
persons (52,760 men and 17,770 women) were diagnosed with cancer of the urinary bladder 
in 2010, (Cancer Treatment of America; American Cancer Society 2010) and an estimated 14, 680 
died of the disease accounting for 3% and 2% of all cancer deaths in men and women, 
respectively (Cancer Treatment of America; American Cancer Society 2010). Estimates of new 
cancer cases classify urothelial bladder cancer (UBC) as the fourth most common in men and 
the eighth most common in women. The prevalence of UBC in the US is estimated at about 
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one million cases annually, and worldwide, UBC ranks as the ninth most frequent cancer 
(Cancer Treatment of America; Prout, Barton et al. 1992; Grasso 2008; American Cancer Society 
2010).  
Bladder cancer is a disease of aging; the incidence of UBC rises with age with an average of 
onset at 69 for men and 67 for women (Cancer Treatment of America; Prout, Barton et al. 1992; 
Dalbagni and Herr 2000; Grasso 2008; American Cancer Society 2010). Bladder cancer that 
occurs at ages 40 or younger tends to be low grade Ta cancer with almost negligible 
recurrence potential. Given sufficient time, however 50-70% of UBC patients will develop 
recurrent disease. Recurrences tend to be characterized by multiplicity in time and space, 
primarily if the initial tumors occurred early in life and were large or multiple in numbers. 
A majority, 70-75%, of UBC are superficial, that is, non-muscle invasive, and non-lethal, but 
they are characterized by frequent recurrences. However, the remaining 25-30% of the 
annual cases of UBC invades into the muscular propria, making them life threatening, 
because approximately 50% harbor micro-metastases that often manifest within three years 
out from diagnosis (Droller 2006).  
The non-muscle invasive UBC (NMIUBC) that are confined to the mucosa/urothelium Ta, 
remain non-lethal with a progression rate of less than 5%, and occur often as large or 
multiple tumors. Ten to twenty percent of the superficially-invasive UBC that is confined to 
the lamina propria, T1, converts to muscle invasive disease on repeat resection (Dalbagni 
and Herr 2000).  
Variable morphology, natural history, and prognosis demonstrate that transitional cell 
carcinoma (TCC) or urothelial carcinoma (UC) of the bladder is not a single disease, but 
occurs in three distinct forms, each possessing characteristic features that include low grade 
papillary, noninvasive; carcinoma in situ (CIS); and high grade, invasive (Grasso 2008). 
Seventy to eighty-five percent of new bladder cancer cases, are superficial or non-muscle 
invasive UBC, which include disease confined to the mucosa in CIS: CIS (10%), and Ta (70%), 
or lamina propria in T1 (20%) (Prout, Barton et al. 1992; Dalbagni and Herr 2000; Droller 
2006; Grasso 2008). These types of tumors are considered to have variable invasive potential 
with a progression rate to invasive cancer of 15% to 50% (Prout, Barton et al. 1992; Dalbagni 
and Herr 2000; Grasso 2008). However, more than 70% of patients with NMIUBC have one 
or more recurrences within 5 years of initial diagnosis (Prout, Barton et al. 1992; Dalbagni 
and Herr 2000; Droller 2006; Grasso 2008). Further analysis shows that approximately 50% 
of patients diagnosed with solitary bladder cancer will experience recurrences within 4 
years, while 70% of multiple bladder tumors reoccur within one year (Prout, Barton et al. 
1992; Dalbagni and Herr 2000; Droller 2006; Grasso 2008).  
The fact that the bladder serves as a reservoir for urine and its waste product contents 
predisposes it to the constant cumulative exposure to carcinogens which include industrial 
toxins and cigarette smoke chemicals. The multiple-step process of carcinogenesis includes 
induction/activation, promotion and progression, which exists as a continuum in the 
bladder environment. Consequently, preventive intervention can be difficult to implement 
under these conditions of cumulative exposures, and the definitive strategy will be to 
minimize constant cumulative exposure of carcinogenic agents from smoking and industrial 
sources. Increased carcinogenic exposure by itself cannot explain the 40% increase in 
bladder cancer incidence in the last 15 years in the US. The explanation certainly includes 
increased smoking that has added a large population of women, cumulative industrial 
exposure, and host factors. These host characteristics are likely to influence racial differences 
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in the incidence of bladder cancer. Caucasians have overall bladder cancer risk of 3.9% 
versus 0.8% overall chance in African Americans: 2.8% in men and 1.5% in women (Droller 
2006).  
Earliest reported association of industrial carcinogenic exposure and development of 
bladder cancer was by Rehn (Dietrich and Dietrich 2001). Observations have also 
documented associations between carcinogen ingestion in animals and development of 
bladder cancer (Okey, Harper et al. 1998; Sporn and Lippman 2003). Several legislative 
measures have been implemented in an attempt to decrease the intensity and cumulative 
nature of the carcinogen exposure. However, cigarette smoking trumps all considerations of 
environmental and industrial exposure and is the major factor underlying the spread and 
occurrence of bladder cancer around the globe.  
It is estimated that 30% of bladder cancer mortality is attributable to a history of tobacco 
abuse/dependence (American Cancer Society), and studies have tried to characterize the 
different carcinogenic agents in cigarette smoke that define the causal relationship between 
smoking and development of urothelial cancer (American Cancer Society; Droller 2006). 
Investigators have tried to correlate bladder cancer risk with the manufacturing processes 
such as the type of filter used, type of tobacco used, and the curing technique: black versus 
blonde (Droller 2006). The curing technique determines the concentration of the carcinogens 
in the cigarette. The smoke of black (air-cured) versus blonde (flue-cured) has been analyzed 
to show higher concentration of carcinogens in black tobacco. How these commercial 
practices influence urothelial carcinogenesis remains to be elucidated. 
Several specific carcinogens in cigarette smoke have been implicated in the development of 
urothelial cancer, including polycyclic aromatic hydrocarbons, aromatic and aryl amines 
(including 4-amino biphenyl), unsaturated aldehydes (e.g. acrolein) and oxygen-free radicals 
(American Cancer Society; Sabichi and Lippman; Droller 2006). Aromatic amines were the first 
carbon compounds of industrial by-products that were suspected in work- related urothelial 
cancer, found primarily in those workers who were exposed to the dye, rubber, and plastic 
manufacturing. These epidemiological data suggest up to 100-fold increased risk that is 
mediated by cumulative intensity and duration of exposure. Regulatory and legislative efforts 
to retard the work place risk contributed to the birth of occupational safety and health 
administration in the industrialized countries around the world. 
In spite of extensive efforts since then to curb workplace exposure to industrial carcinogens, 
textile, dry cleaning, hair dressing, and coal gasification continue to generate the 
carcinogens in the manufacturing process. The culprit agents are per-chloroethylene (an 
organic solvent used in dry cleaning), chemical dyes, aromatic amines (used in textile 
industry), and hair dyes that contain chemical carcinogens. These agents have been 
associated with bladder cancer development. Other carcinogens, outside of the workplace, 
that have been associated with the development of urothelial cancer include arsenic in 
ground water in southeastern Michigan in the US and southwestern Taiwan (Haack, 
Treccani et al. 2000; Kim, Nriagu et al. 2000; Welch, Westjohn et al. 2000; Droller 2006); 
ingestion of fang chi (Chinese herb used in weight control); ingestion of ochratoxin A in the 
Balkan countries resulting indirectly from animals that consumed blackened fern (Droller 
2006). Several medications and medical therapies have also been associated with urothelial 
cancer development including phenacetin used to treat headaches, cyclophosphamide 
(cytoxan) used to treat pediatric and adult hematologic malignancies (lymphoma and 
leukemia), and pelvic radiation for cervical and prostate cancer. 
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In parts of the world with endemicity, there are reports of association between Schistosoma 
haematobium infection and the development of urothelial cancer, primarily squamous cell 
carcinoma, and some cases of transitional cell cancer (Sabichi and Lippman; Okey, Harper et 
al. 1998; Sporn and Lippman 2003; Droller 2006). The inciting factors include an 
inflammatory response to the deposited parasitic ova of Schistosoma haematobium in the 
periurethral areas of the bladder ,as well as conversion of nitrates to nitrites with the 
nitrosamines mediating the development of urothelial cancer. Other carcinogenic exposures 
such as fertilizers and cigarette smoke may also play putative roles in the urothelial 
carcinogenesis in these patients.  
In urothelial carcinogenesis, several host factors have been recognized as playing either 
permissive or protective roles. Acetylation of aromatic amines remains an important 
mechanism of carcinogenic inactivation in urothelial carcinogenesis. The detoxification of 
carcinogens is mediated by genes namely NAT1 and NAT2 which are responsible for 
generating the detoxifying enzymes N-acetyl transferase, and NAT2 remains the 
predominant gene involved. Individuals who are homozygous for NAT2 are classified as 
slow acylators and they detoxify carcinogens quite slowly allowing prolonged contact with 
DNA to induce mutations and carcinogenesis (Sabichi and Lippman; Weber 1987; Droller 
2006). These individuals have a two- to four-fold increased risk for the development of 
urothelial cancer. On the other hand, the heterozygous fast acylators are able to rapidly 
detoxify these aromatic amines that lower their risk of developing urothelial cancer. 
Researchers have suggested that the potential differences in racial and ethnic risk of 
urothelial cancer development are attributable to the difference in the expression of these 
two genes (Sabichi and Lippman; Weber 1987; Droller 2006; Lattouf 2009).The P450 
cytochrome oxidase system is also important in metabolism and detoxification of urothelial 
carcinogens. The CYP1A2 might be particularly important in metabolizing aromatic amines 
(Sabichi and Lippman; Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 2006). 
Also, individuals deficient in the enzyme glutathione transferase may be at risk for deficient 
metabolism of polycyclic aromatic amines, which could put them at a 30-50% risk of 
developing bladder cancer (Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 
2006). 
2. Molecular biology of carcinogenesis and chemoprevention 
The classic multistep process of carcinogenesis which has been widely accepted includes 
initiation, promotion, and progression. A clear-cut sequential compartmentalization 
probably does not always occur, but the multistep structure could be exploited strategically 
for chemopreventative measures. The first step, initiation, depends upon three cellular 
functions, namely carcinogen metabolism, DNA repair, and cell proliferation. Cell damage 
can occur by activation/deactivation mediated by the carcinogen; this cell can cycle through 
DNA repair or exists as an altered gene (no tumor development) and can be propagated as 
such, or go through cell proliferation. In the promotion phase, the altered cell continues to 
undergo repeated bombardment by the promoter agent (initiator or not) leading to 
additional genomic damage and subsequent clonal expansion into a tumor. In the 
progression phase, the tumor acquires multicellular defective mutations enhanced by 
acquired or inherited mutations in the control genes such as p53, Rb, or DNA mismatch 
repairs (Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 2006). Consequently a 
tumor is born that lacks cellular growth controls, and has proliferative autonomy. The 
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challenge in designing a preventive strategy is selecting whether to target genomic or 
cellular events as well as determining the order of subsequent sequential targeting.  
Genotoxic carcinogens can be enzymatically bioactivated and converted into water soluble 
metabolites to be excreted in urine or bile. These carcinogens can also be inadvertently 
transformed into electrophiles which react with DNA. Metabolism of carcinogens or broadly 
biotransformation may depend upon genetic and environmental factors in an individual 
who is exposed to the carcinogens. The drug metabolizing enzymes are classified into Phase 
I and Phase II enzymes, with Phase I enzyme being primarily typified by cytochrome P450 
mono-oxygenase (CYP) super family. These enzymes function by unmasking the parent 
substrates (Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 2006). The Phase II 
enzymes including sulfotransferase, glutathione transferase (GST), and acetyltransferase 
primarily detoxify reactive metabolites. They catalyze the conjugation of bulky water 
insoluble components into hydroxyl groups which can easily be excreted. 
As discussed above, carcinogenesis is a multistep process; therefore chemopreventive agents 
could affect different mechanisms. In practice chemoprevention would require continuous 
administration of a non-toxic compound over a long period or lifetime of the at-risk 
individual. However, the chemoprevention strategy would begin with the population 
approach that advocates a dietary program of increased consumption of fruits and 
vegetables which have been reported to reduce general cancer risk (Sabichi and Lippman; 
Sporn and Lippman 2003; Lattouf 2009). At the individual level, the approach would be to 
reduce the intensity of cumulative exposure through programs that include 
reduction/elimination of exposure to the carcinogens, dilution and elimination of bladder 
content by drinking plenty of water and urinating frequently, followed by introduction of 
the at-risk individual to the chemopreventive agent(s). The potential chemoprevention 
agents can be broadly classified into two categories: (a) agents that decrease bioactivation or 
increase detoxification of carcinogens, and (b) agents that alter promotion and progression 
(Okey, Harper et al. 1998; Sporn and Lippman 2003). 
2.1 Agents that decrease bioactivation or increase detoxification of carcinogens 
The cytochrome P450 enzyme family, which typifies the Phase I enzymes, acts 
bidirectionally by bioactivating procarcinogens into reactive metabolites that bind to DNA, 
but also enhances overall clearance of both the procarcinogens and carcinogens from the 
body. The first pass clearance of the carcinogen by the high activity of P450 enzymes in the 
human liver exposes the susceptible peripheral organ/ tissue to reduced concentrations of 
the carcinogens (Okey, Harper et al. 1998; Sporn and Lippman 2003)..  
In bladder cancer, the Phase II enzymes include the detoxifier glutathione transferases 
which conjugate reactive metabolites with glutathione. These Phase II enzymes can be 
induced by plant products such as sulforaphane from broccoli. This induction can be 
highly protective in animals against major carcinogens. However, they can also act 
bidirectionally to favor Phase I class of enzymes (Okey, Harper et al. 1998; Sporn and 
Lippman 2003). 
Interestingly, oltipraz, an anti-schistosomiasis drug, functions bidirectionally to inhibit the 
predominant activating enzyme CYPIA2, and also induces a glutathione S-transferase Phase 
II enzyme that detoxifies carcinogens by conjugation. Another cytochrome P450 modulator 
is indole-3-carbinole (I3C) which is abundant in broccoli, brussels sprouts, and cruciferous 
vegetables (Okey, Harper et al. 1998; Sporn and Lippman 2003). 
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The phytochemicals that reduce adduct formation include vitamin E (-tocopherol) and 
vitamin C (ascorbic acid). These act as scavengers of the reactive metabolites, or act as 
antioxidants (Okey, Harper et al. 1998; Sporn and Lippman 2003). However, they have not 
been found to decrease the risk of cancer in high-risk populations.  
2.2 Agents that alter promotion and progression 
Inflammation, increased cell proliferation/decreased differentiation, deficiency of apoptosis, 
and cumulative genetic instability constitute putative molecular and cellular events that 
induce promotion and progression during carcinogenesis (Okey, Harper et al. 1998; Sporn 
and Lippman 2003; Droller 2006). These cellular events are attractive potential targets for 
chemopreventative intervention.  
Synthetic retinoids have been shown to alter gene expression and stimulate apoptosis. 
However, these have failed as primary chemopreventive agents, but have been shown to 
delay the appearance of secondary primary cancers of head and neck (Sabichi and Lippman; 
Okey, Harper et al. 1998; Sporn and Lippman 2003). However, natural retinoids such as -
carotene have shown a paradoxical increase in lung cancer in smokers and asbestos-exposed 
workers.  
Targeting inflammation has become an attractive approach in chemoprevention as scientists 
gain better understanding of the association between inflammation and increased cancer 
risk, particularly colon cancer. Both the older-generation non-specific inhibitors of 
cyclooxygenase including: aspirin and non-steroidal anti-inflammatory agents (NSAIDS) 
and the newer synthetic selective COX-2 inhibitors such as Celecoxib have shown promising 
results in preventing colon cancer in rodent models and in humans(Sporn and Lippman 
2003).  
3. Conventional strategies in preventing recurrence/occurrence and 
progression  
Approaches to bladder cancer prevention include primary prevention which aims at 
avoiding cancer development in healthy populations, secondary prevention, which aims at 
preventing premalignant lesions from undergoing promotion and progression into cancer 
under conducive conditions during carcinogenesis; and tertiary prevention, which aims at 
aborting cancer progression in patients who have been treated for the cancer. In bladder 
cancer, primary prevention is widely regarded as impractical. Even if good 
chemopreventive agents were available the risk-benefit ratio would have to be low in such a 
large at risk population. The other challenges to primary intervention strategy are discussed 
in the sections above about the uncertainty of appropriate molecular/cellular targets to 
prevent tumor initiation. In practice techniques of secondary and tertiary prevention are 
indistinguishable. 
Following the initial diagnosis with transurethral resection of bladder tumor (TURBT), there 
are several interventions that may be undertaken to retard cancer recurrence and 
progression: selected patients may undergo repeat TURBT to better delineate the nature of 
their disease (Prout, Barton et al. 1992; Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et 
al. 1995; Dalbagni and Herr 2000), approximately 20% will receive intravesical 
chemotherapy to potentially eradicate residual disease (Prout, Barton et al. 1992; 
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Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000) and 
the majority will be placed on some type of endoscopic surveillance schedule. The necessity 
for early adjuvant treatment, mainly intravesical instillation of immunotherapeutic or 
chemotherapeutic agents in the management of high-risk CIS, Ta/high grade and T1/any 
grade is recognized globally (Prout, Barton et al. 1992; Oosterlinck, Kurth et al. 1993; Lamm, 
Blumenstein et al. 1995; Dalbagni and Herr 2000). The hope is that this treatment, by altering 
the neoplastic potential of the urothelium, will reduce the risk for recurrence and 
progression. The subsets of the patients with NMIUBC who fail the conventional 
intravesical therapies will ultimately be subjected to radical cystectomy with resultant loss 
of bladder function, body image and sexual function (Prout, Barton et al. 1992; Oosterlinck, 
Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000). The newest 
strategy in the management of NMIUBC is Photodynamic Diagnosis (PDD) with Hexvix 
(PhotoCure ASA, Oslo, Norway) to minimize recurrences/occurrences and progression. PPD 
uses Hexvix which is an ester derivative of 5-Aminolevulinic Acid (ALA) (Jichlinski, Guillou 
et al. 2003; Fradet, Grossman et al. 2007) was recently approved by the US Food and Drug 
Administration (FDA) for management of NMIUBC primarily to improve the diagnostic 
and staging accuracy of cystoscopy leading to improvement in survival. Photodynamic 
diagnosis occurs when a photosensitizing agent is first concentrated in malignant or 
abnormal tissue, and then activated by light (Henderson 1992). The activated 
photosensitizer either returns to ground state, and releases energy as fluorescence, which 
can be used in detection (PDD), or the photosensitizer enters into its triplet state, and causes 
physico-chemical reactions to generate reactive oxygen species (ROS), for therapy as in 
Photodynamic therapy (PDT). Hexvix-PDD has been reported to improve the diagnostic 
rate of Ta and T1 papillary bladder cancers by 16.4% and the detection of CIS by 31% (as 
compared to white light cystoscopy) (Jichlinski, Guillou et al. 2003). Recently, Karl et al., 
reported that PDD during initial TURBT for T1G3 NMBIC exhibited a significant reduction 
in recurrence rate; led to detection of additional 35.4% CIS versus 21.8% in the control group 
(standard white light TURBT).The authors concluded that the initial use of PDD-directed 
TURBT could provide a superior cancer control and effective treatment of patients with 
T1G3 NMIBC (Karl 2010). 
Bacillus Calmette-Guerin (BCG), an immunotherapy, remains the most effective and widely 
used intravesical agent to prevent recurrence and progression (Oosterlinck, Kurth et al. 
1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000). Mitomycin, thiotepa and 
epirubicin are the commonly used intravesical chemotherapeutic agents. while intravesical 
Valrubicin is FDA-approved as an alternative intravesical therapy to radical cystectomy for 
BCG refractory CIS patients (Dalbagni and Herr 2000). Administering Mitomycin or 
epirubicin immediately following TURBT has been reported as effective in preventing 
tumor implant; however, this approach has failed to ultimately prevent disease progression 
or mortality (Oosterlinck, Kurth et al. 1993). Of course, each intravesical agent is associated 
with both local and systemic side effects. Despite current treatment strategies, 30-80% of 
these patients develop recurrences within 5 years, and this high rate of recurrence of NMIBC 
invariably leads to a high economic impact (Hedelin, Holmang et al. 2002; Botteman, Pashos 
et al. 2003; Uchida, Yonou et al. 2007; Hong and Loughlin 2008; Sievert, Amend et al. 2009). 
The disease progression rate to muscle invasiveness is 42-83% in BCG-treated patients who 
have concomitant CIS and papillary NMIUBC, and 30-50% in those BCG-treated patients 
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The phytochemicals that reduce adduct formation include vitamin E (-tocopherol) and 
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Synthetic retinoids have been shown to alter gene expression and stimulate apoptosis. 
However, these have failed as primary chemopreventive agents, but have been shown to 
delay the appearance of secondary primary cancers of head and neck (Sabichi and Lippman; 
Okey, Harper et al. 1998; Sporn and Lippman 2003). However, natural retinoids such as -
carotene have shown a paradoxical increase in lung cancer in smokers and asbestos-exposed 
workers.  
Targeting inflammation has become an attractive approach in chemoprevention as scientists 
gain better understanding of the association between inflammation and increased cancer 
risk, particularly colon cancer. Both the older-generation non-specific inhibitors of 
cyclooxygenase including: aspirin and non-steroidal anti-inflammatory agents (NSAIDS) 
and the newer synthetic selective COX-2 inhibitors such as Celecoxib have shown promising 
results in preventing colon cancer in rodent models and in humans(Sporn and Lippman 
2003).  
3. Conventional strategies in preventing recurrence/occurrence and 
progression  
Approaches to bladder cancer prevention include primary prevention which aims at 
avoiding cancer development in healthy populations, secondary prevention, which aims at 
preventing premalignant lesions from undergoing promotion and progression into cancer 
under conducive conditions during carcinogenesis; and tertiary prevention, which aims at 
aborting cancer progression in patients who have been treated for the cancer. In bladder 
cancer, primary prevention is widely regarded as impractical. Even if good 
chemopreventive agents were available the risk-benefit ratio would have to be low in such a 
large at risk population. The other challenges to primary intervention strategy are discussed 
in the sections above about the uncertainty of appropriate molecular/cellular targets to 
prevent tumor initiation. In practice techniques of secondary and tertiary prevention are 
indistinguishable. 
Following the initial diagnosis with transurethral resection of bladder tumor (TURBT), there 
are several interventions that may be undertaken to retard cancer recurrence and 
progression: selected patients may undergo repeat TURBT to better delineate the nature of 
their disease (Prout, Barton et al. 1992; Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et 
al. 1995; Dalbagni and Herr 2000), approximately 20% will receive intravesical 
chemotherapy to potentially eradicate residual disease (Prout, Barton et al. 1992; 
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Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000) and 
the majority will be placed on some type of endoscopic surveillance schedule. The necessity 
for early adjuvant treatment, mainly intravesical instillation of immunotherapeutic or 
chemotherapeutic agents in the management of high-risk CIS, Ta/high grade and T1/any 
grade is recognized globally (Prout, Barton et al. 1992; Oosterlinck, Kurth et al. 1993; Lamm, 
Blumenstein et al. 1995; Dalbagni and Herr 2000). The hope is that this treatment, by altering 
the neoplastic potential of the urothelium, will reduce the risk for recurrence and 
progression. The subsets of the patients with NMIUBC who fail the conventional 
intravesical therapies will ultimately be subjected to radical cystectomy with resultant loss 
of bladder function, body image and sexual function (Prout, Barton et al. 1992; Oosterlinck, 
Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000). The newest 
strategy in the management of NMIUBC is Photodynamic Diagnosis (PDD) with Hexvix 
(PhotoCure ASA, Oslo, Norway) to minimize recurrences/occurrences and progression. PPD 
uses Hexvix which is an ester derivative of 5-Aminolevulinic Acid (ALA) (Jichlinski, Guillou 
et al. 2003; Fradet, Grossman et al. 2007) was recently approved by the US Food and Drug 
Administration (FDA) for management of NMIUBC primarily to improve the diagnostic 
and staging accuracy of cystoscopy leading to improvement in survival. Photodynamic 
diagnosis occurs when a photosensitizing agent is first concentrated in malignant or 
abnormal tissue, and then activated by light (Henderson 1992). The activated 
photosensitizer either returns to ground state, and releases energy as fluorescence, which 
can be used in detection (PDD), or the photosensitizer enters into its triplet state, and causes 
physico-chemical reactions to generate reactive oxygen species (ROS), for therapy as in 
Photodynamic therapy (PDT). Hexvix-PDD has been reported to improve the diagnostic 
rate of Ta and T1 papillary bladder cancers by 16.4% and the detection of CIS by 31% (as 
compared to white light cystoscopy) (Jichlinski, Guillou et al. 2003). Recently, Karl et al., 
reported that PDD during initial TURBT for T1G3 NMBIC exhibited a significant reduction 
in recurrence rate; led to detection of additional 35.4% CIS versus 21.8% in the control group 
(standard white light TURBT).The authors concluded that the initial use of PDD-directed 
TURBT could provide a superior cancer control and effective treatment of patients with 
T1G3 NMIBC (Karl 2010). 
Bacillus Calmette-Guerin (BCG), an immunotherapy, remains the most effective and widely 
used intravesical agent to prevent recurrence and progression (Oosterlinck, Kurth et al. 
1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000). Mitomycin, thiotepa and 
epirubicin are the commonly used intravesical chemotherapeutic agents. while intravesical 
Valrubicin is FDA-approved as an alternative intravesical therapy to radical cystectomy for 
BCG refractory CIS patients (Dalbagni and Herr 2000). Administering Mitomycin or 
epirubicin immediately following TURBT has been reported as effective in preventing 
tumor implant; however, this approach has failed to ultimately prevent disease progression 
or mortality (Oosterlinck, Kurth et al. 1993). Of course, each intravesical agent is associated 
with both local and systemic side effects. Despite current treatment strategies, 30-80% of 
these patients develop recurrences within 5 years, and this high rate of recurrence of NMIBC 
invariably leads to a high economic impact (Hedelin, Holmang et al. 2002; Botteman, Pashos 
et al. 2003; Uchida, Yonou et al. 2007; Hong and Loughlin 2008; Sievert, Amend et al. 2009). 
The disease progression rate to muscle invasiveness is 42-83% in BCG-treated patients who 
have concomitant CIS and papillary NMIUBC, and 30-50% in those BCG-treated patients 
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with primary CIS (Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni 
and Herr 2000). Frequent follow ups and re-treatment of patients due to the recurrences 
exert heavy untold burden on the affected patients; eventually leading to morbidity as well 
as increased expenditure because of continuous treatment (Hedelin, Holmang et al. 2002; 
Botteman, Pashos et al. 2003; Uchida, Yonou et al. 2007; Hong and Loughlin 2008; Sievert, 
Amend et al. 2009). 
3.1 Chemoprevention in the armamentarium of management of NMIUBC 
Early detection and advances in treatments over the last two decades have resulted in an 
overall reduction in bladder cancer mortality (Cancer Treatment of America; American 
Cancer Society 2010). The public health and socioeconomic burden of bladder cancer could 
be reduced through practice of systematic prevention measures including 
elimination/minimization of exposure to carcinogens, hydration for dilution and frequent 
urination to expulse potential carcinogens; and practice of active dietary and/or 
pharmacologic preventative interventions. Unfortunately, in bladder cancer there are still no 
definite interventions that have been shown to be effective, and research in this area has 
yielded no evidence-based data to inform on strategies for systematic practice of bladder 
cancer prevention. Bladder urothelial cancer has biologic and clinical characteristics that 
favor it as an ideal cancer for chemoprevention. These special features include its 
susceptibility; carcinogenesis; frequent recurrences, and clinical presentation.  
3.2 Cessation of smoking 
The most cost-effective measure in bladder cancer prevention strategy would certainly be 
smoking cessation. This, of course, would be very difficult because of the addictive nature of 
the current cadre of manufactured cigarettes. In the meantime therapeutic intervention is 
needed to complement and perhaps even supplant the current socio-cultural as well as the 
legislative strategies to reduce the economic burden, suffering and death from bladder 
cancer through tobacco control. In the following section we will review the available 
evidence for the various chemotherapeutic agents. 
4. Bladder cancer chemoprevention strategies: Non-pharmacologic and 
dietary approach (see also Table 1) 
4.1 Fluid intake  
The Health Professional Follow Up Study validated the concept that increased fluid intake 
could substantially lower the risk of UBC due to lowered intensity and cumulative exposure 
of carcinogens (Michaud, Spiegelman et al. 1999). The study involved mailing 
questionnaires to 47,903 men; and analysis of their responses regarding daily fluid intake. 
The data showed inverse association between total daily fluid intake and risk of urothelial 
cancer (UC) with a relative risk of 0.51 (0.32-0.81, 95% confidence interval: CI) in those who 
consumed the largest amount of fluid. Daily water consumption offered the best protection 
when compared with other fluids. However, Geoffrey-Perez and colleagues countered by 
reporting that there was an absence of association between bladder cancer risk and fluid 
consumption (Geoffroy-Perez and Cordier 2001). Intuitively it remains logical that dilution 
of bladder carcinogenic contents with frequent urination would be beneficial and less 
expensive practice.  
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4.2 Fat and caloric intake 
In the Spanish study, Riboli and associates reported an association between fat consumption 
and urothelial cancer that showed a 2-fold increase in cancer incidence (Riboli, Gonzalez et 
al. 1991). Surveillance Epidemiology and End Results (SEER) population-based study data 
provided further evidence that fat rich diets are associated with an increase in incidence of 
UC (OR 2.24 for the highest quartile, 95% CI, 1.25-4.03, P=0.006) (Bruemmer, White et al. 
1996). A Swedish study suggests a dose dependent effect of fat diet on the incidence of UC 
(Steineck, Hagman et al. 1990). In a meta-analysis of 36 studies evaluating 6 dietary variables 
in relation to UC, Steinmaus and group reported a positive association between intake of fat 
and UC (Relative ratio, RR 1.37, 95% CI, 1.16-1.62), but not with meat consumption (RR 1.08, 
95% CI, 0.82-1.42) (Steinmaus, Nunez et al. 2000). However, there was no positive 
association between total caloric intake and UC over 12 years in the Health Professional 
Follow-Up Study (Michaud, Spiegelman et al. 2000). The traditional flaws of epidemiologic 
studies certainly affect the results of these studies including recall bias and lack of 
prospective randomized data. Other confounding factors include concomitant increased in 
caloric intake with increased fat intake. Despite these drawbacks of the reports, decreased 
fat intake should be a recommendation for prevention strategy of UC.  
4.3 Green tea 
Drinking tea has been reported to confer protective health benefits which include 
prevention of human cancers including prostate and bladder cancers (Trevisanato and Kim 
2000). 
The polyphenols found in green tea are potent antioxidants; they also inhibit ornithine 
decarboxylase which is an enzyme that promotes tumor proliferation via nucleic acid 
regulation (Steele, Kelloff et al. 2000). The incidence of UC in Asian populations with 
increased tea consumption is lower than in North America; a weak inverse relationship 
between tea intake and UC has been reported in one epidemiological study (Kemberling, 
Hampton et al. 2003). In order to settle the ongoing controversy, NCI-sponsored phase 2 and 
3 clinical trials are in progress (National Cancer Institute). 
4.4 Soy 
Soy products have potential apoptotic and anti-angiogenic actions attributable to their high 
isoflavone content (Su, Yeh et al. 2000).Their role in UC chemoprevention, unlike in prostate 
cancer, has yet to be elucidated. Contrary Su and group reported in a Singapore-based 
population study an increased UC incidence associated with high consumption of soy food 
(95% CI, 1.1-5.1) (Su, Yeh et al. 2000).This risk was independent of smoking. There is no data 
yet favoring recommendation of soy for chemoprevention in UC.  
5. Bladder cancer chemoprevention strategies: Pharmacologic agents  
5.1 Vitamins and supplements 
Researchers have long regarded vitamins and the so-called micronutrients as ideal agents 
for primary chemoprevention for human cancer. For the reasons discussed earlier primary 
chemoprevention in human bladder cancer lacks an effective agent as well as evidence-
based data to encourage wide clinical practice.  
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the current cadre of manufactured cigarettes. In the meantime therapeutic intervention is 
needed to complement and perhaps even supplant the current socio-cultural as well as the 
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cancer through tobacco control. In the following section we will review the available 
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The Health Professional Follow Up Study validated the concept that increased fluid intake 
could substantially lower the risk of UBC due to lowered intensity and cumulative exposure 
of carcinogens (Michaud, Spiegelman et al. 1999). The study involved mailing 
questionnaires to 47,903 men; and analysis of their responses regarding daily fluid intake. 
The data showed inverse association between total daily fluid intake and risk of urothelial 
cancer (UC) with a relative risk of 0.51 (0.32-0.81, 95% confidence interval: CI) in those who 
consumed the largest amount of fluid. Daily water consumption offered the best protection 
when compared with other fluids. However, Geoffrey-Perez and colleagues countered by 
reporting that there was an absence of association between bladder cancer risk and fluid 
consumption (Geoffroy-Perez and Cordier 2001). Intuitively it remains logical that dilution 
of bladder carcinogenic contents with frequent urination would be beneficial and less 
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Follow-Up Study (Michaud, Spiegelman et al. 2000). The traditional flaws of epidemiologic 
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cancer, has yet to be elucidated. Contrary Su and group reported in a Singapore-based 
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for primary chemoprevention for human cancer. For the reasons discussed earlier primary 
chemoprevention in human bladder cancer lacks an effective agent as well as evidence-
based data to encourage wide clinical practice.  
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5.1.1 Vitamin A and analogues 
Epidemiologic data in humans regarding the efficacy of Vitamin A are inconsistent. Many 
reports have suggested a therapeutic benefit from retinoid supplements. Data includes the 
SEER database controlled study, which compared 1592 UC participants to a matched 
neighborhood controls (Castelao, Yuan et al. 2004). Carotenoids were found to be beneficial 
in previous or current smokers. Authors using fenretinide in a randomized study failed to 
demonstrate the difference in tumor detection by flow cytometry between treatment and 
placebo arms in a sample of 99 participants (Decensi, Torrisi et al. 2000). Fenretinide is a 
synthetic derivative of Vitamin A which is FDA approved for the treatment of macular 
degeneration, and cystic fibrosis; and it has been investigated for use in cancer 
chemoprevention. Studer and group treated 90 Ta and T1 patients after transurethral 
resection with etretinate (Studer, Jenzer et al. 1995). They observed that time to first tumor 
occurrence was the same in both treatment and placebo groups, however, time to second 
tumor occurrence was lower for treatment group versus placebo (20.3 v 12.7 months, 
P>0.006). The data suggests that the agent acts not on established bladder cancer, but acts to 
prevent new cancer. Vitamin A overdose is known to cause low blood pressure, fever, and 
pulmonary insufficiency. Synthetic formulations of vitamin A are reported to show less 
significant adverse events (Sporn and Lippman 2003). 
Sabichi and colleagues reported on a negative Phase III chemoprevention trial that showed 
that Fenretinide was well tolerated but failed to show a significant reduction in high 
incidence of recurrent non-muscle invasive urothelial bladder cancer (Sabichi, Lerner et al. 
2008). The authors speculated that variable of dosing and scheduling could have affected the 
clinical results. However, data from other randomized clinical studies in contralateral breast 
cancer, ovarian cancer and oral premalignancy suggested preventative benefit of fenretinide 
in these malignancies (Sporn and Lippman 2003). In another clinical prevention trial in 
bladder cancer, this agent was reported as being less toxic and more efficacious than the 
retinoid etretinate (Sabichi, Lerner et al. 2008).  
5.1.2 Vitamin B6 (Pyridoxine) 
Vitamin B6 has been evaluated in patients with history of recurrent UC. The Veterans 
Administration Study by Byar and group showed that Pyridoxine provided the best benefit 
(P=0.03) in a 3-ARM trial of intravesical thiotepa, Pyridoxine and placebo in 121 patients 
with history of recurrent NMIUBC (Byar and Blackard 1977). The authors also showed that 
the efficacy of Pyridoxine was equivalent to that of thiotepa. The theory was that Pyridoxine 
would correct the abnormalities of Tryptophan metabolism often found in patients with 
bladder cancer. This data was not supported in a large study of 291 patients in the EORTC 
trial of Pyridoxine versus placebo with neither treatment showing any benefit in preventing 
occurrence or recurrence of UC (Newling, Robinson et al. 1995). 
5.1.3 Vitamin C 
Ascorbic acid (Vitamin C) is a potent antioxidant reported in human epidemiological studies 
to prevent UC (Shibata, Paganini-Hill et al. 1992; Michaud, Spiegelman et al. 2000). The 
effect is also thought to be dose dependent, with improved benefit associated with higher 
consumption (Shibata, Paganini-Hill et al. 1992; Michaud, Spiegelman et al. 2000). Favorable 
reports are inconsistent in large cohorts. 
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5.1.4 Vitamin E 
Vitamin E is another antioxidant and is capable of reducing the carcinogenic N-nitroso 
compounds. Vitamin E has been reported in multiple studies to show benefit in reducing 
incidence of UC (Bruemmer, White et al. 1996; Michaud, Spiegelman et al. 2000). However, a 
meta-analysis by Miller and associates showed a potential increased in all-cause mortality 
associated with Vitamin E consumption (Miller, Pastor-Barriuso et al. 2005). This finding has 
dampened enthusiasm in the use of Vitamin E in chemoprevention for UC. 
5.1.5 Selenium  
There is no data yet suggesting a chemopreventive role for this oligoelement in UC. 
5.1.6 Mega dose vitamins 
Vitamins and dietary supplements/modifications have received slightly skewed publicity 
as alternative protective strategies against bladder cancer (Kamat and Lamm 2002). 
Individual vitamins including Vitamin A, and its analogues, Vitamin B6 (pyridoxine), 
Vitamin C, Vitamin E have been studied individually, reported and proposed as dietary 
supplements to prevent bladder cancer.as discussed above (Byar and Blackard 1977; 
Shibata, Paganini-Hill et al. 1992; Newling, Robinson et al. 1995; Studer, Jenzer et al. 1995; 
Decensi, Torrisi et al. 2000; Kamat and Lamm 2002; Castelao, Yuan et al. 2004; Miller, 
Pastor-Barriuso et al. 2005; Sabichi, Lerner et al. 2008). However, Lamm et al. combined 
mega doses of Vitamins A(40,000U), B6(100mg), C(2000 mg), E(400U) and Zinc (90mg) in 
a randomized 2x2 factorial design study in which 65 patients were randomized to receive 
intraderrmal BCG (Lamm, Riggs et al. 1994). Participants who demonstrated a response to 
induction intravesical BCG, were randomized to receive either Megadose vitamins or 
recommended daily allowance (RDA).The use of intradermal BCG did not appear to affect 
the clinical outcome. The Mega-dose vitamins treatment group showed a 50% reduction in 
overall NMIUBC recurrence at 4 years, The fact that there was no reduction in tumor 
recurrence rate in the Megadose vitamins group in the first 10 months, would suggest that 
these supplements/agents do not affect existing tumors but hinder the formation of new 
tumors. 
5.2 Difluoromethylornithine 
Difluoromethylornithine (DFMO) is a competitive inhibitor of ornithine decarboxylase 
(ODC) which is an enzyme that induces polyamine production necessary for tumor growth. 
A negative study was reported by Messing and associates who observed that daily oral 
supplementation of difluoromethylornithine (DFMO) compared with placebo, did not 
prevent frequent recurrence and progression of low grade NMIBC in patients who had been 
completely resected at enrollment (Messing, Kim et al. 2006). 
5.3 COX Inhibitors 
NSAID inhibit the cyclooxygenase (COX) enzyme, which breaks down arachidonic acid into 
leukotrienes and prostaglandins. Prostaglandin-2 can enhance cell proliferation, 
angiogenesis, and inhibit apoptosis (Sabichi and Lippman; Okey, Harper et al. 1998; Sporn 
and Lippman 2003). In vitro evidence suggests that there is an over expression of COX 2 
isoform in UC (Okey, Harper et al. 1998; Sporn and Lippman 2003). Theoretically, COX 2 
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isoform inhibitors could be used in chemoprevention of UC. Castelao and colleagues 
reported on a population-based, case-control study, in which they evaluated non-steroidal 
anti-inflammatory drugs (NSAIDs) in NMIUBC (Castelao, Yuan et al. 2000). This study 
found a 19% decrease in UC risk in those patients treated with oral agents, except those 
patients treated with phenacetine and pyrazolone derivatives (Castelao, Yuan et al. 2000). 
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Table 1. Summary of Reports (discussed above) of various Chemopreventative Strategies 
(refs:28-51) 
6. Future research and experimental cancer chemoprevention 
Research continues intensely in the evaluation of pharmaceutical agents for 
chemoprevention in bladder cancer. However, dietary supplement, multivitamins and 
phytochemicals/botanical agents are being evaluated in the prevention of many human 
cancers (Byar and Blackard 1977; Shibata, Paganini-Hill et al. 1992; Lamm, Riggs et al. 
1994; Newling, Robinson et al. 1995; Studer, Jenzer et al. 1995; Castelao, Yuan et al. 2000; 
Decensi, Torrisi et al. 2000; Michaud, Spiegelman et al. 2000; Kamat and Lamm 2002; 
Castelao, Yuan et al. 2004; Miller, Pastor-Barriuso et al. 2005; Messing, Kim et al. 2006; 
Sabichi, Lerner et al. 2008). Investigators have reported on results of screening strategies 
for synthetic pharmaceuticals in an experimental bladder cancer prevention model using 
the chemically-induced rat bladder tumor model (Sindhwani, Hampton et al. 2001; Lubet, 
You et al. 2006; Park, Kim et al. 2006; Tian, Wang et al. 2008; Parada, Reis et al. 2011).  
They reported that low dose aspirin and resveratrol were least effective in preventing 
large tumor formation, while naproxen and Iressa were most effective (Lubet, You et al. 
2006). 
In recent years there has been a substantial interest in the application of botanically 
derived phytochemicals to reduce the incidence of variety of human tumors. Intense 
research is ongoing to provide evidence-based recommendations to incorporate plant 
foods or botanical products or dietary modifications into the practice of clinical cancer 
chemoprevention. There is the salient speculation that Curcumin, a very popular Indian 
food spice, derived from the rhizome plant called curcuma longa Linn (Zingiberaceae), 
has been responsible for lower incidence of urothelial malignancies (Sindhwani, Hampton 
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They reported that low dose aspirin and resveratrol were least effective in preventing 
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2006). 
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research is ongoing to provide evidence-based recommendations to incorporate plant 
foods or botanical products or dietary modifications into the practice of clinical cancer 
chemoprevention. There is the salient speculation that Curcumin, a very popular Indian 
food spice, derived from the rhizome plant called curcuma longa Linn (Zingiberaceae), 
has been responsible for lower incidence of urothelial malignancies (Sindhwani, Hampton 
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et al. 2001; Tian, Wang et al. 2008)and lower rate of colorectal cancer (Tian, Wang et al. 
2008) in the populations that consume Curcumin as a staple part of their diet (Sindhwani, 
Hampton et al. 2001; Tian, Wang et al. 2008). Investigators have reported on Curcumin 
induced apoptosis in MBT-2 cells[56] G2/M cell cycle arrest in T-24 cells (Sindhwani, 
Hampton et al. 2001; Tian, Wang et al. 2008). Curcumin inhibition of intravesical tumor 
implant in mouse model (Sindhwani, Hampton et al. 2001) and prevention of OH-BBN 
induced bladder carcinogenesis in rodent, as well as inhibition of tumor development and 
growth in an intravesical murine bladder model (Sindhwani, Hampton et al. 2001; Tian, 
Wang et al. 2008). 
Seventy-five percent of all pharmaceuticals were discovered by studying the use of plants in 
traditional medicine. Of the 92 antitumor drugs approved by the FDA between 1983 and 
1994, 62 (67%) were either of natural origin or based on a natural compound (Chung, 
Anscher et al. 2001).  
7. Conclusions and clinical practice suggestions  
Bladder cancer is a common, but serious health problem globally. It is immensely impacted 
by environmental carcinogens, tobacco smokes, and infectious etiologies in endemic areas. 
The bladder urothelial cancer special features which include its susceptibility; 
carcinogenesis; frequent recurrences, and clinical presentation favor it as an ideal cancer for 
chemoprevention. Unfortunately, in bladder cancer there are still no definite interventions 
that have been shown to be effective, and research in this area has yielded no evidence-
based data to inform on strategies for systematic practice of bladder cancer prevention. The 
positive data from the clinical trials with vitamins individually or in combinations suggest 
that these agents might act not on established bladder cancer, but act to prevent occurring of 
new cancers, probably by hindering promotion of altered cells to overt cancer. Cessation of 
smoking will always remain the lofty but impractical goal of prevention strategies in 
urothelial bladder cancer; however, a plausible paradigm would suggest a chemoprevention 
strategy that should begin with the population approach that advocates a dietary program 
of increased consumption of fruits and vegetables which have been reported to reduce 
general cancer risk. The at–risk individual would embark on additional programs to 
reduce/eliminate the intensity of cumulative exposure to the carcinogens, dilution and 
elimination of bladder content by drinking plenty of water and urinating frequently, 
followed by introduction of the specific chemopreventive agent(s), probably in combination 
with the vitamins. 
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1. Introduction  
Bladder cancer is one of the most common cancers among men and women, with men being 
twice as likely affected from the disease (Jemal et al., 2005). The most common type of 
bladder cancer is transitional cell carcinoma (TCC), which is derived from the urothelium 
and constitutes more than 90 % of all bladder cancers (Bischoff & Clark, 2009). Cisplatin-
based combination therapy is the standard therapy for the treatment of advanced or 
metastatic bladder cancers (Cohen et al., 2006, Kaufman, 2006). However, the outcome of 
patients with metastatic bladder cancer remains poor, as tumors become resistant to 
cisplatin therapy. It is still not entirely known, which factors influence the response of 
bladder cancers to the drug and how this cancer acquires cisplatin resistance. Cisplatin is a 




Fig. 1. A: The chemical structure of cisplatin. B: After entering the cells, cisplatin is 
transformed to a positively charged molecule that reacts with DNA C: Cisplatin induced 
lesions. Cisplatin preferably binds to the nucleophilic N7 position of the purine bases 
guanine or adenine, leading to different types of lesions  including monoadducts, 
intrastrand crosslinks, interstrand crosslinks and DNA-protein crosslinks 
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After entering the cell, it is activated through a series of aquation reactions, in which the 
chloro ligands are replaced by water molecules (Figure 1B). The resulting positively charged 
molecule can react with nucleophilic sites on macromolecules, leading to DNA, RNA and 
protein adducts. It preferably binds to the nucleophilic N7 position of the purine bases 
guanine or adenine, which leads to different types of lesions (Figure 1C) (Jamieson & 
Lippard, 1999). In a first reaction, cisplatin binds to DNA, leading to monoadducts, which in 
a second reaction lead to the formation of DNA crosslinks. The most frequently observed 
cisplatin DNA lesions are DNA intrastrand crosslinks between adjacent guanines (65 % of 
all lesions) or intrastrand crosslinks between guanine and adenine (25 %). Interstrand 
crosslinks between two guanines on the opposite strands of DNA account for less than 5% 
of all cisplatin-induced lesions. It is still unknown, which of the various DNA lesions 
ultimately results in cell death (Chu, 1994, Jordan & Carmo-Fonseca, 2000, Kartalou & 
Essigmann, 2001).  
The efficacy of cisplatin in cancer chemotherapy, however, is limited by resistance. While 
cancers of the bladder, lung and ovary respond initially in 50 % or more of cases, they will 
almost inevitably relapse with drug-resistant disease. The mechanisms of cisplatin resistance 
have been studied in numerous cell culture models of cisplatin sensitive and resistant cancer 
cells lines. It has been shown that a cancer cell can develop cisplatin resistance through 
different mechanisms (Figure 2). Cisplatin resistance can be due to (i) changes in drug 
transport, leading to reduced cellular cisplatin accumulation, (ii) increased drug 
detoxification, also resulting in reduced cellular cisplatin accumulation, (iii) changes in 
DNA repair mechanisms including nucleotide excision repair, interstrand crosslink repair 
and mismatch repair, (iv) changes in DNA tolerance mechanisms, and finally (v) alterations 
in the apoptotic cell death pathways (Köberle et al., 2010, Rabik & Dolan, 2007, Siddik, 2003). 
In this chapter we describe and discuss the contribution of these mechanisms for the 
development of cisplatin resistance in bladder cancer cells in vitro and compare the 
preclinical findings to data obtained in clinical studies. A better understanding of the 
molecular basis of cisplatin resistance may lead to new anticancer strategies that will 
sensitize unresponsive bladder cancers to cisplatin-based chemotherapy.  
 
 
Fig. 2. Mechanisms of resistance towards cisplatin include: Reduced drug accumulation due 
to changes in drug uptake, efflux or detoxification. Alterations in DNA repair such as 
increased removal of the damage by nucleotide excision repair (NER) or interstrand 
crosslink repair (ICL repair) as well as decreased mismatch repair (MMR). Enhanced 
translesion synthesis (TLS) to tolerate unrepaired cisplatin lesions. Alterations in apoptosis 
pathways: changes in expression levels of pro- and anti-apoptotic proteins. 
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2. Intracellular drug accumulation as a determinant of cellular cisplatin 
sensitivity 
2.1 Cellular uptake and efflux of cisplatin 
Reduced intracellular cisplatin accumulation has been associated with cisplatin resistance in 
numerous cancer cell lines (Siddik, 2003). A correlation between intracellular cisplatin 
accumulation and cisplatin resistance was observed in a series of seven bladder cancer cell 
lines displaying different sensitivities to cisplatin (Koga et al., 2000). Similarly, using a bladder 
cancer cell line and its cisplatin-resistant subline, we found reduced accumulation of cisplatin 
in the resistant subline when compared to its parental cells (Köberle et al., 1996). Reduced 
accumulation may result from changes in drug transport or increased drug detoxification. 
Even though the exact mechanism by which cisplatin is taken up by the cells is not fully 
understood, both passive diffusion and active transport appear to be involved. For active 
transport the copper transporter 1 (Ctr1), which controls intracellular copper homeostasis, 
seems to play an important role (Kuo et al., 2007, Safaei, 2006). It has been reported that loss of 
Ctr1 lead to cisplatin resistance in various cell lines (Holzer et al., 2006, Ishida et al., 2002, Song 
et al., 2004). However, no data as to Ctr1 expression in bladder cancer cell lines or tumor tissue 
have been reported to date. Therefore, no conclusion about the importance of uptake for 
cisplatin response can be drawn for bladder cancer cells (Table 1). 
Increased efflux of cisplatin from the cell may also lead to resistance. Efflux pumps such as 
MRP1/2 (multidrug resistance associated protein) and p-glycoprotein/multidrug resistance 
1 (MDR1) are implicated as efflux pumps for cisplatin (Taniguchi et al., 1996, Yeh et al., 
2005). Tada and co-workers investigated the relationship between expression of p-
glycoprotein expression or MRP1/2 and drug sensitivity in 47 clinical samples of bladder 
cancer. They showed that expression of p-glycoprotein and MRP1/2 was higher in samples 
of recurrent tumors than in untreated primary tumors (Tada et al., 2002), indicating that 
increased efflux can contribute to the development of drug resistance and poor clinical 
outcome in bladder cancers (Table 1). 
2.2 Detoxification of cisplatin by intracellular thiol molecules 
Cisplatin resistance can be the result of increased inactivation of the drug by intracellular 
thiol-containing molecules such as glutathione and metallothionein. Glutathione is a 
tripeptide that plays an important role for the detoxification of xenobiotic substances by 
scavenging free radicals. Cisplatin can be conjugated with glutathione, which will inhibit its 
binding to DNA and other cellular molecules. This reaction is catalyzed by the glutathione-
S-transferase (GST) (Mannervik, 1987). Extensive studies about the role of the glutathione 
system for cisplatin resistance have been carried out in cell lines and in cancer tissue. A 
correlation between expression of the glutathione system and cisplatin resistance has been 
reported for ovarian, cervical and lung cancer cell lines (Jansen et al., 2002, Meijer et al., 
1992, Mellish et al., 1993). Attempts to correlate expression of the glutathione system with 
cisplatin resistance in bladder cancer cell lines showed inconsistent findings. Bedford and 
co-workers investigated the expression of the glutatione system in different bladder cancer 
cells lines and reported higher levels of glutathione and GST in the less sensitive cells 
(Bedford et al., 1987). Similarly, using a model system of a bladder cancer cell line and two 
derived sublines with acquired cisplatin resistance, Kotoh and co-workers observed an 
increased glutathione content and elevated GST activity in the sublines (Kotoh et al., 1997). 
Buthionine sulphoximine (BSO), which depletes glutathione, or indomethacin, which blocks 
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GST, significantly decreased the cisplatin resistance in T24 bladder cancer cells, which is yet 
another indication that the glutathione-based detoxification system is involved in cisplatin 
resistance in bladder cancer cells (Byun et al., 2005). However, no correlation between 
glutathione content and resistance to cisplatin was observed in a study by Koga and co-
workers (Koga et al., 2000). In this study, the expression of GST was also not significantly 
related to cisplatin resistance. In another study with bladder cancer cells, which were either 
sensitive or progressively resistant to cisplatin, it was observed that expression of GST was 
increased in the cisplatin resistant cells, however, the increase in glutathione contents did 
not reach statistical significance (Hour et al., 2000). In conclusion, bladder cancer cells may 
gain cisplatin resistance through up-regulation of GST, while glutathione contents seems to 
play a less important role for the development of cisplatin resistance. 
Metallothioneins (MT) belong to a family of low molecular weight, thiol-rich proteins that 
play a role in metal homeostasis and detoxification (Kagi & Schaffer, 1988). MTs can bind to 
cisplatin, leading to the inactivation of the drug. For numerous cancer cell lines (derived 
from prostate, lung, ovary and cervical cancer), a correlation between MT expression and 
cisplatin resistance has been observed (Kasahara et al., 1991, Kondo et al., 1995, Mellish et 
al., 1993, Surowiak et al., 2007). For bladder cancer cell lines cisplatin resistance, was also 
correlated with increased levels of MT (Siegsmund et al., 1999, Singh et al., 1995). A role of 
MT for cisplatin resistance in bladder cancer has been proposed by Satoh and co-workers 
(Satoh et al., 1994). The authors investigated the effect of modulation of the MT levels for the 
antitumor activity of cisplatin in nude mice inoculated with human bladder cancer cells. 
While increasing MT levels reduced the antitumor activity of cisplatin, decreased levels of 
MT diminished the resistance to the drug (Satoh et al., 1994). Using a different bladder 
tumor model in mice, it was also suggested that MT might play a role for acquired 
resistance towards cisplatin (Saga et al., 2004). The clinical relevance of MT levels for 
cisplatin chemotherapy in bladder cancers has been investigated in a number of studies. In 
an investigation involving 118 patients with bladder cancer, it was observed that 
overexpression of MT was associated with a poorer outcome from cisplatin-based 
chemotherapy (Siu et al., 1998). Similarly, for intrinsic cisplatin resistance of urinary tract 
TCCs, an involvement of MT has been suggested (Kotoh et al., 1994), and MT 
overexpression was proposed to be a mechanism for cisplatin resistance in bladder cancer 
tissue (Wood et al., 1993). In line with this observations are more recent studies, which also 
reported that high levels of MT expression in bladder cancer tissue were correlated with 
poor survival after cisplatin chemotherapy (Hinkel et al., 2008, Wülfing et al., 2007). Taken 
together, the data indicate that high levels of MT in bladder cancers might be a major 
problem for effective cisplatin-based chemotherapy. In our opinion, expression of MT is one 
of the main cellular factors for both intrinsic and acquired cisplatin resistance in bladder 
cancers (Table 1).  
3. DNA repair and cisplatin resistance 
The contribution of DNA repair for cisplatin resistance has been investigated for many 
years. In model systems of tumor cell lines and sublines with acquired cisplatin resistance, 
increased removal of cisplatin induced lesions has been observed in the sublines. For 
example, ovarian cancer cells with acquired resistance towards cisplatin show an increased 
removal of cisplatin induced lesions in comparison with their cisplatin sensitive 
counterparts (Johnson et al., 1994a, Johnson et al., 1994b, Parker et al., 1991). Similarly, colon  
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acquired resistance to cisplatin might be related to the increased DNA repair capacity. In 
contrast, when we investigated DNA damage removal in a bladder cancer cell line with 
acquired cisplatin resistance, we observed no enhanced repair compared to the parental cell 
line, suggesting that this bladder cancer cell line did not acquire resistance to cisplatin by 
increasing the DNA repair capacity (Köberle et al., 1996). However, when we compared 
bladder cancer cell lines with cisplatin sensitive testis tumor cells, we observed that bladder 
cancer cells are proficient in removing cisplatin damage from the DNA, while testis tumor 
cells were repair deficient (Köberle et al., 1997), supporting the hypothesis that susceptibility 
to cisplatin might be related to the repair capacity.  
3.1 Nucleotide excision repair 
Cisplatin-induced GpG and GpA DNA intrastrand crosslinks are repaired by nucleotide 
excision repair (NER). NER is a multistep mechanism, which deals with bulky helix-
distorting lesions such as UV-induced cyclobutane pyrimidine dimers and 6-4 
photoproducts, and DNA lesions induced by many chemotherapeutic drugs (Gillet & 
Schärer, 2006, Shuck et al., 2008, Wood et al., 2000). The repair of the lesions begins with 
recognition of the damage and incision on both sides of the lesion, followed by DNA 
synthesis to replace the excised fragment. The core incision reaction requires the protein 
factors XPA, RPA, XPC-HR23B, TFIIH, ERCC1-XPF and XPG (Aboussekhra et al., 1995). It is 
possible to carry out the core NER reaction in a cell free system using cellular protein 
extracts (Shivji et al., 1999, Shivji et al., 2005). Using this system, it could be confirmed that 
the increased removal of cisplatin lesions, which has been observed in cisplatin resistant 
ovarian cancer cells, is in fact due to enhanced NER (Ferry et al., 2000). We found that 
cellular protein extracts of a bladder cancer cell line were proficient for NER (Köberle et al., 
1999). Furthermore, the core NER proteins are expressed to a similar extent in bladder 
cancer cell lines compared to normal non-cancerous cells (Köberle et al., 1999, Welsh et al., 
2004). The removal of cisplatin induced DNA platination, which we previously observed in 
bladder cancer cell lines (Köberle et al., 1997), is therefore, at least in part, due to NER 
proficiency in these cells. 
Conclusive evidence for functionally increased NER in cisplatin-resistant cancers, however, 
has not yet been presented. This is due to the lack of methods to easily and reliably measure 
NER activities in tissue samples. For example, even in protein extracts prepared from cell 
lines, a significant variability in NER capacity is observed. Even more, in protein extracts 
prepared from biopsies of human ovarian carcinoma, Jones and co-workers found that the 
NER capacity varied significantly by as much as ten-fold (Jones et al., 1994). This could be 
due to either inter-individual variations or to technical problems to obtain active extracts 
from tissue material. Therefore, as measuring NER capacity in tissue samples is a 
challenging task, a different approach is to investigate the expression of NER factors on the 
mRNA or protein level and attempt to correlate these with response to chemotherapy. In 
these studies, special emphasis was given to ERCC1, the first human DNA repair gene 
cloned (Westerveld et al., 1984). In preclinical studies, a correlation between ERCC1 
expression and cisplatin resistance has been presented (Li et al., 1998, Li et al., 2000, Metzger 
et al., 1998). By demonstrating that down-regulation of ERCC1 by siRNA sensitized bladder 
cancer cell lines to cisplatin, we could confirm the importance of ERCC1 for cisplatin 
resistance in bladder cancer cells (Usanova et al., 2010). 
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In cancer tissues, ERCC1 mRNA or protein levels show an inverse correlation with the 
response to platinum therapy or overall survival. High ERCC1 mRNA levels are associated 
with resistance to cisplatin-based chemotherapy in ovarian, cervical, gastric, colorectal, head 
and neck, esophageal and lung cancer (Dabholkar et al., 1992, Dabholkar et al., 1994, 
Gossage & Madhusudan, 2007, Handra-Luca et al., 2007, Jun et al., 2008, Kim et al., 2008, 
Metzger et al., 1998, Olaussen et al., 2006, Weberpals et al., 2009). Based on these findings, it 
was suggested that ERCC1 can be used as a predictive and prognostic marker for the 
outcome of cisplatin-based chemotherapy. For patients with advanced bladder cancer, a 
significantly higher survival rate was reported when ERCC1 levels in the tumor tissue were 
low (Bellmunt et al., 2007). However, in another study, no significant difference in overall 
survival between bladder cancer patients with ERCC1 negative tumors and ERCC1 positive 
tumors was observed (Kim et al., 2010). On the other hand, the authors reported that 
progression free survival was longer in patients with ERCC1 negative bladder cancers 
compared to ERCC1 positive cancers (Kim et al., 2010). Based on these conflicting results, it 
is difficult to conclude that ERCC1 expression in bladder cancer negatively contributes to 
the clinical outcome. Furthermore, even though ERCC1 positive tumors would be expected 
to have a high NER capacity, and ERCC1 negative tumors would be expected to have low 
NER capacity, these conclusions must be drawn with caution, as functional NER assays for 
tissue material are still missing. It therefore remains speculative whether altered ERCC1 
levels have an impact on NER in tumor tissue. Therefore, the question about the 
contribution of enhanced NER for cisplatin resistance in cancers, especially in bladder 
cancers, remains to be solved (Table 1).  
3.2 Interstrand crosslink repair 
Besides intrastrand adducts, cisplatin induces interstrand crosslinks (ICLs), which are 
removed by ICL repair, a process less understood than NER (McHugh et al., 2001). Repair of 
ICLs is a challenging problem for cells. In bacteria and lower eukaryotes, NER and 
homologous recombination are involved in ICL repair (Cole, 1973, Jachymczyk et al., 1981). In 
mammalian cells, these both pathways may also operate (De Silva et al., 2000). Besides that, 
mammalian cells have additional pathways of ICL repair involving DNA polymerases that can 
bypass the lesion (Sarkar et al., 2006, Shen et al., 2006, Zheng et al., 2005). A contribution of 
increased ICL repair for acquired resistance to cisplatin has been described for ovarian cancer 
cells in culture (Zhen et al., 1992). It also seems to play a role for clinical cisplatin resistance, as 
in paired tumor samples obtained prior to treatment and at relapse following platinum 
chemotherapy, increased repair of cisplatin ICLs in cells of relapsed ovarian cancer was 
observed (Wynne et al., 2007). We found that bladder cancer cell lines, which are relatively 
resistant to cisplatin, are proficient in repairing ICLs (Usanova et al., 2010). Biochemical and 
cell biological data implicate that ERCC1 is not only involved in NER, but also in ICL repair 
(Kuraoka et al., 2000, Niedernhofer et al., 2004, Sijbers et al., 1996). Our own experiments 
revealed that down-regulation of ERCC1 by siRNA affected ICL repair in the bladder cancer 
cell lines and rendered the cells more sensitive to cisplatin supporting the notion about the 
importance of ICL repair for cisplatin resistance in cancer cells. However, to date there is no 
information as to ICL repair in bladder cancer tissue (Table 1). 
3.3 Translesion synthesis (TLS) 
As described in 3.1 and 3.2, cisplatin damage is removed by NER and ICL repair. However, 
some lesions may remain. A mechanism, by which cells can tolerate unrepaired DNA 
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NER activities in tissue samples. For example, even in protein extracts prepared from cell 
lines, a significant variability in NER capacity is observed. Even more, in protein extracts 
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due to either inter-individual variations or to technical problems to obtain active extracts 
from tissue material. Therefore, as measuring NER capacity in tissue samples is a 
challenging task, a different approach is to investigate the expression of NER factors on the 
mRNA or protein level and attempt to correlate these with response to chemotherapy. In 
these studies, special emphasis was given to ERCC1, the first human DNA repair gene 
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lesions, is translesion synthesis (TLS). TLS is carried out by a group of specialized DNA 
polymerases, which are capable of bypassing unrepaired DNA lesions. For mammalian cells 
pol η (POLH), pol ι (POLI), pol κ (POLK), REV1 and pol ζ (REV3 and REV7) are the main 
TLS polymerases, which have been shown to possess different substrate specificity. 
Depending on the type of damage, different combinations of TLS polymerases act in concert 
to bypass the DNA lesions (Shachar et al., 2009). Cisplatin GpG intrastrand crosslinks seem 
to be bypassed by pol η and pol  ζ (Alt et al., 2007, Shachar et al., 2009). For pol κ conflicting 
results have been reported. While an in vitro assay suggests that pol κ is unable to bypass a 
GpG intrastrand crosslink, in vivo TLS assays implicated pol κ in combination with pol η for 
TLS across cisplatin GpG intrastrand crosslinks (Ohashi et al., 2000, Shachar et al., 2009). The 
importance of TLS in the tolerance towards cisplatin has been shown in cell lines deficient in 
TLS polymerase activity (Cruet-Hennequart et al., 2008, Cruet-Hennequart et al., 2009, 
Albertella et al., 2005a, Roos et al., 2009, Wittschieben et al., 2006). Similarly, TLS 
polymerases may play a role for cisplatin resistance in tumor samples (Albertella et al., 
2005b, Ceppi et al., 2009, Wang et al., 2009). However, no data have been reported as to the 
expression of TLS polymerases in bladder cancer cell lines and tumor specimens. We 
therefore can neither include nor exclude TLS polymerases as a factor determining efficacy 
of cisplatin therapy in the clinic (Table 1). 
3.4 DNA mismatch repair (MMR) 
Mismatch repair (MMR) is the pathway that removes mispaired nucleotides or 
insertion/deletion loops, which arise during DNA replication or as a result of damage to 
DNA. MMR consists of following steps: (1) recognition of the mismatch, (2) identification 
and excision of the mispairs or looped intermediates, and (3) resynthesis of the excised 
strand (Kunkel & Erie, 2005). In early investigations it has been observed that loss of MMR 
led to resistance to cisplatin and other platinating agents (Aebi et al., 1996, Fink et al., 1996). 
A possible explanation for the association of absence of a repair mechanism with increased 
drug resistance was the observation that MMR proteins can bind to cisplatin damage 
possibly leading to futile repair and therefore increased drug lethality. The mismatch repair 
complex MutS (which is a heterodimer containing MSH2 and MSH6) binds to cisplatin 
DNA lesions in vitro (Duckett et al., 1996, Mello et al., 1996). Binding of MutS to cisplatin 
crosslinks could start the MMR process by recruiting the mismatch repair complex MutL 
(consisting of MLH1 and PMS2). It is assumed that lethal intermediates arise by the attempt 
of the MMR machinery to remove cisplatin lesions, and these lethal intermediates might set 
off a futile MMR cycle, similar to what has been reported for methylating agents (Dunkern 
et al., 2001). An alternative model suggests that binding of the MMR complex to cisplatin 
DNA damage might cause direct activation of the DNA damage response (DDR). A third 
model is based on the finding that TLS polymerases can bypass of 1,2-intrastrand crosslinks 
(Alt et al., 2007, Shachar et al., 2009). Since TLS polymerases are error prone causing mis-
incorporation of bases, mismatches will be generated that are recognised by the MutS 
complex. This in turn causes a futile repair cycle that triggers DDR. New data suggest that 
mitochondrial pro-death signaling involving cytochrome c and caspases-9 and -3 is required 
for the execution of MMR protein-mediated induction of cell death by cisplatin (Topping et 
al., 2009). The importance of MMR for cisplatin resistance has been investigated in a number 
of cancer cell lines, however, with conflicting results. On the one hand it was observed that 
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MMR deficient cell lines were more tolerant to cisplatin (Bignami et al., 2003, Fink et al., 
1996, Papouli et al., 2004). This was explained by the hypothesis that cisplatin lesions are not 
processed into lethal intermediates. In other studies, however, it was shown that defective 
MMR is only a minor contributor for the cisplatin resistance phenotype or is not involved at 
all ( Branch et al., 2000, Claij & te Riele, 2004, Massey et al., 2003). We found that the MMR 
protein MSH2 was expressed at lower levels in bladder cancer cells compared to cisplatin 
sensitive testis tumor cells. However, no difference was observed in the expression level of 
the MMR proteins hMLH1 and PMS2 in this model system of cisplatin resistant and 
sensitive cell lines. Even more, no difference in the levels of MSH2, MLH1 and PMS2 was 
observed in parental RT112 bladder cancer cells and the subline with acquired cisplatin 
resistance (Köberle, unpublished results), suggesting that MMR may not be of importance 
for cisplatin resistance in our model system.  
The clinical relevance of loss of MMR for cisplatin chemotherapy has been investigated in 
a number of clinical studies, and it was concluded that MMR deficiency is associated with 
chemotherapy resistance in ovarian and testicular germ cell tumors (Gifford et al., 2004, 
Helleman et al., 2006, Wei et al., 2002). In 115 patients with bladder cancers, the 
expression pattern of hMSH2 protein was investigated and a reduced expression of 
hMSH2 was significantly more frequent in high grade tumors (Jin et al., 1999). Similarly, 
Catto and co-workers reported that reduced expression of hMLH1 and hMSH2 was seen 
more commonly in muscle invasive and high grade bladder cancer (Catto et al., 2003). In 
contrast, in a set of 130 urothelial carcinomas of the bladder, hMSH2 and hMSH6 negative 
tumors were found to have a favorable impact on overall patient survival (Mylona et al., 
2008). In a number of studies, the degree of microsatellite instability (MSI) was 
investigated in different cancer tissues, such as colorectal-, ovarian- and gastric carcinoma 
(Dietmaier et al., 1997, Ichikawa et al., 1999, Ottini et al., 1997). MSI is the result from 
inactivating mutations in MMR genes and suggests MMR deficiency (Parsons et al., 1993, 
Strand et al., 1993). However, MSI has been observed only infrequently in bladder cancer 
tissues (Bonnal et al., 2000, Gonzalez-Zulueta et al., 1993, Hartmann et al., 2002). 
Furthermore, reduced expression of hMLH1 and hMSH2 was not correlated with MSI in 
bladder cancer (Catto et al., 2003). Based on these conflicting data, a conclusion as to 
whether MMR impacts the development of cisplatin resistance in bladder cancer in the 
clinic cannot be drawn to date (Table 1).  
4. DNA damage response and apoptosis pathways in cisplatin resistance 
It is known that cisplatin treatment induces apoptosis in cells, thereby killing the cells (Chu, 
1994). The apoptotic pathways, which are induced following cisplatin treatment, were 
extensively studied, hence not yet fully understood. Cisplatin-induced apoptosis may be 
triggered through the extrinsic death receptor pathway, which is mediated through the JNK 
signaling cascade. Alternatively, the intrinsic mitochondrial pathway may be induced, 
mediated through p53 and anti- or pro-apoptotic members of the Bcl-2 family proteins 
(Brozovic et al., 2004, Pabla et al., 2008, Siddik, 2003). Decreased expression or loss of pro-
apoptotic proteins may result in cisplatin resistance, similarly may increased expression of 
anti-apoptotic proteins lead to cisplatin resistance (Brozovic & Osmak, 2007). The 
contribution of these mechanisms for preclinical and clinical cisplatin resistance of bladder 
cancer cells will be discussed in the following section. 
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lesions, is translesion synthesis (TLS). TLS is carried out by a group of specialized DNA 
polymerases, which are capable of bypassing unrepaired DNA lesions. For mammalian cells 
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al., 2009). The importance of MMR for cisplatin resistance has been investigated in a number 
of cancer cell lines, however, with conflicting results. On the one hand it was observed that 
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MMR deficient cell lines were more tolerant to cisplatin (Bignami et al., 2003, Fink et al., 
1996, Papouli et al., 2004). This was explained by the hypothesis that cisplatin lesions are not 
processed into lethal intermediates. In other studies, however, it was shown that defective 
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resistance (Köberle, unpublished results), suggesting that MMR may not be of importance 
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tumors were found to have a favorable impact on overall patient survival (Mylona et al., 
2008). In a number of studies, the degree of microsatellite instability (MSI) was 
investigated in different cancer tissues, such as colorectal-, ovarian- and gastric carcinoma 
(Dietmaier et al., 1997, Ichikawa et al., 1999, Ottini et al., 1997). MSI is the result from 
inactivating mutations in MMR genes and suggests MMR deficiency (Parsons et al., 1993, 
Strand et al., 1993). However, MSI has been observed only infrequently in bladder cancer 
tissues (Bonnal et al., 2000, Gonzalez-Zulueta et al., 1993, Hartmann et al., 2002). 
Furthermore, reduced expression of hMLH1 and hMSH2 was not correlated with MSI in 
bladder cancer (Catto et al., 2003). Based on these conflicting data, a conclusion as to 
whether MMR impacts the development of cisplatin resistance in bladder cancer in the 
clinic cannot be drawn to date (Table 1).  
4. DNA damage response and apoptosis pathways in cisplatin resistance 
It is known that cisplatin treatment induces apoptosis in cells, thereby killing the cells (Chu, 
1994). The apoptotic pathways, which are induced following cisplatin treatment, were 
extensively studied, hence not yet fully understood. Cisplatin-induced apoptosis may be 
triggered through the extrinsic death receptor pathway, which is mediated through the JNK 
signaling cascade. Alternatively, the intrinsic mitochondrial pathway may be induced, 
mediated through p53 and anti- or pro-apoptotic members of the Bcl-2 family proteins 
(Brozovic et al., 2004, Pabla et al., 2008, Siddik, 2003). Decreased expression or loss of pro-
apoptotic proteins may result in cisplatin resistance, similarly may increased expression of 
anti-apoptotic proteins lead to cisplatin resistance (Brozovic & Osmak, 2007). The 
contribution of these mechanisms for preclinical and clinical cisplatin resistance of bladder 
cancer cells will be discussed in the following section. 
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4.1 p53 and cisplatin resistance of bladder cancer cells 
The tumor suppressor protein p53 is activated in cancer cells after treatment with 
chemotherapeutic drugs and has a central role for the induction of apoptosis. The influence 
of the p53 status for cisplatin resistance has been studied in numerous cancer cell lines, 
however, with contradictory results. While no correlation between cisplatin resistance and 
p53 status was observed in testis and ovarian cancer cell lines (Burger et al., 1997, De Feudis 
et al., 1997), other studies using breast, lung, colon, kidney, ovarian, leukaemia, melanoma 
and prostate cancer cell lines showed that p53 mutated cell lines were more resistant to 
cisplatin compared to p53 wild-type cell lines (Branch et al., 2000, O'Connor et al., 1997). 
Contradictory results about the importance of p53 status for cisplatin resistance are also 
reported for bladder cancer cells. Comparing the cisplatin sensitivity in bladder cancer cell 
lines with different p53 status revealed that p53 wild type bladder cancer cells were more 
susceptible to cisplatin, while mutant cell lines were resistant (Kawasaki et al., 1996, 
Konstantakou et al., 2009). In line with these findings, it was also shown that cisplatin 
resistance in bladder cancer cells was enhanced by overexpression of mutant p53 protein 
(Miyake et al., 1999). Our own studies revealed that cisplatin resistant bladder cancer cell 
lines were mutated for p53, while cisplatin sensitive testis tumor cells showed functional 
p53 activity after cisplatin treatment (unpublished results). Contrary to these observations, 
Chang and co-workers investigated the effect of p53 mutations for drug sensitivity and 
found that bladder cancer cell lines expressing various human mutated p53 proteins 
displayed enhanced cisplatin sensitivity (Chang & Lai, 2001). Even more, when cisplatin 
sensitivity was measured in a series using 89 bladder cancer cell lines with different p53 
status, it was found that p53 heterozygous cells were most susceptible to cisplatin (Chang & 
Lai, 2000). Altogether, we therefore conclude that, at least in bladder cancer cell lines, p53 
mutations do not always lead to the development of cisplatin resistance.  
In a number of studies it has been investigated whether the p53 status can be a predictor for 
the response to platinum-based chemotherapy in the clinic. Gadducci and co-workers 
reported that ovarian cancer patients with tumors harbouring p53 mutations experience a 
lower chance to achieve a complete response following cisplatin therapy, while patients 
with wild-type p53 tumors have a good chance to respond (Gadducci et al., 2002). In bladder 
cancers, mutations in the p53 gene are a frequent event (Esrig et al., 1994). However, there 
are conflicting results whether the p53 status can be used to predict the responsiveness to 
cisplatin treatment in bladder cancers (Nishiyama et al., 2008). On the one hand, it was 
shown that in a cohort of patients with TCC only the patients with altered p53 in the tumor 
would benefit from adjuvant cisplatin chemotherapy (Cote et al., 1997). On the other hand, 
p53 immunoreactivity could not be used to predict tumor response and patient survival in a 
cohort of 83 patients (Qureshi et al., 1999). Similarly, no clear conclusion as to whether p53 
wild type was related to increased resistance or increased responsiveness could be drawn by 
Watanabe and co-workers in a study investigating 75 tumor specimens (Watanabe et al., 
2004). Therefore, it cannot be concluded to date that the p53 status influences cisplatin 
responsiveness in bladder cancers (Table 1). 
4.2 Anti-apoptotic proteins and cisplatin resistance 
Cisplatin resistance has been associated with the expression of a number of anti-apoptotic 
proteins, both in cell cultures and in clinical samples. Expression of the anti-apoptotic 
proteins Bcl-2 and Bcl-xL resulted in cisplatin resistance in ovarian cancer cell lines (Yang et 
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al., 2004). In bladder cancer cell lines, which were resistant to cisplatin and etoposide, 
Chresta and co-workers also observed high levels of Bcl-2 (Chresta et al., 1996). In addition, 
levels of the pro-apoptotic protein Bax were very low in the three bladder cancer cell lines 
under investigation (Chresta et al., 1996). We also observed low endogenous levels of Bax in 
cisplatin resistant bladder cancer cells compared to cisplatin sensitive testis tumor cell lines 
(unpublished observations). Furthermore, cisplatin treatment lead to translocation of Bax to 
the mitochondrial membrane in testis tumor cells, which was not observed in bladder cancer 
cell lines (unpublished observations). An association between cisplatin resistance, Bcl-2 
expression and Bax translocation has also been proposed by Cho and co-workers who 
observed in cisplatin resistant bladder cancer sublines that Bcl-2 was up-regulated, which 
resulted in inhibition of Bax translocation to the mitochondrial membrane and reduced cell 
death (Cho et al., 2006). To elucidate the role of Bcl-2 for cisplatin resistance in bladder 
cancer cells, Miake and co-workers transfected the human bladder transitional cell 
carcinoma line KoTTC-1 with an expression plasmid for Bcl-2 and observed that 
overexpression conferred resistance to cisplatin (Miyake et al., 1998). Stably expressing Bcl-2 
cells were then injected  subcutaneously into nude mice to determine whether the Bcl-2 
status can affect the efficacy of cisplatin treatment. Using this tumor cell implantation 
model, the authors could show that mice with tumors expressing Bcl-2 have an inferior 
prognosis compared to mice with tumors with no detectable Bcl-2 protein (Miyake et al., 
1998). Altogether, the data suggest that Bcl-2 might  be one of the factors influencing 
cisplatin resistance in bladder cancer cells. In proof of principle experiments, Bcl-2 levels in 
bladder cancer cells were decreased using Bcl-2 antisense oligonucleotides. These studies 
revealed that down-regulation of Bcl-2 expression resulted in a significant increase in 
toxicity of cisplatin in various bladder cancer cell lines (Bolenz et al., 2007, Hong et al., 2002), 
supporting the notion that expression of Bcl-2 may be associated with cisplatin resistance in 
bladder cancer cells (Table 1). 
Expression levels of the anti-apoptotic factors Bcl-2 and Bcl-xL were determined in tumor 
samples from a diverse range of tissue to investigate for a possible involvement in clinical 
resistance, however, with contradictory results. While in ovarian carcinoma patients, 
expression of Bcl-xL was correlated with a decreased response to platinum chemotherapy 
(Williams et al., 2005), no association between response and Bcl-2 expression was observed 
in breast cancer patients (Parton et al., 2002). For bladder cancers, the clinical relevance of 
Bcl-2 expression for cisplatin resistance has been shown by Cooke and co-workers. The 
authors observed in a cohort of 51 patients with bladder cell carcinoma who received neo-
adjuvant cisplatin chemotherapy that patients with Bcl-2 negative tumors had a significantly 
better prognosis (Cooke et al., 2000). An improved survival of patients with Bcl-2 negative 
tumors was also observed in a cohort of 89 patients with invasive bladder cancers who 
received cisplatin-based chemotherapy (Kong et al., 1998). In conclusion, expression of the 
anti-apoptotic factor Bcl-2 appears to affect the efficacy of cisplatin therapy for bladder 
cancers and might be used as a prognostic marker to predict the response to treatment. 
The inhibitor of apoptosis (IAP) gene family encodes proteins, which have been reported to 
play an important role in cellular drug resistance. These proteins have been shown to be 
endogenous inhibitors of caspases, thus resulting in inhibition of cell death. Survivin, one of 
the members of the IAP family, is activated by cisplatin, which in part protects cells from 
cisplatin-induced apoptosis (Belyanskaya et al., 2005). An associated between survivin levels 
and cisplatin resistance has been reported for a number of cell lines derived from various 
cancer tissues including thyroid, lung and colon (Tirro et al., 2006) (Belyanskaya et al., 2005, 
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The tumor suppressor protein p53 is activated in cancer cells after treatment with 
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p53 activity after cisplatin treatment (unpublished results). Contrary to these observations, 
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lower chance to achieve a complete response following cisplatin therapy, while patients 
with wild-type p53 tumors have a good chance to respond (Gadducci et al., 2002). In bladder 
cancers, mutations in the p53 gene are a frequent event (Esrig et al., 1994). However, there 
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shown that in a cohort of patients with TCC only the patients with altered p53 in the tumor 
would benefit from adjuvant cisplatin chemotherapy (Cote et al., 1997). On the other hand, 
p53 immunoreactivity could not be used to predict tumor response and patient survival in a 
cohort of 83 patients (Qureshi et al., 1999). Similarly, no clear conclusion as to whether p53 
wild type was related to increased resistance or increased responsiveness could be drawn by 
Watanabe and co-workers in a study investigating 75 tumor specimens (Watanabe et al., 
2004). Therefore, it cannot be concluded to date that the p53 status influences cisplatin 
responsiveness in bladder cancers (Table 1). 
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Cisplatin resistance has been associated with the expression of a number of anti-apoptotic 
proteins, both in cell cultures and in clinical samples. Expression of the anti-apoptotic 
proteins Bcl-2 and Bcl-xL resulted in cisplatin resistance in ovarian cancer cell lines (Yang et 
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al., 2004). In bladder cancer cell lines, which were resistant to cisplatin and etoposide, 
Chresta and co-workers also observed high levels of Bcl-2 (Chresta et al., 1996). In addition, 
levels of the pro-apoptotic protein Bax were very low in the three bladder cancer cell lines 
under investigation (Chresta et al., 1996). We also observed low endogenous levels of Bax in 
cisplatin resistant bladder cancer cells compared to cisplatin sensitive testis tumor cell lines 
(unpublished observations). Furthermore, cisplatin treatment lead to translocation of Bax to 
the mitochondrial membrane in testis tumor cells, which was not observed in bladder cancer 
cell lines (unpublished observations). An association between cisplatin resistance, Bcl-2 
expression and Bax translocation has also been proposed by Cho and co-workers who 
observed in cisplatin resistant bladder cancer sublines that Bcl-2 was up-regulated, which 
resulted in inhibition of Bax translocation to the mitochondrial membrane and reduced cell 
death (Cho et al., 2006). To elucidate the role of Bcl-2 for cisplatin resistance in bladder 
cancer cells, Miake and co-workers transfected the human bladder transitional cell 
carcinoma line KoTTC-1 with an expression plasmid for Bcl-2 and observed that 
overexpression conferred resistance to cisplatin (Miyake et al., 1998). Stably expressing Bcl-2 
cells were then injected  subcutaneously into nude mice to determine whether the Bcl-2 
status can affect the efficacy of cisplatin treatment. Using this tumor cell implantation 
model, the authors could show that mice with tumors expressing Bcl-2 have an inferior 
prognosis compared to mice with tumors with no detectable Bcl-2 protein (Miyake et al., 
1998). Altogether, the data suggest that Bcl-2 might  be one of the factors influencing 
cisplatin resistance in bladder cancer cells. In proof of principle experiments, Bcl-2 levels in 
bladder cancer cells were decreased using Bcl-2 antisense oligonucleotides. These studies 
revealed that down-regulation of Bcl-2 expression resulted in a significant increase in 
toxicity of cisplatin in various bladder cancer cell lines (Bolenz et al., 2007, Hong et al., 2002), 
supporting the notion that expression of Bcl-2 may be associated with cisplatin resistance in 
bladder cancer cells (Table 1). 
Expression levels of the anti-apoptotic factors Bcl-2 and Bcl-xL were determined in tumor 
samples from a diverse range of tissue to investigate for a possible involvement in clinical 
resistance, however, with contradictory results. While in ovarian carcinoma patients, 
expression of Bcl-xL was correlated with a decreased response to platinum chemotherapy 
(Williams et al., 2005), no association between response and Bcl-2 expression was observed 
in breast cancer patients (Parton et al., 2002). For bladder cancers, the clinical relevance of 
Bcl-2 expression for cisplatin resistance has been shown by Cooke and co-workers. The 
authors observed in a cohort of 51 patients with bladder cell carcinoma who received neo-
adjuvant cisplatin chemotherapy that patients with Bcl-2 negative tumors had a significantly 
better prognosis (Cooke et al., 2000). An improved survival of patients with Bcl-2 negative 
tumors was also observed in a cohort of 89 patients with invasive bladder cancers who 
received cisplatin-based chemotherapy (Kong et al., 1998). In conclusion, expression of the 
anti-apoptotic factor Bcl-2 appears to affect the efficacy of cisplatin therapy for bladder 
cancers and might be used as a prognostic marker to predict the response to treatment. 
The inhibitor of apoptosis (IAP) gene family encodes proteins, which have been reported to 
play an important role in cellular drug resistance. These proteins have been shown to be 
endogenous inhibitors of caspases, thus resulting in inhibition of cell death. Survivin, one of 
the members of the IAP family, is activated by cisplatin, which in part protects cells from 
cisplatin-induced apoptosis (Belyanskaya et al., 2005). An associated between survivin levels 
and cisplatin resistance has been reported for a number of cell lines derived from various 
cancer tissues including thyroid, lung and colon (Tirro et al., 2006) (Belyanskaya et al., 2005, 
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Hopkins-Donaldson et al., 2006, Pani et al., 2007). Bladder cancer cell lines showed a high 
expression of survivin compared to non-cancerous uro-epithelial cells (Yang et al., 2010).  
In clinical studies it has been investigated whether survivin might serve as a prognostic 
marker to predict clinical outcome. In tumor material of 30 patients with advanced bladder 
cancer, survivin expression has been identified as a marker for poor clinical outcome (Als et 
al., 2007). Similarly, Shariat and co-workers identified survivin as an independent predictor 
for recurrence of the disease in a cohort of 726 patients (Shariat et al., 2009). 
The X-linked inhibitor of apoptosis (XIAP) is another member of the family of IAP proteins. 
Preclinical studies indicate that XIAP expression may be associated with cisplatin resistance. 
In ovarian carcinoma cell lines, for example, enhanced expression of XIAP was connected to 
the acquisition of cisplatin resistance (Mansouri et al., 2003). Bilim and co-workers reported 
considerable levels of XIAP in a panel of 4 bladder cancer cell lines, which are known to be 
cisplatin resistant (Bilim et al., 2003). The clinical relevance of XIAP for the efficacy of 
cisplatin treatment has been studied in a number of studies. Parton and co-workers found 
no association between XIAP expression and response to chemotherapy in ovarian cancer 
tissue (Parton et al., 2002). An inverse correlation between XIAP expression in the cancer 
tissue and pathological response was observed for patients with advanced bladder cancer 
(Pinho et al., 2009). The correlation, however, was not statistically significant. This study 
also demonstrated that bladder cancer patients with high levels of XIAP-associated factor 1 
protein (XAF1) in the cancer tissue had a better prognosis after cisplatin based 
chemotherapy (Pinho et al., 2009). XAF1 inhibits the anti-caspase activity of XIAP, therefore 
antagonizing the anti-apoptotic action (Liston et al., 2001). Most likely, this resulted in 
increased sensitivity towards cisplatin. Another study investigated the expression of XIAP 
in bladder tumor specimens of 108 patients and found that XIAP was expressed at 
significantly higher levels in tumors compared to normal urothelium (Bilim et al., 2003). 
Unfortunately, it was not investigated, whether XIAP positivity was correlated with clinical 
response to cisplatin. However, it was suggested that XIAP upregulation might play a role 
in early TCC carcinogenesis (Bilim et al., 2003). 
Altogether, information about expression of factors involved in cisplatin-induced apoptotic 
cell death pathways and its relation to cisplatin resistance is still emerging (Table 1). More 
information about the clinical relevance of apoptosis-related factors for the clinical outcome 
is needed, as this may identify new targets for pharmacological intervention.  
5. Strategies for overcoming cisplatin resistance 
As cisplatin resistance influences the clinical outcome, strategies are needed to circumvent 
the resistance phenotype. In a number of preclinical studies, modulators of cisplatin 
resistance were specifically targeted, and it was investigated whether this would influence 
cisplatin sensitivity. For example, the glutathione system may be modulated by glutathione 
depletion or GST blocking agents. Using these approaches, Buyn and co-workers could 
significantly enhance the cisplatin toxicity in bladder cancer cell lines (Byun et al., 2005). 
Similarly, inhibition of DNA repair has the potential to enhance the cytotoxicity of 
anticancer agents, as preclinical studies have confirmed that modulation of repair pathways 
can enhance the sensitivity to DNA damaging agents (Damia & D'Incalci, 2007, Ding et al., 
2006). We found that siRNA-mediated down-regulation of the repair factor ERCC1-XFP 
decreased the repair of cisplatin-induced ICLs in bladder cancer cells and subsequently 
resulted in reduced cisplatin resistance (Usanova et al., 2010). In a number of studies, the 
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effect of down-regulation of anti-apoptotic proteins for cisplatin resistance was studied. 
Down-regulation of Bcl-2 and Bcl-xL with antisense oligonucleotides enhanced the cisplatin 
sensitivity in four human bladder cancer cell lines (Bolenz et al., 2007). Antisense 
oligonucleotides against Bcl-2 were also used by Schaaf and co-workers who also observed 
an synergistic effect on cisplatin sensitivity (Schaaf et al., 2004). These findings show that 
reducing anti-apoptotic proteins positively influences cisplatin efficacy in bladder cancer 
cell lines and imply that targeting these factors may be a new therapeutic strategy for the 
treatment of bladder cancer. 
6. Novel therapeutic strategies for bladder cancer treatment 
Gemcitabine (2´,2´-difluorodeoxycytidine) is a deoxycytidine analogue, which can inhibit 
the ribonucleotide reductase or may be incorporated into DNA as a false base. Both 
mechanisms result in inhibition of DNA synthesis thereby leading to induction of apoptosis 
(Mini et al., 2006). Gemcitabine is used either as a single agent or in combination with other 
chemotherapeutic drugs for the treatment of cancer. For patients with locally advanced and 
metastatic bladder cancer, combination treatment of cisplatin or carboplatin and 
gemcitabine is the current standard chemotherapy regimen (von der Maase et al., 2005). 
Even though drug resistance is a major clinical problem, the resistance phenotype of bladder 
cancer cells to gemcitabine has not been investigated in great detail. An increase in 
expression of the anti-apoptotic protein clusterin has been described as a mechanism for 
acquired gemcitabine resistance in bladder cancer cells  (Muramaki et al., 2009). Knock-
down of clusterin sensitized gemcitabine-resistant bladder cancer cells indicating clinical 
significance (Muramaki et al., 2009). Gemcitabine resistance in bladder cancer cells might 
differ from cisplatin resistance as gemcitabine has been used for the treatment of cisplatin-
refractory metastatic bladder cancer (Soga et al., 2010). The beneficial effect of gemcitabine 
for the treatment of cisplatin-refractory urothelial carcinoma, however, was not observed in 
the study of Lin and co-workers who reported that gemcitabine and ifosfamide showed 
insufficient clinical activity in patients with cisplatin-refractory bladder cancer (Lin et al., 
2007). More promising approaches to increase the activity of cisplatin plus gemcitabine for 
treating metastatic bladder cancer have been reported in a number of recent studies. 
Addition of vitamin D3 increased the antitumor activity of cisplatin plus gemcitabine in 
bladder cancer cells and enhanced the antitumor activity in a xenograft model (Ma et al., 
2010). The antibody Bevacizumab, which is directed against vascular endothelial growth 
factor (VEGF), has been shown to have a beneficial effect on cisplatin plus gemcitabine in 
patients with metastatic bladder cancer (Hahn et al., 2011). More clinical trials combining 
novel agents with cisplatin and gemcitabine, however, are needed to improve the treatment 
of bladder cancers.  
7. Conclusion 
Cisplatin-based combination therapy is the standard therapy for the treatment of advanced 
or metastatic cancer of the bladder. However, the efficacy of cisplatin is limited by intrinsic 
or acquired resistance to the drug. Mechanisms determining cisplatin resistance include 
drug transport, detoxification, DNA repair and expression of pro- and anti-apoptotic 
proteins. The clinical significance of these mechanisms for bladder cancers is not yet fully 
understood and still evolving.  A better understanding about resistance mechanisms in 
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Preclinical studies indicate that XIAP expression may be associated with cisplatin resistance. 
In ovarian carcinoma cell lines, for example, enhanced expression of XIAP was connected to 
the acquisition of cisplatin resistance (Mansouri et al., 2003). Bilim and co-workers reported 
considerable levels of XIAP in a panel of 4 bladder cancer cell lines, which are known to be 
cisplatin resistant (Bilim et al., 2003). The clinical relevance of XIAP for the efficacy of 
cisplatin treatment has been studied in a number of studies. Parton and co-workers found 
no association between XIAP expression and response to chemotherapy in ovarian cancer 
tissue (Parton et al., 2002). An inverse correlation between XIAP expression in the cancer 
tissue and pathological response was observed for patients with advanced bladder cancer 
(Pinho et al., 2009). The correlation, however, was not statistically significant. This study 
also demonstrated that bladder cancer patients with high levels of XIAP-associated factor 1 
protein (XAF1) in the cancer tissue had a better prognosis after cisplatin based 
chemotherapy (Pinho et al., 2009). XAF1 inhibits the anti-caspase activity of XIAP, therefore 
antagonizing the anti-apoptotic action (Liston et al., 2001). Most likely, this resulted in 
increased sensitivity towards cisplatin. Another study investigated the expression of XIAP 
in bladder tumor specimens of 108 patients and found that XIAP was expressed at 
significantly higher levels in tumors compared to normal urothelium (Bilim et al., 2003). 
Unfortunately, it was not investigated, whether XIAP positivity was correlated with clinical 
response to cisplatin. However, it was suggested that XIAP upregulation might play a role 
in early TCC carcinogenesis (Bilim et al., 2003). 
Altogether, information about expression of factors involved in cisplatin-induced apoptotic 
cell death pathways and its relation to cisplatin resistance is still emerging (Table 1). More 
information about the clinical relevance of apoptosis-related factors for the clinical outcome 
is needed, as this may identify new targets for pharmacological intervention.  
5. Strategies for overcoming cisplatin resistance 
As cisplatin resistance influences the clinical outcome, strategies are needed to circumvent 
the resistance phenotype. In a number of preclinical studies, modulators of cisplatin 
resistance were specifically targeted, and it was investigated whether this would influence 
cisplatin sensitivity. For example, the glutathione system may be modulated by glutathione 
depletion or GST blocking agents. Using these approaches, Buyn and co-workers could 
significantly enhance the cisplatin toxicity in bladder cancer cell lines (Byun et al., 2005). 
Similarly, inhibition of DNA repair has the potential to enhance the cytotoxicity of 
anticancer agents, as preclinical studies have confirmed that modulation of repair pathways 
can enhance the sensitivity to DNA damaging agents (Damia & D'Incalci, 2007, Ding et al., 
2006). We found that siRNA-mediated down-regulation of the repair factor ERCC1-XFP 
decreased the repair of cisplatin-induced ICLs in bladder cancer cells and subsequently 
resulted in reduced cisplatin resistance (Usanova et al., 2010). In a number of studies, the 
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effect of down-regulation of anti-apoptotic proteins for cisplatin resistance was studied. 
Down-regulation of Bcl-2 and Bcl-xL with antisense oligonucleotides enhanced the cisplatin 
sensitivity in four human bladder cancer cell lines (Bolenz et al., 2007). Antisense 
oligonucleotides against Bcl-2 were also used by Schaaf and co-workers who also observed 
an synergistic effect on cisplatin sensitivity (Schaaf et al., 2004). These findings show that 
reducing anti-apoptotic proteins positively influences cisplatin efficacy in bladder cancer 
cell lines and imply that targeting these factors may be a new therapeutic strategy for the 
treatment of bladder cancer. 
6. Novel therapeutic strategies for bladder cancer treatment 
Gemcitabine (2´,2´-difluorodeoxycytidine) is a deoxycytidine analogue, which can inhibit 
the ribonucleotide reductase or may be incorporated into DNA as a false base. Both 
mechanisms result in inhibition of DNA synthesis thereby leading to induction of apoptosis 
(Mini et al., 2006). Gemcitabine is used either as a single agent or in combination with other 
chemotherapeutic drugs for the treatment of cancer. For patients with locally advanced and 
metastatic bladder cancer, combination treatment of cisplatin or carboplatin and 
gemcitabine is the current standard chemotherapy regimen (von der Maase et al., 2005). 
Even though drug resistance is a major clinical problem, the resistance phenotype of bladder 
cancer cells to gemcitabine has not been investigated in great detail. An increase in 
expression of the anti-apoptotic protein clusterin has been described as a mechanism for 
acquired gemcitabine resistance in bladder cancer cells  (Muramaki et al., 2009). Knock-
down of clusterin sensitized gemcitabine-resistant bladder cancer cells indicating clinical 
significance (Muramaki et al., 2009). Gemcitabine resistance in bladder cancer cells might 
differ from cisplatin resistance as gemcitabine has been used for the treatment of cisplatin-
refractory metastatic bladder cancer (Soga et al., 2010). The beneficial effect of gemcitabine 
for the treatment of cisplatin-refractory urothelial carcinoma, however, was not observed in 
the study of Lin and co-workers who reported that gemcitabine and ifosfamide showed 
insufficient clinical activity in patients with cisplatin-refractory bladder cancer (Lin et al., 
2007). More promising approaches to increase the activity of cisplatin plus gemcitabine for 
treating metastatic bladder cancer have been reported in a number of recent studies. 
Addition of vitamin D3 increased the antitumor activity of cisplatin plus gemcitabine in 
bladder cancer cells and enhanced the antitumor activity in a xenograft model (Ma et al., 
2010). The antibody Bevacizumab, which is directed against vascular endothelial growth 
factor (VEGF), has been shown to have a beneficial effect on cisplatin plus gemcitabine in 
patients with metastatic bladder cancer (Hahn et al., 2011). More clinical trials combining 
novel agents with cisplatin and gemcitabine, however, are needed to improve the treatment 
of bladder cancers.  
7. Conclusion 
Cisplatin-based combination therapy is the standard therapy for the treatment of advanced 
or metastatic cancer of the bladder. However, the efficacy of cisplatin is limited by intrinsic 
or acquired resistance to the drug. Mechanisms determining cisplatin resistance include 
drug transport, detoxification, DNA repair and expression of pro- and anti-apoptotic 
proteins. The clinical significance of these mechanisms for bladder cancers is not yet fully 
understood and still evolving.  A better understanding about resistance mechanisms in 
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bladder cancers is essential for developing therapeutic strategies aimed at circumventing 
cisplatin resistance for improving cancer therapy. 
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1. Introduction 
Bladder cancer occurs with a relatively high incidence in industrial nations. For example, 
bladder cancer is the fourth most common type of cancer in American men. The estimated 
U.S. incidence in 2008 was 68,810 cases and the mortality was 14,100 cases (Jemal et al., 
2008). Of newly diagnosed bladder cancer cases, approximately 70% - 80% will present with 
non muscle-invasive disease. Among such cases, 50% - 70% will recur, and 10% - 30% will 
progress to muscle-invasive disease (Soloway et al., 2002; Saad et al., 2002). Radical 
cystectomy with or without chemotherapy is the standard therapy for muscle-invasive 
disease; however, some patients will experience metastatic relapse after radical surgery. A 
few patients present with metastatic disease upon their initial presentation at the hospital. 
Such advanced bladder cancer remains an incurable terminal disease, and accounts for 3% 
of the cancer-related mortality in the United States. Deaths from bladder cancer are mainly 
related to distant spread; hence, prevention of metastatic disease remains a crucial goal in 
this disease. Systemic chemotherapy achieves palliation, survival benefit, and occasional 
long-term remissions. For the last two decades, cisplatin-based combination therapies have 
evolved as the standard. The MVAC regimen (Sternberg et al., 1988) was reported to 
demonstrate an impressive complete remission rate of 37% in advanced urothelial 
carcinoma (UC), and in a subsequent comparative study was found to be superior to the 
single agent cisplatin (Saxman et al., 1997). In this chapter, we review the recent progress in 
chemotherapeutic regimens not only for advanced bladder cancer, but also for advanced UC 
in the upper urinary tract. We also show current data on the efficacy of combination therapy 
with gemcitabine and platinum anti-cancer drugs, which is mainly used as a second-line 
treatment in our institution.  
2. The first successful chemotherapeutic regimen for advanced Urothelial 
Carcinoma (UC) 
Despite recent developments in anti-cancer drugs, advanced UC remains an incurable disease, 
with a median survival time of only 12 to 14 months (Jemal et al., 2003). The most reliable 
treatment option for advanced UC is considered to be combination chemotherapy including a 
platinum anti-cancer drug. The combination chemotherapy regimen of methotrexate / 
vinblastine / doxorubicin / cisplatin (MVAC) as reported originally by Sternberg (Sternberg et 
al., 1988) is currently being used worldwide with superior efficacy. However, MVAC 
treatment is associated with substantial toxicities and has a toxic death rate of approximately  
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
290 
activity and overexpression of antiapoptotic  proteins in ovarian cancer. J Cancer 
Res Clin Oncol, Vol. 130, pp. 423-428. 
Yeh, J. J.; Hsu, N. Y.; Hsu, W. H.; Tsai, C. H.; Lin, C. C. & Liang, J. A. (2005). Comparison of 
chemotherapy  response  with P-glycoprotein, multidrug resistance-related protein-
1, and lung resistance-related  protein expression  in untreated small cell lung 
cancer. Lung, Vol. 183, pp. 177-183. 
Zhen, W.; Link, C. J.; Jr.; O'Connor, P. M.; Reed, E.; Parker, R.; Howell, S. B. & Bohr, V. A. 
(1992). Increased  gene-specific repair of cisplatin interstrand cross-links in 
cisplatin-resistant human ovarian cancer cell  lines. Mol Cell Biol, Vol. 12, pp. 3689-
3698. 
Zheng, H.; Tomschik, M.; Zlatanova, J. & Leuba, S. H. (2005). Evanescent field fluorescence 
microscopy (EFFM) for  analysis of protein/DNA interactions at the single-
molecule level. In Protein-protein interactions, a molecular cloning manual, 2nd edition, 
E. Golemis, & P. Adams, eds. (Cold Spring Harbor, NY, Cold Spring Harbor  
Laboratory Press), pp. 1-19 Chapter 20. 
14 
Chemotherapy for Metastatic Disease 
Takehiro Sejima, Shuichi Morizane, Akihisa Yao,  
Tadahiro Isoyama and Atsushi Takenaka 
Division of Urology, Department of Surgery, Tottori University Faculty of Medicine 
Japan 
1. Introduction 
Bladder cancer occurs with a relatively high incidence in industrial nations. For example, 
bladder cancer is the fourth most common type of cancer in American men. The estimated 
U.S. incidence in 2008 was 68,810 cases and the mortality was 14,100 cases (Jemal et al., 
2008). Of newly diagnosed bladder cancer cases, approximately 70% - 80% will present with 
non muscle-invasive disease. Among such cases, 50% - 70% will recur, and 10% - 30% will 
progress to muscle-invasive disease (Soloway et al., 2002; Saad et al., 2002). Radical 
cystectomy with or without chemotherapy is the standard therapy for muscle-invasive 
disease; however, some patients will experience metastatic relapse after radical surgery. A 
few patients present with metastatic disease upon their initial presentation at the hospital. 
Such advanced bladder cancer remains an incurable terminal disease, and accounts for 3% 
of the cancer-related mortality in the United States. Deaths from bladder cancer are mainly 
related to distant spread; hence, prevention of metastatic disease remains a crucial goal in 
this disease. Systemic chemotherapy achieves palliation, survival benefit, and occasional 
long-term remissions. For the last two decades, cisplatin-based combination therapies have 
evolved as the standard. The MVAC regimen (Sternberg et al., 1988) was reported to 
demonstrate an impressive complete remission rate of 37% in advanced urothelial 
carcinoma (UC), and in a subsequent comparative study was found to be superior to the 
single agent cisplatin (Saxman et al., 1997). In this chapter, we review the recent progress in 
chemotherapeutic regimens not only for advanced bladder cancer, but also for advanced UC 
in the upper urinary tract. We also show current data on the efficacy of combination therapy 
with gemcitabine and platinum anti-cancer drugs, which is mainly used as a second-line 
treatment in our institution.  
2. The first successful chemotherapeutic regimen for advanced Urothelial 
Carcinoma (UC) 
Despite recent developments in anti-cancer drugs, advanced UC remains an incurable disease, 
with a median survival time of only 12 to 14 months (Jemal et al., 2003). The most reliable 
treatment option for advanced UC is considered to be combination chemotherapy including a 
platinum anti-cancer drug. The combination chemotherapy regimen of methotrexate / 
vinblastine / doxorubicin / cisplatin (MVAC) as reported originally by Sternberg (Sternberg et 
al., 1988) is currently being used worldwide with superior efficacy. However, MVAC 
treatment is associated with substantial toxicities and has a toxic death rate of approximately  
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
292 
3 - 4% (Sternberg et al., 1989; Loehrer et al., 1992). Therefore, the need for an alternative less 
toxic combination chemotherapy that can provide efficacy similar or superior to the MVAC 
regimen has been identified. Gemcitabine, a nucleoside analogue, has demonstrated activity 
against a range of solid tumors, including metastatic UC (Gatzemeier et al., Moore, 1996; 
Stadler et al., 1997). In particular, gemcitabine alone has yielded a response rate of 23 - 29%, 
with a complete response rate of 4 - 13%, in both previously treated and untreated metastatic 
UC patients (Sternberg, 2000). The good activity and toxicity profiles of single-agent 
gemcitabine treatment and its synergism with cisplatin in pre-clinical models (Peters et al., 
1995) led to the development of this combination for the treatment of advanced UC. After 
obtaining results from phase 2 trials of combination therapy comprising gemcitabine plus 
cisplatin (GC) as first- or second-line treatment for UC, von der Maase et al. published a large 
multinational phase 3 trial comparing MVAC with GC therapy, with a total of 405 patients 
accrued (von der Maase et al., 2000). The final results show that the two regimens are similar in 
terms of response rate, time to progression and survival. However, the GC combination 
showed a better safety profile and tolerability than MVAC. The representative randomized 
trials on MVAC and GC are summarized in Table 1. Carboplatin shares a common mechanism 
of action with cisplatin, but the two have different pharmacokinetic and dose-limiting 
toxicities (Van Echo et al., 1989). Patients with UC are often elderly, and frequently have 
clinical or subclinical renal function impairment. Thus, the substitution of carboplatin for 
cisplatin offers a promising alternative for these patients. There have been several phase 2 
reports showing that gemcitabine / carboplatin achieved clinical results equivalent to those of 
GC (Xu et al., 2007; Dogliotti et al., 2007). It can thus be speculated that the combination of 
gemcitabine plus a platinum anti-cancer drug (cisplatin or carboplatin) is currently being used 
worldwide in the treatment of advanced UC. 
 
 
Table 1. Summary of representative randomized trials exploring chemotherapy in metastatic 
urothelial cancer 
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3. The efficacy and safety of combination chemotherapy with gemcitabine 
and a platinum anti-cancer drug. A regimen mainly used as second-line 
chemotherapy for patients with advanced UC at Tottori university hospital 
Our original data regarding the effects of combination therapy with gemcitabine plus 
platinum anti-cancer drug as second-line chemotherapy for cases of advanced UC are 
described below. These data were gathered mainly as a result of limitations in the Japanese 
insurance system, which until recently did not cover the use of gemcitabine for the 
treatment of UC. That is, before February 2009, the use of gemcitabine was not allowed for 
general use in Japan, and thus only referral academic institutions such as ours were able to 
conduct gemcitabine therapy. Because the incurable rate is still high in advanced UC 
patients to date in spite of the medical progress of many anti-cancer drugs in Japan and 
other countries, physicians often encounter patients with advanced UC who need to 
undergo more than one kind of chemotherapy. Therefore sequential data of second-line 
chemotherapy like ours is considered to be useful for urological oncologists worldwide. In 
this paragraph, the therapeutic data for cases of upper urinary tract UC are also included. 
This book is of course about bladder cancer; however, it is often difficult to isolate the 
therapeutic data for bladder cancer from the data for all cases of UC. Therefore, we regret 
that we cannot describe the results for bladder cancer data specifically.  
3.1 Patients’ characteristics 
From December 2004 until September 2011, 30 patients received the combination 
chemotherapy of gemcitabine plus a platinum anti-cancer drug (cisplatin or carboplatin) at 
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our institution. All patients were evaluated for efficacy and for toxicity. The pretreatment 
characteristics of the patients are listed in Table 2. 23 patients (77%) had previously received 
combination chemotherapy of methotrexate / epirubicin / cisplatin (MEC). 
3.2 Treatment plan 
In the first cycle of the therapy, the creatinine clearance (Ccr) (ml / min) of each patient was 
measured prior to initiation of the therapy. In the patients with Ccr > 60, cisplatin was 
administered, while in those with Ccr ＜ 60, carboplatin was administered as the platinum 
anti-cancer drug. Gemcitabine (1,000 mg / m2) was given by intravenous infusion over 30 – 
60 min on days 1, 8, and 15. Cisplatin (70 mg / m2) was given by intravenous infusion over 
30 – 60 min on day 2 in the cisplatin group, whereas carboplatin dosed to an AUC of 5 was 
given by intravenous infusion over 30 – 60 minutes on day 2 in the carboplatin group. 
Basically, each cycle consisted of 21 days. However, an extension of the days in each cycle 
was permitted based on the judgment of the physician in charge if any severe adverse 
events were noted. All toxicities were recorded according to the National Cancer Institute 
Common Toxicity Criteria (NCI-CTC) version 3.0. Dose adjustment during the treatment 
was based on hematological and non-hematological assessment of toxicities. In the 
hematological assessment of toxicities, leukocyte and platelet counts were generally 
measured weekly. For cases where leukocytes < 2,000 / mm3 or platelets < 75,000 / mm3, or 
where there was evidence of bleeding, gemcitabine was omitted. No new cycle was started 
unless leukocytes were > 2,000 / mm3 and platelets were > 75,000 / mm3. The platinum anti-
cancer drug dose was reduced by 50% for grade 2 neurotoxicity, omitted for grade 3, and 
stopped for grade 4. For renal toxicity, the dose of platinum anti-cancer drug was reduced 
by 50% for Ccr 50 – 59, and omitted for Ccr ＜ 50. For other grade 3 non-hematological 
toxicities (except nausea, vomiting, and alopecia), gemcitabine and platinum anti-cancer 
drug doses were reduced by 50% or omitted per the physician in charge. For grade 4 
toxicities, doses were reduced by 50% or stopped (unless the patient was responding to the 
therapy).  
3.3 Dose administration 
The median number of consecutive cycles per patient was 3 (range: 1 – 7). 16 patients (53%) 
underwent more than 3 cycles of the therapy. Cisplatin was administered in 12 patients 
(40%), while carboplatin was administered in 18 patients (60%) as the platinum anti-cancer 
drug (Table 3). 
3.4 Efficacy 
All 30 patients were assessed with regard to clinical outcome and treatment efficacy 
according to RECIST criteria at the end of the study. With regard to clinical outcome (Table 
3), we observed 2 (7%) cases of complete response (CR) and 7 (23%) cases of partial response 
(PR), with an overall response rate (ORR) of 30%. The visceral field of metastasis or relapse 
in patients of CR and PR was the lungs in 3 cases, lymph nodes in 5 cases, and local relapse 
(post-nephroureterectomy) in 1 case. There were no cases with responses in other visceral 
fields such as bone. Stable disease (SD) was identified in 10 patients (33%), and progressive 
disease (PD) in 9 patients (30%). 2 patients (7%) were not evaluated. The median time to 
follow-up was 11.7 months (range: 0.8 – 65.8 months). The median overall survival (OS) was 
11.1 months. Kaplan-Meier curves for OS are shown in Fig. 1. 
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Fig. 1. Overall survival rate of all 30 patients with advance UC treated at Tottori University 
Hospital 
3.5 Toxicity 
Only 1 patient discontinued the therapy simply for reasons of toxicity; this patient showed a 
Grade 2 allergic reaction to gemcitabine, which was administered on day 15. Since this 
patient eventually received one whole cycle of the therapy, we assessed the efficacy of the 
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treatment as such. Grade 3 / 4 neutropenia was the most frequent toxicity, occurring in 63% 
of the patients. Grade 3 / 4 thrombocytopenia was also a frequent toxicity, occurring in 57% 
of the patients. Grade 3 / 4 non-hematologic toxicities included nausea and vomiting in 1 
patient (3%). Major toxicities according to NCI-CTC are summarized in Table 4. No other 
types of major toxicities such as nephrotoxicity or neurotoxicity were observed in any 
patients. In order to analyze the cumulative damage due to hematologic side effects, the 
nadir values of blood counts were analyzed. The nadir values of hemoglobin and the nadir 
counts of leukocytes and platelet cells in the first cycle were practically the same as those in 
the other progressive cycles. In other words, hematological toxicities were not enhanced by 
the progressive repetition of cycles (data not shown). 
 
 
Table 4. Mayor toxicities according to NCI-CTC 
3.6 Conclusions 
The efficacy of gemcitabine plus a platinum anti-cancer drug as a second-line chemotherapy 
for advanced UC was found to be modest. The toxicity of the therapy was tolerable despite 
damage from previous chemotherapy and repeated cycles. The present data, obtained as a 
result of particular limitations in the medical insurance industry in Japan, will be helpful 
when considering the best course of second-line chemotherapy for cases of advanced UC in 
the future. 
4. Is there any effective combination chemotherapy except MVAC or GC for 
advanced UC? 
― The combination therapy of methotrexate / epirubicin / cisplatin (MEC) ― 
The combination chemotherapy of methotrexate, epirubicin and cisplatin (MEC) was mainly 
developed in Japan for the purpose of establishing a regimen less toxic than MVAC but with 
equal efficacy. Several academic Japanese institutions including the Japanese Urothelial Cancer 
Research Group promoted a randomized trial comparing MEC and MVAC (Kuroda et al., 
1998). Total of 89 patients were assigned to three groups receiving either standard MEC (S-
MEC), dose-intensified MEC (I-MEC) or MVAC. The S-MEC regimen consisted of 
methotrexate (30 mg / m2), epirubicin (50 mg / m2) and cisplatin (100 mg / m2), and that of 
the I-MEC regimen was methotrexate (36 mg / m2), epirubicin (60 mg / m2) and cisplatin (120 
mg / m2). In both groups, methotrexate was administered on day 1 and 15, epirubicin was 
administered on day 1, and cisplatin was administered on day 2. In the I-MEC group, G-CSF 
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(2μg / kg) was administered from day 3 until day 12 routinely. The response rates (CR + PR) 
were 52% with S-MEC, 76% with I-MEC and 47% with MVAC. All of the adverse events were 
rendered tolerable in the S-MEC and I-MEC groups through the use of G-CSF agents. We had 
been utilizing MEC as a first choice therapy until 2008 in our institution because it was less 
toxic than but as effective as MVAC. As a matter of fact, most of the patients in our study of 
second-line combination chemotherapy with gemcitabine and the platinum anti-cancer drugs 
described above had been receiving MEC as the first line chemotherapy at other institutions. 
5. Prevention of micro metastasis and effort of tumor reduction by 
neoadjuvant chemotherapy at radical cystectomy 
In T2-4 (invasive) bladder cancer, neoadjuvant chemotherapy with MVAC or cisplatin, 
methotrexate, and vinblastine has demonstrated significant progression-free survival (PFS) 
and OS benefit in several randomized trials. One representative trial is the Intergroup 8710 
trials reported by Grossman et al. in which cystectomy alone was compared with 
neoadjuvant MVAC followed by radical cystectomy. The group receiving neoadjuvant 
chemotherapy had an increased likelihood of eliminating residual cancer in the cystectomy 
specimen (pT0) and had an associated improved survival. Moreover, neoadjuvant 
chemotherapy did not adversely affect the patient’s chance of undergoing a cystectomy and 
did not increase the risk of postoperative complications (Grossman et al., 2003). In the 
combined analysis of 2 Nordic studies, neoadjuvant platinum-based combination 
chemotherapy was associated with an 8% increase in survival at 5 years (Sherif et al., 2004). 
A meta-analysis of randomized controlled trials demonstrated a survival benefit to receiving 
neoadjuvant chemotherapy (Winquist et al., 2004). Carboplatin-based regimens have been 
evaluated in the neoadjuvant setting only in phase 2 trials, and hence their use in the 
neoadjuvant or adjuvant setting cannot be recommended (Smith et al., 2008; deVele White et 
al., 2009). The studies of adjuvant chemotherapy have demonstrated conflicting results. 
They have had design flaws and small sample sizes and are therefore underpowered to give 
a conclusive answer regarding the benefits. 
6. Other recent chemotherapeutic regimens including taxanes 
The taxanes are diterpenes produced by the plants of the genus Taxus (yews), and include 
such compounds as docetaxel and paclitaxel, the latter of which was originally derived from 
the Pacific yew tree. The principal mechanism of action of the taxane class of drugs is the 
disruption of microtubule function. Microtubules are essential to cell division, and taxanes 
stabilize GDP-bound tubulin in the microtubule, thereby inhibiting the process of cell 
division. Thus, in essence, taxanes are mitotic inhibitors. Both paclitaxel and docetaxel have 
been studied as chemotherapeutic agents for metastatic bladder cancer. Paclitaxel-based 
regimens in combination with either cisplatin or carboplatin have been evaluated with 
response rates between 16% and 36% and median survival ranging from 6 to 10 months 
depending on the characteristics of the patients enrolled and whether they are ciplatin-
sensitive or a refractory population (Vaishampayan et al., 2005; Uhm et al., 2007). A phase 3 
study comparing docetaxel and cisplatin (DC) with G-CSF versus MVAC with G-CSF found 
MVAC to be more effective than DC for metastatic cancer; MVAC demonstrated both a 
superior median time to progression (9.4 vs 6.1 months; P = 0.003) and median survival time 
(14.2 vs 9.3 months; P = 0.026) (Bamias et al., 2004). Other recent representative reports of 
taxanes with cisplatin therapy are shown in Table 5. Antifolates such as trimetrexate and 
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taxanes with cisplatin therapy are shown in Table 5. Antifolates such as trimetrexate and 
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premetrexed have been better tolerated with promising response rates and should be 
promising for future evaluation (Witte et al. 1994; Sweeney et al., 2006). Oxaliplatin-based 
regimens have been evaluated and also shown to be of modest benefit (Carles et al., 2007). 
 
 
Table 5. Recent representative reports of taxanes with cisplatin therapy for advanced 
urotherial cancer 
7. Role of targeted therapies in bladder cancer 
The actual clinical advent of targeted therapies has been slower in UC, as compared to other 
solid tumors due to large variations in histology worldwide, as well as the difficulty in 
accruing to clinical trials with this malignancy. Vaishampayan et al. evaluated and reported 
the frequency of overexpression of Her-2 in bladder cancer and correlated with the Her-2 
expression in metastatic sites. Interestingly, the overexpression of her-2 by 
immunohistochemistry (IHC) (2+ or 3+) was 37% in primary bladder tumor tissue, the 
expression in metastatic sites such as lymph nodes was 63% and  the expression in visceral 
metastases was 86% (Vaishampayan, 2009). 45% of Her-2/neu-negative primaries had Her-
2/neu-positive lymph node metastases, while 92% of Her-2-positive primary tumors were 
associated with Her-2-positive metastasis. This finding suggested that Her-2 over-
expression could be a useful therapeutic target for advanced UC. Hence, a phase 2 trial was 
conducted and reported evaluating the role of trastuzumab with chemotherapy in 
metastatic UC. An extremely promising 70% response rate and a favorable median survival 
of 14 months were noted despite 55% of the patients having visceral metastases (Hussain et 
al., 2007). Another novel approach using molecular targeted therapy for advanced UC 
patients is the combination therapy of bevacizumab and chemotherapeutic agents. A phase 
2 study of bevacizumab in combination with cisplatin and gemcitabine in metastatic or 
locally advanced bladder cancer involving 36 patients showed a complete response in 6 
(17%), and a partial response in 18 (50%); this combination is now being studied in a phase 3 
trial (Dovedi & Davies, 2009; Hahn et al., 2011). Another study with anti-angiogenic therapy 
is the evaluation of sunitinib in a placebo-controlled double-blind trial with the goal of 
sustaining or prolonging response, after initial chemo-therapy in advanced bladder cancer 
(Bradley et al., 2007). Epithelial growth factor receptor has also been identified as an exciting 
target in UC. The over-expression of EGFR by IHC is noted in about 92% (35 of 38) of the 
bladder cancer cases at Wayne State University; however, its association with survival 
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outcome has not been established (Bellmunt et al., 2003). Given the possibility of EGFR-
targeted therapy, a phase 2 randomized trials of cisplatin and gemcitabine with or without 
cetuximab (a monoclonal antibody to EGFR) is ongoing as a frontline therapy for metastatic 
UC. Current and future additional trials of targeted therapy are listed in Table 6. 
 
 
Table 6. Current and future trial with targeted therapy 
8. Conclusions 
Since the breakthrough progress of development MVAC chemotherapy by Sternberg for 
advanced UC patients, the survival of such patients has been prolonged compared with 
those of untreated patients. However, despite the development of anti-cancer drugs, 
metastatic bladder cancer is still not considered a curable disease. Numerous efforts to 
achieve improved curability are going, including investigations into molecular targeted 
therapy, which has just been developed as a breakthrough treatment for patients with 
advanced renal cell carcinoma in the same field of urologic oncology.  
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Over the last two decades open radical cystectomy and urinary diversion have become a 
widely accepted form of treatment in both men and women with transitional cell carcinoma 
of the bladder. In the mid-1980s orthotopic urinary diversion with anastomosis to the 
urethra became an oncologically and functionally acceptable option in appropriately 
selected male patients. With better understanding of the anatomy and of the continence 
mechanism, orthotopic urinary diversion was subsequently performed in the early 1990s in 
female patients1.  
Until today open radical cystectomy is still considered the gold standard treatment for 
patients with muscle-invasive transitional cell carcinoma of the bladder 2, 3. This is based on 
the following observations: First, the best long-term survival rates and lowest local 
recurrence rates have been reported after radical cystectomy 4 5. Second, the morbidity and 
mortality of radical cystectomy have significantly improved during the last decades, and 
good functional results in patients with orthotopic urinary diversions have been achieved 6 
7. Third, radical cystectomy and pelvic lymph node dissection provides the most accurate 
tumor staging, thus helps selecting patients for adjuvant treatment protocols 8 9.  
Radical cystectomy performed through a laparoscopic approach was first described in 1992 
10. Since then, laparoscopic radical cystectomy has been reported in over 500 patients and 
current results suggest that this approach may cause less blood loss, decreased 
postoperative pain and faster recovery compared to open surgery 11 12. However, due to the 
technical difficulty (two-dimensional laparoscopic view, counterintuitive motion, poor 
ergonomics, and nonwristed instrumentation), the steep learning curve and the lack of long-
term oncological results, this treatment has not been adopted by mainstream urology.  
The introduction of robot assisted surgery for pelvic laparoscopy, especially in performing 
radical prostatectomy, has changed the possibilities of performing complicated operations in 
the small pelvis. Three-dimensional vision with ten-fold magnification and the dexterity 
provided by the endo-wrist (six degrees of freedom) allows the surgeon to operate the tips 
of the laparoscopic instruments like an open surgeon 13. Thus, the surgeon will benefit from 
a faster learning curve as compared to conventional laparoscopy. Further, these advantages 
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have allowed surgeons to translate standard open surgical procedures to a minimally 
invasive approach, especially its potential in operating in a narrow pelvis as well as for the 
reconstruction of the urinary tract.  
With the beginning of robot-assisted pelvic surgery a decade ago, radical cystectomy and 
reconstruction of the urinary tract is currently possible. However, until today, results on 
robot-assisted radical cystectomy (RARC) are mainly reported from a few centers 
worldwide. Further, results on RARC with intracorporeal urinary diversion are sparse, as 
most surgeons perform the reconstructive part outside the abdomen due to technical 
difficulties and longer operative time.  
2. Robot-assisted radical cystectomy 
The history of robot-assisted radical cystectomy started with Beecken et al. who was the first 
to perform a RARC with intracorporeal formation of an ileal orthotopic bladder substitute in 
2002 14. Operating time was 8.5 hours and blood loss 200ml. At five months post-operatively 
the oncological and functional result of the reservoir were considered excellent. Menon et al. 
reported the first series of RARC in 17 patients in 2003 15. In their series, an ileal conduit was 
performed in three patients, a W-pouch in ten, a double chimney in two, and a T-pouch in 
two cases. Mean operating time for radical cystectomy was 140 min and 120–168 min for the 
different urinary diversions, which were all performed extracorporeally. Mean blood loss 
was less than 150 mL, and surgical margins were negative in all cases.  
Since then, several case series have been published, however, most RARC series comprise 
less than 100 cases per center [table 1]. Additionally, our current knowledge on RARC is 
mainly based on reports from less than twenty different surgical centers worldwide. In 
order to provide a better overview on the value of RARC, data from a mix of 15 academic 
and private centers from the USA and Europe are prospectively collected and the results 
reported by the International Robotic Cystectomy Consortium (IRCC) 16 17 18. Despite 
increasing evidence that RARC seems as effective as open radical cystectomy, it is still too 
premature to draw any firm conclusions about the status of RARC.  
3. Patient selection 
Which patients are suitable for RARC using a minimal invasive approach? As patients 
planned for radical cystectomy are in general older and have a higher prevalence of 
smoking-related co-morbidities, pulmonary diseases may cause intraoperative problems. 
Some of these patients may even not be suitable for robot-assisted interventions because of 
the need for CO2 insufflation and the steep Trendelenburg position. The cardiac and 
respiratory systems are especially vulnerable to the extreme and lengthy head-down 
position. However, in order to minimize these risks, a 25° Trendelenburg position during 
radical cystectomy and lymph node dissection is possible without affecting the surgical 
quality 19. For the urinary diversion the Trendelenburg position can further be decreased to 
15°, thus minimizing potential pulmonary complications.  
A question mark regarding contra-indications in selecting patients for RARC remains. 
Presence of bulky disease, locally advanced disease, or enlarged lymph nodes have been 
considered relative contra-indications 20 21. Khan et al. reported specific surgery-related 
complications at RARC 22. They found that patients with multiples intravesical therapies, 
such as mitomycin or BCG, are more likely to have adhesions between the bladder and the 
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n. a. not available, # report on 4 female pts., ≠one case without urinary diversion, renal failure, ǂ results 
from pts. < 70years vs. ≥ 70 years) 
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surrounding structures, especially the rectum, rendering dissection difficult. Thus, careful 
dissection is required in developing the rectovesical plane to avoid injury of the rectum. 
Prior abdominal surgery, radiotherapy or neoadjuvant chemotherapy may be relative-
contraindications for RARC, as these factors can significantly increase the degree of 
technical difficulty  22 23. 
Patient selection makes a direct comparison between open radical cystectomy series and 
smaller RARC series difficult. Results from open high-volume centers indicate that 
approximately two-thirds of patients at radical cystectomy have organ-confined disease, 
whereas one-third has non-organ-confined disease 24 25 26 27 28 29. In general, the percentage of 
patients with non-organ-confined disease undergoing RARC is substantially lower than 
figures reported from major series from open radical cystectomy [table 2] 30 31 32 21, 33-40. 
Recent multi-institutional results from the International Robotic Cystectomy Consortium 
(IRCC) of 527 patients treated with RARC show similar figures regarding the numbers of 
patients with organ-confined (65%) vs. non-organ-confined (35%) disease, as with open 
radical cystectomy series 18. However, data on neoadjuvant chemotherapy were not 
reported in this series.  
4. Surgery-related complications 
Although the number of RARC cases reported in the literature is relatively small, the 
intraoperative complication rate seems comparable to open radical cystectomy series. Nix et 
al. found in a prospective randomized trial of robotic (n = 21) versus open (n = 20) radical 
cystectomy no difference in the absolute number of complications (p = 0.279) 41. Less blood 
loss was observed in the robotic group (mean 258 mL) compared to the open group (mean 
575 mL). Similarly, Wang et al. reported no difference regarding intraoperative 
complications in their prospective trial between robotic (n = 33) and open radical cystectomy 
(n = 21) 32. Again, less blood loss was noted with RARC (mean 400 mL, range 100–1200 mL) 
compared to open radical cystectomy (mean 750 mL, range 250–2500 mL). Galich et al., in a 
comparative analysis of early postoperative outcomes following robotic (n = 13) and open (n 
= 24) radical cystectomy, found no difference between groups regarding surgery-related 
complications and blood loss 33. Kauffman et al. collected data on 79 consecutive patients 
treated with RARC and extracorporeal urinary diversion 42. In their series, high-grade 
complications (Clavien III–V) occurred in 16 patients (21%) during the first 3 months 
postoperatively. Urinary obstruction, intra-abdominal abscess, uro-enteric fistulas, and 
gastrointestinal bleeding were the most common high-grade complications. The high 
percentage of overall urinary obstruction (8%) despite extracorporeal urinary diversion 
without robotic assistance is of concern 42. Khan et al. reported an 8% ureteric stricture rate, 
with 6% strictures occurring on the left side in their series of 50 RARC cases 22. Results from 
open radical cystectomy series report an uretero-intestinal stricture rate of less than 3% 5. 
Performing the anastomosis between the ureters and the urinary diversion outside the 
abdomen through a small abdominal incision may only be possible with relatively long 
ureters, thus increasing the risk for ischemic complications. Resection of the ureters at the 
level where they cross over the common iliac artery minimizes the risk of strictures at the 
uretero-intestinal anastomosis due to ischemia 43.  
Different parameters may affect outcome and risk for surgery-related complications such as 
age, higher ASA score or previous surgery. Butt et al. did not find a significant association 
between age, BMI, ASA score and complication rate in their series of 66 RARC cases 44. 
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Similar, Coward et al. did not find worse outcomes in terms of complications when 
comparing older patients (≥ 70 years) with higher ASA scores vs. younger patients (< 70 
years) treated with RARC 45.  
Schumacher et al. assessed the surgery-related complications at RARC with total 
intracorporeal urinary diversion during their learning curve 35. A total of 45 patients were 
pooled in 3 consecutive groups of 15 cases each to evaluate the complications according to 
the Clavien classification 46. Overall, fewer complications were observed between the groups 
over time, with a significant decrease in late versus early complications (P = 0.005 and P = 
0.058). However, the early Clavien grade III complications remained significant (27%) and 
did not decline with time; thus indicating the complexity of the intracorporeal urinary 
diversion. Khan et al., assessed early surgery-related complications using also the Clavien 
Classification 22. Early complications were observed in 34% of patients. Clavien grade IIIa/b 
complications were seen in 29% of their patients. Both series have somehow a lower 
complication rate compared to the 64% complication rate from a large series of 1142 open 
radical cystectomy patients from the Memorial-Sloan-Kettering Cancer Center (MSKCC) 47. 
The higher percentage of non-organ-confined tumors in the open series from MSKCC may 
be one factor to explain this difference in favor of the robotic approach. 
Hayn et al., from the IRCC assessed whether previous robotic surgical experience affects on 
the implementation and execution of robot-assisted radical cystectomy 17. They found that 
previous robot-assisted radical prostatectomy (RARP) case volume might affect the 
operative time, blood loss, and lymph node yield at RARC. In addition, surgeons with 
increased RARP experience operated on patients with more advanced tumors. Previous 
RARP experience, however, did not appear to affect the surgical margin status. 
5. Lymphadenectomy 
Pelvic lymphadenectomy at radical cystectomy is the standard treatment for patients with 
muscle-invasive bladder cancer. Radical cystectomy series report that approximately 25% of 
patients initially staged T1–T4 N0 M0 who undergo lymphadenectomy have lymph node 
metastases; and the absolute number of positive nodes removed affects survival 9 48. 
It has been stated that, as a guideline, removal of >20 nodes per patient should be the aim 48. 
Others have reported an improved cancer-specific survival rate of 65% when ≥ 16 nodes 
were retrieved compared to 51% when < 16 nodes were retrieved 49. Whereas some experts 
do recommend that at least 10 nodes should be removed at pelvic lymph node dissection 50 
51. While assessing the lymph node counts obtained after lymph node dissection at radical 
cystectomy from various institutional series, huge differences in node count are noted. 
Median node count has been reported to vary from 8 to 80, and is also affected by the extent 
of a pelvic lymphadenectomy 9 24 52 53 47 48 54 55 56 57 58. Interindividual variances, sending 
separate or en-bloc nodal packages, and the pathologic work-up of the specimens may 
explain differences in reporting on the number of nodes removed/detected by the 
pathologist 58 59. Other factors such as the commitment of the surgeon in performing a 
lymph node dissection or selecting patients for more or less extensive lymphadenectomy 
may explain differences in nodal count 60.  
Controversy still persists regarding the boundaries and terminology used in lymph node 
dissection. Mills et al. describe a standard lymph node dissection that includes removal of 
nodal tissue up to and including the common iliac bifurcation, including the internal iliac 
vessels, presacral area, obturator fossa, external iliac vessels, and distal part of the common 
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Others have reported an improved cancer-specific survival rate of 65% when ≥ 16 nodes 
were retrieved compared to 51% when < 16 nodes were retrieved 49. Whereas some experts 
do recommend that at least 10 nodes should be removed at pelvic lymph node dissection 50 
51. While assessing the lymph node counts obtained after lymph node dissection at radical 
cystectomy from various institutional series, huge differences in node count are noted. 
Median node count has been reported to vary from 8 to 80, and is also affected by the extent 
of a pelvic lymphadenectomy 9 24 52 53 47 48 54 55 56 57 58. Interindividual variances, sending 
separate or en-bloc nodal packages, and the pathologic work-up of the specimens may 
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Controversy still persists regarding the boundaries and terminology used in lymph node 
dissection. Mills et al. describe a standard lymph node dissection that includes removal of 
nodal tissue up to and including the common iliac bifurcation, including the internal iliac 
vessels, presacral area, obturator fossa, external iliac vessels, and distal part of the common 
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iliac artery 61. In order to avoid injury to the hypogastric nerves, nodes medial to the ureter 
(proximal half of the common iliac artery, aortic bifurcation) are not removed. In contrast, 
Stein et al. define an extended lymph node dissection as including all nodal tissue in the 
boundaries of: the aortic bifurcation and common iliac vessels (proximally); the 
genitofemoral nerve (laterally); the circumflex iliac vein and lymph node of Cloquet 
(distally); the hypogastric vessels (posteriorly), including the obturator fossa, pre-sciatic 
nodes bilaterally; and the presacral lymph nodes anterior to the sacral promontory 62. 
Data on lymph node yield and oncological outcome in RARC series are still limited, 
however, node counts are similar to open radical cystectomy series 21 31 35 34 36 63. Earlier 
reports from various RARC series describe mostly the boundaries of a limited (obturator 
fossa only) or standard template with less than a median of 20 nodes removed 63. A recent 
report by Pruthi et al. performing an extended lymph node dissection, described a median 
node yield of 28 nodes (range 12–39) 64. Schumacher et al. found similar node counts in their 
series of 45 patients with a mean of 22.5 nodes (range 10 - 52) removed 35. Applying a 
template up to the aortic bifurcation resulted in a mean of 32 nodes removed. Richards et al. 
compared lymph node counts from 35 open radical cystectomy cases to their first 35 RARC 
cases 65. Median total lymph node yield was similar between groups, with 15 nodes (range 
11 - 22) in the open cystectomy group compared to 16 nodes (range 11 - 24) in the RARC 
group. Lavery et al, reported in their first 15 RARC cases undergoing an extended pelvic 
lymphadenectomy up to the aortic bifurcation a mean nodal yield of 41.8 nodes (range 18 - 
67) 66. Kauffmann et al. applying a similar template at RARC found a mean of 19.1 nodes 
(range 0 - 56) removed 42. Evaluating the number of nodes removed from different 
institutions, the IRCC reported that at RARC 82.9% underwent a pelvic lymphadenectomy, 
which resulted in a mean of 17.8 nodes (range 0 - 68) removed 18.  According to these 
reports, it seems that robotic lymphadenectomy applying an extended lymph node dissection 
template, if indicated, up to the aortic bifurcation is technically feasible with intraoperative 
morbidity similar to open series 63. 
6. Urinary diversion 
The first case of RARC with intracorporeal urinary diversion was performed by Beecken et 
al. in 2002 14. Operative time was 8.5 hours, and therefore attention was turned towards 
extracorporeal urinary diversion in order to decrease operative times. Menon et al. were the 
first to describe their technique of extracorporeal diversion, using a 5–8 cm mid-line incision 
15. Until today, the majority of urinary diversions in conjunction with RARC are done 
extracorporeally [table 1] 67. However, standardization of the intracorporeal procedure and 
decreasing operative times might turn the interest towards this approach 19 68. We have 
previously reported our results in a series of 18 patients treated with RARC and totally 
intracorporeal urinary diversion, later, results in 45 patients were published 19 35. Mean 
operative time was 476 min (range 325–760) and mean blood loss 669 mL (range 200–2200) 
35. Whether there is an advantage of performing the complete procedure intracorporeally or 
not is less clear. At least in female patients, the specimen can be removed through an 
incision via the vaginal wall, thus avoiding a mid-line incision. The technical difficulties in 
performing the urinary diversion totally intracorporeally have so far prevented its wide-
spread adoption. Results reported by Schumacher and co-workers indicate at least at the 
beginning of their learning curve increased surgery-related complications using an 
intracorporeal urinary diversion approach 35. Rehman et al. reported on 9 patients treated 
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with RARC and totally intracorporeal confection of an ileal conduit 69. One postoperative 
iatrogenous necrosis of the ileal conduit, probably caused by retraction of the organ bag 
occurred.  
7. Oncologic outcome 
To objectively assess oncological outcomes in patients treated either with open radical 
cystectomy or RARC for bladder cancer one needs to focus on: long-term cancer control, 
surgical quality (positive margins), tumor spillage, and port site metastasis.  
Today, the highest long-term survival rates were reported for open radical cystectomy with 
an extended lymph node dissection. Stein et al. reported 5-year and 10-year recurrence-free 
survival rates of 68% and 60%, respectively, among 1,054 patients treated with radical 
cystectomy and extended lymph node dissection with curative intent 24. For lymph node-
negative, organ-confined disease, 5-year and 10-year recurrence-free survival rates were 
85% and 82%. Similar results have been reported from other high-volume centers 
performing open radical cystectomy 25 26 27 28 29.  
Whether the same cancer control rates equivalent to results from open radical cystectomy 
series can be achieved with RARC is still unknown; to date there are no long-term data 
available 70. Median time to any recurrence after radical cystectomy is approximately 12 
months, whereas 86% of recurrences occur within 3 years 24. The mean follow-up in the 
current RARC series ranged from 3 to 77 months [tables 1 and 2]. However, in all of these 
RARC series median follow-up is short (<24 months), and reported survival data in which 
all patients have passed at least a 12 months follow-up do not exist. 
The surgical quality at radical cystectomy independent of the surgical approach is essential 
for optimal local cancer control. Thus, negative margins must be achieved to avoid local 
tumor recurrence, which ultimately results in the death of the patient. Positive surgical 
margins have been reported to be 5% or less in high-volume open radical cystectomy series 
25 26 27 28 29. The incidence of positive margins at RARC ranged from 0% to 13% 21 30 31 32 34 36 37 
38 39 40 71 72. Guru et al, reported a 10.3% positive margin rate at RARC, whereas Yuh et al. 
found 13% positive margins in their patients 36 40. Whether this high positive margin rate is 
attributable to the learning curve in these series is not clear. Data from the IRCC showed an 
overall 7% positive margin rate in their pooled 496 patients 17. For patients with pathologic 
stage ≤ T3, 3.7% had a positive margin, whereas for patients with pathologic stage T3 or T4, 
16% had a positive margin. The authors found with increasing surgical experience at RARC 
an improvement of their positive margin rate 17. 
Port site metastasis in urological malignancies are of concern; they do occur, albeit 
infrequently. The etiology of port site metastasis is unknown. Port site metastasis has been 
reported after RARC and laparoscopic radical cystectomy for bladder cancer 73 74. 
8. Post-operative recovery 
Perioperative pathophysiology and care suggest that a multitude of factors contribute to 
postoperative morbidity, length of hospital stay, and convalescence in patients undergoing 
surgery 75. Radical cystectomy is still associated with significant perioperative morbidity—
this despite the implementation of accelerated postoperative recovery programs, or so-
called “fast-track” surgery 76. Comparison between historical cystectomy series and recent 
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studies regarding post-operative recovery are difficult, as the concept of “fast-track” surgery 
has only been adopted by the urologic community during the last decade.   
In order to reduce perioperative morbidity at cystectomy, Pruthi and co-workers have 
implemented and continuously improved the perioperative management in their 362 
patients 77. Reported findings from the last 100 (open and RARC) of these 362 cystectomy 
cases showed favorable return of bowel function (mean time to flatus 2.2 days, and mean 
time to bowel movements 2.9 days), the majority of patients being discharged after a mean 
of 5 days. Readmission was observed in 12% of patients, and the most common reasons for 
readmission were urinary tract infection (3%), gastrointestinal disorders (2%), and deep 
venous thrombosis (2%). The same group has published a randomized trial and assessed 
perioperative outcomes in patients treated with open versus robotic radical cystectomy 41. 
Patients undergoing robotic cystectomy had longer operative times (4.2 versus 3.5 hours; p < 
0.001) and less blood loss (258 versus 575 mL; p < 0.001) than did patients with open 
cystectomy. Further, patients in the robotic group demonstrated a faster return of bowel 
activity (median time to flatus 2.3 days versus 3.2 days, and time to bowel movement 3.2 
days versus 4.3 days). Hospital stay did not differ between groups (robotic 5.1 days, open 
6.0 days; p = 0.239). Patients in the robotic group required significantly less analgesia than 
did patients with the open approach (p = 0.019). Similar results have been reported by Ng et 
al., comparing 104 open cystectomy with 83 RARC cases 78. The robotic group demonstrated 
decreased blood loss (460 mL versus 1172 mL; p < 0.0001) and shorter length of hospital stay 
(5.5 days versus 8 days; p < 0.0001) than did the open cystectomy group. Wang et al., 
comparing open radical cystectomy with RARC patients, reported reduced blood loss, faster 
return to regular diet, and shorter hospital stay in the robotic group 32. One may argue that 
fewer non-organ-confined tumors (28%) in the RARC group may have influenced their 
results compared to 57% non-organ-confined tumors in the open group. A recent study by 
Coward et al. found similar results regarding time to flatus (median 2 days) and time to 
bowel movements (median 3 days) after RARC in their series 45.  
Despite the presumed advantages of less postoperative pain, faster return of bowel 
movements, shorter hospital stay, and overall quicker recovery over open surgery, the exact 
role of laparoscopy in improving perioperative outcomes remains unclear.   
9. Quality of life 
Quality of life (QoL) and postoperative recovery after surgery are important factors with 
direct financial implications for the health care system. Karvinen et al. reported on the effect 
of exercise and QoL in survivors of bladder cancer 79. Findings from their study indicate that 
exercise is positively associated with QoL and the ability to perform physical activity results 
in increased QoL. If patients are able to return more quickly to preoperative levels with 
minimally invasive surgery, i.e. robotic surgery, they might be able to initiate exercise 
sooner, which in turn improves their QoL.  
Yuh et al. evaluated QoL in a small single-center study after RARC 20. Despite some 
inheriting limitations of the study design, QoL appeared to return to base-line by 3 months 
after RARC, and improved further at 6 months. The authors postulated that short-term 
improvement in QoL might also have positive implications regarding initiating adjuvant 
treatment protocols in these patients. Further studies are required to assess the physical and 
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psychological implications of robotic surgery on QoL in patients undergoing radical 
cystectomy.  
Functional results have been reported after open nerve-sparing radical cystectomy and 
orthotopic bladder substitution, however, reports from RARC series assessing continence 
and potency rates are sparse 7 80. 
10. Costs 
The introduction of new and costly technologies into daily clinical practice has been 
criticized, especially during periods of economic uncertainty. With the introduction of 
expensive robotic technology cost-effectiveness has become more important. For robot-
assisted radical prostatectomy some studies have shown volume-dependant cost advantages 
81 82. Less information on cost-analysis is available for RARCS.  
Smith et al., from North Carolina, US, performed a cost analysis at their institution between 
robotic and open radical cystectomy 83. The financial costs of robotic and open radical 
cystectomy were categorized into operating room and hospital components, and further 
divided into fixed and variable costs for each. Variable costs were related to several factors, 
such as length of hospital stay. For each procedure the means of 20 cases were used to 
perform a comparative cost analysis. Based on their results, robotic cystectomy is associated 
with an overall higher financial cost of $1,640.  
Martin et al. performed a detailed cost-analysis for open radical cystectomy vs. RARC cases  
84. They found that the most critical parameters for increased costs were operative time and 
hospital stay, which favored the robotic approach at their institution. Further, they stated 
that the real cost advantages are mostly seen when indirect costs are considered, such as 
treatment of perioperative complications or readmission rates due to complications.  
Costs are difficult to measure and comprise other factors than just the perioperative period. 
Thus, earlier return to normal activity and reduced sick-leave might be important factors 
justifying these additional costs offered by the robotic approach.  
11. Conclusions 
Based on the current literature RARC is evolving rapidly as an alternative technique to open 
surgery in patients requiring radical cystectomy and urinary diversion. Lymph node yield 
and perioperative outcomes are similar to open radical cystectomy series; however, long-
term oncological results are unknown. Several small prospective or randomized single-
center trials showed comparable results between RARC and open cystectomy. However, the 
surgical procedure is technically demanding, especially when performing the urinary 
diversion totally intracorporeal. It is advisable to concentrate this type of surgery to high-
volume centers where robotic expertise and technology is available.   
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open surgery with technical advantages of the surgical robot which allows a precise, gentle, 
quick and safe surgery during performing radical cystectomy for bladder cancer (Menon et 
al., 2003). 
Therefore, following the introduction of da Vinci-S 4-arm surgical robot (Intuitive Surgical, 
Sunnyvale, California) many centers have started to publish their experiences with the use 
of a surgical robot in performing these complex surgical procedures (Akbulut et al., 2011; 
Rehman et al., 2011; Kauffman et al., 2011; Hellenthal et al., 2010; Kasraeian et al., 2010; 
Pruthi et al., 2010; Schumacher et al., 2009). 
3. Open versus robotic approach 
3.1 Comparison of complications 
A prospective study from Weill Cornell Medical College, Department of Urology, New 
York, NY, USA has recently evaluated prospective complications of open (n=104) versus 
robotic (n=83) cystectomy procedures (Ng et al., 2010). Complications were classified due to 
modified Clavien system. Significantly lower major complications were detected in the 
robotic group compared to the open surgical approach (17% versus 31%, p=0.03). Robotic 
cystectomy was found to be an independent predictor of fewer overall and major 
complications at 0-30 day (perioperative) and 31-90 day periods. Another well known study 
from The University of North Carolina at Chapel Hill, Division of Urologic Surgery, Chapel 
Hill, North Carolina, USA randomized 21 patients to robotic approach and 20 to the open 
technique. No significant difference in regard to overall complication rate or hospital stay 
was detected between the two groups of patients (Nix et al., 2010). In our initial experience 
of 12 cases whom we performed robot assisted laparoscopic nerve sparing radical 
cystoprostatectomy with bilateral extended lymph node dissection and intracorporeal 
Studer pouch construction, we had 6 minor complications (Grade 1 and 2) 2 major 
complications (Grade 3-5) in the perioperative period (0-30 day) and 3 minor and 2 major 
complications in the 31-90 day period due to modified Clavien system (Akbulut et al., 2011). 
Although the number of prospective and randomized studies comparing these two 
approaches is limited currently in the literature, robotic approach does not seem to add an 
additional complication risk when compared to open surgery.  
3.2 Comparison of oncologic parameters 
Lymph node yield, surgical margins, recurrence-free survival and overall survival are 
important parameters in evaluating surgical oncologic efficacy. The University of North 
Carolina study which randomized 21 patients to robotic approach and 20 to the open 
technique did not find any significant difference in the number of lymph nodes removed 
between two groups (19 versus 18, p>0.05). Likewise, surgical margins were negative in all 
patients in both approaches (Nix et al., 2010). The Weill Cornell Medical College study, 
having larger numbers of patients similarly did not find significant differences concerning 
these two parameters between the two approaches (Ng et al., 2010). Mean lymph node yield 
was 15.7 in the open surgical approach and was 17.9 in the robotic approach (p>0.05). 
Positive surgical margins were detected 8.7% of the patients in open approach and 7.2% of 
the patients in robotic approach (p>0.05). In our initial series of 12 patients, mean lymph 
node yield was 21.3.8.8 (Akbulut et al., 2011). 
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A recent review from the Memorial Sloan-Kettering Cancer Center has recently evaluated 
the oncological outcomes after radical cystectomy for bladder cancer comparing open versus 
minimally invasive approaches (Chade et al., 2010). Although the follow-up is limited in 
robotic series compared to open surgical approach, robotic assisted studies reported 
recurrence-free survival rates of 86% to 91% at 1 to 2 years and 90% to 96% overall survival 
in 1 to 2 years of follow-up. On the other hand, large open surgery studies showed 62% to 
68% recurrence-free survival at 5 years and 50% to 60% at 10 years, with overall survival of 
59% to 66% at 5 years and 37% to 43% at 10 years. 
With these limited current data, robotic approach seems to provide sufficient short-term 
surgical oncologic efficacy in patients with bladder cancer. 
3.3 Comparison of cost 
Controversial reports exist regarding the cost analysis of open versus robotic approaches. 
One study revealed that robotic assisted laparoscopic radical cystectomy is associated with a 
higher financial cost than the open approach in the perioperative setting (Smith et al., 2010). 
Whereas, another study suggested that although robotic approach is more expensive in 
terms of operative costs and robotic supplies, due to decreased hospital stay in robotic 
approach and higher complication rates with open surgical approach make total actual costs 
much higher than robotic approach (Martin et al., 2011).  
4. Surgical oncologic safety of robotic approach (lymph node yield and 
surgical margins) 
Regarding open radical cystectomy, lymph node yield and positive surgical margin rates are 
considered as the significant factors related to surgical quality (Herr et al., 2004; Skinner et 
al., 2007; Stein et al., 2003). Herr et al and Skinner et al suggested a lymph node yield of 
greater than 10 and a positive surgical margin rate of less than 10% in surgical oncologic 
adequacy (Herr et al., 2004; Skinner et al., 2007). Stein et al suggested a lymph node yield of 
greater than 15 obtained during open radical cystectomy in order to be oncologically 
acceptable and sufficient (Stein et al., 2003). 
Guru et al evaluated whether robot assistance allows adequate pelvic lymph node dissection 
particularly during the initial experience (Guru et al., 2008). In a series of 67 patients, mean 
number of lymph nodes retrieved was 18 (6-43) (Guru et al., 2008). Mean lymph node yield 
was 41.8 (18-67) in another series of 15 consecutive patients who underwent robotic radical 
cystectomy for bladder cancer (Lavery et al., 2010). Recently, International Robotic 
Cystectomy Consortium (IRCC) evaluated 527 patients who underwent robotic cystectomy 
for bladder cancer and mean lymph node yield was 17.8 (range 0-68) (Hellenthal et al., 
2011). Mean lymph node yield was 21.3 (range, 8-38) and 24.8.9.2 in our initial series of 12 
(Akbulut et al., 2011) and 27 cases (unpublihsed data), respectively.  
Positive surgical margin rates were reported as 6.8%, 0%, 7.2% and 2% in 513, 83, 100 and 50 
robotic cystectomy patients (Hellenthal et al., 2010; Pruthi et al., 2010; Ng et al., 2010; 
Shamim Khan et al., 2010). In our initial series of 12 patients, positive surgical margin rate 
was 0% (Akbulut et al., 2011). We had only one patient with positive surgical margin (3.7%) 
who had pT4b disease in the total of 27 patients underwent totally intracorporeal robotic 
cystectomy (unpublihsed data). 
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5. Learning curve of robotic approach 
Robotic-assisted laparoscopic radical cystectomy with bilateral extended lymph node 
dissection and particularly intracorporeal urinary diversion (Studer or ileal conduit) are 
complex procedures. Therefore, a learning curve is required in order to perform these 
procedures successfully. 
Regarding the completion of the learning curve of robotic cystectomy, some authors have 
suggested to perform a certain number of cases in the literature. International Robotic 
Cystectomy Consortium (IRCC) suggested that 21 cases were needed to be performed for 
operative time to reach 6.5 hours and 8, 20 and 30 patients were required to reach a lymph 
node yield of 12, 16 and 20, respectively (Hayn et al., 2010). On the other hand, others 
reported that after the first 20 cases of robotic cystectomy, no further significant 
improvement was detected in terms of intraoperative parameters, pathologic outcomes 
and complication rates (Pruthi et al., 2008). Following evaluation of 100 cases of robotic 
cystectomy, Guru et al stated that operative results and oncologic outcomes for robotic-
assisted radical cystectomy constantly improve as the technique evolves (Guru et al., 
2009). 
We have started performing robotic urological procedures at our institution in February 
2009, following initially performing more than 50 cases of robot assisted laparoscopic radical 
prostatectomy cases some of which also included pelvic lymph node dissection. We 
recommend to start performing robotic cystectomy cases after a certain experience gained 
particularly on robotic radical prostatectomy. Additionally, a good knowledge of the pelvic 
anatomy and adequate open surgical experience are essential.   
6. Surgical technique 
6.1 Patient position 
Patient is placed in deep (30°) Trendelenburg position at the beginning of the procedure 
until the completion of robotic cystectomy, bilateral extended lymph node dissection and 
transposition of the left ureter under the mobilized sigmoid colon. During performing 
intracorporeal Studer pouch reconstruction or ileal conduit formation, patient position is 
adjusted to mild (5°) Trendelenburg position.  
A Veress needle is introduced into the abdominal cavity about 2 cm above the umbilicus. 
Intra-abdominal pressure is set to 10-12 mmHg during performing bilateral extended lymph 
node dissection. Regarding rest of the surgery, intra-abdominal pressure is set to 16-18 
mmHg.  
6.2 Abdominal port locations 
Overall, we use 6 trocars with the 4th-arm of the surgical robot placed on the patient’s right 
which provides easy control to the right-handed console surgeon (Figure 1). 
Camera port (12-mm) is placed 2 cm above the umblicus. Two robotic trocars (8-mm) are 
placed 8 cm apart from the camera port at the level of the umblicus. An 8-mm sized robotic 
trocar is placed 3 cm vertically above from the right iliac crest for the 4th-arm. We use 2 
assistant trocars on the left abdomen for the assistant surgeon: A 15-mm trocar for 
introducing for tissue staplers for bowels and endobags for specimens is placed 3 cm 
vertically above from the left iliac crest and a 12-mm trocar is placed between the camera 
port and the 2nd-robotic arm. 
Robotic-Assisted Laparoscopic Radical Cystoprostatectomy  




Fig. 1. Abdominal port locations (Archive of Ankara Atatürk Training and Research Hospital, 1st 
Urology Clinic, Ankara, Turkey) 
6.3 Robotic-assisted laparoscopic bilateral neurovascular bundle sparing radical 
cystoprostatectomy in male patients (Akbulut et al., 2011; Canda et al., 2011; Canda et 
al., 2011; Akbulut et al., 2010)  
Surgery starts with dissection of the ureters. They are double clipped and cut where they 
enter the bladder. Most distal parts are sent for frozen section analysis (Figure 2).  
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Fig. 2. Ureters are dissected, double clipped and cut where they enter the bladder (left side). 
Arrow: left ureter, arrowhead: incised and opened peritoneum on the left side. (Archive of 
Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
Peritoneum on the anterior wall of the Douglas’ pouch is incised and posterior dissection of 
the prostate is carried out (Figure 3).  
Following the identification of seminal vesicles, Denonvilliers’ fascia is opened (Figure 4). 
Tissue lateral to the tip of the seminal vesicles corresponding to the mid point of the 
pararectal plexus is marked with Hem-o-lok® clips on both sides (Figure 5). Prostate is 
dissected off of the rectum. Lateral bladder pedicles are severed with vessel sealing system 
(Ligasure®) until the Hem-o-lok® clips placed at the tips of the seminal vesicles to mark 
pararectal plexus of which the neurovascular bundles originate (Figure 6). Then, endopelvic 
fascia is opened on both sides. Dorsal venous complex is ligated by 0/0 vicryl (40 mm ½ RB 
needle). High anterior release (intra-fascial) neurovascular bundle preservation is performed 
on both sides by dissecting the periprostatic fascia over the prostatic capsule alongside the 
prostate down until the dorsal venous complex suture and bilateral neurovascular bundle 
dissections are completed (Figure 7).  
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needle). High anterior release (intra-fascial) neurovascular bundle preservation is performed 
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Fig. 3. Incision of the peritoneum on the anterior Douglas’ pouch wall (arrows). (Archive of 
Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
 
 
Fig. 4. Opening Denonvilliers’ fascia (arrow). (Archive of Ankara Atatürk Training and Research 
Hospital, 1st Urology Clinic, Ankara, Turkey) 
 




Fig. 5. Tip of the seminal vesicle is marked with a Hem-o-lok® clip and cut (arrow). (Archive of 
Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
 
 
Fig. 6. Severence of lateral bladder pedicles with vessel sealing system (arrow). (Archive of 
Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
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Fig. 7. High anterior release of the periprostatic fascia (arrow) over the prostatic capsule 
alongside the prostate in preserving neurovascular bundles on the left side. (Archive of 
Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
Starting from the umblical level, urachus is dissected by incising lateral to the medial 
umblical ligaments on the anterior abdominal wall. Puboprostatic ligaments are cut. Ligated 
dorsal venous complex (Figure 8) and ligated membraneous urethra (Figure 9) with 0/0 
vicryl (40 mm ½ RB needle) to prevent tumor spillage are cut. Cystoprostatectomy is 
completed (Figure 10) and specimen is put into the endobag. Urethral stump is sampled for 
frozen section analysis. 
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Fig. 6. Severence of lateral bladder pedicles with vessel sealing system (arrow). (Archive of 
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Fig. 8. Dorsal venous complex is ligated and cut (arrow). (Archive of Ankara Atatürk 
Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
 
 
Fig. 9. Membraneous urethra is cut after being ligated and foley catheter is inserted back in 
until its tip reaches the specimen to show the anatomic details apparently. Arrow: 
appearance of the urethral catheter. DVC: dorsal venous complex (ligated and cut) (Archive 
of Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
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Fig. 10. Bilaterally preserved neurovascular bundles following the removal of the 
cystoprostatectomy specimen into the endobag (arrows). (Archive of Ankara Atatürk Training 
and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
6.4 Robot assisted laparoscopic bilateral extended lymph node dissection (Canda et 
al., 2011; Akbulut et al., 2010; Akbulut et al., 2011) 
We use the landmarks below during performing robot assisted laparoscopic bilateral 
extended lymph node dissection:  
Superior border: inferior mesenteric artery and accompanying vena cava superior 
Inferior border: node of Cloquet and circumflex iliac vein 
Medial border: cut edge of the endopelvic fascia over the neurovascular bundles and internal 
iliac vessels 
Lateral border: genitofemoral nerves, psoas muscles and ureters  
Initially, starting from the genitofemoral nerve lymphatic tissue around external iliac artery 
& vein are removed until the obturator nerve is seen (Figure 11).  
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Fig. 11. Arrowhead: Genitofemoral nerve (left). Arrow: External iliac artery (left). LNs: 
Lymph node tissue. (Archive of Ankara Atatürk Training and Research Hospital, 1st Urology 
Clinic, Ankara, Turkey) 
Then, bifurcation of common iliac artery are identified and lymphatic tissues located below 
the obturator nerve and surrounding the internal iliac artery are removed. Later, lymphatic 
tissues medial to the genitofemoral nerve and around the common iliac artery are dissected 
until the aortic bifurcation. Same lymphatic dissection is performed on the other side. Then, 
lymphatic tissues which are located distal to the aortic bifurcation, overlying and distally 
located to the vena caval bifurcation and common iliac arteries and veins are removed 
followed by presacral lymph nodes anterior to the sacrum. Lastly, preaortic and paracaval 
lymphatic dissections are performed. Inferior mesenteric artery on the aorta makes the most 
proximal end of the extended lymphatic dissection (Figure 12). Hem-o-lok® clips are used in 
order to tie off the most distal parts of the lymphatic vessels draining the limbs to prevent  
or reduce lymphatic leakage and lymphocele formation. 
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Fig. 12. Completed bilateral extended lymph node dissection and appearance of the 
major abdominal vasculature that are skeletonized. A: abdominal aorta, VCI: vena cava 
inferior, Arrows: right and left common iliac arteries, Arrowhead: right external iliac 
artery. (Archive of Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, 
Ankara, Turkey) 
Having completed the extended lymph node dissection, sigmoid colon is mobilized and 
left ureter is transposed to the right gutter underneath the sigmoid colon above the 
vasculature. 
6.5 Robot assisted laparoscopic intracorporeal Studer pouch reconstruction (Canda 
et al., 2011; Akbulut et al., 2010; Akbulut et al., 2011) 
Using a double armed 3/0 monocryl (17 mm ½c RB needle) urethral remnant is 
anostomosed to the assigned 1 cm opening on the antimesenteric wall of the most 
dependent part of the segregated ileum, initially (Figures 13,14). A 10 cm ileal segment on 
the right and a 40 cm ileal segment on the left side of urethroileal anastomosis are 
assigned for the pouch sparing the distal 20 cm ileal segment adjacent to the ceacum. 
Laparoscopic intestinal staplers are introduced through the 15 mm assistant port on the 
left side and placed perpendicular across the ileum and adjacent mesointestinum of 
approximately 2 cm (Figure 15). Side-to-side ileoileostomy is performed using two 
additional laparoscopic intestinal staplers between proximal and distal ends of the ileum 
(Figure 16).  
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Fig. 13. Segregated antimesenteric ileal wall. (Archive of Ankara Atatürk Training and Research 
Hospital, 1st Urology Clinic, Ankara, Turkey) 
 
 
Fig. 14. Urethral remnant is sutured to the assigned antimesenteric ileal wall which is segregated. 
(Archive of Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
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Fig. 15. Laparoscopic intestinal stapler introduced through the 15 mm assistant port on the left 
side and placed perpendicular across the ileum with adjacent 2 cm of mesointestinum included. 
(Archive of Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
 
Fig. 16. Formation of side-to-side ileoileostomy by using laparoscopic intestinal staplers 
between proximal and distal ends of the ileum. (Archive of Ankara Atatürk Training and 
Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
 




Fig. 13. Segregated antimesenteric ileal wall. (Archive of Ankara Atatürk Training and Research 
Hospital, 1st Urology Clinic, Ankara, Turkey) 
 
 
Fig. 14. Urethral remnant is sutured to the assigned antimesenteric ileal wall which is segregated. 
(Archive of Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
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Fig. 15. Laparoscopic intestinal stapler introduced through the 15 mm assistant port on the left 
side and placed perpendicular across the ileum with adjacent 2 cm of mesointestinum included. 
(Archive of Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
 
Fig. 16. Formation of side-to-side ileoileostomy by using laparoscopic intestinal staplers 
between proximal and distal ends of the ileum. (Archive of Ankara Atatürk Training and 
Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
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Proximal 10 cm segment of the segregated ileum is spared as afferent loop. Then, a 60 cm 
feeding tube is inserted through the urethra and advanced within the lumen of the ileal 
segment until the proximal end of the afferent loop. Next, sparing the afferent loop, anti-
mesenteric border of the remaining ileal segment is incised. Asymmetric closure of the 
posterior wall is accomplished with interrupted 2/0 vicryl (30 mm ½c RB needle) sutures 
followed by a running suture of 3/0 monocryl (26 mm ½c RB needle). Anterior wall 
















Fig. 17. Anterior wall closure. (Archive of Ankara Atatürk Training and Research Hospital, 1st 
Urology Clinic, Ankara, Turkey) 
Distal ureteric ends are spatulated and anastomosed to each other at their medial edges in 
order to develop a common ureteral duct (Figure 18).  
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Fig. 18. Distal ureteric ends are spatulated and anastomosed to each other at their medial 
edges in order to develop a common ureteral duct before reconstruciton of a Wallace type 
uretero-ureteral and intestinal anastomosis. (Archive of Ankara Atatürk Training and Research 
Hospital, 1st Urology Clinic, Ankara, Turkey) 
Double J stents with long strings at their distal ends are passed through inside the feeding 
tube over a guide wire to the uretero-intestinal anostomosis site and fed up to the ureters 
and renal pelves (Figure 19). Distal tips of the stents are tied to the tip of a 22F urethral 
catheter outside the body, which will then be passed through the urethra into the completed 
Studer pouch over a guide-wire.  
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Fig. 19. Use of a feeding tube for inserting the double J catheters through the urethra, within 
the lumen of the ileum and into the ureters up to the renal pelves. (Archive of Ankara Atatürk 
Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey) 
A Wallace type uretero-intestinal anostomosis is performed between common ureteral 
duct and proximal end of the afferent loop. To do this anostomosis, medial edge of the 
ureteral duct is sutured to the medial edge of the ileal wall with a double armed 4/0 
monocryl (22 mm ½c RB needle) running suture. After internalization of the double-J 
stents, rest of the ureteroileal anastomosis is completed (Figure 20). Ureteroileal 
anastomosis is retroperitonealized by using several interrupted sutures in the right gutter 
laterally. 
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Fig. 20. Stapler line is excised at the proximal end of the afferent loop and posterior wall 
is anastomosed halfway between the ileal wall and medial edge of the uretero-ureteric 
anastomosis with a double armed 4/0 monocryl (22 mm ½c RB needle) running suture. 
(Archive of Ankara Atatürk Training and Research Hospital, 1st Urology Clinic, Ankara, 
Turkey)  
Watertightness of the created Studer pouch is tested filling it with 150 cc of saline (Figure 21).  
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Fig. 20. Stapler line is excised at the proximal end of the afferent loop and posterior wall 
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Fig. 21. Completed intracorporeal Studer pouch. (Archive of Ankara Atatürk Training and 
Research Hospital, 1st Urology Clinic, Ankara, Turkey)  
Robotic-assisted laparoscopic radical cystoprostatectomy with intracorporeal Studer urinary 
diversion leads to better wound healing with excellent cosmetic result (Figure 22). 
 
 
Fig. 22. Postoperative 6th-month abdominal appearance of a male patient who underwent 
robotic-assisted laparoscopic bilateral neurovascular bundle sparing radical 
cystoprostatectomy with bilateral extended lymph node dissection and intracorporeal 
Studer pouch formation for bladder cancer. (Archive of Ankara Atatürk Training and Research 
Hospital, 1st Urology Clinic, Ankara, Turkey)  
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Patients are discharged after tolerating an oral diet and sufficient ambulation following 
removal of the lodge drain. A cystography is done by filling the bladder with 200 cc of 
diluted contrast material on the postoperative 21st-day. When no leakage is seen, urethral 
catheter is removed. If leakage is detected, urethral catheter is kept for one more week and 
removed after another cystography.  
6.6 Robotic-assisted laparoscopic intracorporeal ileal conduit formation (Canda et al., 
2011) 
Initially, sigmoid colon is mobilized and left ureter is transposed to the right gutter 
underneath the sigmoid colon above the vasculature. 20 cm ileal segment including the 
terminal ileum adjacent to the ceacum is spared and a 15-20 cm of ileal segment is 
segregated by using tissue staplers.  
A Wallace type uretero-ureteric anastomosis is performed as explained above. For inserting 
the JJ stents into the renal pelves, a feeding tube is passed through the urethra and advanced 
within the lumen of the ileal segment. Its tip is held close to anastomozed ureteral lumens 
and JJ stents are passed over a guide wire up to the renal pelves. Then, uretero-ileal 
anostomosis is performed by using a double armed running 3/0 monocryl suture (Figure 
23). Ureteroileal anastomosis is retroperitonealized by using several interrupted sutures in 





Fig. 23. Uretero-ileal anostomosis with JJ stents and intracorporeal ileal conduit. Arrowhead: 
ileal conduit, Arrow: Wallace type uretero-ureteric anastomosis. (Archive of Ankara Atatürk 
Training and Research Hospital, 1st Urology Clinic, Ankara, Turkey)  
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The 8-mm robotic trocar site opening located next to the supraumblical camera port on right 
is used for ileal conduit stoma following its enlargement. Interrupted 2/0 vicryl sutures are 
used in order to fix the ileal loop serosa to the anterior rectus sheet. Ileal opening is everted 
by interrupted 2/0 vicryl sutures to create a nipple type stoma. 
Patients are discharged after tolerating an oral diet and sufficient ambulation following 
removal of the lodge drains.  
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1. Introduction 
Prior to the introduction of the ileal conduit more than four decades ago, the options for 
urinary diversion after cystectomy were extremely limited. Direct cutaneous anastomoses of 
the collecting system (cutaneous pyelostomies, ureterostomies) offered patients a short-term 
diversion, but the benefits were outweighed by significant complications: recession or 
stenosis of the stoma. The first choice of diversion was the ureterosigmoidostomy with or 
without antireflux technique. Then it fell in popularity and was replaced with 
continent/non-continent uretero-ileo-cutaneous diversions. Only in the last years the 
continent orthotopic neobladder has been widely employed as first procedure choice. At 
present, patients can be offered a non-continent cutaneous diversion, a continent cutaneous 
diversion or an orthotopic neobladder urinary reconstruction (ONR). 
2. Surgical indications 
Urinary diversion is necessary in patients who undergo cystectomy. 
The choice of a specific urinary diversion should be performed on the basis of the mental 
status of the patient, renal function and overall health (Table1). 
The main surgical indications to perform a urinary diversion or a bladder replacement using 
transposed intestinal segments are bladder cancer, neurogenic bladder dysfunction, 
idiopathic detrusor overactivity and chronic inflammatory conditions (such as interstitial 
cystitis, tuberculosis, schistosomiasis and postradiation bladder contraction) [1]. 
If surgical cystectomy is indicated due to invasive bladder cancer the choice for replacing 
the lower urinary tract function rests between conduit diversion, bladder replacement or 
continent diversion [2].  
In patients affected by neurogenic bladder dysfunction due to congenital or acquired 
disorders (e.g. Neural tube defect or spinal cord injured patients) the main indications for 
such surgery is represented by intractable incontinence, deteriorating renal function and 
high bladder pressures. The choices would include either bladder reconstruction, 
replacement or continent diversion [3].  
Equally in subjects with severe idiopathic detrusor overactivity, if conservative measures 
fail the surgical therapy which may involve transposition of intestinal segments into the 
urinary tract (e.g. Clam enterocystoplasty) can provide effective treatment for some 
patients [4].  
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Finally in patients affected by idiopathic interstitial cystitis with a failure of all conservative 
treatments the surgical choices range from ileal conduit diversion to orthotopic neobladder 
reconstruction (ONR). In this context in case of bladder tuberculosis resulting in intolerable 
frequency, pain, urgency and haematuria with a small and incapable bladder the surgical 
therapy ranges from ileal conduit diversion to augmentation cystoplasty [5]. 
Choice of urinary diversion 
At present urologists have a variety of urinary diversions using different types of bowel 
segments based on an individual patient’s need and desire. In the past the 
ureterosigmoidostomy and the rectal neobladder as described by Mouclaire were the 
earliest forms of continent urinary diversion however, due to the rate of complications, 
these surgical solutions are at present abandoned. The ileal conduit remains the most 
common form of non-continent urinary diversion practiced worldwide today and it is the 
standard to which all other urinary diversions are compared [6]. Continent cutaneous 
diversions using detubularized colonic segments requiring timed intermittent self-
catheterization. These diversions gained popularity in the 1980s and are still applied 
today in patients for whom an ONR is not indicated. In this way the ONR represents the 
most innovative surgical solution of the last thirty years because it seems to offer a 
satisfactory quality of life. 
Urinary diversions used today in patients undergoing radical cystectomy can be categorized 
into three basic categories as follows : I) bowel conduits II) continent cutaneous stomal 
reservoirs using colonic segments III) orthotopic neobladder reconstruction (ONR) [7]. On 
the basis of the above reported classification we will restrict our focus on the ileal conduit, 
on the continent cutaneous diversions and the ONR by the use of ileal bowel. 
The ileal conduit is the simplest and most commonly performed urinary diversion for which 
the longest follow-up is available and due to the short operative time it is often applied in 
patients with significant medical comorbidities in an attempt to minimize postoperative 
complications and the need for reoperation [8]. 
The continent urinary diversion involves the creation of a low pressure reservoir of good 
capacity using a detubularised intestinal segments as described by Kock [9]. In this setting 
several techniques can be used to maintain continence adopting the principle of the nipple 
valve and one of the most popular type is the flap valve by the use of the appendix 
implanted into the reservoir as described by Mitrofanoff [10]. In this surgical technique the 
distal end of the continence channel is brought out as a stoma through the abdominal wall 
for clean intermittent self-catheterisation, thus avoiding the use of a stoma bag but requiring 
the ability of the patient to catheterize the stoma. 
In ONR the most used intestinal segment is the ileum due to its easy and ductile use while 
colonic segments although they had already been employed at the beginning of the “ONR 
era” they showed a higher number of late complications in comparison with ileum 
segments [11].  
Patients selection criteria: Absolute and relative contraindications 
The primary goals of urinary diversion are to provide the best local cancer control, to reduce 
the potential range of complications and to guarantee the best quality of life for the patient. 
The decision process is complex and involves consideration of issues related to cancer stage 
and location, medical comorbidities, technical surgical issues, treatment needs, and patient 
desires related to quality-of-life and lifestyle (Table 2). In this setting, patients should be 
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aware that intraoperative pathological findings could modify the type of urinary diversion 
planned, as in the case of a short mesentery or cancer-related issues such as positive urethral 
margin, or gross extravesical disease precluding a negative surgical margin. For this reason, 
all patients planned for an ONR should have a stoma site marked preoperatively by an 
enterostomal therapist and at the same time have read and accepted the informed consent 
for an alternative urinary diversion [7,12,13].  
In this way an absolute contraindication to continent diversion of any type is compromised 
renal function that results from long-standing obstruction or chronic renal failure, with 
serum creatinine levels above 150 to 200 mol/L.  
In patients with borderline renal function, creatinine clearance should be evaluated because 
at least a creatinine clearance of 60 mL/min is recommended for continent diversions [14]. A 
severe hepatic dysfunction is also a contraindication for continent diversion [15] because the 
reabsorption and recirculation of urinary metabolites require normal liver function [16-17-
20]. In fact the interposition of intestine in the urinary tract results in a marked increase in 
the absorption of urinary ammonia into the portal circulation resulting in a metabolic 
adaptation in a normal functioning liver without a hyperammonemia with a consequent 
altered mental status [19]. 
Regarding related contraindications, we know that these are steadily decreasing. However 
some, such as mental impairment, external sphincter dysfunction or recurrent urethral 
stricture, deserve serious consideration.  
Notably, old age is not a contraindication for ONR. Older patients, as part of the informed 
consent, need to be aware that they have a greater incidence of enuresis or nocturnal 
incontinence than do younger men, but age by itself should not be a contraindication. In this 
context, physiologic rather than chronologic age must be taken into consideration [20]. 
Although urinary continence rates are somewhat lower in patients over 70 years of age, 
satisfactory continence rates and functional outcomes can be obtained. [21,22].  
Obesity does not preclude orthotopic diversion and in some cases an orthotopic diversion 
may be advantageous because of the difficulty of constructing an optimal stoma for a 
urostomy appliance with conduits and the difficulty in negotiating a catheter through a 
thick abdominal wall for catheterization of a continent cutaneous pouch. In addition, large 
fluctuations in patient weight can change the angle of the originally constructed pouch 
making it difficult to catheterize [23]. 
Satisfactory functional outcomes with ONR after cystectomy have been reported in carefully 
selected patients who have received previous definitive, full dose pelvic irradiation [24,25]. 
However, these are technically complex and demanding procedures with a high risk for 
perioperative complications [26]. Common complications reported in post-radiation surgical 
series include ureteral stricture in up to 32% of patients, prolonged incontinence in up to 
44%, stomal problems in up to 39%, and fistulas in up to 7%. Reoperations to address these 
complications occur in 8% to 69% of patients and the most common reasons for reoperation 
include stomal revisions, ureteral anastomotic revisions, and procedures to correct 
incontinence and repair of fistulas [24,27]. 
Patients with compromised intestinal function, particularly inflammatory bowel disease, 
may be better served by an incontinent bowel conduit. A thorough evaluation of the colon 
by a contrast enema, sigmoidoscopy, or colonoscopy is recommended when planning to 
use large bowel segments for the urinary diversions to rule out colonic pathology such as 
diverticulosis, inflammatory bowel disease, or occult colon cancer, which would prevent 
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aware that intraoperative pathological findings could modify the type of urinary diversion 
planned, as in the case of a short mesentery or cancer-related issues such as positive urethral 
margin, or gross extravesical disease precluding a negative surgical margin. For this reason, 
all patients planned for an ONR should have a stoma site marked preoperatively by an 
enterostomal therapist and at the same time have read and accepted the informed consent 
for an alternative urinary diversion [7,12,13].  
In this way an absolute contraindication to continent diversion of any type is compromised 
renal function that results from long-standing obstruction or chronic renal failure, with 
serum creatinine levels above 150 to 200 mol/L.  
In patients with borderline renal function, creatinine clearance should be evaluated because 
at least a creatinine clearance of 60 mL/min is recommended for continent diversions [14]. A 
severe hepatic dysfunction is also a contraindication for continent diversion [15] because the 
reabsorption and recirculation of urinary metabolites require normal liver function [16-17-
20]. In fact the interposition of intestine in the urinary tract results in a marked increase in 
the absorption of urinary ammonia into the portal circulation resulting in a metabolic 
adaptation in a normal functioning liver without a hyperammonemia with a consequent 
altered mental status [19]. 
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satisfactory continence rates and functional outcomes can be obtained. [21,22].  
Obesity does not preclude orthotopic diversion and in some cases an orthotopic diversion 
may be advantageous because of the difficulty of constructing an optimal stoma for a 
urostomy appliance with conduits and the difficulty in negotiating a catheter through a 
thick abdominal wall for catheterization of a continent cutaneous pouch. In addition, large 
fluctuations in patient weight can change the angle of the originally constructed pouch 
making it difficult to catheterize [23]. 
Satisfactory functional outcomes with ONR after cystectomy have been reported in carefully 
selected patients who have received previous definitive, full dose pelvic irradiation [24,25]. 
However, these are technically complex and demanding procedures with a high risk for 
perioperative complications [26]. Common complications reported in post-radiation surgical 
series include ureteral stricture in up to 32% of patients, prolonged incontinence in up to 
44%, stomal problems in up to 39%, and fistulas in up to 7%. Reoperations to address these 
complications occur in 8% to 69% of patients and the most common reasons for reoperation 
include stomal revisions, ureteral anastomotic revisions, and procedures to correct 
incontinence and repair of fistulas [24,27]. 
Patients with compromised intestinal function, particularly inflammatory bowel disease, 
may be better served by an incontinent bowel conduit. A thorough evaluation of the colon 
by a contrast enema, sigmoidoscopy, or colonoscopy is recommended when planning to 
use large bowel segments for the urinary diversions to rule out colonic pathology such as 
diverticulosis, inflammatory bowel disease, or occult colon cancer, which would prevent 
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their use. A family or personal history of colon cancer or familial polyposis may 
predispose the patient to developing an adenocarcinoma in a colonic urinary reservoir 
segment and should be taken into consideration during the diversion selection process 
[28,29]. 
In conclusion the goal of patient counseling about urinary diversion should be to determine 
the method that is the safest for cancer control, that has the fewest complications over both 
the short and the long term and that provides the easiest adjustment for patients’ lifestyle, 
thereby supporting the best quality of life [7]. The ileal conduit is still the best urinary 
diversion method in many patients who have bladder cancer with associated chronic 
medical disease or certain surgical factors that render other urinary diversion techniques 
difficult to carry out. Finally we believe that all patients are potentially candidates for an 




Bowel Segment Primary Indication 
Gastric   Children requiring diversion  
(extrophy,pelvic radiation); Renal insufficiency 
Jejunum Pelvic radiation; Deficient ureteral length; 
Compromised viability of other small or large bowel 
Ileum or ileal-colic reservoirs Malignancies requiring removal of the bladder; 
Severe hemorrhagic cystitis; Incontinence 
Colon (ureterosigmoidostomy) Children requiring diversion (extrophy, pelvic 
radiation); No other bowel segment alternative 
Transverse colon conduit Malignancies requiring removal of the bladder; 
Small bowel not practical 




 Impaired renal function 
 Impaired hepatic function 
 Inadequate intellectual capacity 
 Positive apical urethral margin (for neobladder) 
 Unmotivated patient 
Relative contraindications 
 Advanced age 
 Need for adjuvant chemotherapy 
 Prior pelvic radiation 
 Bowel disease (especially inflammatory bowel disease) 
 Urethral pathology 
 Local disease and high risk of local recurrence 
Table 2. Absolute and Relative Contraindications for Continent Cutaneous/Orthotopic 
Neobladder Urinary Diversions [1,6] 
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3. Non continent cutaneous diversions: Surgical aspects and postoperarative 
complications 
The ileal and the colon conduit represent the non-continent cutaneous urinary diversions. 
The ileal conduit has been the mainstay of urinary diversion over the past forty-five years 
and, in authors’ opinion, it remains the first choice against all other compared urinary 
diversions. It consists of diverting urine to a short intestinal segment brought out through 
the anterior abdominal wall. The ileal resection can induce malabsorption of bile salts and 
vitamin B12. The colon conduit was less employed because of resulted in electrolyte 
abnormalities and was more amenable to antireflux ureteral implantation techniques. The 
non-refluxing technique is employed for a better maintenance of upper urinary tract 
integrity. 
Ileal conduit 
Ureteroileal urinary diversion is the most common method of non-continent urinary 
diversion. The basic technique for creation of the ileal loop has not changed significantly 
since the original description by Seiffer 1935. The procedure was subsequently popularized 
by Bricker.  
The patient is placed in supine position and a vertical midline or paramedian incision from 
the symphysis pubis to the umbilicus or beyond is required for good exposure [30]. 
The ureters are identified and transected approximately 3 or 4 cm above the bladder and 
then they are minimally mobilized taking care to preserve the surrounding adventitia and 
fat. The conduit is constructed using an ileal segment 15 to 20 cm long that is isolated 
approximately 20 cm proximal to the ileocecal valve [31,32,33]. 
Once the appropriate length of bowel is selected and isolated, the mesentery is divided 
proximally and distally and individual mesenteric blood vessels are ligated. The bowel is 
divided, thus isolating the segment selected for conduit construction. The continuity of the 
small intestine is reestablished, allowing for normal bowel function. The base of the conduit 
is closed and the ureters are reimplanted directly, creating an antirefluxing ureteroileal 
anastomosis.  
Ureteral stents (small-diameter, multichannel, silicone catheters) are placed through the 
ureteral anastomosis, the conduit and into the pelvis to facilitate urinary drainage while the 
anastomosis is healing [33-34].The conduit is usually positioned in the right lower quadrant 
of the abdomen in an isoperistaltic direction [32].  
To create the stoma, a small circle of skin is excised at the premarked site. And the 
underlying cylinder of fat is removed. The fascia is incised in a cruciate fashion. The end of 
the conduit is brought through the lateral aspect of the rectus abdominis muscle and 
anchored to the fascia, and the stoma is then formed [34]. The stoma should protrude, 
without tension approximately 2,5-3 cm above the skin surface. A Rutzen bag can be applied 
to the stoma on the fifth or sixth postoperative day with complete comfort for the patient 
[34]. 
Jejunal conduit 
Jejunal conduit urinary diversion is used rarely, since many better alternatives are available. 
However, jejunal conduits have been used in cases in which there has been significant ileal 
and colonic disease caused by previous irradiation and inflammatory bowel disease or there 
has been loss of the middle and distal ureter [35]. 
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is closed and the ureters are reimplanted directly, creating an antirefluxing ureteroileal 
anastomosis.  
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ureteral anastomosis, the conduit and into the pelvis to facilitate urinary drainage while the 
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anchored to the fascia, and the stoma is then formed [34]. The stoma should protrude, 
without tension approximately 2,5-3 cm above the skin surface. A Rutzen bag can be applied 
to the stoma on the fifth or sixth postoperative day with complete comfort for the patient 
[34]. 
Jejunal conduit 
Jejunal conduit urinary diversion is used rarely, since many better alternatives are available. 
However, jejunal conduits have been used in cases in which there has been significant ileal 
and colonic disease caused by previous irradiation and inflammatory bowel disease or there 
has been loss of the middle and distal ureter [35]. 
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As is discussed later, electrolyte disturbances can occur after incorporation of intestinal 
segments into the urinary tract; these are more common when the jejunum is used for 
conduit construction. In approximately 40% of patients with jejunal urinary conduits, 
hyponatremic, hyperkalemic, hypochloremic metabolic acidosis and azotemia develop [36]. 
The jejunum is unable to maintain large solute gradients, so large amounts of water and 
solute pass through the jejunal wall. Sodium and chloride are rapidly excreted into the 
conduit, and potassium is passively absorbed [36-37]. 
Aldosterone is produced, resulting in reabsorption of hydrogen and excretion of potassium 
into the distal tubule of the kidney and consequent acidosis and movement of potassium 
from the body's intracellular stores. As water is lost into the conduit, extracellular fluid 
volume is reduced, as is the glomerular filtration rate. The renin-angiotensin system is 
activated, which further stimulates aldosterone secretion. Urea may be absorbed from the 
jejunal lumen, which (with dehydration) contributes to azotemia [36]. As with other bowel 
segments incorporated into the urinary tract, the length of jejunum should be as short as 
possible to reduce metabolic abnormalities. The ureters are brought out from the 
retroperitoneum below the ligament of Treitz. An appropriate segment of jejunum is 
identified and isolated and it is important to preserve an adequate blood supply to the 
segment. In contrast to the ilal conduit, the isolated jejunum should lie above the 
reanastomosed jejunum. The proximal end of the conduit is directed towards the 
retroperitoneum and the conduit is oriented in an isoperistaltic direction. The ureters are 
anastomosed to the jejunum, with placement of stents to reduce early postoperative 
electrolyte abnormalities. The mesenteric window is closed using nonasorbable sutures. The 
stoma is created in the same way as described for an ileal conduit and is usually located in 
the right upper quadrant [38].  
Colon conduit 
There are several advantages to using the large bowel for the construction of urinary 
conduits: nonrefluxing ureterointestinal anastomoses are easily performed, possibly 
abrogating the deleterious effects of reflux on the upper urinary tracts [37-39].  
In the colon conduit stomal stenosis is uncommon because of the wide diameter of the large 
bowel but limited absorption of electrolytes occurs; the blood supply to the transverse and 
sigmoid colon is abundant [39]. Either the transverse or the sigmoid colon can be used, 
allowing for placement of the conduit high or low in the abdomen, depending on the 
integrity and condition of the ureters. Use of the transverse colon for conduit construction is 
especially well suited for patients who have received extensive pelvic irradiation or when 
the middle and distal ureters are absent [37,39]. 
The blood supply of the transverse colon is based on the middle colic artery.  
The greater omentum is separated from the superior surface of the transverse colon, and a 
segment of bowel, usually 15 cm in length, is selected for the conduit [39]. Short mesenteric 
incisions are made, and the colon is divided proximally and distally. Once the conduit is 
isolated, bowel continuity is reestablished. The proximal end of the conduit is closed and 
fixed in the midline posteriorly. The ureters are brought through small incisions in the 
posterior peritoneum and reimplanted into the base of the conduit [39]. The stoma may be 
positioned on either the patient's right or left side. 
A sigmoid conduit is constructed in a similar manner. Great care should be taken to 
preserve the blood supply by carefully selecting a segment with a good blood supply and by 
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making short mesenteric incisions. The conduit is positioned lateral to the reapproximated 
sigmoid colon. Ureteral reimplantation and stoma construction are completed [39]. 
The ureters can be reimplanted into the large intestine either in a way that prevents reflux or 
by anastomosis directly into the bowel. Ureteral reflux is prevented by constructing a short 
tunnel (approximately 2-3 cm in length) of bowel mucosa, through which the distal ureter 
runs [37,39]. Frequently, this is accomplished by incising the tenia of the large bowel for a 
distance of 3-4 cm. The incision is carried through the muscular fibers of the bowel wall, 
sparing the mucosa. A small elliptic segment of mucosa is removed, and a mucosa-to-
mucosa anastomosis is performed between the ureter and the mucosa of the bowel. The 
muscularis of the tenia is repositinated over the ureter to create the tunnel [39]. 
Cutaneous ureterostomy 
This surgical technique is based on the simple bilateral ureterostomy or alternatively on the 
transureteroureterostomy. From a technical point of view the first surgical solution is easier 
and faster than the transureteroureterostomy. In particular, in order to carry out of a 
transureteroureterostomy with cutaneous ureterostomy the ureters are isolated with care to 
preserve the blood supply. A retroperitoneal course anterior to the great vessels for the least 
dilated is created [40,41]. If only a single ureter is obstructed, a simple stoma can be created 
by sewing the end of the ureter flush with the skin at the stoma site. Another option, when 
the ureter is narrow, is to create a V-flap stoma. If both ureters are dilated, a single stoma 
can be created by suturing the ureters together, everting them and anastomosing the ends to 
the skin. When a single ureter is dilated, transureterostomy with retroperitoneal passage of 
the smaller ureter to the controlatereral side is combined with the cutaneous ureterostomy 
[38].  
Postoperative complications 
Complications occurring after urinary diversion are generally a product of surgical 
technique, the underlying disease process and its treatment, the age of the patient, and the 
length of follow-up. Postoperative complications are divided into early and late.  
Early complications (occurring in approximately 10% of patients) are wound infection, 
followed by ureteroileal leakage, intestinal obstruction, intestinal fistula and acute 
pyelonephritis [30]. 
Late complications (10-20% of patients) include metabolic disorders, stomal stenosis, cronic 
pyelonephritis, and calculi [30]. 
Metabolic and nutritional disorders 
Fluid, electrolyte, nutrient, and waste product excretion or absorption normally occurs 
across the intestinal wall. The extent of absorption or excretion is dependent on the 
concentration of these substances in the lumen or blood and on which segment of bowel is 
in contact with them.  
Metabolic abnormalities may occur when intestinal segments are interposed into the urinary 
tract [33].  
The pathogenesis and nature of metabolic abnormalities occurring after incorporation of the 
ileum or colon into the urinary tract differ from those associated with jejunal conduits [35]; 
when such segments are used, sodium and chloride are absorbed across the bowel surface. 
Chloride is absorbed in slight excess of sodium, resulting in a net loss of bicarbonate into the 
bowel lumen. Preexisting renal failure contributes to the development and severity of the 
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disorder, as does a large bowel surface area and long contact time. Hyperchloremic acidosis 
is more common in patients who undergo ureterosigmoidostomy than in patients who 
undergo simple conduit construction using either the ileum or the colon, because of the 
larger surface area and longer contact time with urine associated with 
ureterosigmoidostomies [42].  
Hyperchloremic metabolic acidosis may manifest clinically as weakness, anorexia, vomiting, 
Kussmaul breathing, and coma. One potential long-term complication of chronic acidosis 
may be decreased bone calcium content and osteomalacia [36]. 
Bile salts are important for fat digestion and uptake of vitamins A and D. Bile salt 
metabolism may be altered after ileal resection [43]. 
Resecton of small segments of the ileum may be associated with mild malabsorption and 
steatorrhea owing to increased concentrations of bile salts delivered to the colon. 
The increased concentration of such salts leads to decreased colonic absorption of water and 
electrolytes [35].The distal ileum is important for reabsorption of bile acidis, the use of this 
part of intestine for uncontinent urinary diversion causes abnormal high concentrations of 
bile acids in the colon leading to diarrhea due to the altered sodium absorption [43]. 
Vitamin B12 deficiency may occur as a result of resecting the terminal ileum to resconstruct 
the lower urinary tract. The signs of vitamin B 12 deficiency include megaloblastic 
macrocytic anemia and neurologic injury, which become permanent if allowed to persist 
[33,35,42,44]. 
Stomal complications 
Stoma related complications occurred in 15% of patients with the most frequent being 
parastomal hernia, stenosis and various skin irritations or fungal infections [32,33]. The 
majority of stoma related complications occurred within the first 5 years after surgery [32].  
Stomal stenosis can lead to conduit elongation and upper-tract obstruction. This condition 
can be diagnosed relatively easily by catheterizing the stoma and measuring the residual 
urine volume. It is corrected by revision of the stoma [42]. 
Skin irritation or infections are most common in procedures in which an appliance is worn 
and there is prolonged contact of the skin with urine. Some patients' skin may be sensitive to 
adhesive agents [30]. 
Urinary tract infection and pyelonephritis 
Pyelonephritis occurs in approximately 12% of patients who have undergone urinary 
diversion. The infectious complications occurred at a median of 1.8 years after surgery 
[45].  
Treatment is based on a properly collected urine sample for culture. A urine sample should 
not be collected from the pouch; rather, the pouch should be removed, the stoma cleansed 
with an antiseptic, and a catheter advanced gently through the stoma. 
If infection has occurred in a patient with a simple conduit, the volume of residual urine 
within the conduit should be recorded. Obstruction and stasis of urine within the 
reconstructed urinary tract are risk factors for the development of infection [32]. 
Although many patients with preexisting dilation of the upper urinary tract show 
improvement or resolution of the dilation after urinary diversion or bladder substitution, 
progressive renal deterioration as manifested by hydronephrosis or an increasing serum 
creatinine level (or both) occur in a certain percentage of patients who undergo these 
procedures [42]. The incidence of either complication increases after 10 years. Pyelographic 
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evidence of upper urinary tract deterioration has been noted in up to 50% of patients who 
have undergone urinary diversion at an early age. 
Recurrent upper urinary tract infection and high-pressure ureteral reflux and obstruction, 
usually in combination, contribute to the likelihood of renal deterioration. 
Calculi 
Calculi occur in approximately 8% of patients who undergo urinary diversion, at a median 
of 2.5 years after surgery [33]. 
Such patients have several risk factors for the development of various calculi. 
Nonabsorbable staples, mesh, or suture material used to construct conduits or reservoirs 
may act as a nidus for stone formation [33].  
Colonization in either conduits or reservoirs is common, whereas symptomatic infection is 
much rarer. 
Certain bacteria can contribute to stone formation; some bacteria commonly found in the 
urinary tract, including: Proteus, Klebsiella, and Pseudomonas species, produce urease, a 
urea-splitting enzyme that contributes to the formation of ammonia and carbon dioxide. 
Hydrolysis of these products results in an alkaline urine supersaturated with magnesium 
ammonium phosphate, calcium phosphate, and carbonate apatite crystals. 
Management of such infection-related stones requires stone removal, resolution of infection, 
and, often, use of adjunctive agents to complete stone dissolution [33]. 
The likelihood of stone formation is increased by the development of systemic acidosis, as 
described previously. Prolonged contact of the urine with the intestinal surface facilitates 
the exchange of chloride for bicarbonate [33]. 
Bicarbonate loss results in systemic acidosis and hypercalciuria. The combination of 
hypercalciuria and alkaline urine predisposes a patient to the development of calcium 
calculi. In addition, the terminal ileum is responsible for bile salt absorption; if this portion 
of the intestine is used for conduit or bladder reservoir construction, excess bile salts in the 
intestine may bind calcium and result in increased absorption of oxalate, which may lead to 
the development of oxalate-containing calculi [36]. 
Hypocitraturia may also be a risk factor for stone disease in patients undergoing bladder 
replacement [36].  
Excess conduit length, urine stasis, and dehydration make the development of calculi more 
likely. 
4. Orthotopic neobladder reconstruction (ONR): Surgical aspects and 
postoperative complications 
In 1979, Camey and Le Duc published their clinical experience with ONR. This orthotopic 
bladder substitute has evolved into the most ideal form of urinary diversion available today 
and should be considered the gold standard with which other forms of diversion are 
compared. Before 1990, the orthotopic substitution was reserved for male patients with 
invasive bladder cancer while the same surgical approach was considered contraindicated 
in the female subjects because the urethra was removed during cystectomy to assure 
adequate oncological results. It was also believed that the female patient would be unable to 
maintain the continence mechanism if orthotopic diversion was performed after cystectomy. 
Actually, it has been shown that the urethra can be saved in the most women undergoing 
cystectomy for bladder cancer without compromising the oncological results [46]. 
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Models of ONR 
Radical cystectomy is the standard treatment for localized muscle-invasive bladder cancer. 
Different types of intestinal segments have been used for urinary diversion, including 
stomach, ileum, colon in humans and animals. However, the terminal ileum is most often 
used for bladder substitution. Therefore, the ideal diversion should be fully continent, 
cosmetically impeccable, allowing easy and complete emptying within socially acceptable 
intervals, and preserve renal function [47]. 
- In Camey II orthotopic substitution a total of 65 cm of ileum is isolated, with an area of 
the ileum identified to reach the region of the urethra in a tension-free manner. After 
the integrity of the bowel is restored, the mesenteric trap is closed, and the isolated 
portion of ileum is opened along the antimesenteric border for the entire length, except 
the area previously identified for urethral anastomosis. In this region, the ileal incision 
is directed toward the mesenteric border. The ileum is then placed in a transverse U 
orientation. The medial borders of the U are sutured together with a running absorbable 
suture. A fingertip opening is made in the preselected area for the ileourethral 
anastomosis, the entire ileal plate is brought down to the pelvis, and urethroenteric 
anastomosis is performed. The ureteroileal anastomosis is then performed by a Le Duc 
technique. The reservoir is completed by folding the ileal plate and suturing with a 
running absorbable suture. The ends of the U are anchored to the pelvic floor to reduce 
tension [48]. 
- The ileal neobladder developed by Hautmann was an ileal reservoir with a “W 
configuration” that wanted to guarantee a reduction of nighttime incontinence. A 
segment of terminal ileum of approximately 70 cm is selected. The bowel is 
reconstituted, and the mesenteric trap is closed. The ileal section that reaches the 
urethra most easily is identified and marked with a traction suture along the 
antimesenteric border. The isolated bowel segment is then arranged in either an M or W 
shape and is incised. The entire segment is opened along the antimesenteric border 
except for a 5-cm section along the traction suture, where the incision is directed toward 
the anterior mesenteric border to make a U-shaped flap. This facilitates anastomosis of 
the neobladder to the urethra. The four limbs of the M or W are then sutured to one 
another with a running absorbable suture. In the center of the previously developed 
flap, a segment of the ileal wall is excised. The ileourethral anastomosis is then 
performed with the sutures tied from “inside” the neobladder. Once the ileal 
neobladder is situated in the pelvis and the urethral sutures are tied, the ureters are 
implanted from inside the neobladder through a small incision in the ileum at a 
convenient site as reported by Abol-Enein (Fig.1) or in monolateral fashion as described 
by Siracusano [49]. The remaining portion of the anterior wall is then closed with a 
running absorbable suture. 
- The Studer ileal bladder substitute uses a portion of terminal ileal segment: 54 to 60 cm 
is isolated approximately 25 cm proximal to the ileocecal valve. Bowel continuity is 
restored, and the ends of the isolated segment are closed with a running absorbable 
suture. The distal 40-cm segment of ileum is placed in a U shape and opened along the 
antimesenteric border. The ureters are split and anastomosed in an end-to-side fashion 
to the proximal afferent tubular portion of ileum. The two medial borders of the U-
shaped ileum are then oversewn with a running absorbable suture. The bottom of the U 
is folded over between the two ends of the U. After the lower half of the anterior wall  
 




Fig. 1. Spatulated ureters are anastomosed to intestinal mucosa of the lateral wall of the 
trough. The ureters are anastomosed on 8 Fr anti-reflux double “J” stents (By Siracusano Eur 
Urol 38 : 313, 2000) 
and part of the upper half are closed, a finger is introduced through the remaining 
reservoir opening to determine the most caudal part of the neobladder. A hole is cut out 
in this dependent portion of ileum, away from the suture line, which allows urethral 
anastomosis. The urethroenteric anastomosis is performed, and the remaining portion 
of the reservoir is then closed [50].  
- The Kock ileal reservoir utilizes intussuscepted nipple valves for both the afferent 
and efferent limbs to prevent urinary reflux. A total of 61 cm of terminal ileum is 
isolated. 22-cm segments are placed in a U configuration and opened adjacent to the 
mesentery. The more proximal 17-cm segment of ileum will be used to make the 
afferent intussuscepted nipple valve. The posterior wall of the reservoir is then 
formed by joining the medial portions of the U with a continuous running suture. A 
5- to 7-cm antireflux valve is made by intussusception of the afferent limb with the 
use of Allis forceps clamps. The afferent limb is fixed with two rows of staples placed 
within the leaves of the valve. The valve is fixed to the back wall from outside the 
reservoir. After completion of the afferent limb, the reservoir is completed by folding 
the ileum on itself and closing it (anterior wall). The most dependent portion of the 
reservoir becomes the neourethra. Ureteroileal anastomosis is performed first, and 
urethroenteric anastomosis is completed in a tension-free, mucosa-to-mucosa fashion 
[51]. 
- The “vescica ileale padovana” (VIP) is a modified form of Camey II with a more 
spherical reservoir. A portion of terminal ileum 40 cm long is isolated approximately 20 
cm proximal to the ileocecal valve and opened along the antimesenteric border. The 
distal 10-cm segment is intended to constitute a tunnel for ileal-urethral anastomosis, 
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formed by joining the medial portions of the U with a continuous running suture. A 
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spherical reservoir. A portion of terminal ileum 40 cm long is isolated approximately 20 
cm proximal to the ileocecal valve and opened along the antimesenteric border. The 
distal 10-cm segment is intended to constitute a tunnel for ileal-urethral anastomosis, 
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while the proximal 30-cm segment of ileum is folded in a jellyroll fashion to produce a 
posterior plate. The pouch is then closed anteriorly [52]. 
- The T pouch ileal neobladder is a variant of Koch ileal reservoir but with a new, safe 
and simple antireflux technique. The T pouch is constructed from a 44-cm segment of 
terminal ileum placed in a V formation with a more proximal 8- to 10-cm segment of 
ileum used to form the antireflux limb. The entire mesentery remains intact to provide 
excellent viability. Windows of Deaver are opened (with Penrose drains placed into 
each window) in the distal 3 to 4 cm of the isolated afferent limb. The blood supply 
remains intact to this afferent ileal segment. A series of interrupted silk sutures are used 
to approximate the serosa of the adjacent 22-cm limbs (cephalad portion), with the 
passage of sutures through the corresponding window of Deaver. After the silk suture 
is passed through the window of Deaver, it is placed at a corresponding site on the 
adjacent 22-cm segment and then brought back through the same window of Deaver 
and tied down. The anchored portion of afferent limb is tapered on the antimesenteric 
border. The ileal segments are opened adjacent to the mesentery beginning at the apex 
and carried upward to the ostium of the afferent limb. Once the incision reaches the 
ostium of the afferent limb, it is directed to the antimesenteric border and then carried 
upward. This provides excellent ileal flaps to cover the tapered afferent ileal segment 
that is anchored into the serous trough. The ostium of the afferent segment is sutured to 
the ileal flaps. The ileal flaps are then brought over and oversewn to cover the tapered 
afferent ileal segment. This completes the posterior wall of the reservoir and forms the 
antireflux flap-valve mechanism. The reservoir is folded and closed in the opposite 
direction from which it was opened. The ureteroileal anastomosis is performed to the 
proximal portion of the afferent ileal segment. The anterior suture line is stopped just 
short of the right side. Then the result will be anastomosed to the urethra [53]. 
- The surgeons of Turin University propose an operative technique of a new Y-shaped ileal 
neobladder reconstruction. The procedure is performed with the isolation of 40cm of 
ileum, 15-20cm before the ileocecal valve. The isolated segment is arranged in a Y-shape 
with two central segments of 14cm and two limbs of 6cm. The two central segments are 
brought together and detubularized, with a nonabsorbable mechanical stapler inserted 
through an opening made at the lowest point of the neobladder. The Y-neobladder is 
anastomosed to the urethra with five sutures in 2-0 polyglycolic acid, over a 22F silastic 
catheter. The ureters, resected above the crossing with the iliac vessels and spatulated 
anteriorly, are anastomosed to the dorsal aspect of the two limbs with 5.0 polyglycolic 
acid sutures, using the direct Nesbit technique. Ureteral stents, previously placed, are 
brought out through the distal portions of each chimney and then through the anterior 
abdominal wall. The two limbs are fixed to the psoas muscles [54]. 
- In relation to the use of colon for carrying out ONR we report Mansson’s technique and 
the pouches described by the Mainz School and by Reddy respectively. 
In particular Mansson proposes an orthotopic neobladder substitution using a right colon 
segment (Mansson pouch). The entire right colon and cecum are isolated, and a transverse 
ileocolonic anastomosis is performed to provide bowel continuity. The ileal stump at the 
ileocecal valve is closed with a running absorbable suture. The colonic segment is then 
opened along the anterior taenia, leaving the proximal 2 to 3 inches of cecum intact. An 
appendectomy is performed, and the ureters are implanted in an antireflux fashion within 
the reservoir. The colon is then folded in a Heineke-Mikulicz manner and closed with a 
running absorbable suture. The ureterocolonic anastomosis is then performed [55]. 
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- The surgeons of Mainz Institute describe a surgical procedure with a segment of both 
ileum and right colon (Mainz pouch). A 10- to 15-cm segment of cecum, in continuity 
with a 20- to 30-cm segment of ileum, is isolated. An ascending ileocolostomy is 
performed. The entire segment of bowel is opened along the antimesenteric border, 
sacrificing the ileocecal valve. The bowel is placed in a W configuration, with the first 
limb of the W represented by cecum and the middle two limbs represented by ileum. 
The adjacent three limbs are sutured together with an absorbable suture, forming the 
posterior plate of the reservoir. At the cephalic portion of the cecum, tunneled 
ureterocolonic anastomosis is performed. A buttonhole incision is made in the cecum at 
the base of the reservoir, and a ureterocolonic anastomosis is performed. After this, the 
reservoir is closed side to side with absorbable suture [56].  
- Reddy and Lange describe an orthotopic reconstruction with sigmoid segment (Reddy 
pouch). A 35-cm portion of descending colon and sigmoid is isolated and arranged in a 
U configuration. The medial taenia of the U is incised down to an area just short of the 
urethral anastomosis. The incised medial limbs of the U are then brought together with 
an absorbable suture. Ureteral implantation is performed in a tunnel antireflux fashion. 
A small button of colon is removed from the most dependent portion of the reservoir, 
and the urethroenteric anastomosis is performed. The reservoir is then closed side to 
side [57]. 
Complications 
The patients may incur early and late complications as previously reported in non continent 
cutaneous diversions. The early post-operative complications may be identified as 
enterocolitis, acute pyelonephritis or lymphorrhoea. Therefore, chronic urinary retention, 
stricture of neobladder-urethra anastomosis, urosepsis secondary to bilateral 
hydronephrosis and neobladdder stones are the main late complications for this form of 
surgery [58]. Finally the utilization of small bowel for urinary diversion may interfere with 
the physiological renal acid and salt regulation while osteoporosis and osteomalacia might 
theoretically develop from a persistent hypokalemic, hyperchloremic acidosis.  
5. Conclusions 
For many years the ileal conduit and the ureterosigmoidostomy were considered the 
primary choice for urinary diversion following cystectomy. In the last twenty years the 
surgical procedures of urinary tract reconstruction after bladder removal have evolved from 
simply urinary diversions and protecting the upper tract to creating a socially and 
psychologically more acceptable quality of life. Nevertheless at present there is no optimal 
surgical urinary diversion for all patients but surgical solutions that must be applied to each 
type of patient. 
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reservoir is closed side to side with absorbable suture [56].  
- Reddy and Lange describe an orthotopic reconstruction with sigmoid segment (Reddy 
pouch). A 35-cm portion of descending colon and sigmoid is isolated and arranged in a 
U configuration. The medial taenia of the U is incised down to an area just short of the 
urethral anastomosis. The incised medial limbs of the U are then brought together with 
an absorbable suture. Ureteral implantation is performed in a tunnel antireflux fashion. 
A small button of colon is removed from the most dependent portion of the reservoir, 
and the urethroenteric anastomosis is performed. The reservoir is then closed side to 
side [57]. 
Complications 
The patients may incur early and late complications as previously reported in non continent 
cutaneous diversions. The early post-operative complications may be identified as 
enterocolitis, acute pyelonephritis or lymphorrhoea. Therefore, chronic urinary retention, 
stricture of neobladder-urethra anastomosis, urosepsis secondary to bilateral 
hydronephrosis and neobladdder stones are the main late complications for this form of 
surgery [58]. Finally the utilization of small bowel for urinary diversion may interfere with 
the physiological renal acid and salt regulation while osteoporosis and osteomalacia might 
theoretically develop from a persistent hypokalemic, hyperchloremic acidosis.  
5. Conclusions 
For many years the ileal conduit and the ureterosigmoidostomy were considered the 
primary choice for urinary diversion following cystectomy. In the last twenty years the 
surgical procedures of urinary tract reconstruction after bladder removal have evolved from 
simply urinary diversions and protecting the upper tract to creating a socially and 
psychologically more acceptable quality of life. Nevertheless at present there is no optimal 
surgical urinary diversion for all patients but surgical solutions that must be applied to each 
type of patient. 
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1. Introduction 
The H19-IGF2 locus within the imprinted cluster of the human chromosome 11, has been 
implicated in a variety of disorders and cancer pre-disposition including bladder cancer. 
BBN induced bladder cancer model in rats has identified both H19 and IGF2 among 
differentially expressed genes that are induced in response to carcinogen exposure.  
In this chapter, the role of both H19 and IGF2 genes in cancer will be handled in general 
with special focus on bladder cancer. Although IGF2 role in human cancers is relatively well 
established, recent data from our laboratory and others have just revealed a critical role for 
H19 RNA in the process of tumorigenicity including that of the bladder.  H19 functions as a 
stress modulator, being induced by hypoxia, and a survival factor that is involved in several 
fundamental processes of tumorigenesis. Furthermore, we uncovered a molecular 
mechanism that integrates H19, p53 and HIF1-α to hypoxic stress response. Placing the H19 
gene product in this deadly circuit undoubtedly will have major impacts in its utility as a 
target for cancer gene therapy. 
Regulatory sequences of both H19 and IGF2 have already been used to successfully target 
expression of a toxic protein, diphtheria toxin A (DT-A), in carcinoma cells in culture, in 
several xenograft, orthotopic animal models, and in chemically induced BBN model of 
bladder cancer. In case of H19, it is successfully used in patients with bladder carcinoma for 
a period of over 5 years and recently a clinical trial phase I/IIa using this therapeutic 
approach has been successfully completed. It is also successfully used in other types of 
human cancers but will not be handled in the current chapter. 
We will discuss also novel approaches, to create a new family of plasmids. In one approach 
a cytotoxic gene is driven by two different regulatory sequences, selected from the cancer-
specific promoters H19, IGF2-P3 and IGF2-P4 carried on a single construct. In a second 
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approach a single promoter is used to drive two cytotoxic genes having synergistic effect on 
a single construct. Both approaches show superior tumor growth inhibition activity, in 
preclinical studies of bladder cancer. 
Bladder Cancer is the fourth most common cancer in men accounting for about 7% of all 
cancer cases and 3% of all cancer related mortality. Each year, more than 50,000 new patients 
are diagnosed with bladder cancer in the USA and about 10,000 die from this disease (Jemal 
et al., 2010). Carcinogens activity on a susceptible epithelium is believed to be the cause of 
bladder cancer. Many industrialized chemicals are causally related; benzidine, 
βnapthylamine, 4-aminobiphenyl, etc. However, the commonest cause of bladder cancer 
nowadays, is by far cigarette smoking accounting for about half of all bladder cancers 
(Burch et al., 1989). Whether bladder cancer arises from a single transformed cell (clonogenic 
theory) or from multiple transformed cells (field change theory),  is still under debate.  
Painless hematuria is the hallmark of bladder cancer. This dramatic symptom urgently 
brings the patient to see a doctor. Therefore, most bladder tumors are diagnosed during the 
lifetime of the patient. Bladder tumors can also present with irritative urinary symptoms 
(urinary urgency, frequency and dysuria). Bladder tumors can be diagnosed by 
ultrasonography, intravenous urography, or computerized tomography. The resolution of 
these radiologic techniques is low, and only a 5 to 10 mm lesion can be detected. Cystoscopy 
done by inserting an optical instrument into the bladder can diagnose bladder tumors as 
small as 1mm. Urinary cytology is an important adjunct to cystoscopy, especially for the 
diagnosis of the flat lesion carcinoma in-situ (CIS). 
Most bladder tumors arise from the epithelial lining the urinary system-the transitional 
epithelium (urothelium), and are therefore, transitional cell carcinomas (or urothelial 
carcinomas). Bladder cancer is a heterogeneous disease with wide variations in molecular 
pathogenesis, morphology and prognosis. They are classified according to their depth of 
invasion into the bladder wall (stage) and according to the degree of histological anaplasia 
(grade). 
As in most other types of cancer, it is believed that 4-6 DNA hits are required for malignant 
transformation (Duggan et al., 2004). These include deletions, mutations and loss of 
heterozygosity (LOH) of genetic material that carries tumor suppressor genes or proto-
oncogenes, and epigenetic changes such as CpG methylations that modify gene expression. 
There are at least 2 major pathogenic pathways leading to 2 completely different bladder 
cancers. One pathway leads a low grade, papillary bladder cancer (about 75% of all bladder 
tumors). This type of tumor has a proliferative ability but no ability to invade the epithelial 
lamina propria and muscle of the bladder, to metastasize and to kill the patient. The second 
pathway leads to a high grade, solid tumor that has an invasive and metastatic potential 
(about 15% of the tumors). Possibly, there is a third pathway that leads to a high grade 
papillary tumor (about 10% of the tumors) (Goebell &Knowles, 2010). While low grade 
tumors tend to recur but almost never endanger the life of the patient, high grade tumors 
are often lethal.  
It is believed that low grade tumors develop following this pathway: Urothelial 
hyperplasia urothelial atypia low grade TCC. The most prominent molecular change in 
this group is mutation in FGFR3, found up to 88% of these tumors (van Rhijn et al., 2002). In 
most cases these are activation mutation that probably supports tumor proliferation by 
stimulating the RAS-MAPK pathway. The frequency of FGFR3 mutations in high grade 
tumors is much lower. Activation of the phosphatidylinositol 3–kinase (PI3K) pathway by a 
wide range of mechanisms is also typical to low grade tumors (Goebell &Knowles, 2010). 
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High grade bladder tumors develop following this pathway: Urothelial atypia dysplasia 
 CIS Invasive TCCmetastatic disease. The most prominent molecular changes in high 
grade tumors involve inactivation of the p53 and RB pathways. p53, whose activity is 
augmented in the presence of DNA damage, arrests cells at G1-S checkpoint by inducing the 
transcription of the CDK inhibitors-p21/Waf1, and GADD45. Then the cell may either 
correctly repair its DNA or undergo apoptosis. Deletions or mutations in the p53 pathway 
are found in about 70% of the high-grade tumors. 
The Retinoblastoma gene codes for an 110kDa nuclear phosphoprotein acting as a tumor 
suppressor that also arrest cells at G1. It is often mutated by a truncating mutation of the 
carboxyl terminal. Mutations or deletions in Rb gene are found in 30% of the patients with 
advanced bladder cancers. They result in uncontrolled cellular proliferation even without 
mitogenic signals. Hypermethylation of the Rb promoter region can have the same effect. 
Similarly, loss of the cyclin dependent kinase inhibitor p16 either by mutation, deletion, or 
by promoter hypermethylation, as documented in 20-45% of the bladder cancers prevents 
Rb activation by hyper-phosphorylation, or leads to uncontrolled cell cycle progression 
(Schultz, 1998). 
Epithelial to mesenchymal transition (EMT) is an important process typical to high grade 
tumors. It is characterized by down regulation of the adhesion molecule E-cadherin and of 
proteins associated with cell polarity along with up regulation of fibronectin, vimentin and 
matrix metalloproteases (MMPS). EMT is induced by cytokines like the TGFβ and is 
associated with increased invasion, migration and angiogenesis.  
Alterations in chromosome 9 are the most common cytogenetic findings in bladder cancer. 
Of these, the most common are deletions and LOH in the short arm, home of the tumor 
suppressor genes and cell-cycle regulators CDKN2A (encoding for p16 and p14ARF) and 
CDKN2B (encoding for p15).  In a rather consistent manner high grade tumors demonstrate 
LOH of 3p, 8p, 13q, and 17p, while low grade tumors demonstrate LOH of chromosome 9 
only (Knowles et al., 2001). 
Animal models are critical in the understanding of bladder cancer pathogenesis and in the 
quest for new treatments.  Most animal models in bladder cancer are in rodents. Although 
various models exist, we'll focus on carcinogen induced bladder cancer model. 
1.1 Carcinogen induced bladder cancer in mice and rats 
In this model, the rodent is given a carcinogen, most commonly in the drinking water. BBN 
(N -butyl-N- (4-hydroxybutyl) nitrosamine) is a carcinogen given to the rodents in a 
concentration of 0.05% in the drinking water. It induces bladder tumors in 95% of the 
rodents after 25 weeks of administration (Okada et al., 1975). The tumors produced by the 
carcinogen resemble human bladder cancer in histology, etiology, and in kinetics (25 rat 
weeks equal 10 human years- the believed incubation period of human bladder cancer). 
Molecular events occurring during chemical carcinogenesis can be followed (Ariel et al., 
2004). Tumor development and the response to novel treatments can be assessed non-
invasively, without scarifying the animal using ultrasonography (Gofrit et al., 2006). The 
main disadvantages of this model are necessity to handle a carcinogen and the long period 
required for tumor production.  
In our lab we used this model to "fish up" genes involved in bladder tumorigenesis using 
microarray analyses. We identified both H19 and IGF2 among differentially expressed genes 
that are induced in response to carcinogen exposure (Elkin et al., 1998, Ariel et al., 2004) 
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most cases these are activation mutation that probably supports tumor proliferation by 
stimulating the RAS-MAPK pathway. The frequency of FGFR3 mutations in high grade 
tumors is much lower. Activation of the phosphatidylinositol 3–kinase (PI3K) pathway by a 
wide range of mechanisms is also typical to low grade tumors (Goebell &Knowles, 2010). 
 
The H19-IGF2 Role in Bladder Cancer Biology and DNA-Based Therapy 
 
365 
High grade bladder tumors develop following this pathway: Urothelial atypia dysplasia 
 CIS Invasive TCCmetastatic disease. The most prominent molecular changes in high 
grade tumors involve inactivation of the p53 and RB pathways. p53, whose activity is 
augmented in the presence of DNA damage, arrests cells at G1-S checkpoint by inducing the 
transcription of the CDK inhibitors-p21/Waf1, and GADD45. Then the cell may either 
correctly repair its DNA or undergo apoptosis. Deletions or mutations in the p53 pathway 
are found in about 70% of the high-grade tumors. 
The Retinoblastoma gene codes for an 110kDa nuclear phosphoprotein acting as a tumor 
suppressor that also arrest cells at G1. It is often mutated by a truncating mutation of the 
carboxyl terminal. Mutations or deletions in Rb gene are found in 30% of the patients with 
advanced bladder cancers. They result in uncontrolled cellular proliferation even without 
mitogenic signals. Hypermethylation of the Rb promoter region can have the same effect. 
Similarly, loss of the cyclin dependent kinase inhibitor p16 either by mutation, deletion, or 
by promoter hypermethylation, as documented in 20-45% of the bladder cancers prevents 
Rb activation by hyper-phosphorylation, or leads to uncontrolled cell cycle progression 
(Schultz, 1998). 
Epithelial to mesenchymal transition (EMT) is an important process typical to high grade 
tumors. It is characterized by down regulation of the adhesion molecule E-cadherin and of 
proteins associated with cell polarity along with up regulation of fibronectin, vimentin and 
matrix metalloproteases (MMPS). EMT is induced by cytokines like the TGFβ and is 
associated with increased invasion, migration and angiogenesis.  
Alterations in chromosome 9 are the most common cytogenetic findings in bladder cancer. 
Of these, the most common are deletions and LOH in the short arm, home of the tumor 
suppressor genes and cell-cycle regulators CDKN2A (encoding for p16 and p14ARF) and 
CDKN2B (encoding for p15).  In a rather consistent manner high grade tumors demonstrate 
LOH of 3p, 8p, 13q, and 17p, while low grade tumors demonstrate LOH of chromosome 9 
only (Knowles et al., 2001). 
Animal models are critical in the understanding of bladder cancer pathogenesis and in the 
quest for new treatments.  Most animal models in bladder cancer are in rodents. Although 
various models exist, we'll focus on carcinogen induced bladder cancer model. 
1.1 Carcinogen induced bladder cancer in mice and rats 
In this model, the rodent is given a carcinogen, most commonly in the drinking water. BBN 
(N -butyl-N- (4-hydroxybutyl) nitrosamine) is a carcinogen given to the rodents in a 
concentration of 0.05% in the drinking water. It induces bladder tumors in 95% of the 
rodents after 25 weeks of administration (Okada et al., 1975). The tumors produced by the 
carcinogen resemble human bladder cancer in histology, etiology, and in kinetics (25 rat 
weeks equal 10 human years- the believed incubation period of human bladder cancer). 
Molecular events occurring during chemical carcinogenesis can be followed (Ariel et al., 
2004). Tumor development and the response to novel treatments can be assessed non-
invasively, without scarifying the animal using ultrasonography (Gofrit et al., 2006). The 
main disadvantages of this model are necessity to handle a carcinogen and the long period 
required for tumor production.  
In our lab we used this model to "fish up" genes involved in bladder tumorigenesis using 
microarray analyses. We identified both H19 and IGF2 among differentially expressed genes 
that are induced in response to carcinogen exposure (Elkin et al., 1998, Ariel et al., 2004) 
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
366 
 In the following sections we will present the role of both H19 and IGF2 genes in 
tumorigenicity. Then we will discuss pre-clinical and clinical data for the successful 
treatment of bladder cancer by DNA-based drug developed in our laboratory based on both 
the H19 and IGF2 regulatory sequences to drive the expression of a toxic protein, diphtheria 
toxin A (DT-A). This approach also proved to be successful in other cancer types; ovarian 
(Mizrahi et al., 2010), prostate (submitted) in human patients, and pre-clinically under 
development in glioblastoma (under preparation), lung (Hasenpusch et al., 2011), and 
colorectal liver metastasis (Ohana et al., 2005). This chapter will focus only on bladder 
cancer. Pre-clinical data using novel approaches for the treatment of bladder cancer with 
improved cytotoxic effect will be presented as well. 
2. The H19-IGF2 locus and tumorigenesis 
The IGF2 and H19 genes are both located on the short arm of chromosome 11 and are 
reciprocally imprinted. Genomic imprinting of the IGF2 and H19 genes has been shown to 
play a role in the regulation of the IGF2 and H19 expressions during embryonic 
development and in cancer. The role of genomic imprinting in tumor development is not 
well understood and it is beyond the scope of this chapter. Over-expressions of H19 and 
IGF2 genes in many tumors may or may not be associated with loss of imprinting. 
2.1 The pivotal role of H19 RNA in tumorigenesis 
H19 is an oncofetal gene that expresses only RNA and not protein, being expressed in the 
embryo, repressed in the adult, and re-expressed in a variety of human tumors, for review 
(Matouk et al., 2005). H19 is emerging as one of the key players in cancer biology.  We and 
others have demonstrated an essential role of H19 RNA in tumor development, and the 
association and contribution of H19 RNA with various aspects of tumorigenic process. This 
contradicts the initial proposal that H19 gene product has a tumor suppressive activity (Hao 
et al., 1993). 
Our strategy to delineate the role of H19 RNA in tumor development is based on 
determining if tumor development is dependent on H19 expression through both over-
expression and knockdown approaches in different tumor models including bladder cancer. 
To shed light into its mechanism of action our strategy is based on identifying upstream 
effectors and also downstream targets by applying the global gene expression profiling to 
identify genes modulated by both H19 over-expression and knockdown. Here again bladder 
cancer model is included.  
Our results, supported by results from others, reveal that H19 RNA harbors oncogenic 
properties, enhancing the development of carcinogenesis.  In this section we'll present major 
findings that support this issue and highlight its relevance to bladder cancer where possible. 
2.1.1 H19 RNA is essential for human tumor growth 
Although H19 over-expression sometimes associated with loss of imprinting have been 
reported in a large arrays of human cancers, direct evidence of its tumorigenic role was 
lacking. Using two cell line models including bladder carcinoma, we provided evidences, 
that H19 is critical for tumor development. Our in vivo results show that bladder carcinoma  
formed from UMUC3 cells in which the H19 RNA have been knocked down , induce a very 
significant retardation of tumor growth. Similar results were reproduced using other 
carcinoma model (Matouk et al., 2007). 
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Moreover we showed that ectopic H19 expression enhances the tumorigenic potential of 
bladder carcinoma cells in vivo. Tumors induced from T24P bladder carcinoma cell line 
ectopically over-expressing H19 RNA, differ significantly in their growth properties and 
growth kinetics in vivo relative to the control, and are well vascularized with evidences of 
tumor hemorrhage (Matouk et al., 2007). H19 RNA also enhances entry to S-phase of the 
cell cycle of bladder cancer cells under serum starved condition, but not under normal cell 
culture condition (Ayesh et al., 2002). Further supports for the tumorigenic properties 
have been reported in other cancer models. H19 over-expression of ectopic origin confers 
a proliferative advantage for breast epithelial cells in a soft agar assay and in several 
combined immunodeficient mice (Lottin et al., 2002). c-Myc induces the expression of the 
H19 RNA. c-Myc binds to the E-boxes near the imprinting control region to facilitate 
histone acetylation and transcriptional initiation of the H19 gene, to potentiate 
tumorigenesis (Barsyte-Lovejoy et al., 2006). The H19 is reported to be a target gene for 
the hepatocyte growth factor (HGF), further signifying the potential role of H19 RNA in 
hepatocellular carcinoma development (Adriaenssens et al, 2002). Furthermore, H19 RNA 
is important for entry into S-phase after serum starvation recovery by E2F binding to its 
promoter (Berteaux et al, 2005). Recently, it was reported that the Retinoblastoma tumor 
suppressor gene is a target gene for miR-675 which is produced from exon-1 of the H19 
gene (Tsang et al., 2010). 
2.1.2 H19 is induced by hypoxia – the P53 brakes and the HIF-1α engine 
It is well established that every solid tumor encounters hypoxic regions beyond certain 
diameters. Hypoxia is a major trigger for tumor angiogenesis, metastasis, chemo-resistance 
and also associated with poor prognosis at least in some types of human cancers. All of 
these conditions as discussed below are associated with an increase of H19 RNA expression. 
Over-expression of H19 RNA, is accompanied with up-regulation of a 95 kDa membrane 
glycoprotein (p95) observed in a variant of breast and lung carcinomas that are multi- drug 
resistance (Doyle et al., 1996). Moreover, results show that the level of H19 RNA is elevated 
in the multidrug resistance variant of HCC cell lines. Here doxorubicin resistance phenotype 
is related to H19 over-expression (Tsang et al., 2007). 
H19 provides a novel and clinically useful diagnostic marker for prognosticating human 
bladder carcinoma. More striking is the predictive value of H19 for tumor recurrence. We 
have found that in transitional cell carcinoma of the bladder with tumors that express H19 
in most cells have shorter median disease-free survivals (Ariel et al., 2000).  
We have identified downstream targets modulated by H19 over-expression in the T24P 
bladder carcinoma cell line (Ayesh et al., 2002); comparing the m-RNA levels of many genes 
between cells containing high levels of H19 RNA (from H19 expressing plasmid) to that of 
the same cells lacking H19 RNA, showed a clear preference towards genes promoting 
cellular migration, angiogenesis and metastasis.  
All of these observations prompted us to explore the effect of hypoxia on H19 expression 
and to delineate the mechanism of action involved. Indeed, under hypoxic conditions, we 
have reported that in bladder carcinoma cell lines T24P and UMUC3, and hepatocellular 
carcinoma cell line Hep3B the H19 RNA is significantly elevated (Matouk et al., 2007). 
Following these initial studies we screened about thirty different carcinomas cell lines of 
different lineages and origins for their ability to induce H19 RNA in hypoxic stress (Matouk 
et al., 2010). We observed very different patterns of response to hypoxia. To gain insight into 
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the possible mechanism associated with the H19 response to hypoxia, we searched for a 
common denominator among these cell lines. 
It is well established today that the tumor suppressor signaling pathway of p53 can be 
activated by stress signals such as hypoxic stress and can either trans-activate or trans-
repress its target genes to influence the cellular response. The key processes regulated by 
p53 pathway include cell cycle arrest, apoptosis, DNA repair, senescence, metastasis and 
angiogenesis, depending on cell types, nature of the inducer, cell intrinsic environment, and 
the activities of other signal transduction pathways. These observations suggests a possible 
association between the status of p53 (wild type or mutant) and H19 responsiveness to 
hypoxic stress. Moreover the involvement of the wild type tumor suppressor gene p53 in the 
down regulation of the H19 promoter activity which lacks a p53 consensus site and a TATA 
box was previously shown by (Dugimont et al., 1998). Taking all of these observations into 
account and the availability of IARC TP53 mutation database, we explored the possible 
involvement of p53 in determining H19's behavior in hypoxic response.   
We recently demonstrated a tight correlation between H19 RNA elevation by hypoxia and 
the status of the p53 tumor suppressor. In cells harboring wild type p53 (p53wt) H19 RNA is 
not induced upon hypoxia, whereas in cells carrying a mutated p53 (p53mt) the H19 message 
is significantly induced most strongly in p53-null cells. Furthermore through both over-
expression and knockdown approaches we identified HIF1-α as the factor that is responsible 
for H19 elevation under hypoxic stress (Matouk et al., 2010). 
H19 functions, consequently, as a stress modulator and a survival factor and is involved in 
several fundamental processes, including epithelial-mesenchymal transition (EMT), 
malignant transformation, cell-cycle transition, metastasis and neo-angiogenesis. EMT is an 
important process on the way to the malignant phenotype; notably- H19 up-regulation 
occurs in the stroma as well as in the epithelium. In the metastatic tumor stage, which bears 
a striking similarity to the embryonic stage, H19 involvement appears to be essential: 
adherent and cohesive cells lose their anchorage, migrate under stressful conditions to 
remote sites and replicate with neovascular support. Thus, H19 is a central figure in the 
cancer embryonic shift (Matouk et al., 2008).  
In the light of our study, a molecular mechanism that integrates H19, p53 and HIF1-α to 
hypoxic stress response is uncovered. As hypoxia readily occurs in the majority of solid 
tumors driving critical steps in tumor development and metastasis and resistance to 
therapeutic modalities, placing the H19 gene product in this deadly circuit undoubtedly will 
have major impacts in its utility as a target for cancer gene therapy. Indeed a DNA-based 
drug depending on H19 regulatory sequence and diphtheria toxin is now in clinical trial 
with promising results (Ohana et al., 2004, Sidi et al., 2008, Mizrahi et al., 2010). We'll 
concentrate on bladder cancer.    
2.1.3 Targetted therapy for bladder cancer mediated by a plasmid expressing DTA 
under the control of H19 regulatory sequences – clinical data 
During the past few years we have developed a DNA based therapy strategies for treating 
tumors expressing H19 RNA. The successful development of anti-tumor gene therapy 
depends on the use of a combinatorial approach aimed at targeted delivery and specific 
expression of effective anti-tumor agents. We exploit the unique H19 transcriptional 
regulatory sequences for directing tumor-selective expression of toxins. For this purpose we 
use non-viral vectors due to their potential to circumvent the main disadvantage of 
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adenoviral vectors, caused by immune responses directed against adenovirus proteins 
which limit their ability to be administered iteratively. As a toxic gene, we used the 
diphtheria toxin A chain (DT-A), which has suitable properties for achieving efficacious 
cancer cell killing. DT-A peptide catalyzes ADP-ribosylation at the dipthamide residue of 
the cellular translation elongation factor 2 (eEF-2), inhibiting protein synthesis and causing 
cell death. While a very low level of DT-A expression suffices for cell killing, DT-A released 
from the lysed cells is not able to enter the neighboring cells in the absence of the DT-B 
chain.  
All preclinical studies needed to set up the stage for using this approach to treat bladder 
cancer patients will not be handled in this chapter, and are reviewed elsewhere (Matouk et 
al., 2005). 
Clinical studies 
The goals of treatment are to reduce tumor recurrence, decrease the risk of disease 
progression, avoid cystectomy (bladder sparing treatment), and improve survival. 
Preventing progression to muscle invasive disease is of key importance because even with 
aggressive treatment, including radical cystectomy, as few as 50% of patients with muscle 
invasive disease will survive 5 years (  Dalbagni et al., 2001). 
The primary factors that influence risk of disease progression include: 1. the number of 
tumors at primary diagnosis; 2. recurrence rate in a previous period or an early recurrence 
at 3 months after the first resection; 3. size of the tumor (tumors larger than 3 cm are more 
likely to recur than smaller tumors); and stage and grade of the tumor. 
The initial clinical development plan for DTA-H19/PEI for bladder cancer is in the 
intermediate-risk patient population who has failed prophylactic therapy with either BCG 
or chemotherapy. In the Phase 1/2a study, the safety and preliminary efficacy was 
examined in this population. Having determined that the highest dose tested in this trial, the 
20 mg dose of DTA-H19, was well tolerated and elicited complete responses in 2 of 5 
evaluable patients, the Phase 2b clinical protocol will assess the safety of this regimen in a 
larger patient population as well as the efficacy in a marker tumor clinical trial design. 
Compassionate Use in Bladder Cancer. Two patients had recurrent superficial TCC of the 
bladder and had failed multiple courses of Bacille Calmette-Guérin (BCG) and 
chemotherapy, and two additional patients that underwent nephrourectomy due to a 
diagnosis of recurrent superficial TCC that showed BCG intolerance. 
The investigations in the first two bladder cancer patients demonstrated that intravesical 
instillation of DTA-H19/PEI is safe up to a dose of 5 mg in a single administration or a 
cumulative dose of 70 mg intravesically. No local or systemic adverse effects considered 
attributable to DTA-H19 treatment were observed throughout treatment. In addition, DTA-
H19 DNA was not detectable in the circulation by PCR analysis of blood samples taken after 
the first and second week of treatment, and 2 hours after plasmid administration. DTA-H19 
DNA was detectable in a tumor biopsy taken 18 hours after intravesical administration and 
in voided urine for 1 week after treatment. Tumor regression (75% reduction in marker 
tumor size) was observed in marker tumors of both patients. One of the 2 compassionate 
patients was treated over a nearly 5 year period with 22 intravesical administrations of 
either a 2 mg or 4 mg dose of DTA-H19/PEI for a cumulative dose of 70 mg of plasmid 
DNA. Treatments were well tolerated, and although the marker tumor persisted, it did not 
increase in size, stage or grade during the 14-month period before it was finally resected 
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the possible mechanism associated with the H19 response to hypoxia, we searched for a 
common denominator among these cell lines. 
It is well established today that the tumor suppressor signaling pathway of p53 can be 
activated by stress signals such as hypoxic stress and can either trans-activate or trans-
repress its target genes to influence the cellular response. The key processes regulated by 
p53 pathway include cell cycle arrest, apoptosis, DNA repair, senescence, metastasis and 
angiogenesis, depending on cell types, nature of the inducer, cell intrinsic environment, and 
the activities of other signal transduction pathways. These observations suggests a possible 
association between the status of p53 (wild type or mutant) and H19 responsiveness to 
hypoxic stress. Moreover the involvement of the wild type tumor suppressor gene p53 in the 
down regulation of the H19 promoter activity which lacks a p53 consensus site and a TATA 
box was previously shown by (Dugimont et al., 1998). Taking all of these observations into 
account and the availability of IARC TP53 mutation database, we explored the possible 
involvement of p53 in determining H19's behavior in hypoxic response.   
We recently demonstrated a tight correlation between H19 RNA elevation by hypoxia and 
the status of the p53 tumor suppressor. In cells harboring wild type p53 (p53wt) H19 RNA is 
not induced upon hypoxia, whereas in cells carrying a mutated p53 (p53mt) the H19 message 
is significantly induced most strongly in p53-null cells. Furthermore through both over-
expression and knockdown approaches we identified HIF1-α as the factor that is responsible 
for H19 elevation under hypoxic stress (Matouk et al., 2010). 
H19 functions, consequently, as a stress modulator and a survival factor and is involved in 
several fundamental processes, including epithelial-mesenchymal transition (EMT), 
malignant transformation, cell-cycle transition, metastasis and neo-angiogenesis. EMT is an 
important process on the way to the malignant phenotype; notably- H19 up-regulation 
occurs in the stroma as well as in the epithelium. In the metastatic tumor stage, which bears 
a striking similarity to the embryonic stage, H19 involvement appears to be essential: 
adherent and cohesive cells lose their anchorage, migrate under stressful conditions to 
remote sites and replicate with neovascular support. Thus, H19 is a central figure in the 
cancer embryonic shift (Matouk et al., 2008).  
In the light of our study, a molecular mechanism that integrates H19, p53 and HIF1-α to 
hypoxic stress response is uncovered. As hypoxia readily occurs in the majority of solid 
tumors driving critical steps in tumor development and metastasis and resistance to 
therapeutic modalities, placing the H19 gene product in this deadly circuit undoubtedly will 
have major impacts in its utility as a target for cancer gene therapy. Indeed a DNA-based 
drug depending on H19 regulatory sequence and diphtheria toxin is now in clinical trial 
with promising results (Ohana et al., 2004, Sidi et al., 2008, Mizrahi et al., 2010). We'll 
concentrate on bladder cancer.    
2.1.3 Targetted therapy for bladder cancer mediated by a plasmid expressing DTA 
under the control of H19 regulatory sequences – clinical data 
During the past few years we have developed a DNA based therapy strategies for treating 
tumors expressing H19 RNA. The successful development of anti-tumor gene therapy 
depends on the use of a combinatorial approach aimed at targeted delivery and specific 
expression of effective anti-tumor agents. We exploit the unique H19 transcriptional 
regulatory sequences for directing tumor-selective expression of toxins. For this purpose we 
use non-viral vectors due to their potential to circumvent the main disadvantage of 
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adenoviral vectors, caused by immune responses directed against adenovirus proteins 
which limit their ability to be administered iteratively. As a toxic gene, we used the 
diphtheria toxin A chain (DT-A), which has suitable properties for achieving efficacious 
cancer cell killing. DT-A peptide catalyzes ADP-ribosylation at the dipthamide residue of 
the cellular translation elongation factor 2 (eEF-2), inhibiting protein synthesis and causing 
cell death. While a very low level of DT-A expression suffices for cell killing, DT-A released 
from the lysed cells is not able to enter the neighboring cells in the absence of the DT-B 
chain.  
All preclinical studies needed to set up the stage for using this approach to treat bladder 
cancer patients will not be handled in this chapter, and are reviewed elsewhere (Matouk et 
al., 2005). 
Clinical studies 
The goals of treatment are to reduce tumor recurrence, decrease the risk of disease 
progression, avoid cystectomy (bladder sparing treatment), and improve survival. 
Preventing progression to muscle invasive disease is of key importance because even with 
aggressive treatment, including radical cystectomy, as few as 50% of patients with muscle 
invasive disease will survive 5 years (  Dalbagni et al., 2001). 
The primary factors that influence risk of disease progression include: 1. the number of 
tumors at primary diagnosis; 2. recurrence rate in a previous period or an early recurrence 
at 3 months after the first resection; 3. size of the tumor (tumors larger than 3 cm are more 
likely to recur than smaller tumors); and stage and grade of the tumor. 
The initial clinical development plan for DTA-H19/PEI for bladder cancer is in the 
intermediate-risk patient population who has failed prophylactic therapy with either BCG 
or chemotherapy. In the Phase 1/2a study, the safety and preliminary efficacy was 
examined in this population. Having determined that the highest dose tested in this trial, the 
20 mg dose of DTA-H19, was well tolerated and elicited complete responses in 2 of 5 
evaluable patients, the Phase 2b clinical protocol will assess the safety of this regimen in a 
larger patient population as well as the efficacy in a marker tumor clinical trial design. 
Compassionate Use in Bladder Cancer. Two patients had recurrent superficial TCC of the 
bladder and had failed multiple courses of Bacille Calmette-Guérin (BCG) and 
chemotherapy, and two additional patients that underwent nephrourectomy due to a 
diagnosis of recurrent superficial TCC that showed BCG intolerance. 
The investigations in the first two bladder cancer patients demonstrated that intravesical 
instillation of DTA-H19/PEI is safe up to a dose of 5 mg in a single administration or a 
cumulative dose of 70 mg intravesically. No local or systemic adverse effects considered 
attributable to DTA-H19 treatment were observed throughout treatment. In addition, DTA-
H19 DNA was not detectable in the circulation by PCR analysis of blood samples taken after 
the first and second week of treatment, and 2 hours after plasmid administration. DTA-H19 
DNA was detectable in a tumor biopsy taken 18 hours after intravesical administration and 
in voided urine for 1 week after treatment. Tumor regression (75% reduction in marker 
tumor size) was observed in marker tumors of both patients. One of the 2 compassionate 
patients was treated over a nearly 5 year period with 22 intravesical administrations of 
either a 2 mg or 4 mg dose of DTA-H19/PEI for a cumulative dose of 70 mg of plasmid 
DNA. Treatments were well tolerated, and although the marker tumor persisted, it did not 
increase in size, stage or grade during the 14-month period before it was finally resected 
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along with one other new low grade papillary tumor. No increase in stage or grade of TCC 
was observed. 
The patient that had a nephroureterectomy due to a diagnosis of high-grade TCC in the 
renal pelvis was treated with 6 weekly 10 mg injections of DTA-H19/PEI via the left 
nephrostome at a total volume of 15 ml each. After completion of the 6 plasmid infusions 
the patient underwent nephroscopy that revealed the following: renal pelvis with no 
presence of tumors and several papillary tumors on the left bladder wall in the trigon. 
Findings were biopsied, analyzed, and diagnosed as low grade TCC. Four months later, the 
patient underwent nephrography during which no tumors were observed. Urine cytology 
confirmed the absence of tumor cells.  
There were no significant events or side effects throughout the patient’s treatments. Overall, 
this was a good tumor response in a patient with only one kidney who was considered to be 
anephric and with dialysis during the last year. The treatment was well-tolerated by the 
patient, and there was no evidence of any negative systemic or urinary tract effect. During 
the treatments, the patient was fully functional, continued to work, and did not suffer any 
effect to his quality of life (QOL).  The second patient that had nephroureteterectomy had 
multiple recurrences with the appearance of multi-focal lesions in the bladder. The patient 
underwent additional resection of a number of lesions that were localized inside and on the 
walls of the bladder. Since the patient was not a candidate to receive BCG treatment due to 
his compromised immune system, and after being refractory to Mitomycin C or Synergo, 
and refusal to undergo cystectomy, he was offered treatment with DTA-H19/PEI. He was 
treated with 20 mg of DTA-H19/PEI twice a week for the period of 4 weeks and once a 
week for another 2 weeks. Cytoscopy conducted at the end of the treatment showed an 
improvement in the number of lesions and in the general appearance of the bladder. The 
histological diagnosis of the biopsy showed low grade Ta. 
Phase 1/2a Clinical Trial in Conventional Treatment Refractory Bladder Cancer Patients. A 
Phase 1/2a clinical trial was designed to determine the maximum tolerated dose (MTD) and 
assess the safety and preliminary efficacy of 5 different doses (2 mg, 4 mg, 6 mg, 12 mg, and 20 
mg of DTA-H19) of DTA-H19/PEI given as 6 intravesical infusions into the bladder of patients 
with superficial bladder cancer (stages Ta and carcinoma in situ (CIS)) who had failed 
intravesical therapy with BCG. Patients had a diagnosis of superficial Stage Ta or CIS, grade 1 
or 2 superficial bladder cancer that was confirmed by histopathology and that expressed H19 
which was shown by in situ hybridization (ISH). Treatments were given weekly for 3 weeks 
followed 1 week later by safety and disease assessments, then another 3 weekly instillations 
were performed. Each dose cohort received the same dose for all treatments. Doses were 
escalated if none of the first 3 patients in the preceding dose cohort experienced a dose-limiting 
toxicity (DLT) after the first 3 weekly intravesical treatments. A DLT was defined as any grade 
3 or greater toxicity by the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI-CTCAE) that was considered to be related to the investigational product 
during the first 3 weekly intravesical treatments. Prior to initiating treatment, papillary tumors 
were resected leaving a single marker tumor. Videocystoscopy was performed 4, 8, and 12 
weeks after the start of treatment for a safety evaluation of the bladder and also to record the 
presence or absence of the marker tumor and any other lesions suspicious for TCC of the 
bladder. If the marker tumor was still present at the Week 12 assessment, it was to be resected. 
If any new lesions were observed at Week 12, they were also to be resected. Patients whose 
disease had not progressed (i.e., no new tumors, increase in the size of the marker tumor by at 
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least 50%, or increase in stage or any grade 3) were offered continued once monthly treatments 
and follow-up for up to 1 year.  
A total of 18 patients were enrolled in this study. No DLTs were observed in this study. As 
the highest dose of product tested was the 20 mg dose of DTA-H19/PEI, this dose was 
considered the MTD for this study. The most frequently reported adverse events (AEs) 
considered at least possibly related to investigational products for any dose cohort were 
mild to moderate in severity and were most commonly renal and urinary disorders.  
Of the 18 patients evaluable for tumor response at Week 12, a total of 4 patients had a 
complete response (CR) [complete disappearance of the marker tumor and no recurrence) 
including 2 of the 3 patients in the 2 mg dose cohort, and 2 of 6 patients in the 20 mg dose 
cohort. In addition, 2 patients (one in each of the 2 mg and 12 mg dose groups) had an 
incomplete partial response [IPR - complete disappearance of the marker tumor but with 
new tumor(s) occurring] suggesting that DTA-H19/PEI did have an effect on these marker 
tumors as well. Other responses included 1 partial response (PR - reduction in size of 
marker tumor by 50% and no new tumors present) (12 mg dose cohort) and 5 patients with 
SD (marker tumor still present but has not increased in size by more than 50% and no new 
tumors) (3 patients in the 4 mg dose cohort, 1 patient in the 12 mg dose cohort, and 1 patient 
in the 20 mg dose cohort). Thus, in this small study, there was evidence of tumor ablation 
over the dose range from 2 to 20 mg of DTA-H19/PEI. The 20 mg dose of DTA-H19/PEI 
was selected for evaluation in the Phase 2b clinical trial because this dose had an acceptable 
safety profile, showed objective tumor responses, and as the mechanism of action of DTA-
H19/PEI is tumor-specific cytotoxicity, theoretically the highest safe dose has the greatest 
likelihood of an efficacious outcome.  
2.2 Insulin-like growth factor 2 (IGF2) and tumorigenesis 
IGF2 expression is driven by four different promoters (P1-P4) that produce 4 different 
transcripts all of which give rise to the same mature protein, a 67-amino acid polypeptide. 
The four promoters are activated in a development-dependent and tissue-specific manner. 
In fetal liver, promoters P2–P4 are active, of which P3 is the most active promoter, and 
promoter P1 is inactive. However, in liver tissue, shortly after birth, the IGF2 promoter P1 is 
exclusively active. The imprinting of the human IGF2 gene is promoter-specific. The P2, P3 
and P4 promoters display monoallelic activity in embryonic, neonatal and postnatal liver 
specimens, whereas in adult, P1 is transcribed from both alleles. 
The IGF2 peptide is a member of the insulin-like growth-factor family and is known to play 
an important role in the growth and differentiation of various tissues (Rechler 1990). This 
family also includes IGF1, insulin and relaxin.  IGF2 is released to the extracellular fluid 
where it interacts with different cell membrane receptors and binding proteins. IGF2 binds 
three different types of receptors: IGF type 1 (IGF-1R), insulin receptor (IR) and IGF-
2/mannose 6-phospate receptors (IGF-2R/M6P). The receptors, however, differ completely 
in structure and function (Yu and Rohan 2000). Ligand binding to IGF-1R and IR mediates 
mitogenic and anti-apoptotic effects. IGF-2R/M6P has tumor suppressor function and it 
mediates IGF2 degradation (Morison and Reeve 1998, Randhawa and Cohen 2005).      
IGF2 can promote different functions depending on the cell type in which it is acting, and is 
a strong mitogen for a wide variety of cancer cell lines. It acts on the cell division cycle 
(DNA replication and mitosis) and on the cell growth (cellular enlargement), possibly by 
interfering with control cell checkpoint proteins. Moreover, IGF2 functions as an anti-
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along with one other new low grade papillary tumor. No increase in stage or grade of TCC 
was observed. 
The patient that had a nephroureterectomy due to a diagnosis of high-grade TCC in the 
renal pelvis was treated with 6 weekly 10 mg injections of DTA-H19/PEI via the left 
nephrostome at a total volume of 15 ml each. After completion of the 6 plasmid infusions 
the patient underwent nephroscopy that revealed the following: renal pelvis with no 
presence of tumors and several papillary tumors on the left bladder wall in the trigon. 
Findings were biopsied, analyzed, and diagnosed as low grade TCC. Four months later, the 
patient underwent nephrography during which no tumors were observed. Urine cytology 
confirmed the absence of tumor cells.  
There were no significant events or side effects throughout the patient’s treatments. Overall, 
this was a good tumor response in a patient with only one kidney who was considered to be 
anephric and with dialysis during the last year. The treatment was well-tolerated by the 
patient, and there was no evidence of any negative systemic or urinary tract effect. During 
the treatments, the patient was fully functional, continued to work, and did not suffer any 
effect to his quality of life (QOL).  The second patient that had nephroureteterectomy had 
multiple recurrences with the appearance of multi-focal lesions in the bladder. The patient 
underwent additional resection of a number of lesions that were localized inside and on the 
walls of the bladder. Since the patient was not a candidate to receive BCG treatment due to 
his compromised immune system, and after being refractory to Mitomycin C or Synergo, 
and refusal to undergo cystectomy, he was offered treatment with DTA-H19/PEI. He was 
treated with 20 mg of DTA-H19/PEI twice a week for the period of 4 weeks and once a 
week for another 2 weeks. Cytoscopy conducted at the end of the treatment showed an 
improvement in the number of lesions and in the general appearance of the bladder. The 
histological diagnosis of the biopsy showed low grade Ta. 
Phase 1/2a Clinical Trial in Conventional Treatment Refractory Bladder Cancer Patients. A 
Phase 1/2a clinical trial was designed to determine the maximum tolerated dose (MTD) and 
assess the safety and preliminary efficacy of 5 different doses (2 mg, 4 mg, 6 mg, 12 mg, and 20 
mg of DTA-H19) of DTA-H19/PEI given as 6 intravesical infusions into the bladder of patients 
with superficial bladder cancer (stages Ta and carcinoma in situ (CIS)) who had failed 
intravesical therapy with BCG. Patients had a diagnosis of superficial Stage Ta or CIS, grade 1 
or 2 superficial bladder cancer that was confirmed by histopathology and that expressed H19 
which was shown by in situ hybridization (ISH). Treatments were given weekly for 3 weeks 
followed 1 week later by safety and disease assessments, then another 3 weekly instillations 
were performed. Each dose cohort received the same dose for all treatments. Doses were 
escalated if none of the first 3 patients in the preceding dose cohort experienced a dose-limiting 
toxicity (DLT) after the first 3 weekly intravesical treatments. A DLT was defined as any grade 
3 or greater toxicity by the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI-CTCAE) that was considered to be related to the investigational product 
during the first 3 weekly intravesical treatments. Prior to initiating treatment, papillary tumors 
were resected leaving a single marker tumor. Videocystoscopy was performed 4, 8, and 12 
weeks after the start of treatment for a safety evaluation of the bladder and also to record the 
presence or absence of the marker tumor and any other lesions suspicious for TCC of the 
bladder. If the marker tumor was still present at the Week 12 assessment, it was to be resected. 
If any new lesions were observed at Week 12, they were also to be resected. Patients whose 
disease had not progressed (i.e., no new tumors, increase in the size of the marker tumor by at 
 
The H19-IGF2 Role in Bladder Cancer Biology and DNA-Based Therapy 
 
371 
least 50%, or increase in stage or any grade 3) were offered continued once monthly treatments 
and follow-up for up to 1 year.  
A total of 18 patients were enrolled in this study. No DLTs were observed in this study. As 
the highest dose of product tested was the 20 mg dose of DTA-H19/PEI, this dose was 
considered the MTD for this study. The most frequently reported adverse events (AEs) 
considered at least possibly related to investigational products for any dose cohort were 
mild to moderate in severity and were most commonly renal and urinary disorders.  
Of the 18 patients evaluable for tumor response at Week 12, a total of 4 patients had a 
complete response (CR) [complete disappearance of the marker tumor and no recurrence) 
including 2 of the 3 patients in the 2 mg dose cohort, and 2 of 6 patients in the 20 mg dose 
cohort. In addition, 2 patients (one in each of the 2 mg and 12 mg dose groups) had an 
incomplete partial response [IPR - complete disappearance of the marker tumor but with 
new tumor(s) occurring] suggesting that DTA-H19/PEI did have an effect on these marker 
tumors as well. Other responses included 1 partial response (PR - reduction in size of 
marker tumor by 50% and no new tumors present) (12 mg dose cohort) and 5 patients with 
SD (marker tumor still present but has not increased in size by more than 50% and no new 
tumors) (3 patients in the 4 mg dose cohort, 1 patient in the 12 mg dose cohort, and 1 patient 
in the 20 mg dose cohort). Thus, in this small study, there was evidence of tumor ablation 
over the dose range from 2 to 20 mg of DTA-H19/PEI. The 20 mg dose of DTA-H19/PEI 
was selected for evaluation in the Phase 2b clinical trial because this dose had an acceptable 
safety profile, showed objective tumor responses, and as the mechanism of action of DTA-
H19/PEI is tumor-specific cytotoxicity, theoretically the highest safe dose has the greatest 
likelihood of an efficacious outcome.  
2.2 Insulin-like growth factor 2 (IGF2) and tumorigenesis 
IGF2 expression is driven by four different promoters (P1-P4) that produce 4 different 
transcripts all of which give rise to the same mature protein, a 67-amino acid polypeptide. 
The four promoters are activated in a development-dependent and tissue-specific manner. 
In fetal liver, promoters P2–P4 are active, of which P3 is the most active promoter, and 
promoter P1 is inactive. However, in liver tissue, shortly after birth, the IGF2 promoter P1 is 
exclusively active. The imprinting of the human IGF2 gene is promoter-specific. The P2, P3 
and P4 promoters display monoallelic activity in embryonic, neonatal and postnatal liver 
specimens, whereas in adult, P1 is transcribed from both alleles. 
The IGF2 peptide is a member of the insulin-like growth-factor family and is known to play 
an important role in the growth and differentiation of various tissues (Rechler 1990). This 
family also includes IGF1, insulin and relaxin.  IGF2 is released to the extracellular fluid 
where it interacts with different cell membrane receptors and binding proteins. IGF2 binds 
three different types of receptors: IGF type 1 (IGF-1R), insulin receptor (IR) and IGF-
2/mannose 6-phospate receptors (IGF-2R/M6P). The receptors, however, differ completely 
in structure and function (Yu and Rohan 2000). Ligand binding to IGF-1R and IR mediates 
mitogenic and anti-apoptotic effects. IGF-2R/M6P has tumor suppressor function and it 
mediates IGF2 degradation (Morison and Reeve 1998, Randhawa and Cohen 2005).      
IGF2 can promote different functions depending on the cell type in which it is acting, and is 
a strong mitogen for a wide variety of cancer cell lines. It acts on the cell division cycle 
(DNA replication and mitosis) and on the cell growth (cellular enlargement), possibly by 
interfering with control cell checkpoint proteins. Moreover, IGF2 functions as an anti-
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apoptotic agent. For example, it blocks c-Myc and SV40 T-antigen induced apoptosis in Raf-
1 fibroblast cells (Ishii et al., 1993,  Morali et al.,  2000).  
The mitogenic and metabolic actions of IGF2 in embryonic development and tumorigenesis 
are mediated by the IGF-1R and/or IR-A and are tightly regulated at different levels. These 
levels include the IGF-receptors availability, IGF2 interaction with its receptors and binding 
proteins (IGFBPs) and its degradation following internalization of the IGF2 after binding to 
its receptor, especially IGF-2R. Moreover, the IGF2 mRNA and protein levels are regulated 
by different ways. Any abnormality at one or more of these levels can be correlated to 
tumorigenesis. Over-expression of growth factors, or their receptors is a common event in 
malignancy and provides the underlying mechanisms for one of the hallmarks of cancer, 
namely uncontrolled proliferation (Hanahan and Weinberg 2000).  
Transgenic mice, over-expressing the IGF2 gene, developed spontaneous tumors at a high 
frequency (Bates et al.,  1995, Moorehead et al.,  2003, Rogler et al.,  1994), suggesting that 
over-expressed IGF2 may be involved not only in the progression of tumors but also in the 
initiation of neoplasia. IGF2 over-expression is significantly correlated to the increased 
tumor progression and proliferative activity as well as to decreased patient survival 
(Kawamoto et al., 1998, Rogler et al., 1994, Takanami et al., 1996) 
Several mechanisms can potentially result in IGF2 over-expression in cancer, including, loss 
of imprinting (LOI) of the maternal allele, loss of heterozygosity (LOH) with paternal 
duplication, amplification of the IGF2 gene and abnormally activated signaling pathway 
leading to transcriptional up-regulation of the active alleles reviewed by (Hahn et al.,  2000). 
IGF2 imprinting is relaxed in many different types of tumors, including bladder cancer 
(Byun et al., 2007).  
The link between IGF2 and metastasis may be the basis for the identification of IGF2 and 
IGF-IR as predictors of poor outcome in many types of cancer.  
In the rat model of bladder cancer induced by BBN, we observed over-expression of igf2 in 
the tumor, relative to the low level of expression in the normal tissue (Ariel et al., 2004).  
Moreover we detected high levels of IGF2 mRNA expression from P3, P4 or both promoters 
in TCC samples. Whereas normal bladder samples showed no expression from either 
promoter. The human IGF2-P3 and IGF2-P4 promoters are highly active in bladder 
carcinoma. We showed that these constructs were able to selectively kill tumor cell lines and 
inhibit tumor growth in-vitro and in-vivo in accordance to the transcriptional activity of the 
above-mentioned regulatory sequences, when they are used to drive the expression of DTA 
(Ayesh et al., 2003, Amit et al., 2011).    
3. Double promoter vectors: Novel approaches for the treatment of bladder 
cancer with improved cytotoxic effect 
3.1 Double promoter DTA-expressing vectors 
We have shown that IGF2 or H19 are significantly expressed in 50-84% of human bladder 
carcinoma respectively (Elkin et al, 1995) but not in normal bladder. Whereas combined 
expression (e.g. H19 and IGF2-P3/P4) was detected at high levels in nearly 100% of human 
bladder cancer samples. By that proving that the double promoter vectors are suitable for 
treating all bladder cancer patients. P3 and P4 were able to express the DTA in tumor cells in 
vitro, and inhibited tumor growth of mice heterotopic model, proving that both promoters 
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could be used successively, in addition to H19 promoter, as part of the double promoter 
constructs (Ayesh et al., 2003, Amit et al., 2010, Amit et al., 2011). 
Double promoter expressing vectors were created, carrying on a single construct two 
separate DNA sequences expressing the diphtheria toxin A-fragment (DTA), from two 
different regulatory sequences, selected from cancer-specific promoters H19, IGF2-P3 and 
IGF2-P4. This novel approach, create a new family of plasmids regulated by two regulatory 
sequences, which in their natural genome position are both proximately located and are 
reciprocally imprinted.  
These vectors were then used to transfect and to eradicate tumor cells in culture or to inhibit 
tumor growth (in vivo), in heterotopic and orthotopic CD1 nude mice, bladder tumor 
models.  
The activity of the double promoter vectors was tested and compared to the activity of the 
single promoter vectors. The double promoter vectors exhibited superior activity compared 
to the single promoter vectors. Furthermore, an augmented-than-additive activity was 
exhibited, compared to combination activity of the single promoter vectors, in cell lines and 
in heterotopic bladder cancer mice (Amit et al., 2010, Amit et al., 2011).  
3.2 A single promoter driving two cytotoxic genes with synergistic effect 
Because it is unlikely that gene transfer reaches every cell of a cancer, DNA based therapy 
approaches are thought to require the induction of a ‘bystander’ effect. An interesting 
approach for this purpose is cytokine DNA based therapy. TNF- is a multifunctional and 
immuno-regulatory cytokine that exhibits direct tumor cell cytotoxicity, possesses anti-
angiogenic properties, and enhances antitumor immunity by activating immune cells such 
as dendritic cells and T cells. Systemic delivery of the TNF-α protein has had limited success 
clinically because of severe dose limiting toxic effects. This limitation can be overcome by 
the use of a gene delivery approach, combined with a tumor specific promoter to express 
TNF- in the tumor tissue. 
In this approach, an enhanced cytotoxic effect could be achieved that could also overcome 
the resistance developed by tumor cells to either one of the toxin. It was reported that 
several cell lines – none are bladder cancer- are resistant to Diphtheria toxin and therefore 
would not be affected by the pH19-DTA vector. Adding TNF-α to the existing system was in 
agreement with supporting evidence of some publications showing a synergistic effect in 
cell cytotoxicity mediated by TNF-α and diphtheria toxin. This was shown on ovarian 
cancer cell lines- sensitive or resistant to both diphtheria toxin and TNF-α and on renal cell 
carcinoma cell lines (Morimoto et al., 1991, Mizutani et al., 1994). Using a construct in which 
both TNF-α and DTA expressions are driven by H19 tumor specific promoter, would 
overcome the dose limiting toxic effects of the systemic delivery of TNF-α protein. 
So, we investigated a plasmid carrying, in addition to DTA, the gene for human hTNF-α. 
The pH19-TNF-IRES-DTA plasmid was built while the construct carries a viral IRES 
sequence (from the ECMV virus) 3' of the TNF.  This IRES construct is 619 pb long and 
responsible the synthesis of DTA from the m-RNA transcript. 
3.2.1 Synergistic effect in the killing activity of DTA and TNF in vitro using different 
cell line models 
In vitro the cytotoxic effect in cells treated with the pH19-TNF-IRES-DTA plasmid was 
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apoptotic agent. For example, it blocks c-Myc and SV40 T-antigen induced apoptosis in Raf-
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could be used successively, in addition to H19 promoter, as part of the double promoter 
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were also treated with a plasmid carrying either the DTA or TNF under the control of the 
H19 promoter. Cells from human, mouse and rat origin expressing H19 RNA were co-
transfected with 2 g/well of LucSV40 and the indicated concentrations of pH19-DTA, 
pH19-TNF or pH19-TNF-IRES-DTA plasmids. Luciferase activity was determined and 
compared to that of cells transfected with LucSV40 alone (Figure 1). In order to rule out the 
possibility of a false positive result due to the combined plasmid’s structure effect, we 
reversed the TNF sequence in the pH19-TNF-IRES-DTA plasmid to eliminate the expression 
of TNF (pH19-TNFrev-IRES-DTA). The killing potency of the pH19-TNF-IRES-DTA plasmid 
was significantly higher compared to the pH19-DTA plasmid alone, even at very low 
concentrations. As the concentrations got higher the difference was diminished (Figure 1). 
It should be noted that the use of the pH19-DTA plasmid alone was sufficient to cause a 
substantial decrease in luciferase activity, leading to 80-90% decrease in high concentrations, 
whereas the use of pH19-TNF alone showed little decrease, if any, and in some cases even an 
increase. When expressed in conjunction with the DTA domain, it clearly enhances cell death.  
 
 
Fig. 1. Enhanced killing activity of pH19-TNF-IRES-DTA vector in different bladder 
carcinoma cell lines. 
The killing potential of the pH19-DTA (blue), pH19-TNF (pink) or pH19-TNF-IRES-DTA(orange) 
vectors  in human UMUC-3 and HT-1376, mouse T-50 and rat NBT-II was measured as a reduction 
of luciferase activity induced by LucSV40. Cells were co-transfected with 2 g/well of LucSV40 and 
the indicated concentrations of pH19-DTA, or pH19-TNFα, or pH19-TNF-IRES-DTA. The pH19-
TNFrev-IRES-DTA(green) served as a control. 
3.2.2 In-vivo tumor growth inhibition by the pH19-DTA, pH19-TNF or pH19-TNF-IRES-
DTA vectors in a carcinogen rat bladder cancer model 
In vivo we utilize the carcinogen (BBN) induced rat bladder cancer model. Rats were treated 
with the above mentioned plasmids used in the in-vitro studies. An additional control 
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plasmid carrying the gene of Luciferase under the regulation of the H19 promoter (pH19-
Luc) was included.  
The therapeutic plasmid was given at two different times in order to investigate the 
correlation of the treatment efficiency to the severity and invasiveness of the disease. In the 
first, the plasmid treatments started after the rats received BBN for 20 weeks. By this time, 
the rats had developed visible tumors is their bladders. In the second, the plasmid treatment 
started only 16 weeks after the beginning of BBN administration in which tumors were 
visible only by histopathological examination. 
 
 
Fig. 2. Enhanced killing activity of pH19-TNF-IRES-DTA vector in the BBN rat bladder 
cancer model depending on time schedule of the treatments. 
Tumor index (volume X weight) of rat’s bladders as measured after treatment with three injections of 
pH19-DTA(green), pH19-TNF(brown) or pH19-TNF-IRES-DTA(red), and pH19-Luc(blue). A. 
Results of tumor index of rat’s bladders which started treatments after 20 weeks. B. Results of tumor 
index of rat’s bladders which started treatments after 16 weeks. 
Each rat, in both experiments and in each group, received intravesical injection of 50 µg of 
the plasmid administered 3 times with an interval of 3 days between treatments. Four days 
after the last treatment, all rats were sacrificed and bladders were removed, weighed, 
photographed, excised and taken either for histological analysis or for DNA/RNA 
preparation. Tumor index was derived as mentioned. Figure 2 shows the results of the in 
vivo experiments, where rats were treated from these two time points and onward. 
We decided to try and estimate the tumor’s volume by picturing each tumor at several 
angles, allowing us to use image analysis software in order to receive a reasonable 
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estimation. This was multiplied by the bladder’s weight in order to give us a new, more 
comprehensive index of the tumor’s status. It can be seen in the results that when starting 
the treatments after 20 weeks of BBN administration, virtually no effect is achieved in any of 
the plasmids. On the other hand, starting the treatments after 16 weeks showed a 
remarkable inhibition of tumor progression compared to the control. When administrated 
with pH19-DTA the tumor was delayed by approximately 30%, while when using the pH19-
TNF-IRES-DTA vector about 50% inhibition was measured. No effect was seen when pH19-
TNF was used. These results suggest that when treatment begins in an early stage it can be a 
highly potent one. 
4. Concluding remarks and future perspectives 
Our ability to understand the biology of bladder cancer at the molecular level utilizing the 
ever growing biotechnologies is an important step for understanding a wide range of 
signaling events in both healthy cells and in the context of carcinogenesis. Substantial 
progress has been made in this avenue. Many new genes that are involved in bladder 
carcinogenesis have been identified. It is clear the H19-IGF2 locus is playing a central role in 
this aspect. As the role of IGF2 in embryogenesis and tumorigenesis is relatively well 
understood, H19 as a stress modulator is recently emerging to be involved in several 
fundamental processes of tumorigenesis including that of the bladder.  Yet the exact 
molecular mechanisms that integrate H19 to such diverse events and circuits that are 
malfunctioning in cancer need further investigations. 
In our lab, different regulatory sequences, selected from cancer-specific promoters of  H19, 
IGF2-P3 and IGF2-P4 linked to the potent toxin (DTA),  have been successfully used to drive 
cytotoxicity  to cancer cells in vitro, in vivo, in different tumor models, and more 
importantly in bladder cancer patients, at least in the case of H19,  with promising results. 
Similar approaches are also used in other types of human cancers including ovarian, 
hepatocellular, and pancreatic cancers and are clinically encouraging. Preclinically, this 
approach also shows promising results in lung cancer, glioblastoma and colorectal cancer 
metastasis to the liver.  We are working on novel approaches to increase the cytotoxicity of 
the therapeutic plasmids, and to increase the numbers of patients that can benefit from this 
therapy. Furthermore, and given the central role of hypoxia and also p53 in the resistance of 
conventional therapeutic options and the involvement of the IGF2-H19 locus, we are 
developing sequential treatments of the therapeutic plasmids with conventional 
chemotherapeutic drugs with encouraging results. Moreover, the preclinical utility of short 
interfering RNA to knockdown both H19 and IGF2 is under development.  
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1. Introduction 
Bladder cancer is one of the most common cancers in the world. In 2006, there were about 
61,240 diagnosed cases of bladder cancer and approximately 13,060 deaths attributable to 
this disease, being the prevalence estimated worldwide more than 1,000,000 patients (Jemal 
et al., 2006; Lerner, 2005). Taking into account that its incidence seems to be increasing, 
bladder cancer is clearly a significant public health issue around the world. Thus, it is 
necessary to intensify research on this topic.  
Urinary bladder cancer originates mainly from epithelial cells of the urothelium (Lopez-
Beltran et al., 2004; Montironi et al., 2005). When initially diagnosed, most bladder cancers 
(about 70%) do not present muscle invasion, and are thus known as non-muscle invasive 
bladder cancer (pTa and pT1). In these cases, a simple transurethral resection is sufficient to 
remove the tumor. However, some patients experience recurrence or even tumor 
progression.  The progression of the tumor involves invasion of tumor cells, which penetrate 
deeper layers of the bladder such as the detrusor muscle (pT2), perivesical tissue (pT3) and 
extravesical organs (pT4) (Figure 1). Since this progression threatens the patient's life, more 
aggressive therapies are necessary (Sobin et al., 1997).  
Intensive research in bladder cancer, as well as that in most tumors, is being carried out to 
elucidate the reason for the appearance of tumors, and to find out which factors are 
involved in their development and which are related to the tumor progression process. 
These investigations, which provide insights into the biology of the tumor, are essential for 
the implementation of new therapeutic and/or preventive modalities (Bhattacharya et al., 
2010; Zhang et al., 2011). 
Research on basic science is focused on the mechanisms that lead cells towards 
transformation and development of cancer, using simple experimental models where it is 
easier to interpret the results. Cell culture techniques are widely used to study different 
oncological processes. The cell culture is the growth of any cell type, usually tumor cells, in 
with nutrient-containing solutions. The cells grow attached to the plastic surface, forming a 
monolayer, usually in a two-dimensional way. This technique allows studying processes 
such as mutagenesis, invasion, migration, and production of proteolytic enzymes. Although 
cell culture is a very important tool, it has certain limitations. Many biological processes 
depend on the three-dimensional architecture. In addition, monolayer culture is usually 
 19 
Animal Models for Basic and Preclinical 
Research in Bladder Cancer 
Ana María Eiján1,2, Catalina Lodillinsky2 and Eduardo Omar Sandes1 
1Research Area of the Institute of Oncology Angel H. Roffo, University of Buenos Aires, 
 2Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) 
Argentina 
1. Introduction 
Bladder cancer is one of the most common cancers in the world. In 2006, there were about 
61,240 diagnosed cases of bladder cancer and approximately 13,060 deaths attributable to 
this disease, being the prevalence estimated worldwide more than 1,000,000 patients (Jemal 
et al., 2006; Lerner, 2005). Taking into account that its incidence seems to be increasing, 
bladder cancer is clearly a significant public health issue around the world. Thus, it is 
necessary to intensify research on this topic.  
Urinary bladder cancer originates mainly from epithelial cells of the urothelium (Lopez-
Beltran et al., 2004; Montironi et al., 2005). When initially diagnosed, most bladder cancers 
(about 70%) do not present muscle invasion, and are thus known as non-muscle invasive 
bladder cancer (pTa and pT1). In these cases, a simple transurethral resection is sufficient to 
remove the tumor. However, some patients experience recurrence or even tumor 
progression.  The progression of the tumor involves invasion of tumor cells, which penetrate 
deeper layers of the bladder such as the detrusor muscle (pT2), perivesical tissue (pT3) and 
extravesical organs (pT4) (Figure 1). Since this progression threatens the patient's life, more 
aggressive therapies are necessary (Sobin et al., 1997).  
Intensive research in bladder cancer, as well as that in most tumors, is being carried out to 
elucidate the reason for the appearance of tumors, and to find out which factors are 
involved in their development and which are related to the tumor progression process. 
These investigations, which provide insights into the biology of the tumor, are essential for 
the implementation of new therapeutic and/or preventive modalities (Bhattacharya et al., 
2010; Zhang et al., 2011). 
Research on basic science is focused on the mechanisms that lead cells towards 
transformation and development of cancer, using simple experimental models where it is 
easier to interpret the results. Cell culture techniques are widely used to study different 
oncological processes. The cell culture is the growth of any cell type, usually tumor cells, in 
with nutrient-containing solutions. The cells grow attached to the plastic surface, forming a 
monolayer, usually in a two-dimensional way. This technique allows studying processes 
such as mutagenesis, invasion, migration, and production of proteolytic enzymes. Although 
cell culture is a very important tool, it has certain limitations. Many biological processes 
depend on the three-dimensional architecture. In addition, monolayer culture is usually 
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
384 
restricted to a single or at most two cell types. In contrast, tumors are complex and consist of 
tumor cells and other cell types such as stroma and immune cells that interact to either 
promote or inhibit tumor growth. To overcome these limitations, it is necessary to use three-
dimensional models, such as tissue or organ cultures (Varley et al., 2011).  
 
 
Fig. 1. A: Histology of a normal bladder from a C57BL/6J mouse (Hematoxylin- eosin).  
B: Scheme of the invasion status of bladder tumors. Non-muscle invasive tumors pTa when 
are confined to epithelium, and pT1 when  penetrating into the chorion. Invasive tumors 
when penetrate deeper layers of the bladder such as the detrusor muscle (pT2), perivesical 
tissue (T3) and extravesical organs (pT4). 
To corroborate in vitro results, the next step in the investigation is the assay in a living 
organism. Animal models are important tools which allow studying the mechanisms of 
carcinogenesis as well as carrying out preclinical studies of new therapeutic modalities. It is 
important to design a model as similar to human disease as possible, so that observations 
can be readily transferred to clinical studies.  
2. General characteristics of animal models 
Animal models constitute the essential link between cell-based experiments and the 
translation of novel agents into human patients with cancer. They are used to study the 
development and progression of diseases and to test new treatments before they are 
provided to humans. Therefore, models should be as close to human pathology as possible. 
In evolutionary biological terms, large animals have more similarity to humans. However, 
the most widely used animal models are rodents, in particular mice and rats. Although 
imperfect in their translatability into clinical efficacy, these animals have the advantage that 
they reproduce easily in short time, are easy to maintain with low cost, and can be 
manipulated genetically, thus remaining a critical tool in bladder cancer research. 
Models allow researchers to study different characteristics of the tumor biology such as 
tumor growth, latency, growth rate, invasion and metastasis. Studies of carcinogenic 
substances or prevention of carcinogenesis may be carried out in animal models. Also, 
analysis of the response to cytotoxicity and immunotherapy treatments can be performed 
(Bhattacharya et al., 2010; Takeuchi et al., 2011; Zhang et al., 2011). 
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According to the site of tumor inoculation, models are classified as heterotopic or orthotopic 
(see points 2.1.4 and 2.1.5.). In addition, depending on the species in which the tumor cell 
lines are inoculated, models may be xenogeneic or syngeneic models (see below). 
2.1 Mouse models in bladder cancer 
2.1.1 Xenogeneic models  
Animals with transplanted human cancers are called xenogeneic or xenograft models. Nude 
mice are commonly used to inoculate human tumor fragments or bladder cancer cells. These 
mice have a spontaneous mutation in chromosome 11 named nude (nu), which gives certain 
phenotypic and functional changes. Homozygous nude mice show absence of hair, the 
feature that gave the name to the mutation. However, a few years after the appearance of 
the mutation, it was found that nude mice do not have a functional thymus. As a 
consequence, these animals have a low number of mature T lymphocytes, which allows 
them to accept xenograft transplantation. This feature of nude mice has contributed to the 
development of research in cancer, making these animal models useful to study the in vivo 
growth of human tumors and human cancer cell lines in which the efficacy of therapeutic 
agents such as monoclonal antibodies, cytotoxic drugs and radiotherapy can be tested. 
Below are a few examples of the relevant experiments in bladder cancer therapy using 
xenograft models. 
One of the main features of tumors is their capacity to grow uncontrollably, invading the 
surrounding tissue, inducing neoformation of blood (angiogenesis) and lymphatic vessels 
and spreading in the body, forming secondary tumors or metastasis. In most cases, the 
death of patients with bladder cancer is due to the generation of metastasis. Angiogenesis, 
which is intricately involved in growth and metastasis and is in fact a prerequisite for these 
processes (Fidler, 1990; Folkman, 1986), is regulated by a fine balance between stimulatory 
and inhibitory factors produced by the tumor and the surrounding stroma (Liotta et al., 
1991). Bladder tumors produce high levels of several stimulatory factors, being the vascular 
endothelial growth factor (VEGF) overexpressed in bladder cancer (Crew et al., 1997; O'Brien 
et al., 1995). The action of this factor is mediated by its membrane receptor (VEGFR). Both 
VEGF and VEGFR are considered as important therapeutic targets. Some papers have 
studied the effects of a neutralizing monoclonal antibody targeted at murine VEGFR by 
using a xenograft model.  In combination with cytotoxic compounds, such as paclitaxel, this 
monoclonal antibody impairs tumor growth and angiogenesis and. thus prevents metastatic 
spread and prolongs mouse survival (Davis et al., 2004; Inoue et al., 2000).  
Xenograft models have also been used in radiopharmaceutical studies (Pfost et al., 2009). 
Pfost et al. coupled monoclonal antibodies that recognize epidermal growth factor receptors 
on bladder cancer cells with 213Bi, a radioactive alpha particle emitter, and found that 
therapy with 0.37 MBq of radiation after tumor cell inoculation in the bladder of nude mice 
results in higher survival of mice when compared with conventional treatment with 
Mitomycin C. These authors were also able to show that Mitomycin C produces 
nephrotoxicity, whereas 213Bi-anti-EGFR-mAb treatment showed no signs of nephrotoxicity. 
These results suggest that radioimmunotherapy using intravesically instilled 213Bi-anti-
EGFR-mAb is a promising option for the treatment of bladder cancer in patients. 
Xenogeneic models have also been used for the detection of growth and metastasis spread 
by bioluminescence techniques (Hadaschik et al., 2007). To monitor tumor growth and 
therapeutic efficacy, noninvasive imaging concepts are preferable. For that purpose, tumor 
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surrounding tissue, inducing neoformation of blood (angiogenesis) and lymphatic vessels 
and spreading in the body, forming secondary tumors or metastasis. In most cases, the 
death of patients with bladder cancer is due to the generation of metastasis. Angiogenesis, 
which is intricately involved in growth and metastasis and is in fact a prerequisite for these 
processes (Fidler, 1990; Folkman, 1986), is regulated by a fine balance between stimulatory 
and inhibitory factors produced by the tumor and the surrounding stroma (Liotta et al., 
1991). Bladder tumors produce high levels of several stimulatory factors, being the vascular 
endothelial growth factor (VEGF) overexpressed in bladder cancer (Crew et al., 1997; O'Brien 
et al., 1995). The action of this factor is mediated by its membrane receptor (VEGFR). Both 
VEGF and VEGFR are considered as important therapeutic targets. Some papers have 
studied the effects of a neutralizing monoclonal antibody targeted at murine VEGFR by 
using a xenograft model.  In combination with cytotoxic compounds, such as paclitaxel, this 
monoclonal antibody impairs tumor growth and angiogenesis and. thus prevents metastatic 
spread and prolongs mouse survival (Davis et al., 2004; Inoue et al., 2000).  
Xenograft models have also been used in radiopharmaceutical studies (Pfost et al., 2009). 
Pfost et al. coupled monoclonal antibodies that recognize epidermal growth factor receptors 
on bladder cancer cells with 213Bi, a radioactive alpha particle emitter, and found that 
therapy with 0.37 MBq of radiation after tumor cell inoculation in the bladder of nude mice 
results in higher survival of mice when compared with conventional treatment with 
Mitomycin C. These authors were also able to show that Mitomycin C produces 
nephrotoxicity, whereas 213Bi-anti-EGFR-mAb treatment showed no signs of nephrotoxicity. 
These results suggest that radioimmunotherapy using intravesically instilled 213Bi-anti-
EGFR-mAb is a promising option for the treatment of bladder cancer in patients. 
Xenogeneic models have also been used for the detection of growth and metastasis spread 
by bioluminescence techniques (Hadaschik et al., 2007). To monitor tumor growth and 
therapeutic efficacy, noninvasive imaging concepts are preferable. For that purpose, tumor 
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cells are stably transfected with genes coding for fluorescent proteins (Tanaka et al., 2003) or 
enzymes catalyzing bioluminescence (Hadaschik et al., 2007), allowing for the continuous 
visualization of tumor development after intravesical instillation of tumor cells. 
Although, as described above, xenograft models are important tools to study the behavior of 
human tumors in vivo, they also have an important limitation: they are immunodeficient. 
This makes this animal model not suitable to study interactions between the host immune 
system and the tumor. Furthermore, xenograft models are useless for research on the 
biological mechanisms related to carcinogenesis or on the possible compounds able to 
prevent carcinogenesis. In contrast, syngeneic animal models are more appropriate to 
approach these issues.  
2.1.2 Syngeneic models 
Syngeneic models include the appearance of spontaneous tumors, induction of tumors by 
chemical carcinogens, and inoculation of tumor cells in mice genetically identical to those in 
which tumors were developed. All of them are useful for studies in which the host-tumor 
interaction must be taken into account. 
Immunotherapy  
In patients, non-muscle invasive bladder cancers are usually managed with transurethral 
resection followed by the intravesical administration of Bacillus Calmette-Guerin (BCG). 
This immune therapy has been used without modification since 1976 (Morales et al., 1976). 
In addition to the direct anti-tumor effect (Sandes et al., 2007), it is widely recognized that 
intravesical BCG therapy is more potent in preventing tumor recurrence than any other 
intravesical chemotherapy (Sylvester, 2009). However, about 20% of patients either fail to 
respond initially or relapse within the first five years of treatment (Smaldone et al., 2009). 
The exact mechanisms of BCG action have not been completely elucidated yet. However, it 
is known that BCG generates a local immunological reaction with activation of immune cells 
as well as secretion of cytokines involving Th1 cell cytotoxicity (Riemensberger et al., 2002). 
To investigate the immune mechanisms by which BCG prevents bladder tumor recurrence 
and progression as well as the mechanisms of immune suppression to explain the lack of 
effectiveness of BCG observed in some patients, animal models with a competent immune 
system are needed. Syngeneic mouse bladder cancer models have thus been used for this 
purpose.  
Animal models using subcutaneous or orthotopic inoculation of bladder cancer cell lines 
are being designed to study potential therapies to reverse these immune suppressive 
mechanisms. Mangsbo et al. have studied a syngeneic model by inoculating MB49 bladder 
cancer cell lines in the subcutis of C57BL/6J mice. This experimental model closely 
mimicks human bladder cancer, because MB49 cells express negative regulatory proteins 
of the immune response (Inman et al., 2007; Nakanishi et al., 2007). Among others, the 
programmed death ligand 1 (PD-L1) and the cytotoxicity T lymphocyte antigen-4 (CTLA-
4) render T regulatory cells (Tregs) that can oppose to BCG immunotherapy. Antibodies 
able to block PD-L1 and CTLA-4 administered intratumorally improves long-term 
survival and leads to increased levels of tumor-reactive T cells and decreased numbers of 
Tregs at the tumor site. Therefore, this experimental model has allowed an approach to 
the understanding of immune suppression during immune therapy with BCG and 
represents a new therapeutic option in the treatment of bladder cancer (Mangsbo et al., 
2010). 
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It is known that BCG is neither free of mild or intermediate side effects such as fever and 
granulomatous prostatitis nor of severe side effects such as pneumonitis, hepatitis and BCG 
sepsis (DeHaven et al., 1992). To avoid such unfavorable events, it is necessary to develop a 
more active and less toxic immunotherapeutic agent. A mouse syngeneic model using 
subcutaneous inoculation of MBT2 bladder cancer cell lines has been used to evaluate the 
effectiveness of liposomes containing walls from BCG bacteria as immune therapy. With this 
experimental design, Joraku et al. have demonstrated inhibition of tumor growth with 
increased immunity. Thus, this non-live bacterial agent may contribute to providing a more 
active and less toxic tool as a substitute for live BCG in immunotherapy (Joraku et al., 2009). 
Besides the study of the immune mechanism, other studies involving the tumor-host 
interaction have used syngeneic models. For example, in our laboratory, we have 
evaluated the mechanism of action of BCG using animals inoculated subcutaneously with 
MB49 bladder cancer cells, and found that macrophages from tumor-bearing mice treated 
with BCG intratumorally were able to produce soluble factors including fibroblast growth 
factor-2 (FGF-2), which induces fibroblast proliferation. We also found that in vivo BCG 
therapy reduces tumor growth with a concomitant increase in collagen deposition and 
expression of alpha-smooth muscle actin and FGF-2. These results suggest that tissue 
repair mechanisms similar to healing are involved in BCG immunotherapy of bladder 
cancer (Lodillinsky et al., 2010). 
Carcinogenesis and chemo-prevention  
Bladder cancer is a candidate for chemo-prevention intervention for several reasons. In the 
first place, bladder cancer patients present successive recurrences that must be prevented. 
Also, in addition to genetic susceptibility, this cancer is closely related to exposure to 
environmental contaminants, including cigarette smoking, which implies the constant 
contact of carcinogenetic substances with the urothelium. 
Animal models are widely used to select chemical synthesis products, purified natural 
products or even mixtures of natural products with potential to prevent tumor 
development, which can then be used in clinical trials. The idea is to use organ-specific 
animal models to determine which agents are likely to be helpful in preventing specific 
forms of cancer. These animal models can be obtained by chemical induction, spontaneous 
occurrence or use of transgenic animals.  
To be useful, animal models must meet several characteristics. The model should be of 
clinical relevance, not only in terms of organ specificity but also in terms of the histology 
and the genetic abnormalities. Furthermore, premalignant lesions should be developed 
with genetic and histological features as similar as possible to those observed in the 
development of human cancer. In addition, the model must be consistent in generating 
tumors in a significant number of animals in a reasonable period. Finally, the model must 
be predictive in terms of clinical efficacy, i.e. that the positive or negative results obtained 
in the animal model should later correlate with positive and negative results in human 
trials (Steele et al., 2010). 
One of most useful models is the induction of bladder cancer in mice and rats with 
hydroxybutyl(butyl)nitrosamine (OH-BBN). This carcinogen compound induces 
premalignant lesions that progress to transitional bladder tumors, and in little proportion of 
squamous tumors (Grubbs et al., 2000). Recent studies by Lu et al. have compared bladder 
tumors in rats and mice induced by OH-BBN with human bladder tumors, using a global 
gene expression approach cross-species analysis, and shown the similarity between this 
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cells are stably transfected with genes coding for fluorescent proteins (Tanaka et al., 2003) or 
enzymes catalyzing bioluminescence (Hadaschik et al., 2007), allowing for the continuous 
visualization of tumor development after intravesical instillation of tumor cells. 
Although, as described above, xenograft models are important tools to study the behavior of 
human tumors in vivo, they also have an important limitation: they are immunodeficient. 
This makes this animal model not suitable to study interactions between the host immune 
system and the tumor. Furthermore, xenograft models are useless for research on the 
biological mechanisms related to carcinogenesis or on the possible compounds able to 
prevent carcinogenesis. In contrast, syngeneic animal models are more appropriate to 
approach these issues.  
2.1.2 Syngeneic models 
Syngeneic models include the appearance of spontaneous tumors, induction of tumors by 
chemical carcinogens, and inoculation of tumor cells in mice genetically identical to those in 
which tumors were developed. All of them are useful for studies in which the host-tumor 
interaction must be taken into account. 
Immunotherapy  
In patients, non-muscle invasive bladder cancers are usually managed with transurethral 
resection followed by the intravesical administration of Bacillus Calmette-Guerin (BCG). 
This immune therapy has been used without modification since 1976 (Morales et al., 1976). 
In addition to the direct anti-tumor effect (Sandes et al., 2007), it is widely recognized that 
intravesical BCG therapy is more potent in preventing tumor recurrence than any other 
intravesical chemotherapy (Sylvester, 2009). However, about 20% of patients either fail to 
respond initially or relapse within the first five years of treatment (Smaldone et al., 2009). 
The exact mechanisms of BCG action have not been completely elucidated yet. However, it 
is known that BCG generates a local immunological reaction with activation of immune cells 
as well as secretion of cytokines involving Th1 cell cytotoxicity (Riemensberger et al., 2002). 
To investigate the immune mechanisms by which BCG prevents bladder tumor recurrence 
and progression as well as the mechanisms of immune suppression to explain the lack of 
effectiveness of BCG observed in some patients, animal models with a competent immune 
system are needed. Syngeneic mouse bladder cancer models have thus been used for this 
purpose.  
Animal models using subcutaneous or orthotopic inoculation of bladder cancer cell lines 
are being designed to study potential therapies to reverse these immune suppressive 
mechanisms. Mangsbo et al. have studied a syngeneic model by inoculating MB49 bladder 
cancer cell lines in the subcutis of C57BL/6J mice. This experimental model closely 
mimicks human bladder cancer, because MB49 cells express negative regulatory proteins 
of the immune response (Inman et al., 2007; Nakanishi et al., 2007). Among others, the 
programmed death ligand 1 (PD-L1) and the cytotoxicity T lymphocyte antigen-4 (CTLA-
4) render T regulatory cells (Tregs) that can oppose to BCG immunotherapy. Antibodies 
able to block PD-L1 and CTLA-4 administered intratumorally improves long-term 
survival and leads to increased levels of tumor-reactive T cells and decreased numbers of 
Tregs at the tumor site. Therefore, this experimental model has allowed an approach to 
the understanding of immune suppression during immune therapy with BCG and 
represents a new therapeutic option in the treatment of bladder cancer (Mangsbo et al., 
2010). 
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It is known that BCG is neither free of mild or intermediate side effects such as fever and 
granulomatous prostatitis nor of severe side effects such as pneumonitis, hepatitis and BCG 
sepsis (DeHaven et al., 1992). To avoid such unfavorable events, it is necessary to develop a 
more active and less toxic immunotherapeutic agent. A mouse syngeneic model using 
subcutaneous inoculation of MBT2 bladder cancer cell lines has been used to evaluate the 
effectiveness of liposomes containing walls from BCG bacteria as immune therapy. With this 
experimental design, Joraku et al. have demonstrated inhibition of tumor growth with 
increased immunity. Thus, this non-live bacterial agent may contribute to providing a more 
active and less toxic tool as a substitute for live BCG in immunotherapy (Joraku et al., 2009). 
Besides the study of the immune mechanism, other studies involving the tumor-host 
interaction have used syngeneic models. For example, in our laboratory, we have 
evaluated the mechanism of action of BCG using animals inoculated subcutaneously with 
MB49 bladder cancer cells, and found that macrophages from tumor-bearing mice treated 
with BCG intratumorally were able to produce soluble factors including fibroblast growth 
factor-2 (FGF-2), which induces fibroblast proliferation. We also found that in vivo BCG 
therapy reduces tumor growth with a concomitant increase in collagen deposition and 
expression of alpha-smooth muscle actin and FGF-2. These results suggest that tissue 
repair mechanisms similar to healing are involved in BCG immunotherapy of bladder 
cancer (Lodillinsky et al., 2010). 
Carcinogenesis and chemo-prevention  
Bladder cancer is a candidate for chemo-prevention intervention for several reasons. In the 
first place, bladder cancer patients present successive recurrences that must be prevented. 
Also, in addition to genetic susceptibility, this cancer is closely related to exposure to 
environmental contaminants, including cigarette smoking, which implies the constant 
contact of carcinogenetic substances with the urothelium. 
Animal models are widely used to select chemical synthesis products, purified natural 
products or even mixtures of natural products with potential to prevent tumor 
development, which can then be used in clinical trials. The idea is to use organ-specific 
animal models to determine which agents are likely to be helpful in preventing specific 
forms of cancer. These animal models can be obtained by chemical induction, spontaneous 
occurrence or use of transgenic animals.  
To be useful, animal models must meet several characteristics. The model should be of 
clinical relevance, not only in terms of organ specificity but also in terms of the histology 
and the genetic abnormalities. Furthermore, premalignant lesions should be developed 
with genetic and histological features as similar as possible to those observed in the 
development of human cancer. In addition, the model must be consistent in generating 
tumors in a significant number of animals in a reasonable period. Finally, the model must 
be predictive in terms of clinical efficacy, i.e. that the positive or negative results obtained 
in the animal model should later correlate with positive and negative results in human 
trials (Steele et al., 2010). 
One of most useful models is the induction of bladder cancer in mice and rats with 
hydroxybutyl(butyl)nitrosamine (OH-BBN). This carcinogen compound induces 
premalignant lesions that progress to transitional bladder tumors, and in little proportion of 
squamous tumors (Grubbs et al., 2000). Recent studies by Lu et al. have compared bladder 
tumors in rats and mice induced by OH-BBN with human bladder tumors, using a global 
gene expression approach cross-species analysis, and shown the similarity between this 
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animal model and bladder cancer in humans. These genes are likely to have conserved 
functions contributing to bladder carcinogenesis. To strengthen this analysis, these authors 
studied the molecular pathway commonly activated in both human and rodent bladder 
cancer and found a number of pathways that affect the cell cycle, HIF-1 and MYC 
expression, and regulation of apoptosis in both rodent and human bladder cancer. Also, 
they compared expression changes at mRNA and protein levels in the rat model and 
identified several genes/proteins exhibiting concordant changes in human bladder tumors. 
They concluded that rodent models (in OH-BBN-treated B6D2F1 mice and Fischer-344 rats) 
of bladder cancer accurately represent the clinical situation to an extent that will allow 
successful miming of target genes, showing that these models are powerful tools for 
chemoprevention research (Lu et al., 2010). Using this experimental model, it has been 
demonstrated that NSAIDs (such as indomethacin, naproxen, NO-naproxen, and celecoxib), 
various EGFR inhibitors, and purified natural compounds (such as tea polyphenols and 
sulforaphane) have striking efficacy to prevent bladder tumor development (Ding et al., 
2010; Grubbs et al., 2000; Lubet et al., 2005; Steele et al., 2009; Yao et al., 2004). 
Two disadvantages inherent in these models are the long experimental times (usually 
periods between 8 to 12 months) and the occupational exposure of workers. To avoid the 
use of carcinogens, knockout or transgenic mouse models can be used. These models are 
used in chemoprevention trials as well as in studies on the relevance of  each gene in tumor 
development. 
2.1.3 Transgenic models 
Activation of oncogenes or inactivation of tumor suppressors in the urothelium is 
considered critical for the development of urothelial cancer. Transgenic mice have proven to 
be powerful tools to unravel the mechanisms of carcinogenesis and to understand the 
molecular basis of the disease. Transgenic mice are a particular case of syngeneic models, 
which are genetically modified to study the importance of a particular gene in cancer 
development and progression. Knockout mice, which are genetically modified mice, can be 
used to study the effect on the deficiency of a particular gene. 
Alterations in the suppressor genes RB1 and p53 as well as the activation of oncogenes such 
as Ha-ras are commonly found in human urothelial tumors. Transgenic mice with 
alterations in these genes have been designed. By way of example, we will next describe 
some of the models developed and the conclusions that have been reached. 
Mouse embryos lacking the retinoblastoma (Rb) gene die 14 days into gestation and mice 
lacking the p53 gene succumb to thymic lymphomas at seven months of age. So, the role of 
these genes in the analysis of tumorigenesis was delayed until conditional transgenic mice 
were developed. These models achieve the loss of gene function only in a particular tissue. 
The specific urothelium knockout system was developed using the Cre/loxP strategy. 
Transgenic mouse lines in which a 3.6-kb mouse uroplakin II promoter is used to drive the 
expression of Cre recombinase (Cre) have been generated (Mo et al., 2005). The use of this 
model has allowed understanding the role of antitumor genes such as RB, p53 and PTEN in 
bladder carcinogenesis (Ahmad et al., 2011; Ayala de la Pena et al., 2011; He et al., 2009). 
Conditional inactivation of both RB1 alleles in the mouse urothelium instead of accelerate 
urothelial proliferation, profoundly activated the p53 pathway, leading to extensive 
apoptosis in urothelial cells. Thus, pRb loss triggers fail-safe mechanisms whereby urothelial 
cells can evade tumorigenesis. Additional loss of p53 in pRb-deficient urothelial cells can 
 
Animal Models for Basic and Preclinical Research in Bladder Cancer 
 
389 
remove these p53-dependent tumor barriers, resulting in hyperplasia or umbrella cell 
nuclear atypia. Also, superficial papillary bladder tumors of low-grade (rare occurrence) but 
not invasive carcinomas have been detected. Furthermore, mice deficient in both pRb and 
p53 are highly susceptible to carcinogen exposure, developing invasive carcinomas that 
resemble human bladder cancer (He et al., 2009). Another transgenic mouse with 
inactivation of the tumor suppressor p53 has been obtained by expression of SV40 large T 
antigen, directed to the urothelium with the specific promoter uroplakin-II. In the same way 
as in the transgenic mice described above, this construction has allowed demonstrating that 
the elimination of p53 alone is not sufficient for the generation of bladder tumor (Ayala de la 
Pena et al., 2011). The function of proto-oncogene activation has been assessed by using Ha-
ras trangenic mice (Zhang et al., 2001). 
Transgenic mice with compromised immune systems have also been developed. Mice 
knockout to IFN gamma (IFNɣ -/-), interleukins 17, 12 and 23  (IL-17 -/-; IL-12-/- and IL-23 
-/-), among others, are being used to understand how different components of the immune 
system either promote or inhibit the development of bladder tumors (Kortylewski et al., 
2009; Langowski et al., 2006; Wang et al., 2009). 
In both syngeneic and xenogeneic models, tumors can grow in heterotopic or orthotopic 
sites. Below we describe the advantages and disadvantages of both modalities. 
2.1.4 Heterotopic tumor growth 
This site of inoculation refers to the growth of a tumor in a site different from its target 
organs, generally using subcutaneous inoculation. This approach is advantageous in cases 
where the orthotopic inoculation (see below) is complex such as in bladder, kidney, and 
bowels. Tumor inoculation is simple and can be carried out by an operator with minimum 
training. Furthermore, the tumor can be easily detected and the tumor evolution can be 
easily assessed by using palpation of the skin and measurement with a caliper, respectively. 
To assess tumor growth, at least two perpendicular diameters, the larger diameter (D) and 
the smaller diameter (d), must be measured. Some researchers also measure depth (Figure 
2). However, the latter is difficult to determine and generally produces large errors. Tumor 
size can be calculated from these data, using various formulas such as geometric mean 
((Dxd)1/2 expressed in millimeters), arithmetic average (Dxd/2 expressed in mm2), or volume 
of the ellipsoid (4/3 π Dxd2, expressed mm3). Not all tumors grow in the same way; some of 
them are more compact, whereas others develop necrosis. Therefore, to choose the most 
appropriate formula for each tumor, it is first necessary to validate the formula that best fits, 
when compared with tumor weight. 
The main disadvantage of the heterotopic model is the fact that an anatomic site other than 
an orthotopic site can differentially develop tumor growth. The tumorigenesis and 
metastatic potential of tumors depend not only on the characteristics of the tumor cells, but 
also on the tumor environment and therefore on the site of injection. Human tumors can be 
formed by different cell subpopulations with varying ability to metastasize and 
susceptibility to treatment, depending on the site of inoculation (Fidler, 1986). It has been 
observed that subcutaneous inoculation of murine MB49 bladder cancer cell lines induces 
lung metastases,  and that inoculation of these cells in the bladder does not (Lodillinsky et 
al., 2009). Similar observations have been made for human tumors using 253J B-V cells 
(Black et al., 2007). After 28 days of tumor growth either in the bladder or in the subcutis, 
Black et al. were able to determine that the tumor size was similar in both sites, but that only 
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animal model and bladder cancer in humans. These genes are likely to have conserved 
functions contributing to bladder carcinogenesis. To strengthen this analysis, these authors 
studied the molecular pathway commonly activated in both human and rodent bladder 
cancer and found a number of pathways that affect the cell cycle, HIF-1 and MYC 
expression, and regulation of apoptosis in both rodent and human bladder cancer. Also, 
they compared expression changes at mRNA and protein levels in the rat model and 
identified several genes/proteins exhibiting concordant changes in human bladder tumors. 
They concluded that rodent models (in OH-BBN-treated B6D2F1 mice and Fischer-344 rats) 
of bladder cancer accurately represent the clinical situation to an extent that will allow 
successful miming of target genes, showing that these models are powerful tools for 
chemoprevention research (Lu et al., 2010). Using this experimental model, it has been 
demonstrated that NSAIDs (such as indomethacin, naproxen, NO-naproxen, and celecoxib), 
various EGFR inhibitors, and purified natural compounds (such as tea polyphenols and 
sulforaphane) have striking efficacy to prevent bladder tumor development (Ding et al., 
2010; Grubbs et al., 2000; Lubet et al., 2005; Steele et al., 2009; Yao et al., 2004). 
Two disadvantages inherent in these models are the long experimental times (usually 
periods between 8 to 12 months) and the occupational exposure of workers. To avoid the 
use of carcinogens, knockout or transgenic mouse models can be used. These models are 
used in chemoprevention trials as well as in studies on the relevance of  each gene in tumor 
development. 
2.1.3 Transgenic models 
Activation of oncogenes or inactivation of tumor suppressors in the urothelium is 
considered critical for the development of urothelial cancer. Transgenic mice have proven to 
be powerful tools to unravel the mechanisms of carcinogenesis and to understand the 
molecular basis of the disease. Transgenic mice are a particular case of syngeneic models, 
which are genetically modified to study the importance of a particular gene in cancer 
development and progression. Knockout mice, which are genetically modified mice, can be 
used to study the effect on the deficiency of a particular gene. 
Alterations in the suppressor genes RB1 and p53 as well as the activation of oncogenes such 
as Ha-ras are commonly found in human urothelial tumors. Transgenic mice with 
alterations in these genes have been designed. By way of example, we will next describe 
some of the models developed and the conclusions that have been reached. 
Mouse embryos lacking the retinoblastoma (Rb) gene die 14 days into gestation and mice 
lacking the p53 gene succumb to thymic lymphomas at seven months of age. So, the role of 
these genes in the analysis of tumorigenesis was delayed until conditional transgenic mice 
were developed. These models achieve the loss of gene function only in a particular tissue. 
The specific urothelium knockout system was developed using the Cre/loxP strategy. 
Transgenic mouse lines in which a 3.6-kb mouse uroplakin II promoter is used to drive the 
expression of Cre recombinase (Cre) have been generated (Mo et al., 2005). The use of this 
model has allowed understanding the role of antitumor genes such as RB, p53 and PTEN in 
bladder carcinogenesis (Ahmad et al., 2011; Ayala de la Pena et al., 2011; He et al., 2009). 
Conditional inactivation of both RB1 alleles in the mouse urothelium instead of accelerate 
urothelial proliferation, profoundly activated the p53 pathway, leading to extensive 
apoptosis in urothelial cells. Thus, pRb loss triggers fail-safe mechanisms whereby urothelial 
cells can evade tumorigenesis. Additional loss of p53 in pRb-deficient urothelial cells can 
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remove these p53-dependent tumor barriers, resulting in hyperplasia or umbrella cell 
nuclear atypia. Also, superficial papillary bladder tumors of low-grade (rare occurrence) but 
not invasive carcinomas have been detected. Furthermore, mice deficient in both pRb and 
p53 are highly susceptible to carcinogen exposure, developing invasive carcinomas that 
resemble human bladder cancer (He et al., 2009). Another transgenic mouse with 
inactivation of the tumor suppressor p53 has been obtained by expression of SV40 large T 
antigen, directed to the urothelium with the specific promoter uroplakin-II. In the same way 
as in the transgenic mice described above, this construction has allowed demonstrating that 
the elimination of p53 alone is not sufficient for the generation of bladder tumor (Ayala de la 
Pena et al., 2011). The function of proto-oncogene activation has been assessed by using Ha-
ras trangenic mice (Zhang et al., 2001). 
Transgenic mice with compromised immune systems have also been developed. Mice 
knockout to IFN gamma (IFNɣ -/-), interleukins 17, 12 and 23  (IL-17 -/-; IL-12-/- and IL-23 
-/-), among others, are being used to understand how different components of the immune 
system either promote or inhibit the development of bladder tumors (Kortylewski et al., 
2009; Langowski et al., 2006; Wang et al., 2009). 
In both syngeneic and xenogeneic models, tumors can grow in heterotopic or orthotopic 
sites. Below we describe the advantages and disadvantages of both modalities. 
2.1.4 Heterotopic tumor growth 
This site of inoculation refers to the growth of a tumor in a site different from its target 
organs, generally using subcutaneous inoculation. This approach is advantageous in cases 
where the orthotopic inoculation (see below) is complex such as in bladder, kidney, and 
bowels. Tumor inoculation is simple and can be carried out by an operator with minimum 
training. Furthermore, the tumor can be easily detected and the tumor evolution can be 
easily assessed by using palpation of the skin and measurement with a caliper, respectively. 
To assess tumor growth, at least two perpendicular diameters, the larger diameter (D) and 
the smaller diameter (d), must be measured. Some researchers also measure depth (Figure 
2). However, the latter is difficult to determine and generally produces large errors. Tumor 
size can be calculated from these data, using various formulas such as geometric mean 
((Dxd)1/2 expressed in millimeters), arithmetic average (Dxd/2 expressed in mm2), or volume 
of the ellipsoid (4/3 π Dxd2, expressed mm3). Not all tumors grow in the same way; some of 
them are more compact, whereas others develop necrosis. Therefore, to choose the most 
appropriate formula for each tumor, it is first necessary to validate the formula that best fits, 
when compared with tumor weight. 
The main disadvantage of the heterotopic model is the fact that an anatomic site other than 
an orthotopic site can differentially develop tumor growth. The tumorigenesis and 
metastatic potential of tumors depend not only on the characteristics of the tumor cells, but 
also on the tumor environment and therefore on the site of injection. Human tumors can be 
formed by different cell subpopulations with varying ability to metastasize and 
susceptibility to treatment, depending on the site of inoculation (Fidler, 1986). It has been 
observed that subcutaneous inoculation of murine MB49 bladder cancer cell lines induces 
lung metastases,  and that inoculation of these cells in the bladder does not (Lodillinsky et 
al., 2009). Similar observations have been made for human tumors using 253J B-V cells 
(Black et al., 2007). After 28 days of tumor growth either in the bladder or in the subcutis, 
Black et al. were able to determine that the tumor size was similar in both sites, but that only 
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tumors growing orthotopically in the bladder developed metastasis to lymph nodes and 
lungs. The orthotopic tumors, as compared to the subcutaneous tumors, have an increased 
microvessel density, increase in growth factors expression and proteolytic enzyme activity. 
Therefore, models of orthotopic growth are more appropriate for studies related to 
metastasis dissemination or response to any treatment. 
 
 
Fig. 2. Heterotopic tumor growth: MB49 bladder cancer cells growing in the subcutis of 
C57BL/6J mice.  
There are some heterotopic models such as inoculation into the tail vein or the left ventricle 
of the heart which have been widely used to evaluate the process of extravasations and 
colonization in the lung or bone, respectively (Growcott, 2009; Wu et al., 2010). Although 
very used, these models consider only a limited aspect of the metastatic process (Figure 3).  
 
 
Fig. 3. Lung metastases: inoculation of MB49 (panel A) or MB49-I (panel B) bladder cancer 
cell lines into the tail vein induces lung metastasis. The lungs are colored in black by 
intratracheal inoculation of Indian ink. Metastases are seen in yellow by the stain and 
Bouin’s fixative solution. 
2.1.5 Orthotopic tumor growth 
Growth in the target organ allows for better analysis of the interaction between the host and 
the tumor. When tumors are chemically induced, the carcinogen is chosen such that the 
tumor develops in the desired organ. Thus, tumor growth occurs in the orthotopic site. 
However, in the case that the tumor is generated by inoculation of a tumor fragment or 
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tumor cell lines, the orthotopic inoculation is not always easy to perform. However, this 
difficulty must be overcome since the results obtained with heterotopic models are not 
always easy translated into clinical trials.  
As previously mentioned, there are examples showing that different results are observed 
when the tumor is inoculated subcutaneously or orthotopically in the bladder. In studies of 
chemoprevention, inhibition of bladder cancer development by allyl isothiocyanate was 
detected for tumors growing orthotopically but not in the subcutis (Bhattacharya et al., 
2010). Furthermore, as described in the previous section, considerable variation has been 
detected between the two models in assays of immunotherapy, angiogenesis, invasion and 
metastatic spread, among others. Taking these limitations into account, to achieve a correct 
interpretation of results and a translatable preclinical model, it is necessary to inoculate the 
tumor in the bladder.  
Inoculation into the bladder requires a qualified technician. Mice must first be anesthetized 
and subsequently, a 24-gauge Teflon i.v. catheter must be inserted through the urethra into 
the bladder using an inert lubricant to avoid discomfort in mice. For successful implantation 
of the bladder tumor cells, the urothelium must first be damaged. There are different 
techniques to induce such damage in the bladder. One of them involves the use of 
hydrochloric acid (0.1 ml 0.1 M HCl for 15 minutes) and subsequent neutralization with 
alkali and extensive washing with saline (Zhang et al., 2011). Another technique involves 
instillation of a solution of silver nitrate (NO3Ag ) (Chade et al., 2008). Both forms of injury 
allow the generation of tumors uniformly distributed in the bladder. The inoculation of 
MB49 tumor cells (1x105 to 5x105) in syngeneic mice generates superficial tumors in about 7 
to 15 days. Other techniques, using polylysine instillation, intramurally inoculation via 
laparotomy, or electro cauterization of the urothelium, are also used (Black et al., 2010). 
Cauterization of the bladder mimics transurethral resection of bladder tumor and therefore 
should facilitate adherence of instilled tumor cells to the bladder wall. The method was 
designed by Gunther et al. for the inoculation of MB49 cells in syngeneic mice (Gunther et 
al., 1999). However, it is also used for inoculation of cells from human bladder tumors in 
nude mice (Pfost et al., 2009). The technique involves the insertion of a guiding wire into the 
bladder of a mouse positioned dorsally on the ground plate of the cautery unit via the teflon 
catheter. When it is verified that the wire touches the bladder wall, the wire is attached to 
the cautery unit, and a monopolar coagulation mode is applied for 2 seconds at the lowest 
level (7 W). Then, via the same catheter, an appropriate number of tumor cells are 
inoculated and should remain in the bladder for at least 30 minutes (Figure 4A). 
Another difficulty to be overcome is the determination of the evolution of bladder tumor 
growth. Unlike what happens in the case of a subcutaneous tumor growth, where its size 
can be easily determine at different times of evolution, the growth evolution in the bladder 
is more uncertain. However, hematuria is the hallmark of tumor presence (Figure 4B). Mice 
with 1x104 or 1x105 MB49 cell lines, inoculated by electrocautery, present hematuria about 
15 or 9 days post-inoculation, respectively (Lodillinsky et al., 2009). Inoculation of 5x103 cells 
in the bladder previously treated with NO3Ag generates hematuria in all mice about 7 days 
after tumor implantation (Chade et al., 2008). Palpation of the bladder may give an idea of 
the extent of the tumor, but it is difficult to carry out because the bladder is retropubic. Also, 
in some cases, palpation could be given a wrong interpretation. When there is an 
obstruction of the urethra by blood clots, the bladder is greatly enlarged as a product of the 
accumulation of urine, and may thus lead to a wrong estimate of the extension of the tumor 
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tumors growing orthotopically in the bladder developed metastasis to lymph nodes and 
lungs. The orthotopic tumors, as compared to the subcutaneous tumors, have an increased 
microvessel density, increase in growth factors expression and proteolytic enzyme activity. 
Therefore, models of orthotopic growth are more appropriate for studies related to 
metastasis dissemination or response to any treatment. 
 
 
Fig. 2. Heterotopic tumor growth: MB49 bladder cancer cells growing in the subcutis of 
C57BL/6J mice.  
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(Figure 4C and D). Therefore, in these cases, the true evaluation of tumor size can be 
obtained at the end of the experiment, either by measuring the bladder with a caliper or by 
determining its weight (Figure 4E and F). Experiments of this type, also called end-point, 
have the disadvantage that they focus only on one measure of tumor size and not on its 
evolution throughout the experiment. This problem will soon be overcome by the design of 
non-invasive diagnostic equipment for small animals, similar to those used in medical 
practice in humans, such as ultrasound-doppler, infrared (IR) or bioluminescence imaging. 
By way of example, ultrasound-Doppler sagittal images have been used to evaluate 
angiogenesis in a mouse bladder cancer model (Sugano et al., 2011). Also, bladder cancer 
cells that have been engineered to express certain proteins that emit fluorescence are being 
used in bioluminescence detection of tumor development (Black et al., 2010). 
 
 
Fig. 4. Bladder tumor growth: A) orthotopic inoculation: after cauterization and inoculation 
of the appropriate number of tumor cells, mice should remain upside-down for at least 30 
minutes  so that cells can adhere to the bladder epithelium. B) Hematuria is the hallmark of 
tumor presence. C) Mouse with bladder tumor. D) Mouse with bladder containing urine but 
without tumor. E) Two bladders with tumor. F) Bladders from normal mice.  
2.2 Mouse bladder cancer model for study of invasion and metastasis 
2.2.1 Invasion and metastasis 
The process of tumor invasion and metastasis is the most devastating stage of neoplastic 
disease and worsens prognosis of cancer patients. Adverse effects of systemic anti-tumor 
therapy and organ failure invaded with metastatic tissue are the leading causes of death in 
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these patients (Steeg et al., 2006). It is currently accepted that tumors have a clonal origin, 
which means that they are derived from a single cell. The high proliferative capacity, 
coupled with the genetic instability of tumor cells, generates new mutations, and thus the 
generation of other cell populations conferring tumor heterogeneity. This is considered part 
of an evolutionary process of genetic and epigenetic changes that allow some of the primary 
tumor cells acquire an adaptive advantage to migrate and colonize new environments. 
However, new findings have shown the possibility of a parallel development of cells 
capable of early metastatic spread. This parallel progression model urges to review the 
current diagnostic and treatment (Klein et al. 2009).  
The local invasion process that gives rise to metastatic spread is a multi-step event called 
metastatic cascade. This is a phenomenon with low efficiency, indicating that only a few of 
the cells that emerge from the primary tumor are able to generate metastases. 
Initially, tumor cells release proteolytic enzymes, such as MMPs and cathepsins, which 
degrade the extracellular components of basement membrane, thereby creating gaps that 
allow the invasion of the underlying connective tissue. The tumor cells migrate through the 
extracellular matrix and some may penetrate the lymphatic and blood capillaries, a 
phenomenon knows as intravasation. Once in the bloodstream, cells that manage to survive 
must leave the vessel (extravasation) into different organs (Figure 5). When the 




Fig. 5. During the metastatic cascade, tumor cells undergo genotypic and phenotypic 
changes that increase their capacity for invasion and migration. Some tumor cells are 
capable of degrading the basal membrane and migrating through connective tissue. Cells 
from connective tissue, such as macrophages and fibroblasts, through the release of growth 
factors, cytokines and proteolytic enzymes, can enhance the invasive behavior of tumor 
cells. 
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The study of gene expression in primary tumor cells and metastatic cells has begun to lift 
the veil that prevented the understanding of the complex process of metastasis. These 
studies have identified a set of genes involved in the development of metastasis, called 
"metastogenic genes". Although there may be some overlap, these genes have been classified 
into three categories: a) initiation genes, b) progression genes and c) virulence genes 
(Nguyen et al., 2007).  
Initiation genes are associated with the processes of invasion, angiogenesis and epithelial-
mesenchymal transition (EMT). Since during invasion the migration of cells is an important 
step, genes encoding for GTPases involved in cytoskeleton remodeling such as RhoC have 
been included in this category. Among those involved in angiogenesis are those encoding 
the vascular endothelium growth factor, and matrix metalloproteinase 9 (MMP9). EMT 
allows changes that give advantages in terms of migration and invasion. Certain genes that 
encode for transcription factors associated with this transition such as TWIST1 are also 
included in this group. 
Progression genes are linked to the negative regulation of the immune response, vascular 
remodeling and extravasations. Examples are the gene coding for cyclooxygenase 2 (COX-
2), matrix metalloproteinase 1 (MMP-1) and angiopoietin-like 4 (ANGPTL4), among others.  
Finally, virulence genes are those which give the tumor cell an adaptive advantage to 
survive within an organ-specific microenvironment (Chiang et al., 2008). Among them are 
intercellular signaling molecules such as cytokines and interleukins (CXCR4 and IL-11), 
molecules of the family of tumor necrosis factor (TNF) that are associated with bone 
metabolism (RANKL) and mediators of the angiogenic process such as the Endothelin-1. 
Recent findings have identified the expression pattern characteristic of primary tumor gene, 
which is similar to a genetic signature that predicts the metastatic potential of the tumor 
(Bertucci et al., 2007, Van't Veer et al., 2002). This implies that the genetic profile expressed in 
metastases in specific organs is not always the same. Different groups of genes allow tumor 
cells to interact with stromal cells of the target organ. For example, the genes involved in 
breast cancer metastasis to bone are different from those involved in metastasis to the lung. 
This knowledge would allow the development of therapeutic strategies specific for each 
gene expression pattern or "signature " of a metastasis. 
2.2.3 Epithelial-mesenchymal transition 
During the invasion process, the tumor cells show a phenotypic change called epithelial-
mesenchymal transition (EMT), which is characterized by a morphological change that is 
due to a genetic reprogramming process which normally occurs during embryonic 
development and tissue repair such as scarring (Peinado et al., 2007). This reprogramming 
involves the expression of a group of transcriptional repressors (Zeb-1 and 2, Twist, Snail 
and Slug) that recruit histone deacetylases, controlling the expression of genes associated 
with the epithelial phenotype. An example of this is the decreased expression of E-cadherin, 
which leads to a loss of homotypic adhesion. Certain cytokines of the family of transforming 
growth factor beta (TGFbeta) and bone morphogenetic protein (BMP) are responsible for 
increasing the expression of these repressors (McConkey et al., 2009).  
Simultaneously with an underexpression of proteins of the epithelial phenotype, an 
overexpression of molecules associated with the mesenchymal phenotype has been 
detected. The expression of vimentin and loss of apical-basal polarization is a characteristic 
change of cells undergoing EMT (Peinado et al., 2007).  
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2.2.4 Proteolytic enzymes in bladder cancer invasion 
Proteolytic activity is of fundamental importance for the development, growth and 
maintenance of homeostasis of all the tissues in any organism. In each particular tissue, the 
activity of proteolytic enzymes is regulated at different levels, both at gene expression, 
transcriptional regulation and by specific endogenous inhibitors (Durkan et al., 2003; Kumar 
et al., 2010). In addition, these enzymes can activate each other through a mechanism 
cascade that also regulates their activity. The genetic instability of tumor cells leads to 
alterations in the genes encoding proteolytic enzymes and/or their inhibitors, which lead to 
an increased proteolytic activity in the tumor. It is well documented that proteolytic 
enzymes are involved in the process of invasion and metastasis. Matrix metalloproteinases 
(MMPs),cathepsins (B, L) and urokinase-type plasminogen activator (uPA) are the three 
main groups of enzymes described in the process of tumor invasion.  
MMPs, of which several isoforms are known, have a major role in matrix destruction and 
are involved in metastasis by mediating basement membrane destruction and angiogenesis 
(Kim et al., 2004). Of all known isoforms, MMP-2 and MMP-9 are strongly associated with 
invasion in bladder cancer (Eissa et al., 2007; Papathoma et al., 2000). 
Cathepsins have also been involved in cancer invasion. Cathepsin B (CB) is one of the most 
abundant lysosomal cysteine proteinase in mammalian tissue. It is synthesized as a 
glycosylated zymogen named pro-CB and subsequently converted to an active form of 33 
kDa or 27-29 kDa.  CB has an important role in the lysosomal degradation of proteins and is 
also involved in the degradation of the extracellular matrix in neoplastic and inflammatory 
diseases. Particularly, results from our laboratory have shown that the high expression of 
the active form of CB in transitional bladder tumors is associated with worse prognosis 
factors such as invasiveness and high histological grade (Eiján et al., 2003). 
The proteolytic activity of uPA is a system regulated by urokinase, its specific receptor 
uPAR and the specific plasminogen activator inhibitor 1 (PAI-1). This system plays a major 
role in tumorigenesis, tumor progression, tumor invasion and metastasis formation. It is 
generally assumed that the pro-malignant effect of the uPA-uPAR system is mediated by 
increased local proteolysis, thus favoring tumor invasion, as well as by the pro-angiogenic 
effect (Binder et al., 2008). Consistent with this activity it has been shown, in a rat orthotopic 
model, that intravesical administration of PAI-1, which inhibits uPA activity in tumors, 
reduces the growth and progression of bladder cancer (Chen et al., 2009). 
2.2.5 Orthotopic mouse bladder cancer invasion model 
Certain fundamental properties of metastatic cells such as migration and invasion can be 
studied in the laboratory using tumor cell cultures. Using various tools of genetic 
engineering, genes that encode molecules that emit fluorescence (green fluorescent protein), 
bioluminescent molecules (luciferase) or molecules with color (beta galactosidase) can be 
introduced into the cell. This technique is known as reporter gene and has allowed the 
analysis of molecular processes at the level of cell groups or isolated cells (Ghajar et al., 2008; 
Menon et al., 2009). In vitro experiments have also been useful to shed light on genes that 
might be involved in certain steps of the metastatic cascade. So, the use of genetic and 
pharmacological methods has shown that the expression of certain genes facilitate the 
assembly of new tumor blood vessels, tumor cells out of circulation and the passage of 
circulating tumor cells through the pulmonary capillaries to grow lung metastases (Gupta et 
al., 2007; Valastyan et al., 2009). However, in vitro models allow a simple analysis and do not 
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always allow evaluating interactions with the tumor microenvironment. It is therefore 
important to develop animal models to analyze the factors associated with tumor 
progression (Bos et al., 2010). To this end, we have added the advances in multiphoton 
intravital microscopy, which allows observing the in vivo behavior of tumor cells labeled 
with green fluorescent protein in the process of invasion and metastasis (Condeelis et al., 
2003). 
There are only few useful animal models to study the processes of invasion and metastasis. 
Dinney et al. have designed an orthotopic murine model with different degrees of invasion. 
To this end, they seeded human 253J cells into the bladder wall of immunodeficient mice 
(nude) and then selected subpopulations of the parental line by in vivo reimplantation in the 
bladder. After five serial passages, tumors were more tumorigenic and showed metastatic 
capacity (Dinney et al., 1995). These authors observed that these variants had a tumoral 
abnormal  karyotype, increased expression of molecules such as epidermal growth factor 
receptor (EGFR), interleukin 8 (IL-8) and MMP-9, and also observed an increased 
anchorage-independent growth and increased capacity to migrate in Matrigel ® (trade name 
of a protein mixture secreted by mouse sarcoma cells Engelbreth-Holm-Swarm), commonly 
used in the study of invasive and migratory behavior of tumor cells in contact with 
extracellular matrix components.  
This is a xenogeneic model in which it is possible to study the changes experienced by the 
tumor cells to acquire their invasive and metastatic phenotype. While this is an ingenious 
and very useful model, the fact that it is an immunodeficient mouse slightly restricts the 
applicability of the model. 
 
 
Fig. 6. MB49-I cell line obtained by successive in vivo passages of primary tumor obtained 
by inoculation of the MB49 bladder tumor cell line. The orthotopic inoculation in bladder of 
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surgically removed and 2-mm tumor pieces were transplanted by trocar into the left flank of 
mice. This process was repeated 13 consecutive times. We found that the growth rate was 
increased in transplants #6 to #10 and then became stable. Therefore, primary culture from 
transplant #13 was carried out and the cell line originated was named MB49-I. The 
orthotopic inoculation of MB49 or MB49-I in the bladder generates non-muscle invasive or 
muscle invasive tumors respectively (Figure 6).  
This new line has more aggressive characteristics. The MB49-I cell line has higher activity of 
the MMP-9, uPA and CB as well as increased in vitro invasion of Matrigel ®. Given the 
association of these enzymes with bladder cancer progression, our model has close 
similarities to human disease. The histopathological study in vivo showed results consistent 
with in vivo tests. Intravesical inoculation of MB49 cells was able to develop tumors without 
muscle invasion. By contrast, inoculation of the MB49-I cell line generated carcinoma with a 
disorganized structure and larger tumors with cellular atypia, muscle layer invasion and 
lung metastasis (Figure 7).  
 
 
Fig. 7. Haematoxylin-eosin staining for bladder tumors. A: It can see two formations of a 
tumor of bladder MB49: one sessile and one pedunculated,  which do not invade the muscle 
wall. B: MB49 the polypoid formation is magnified 400X. C: image of a tumor MB49-I, we 
observe a large tumor invading the muscular layer. D: MB49-I bladder tumor with higher 
magnification, where the tumor cells are intermingled with the muscle fibers. 
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Cellular plasticity is a fundamental process during tumor progression. It is now accepted 
that epithelial-mesenchymal transition is associated with tumor progression. A mark of this 
transition is the loss of cytokeratin and an increase in vimentin. MB49-I has not only 
morphological diversity, but also decreased cytokeratin and increased vimentin expression 
in vitro and in vivo. 
Since both the xenogeneic and syngeneic models described here resemble human bladder 
cancer, they could be useful to study tumor progression, tissue remodeling, and invasive 
and metastatic processes, and to assay anti-invasive and metastatic agents.  
3. Conclusions 
Since animal models can reproduce the tumor-host interactions, performing studies using 
these models is a mandatory step to translate from basic research to the clinic. Taking into 
account that animal experiments are performed to obtain an improvement for human-
health, but must generate a reduced impact on the animals, these experiments should be 
made according to international rules of bioethics. To accomplish the maximum welfare of 
the animal, every protocol, indicating the justification of each experiment and the 
methodology to be used, must be approved by the institutional ethics committee for the use 
of laboratory animals.   
The ideal animal model should meet all the characteristics of the human pathology, such as 
growth parameters, histology, evolution and metastatic dissemination. However, in the 
practice, the ideal model does not always have a complete similarity. The researcher must 
thus decide which model best fits the question to be answered. Alternatively, the researcher 
can design his/her own model that most closely approaches the point of interest.  
The generation of transgenic animals is one of the most developed branches in animal 
models. Technical refinements have allowed generating genetically modified mice either 
stable or conditional, making them a valuable tool.  
Animal models that mimic human bladder cancer in terms of invasion have also been 
developed. The use of successive transplants of tumors derived from a cancer cell line can 
generate invasive bladder tumors. Both the syngeneic and xenogenic invasive models of 
tumor are useful in the study of tumor progression. Finally, it is important to note that for a 
better understanding of the tumor mechanism and the relationship with the host, the best 
models are those, like MB49-I, in which the tumor is inoculated in an orthotopic site. 
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1. Introduction  
Arsenic can be found in nearly every part of the geosphere. It is viewed as the most harmful 
toxin in drinking water worldwide. At many places on earth the drinking water contains 
concentrations above 10 µg/l, which significantly exceed the tolerable value recommended 
by the WHO (World health organization [WHO], 2001). This is considered as a health threat 
for millions of people, especially in Bangladesh, Vietnam, and Latin America, where the 
geogenic origin has already been proved (Ng et al., 2003). The sources of this considerable 
arsenic occurrence (Fig. 1) are geogenic (erosion), mining activities, and geothermal waters 
(Smedly & Kinniburgh, 2002).  
 
 
Fig. 1. Map of arsenic affected aquifers (Smedly & Kinniburgh, 2002) 
The main arsenic species detected in drinking water are arsenite and arsenate. But the 
geothermal waters (Hot Spots) in the Yellostone Nationalpark, USA, predominantly contain 
several mg/l of methylated thioarsenicals such as mono-, di-, tri-, and tetrathioarsenate, as 
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well as methylated arsenoxy- and -thioanions (Planer-Friedrich et al., 2007). In the 
surrounding atmosphere 0.5 – 200 mg/m3 of volatile arsenic species can be detected, which 
have been identified, among others, as (CH3)2AsCl, (CH3)3As, (CH3)2AsSCH3, and CH3AsCl2 
(Planer-Friedrich et al., 2006). 
A second important source of arsenic is the air, whereas only one third of the occurring 
arsenic is of natural origin. Further anthropogenic sources are ore mining, smelteries, and 
the combustion of fossil fuels [Lozna & Biernat, 2008].  
Among polluted air and contaminated drinking water also the human diet is of importance. 
For example, high doses of arsenic can be detected in fish, seafood, and algae, so that in 2004 
the Food Agency of the UK warned against the consumption of Hijiki (hijikia fusiforme, 
black sea weed) (Food Standards Agency of the UK, 2004) as it contains inorganic arsenic up 
to 100 mg/kg. High arsenic concentrations can be found in the urine of the consumers 
(Nakjima et al., 2006). Francesconi published in 2010 the detection of up to 50 different 
arsenic compounds in fish and seafood, whereas their toxicity still is widely unknown 
(Francesconi, 2010).  
Especially rice and rice products exhibit considerable noxious effects as they contain high 
doses of toxic inorganic arsenic (Meharg et al., 2008; Signes-Pastor et al., 2009;  Sun et al., 2009) 
and form the nutrition base especially of the Asian people. But not only the rice from Asia but 
also the rice from the middle of the USA is contaminated with arsenic, the latter sustaining its 
contaminant not basically from natural sources but from pesticides anciently used on the 
cotton plantations. Finally DDT was introduced replaced arsenic in biocides (Hirner & 
Hippler, 2011). Fig. 2 summarises the several pathways of the human exposure to arsenic. 
 
 
Fig. 2. Pathways of human exposure to arsenic (Dopp, 2007) 
Chronic low-dose exposure may cause various diseases including bladder and other 
cancers. After ingestion arsenic is distributed to several organs, where it undergoes 
biotransformation. In 2005 Hayakawa et al. suggested a metabolic pathway (Fig. 3) for 
arsenic in rat liver tissue homogenate. Hereby arsenic-glutathione complexes are formed, 
which are then methylated by arsenic methyltransferase (Cyt19) and S-adenosyl-L-
methionine (SAM) (Hayakawa et al., 2005).  
This biotransformation of arsenic is generally regarded as a detoxifying process. Nevertheless, 
the trivalent arsenic intermediates and metabolites such as MMA(III) (monomethylarsonous 
acid) and DMA(III) (dimethylarsinous acid) are considered the most cyto- and genotoxic 
species (Dopp et al., 2010a). The liver is the main site of arsenic metabolism, and the renal 
route is the most important excretion pathway. A number of human studies have revealed that 
predominantly monomethylarsonic acid (MMA(V)) and dimethylarsinic acid (DMA(V)) can 
be detected in urine samples of arsenic-exposed individuals. Furthermore, Aposhian et al. 
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detected concentrations of about 50 nM MMA(III) in the urine of an arsenic-exposed human 
population in Romania (Aposhian et al., 2000). Studies in rats have shown that ingestion of 
DMA(V) causes bladder cancer (Wei et al., 1999) after chronic exposure. Subsequent 
experiments indicated that a large number of secondary arsenic metabolites are formed and 
renally excreted. For example, thiolated arsenicals such as dimethylmonothioarsonic acid 
(DMMTA(V)) were detected in the urine of DMA(V)-exposed rats (Yoshida et al., 1998). It is 
still unknown, however, which of the various arsenic metabolites is responsible for the 
development of bladder cancer. The metabolism of arsenic is of great importance for 
toxicological studies. As summarised by Dopp et al. (2010b) and Hirner & Rettenmeier (2010), 
the cyto- and genotoxic effects are highly dependent on the particular arsenic species, its 
cellular uptake, and its intracellular metabolism. For example, the toxicity of MMA(III) is 20 
















































Fig. 3. Mechanism of arsenic biomethylation according to Hayakawa (Hayakawa et al., 2005) 
Acute arsenic toxicity causes abdominal pain, nausea and faintness, vomiting, diarrhoea, 
and seizures (Gorby & Albuquerque, 1988). In contrast, chronic arsenic toxicity is less 
conspicuous. Characteristic symptoms are Mees' lines and hyperkeratosis predominantly at 
palms and soles of the feet. Furthermore, vascular diseases and peripheral neuropathy, and 
diabetes mellitus may occur (Smith et al., 2000). Until now, more than 60 million people in 
Bangladesh and India are still at risk of arsenic induced diseases due to arsenic 
concentrations of 10 - 50 µg/l or even higher (Chakraborti et al., 2004).  
Moreover, chronic arsenic exposure is also associated with an increased risk of cancer. 
Especially arsenic induced lung cancer, as well as skin, kidney, and bladder cancer were 
reported (Chiou et al, 1995; Chen et al., 2010; Tseng, 2007).  
The mechanisms of arsenic toxicity are only poorly understood. The structural likeness of 
arsenate and phosphate (Fig. 4), which is called molecular mimicry, results for example in 
the use of the same cellular transporters. Furthermore, there are plenty of biomolecules 
known, in which arsenate replaces phosphate, such as arsenosugars, arsenolipids and 
arsenobetaine (Rosen et al., 2011).  
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Fig. 4. Molecular mimicry of phosphate (A) and arsenate (B) (Rosen et al., 2011, modified) 
The relevance of this molecular mimicry is pointed out in the study of Wolfe-Simon et al. 
(2011), reporting that phosphate can be substituted by arsenate in macromolecules of a 
bacterium, strain GFAJ-1 of the Halomonadaceae, isolated from Mono Lake, CA. However, 
these data are currently controversially discussed in the literature. Hereby few points have 
to be considered, first the rapid hydrolysis of arsenate esters, and second the notably altered 
three dimensional structure of macromolecules like DNA (Rosen et al., 2011). 
One generally accepted mechanism for arsenic toxicity is the generation of reactive oxygen 
species (ROS). While ROS physiologically occur during cellular respiration or aerobic 
metabolism they also can result from exposure to oxidants. Already low levels of As(III) and 
MMA(III) are reported to generate ROS and therefore cause oxidative stress (Eblin et al., 
2008; Wnek et al., 2009). These highly reactive radicals are discussed to exhibit their toxicity 
via induction of DNA damage, formation of DNA adducts, or alteration of DNA 
methylation and histone modifications (Wnek et al., 2009), and finally leading to 
carcinogenesis (Kitchin & Ahmad, 2003; Huang et al., 2004). In addition, arsenic is known to 
interfere with nucleotide and base excision repair at very low, non-cytotoxic concentrations 
and was observed for both trivalent and pentavalent metabolites. Hereby, MMA(III) and 
DMA(III) were reported to exhibit the strongest effects (Hartwig et al., 2003). One key 
mechanism is the inactivation of poly (ADP-ribose) polymerase (PARP) already at extremely 
low, environmentally relevant concentrations (Hartwig et al., 2002; Hartwig et al., 2003). 
Wnek et al. (2009) reported that the relative PARP activity was significantly reduced during 
chronic exposure of immortalised human urothelial cells (UROtsa) to 50 nM MMA(III). 
After removal of MMA(III) PARP activity increased again. Trivalent arsenic species are 
known to attach to zinc-binding structures generally found in DNA repair enzymes leading 
to alteration or inhibition of those proteins and finally the loss of genomic integrity (Kitchin 
& Wallace, 2008). In contrast, former studies report the insensitivity of isolated and purified 
DNA repair enzymes against inhibition by arsenic (Hu et al., 1998). This leads to the 
assumption that there are different modes of action for arsenic inhibited DNA repair, on the 
one hand by directly targeting DNA repair proteins, and on the other hand by altered signal 
transduction or gene expression.  
Another mechanism of arsenic induced carcinogenesis is the altered cytoplasmic and 
nuclear signal transduction, modifying proteins involved in cell proliferation, 
differentiation, and apoptosis (Wnek et al., 2009). Hereby ROS were detected to be one key 
mechanism for the influence of As(III) and MMA(III) on the mitogen-activated protein 
kinase (MAPK) signaling pathway leading to consistent changes in cellular signalling (Eblin 
et al., 2008). The persistence of MMA(III)-induced altered cellular functions even after the 
removal of arsenic exposure point to lasting genomic or epigenetic changes and thus the 
highly carcinogenic potential of arsenic and its metabolites. 
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Furthermore, not only the molecular changes in the genome of arsenic exposed tissue and 
the altered signal transduction are of interest, but also the resulting phenotypical alterations. 
For the medical treatment of cancer it is of great interest whether the tumour has metastatic 
potential. Therefore, the tumour requires invasive growth into the surrounding tissue and 
the blood vessels. For example, the decrease of E-cadherin expression on the cellular surface 
is necessary for the detachment from the original tumour, and the increased expression of 
integrins is an important requirement for the attachment in the surrounding tissues like cells 
or extracellular matrix.  
To better understand the underlying mechanisms of arsenic toxicity and carcinogenicity, 
further studies have to be carried out to correlate genotypic and metabolic effects with 
phenotypical alterations, especially under chronic exposure conditions. Therefore, it is 
important to detect and analyse intracellular arsenic species and their metabolic products. In 
own studies we have investigated the cellular uptake of arsenic species in non-methylating 
human urothelial (UROtsa) and methylating human hepatic cells (HepG2) and have 
speciated and quantified the intracellularly detected arsenic. Induced genotoxic effects in 
UROtsa cells were measured with the Alkaline Comet Assay and the malignant 
transformation after chronic arsenic treatment was assayed by using the Colony Formation 
Assay and the Migration and Invasion Assay. Our latest results are presented here.  
2. Experimental 
2.1 Cell culture 
Studies were carried out using the human immortalized urothelial cell line UROtsa 
(generous gift from Prof. M. Styblo, University of North Dakota, USA). The UROtsa cells 
were maintained in Earle’s minimal essential medium (MEM) (CC-PRO, Oberdorla, 
Germany) enriched with 10 % FBS (fetal bovine serum; GIBCO, Darmstadt, Germany), 0.5 % 
Gentamycin (CC-Pro GmbH, Oberdorla, Germany) and 1 % L-glutamine (CC-Pro GmbH, 
Oberdorla, Germany).  
For comparison of a methylating and non-methylating cell line, HepG2 cells (human liver 
cells, methylating cells) were used as a second cell line. HepG2 cells were obtained from 
ATCC (HB 8065; ATCC, Manassas, VA, USA) and cultured in Earle’s minimal essential 
medium (MEM) (CC-PRO, Oberdorla, Germany) enriched with 10 % FBS (GIBCO, 
Darmstadt, Germany), 0.5 % Gentamycin (CC-Pro GmbH, Oberdorla, Germany), 1 % L - 
glutamine (CC-Pro GmbH, Oberdorla, Germany), 1 % non essential amino acids (CC-Pro 
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Furthermore, not only the molecular changes in the genome of arsenic exposed tissue and 
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medium was replaced again. For cell detachment 0.25 % trypsin without EDTA (CC-Pro 
GmbH, Oberdorla, Germany) was used to prevent the complexation of arsenic. 
2.2 Intracellular arsenic speciation and quantification 
The following methodology (Hippler et al., 2011) was used for intracellular arsenic 
speciation and quantification: Cells were seeded into 150 cm² flasks and grown to 
confluence before experiments were performed. Both cell lines (UROtsa and HepG2) were 
incubated for five minutes to 24 hours in fresh growth medium containing 5 µM MMA(III) 
(exposure medium). The negative control consisted of cells incubated in fresh medium 
without any arsenic compound and subsequently they were handled the same way as the 
exposed cells. Additionally, a second negative control was trypsinised for cell counting. 
After incubation the exposure medium was withdrawn and stored at -80°C. Cells were 
washed with 10 ml PBS and 10 ml Ampuwa (sterile deionised water). For the next washing 
step 10 ml 0.1 mM DMPS (2,3-bis(sulfanyl)propane-1-sulfonic acid) were used to remove 
traces of extracellular uncombined arsenic ions. The last washing step with 10 ml PBS was 
carried out to remove the residues of DMPS before lysis (Fig. 5.). All washing solutions were 
retained and stored at -80 °C until arsenic speciation analysis. 
 
 
Fig. 5. Washing process prior the intracellular arsenic speciation and quantification: 
Exhaustive cell washing ensures the removal of all extracellular arsenic residues after the 
exposure (Hippler et al., 2011, modified). 
The cell lysis was performed using the Precellys®24 tissue homogeniser (Peqlab 
Biotechnologie GmbH, Erlangen, Germany) as a tool for mechanical lysis. Therefore the cells 
were first detached from the culture flasks using a cell scraper and transferred to 0.5 ml 
tubes containing ceramic beads with a diameter of 1.4 mm (Peqlab Biotechnologie GmbH, 
Erlangen, Germany). Exhaustive homogenisation was obtained within three intervals of 20 
seconds and 6500 rpm. Final centrifugation using a MiniSpin plus centrifuge at 14.000 x g 
(Eppendorf AG, Hamburg, Germany) assured a complete separation of the cell lysates from 
membranes and other solid, insoluble cellular structures. This non-soluble fraction of each 
sample was then digested using Proteinase K until the pellet was dissolved. Further 
oxidation with hydrogen peroxide (30 %) assured the release of arsenic from peptides and 
other cellular molecules. 
After exposure, lysis and centrifugation all solutions and samples were stored at -80 °C. The 
cell lysates were thawed immediately before HPLC-ICP/MS analysis. Depending on the 
arsenic content of the samples, 1 to 25 µl were injected onto the HPLC-column.  
For quantification a multi-As species standard containing 2 pg to 200 pg As(III), 
MMA(III), DMA(V), MMA(V), DMA(III), and As(V) was injected. Peak areas were 
obtained by monitoring transient signals for As at m/z 75 in non-collision cell mode at 
dwell times of 100 ms. The linearity of the external calibration resulted in an excellent 
calibration (e.g. MMA(V): r² = 0.9999; DMA(V): r² = 0.999). Limits of detection were 
approximately 3 pg As, varying slightly depending on the arsenic species. Table 1 
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presents the conditions for the high performance liquid chromatography (HPLC) and 
inductive coupled plasma mass spectrometry (ICP/MS). For reproduction the whole 
experiment was performed twice. 
 
 
Table 1. Conditions for the high performance liquid chromatography (HPLC) and inductive 
coupled plasma mass spectrometry (ICP/MS) (Hippler et al., 2011, modified) 
2.3 Alkaline Comet Assay 
For detection of genotoxic effects caused by arsenic exposure, the Alkaline Comet Assay was 
used. This assay detects single and double strand breaks of the DNA by single cell gel 
electrophoresis. Therefore UROtsa cells were seeded with a density of 100,000 cells / 2 ml 
medium into each well of a 24-well-plate and incubated over night. For exposure cell culture 
medium was removed and 2 ml of the exposure medium containing the arsenic compounds 
As(III) (arsenite), As(V) (arsenate), MMA(III) (monomethylarsonous acid), MMA(V) 
(monomethylarsonic acid), DMA(V) (dimethylarsinous acid) and TMAO (trimethylarsine 
oxide) in different concentrations were added. The negative control consisted of untreated 
cells; the positive control was exposed to 1 mg/ml N-ethyl-nitrosourea. For exposure to the 
volatile species DMA(III) (dimethylarsinous acid) 1,000,000 cells/10 ml medium were 
seeded into 25 cm² cell culture flasks with vent caps.  
After incubation for 30 min exposure media were removed and the cells were trypsinised as 
described above. The cells were resuspended in PBS and 5,000 cells were seeded into each 
agarose gel consisting of 0.79 % low melting point agarose in PBS. The gels were solidified 
on ice and the cells were lysed over night.  
For electrophoresis the gels were washed with Ampuwa and incubated in 4 °C cold 
electrophoresis solution at pH 13 for 15 min. After electrophoresis for 30 min the gels were 
washed with Ampuwa and neutralised to pH 7.5. Finally the gels were washed with 
deionised water again and incubated in ethanol p.a. to remove the water residues. The gels 
were now dried over night at 4 °C. 
Image analysis was performed with Comet Assay IV Software (Perceptive Instruments Ltd., 
Haverhill, UK) using a fluorescence microscope (Leica Microsystems GmbH, Wetzlar, 
Germany) and a digital camera (Leica Microsystems GmbH, Wetzlar, Germany). Therefore 
the cells were stained with SYBR GREEN (Sigma-Aldrich, Saint Louis, Missouri, USA) and 
50 cells / gel were evaluated.  
HPLC Column Phenomenex Luna 3µ 
C18(2) 100 Ǻ
Forward power (RF) 1580 W
Column temperature 30 °C Plasma gas rate (cool gas flow) 15 L Argon min-1  
Eluent flow rate 0.5 ml min-1 Carrier gas flow rate ~ 0.8 L min-1
Injection volume 1 – 25µl Make-up gas flow rate ~ 0.25 L min-1
Sample depth 5.7 mm
Eluent: Spray chamber Quarz, cooled, 2 °C
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2.4 Colony formation assay 
When a normal cell is transformed to a cancer cell it loses its ability to grow in monolayers. 
After cell transformation (a step towards malignancy) the cells grow in colonies. With help 
of the colony formation assay (Bredfeldt et al., 2006) the development of an anchorage 
independent growth after chronic exposure of cells to arsenic can be determined. The colony 
formation assay was prepared in a 24-well plate. First 500 µL of a base agar containing 0.6 % 
low melting point agarose in cell culture medium were added to each well, solidified at 
room temperature and sterilised under UV light over night.  
UROtsa cells were seeded with a density of 10,000 cells / 500 µL into each well. Additional 
wells were prepared without cells containing only base and top agar for background 
detection. The cells were fed with 250 µL of fresh cell culture medium every 3 – 4 days.  
Image analysis was performed after 2 weeks of incubation using an inverted microscope 
(Leica Microsystems GmbH, Wetzlar, Germany) combined with a Leica digital camera 
(Leica Microsystems GmbH, Wetzlar, Germany). 
2.5 Cellular migration and invasion 
Typical features of transformed and cancer cells are increased proliferation, migration and 
invasion. For the detection of invasion the xCELLigence DP system (Roche Applied Science, 
Mannheim, Germany) was conducted. Therefore CIM-Plates (Roche Applied Science, 
Mannheim, Germany) were coated with 50 µl of 0.02 % collagen (SERVA Electrophoresis 
GmbH, Heidelberg, Germany) on each side of the microporous membrane for 1 h. After 
removing the collagen residues the CIM-Plates were dried for approximately 1 h at room 
temperature under the laminar flow. In between UROtsa cells originated from the chronic 
exposure were trypsinised as described above and brought to a concentration of 1.5 Mio 
cells / ml. For the detection of migration uncoated CIM-Plates were conducted.  
160 µl of the pre-warmed cell culture medium were added to each well of the lower 
chamber and 100 µl were added to each well of the upper chamber. The CIM-Plates were 
then placed into the xCELLigence devices and the background was measured. Now 100 µl 
of the prepared cell suspensions were added (duplicate wells) and the CIM-Plates were 
placed into the xCELLigence again. The measurement was performed for 24 h with intervals 
of 15 min. 
2.6 Statistics 
All experiments were performed in triplicate unless stated otherwise. The statistical 
evaluation for the Alkaline Comet Assay was performed using GraphPad Prism (GraphPad 
Software, San Diego, USA). The mean values of the detected Olive Tail Moments are 
presented in bar graphs with the standard error of mean. For statistical analysis the non-
parametric Mann-Whitney-Test was applied, which approximates the Gaussian distribution 
for more than 20 random samples and compares each test group to the untreated control 
group. The results are given in significance levels p for the confidence interval of 95 %. Then 
one has p > 0.05: non-significant, p ≤ 0.05: *, p ≤ 0.01: **, p ≤ 0.001: ***.  
3. Results 
3.1 Intracellular arsenic speciation and quantification 
To study the intracellular arsenic biotransformation of MMA(III) we incubated UROtsa and 
HepG2 cells with 5 µM MMA(III) for 5 min up to 24 hours, followed by a newly developed 
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sample preparation process (Hippler et al., 2011). Using HPLC-ICP/MS analysis we were 
able to detect more than 99.99% of the total arsenic in the non-soluble fraction of both cell 
lines and only 0.003% in the soluble fraction of UROtsa cells and 0.01% of HepG2 cells, 
respectively. While in the non-soluble fraction of UROtsa cells the arsenic content consisted 
only of a monomethylated species, in HepG2 cells a time dependent occurrence of a 
dimethylated arsenic species additionally to monomethylated arsenic was observed (Fig. 6.). 
The differentiation between trivalent and pentavalent arsenic metabolites was impossible 
due to their oxidative release from the cellular structures.  
 
 
Fig. 6. Quantification of the metabolites in the non-soluble fraction after exposure of HepG2 
and UROtsa cells to 5 µM MMA(III). The analysis was performed using HPLC-ICP/MS 
technique. 
In the soluble fractions of both HepG2 and UROtsa cells only pentavalent arsenic species 
were detected (Fig 7.). In HepG2 cells a time dependent increase and decrease of MMA(V) 
was observed. Additionally we analysed the increase of DMA(V) by time. In contrast, in 
UROtsa cells only MMA(V) but  no DMA(V) was detected. The occurrence of MMA(III) after 
18 and 24 hours of exposure is believed to be the result of cytotoxic effects and can be 
correlated with membrane damage (data not shown).  
 
 
Fig. 7. Quantification of the metabolites in the soluble fraction after exposure of HepG2 and 
UROtsa cells to 5 µM MMA(III). The analysis was performed using HPLC-ICP/MS 
technique.  
3.2 Alkaline Comet Assay 
The Alkaline Comet Assay was conducted to examine the genotoxic effects of different 
arsenic metabolites. Testing the trivalent species we observed significant single and double 
strand breaks in UROtsa cells already after 30 min of exposure (Fig. 8.). Although the 
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biotransformation initially was discussed to serve as a detoxification process, MMA(III) still 
is highly genotoxic and DMA(III) even exhibits the most genotoxic effects. In contrast, 
pentavalent arsenic species did not show any genotoxic effect except for As(V) at very high 
concentrations (Fig. 9).  
 
 
(mean ± SEM with p > 0.05: non-significant, p ≤ 0.05: *, p ≤ 0.01: **, p ≤ 0.001: ***) 
Fig. 8. The Alkaline Comet Assay was conducted to assay single and double strand breaks of 
the DNA after 30 min of exposure to the trivalent arsenic species As(III), MMA(III) and 
DMA(III). The DNA damage is given in the Olive Tail Moment.  
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3.3 Colony formation assay 
To analyse the carcinogenic potential of one of the most important arsenic metabolites, 
MMA(III), UROtsa cells were cultured for 93 weeks and treated twice a week with fresh 
exposure medium containing 50 nM, 75 nM, and 100 nM MMA(III), respectively. Untreated 
UROtsa cells of the same passage served as negative control. The colony formation assay 
was determined to assay the loss of an anchorage dependent growth. As proven by the 
negative control, UROtsa cells are adherent cells and hence they cannot be cultured in soft 
agar (Bredfeldt et al., 2006). In contrast, after chronic exposure to MMA(III) UROtsa cells 
exhibit an anchorage independent growth and form notable colonies after two weeks of 
incubation in soft agar (Fig. 10.).  
3.4 Cellular migration and invasion 
To estimate the malignant potential of chronically exposed human urothelial cells to 
arsenic, their altered motility and invasiveness were examined. The xCELLigence system 
was conducted to assay the migration and invasion ability of UROtsa cells after 92 weeks 
of exposure to MMA(III). Hereby the cells moved through a microporous membrane and 
attached at the opposite side on the electrodes. For the analysis of the invasiveness the 
membranes and electrodes were coated with collagen, a typical extracellular matrix. The 
results show that after exposure to 75 nM and 100 nM MMA(III) for 92 weeks the motility 
of UROtsa cells was increased in comparison to the untreated control of the same passage. 
Only the exposure to 50 nM MMA(III) did not lead to an increase of migrated cells  






Fig. 11. The xCELLigence system was conducted for the analysis of the ability of migration 
after chronic treatment of UROtsa cells with 50 nM, 75 nM, or 100 nM MMA(III), 
respectively, for 92 weeks.  
The examination of the invasion led to similar results. After coating the plate surface with 
collagen all samples exhibited an increased invasion property compared to the untreated 
control (Fig. 12.). In both migration and invasion assays the cells treated with 100 nM 
MMA(III) exhibited the strongest effects, leading to the assumption of an dose-dependent 
manner.  
 




Fig. 12. The xCELLigence system was conducted for the analysis of the ability of invasion 
after chronic treatment of UROtsa cells with 50 nM, 75 nM, or 100 nM MMA(III), 
respectively, for 92 weeks. CIM-Plates were coated with collagen to simulate a biological 
matrix. 
4. Discussion and conclusion  
Arsenic is one of the most harmful toxins in drinking water worldwide and at many places 
on earth millions of people are at risk of arsenic induced diseases including cancer. In our 
study we have investigated the cellular uptake and biotransformation of arsenic species in 
non-methylating human urothelial (UROtsa) and methylating human hepatic cells (HepG2) 
using HPLC-ICP/MS technique. The induced genotoxic effects of several arsenic species in 
UROtsa cells were measured with the Alkaline Comet Assay and the malignant 
transformation after chronic arsenic treatment was assayed by using the Colony Formation 
Assay and the Migration and Invasion Assay.  
The data presented here demonstrate that MMA(III) is rapidly taken up by human 
urothelial cells (UROtsa) and human hepatoma cells (HepG2). MMA(III) is known to be an 
important arsenic metabolite due to its high toxicity. Many studies report monomethylated 
and dimethylated arsenic species as the main metabolites in the urine (Aposhian et al., 2000; 
Fillol et al., 2010). Using an improved isolation method and HPLC-ICP/MS technique we 
were able to analyse not only the fast association of MMA(III) to large membrane structures, 
high-molecular-weight proteins, and other insoluble cell components, but also the presence 
of unbound pentavalent arsenic metabolites in the soluble fractions which only amount to 
0.003% of the total intracellular arsenic in UROtsa cells and 0.01% in HepG2 cells, 
respectively. Furthermore we were able to differentiate between the various methylated 
metabolites and also their oxidation state in this complex cellular matrices.  
The data demonstrate for both cell lines a fast cellular uptake of MMA(III) and the 
subsequent oxidation to MMA(V) already within 5 min of exposure and further increasing 
with time. Additionally, in HepG2 cells we observed a time dependent methylation to 
DMA(V). These findings appear to be in contrast to the reductive intracellular milieu (Du et 
al., 2009) due to glutathione concentrations up to millimolar ranges (Anderson, 1998). 
However, taking different cell compartments and specific metabolic effects of arsenic into 
account could provide a possible explanation. It is largely known from the literature that in 
contrast to their pentavalent analogues trivalent arsenicals bind to proteins (Styblo & 
Thomas, 1997; Yan et al., 2009). This leads to the assumption that MMA(III) rapidly binds to 
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proteins after uptake, which is in compliance with the detection of more than 99.99 % of the 
total arsenic in the non-soluble fraction in both cell lines. We suggest that there is a fast 
subsequent degradation of at least part of the arsenic-conjugated or arsenic-inhibited 
proteins. Protein degradation is predominantly mediated by the proteasomes but can also 
take place in lysosomes, especially during turnover of membrane proteins (Clague & Urbé, 
2010). An increased turnover of arsenic-bound proteins is in agreement with the evidence of 
the catabolism of arsenic-induced improperly folded or damaged proteins via the ubiquitin-
dependent protein degradation pathway in zebrafish liver (Lam et al., 2006). Several studies 
report that protein ubiquitination not only targets protein degradation using the proteasome 
pathway but also the lysosomal pathway (Marques et al., 2004; Barriere et al.; 2007, Shenoy 
et al, 2008; Arancibia-Cárcamo et al, 2009). The lysosome is known to exhibit cellular 
oxidative activities (Chen, 2002) and during oxidative stress large amounts of hydrogen 
peroxide enter the lysosome, leading to the formation of hydroxyl radicals and lysosomal 
destabilisation (Terman et al., 2006). In addition, the lysosome is an important organelle in 
autophagy, helping the cells to remove toxic aggregation-prone proteins and even damaged 
organelles that are incompatible with the unfolding mechanism of the proteasome (Yang et 
al., 2008; Clague & Urbé, 2010; Mehrpour et al., 2010). The increase of protein catabolism, the 
elimination of excess or damaged organelles by autophagy, and the sequestering of 
toxicants is ubiquitous and believed to be a kind of “first-response reaction” to delay 
apoptosis (Kundu & Thompson, 2008; Yang et al., 2008). In the early stage of cell death 
autophagy is activated in HL60 cells soon after exposure to As2O3 to maintain cell survival 




Fig. 13. Proposed arsenic cycle in HepG2 cells after exposure to MMA(III) (Hippler et al. 
2011, modified) 
Summarising all these data we conclude from our results that MMA(III) is immediately 
taken up and rapidly bound to proteins and other cellular structures, followed by, first, the 
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generally accepted methylation to dimethylarsinic in HepG2 cells only, and second, the 
degradation of affected proteins and cellular structures in the lysosome in both HepG2 and 
UROtsa cells (Fig. 13. and 14.). During oxidative degradation in the lysosome arsenic is 
released as MMA(V) and DMA(V), which are either excreted from the cell or reduced by 
antioxidants in the cytosol. The reduced species MMA(III) and DMA(III) can then re-
associate with proteins and cellular structures. In HepG2 cells most of the incorporated 
MMA(III) is methylated and oxidised to DMA(V) after passing this cycle; in UROtsa cells 
the cycle is limited to oxidation and reduction, and finally excretion, due to the fact that 




Fig. 14. Proposed arsenic cycle in UROtsa cells after exposure to MMA(III).  
Especially the trivalent arsenicals are known to exhibit strong genotoxic effects (Dopp et 
al., 2010a). These effects can either be detected as DNA damage using the micronucleus 
test or the comet assay (Dopp et al., 2008), as oxidative damage by assaying the amount of 
8-oxo-dG (8-Oxo-2'-deoxyguanosine) or in form of chromosomal aberrations (Dopp et al., 
2004). In our study we determined the Alkaline Comet Assay to analyse single and double 
strand breaks of the DNA. We detected significant genotoxic effects of all tested trivalent 
arsenic compounds (As(III), MMA(III), and DMA(III)) and the pentavalent arsenate 
already after 30 min of exposure. These results are in compliance with the findings of 
previous studies using several mammalian cell types (Schwertdtle et al., 2003; Raisuddin 
& Jha, 2004; Dopp et al., 2005). This emphasises how urgently the knowledge of the tissue-
dependent arsenic biotransformation (Fig. 13. and 14.) is needed, as the genotoxic effect of 
arsenic metabolites is not only dependent on its oxidative state but also on the state of 
methylation (Hirner & Rettenmeier, 2010; Dopp et al., 2010b). Wnek et al. (2009) reported 
that in UROtsa cells DNA damage caused by MMA(III) is not only a phenomenon of acute 
treatment but also an important effect in chronic, low-level exposure for 12 – 52 weeks. 
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The occurrence of single- and double-strand breaks is significantly decreased after the 
removal of MMA(III) for 2 weeks, but still significantly increased compared to the 
untreated control. The relative poly (ADP-ribose) polymerase (PARP) activity was 
significantly reduced during this chronic exposure and increased again after removal of 
MMA(III). Trivalent arsenic species are known to attach to zinc binding structures 
generally found in DNA repair enzymes and transcription factors, leading to alteration or 
inhibition of those proteins (Kitchin & Wallace, 2008). Together with the findings of Hu et 
al. (1998) it is likely that DNA repair is inhibited by both direct protein interaction and 
altered signal transduction or gene expression. Taken together, this leads to the fact that 
not only direct DNA damage plays a pivotal role in arsenic induced carcinogenesis. 
Inorganic arsenic and its metabolites are also known to be potent epigenetic modulators 
leading to (tissue specific) altered cellular functions, malignant transformation and 
tumorigenesis. Many studies report arsenic induced aberrant DNA methylation patterns 
(Sutherland & Costa, 2003; Smeester et al., 2011; Ren et al.; 2011), resulting in changes in 
the promoter activity that lead to altered gene expression (Jensen et al., 2009). Aberrant 
DNA methylation patterns might be the result of arsenic-induced altered global histone 
modification finally leading to, among others, the silencing of tumour suppressor genes 
(Zhou et al., 2008). Altered global DNA methylation levels have also been correlated with 
the arsenic metabolism as both systems use the same methyl donor SAM (S-adenosyl-
methionine). Sam is known to transfer methyl groups to DNA methyltransferases on the 
one hand, and to AS3MT (arsenic (+3 oxidation state) methyltransferase) to the other hand 
(Ren et al., 2011). Jensen et al. (2009) correlated the occurrence of aberrant DNA 
methylation patterns after chronic low-dose exposure to MMA(III) with the development 
of a malignant phenotype of UROtsa cells (Table 2.).  
 
 
NA=not applicable; ND=not determined. (Jensen et al., 2009, modified) 
Table 2. Cell line name, the treatment metal, concentration (exposure), and duration of 
treatment for each cell line are shown. In addition, the phenotypic properties of each cell 
line including increased growth rate relative to UROtsa (hyperproliferation), anchorage 
independent growth (AIG), and ability of each cell line to form tumours when injected 
subcutaneously into immunocompromised mice are described. The reference cites 
previous publications describing part or all of the information presented for a given cell 
line.  
Cell Line Treatment Exposure Duration Hyperproliferation AIG Tumors in mice
UROtsa None None None NA No No
URO-MSC12 MMA (III) 50 nM 12 weeks Yes No No
URO-MSC24 MMA (III) 50 nM 24 weeks Yes Yes No
URO-MSC36 MMA (III) 50 nM 36 weeks Yes Yes ND
URO-MSC52 MMA (III) 50 nM 52 weeks Yes Yes Yes
URO-MSC24 + 3mo MMA (III) 50 nM 24 weeks ND Yes ND
URO-MSC24 + 6mo MMA (III) 50 nM 24 weeks ND Yes ND
URO-MSC52 + 3mo MMA (III) 50 nM 52 weeks ND Yes Yes
URO-MSC52 + 6mo MMA (III) 50 nM 52 weeks ND Yes Yes
URO-ASSC As (III) 1 µM 52 weeks Yes Yes Yes
URO-CDSC Cd (II) 1 µM 52 weeks Yes Yes Yes
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In our study we analysed the development of the malignant phenotype of UROtsa cells by 
assaying the ability of an anchorage independent growth as well as the ability of migration 
and invasion. Both characteristics are negative in untreated UROtsa cells, but occurred after 
chronic low-dose treatment to MMA(III) (50 nM, 75 nM, and 100 nM, respectively) for more 
than 90 weeks. The results of the soft agar assay do not provide evidence for a dose-
dependent development of anchorage independent growth. In contrast, the data of the 
migration and invasion assays indicate that the motility of UROtsa cells is dose-
dependently increased after chronic exposure to MMA(III). Both, the loss of anchorage 
independent growth and the increased motility / invasive potential, provide evidence for 
the formation of a malignant phenotype in UROtsa cells after chronic low-dose exposure 
to MMA(III). These in vitro results point to a possible model system to study the 
mechanisms of metastasis in arsenic-induced bladder cancer. Further studies have to be 
conducted analysing established molecular markers to support our presented data and 
proposals. For example, the analysis of cell-cell adhesion concerning the protein E-
cadherin (encoded by the CDH1 gene) and its regulation by the ZEB2 protein and CDH1 
promoter methylation would be of great interest for the investigation of the epithelial-
mesenchymal transition (EMT), a basic mechanism required for the acquisition of an 
invasive and subsequently metastatic phenotype in epithelial tumours (Vandewalle et al., 
2005). Furthermore, TWIST overexpression is known to increase migration and decrease 
the sensitivity to arsenic induced cell death in gastric cancer cells (Feng et al., 2009) and 
could serve as another interesting marker to study EMT and metastasis in arsenic-induced 
bladder cancer. 
Fig. 15 summarises the molecular mechanisms of MMA(III)-induced toxicity and 
malignancy in UROtsa cells in vitro after chronic low-dose exposure. In this extended 
model we propose that after uptake and parallel to the fast conjugation to proteins and 
other cellular structures that is followed by lysosomal degradation and autophagy 
MMA(III) also induces DNA damage and epigenetic changes. This might lead to the 
observed alteration of signal transduction and cellular functions as well as the 
accumulation of (epi)genetic aberrations that are supposed to be the basis of 
transformation into a malignant phenotype.  
Because this hypothetic model is based on in vitro research, there is an urgent need for 
further in vivo studies. While in vitro assays give important data for the investigation of 
molecular mechanisms, there is a lack of information concerning the defence of a whole 
organism against cancer including, e. g., the immune response.  
In summary, we were able to present the tissue-dependent metabolism of MMA(III) in 
methylating HepG2 and non-methylating UROtsa cells. We analysed genotoxic effects of 
arsenic species in UROtsa cells and illustrated the dependence of genotoxicity on the 
methylation and oxidation state. This reveals how important the knowledge of the arsenic 
metabolism is, as each metabolite has its unique mechanisms of toxicity. MMA(III) is known 
as one of the most important metabolites due to its high toxicity. We analysed the malignant 
transformation of UROtsa cells after chronic low-dose exposure to MMA(III) and illustrated 
the loss of anchorage dependent growth and the development of increased migration and 
invasion properties. Both are serious phenotypical characteristics in the development of 
cancer. With our in vitro study we were able to give further evidence to arsenic-induced 
bladder cancer.  
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migration and invasion assays indicate that the motility of UROtsa cells is dose-
dependently increased after chronic exposure to MMA(III). Both, the loss of anchorage 
independent growth and the increased motility / invasive potential, provide evidence for 
the formation of a malignant phenotype in UROtsa cells after chronic low-dose exposure 
to MMA(III). These in vitro results point to a possible model system to study the 
mechanisms of metastasis in arsenic-induced bladder cancer. Further studies have to be 
conducted analysing established molecular markers to support our presented data and 
proposals. For example, the analysis of cell-cell adhesion concerning the protein E-
cadherin (encoded by the CDH1 gene) and its regulation by the ZEB2 protein and CDH1 
promoter methylation would be of great interest for the investigation of the epithelial-
mesenchymal transition (EMT), a basic mechanism required for the acquisition of an 
invasive and subsequently metastatic phenotype in epithelial tumours (Vandewalle et al., 
2005). Furthermore, TWIST overexpression is known to increase migration and decrease 
the sensitivity to arsenic induced cell death in gastric cancer cells (Feng et al., 2009) and 
could serve as another interesting marker to study EMT and metastasis in arsenic-induced 
bladder cancer. 
Fig. 15 summarises the molecular mechanisms of MMA(III)-induced toxicity and 
malignancy in UROtsa cells in vitro after chronic low-dose exposure. In this extended 
model we propose that after uptake and parallel to the fast conjugation to proteins and 
other cellular structures that is followed by lysosomal degradation and autophagy 
MMA(III) also induces DNA damage and epigenetic changes. This might lead to the 
observed alteration of signal transduction and cellular functions as well as the 
accumulation of (epi)genetic aberrations that are supposed to be the basis of 
transformation into a malignant phenotype.  
Because this hypothetic model is based on in vitro research, there is an urgent need for 
further in vivo studies. While in vitro assays give important data for the investigation of 
molecular mechanisms, there is a lack of information concerning the defence of a whole 
organism against cancer including, e. g., the immune response.  
In summary, we were able to present the tissue-dependent metabolism of MMA(III) in 
methylating HepG2 and non-methylating UROtsa cells. We analysed genotoxic effects of 
arsenic species in UROtsa cells and illustrated the dependence of genotoxicity on the 
methylation and oxidation state. This reveals how important the knowledge of the arsenic 
metabolism is, as each metabolite has its unique mechanisms of toxicity. MMA(III) is known 
as one of the most important metabolites due to its high toxicity. We analysed the malignant 
transformation of UROtsa cells after chronic low-dose exposure to MMA(III) and illustrated 
the loss of anchorage dependent growth and the development of increased migration and 
invasion properties. Both are serious phenotypical characteristics in the development of 
cancer. With our in vitro study we were able to give further evidence to arsenic-induced 
bladder cancer.  
 




Fig. 15. Proposed molecular mechanisms of MMA(III) induced toxicity and malignancy in 
UROtsa cells after chronic low-dose exposure.  
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1. Introduction 
The Cancer Journal for Clinicians reports there will be 69,250 newly diagnosed cases of 
bladder cancer in 2011, with 52,020 being men and 17,230 being women with an increase by 
50% of annual cases since 1985. Approximately 1 in 5 of those who develop bladder cancer 
will die due to the disease (relative mortality 20.8%, [Siegel et al., 2011, Golijanin et al., 
2006]). Bladder cancer has become the second most prevalent cancer after cancer of the 
prostate in middle-aged to elderly male individuals. Many patients do not die from their 
disease, but typically have multiple recurrences (Pelucchi et al., 2006). This lends to a five-
year cost to Medicare attributed to bladder cancer of over one billion dollars (Yabroff et al., 
2008). Tobacco use and exposure to aromatic amines are well established etiologic 
contributors to bladder cancer and by eliminating or reducing contact with these substances 
has been shown to reduce such risk.  
BCG (bacillus Calmette-Guerin) has become the standard of care in the treatment of 
carcinoma in situ as well as high grade T1 (invasion into the lamina propria) and when not 
appropriate, Mitomycin-C, has been proven to be an acceptable, albeit, less effective 
alternate. The goal of this chapter will be to describe novel agents that may show promise in 
the treatment of bladder cancer. This will include descriptions of the agents, their respective 
mechanism of action (e.g. molecular/biochemical pathways, cell cycle interaction, necrosis), 
clinical data, combinations of combinations of regimens and mode of delivery. and mode of 
delivery. A second goal of this chapter will be to consider whether any of these novel agents 
may have a role in the prevention of bladder cancer.  
2. Chemoprevention 
Kamat in his review of superficial bladder cancer stated that chemoprevention is needed for 
a multitude of reasons: high recurrence rates, increased morbidity from repeat resections, a 
tedious course of disease to see treatment outcomes, ability of agents to be concentrated in 
the urine, and the ability to monitor recurrence with cytology/cystoscopy (Kamat, 2003). 
Table 1 lists potential agents that may be considered for chemoprevention of bladder cancer.  
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 POTENTIAL CHEMOPREVENTION AGENTS 
 Vitamin A 
 Vitamin E 
 Vitamin C 
 Selenium 
 Cactus Pear 
 Isoflavones 
 Garlic 
 Green Tea 
 Difluoromethlyornithine (DFMO) 
 Non-Steroidal Anti-Inflammatory Drugs 
 Statins 
Table 1. Potential Chemoprevention agents for Bladder Cancer 
2.1 Vitamin A 
Vitamin A is necessary for light absorption in the retina and is also known to have a role in 
epithelial growth. Additionally, vitamin A has been researched as a chemotherapeutic and 
chemopreventive agent for a variety of malignancies. Currently, it is utilized to treat acute 
promyelocytic leukemia (Zusi et al., 2002). The mechanism of vitamin A’s inhibition of 
tumor growth is thought to work through modulation of gene expression in cell growth, 
differentiation, and apoptosis (Zanardi et al., 2006). Evidence suggests that it does this 
through a variety of molecular pathways including binding to nuclear retinoic acid 
receptors (RAR) and ligand activating transcription factors such as retinoid X receptors 
(RXR) (Simeone & Tari, 2004). Additionally, vitamin A’s anti-tumor activity may involve, 
among others, interactions with growth factors and cytokines, neoplastic stem cell pathways 
such as WNT, cAMP pathways, mitogen activated protein kinases (MAPKs), PI3K/AKT, 
cyclin-dependent kinases (CDKs), protein kinase C, and epigenetic modulation of gene 
expression (Garattini et al., 2007). Other studies indicate that some synthetic retinoids may 
even reduce VEGF expression, which is an important angiogenic factor in bladder cancer 
growth (Hameed & el-Metwally, 2008). 
Several studies have examined vitamin A and its derivatives for chemoprevention of 
bladder cancer. The first clinical trial was performed in 1978 (Gunby, 1978) and was 
followed by several other prospective and controlled trials. Results for these trials were 
mixed, with some showing significant preventative effects (Alfthan et al., 1983; Studer et al., 
1995; Yoshida et al., 1986) and others showing less promising results (Decensi et al., 2000; 
Prout & Barton, 1992). Mild to severe toxicities were also noted in many of these studies and 
may potentially limit vitamin A’s use as a chemopreventive agent (Hameed & el-Metwally, 
2008). More recently, to enable lower doses of retinoic acids and decrease unwanted side 
effects, combinations of retinoic acid and inhibitors of the CYP26A enzyme (involved in 
degradation of vitamin A) have been explored with some success (Hameed & el-Metwally, 
2008). Although a recent cohort study showed no significant association of several vitamins 
including retinoids with urothelial carcinoma risk (Hotaling et al., 2011), other past studies 
provide some compelling evidence for vitamin A’s efficacy. Thus further research into 
vitamin A’s use in preventing bladder cancer is warranted. 
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2.2 Vitamin E 
Vitamin E is a lipid soluble anti-oxidant and is known to be important in a variety of 
biological processes. It is also thought to possibly lower the risk of many malignancies 
through free radical scavenging, inhibition of N-nitroso compound formation (Mirvish, 
1995), immunological stimulation (Beisel et al., 1981), and potent induction of apoptosis 
(Kline et al., 2004; Sigounas et al., 1997).  
The clinical evidence for vitamin E in bladder cancer prevention has mixed results. A large 
Cohort study with Vitamin E and C and risk of bladder cancer mortality showed a reduced 
risk of mortality with regular intake of vitamin E (Jacobs et al., 2002). A phase III clinical trial 
using megadoses of several vitamins including E, when compared to patients who just 
received the recommended daily allowance (RDA) of the same vitamins, had a 40% 
reduction in bladder tumor recurrence after the first 10 months of the study (Lamm et al., 
1994). However, in this same study, patients also received BCG therapy, which is known to 
promote immune response to tumors and may have confounded the results (Coulter et al, 
2006). Further support comes from a prospective study, which showed an inverse 
relationship between vitamin E supplement consumption and the risk of bladder 
malignancy in men (Michaud et al., 2000).  
In contrast to studies supporting vitamin E, a recent cohort study suggested no association 
of vitamin E intake and risk of urothelial carcinoma (Roswall et al., 2009). In addition, a 
meta-analysis for vitamin E and C intake and prevention of cancer indicated overall poor 
evidence for vitamin E in reduction of bladder cancer recurrence (Coulter et al, 2006). 
Additionally, a recently published cohort study indicated that the use of a variety of 
vitamins and supplements including vitamin E had no significant association with urothelial 
carcinoma risk in age-adjusted or multi-variate models (Hotaling et al., 2011). It should be 
noted that several studies have indicated that high doses of vitamin E may actually increase 
the risk for bladder cancer (The New England Journal of Medicine [NEJM], 1994; Miller et 
al., 2005). Since the evidence for vitamin E as a chemopreventive agent is conflicting, further 
studies should be performed to assess its true value. 
2.3 Vitamin C 
Vitamin C is an important vitamin found abundantly in fruits and vegetables. Proven to be a 
powerful antioxidant and necessary for a variety of metabolic activities, vitamin C 
consumption has also been researched as a method to reduce the risk of bladder cancer. It is 
hypothesized that vitamin C’s anti-tumor activity is derived from inhibition of p53-induced 
replicative senescence, by suppressing both reactive oxygen species production and p38 
MAPK activity (Kim et al., 2008), and sparing vitamin E to jointly reduce reactive α-
tocopheroxy radicals (Park et al., 2010). Malignant transformation may also be decreased by 
vitamin C through reduction of N-nitroso compounds, which are known to be carcinogenic 
(Wu et al., 2000).  
Despite these mechanisms proposed, data to support vitamin C as a chemopreventive agent 
is conflicting. A cohort study using data from 1981-1989 showed a significant reduction in 
relative risk for bladder cancer in patients taking vitamin C (Shibata et al., 1992). A more 
recent prospective study found a strong inverse relationship between vitamin C intake and 
bladder cancer risk in ex-smokers and non-smokers, but did not show the same results with 
current smokers (Michaud et al., 2000). High doses of vitamin C in combination with 
megadoses of vitamins A, B6, E and zinc were also found to be beneficial, in combination 
 




 POTENTIAL CHEMOPREVENTION AGENTS 
 Vitamin A 
 Vitamin E 
 Vitamin C 
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 Green Tea 
 Difluoromethlyornithine (DFMO) 
 Non-Steroidal Anti-Inflammatory Drugs 
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Table 1. Potential Chemoprevention agents for Bladder Cancer 
2.1 Vitamin A 
Vitamin A is necessary for light absorption in the retina and is also known to have a role in 
epithelial growth. Additionally, vitamin A has been researched as a chemotherapeutic and 
chemopreventive agent for a variety of malignancies. Currently, it is utilized to treat acute 
promyelocytic leukemia (Zusi et al., 2002). The mechanism of vitamin A’s inhibition of 
tumor growth is thought to work through modulation of gene expression in cell growth, 
differentiation, and apoptosis (Zanardi et al., 2006). Evidence suggests that it does this 
through a variety of molecular pathways including binding to nuclear retinoic acid 
receptors (RAR) and ligand activating transcription factors such as retinoid X receptors 
(RXR) (Simeone & Tari, 2004). Additionally, vitamin A’s anti-tumor activity may involve, 
among others, interactions with growth factors and cytokines, neoplastic stem cell pathways 
such as WNT, cAMP pathways, mitogen activated protein kinases (MAPKs), PI3K/AKT, 
cyclin-dependent kinases (CDKs), protein kinase C, and epigenetic modulation of gene 
expression (Garattini et al., 2007). Other studies indicate that some synthetic retinoids may 
even reduce VEGF expression, which is an important angiogenic factor in bladder cancer 
growth (Hameed & el-Metwally, 2008). 
Several studies have examined vitamin A and its derivatives for chemoprevention of 
bladder cancer. The first clinical trial was performed in 1978 (Gunby, 1978) and was 
followed by several other prospective and controlled trials. Results for these trials were 
mixed, with some showing significant preventative effects (Alfthan et al., 1983; Studer et al., 
1995; Yoshida et al., 1986) and others showing less promising results (Decensi et al., 2000; 
Prout & Barton, 1992). Mild to severe toxicities were also noted in many of these studies and 
may potentially limit vitamin A’s use as a chemopreventive agent (Hameed & el-Metwally, 
2008). More recently, to enable lower doses of retinoic acids and decrease unwanted side 
effects, combinations of retinoic acid and inhibitors of the CYP26A enzyme (involved in 
degradation of vitamin A) have been explored with some success (Hameed & el-Metwally, 
2008). Although a recent cohort study showed no significant association of several vitamins 
including retinoids with urothelial carcinoma risk (Hotaling et al., 2011), other past studies 
provide some compelling evidence for vitamin A’s efficacy. Thus further research into 
vitamin A’s use in preventing bladder cancer is warranted. 
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2.2 Vitamin E 
Vitamin E is a lipid soluble anti-oxidant and is known to be important in a variety of 
biological processes. It is also thought to possibly lower the risk of many malignancies 
through free radical scavenging, inhibition of N-nitroso compound formation (Mirvish, 
1995), immunological stimulation (Beisel et al., 1981), and potent induction of apoptosis 
(Kline et al., 2004; Sigounas et al., 1997).  
The clinical evidence for vitamin E in bladder cancer prevention has mixed results. A large 
Cohort study with Vitamin E and C and risk of bladder cancer mortality showed a reduced 
risk of mortality with regular intake of vitamin E (Jacobs et al., 2002). A phase III clinical trial 
using megadoses of several vitamins including E, when compared to patients who just 
received the recommended daily allowance (RDA) of the same vitamins, had a 40% 
reduction in bladder tumor recurrence after the first 10 months of the study (Lamm et al., 
1994). However, in this same study, patients also received BCG therapy, which is known to 
promote immune response to tumors and may have confounded the results (Coulter et al, 
2006). Further support comes from a prospective study, which showed an inverse 
relationship between vitamin E supplement consumption and the risk of bladder 
malignancy in men (Michaud et al., 2000).  
In contrast to studies supporting vitamin E, a recent cohort study suggested no association 
of vitamin E intake and risk of urothelial carcinoma (Roswall et al., 2009). In addition, a 
meta-analysis for vitamin E and C intake and prevention of cancer indicated overall poor 
evidence for vitamin E in reduction of bladder cancer recurrence (Coulter et al, 2006). 
Additionally, a recently published cohort study indicated that the use of a variety of 
vitamins and supplements including vitamin E had no significant association with urothelial 
carcinoma risk in age-adjusted or multi-variate models (Hotaling et al., 2011). It should be 
noted that several studies have indicated that high doses of vitamin E may actually increase 
the risk for bladder cancer (The New England Journal of Medicine [NEJM], 1994; Miller et 
al., 2005). Since the evidence for vitamin E as a chemopreventive agent is conflicting, further 
studies should be performed to assess its true value. 
2.3 Vitamin C 
Vitamin C is an important vitamin found abundantly in fruits and vegetables. Proven to be a 
powerful antioxidant and necessary for a variety of metabolic activities, vitamin C 
consumption has also been researched as a method to reduce the risk of bladder cancer. It is 
hypothesized that vitamin C’s anti-tumor activity is derived from inhibition of p53-induced 
replicative senescence, by suppressing both reactive oxygen species production and p38 
MAPK activity (Kim et al., 2008), and sparing vitamin E to jointly reduce reactive α-
tocopheroxy radicals (Park et al., 2010). Malignant transformation may also be decreased by 
vitamin C through reduction of N-nitroso compounds, which are known to be carcinogenic 
(Wu et al., 2000).  
Despite these mechanisms proposed, data to support vitamin C as a chemopreventive agent 
is conflicting. A cohort study using data from 1981-1989 showed a significant reduction in 
relative risk for bladder cancer in patients taking vitamin C (Shibata et al., 1992). A more 
recent prospective study found a strong inverse relationship between vitamin C intake and 
bladder cancer risk in ex-smokers and non-smokers, but did not show the same results with 
current smokers (Michaud et al., 2000). High doses of vitamin C in combination with 
megadoses of vitamins A, B6, E and zinc were also found to be beneficial, in combination 
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with BCG therapy, in a phase III trial of Bladder cancer (Lamm et al., 1994). However, as 
mentioned earlier with Vitamin E, the results in this study may in part be confounded by 
BCG therapy (Coulter et al., 2006).  
Other studies suggest less promising evidence. In a large cohort study of U.S. men and 
women, no associations were found between vitamin C use and bladder cancer death 
(Jacobs et al., 2002). This data is consistent with a cohort study by Hotaling et al. 
indicating the same relationship (Hotaling et al., 2011). A recent prospective study 
showed no significant effect of vitamin C, E or folate on prevention of urothelial 
carcinoma (Roswall et al., 2009) and there is evidence that doses of vitamin C beyond the 
RDA may contribute to oxalate stone formation (Taylor et al., 2004) and may even induce 
bladder carcinogenic activity (Mirvish, 1986). These studies indicating poor support for 
vitamin C’s use, along with other studies supporting vitamin C as a bladder cancer 
chemopreventive agent, indicate that further investigation into vitamin C and bladder 
cancer prevention is required.  
2.4 Selenium 
An essential micronutrient that is primarily known for its function as a co-factor for 
reduction of antioxidant enzymes, selenium is also being researched for its potential in 
reducing the risk of several malignancies including bladder cancer (Silberstein & Parsons, 
2010). A variety of mechanisms have been proposed for selenium’s anti-tumor activity: free 
radical scavenging (Murawaki et al., 2008), modifying thiols, mimiching mimicking 
methionine methionine which leads to to higher methylating efficiency of RNA and thiols 
(Jackson & Combs, 2008), enhancement of p53 activity towards DNA repair or apoptosis 
(Smith et al., 2004) and anti-androgenic activity, which is especially relevant in prostate 
cancer (Husbeck et al., 2006; Gazi et al., 2007). 
The clinical evidence for selenium’s anti bladder cancer activity is somewhat controversial. 
A recent meta-analysis from seven epidemiological studies showed that the overall risk of 
bladder cancer was inversely associated with elevated levels of selenium in serum and 
toenail samples, with the greatest effect seen in women (Amaral et al., 2010). Additionally, 
Wallace et al. showed no association of selenium levels in toenail samples with bladder 
cancer, it did find a significant association with moderate smokers and p53 positive cancers, 
suggesting selenium may affect the risk of bladder malignancies with specific p53 
immunophenotypes (Wallace et al., 2009). This was further demonstrated in a case control 
study performed in Belgium that showed an inverse association between serum selenium 
concentrations and bladder cancer risk (Kellen et al., 2006).  
In contrast to studies supporting selenium, a recent cohort study mentioned earlier, showed 
no significant association with selenium and urothelial carcinoma risk in an age-adjusted or 
multi-variate models (Hotaling et al., 2011). Current literature reviewed, there is a lack of 
interventional studies examining selenium and bladder cancer risk (Silberstein & Parsons, 
2010). 
2.5 Cactus pear 
Cactus fruit, or prickly pear, is a fruit generally used as a dietary supplement and has been 
widely researched for its anti-oxidant effects (Fernández-López et al., 2010; Tesoriere et al., 
2004; Zou et al., 2005). These fruits have a variety of ingredients shown to have health 
benefits including phenolics, flavonoids, and betalains. Recently, cactus pear has also been 
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studied for a possible application in cancer prevention. Although the mechanism is not 
completely understood, a recent study suggests it might be through increasing expression of 
annexin IV, a Ca2+ dependent membrane-binding protein important in apoptosis (Zou et 
al., 2005). Additionally, cactus pear extracts have been proposed to promote immune 
response and to decrease expression of VEGF (Liang et al., 2008), an important angiogenic 
factor in bladder and other malignancies (Zou et al., 2005). 
Despite the proposed mechanisms, data supporting cactus pear for prevention of bladder 
cancer is limited, although some data exists to support use in other types of cancer. In a 2005 
study, Arizona prickly cactus pear solution inhibited tumor growth in several different 
cancer cell cultures including ovarian and cervical (Zou et al., 2005). In another study, 
polysaccharides extracted from cactus pear fruit limited growth of S180 (sarcoma model) 
tumor cells in mice and induced features of apoptosis (Liang et al., 2008). In a 2010 study, 
cactus pear extracts induced reactive oxygen species production and apoptosis in ovarian 
cancer cells (Feugang et al., 2010). A specific species of cactus pear, Opuntia humifusa, was 
found to inhibit human glioblastoma cell lines (Hahm et al., 2010). Another study examining 
nine cactus pear species against prostate, colon, hepatic and mammary cancer cell lines 
showed some cytotoxic activity with certain species (Chavez-Santoscoy et al., 2009). 
However, normal fibroblast controls were also affected in this study with some of the pear 
species, thus the conclusions of this study are limited. More research, especially studies 
utilizing bladder cancer models, are necessary to determine the true potential of cactus pear 
as a chemopreventative agent for bladder cancer. 
2.6 Isoflavones 
Isoflavones are naturally occurring compounds found in soy and other products. They are 
primarily known for their phyotoestrogen and anti-oxidant properties, although recent 
research has suggested they may also help in cancer prevention. Currently, isoflavones have 
shown at least some promise in preventing several types of cancers including but not 
limited to bladder, prostate (Yan & Spitznagel, 2005), breast (Bondesson & Gustafsson, 
2010), lung (Hess & Igal, 2011), and liver (Ma et al., 2010).  
Multiple mechanisms for this anti-tumor activity have been proposed. Several in vitro 
studies suggest that isoflavones may induce G2-M cycle arrest, apoptosis, and angiogenesis 
(Su et al., 2000; Zhou et al., 1998). Another study found that a possible mitochondrial 
mediated apoptosis pathway through regulation of AKT and MAPK pathways (Lin et al., 
2010). Much of the research has focused on the specific isoflavone genistein, which has been 
shown to inhibit cancer through a variety of pathways. One study showed genistein 
inhibited EGF-R and EGF, of which the quantity and distribution are associated with 
urothelial abnormalities (Theodorescu et al., 1998). Another study on genistein showed that 
it might down regulate COX-2 (Hwang et al., 2009), which has been shown to play a role in 
tumorigenesis. A 2006 study indicated genistein down regulates nuclear factor kappa-B in 
bladder tumor tissue and reduces circulating insulin-like growth factor-1 levels, both 
important in tumor metastasis (Singh et al., 2006). Another more recent study showed that 
genistein modulates chromatin configuration and DNA methylation, thus activating tumor-
suppressing genes (Zhang & Chen, 2011). 
The clinical data for isoflavones as chemopreventive agents in bladder cancer has mixed 
results. In a 2000 study using seven human cancer cell lines, the isoflavone genistein 
significantly decreased bladder cancer cell growth and two other isoflavones directly 
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with BCG therapy, in a phase III trial of Bladder cancer (Lamm et al., 1994). However, as 
mentioned earlier with Vitamin E, the results in this study may in part be confounded by 
BCG therapy (Coulter et al., 2006).  
Other studies suggest less promising evidence. In a large cohort study of U.S. men and 
women, no associations were found between vitamin C use and bladder cancer death 
(Jacobs et al., 2002). This data is consistent with a cohort study by Hotaling et al. 
indicating the same relationship (Hotaling et al., 2011). A recent prospective study 
showed no significant effect of vitamin C, E or folate on prevention of urothelial 
carcinoma (Roswall et al., 2009) and there is evidence that doses of vitamin C beyond the 
RDA may contribute to oxalate stone formation (Taylor et al., 2004) and may even induce 
bladder carcinogenic activity (Mirvish, 1986). These studies indicating poor support for 
vitamin C’s use, along with other studies supporting vitamin C as a bladder cancer 
chemopreventive agent, indicate that further investigation into vitamin C and bladder 
cancer prevention is required.  
2.4 Selenium 
An essential micronutrient that is primarily known for its function as a co-factor for 
reduction of antioxidant enzymes, selenium is also being researched for its potential in 
reducing the risk of several malignancies including bladder cancer (Silberstein & Parsons, 
2010). A variety of mechanisms have been proposed for selenium’s anti-tumor activity: free 
radical scavenging (Murawaki et al., 2008), modifying thiols, mimiching mimicking 
methionine methionine which leads to to higher methylating efficiency of RNA and thiols 
(Jackson & Combs, 2008), enhancement of p53 activity towards DNA repair or apoptosis 
(Smith et al., 2004) and anti-androgenic activity, which is especially relevant in prostate 
cancer (Husbeck et al., 2006; Gazi et al., 2007). 
The clinical evidence for selenium’s anti bladder cancer activity is somewhat controversial. 
A recent meta-analysis from seven epidemiological studies showed that the overall risk of 
bladder cancer was inversely associated with elevated levels of selenium in serum and 
toenail samples, with the greatest effect seen in women (Amaral et al., 2010). Additionally, 
Wallace et al. showed no association of selenium levels in toenail samples with bladder 
cancer, it did find a significant association with moderate smokers and p53 positive cancers, 
suggesting selenium may affect the risk of bladder malignancies with specific p53 
immunophenotypes (Wallace et al., 2009). This was further demonstrated in a case control 
study performed in Belgium that showed an inverse association between serum selenium 
concentrations and bladder cancer risk (Kellen et al., 2006).  
In contrast to studies supporting selenium, a recent cohort study mentioned earlier, showed 
no significant association with selenium and urothelial carcinoma risk in an age-adjusted or 
multi-variate models (Hotaling et al., 2011). Current literature reviewed, there is a lack of 
interventional studies examining selenium and bladder cancer risk (Silberstein & Parsons, 
2010). 
2.5 Cactus pear 
Cactus fruit, or prickly pear, is a fruit generally used as a dietary supplement and has been 
widely researched for its anti-oxidant effects (Fernández-López et al., 2010; Tesoriere et al., 
2004; Zou et al., 2005). These fruits have a variety of ingredients shown to have health 
benefits including phenolics, flavonoids, and betalains. Recently, cactus pear has also been 
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studied for a possible application in cancer prevention. Although the mechanism is not 
completely understood, a recent study suggests it might be through increasing expression of 
annexin IV, a Ca2+ dependent membrane-binding protein important in apoptosis (Zou et 
al., 2005). Additionally, cactus pear extracts have been proposed to promote immune 
response and to decrease expression of VEGF (Liang et al., 2008), an important angiogenic 
factor in bladder and other malignancies (Zou et al., 2005). 
Despite the proposed mechanisms, data supporting cactus pear for prevention of bladder 
cancer is limited, although some data exists to support use in other types of cancer. In a 2005 
study, Arizona prickly cactus pear solution inhibited tumor growth in several different 
cancer cell cultures including ovarian and cervical (Zou et al., 2005). In another study, 
polysaccharides extracted from cactus pear fruit limited growth of S180 (sarcoma model) 
tumor cells in mice and induced features of apoptosis (Liang et al., 2008). In a 2010 study, 
cactus pear extracts induced reactive oxygen species production and apoptosis in ovarian 
cancer cells (Feugang et al., 2010). A specific species of cactus pear, Opuntia humifusa, was 
found to inhibit human glioblastoma cell lines (Hahm et al., 2010). Another study examining 
nine cactus pear species against prostate, colon, hepatic and mammary cancer cell lines 
showed some cytotoxic activity with certain species (Chavez-Santoscoy et al., 2009). 
However, normal fibroblast controls were also affected in this study with some of the pear 
species, thus the conclusions of this study are limited. More research, especially studies 
utilizing bladder cancer models, are necessary to determine the true potential of cactus pear 
as a chemopreventative agent for bladder cancer. 
2.6 Isoflavones 
Isoflavones are naturally occurring compounds found in soy and other products. They are 
primarily known for their phyotoestrogen and anti-oxidant properties, although recent 
research has suggested they may also help in cancer prevention. Currently, isoflavones have 
shown at least some promise in preventing several types of cancers including but not 
limited to bladder, prostate (Yan & Spitznagel, 2005), breast (Bondesson & Gustafsson, 
2010), lung (Hess & Igal, 2011), and liver (Ma et al., 2010).  
Multiple mechanisms for this anti-tumor activity have been proposed. Several in vitro 
studies suggest that isoflavones may induce G2-M cycle arrest, apoptosis, and angiogenesis 
(Su et al., 2000; Zhou et al., 1998). Another study found that a possible mitochondrial 
mediated apoptosis pathway through regulation of AKT and MAPK pathways (Lin et al., 
2010). Much of the research has focused on the specific isoflavone genistein, which has been 
shown to inhibit cancer through a variety of pathways. One study showed genistein 
inhibited EGF-R and EGF, of which the quantity and distribution are associated with 
urothelial abnormalities (Theodorescu et al., 1998). Another study on genistein showed that 
it might down regulate COX-2 (Hwang et al., 2009), which has been shown to play a role in 
tumorigenesis. A 2006 study indicated genistein down regulates nuclear factor kappa-B in 
bladder tumor tissue and reduces circulating insulin-like growth factor-1 levels, both 
important in tumor metastasis (Singh et al., 2006). Another more recent study showed that 
genistein modulates chromatin configuration and DNA methylation, thus activating tumor-
suppressing genes (Zhang & Chen, 2011). 
The clinical data for isoflavones as chemopreventive agents in bladder cancer has mixed 
results. In a 2000 study using seven human cancer cell lines, the isoflavone genistein 
significantly decreased bladder cancer cell growth and two other isoflavones directly 
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induced apoptosis (Su et al., 2000). Another study examining the effect of soy 
phytochemicals on poorly differentiated and highly metastatic human bladder cancer cell 
lines in vitro showed significant inhibition by cell cycle arrest in G2-M phases in addition to 
significant apoptosis (Singh et al., 2006). This same study also showed significant inhibition 
of clinically relevant orthotopic bladder tumor models by induction of tumor cell apoptosis 
and reduction of tumor angiogenesis. A study examining the effects of 13-
Methyltetradecanoic acid (13-MTD), a soy fermentation product, on human bladder cancer 
cells found that 13-MTD induced apoptosis (Lin et al., 2010). In contrast to evidence 
supporting use, epidemiological studies have suggested an increased risk for bladder cancer 
with consumption of soy (Brinkman & Zeegers, 2008). Since the evidence is contradictory, 
more research needs to be performed into the potential of soy and soy products to act as 
chemopreventive agents. 
2.7 Garlic 
Garlic is considered both a food and supplement with medicinal properties. Extensive 
research has been performed into the health benefits of garlic and more recently garlic has 
been examined for cancer prevention. Studies suggest it may induce or prevent suppression 
of the immune response (Miroddi et al., 2011), induce cytokine production (Lamm & Riggs, 
2000), scavenge free radicals (Butt et al., 2009), and bind thiol compounds important in 
crucial regulatory functions (Cerella et al., 2011). Numerous other mechanisms have also 
been proposed for specific components of garlic supported by in vitro studies (Shukla & 
Kaira, 2007).  
Although many studies provide evidence of the anti-tumor activity of garlic on other types 
of cancer (Shukla & Kaira, 2007), research into garlic’s anti-tumorigenic properties for 
prevention of bladder cancer is relatively sparse. A 1986 study using urothelial cancer lines 
in transplanted into the hind legs of mice, found a therapeutic effect of garlic when 
intraperitoneally injected (Lau et al., 1986). Another later study found a significant anti-
tumor efficacy of garlic when given orally and subcutaneously in mice with injected 
urothelial carcinoma (Riggs et al., 1997).  
Although some studies support the use of garlic, others fail to support garlic or garlic 
derivatives for chemoprevention of bladder cancer. In a 1993 study, diallyl sulfide, a primary 
component of garlic, failed to prevent the formation of urinary bladder papillomas in a rat 
model (Hadjiolov et al., 1993). A recently published cohort study indicated that the use of a 
variety of vitamins and supplements, including garlic, had no significant association with risk 
of urothelial carcinoma when adjusted for age and in multi-variate models (Hotaling et al., 
2011). Due to these mixed results and lack of clinical studies, further research is needed into 
garlic and its potential as a chemopreventive agent for bladder cancer. 
2.8 Green tea 
Green tea is a widely consumed supplement worldwide with a variety of ingredients that 
have been researched for their health benefits. One application may be for cancer 
chemoprevention. Green tea has shown inhibitory activity on a variety of tumors in 
animal models including skin, lung, oral cavity, esophagus, stomach, intestine, colon, 
liver, pancreas, mammary gland, prostate, and bladder cancers (Lubet et al., 2007; Yang et 
al., 2011). Several mechanisms have been proposed. For example, one ingredient, 
polyphenols, has been shown to have antioxidant properties and may prevent cancer 
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through neutralization of free radicals (Forester & Lambert, 2011). Polyphenols also block 
ornithine decarboxylase (Messing et al., 1987), which is a key enzyme in polyamine 
synthesis and plays a major role in cell division and proliferation (Pegg, 2006). Another 
ingredient, catechins, may exhibit anti-tumor activity through inhibition of nitrosamine 
formations and decreased chromosomal damage (Kamori et al., 1993). Additional research 
on green tea suggests other possible mechanisms for a variety of its ingredients including 
caspase mediation (Oz & Ebersole, 2010), inhibition of angiogenesis (Tsao et al., 2009), and 
others.  
Evidence for green tea in prevention of bladder cancer is variable. In rat models, green tea 
reduced bladder tumor incidence in several studies (Lubet et al., 2007; Sato, 1999; Sato & 
Matsushima, 2003). Additionally, great tea mixture modulated actin remodeling (through 
Rho activity) in an in vitro human bladder cancer model of non-transformed urothelial cell 
lines as well as reducing tumor growth (Lu et al., 2005). Since malignant cells require actin 
remodeling in a variety of malignant behaviors (altering morphology, loss of cohesion, 
invasiveness), this study may point out an additional mechanism for green tea’s potential to 
inhibit bladder cancer (Lu et al., 2005). However, a recent review of the literature suggests 
caution promoting green tea as a chemopreventative agent for bladder cancer due to 
conflicting evidence (Boehm et al., 2009), citing two studies that either showed no 
association (Chyou et al., 1993) or an increased risk of developing bladder cancer (Wakai et 
al., 2004). 
2.9 Difluoromethylornithine (DFMO) 
Although originally tested for prevention of bladder and renal cancers (Dunzendorfer, 
1981), Difluoromethylornithine (DFMO) is a drug primarily used for the treatment of 
hirsutism and trypanosomiasis (African sleeping sickness). Recently, there has been 
renewed interest in using DFMO to prevent a variety of malignancies, including bladder 
cancer. Although DFMO’s mechanism of cancer prevention is not completely understood, it 
is well established as an irreversible inhibitor of ornithine decarboxylase, which plays a role 
in cell division and proliferation (Kelloff et al., 1994). A recent study showed that DFMO, 
when combined with sulindac (an NSAID), significantly reduced the risk of recurring 
colorectal polyps (Meyskens et al., 2008). Another controlled phase III clinical trial showed 
that DFMO might reduce the recurrence of basal cell carcinoma (Balley et al., 2010). In 
addition, DFMO is currently being researched in prevention of esophageal cancer (Sinicrope 
et al., 2011) and breast cancer (Izbicka et al., 2010). However, past studies assessing DFMO’s 
possible efficacy in reducing recurring bladder cancer have mixed results. Initial studies 
using DFMO to suppress malignant urothelial cells from human cell lines (Messing et al., 
1988) as well as suppressing BBN-induced urothelial carcinoma in mice (Boon et al., 1990) 
demonstrated selective inhibition of malignant cells. However, a recent controlled phase III 
clinical trial showed no difference in bladder tumor recurrence rates between placebo and 
DFMO treated patients (Messing et al., 2006). Due to the variable results, further research 
into DFMO as a chemopreventive agent in bladder cancer is recommended. 
2.10 Non-steroidal anti-inflammatory drugs 
NSAIDs, well known for their anti-inflammatory abilities, have also been recently proposed 
as chemopreventative agents. Studies suggest that cyclooxygenase enzymes may have a key 
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induced apoptosis (Su et al., 2000). Another study examining the effect of soy 
phytochemicals on poorly differentiated and highly metastatic human bladder cancer cell 
lines in vitro showed significant inhibition by cell cycle arrest in G2-M phases in addition to 
significant apoptosis (Singh et al., 2006). This same study also showed significant inhibition 
of clinically relevant orthotopic bladder tumor models by induction of tumor cell apoptosis 
and reduction of tumor angiogenesis. A study examining the effects of 13-
Methyltetradecanoic acid (13-MTD), a soy fermentation product, on human bladder cancer 
cells found that 13-MTD induced apoptosis (Lin et al., 2010). In contrast to evidence 
supporting use, epidemiological studies have suggested an increased risk for bladder cancer 
with consumption of soy (Brinkman & Zeegers, 2008). Since the evidence is contradictory, 
more research needs to be performed into the potential of soy and soy products to act as 
chemopreventive agents. 
2.7 Garlic 
Garlic is considered both a food and supplement with medicinal properties. Extensive 
research has been performed into the health benefits of garlic and more recently garlic has 
been examined for cancer prevention. Studies suggest it may induce or prevent suppression 
of the immune response (Miroddi et al., 2011), induce cytokine production (Lamm & Riggs, 
2000), scavenge free radicals (Butt et al., 2009), and bind thiol compounds important in 
crucial regulatory functions (Cerella et al., 2011). Numerous other mechanisms have also 
been proposed for specific components of garlic supported by in vitro studies (Shukla & 
Kaira, 2007).  
Although many studies provide evidence of the anti-tumor activity of garlic on other types 
of cancer (Shukla & Kaira, 2007), research into garlic’s anti-tumorigenic properties for 
prevention of bladder cancer is relatively sparse. A 1986 study using urothelial cancer lines 
in transplanted into the hind legs of mice, found a therapeutic effect of garlic when 
intraperitoneally injected (Lau et al., 1986). Another later study found a significant anti-
tumor efficacy of garlic when given orally and subcutaneously in mice with injected 
urothelial carcinoma (Riggs et al., 1997).  
Although some studies support the use of garlic, others fail to support garlic or garlic 
derivatives for chemoprevention of bladder cancer. In a 1993 study, diallyl sulfide, a primary 
component of garlic, failed to prevent the formation of urinary bladder papillomas in a rat 
model (Hadjiolov et al., 1993). A recently published cohort study indicated that the use of a 
variety of vitamins and supplements, including garlic, had no significant association with risk 
of urothelial carcinoma when adjusted for age and in multi-variate models (Hotaling et al., 
2011). Due to these mixed results and lack of clinical studies, further research is needed into 
garlic and its potential as a chemopreventive agent for bladder cancer. 
2.8 Green tea 
Green tea is a widely consumed supplement worldwide with a variety of ingredients that 
have been researched for their health benefits. One application may be for cancer 
chemoprevention. Green tea has shown inhibitory activity on a variety of tumors in 
animal models including skin, lung, oral cavity, esophagus, stomach, intestine, colon, 
liver, pancreas, mammary gland, prostate, and bladder cancers (Lubet et al., 2007; Yang et 
al., 2011). Several mechanisms have been proposed. For example, one ingredient, 
polyphenols, has been shown to have antioxidant properties and may prevent cancer 
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through neutralization of free radicals (Forester & Lambert, 2011). Polyphenols also block 
ornithine decarboxylase (Messing et al., 1987), which is a key enzyme in polyamine 
synthesis and plays a major role in cell division and proliferation (Pegg, 2006). Another 
ingredient, catechins, may exhibit anti-tumor activity through inhibition of nitrosamine 
formations and decreased chromosomal damage (Kamori et al., 1993). Additional research 
on green tea suggests other possible mechanisms for a variety of its ingredients including 
caspase mediation (Oz & Ebersole, 2010), inhibition of angiogenesis (Tsao et al., 2009), and 
others.  
Evidence for green tea in prevention of bladder cancer is variable. In rat models, green tea 
reduced bladder tumor incidence in several studies (Lubet et al., 2007; Sato, 1999; Sato & 
Matsushima, 2003). Additionally, great tea mixture modulated actin remodeling (through 
Rho activity) in an in vitro human bladder cancer model of non-transformed urothelial cell 
lines as well as reducing tumor growth (Lu et al., 2005). Since malignant cells require actin 
remodeling in a variety of malignant behaviors (altering morphology, loss of cohesion, 
invasiveness), this study may point out an additional mechanism for green tea’s potential to 
inhibit bladder cancer (Lu et al., 2005). However, a recent review of the literature suggests 
caution promoting green tea as a chemopreventative agent for bladder cancer due to 
conflicting evidence (Boehm et al., 2009), citing two studies that either showed no 
association (Chyou et al., 1993) or an increased risk of developing bladder cancer (Wakai et 
al., 2004). 
2.9 Difluoromethylornithine (DFMO) 
Although originally tested for prevention of bladder and renal cancers (Dunzendorfer, 
1981), Difluoromethylornithine (DFMO) is a drug primarily used for the treatment of 
hirsutism and trypanosomiasis (African sleeping sickness). Recently, there has been 
renewed interest in using DFMO to prevent a variety of malignancies, including bladder 
cancer. Although DFMO’s mechanism of cancer prevention is not completely understood, it 
is well established as an irreversible inhibitor of ornithine decarboxylase, which plays a role 
in cell division and proliferation (Kelloff et al., 1994). A recent study showed that DFMO, 
when combined with sulindac (an NSAID), significantly reduced the risk of recurring 
colorectal polyps (Meyskens et al., 2008). Another controlled phase III clinical trial showed 
that DFMO might reduce the recurrence of basal cell carcinoma (Balley et al., 2010). In 
addition, DFMO is currently being researched in prevention of esophageal cancer (Sinicrope 
et al., 2011) and breast cancer (Izbicka et al., 2010). However, past studies assessing DFMO’s 
possible efficacy in reducing recurring bladder cancer have mixed results. Initial studies 
using DFMO to suppress malignant urothelial cells from human cell lines (Messing et al., 
1988) as well as suppressing BBN-induced urothelial carcinoma in mice (Boon et al., 1990) 
demonstrated selective inhibition of malignant cells. However, a recent controlled phase III 
clinical trial showed no difference in bladder tumor recurrence rates between placebo and 
DFMO treated patients (Messing et al., 2006). Due to the variable results, further research 
into DFMO as a chemopreventive agent in bladder cancer is recommended. 
2.10 Non-steroidal anti-inflammatory drugs 
NSAIDs, well known for their anti-inflammatory abilities, have also been recently proposed 
as chemopreventative agents. Studies suggest that cyclooxygenase enzymes may have a key 
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role in carcinogenesis, thus inhibitors have the potential for cancer prevention (Axelsson et 
al., 2010; Flossmann et al., 2007; Khan & Lee, 2011). Recent studies suggest an important role 
of COX-2 inhibitors in bladder cancer therapy. Several studies support increased COX-2 
expression in bladder tumor stage and/or grade (Wadhwa et al., 2005; Yildirim et al., 2010; 
Yu et al., 2008). The primary mechanisms in which NSAIDs are thought to inhibit bladder 
cancer are through stimulation of apoptosis and reduction of angiogenesis (Thun et al., 
2002). Another recent study suggested that COX-2 dependent and independent activation of 
downstream signals, such as CK2α-Akt/uPA, may play a critical role in urothelial 
carcinoma cell survival and is neutralized by selective COX-2 inhibitors (Shimada et al., 
2011).  
Clinical data has mixed results for support of NSAID use in bladder and other cancer 
chemoprevention. A recent pooled analysis of three prospective cohort studies indicated a 
reduced risk in bladder cancer, particularly in non-smokers, with increased use of non-
aspirin NSAIDs, but found no associated decrease in risk of bladder cancer with aspirin use 
(Daughtery et al., 2011). An in vivo bladder cancer model recently showed some efficacy of 
naproxen (Lubet et al., 2010). In a bladder tumor mouse model, rofecoxib, a selective COX-2 
inhibitor, provided a significant reduction in incidence of neoplastic bladder lesions (D’Arca 
et al., 2010). Another study that examined multiple randomized trials using daily aspirin 
versus no aspirin on risk of gastrointestinal and other types of cancer death revealed 
increased survival, although bladder cancer was not specifically included in the analysis 
(Rothwell et al., 2011). Further research is needed into the possibility that NSAID’s may 
prevent bladder cancer. 
2.11 Statins 
Statins are a class of drugs used to lower cholesterol levels through inhibition of 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase. However, there is some evidence 
suggesting that statins may have other properties in addition to their effect on lowering 
cholesterol. It is hypothesized that statins may inhibit tumor growth by neutralization of 
protein prenylation of GTPases, affecting downstream isoprenoids (Demierre et al., 2005), 
which in turn affect immune response, apoptosis, and cell maturation (Issat et al., 2011).  
Currently statins are being researched for their efficacy in preventing a variety of cancers, 
including bladder malignancies. In a study examining atorvastatin and human bladder 
cancer cell lines, a significant anti-proliferative effect was observed when compared to 
controls (Kamat & Nelkin, 2005). In another study using mouse cells transfected with  
H-ras oncogene from human bladder carcinoma, researchers observed a significant in 
vivo inhibition of ras-oncogene transformed cells (Sebti et al., 1991). Other studies also 
point out additional reasons to use statins, since use may also improve local control in 
patients undergoing concurrent therapy for muscle invasive bladder cancer (Tsai et al., 
2006). 
However, not all studies support statin efficacy in preventing bladder and other types of 
cancers. A recent cohort study looking at statins and the occurrence of 10 types of cancer 
including bladder, showed no significant association with statin use (Jacobs et al., 2011). 
Using a female rat model, another recent study showed no significant difference in 
mammary carcinogenesis with simvastatin use (Kubatka et al., 2011). Additionally, a phase 
II clinical trial using atorvastatin with sulindac (NSAID) and probiotic dietary fiber failed to 
provide convincing evidence of decreased recurrence of colorectal carcinoma (Limburg et 
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al., 2011). Adding to the controversy, some data suggest that concurrent statin therapy with 
BCG may reduce clinical efficacy of the BCG therapy (Hoffmann et al., 2006), although this 
has not been consistent in all studies (Burglund et al., 2008) and not all literature supports 
discontinuation of the statin (Kamat & Wu, 2007). These results, in contrast with previous 
studies supporting anti-tumor growth, warrant further investigation into statin use in 
bladder cancer chemoprevention. 
 
 Vitamin A Alters cell growth, differentiation, and apoptosis 
through growth factors, cytokines, and neoplastic stem 
cell pathways 
 Vitamin E A free radical scavenger, inhibits N-nitroso compound 
formation as well as inducing apoptosis (some reports 
state may be a carcinogen) 
 Vitamin C Anti-oxidant, inhibits p-53 and p38 MAPK pathways 
 Selemium Works through methlyation of RNA, anti-androgen, 
and promotes DNA repair 
 Cactus Pear Increases expression of Annexin IV, decreases VEGF, 
and promotes immune response 
 Isoflavones Induction of G2-M cell cycle arrest, apoptosis, and 
angiogenesis  
 Garlic Free radical scavenger, increases cytokines production, 
a thiol binder along with preventing suppression of 
the immune response 
 Green Tea Caspase mediator, angiogensis inhibitor, and 
decreases chromosomal damage 
 DFMO Inhibits malignant urothelial cells through mostly 
unknown mechanisms, possibly inhibition of ornithine 
decarboxylase 
 NSAIDS Stimulates apoptosis and inhibits angiogenesis 
 Statins A neutralizer of protein prenylation of GTPases 
Table 2. Key features of potential chemopreventative agents for bladder cancer. 
3. Inheritance/biomarkers of bladder cancer 
In a review article of the epidemiology of bladder cancer by Peluchhi et al., the risk of 
bladder cancer is increased by 50-100% in first-degree relatives in those that have the 
disease. Similar to cardiac disease, the risk for first-degree relatives is increased if the patient 
is diagnosed earlier than the age of 60 (Peluchhi et al., 2006; Goldgar et al., 1994). Current 
literature suggests a possible X-linked inheritance due to the increased incidence in siblings 
that are brothers (Pina & Hemminki, 2001). 
It is well known of the increased risk that cigarette/tobacco consumption has on bladder 
cancer, Okkels and associates demonstrated the increased risk through the accumulation 
of slow acetylators with the Arylamine N-acetyltransferase 2 (NAT 2) genotype (Okkels et 
al., 1997). The relationship between NAT 1 and NAT 2 leads to the formation of  
DNA-binding metabolites for aromatic amines (carcinogens) in the bladder (Badawi et al., 
1995). 
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role in carcinogenesis, thus inhibitors have the potential for cancer prevention (Axelsson et 
al., 2010; Flossmann et al., 2007; Khan & Lee, 2011). Recent studies suggest an important role 
of COX-2 inhibitors in bladder cancer therapy. Several studies support increased COX-2 
expression in bladder tumor stage and/or grade (Wadhwa et al., 2005; Yildirim et al., 2010; 
Yu et al., 2008). The primary mechanisms in which NSAIDs are thought to inhibit bladder 
cancer are through stimulation of apoptosis and reduction of angiogenesis (Thun et al., 
2002). Another recent study suggested that COX-2 dependent and independent activation of 
downstream signals, such as CK2α-Akt/uPA, may play a critical role in urothelial 
carcinoma cell survival and is neutralized by selective COX-2 inhibitors (Shimada et al., 
2011).  
Clinical data has mixed results for support of NSAID use in bladder and other cancer 
chemoprevention. A recent pooled analysis of three prospective cohort studies indicated a 
reduced risk in bladder cancer, particularly in non-smokers, with increased use of non-
aspirin NSAIDs, but found no associated decrease in risk of bladder cancer with aspirin use 
(Daughtery et al., 2011). An in vivo bladder cancer model recently showed some efficacy of 
naproxen (Lubet et al., 2010). In a bladder tumor mouse model, rofecoxib, a selective COX-2 
inhibitor, provided a significant reduction in incidence of neoplastic bladder lesions (D’Arca 
et al., 2010). Another study that examined multiple randomized trials using daily aspirin 
versus no aspirin on risk of gastrointestinal and other types of cancer death revealed 
increased survival, although bladder cancer was not specifically included in the analysis 
(Rothwell et al., 2011). Further research is needed into the possibility that NSAID’s may 
prevent bladder cancer. 
2.11 Statins 
Statins are a class of drugs used to lower cholesterol levels through inhibition of 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase. However, there is some evidence 
suggesting that statins may have other properties in addition to their effect on lowering 
cholesterol. It is hypothesized that statins may inhibit tumor growth by neutralization of 
protein prenylation of GTPases, affecting downstream isoprenoids (Demierre et al., 2005), 
which in turn affect immune response, apoptosis, and cell maturation (Issat et al., 2011).  
Currently statins are being researched for their efficacy in preventing a variety of cancers, 
including bladder malignancies. In a study examining atorvastatin and human bladder 
cancer cell lines, a significant anti-proliferative effect was observed when compared to 
controls (Kamat & Nelkin, 2005). In another study using mouse cells transfected with  
H-ras oncogene from human bladder carcinoma, researchers observed a significant in 
vivo inhibition of ras-oncogene transformed cells (Sebti et al., 1991). Other studies also 
point out additional reasons to use statins, since use may also improve local control in 
patients undergoing concurrent therapy for muscle invasive bladder cancer (Tsai et al., 
2006). 
However, not all studies support statin efficacy in preventing bladder and other types of 
cancers. A recent cohort study looking at statins and the occurrence of 10 types of cancer 
including bladder, showed no significant association with statin use (Jacobs et al., 2011). 
Using a female rat model, another recent study showed no significant difference in 
mammary carcinogenesis with simvastatin use (Kubatka et al., 2011). Additionally, a phase 
II clinical trial using atorvastatin with sulindac (NSAID) and probiotic dietary fiber failed to 
provide convincing evidence of decreased recurrence of colorectal carcinoma (Limburg et 
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al., 2011). Adding to the controversy, some data suggest that concurrent statin therapy with 
BCG may reduce clinical efficacy of the BCG therapy (Hoffmann et al., 2006), although this 
has not been consistent in all studies (Burglund et al., 2008) and not all literature supports 
discontinuation of the statin (Kamat & Wu, 2007). These results, in contrast with previous 
studies supporting anti-tumor growth, warrant further investigation into statin use in 
bladder cancer chemoprevention. 
 
 Vitamin A Alters cell growth, differentiation, and apoptosis 
through growth factors, cytokines, and neoplastic stem 
cell pathways 
 Vitamin E A free radical scavenger, inhibits N-nitroso compound 
formation as well as inducing apoptosis (some reports 
state may be a carcinogen) 
 Vitamin C Anti-oxidant, inhibits p-53 and p38 MAPK pathways 
 Selemium Works through methlyation of RNA, anti-androgen, 
and promotes DNA repair 
 Cactus Pear Increases expression of Annexin IV, decreases VEGF, 
and promotes immune response 
 Isoflavones Induction of G2-M cell cycle arrest, apoptosis, and 
angiogenesis  
 Garlic Free radical scavenger, increases cytokines production, 
a thiol binder along with preventing suppression of 
the immune response 
 Green Tea Caspase mediator, angiogensis inhibitor, and 
decreases chromosomal damage 
 DFMO Inhibits malignant urothelial cells through mostly 
unknown mechanisms, possibly inhibition of ornithine 
decarboxylase 
 NSAIDS Stimulates apoptosis and inhibits angiogenesis 
 Statins A neutralizer of protein prenylation of GTPases 
Table 2. Key features of potential chemopreventative agents for bladder cancer. 
3. Inheritance/biomarkers of bladder cancer 
In a review article of the epidemiology of bladder cancer by Peluchhi et al., the risk of 
bladder cancer is increased by 50-100% in first-degree relatives in those that have the 
disease. Similar to cardiac disease, the risk for first-degree relatives is increased if the patient 
is diagnosed earlier than the age of 60 (Peluchhi et al., 2006; Goldgar et al., 1994). Current 
literature suggests a possible X-linked inheritance due to the increased incidence in siblings 
that are brothers (Pina & Hemminki, 2001). 
It is well known of the increased risk that cigarette/tobacco consumption has on bladder 
cancer, Okkels and associates demonstrated the increased risk through the accumulation 
of slow acetylators with the Arylamine N-acetyltransferase 2 (NAT 2) genotype (Okkels et 
al., 1997). The relationship between NAT 1 and NAT 2 leads to the formation of  
DNA-binding metabolites for aromatic amines (carcinogens) in the bladder (Badawi et al., 
1995). 
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Tobacco smoke also contains 4-aminobiphenyl (4-ABP), an aromatic amine, and for 
individuals with the NAT 2 phenotype, there is a stronger association, again with the slower 
acetylators (Yu et al., 1994). 
Patients with inherited deletions of the gene, GSTN1, which encodes glutathione S-
transferase M1, is associated with bladder cancer. This is in part due to the role of the gene, 
detoxification of carcinogens, being absent (Brockmoler et al., 1994). Although the 
aforementioned markers have shown an association with bladder cancer, the question that 
has still yet to be answered, is to what degree do GSTN1, NAT 1 and NAT 2, among others 
have on a patient and their risk of bladder cancer, especially with the exposure to 
carcinogens such as tobacco smoke and aromatic amines.  
4. Gene therapy/  T-CELLS 
The immunotherapy action of BCG works through binding and availability to major 
histocompatibility complex (MHC) class I expression on cancer cells (Kitamura et al., 2006). 
In a murine model, Yuasa et al. investigated, using  T-cells (subset of human peripheral T 
cells), to augment immunotherapy in MHC-diminished superficial bladder cancer, which 
has been shown to be more aggressive then MHC-conservative bladder cancer. They 
demonstrated, by examining 123 patients undergoing either TUR or radical cystectomy, that 
not only was MHC class I expression diminished in lymph node and invasive bladder 
cancer, but they also experienced a shorter disease free and overall survival.  
In their murine model (BALB/c SCID mice), using Luc-labeled bladder cancer cells and ex-
vivo  T-cells from peripheral blood from healthy patients, mice were treated with  T-
cells alone or in combination with zoledronic acid. Bladders were examined histologically 
with hematoxylin-eosin staining and immunohistochemically by with ani-human CD3. 
Using zoledronic acid to alter the cytotoix effect,  T-cells showed dose-dependent 
cytotoxicty (Kitamura et al., 2009). This shows potential for using  T-cells to augment other 
intravesical treatments to accentuate their benefits. 
5. Novel treatments 
5.1 Silibinin  
Silibinin, a flavonoid phytochemical found in milk thistle, has been shown in vitro, with 
TCC-SUP (high-grade invasive) and T-24 (high grade), to cause cell cycle arrest along with 
apoptosis. An induction of G1 arrest along with cell growth inhibition was determined by 
various methods including: flow cytometry, cell growth assays (24, 48, and 72 hours of 
treatments), cell cultures, immunoprecipitation and immunoblottin. Cyclin-dependent 
kinase activity when uncontrolled, will lead to continuous cell progression. Cyclins are also 
a determining factor in G1/S and G2/M transition (Singh et al., 2002). Both cyclins and 
cyclin-dependent kinases are reduced with Silibinin as determined by antibodies against 
CDK2 or CDK4 and kinase assays. Cell death through apoptosis, which was only seen with 
high-grade invasive cancer, was determined by Annexin V and Propidium Iodide. For the 
previous experiments, doses of Silibinin varied from 50 to 200 micromolars (Tyagi et al., 
2004). Later, the same investigators, with bladder transitional-cell papilloma RT4 cells, 
induced apoptosis with Slibinin through p53-caspace activation (Tyagi et al., 2006). Through 
further understanding of the biochemical/cell cycle pathways of bladder cancer, the effects 
of Silibinin will be better understood. 
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5.2 Keyhole Limpet Hemocyanin (KLH) 
KLH is a copper-containing, extracellular, respiratory protein that was first investigated by 
Curtis et al., to have immunostimulatory properties (Curtis et al., 1970). Its potential role in 
the treatment of bladder cancer may be in a cytolytic reduction of tumor growth through a 
humoral response and an increase in natural killer cells. There have been reports when 
treating non-muscle invasive bladder cancer to have recurrence rates as low as 31% with less 
side effects (sepsis, cystitis) than BCG (Harris & Markl, 1999; Nseyo & Lamm, 1997). 
Jurincic-Winkler et al. treated thirteen patients with CIS with intravesical KLH (20 mg) on a 
weekly schedule for 6 weeks, then monthly for one year, and bimonthly for a total of 3 
years. Overall, only two patients were free of disease at 66 and 82 months of follow up with 
the majority requiring BCG or cystectomy (Jurincic-Winkler et al., 2000). 
When reviewed, KLH could also be beneficial for carbohydrate-based immunuotherapy in 
the appropriate adenocarcinoma when there are mucin-like epitopes as well as a potential 
treatment for melanomas (Harris & Markl, 1999). Overall, the evidence is lacking for KLH to 
be a major treatment for non-muscle invasive bladder cancer.  
5.3 Apaziquone 
Apaziquone, also referred commonly as EO9, is an indolequinone compound. Through an 
activation mechanism with NAD(P)H: Quinone oxidoreductase-1 (NQO1), Apaziquone, in 
an aerobic environment, has been shown to impact DNA-damaging species (Phillips et al., 
2004). Increase in cell kill is also achieved through alklyating byproducts through redox 
cycling leading to single-strand breaks and DNA cross-linking (Comer & Murphy, 2003). In 
vivo, it has demonstrated activity against colon, non-small cell lung, renal, melanoma and 
central nervous system tumor models (Hendricks et al., 1993). With early promising results, 
it has failed to show favorable phase II outcomes with Phillips et al. citing its rapid 
pharmacokinetic elimination and poor penetration in avascular tissues (Phillips et al., 1998). 
In humans, Apaziquone’s half-life is less than 10 minutes, via extra-hepatic metabolism by 
red blood cells, with its metabolites, EO5a, having decreased cytotoxicity (Schelens et al., 
1994; Vainchtein et al., 2007).  
Current research is aimed at finding adjunct compounds to improve its pharmokinetic 
properties. A quinone-based bioreductive drug, 2,3-bis(aziridinyl)-5-hydroxy-1,4-
naphthoquinone, through its selectivity for NQO1-rich cells under hypoxic conditions, has 
shown such potential (Phillips et al., 2004). 
5.4 Mycobacterium phlei 
This agent, has shown anti-tumor activity, is a cell wall extract, composed of carbohydrates, 
peptides, and lipids that is commonly found on the outer capsule of Mycobacterium phlei, a 
gram-positive microorganism that is located in soil, plants, and drinking water (Chin et al., 
1996; & Mallick et al., 1985). Commonly prepared as a mineral oil emulsion, it has 
demonstrated inhibitory effects on bladder cancer cell lines through inhibition of cellular 
proliferation via apoptosis, as well as by an increase in the production of interleukin-12 though 
stimulation of cancer-infiltrating monocytes and macrophages. Bladder cancer cell lines, in a 
study by Filion et al., that have been tested include: HT-1197 along with HT-1376 (which are 
derived from anaplastic transitional cell carcinomas of the bladder from humans, both grade 
IV and grade III respectively). Cytokine analysis and cellular apoptosis were detected using 
ELISA and cell death was determined by dimethylthiazoldiphenyltetrazolium bromide 
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Tobacco smoke also contains 4-aminobiphenyl (4-ABP), an aromatic amine, and for 
individuals with the NAT 2 phenotype, there is a stronger association, again with the slower 
acetylators (Yu et al., 1994). 
Patients with inherited deletions of the gene, GSTN1, which encodes glutathione S-
transferase M1, is associated with bladder cancer. This is in part due to the role of the gene, 
detoxification of carcinogens, being absent (Brockmoler et al., 1994). Although the 
aforementioned markers have shown an association with bladder cancer, the question that 
has still yet to be answered, is to what degree do GSTN1, NAT 1 and NAT 2, among others 
have on a patient and their risk of bladder cancer, especially with the exposure to 
carcinogens such as tobacco smoke and aromatic amines.  
4. Gene therapy/  T-CELLS 
The immunotherapy action of BCG works through binding and availability to major 
histocompatibility complex (MHC) class I expression on cancer cells (Kitamura et al., 2006). 
In a murine model, Yuasa et al. investigated, using  T-cells (subset of human peripheral T 
cells), to augment immunotherapy in MHC-diminished superficial bladder cancer, which 
has been shown to be more aggressive then MHC-conservative bladder cancer. They 
demonstrated, by examining 123 patients undergoing either TUR or radical cystectomy, that 
not only was MHC class I expression diminished in lymph node and invasive bladder 
cancer, but they also experienced a shorter disease free and overall survival.  
In their murine model (BALB/c SCID mice), using Luc-labeled bladder cancer cells and ex-
vivo  T-cells from peripheral blood from healthy patients, mice were treated with  T-
cells alone or in combination with zoledronic acid. Bladders were examined histologically 
with hematoxylin-eosin staining and immunohistochemically by with ani-human CD3. 
Using zoledronic acid to alter the cytotoix effect,  T-cells showed dose-dependent 
cytotoxicty (Kitamura et al., 2009). This shows potential for using  T-cells to augment other 
intravesical treatments to accentuate their benefits. 
5. Novel treatments 
5.1 Silibinin  
Silibinin, a flavonoid phytochemical found in milk thistle, has been shown in vitro, with 
TCC-SUP (high-grade invasive) and T-24 (high grade), to cause cell cycle arrest along with 
apoptosis. An induction of G1 arrest along with cell growth inhibition was determined by 
various methods including: flow cytometry, cell growth assays (24, 48, and 72 hours of 
treatments), cell cultures, immunoprecipitation and immunoblottin. Cyclin-dependent 
kinase activity when uncontrolled, will lead to continuous cell progression. Cyclins are also 
a determining factor in G1/S and G2/M transition (Singh et al., 2002). Both cyclins and 
cyclin-dependent kinases are reduced with Silibinin as determined by antibodies against 
CDK2 or CDK4 and kinase assays. Cell death through apoptosis, which was only seen with 
high-grade invasive cancer, was determined by Annexin V and Propidium Iodide. For the 
previous experiments, doses of Silibinin varied from 50 to 200 micromolars (Tyagi et al., 
2004). Later, the same investigators, with bladder transitional-cell papilloma RT4 cells, 
induced apoptosis with Slibinin through p53-caspace activation (Tyagi et al., 2006). Through 
further understanding of the biochemical/cell cycle pathways of bladder cancer, the effects 
of Silibinin will be better understood. 
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5.2 Keyhole Limpet Hemocyanin (KLH) 
KLH is a copper-containing, extracellular, respiratory protein that was first investigated by 
Curtis et al., to have immunostimulatory properties (Curtis et al., 1970). Its potential role in 
the treatment of bladder cancer may be in a cytolytic reduction of tumor growth through a 
humoral response and an increase in natural killer cells. There have been reports when 
treating non-muscle invasive bladder cancer to have recurrence rates as low as 31% with less 
side effects (sepsis, cystitis) than BCG (Harris & Markl, 1999; Nseyo & Lamm, 1997). 
Jurincic-Winkler et al. treated thirteen patients with CIS with intravesical KLH (20 mg) on a 
weekly schedule for 6 weeks, then monthly for one year, and bimonthly for a total of 3 
years. Overall, only two patients were free of disease at 66 and 82 months of follow up with 
the majority requiring BCG or cystectomy (Jurincic-Winkler et al., 2000). 
When reviewed, KLH could also be beneficial for carbohydrate-based immunuotherapy in 
the appropriate adenocarcinoma when there are mucin-like epitopes as well as a potential 
treatment for melanomas (Harris & Markl, 1999). Overall, the evidence is lacking for KLH to 
be a major treatment for non-muscle invasive bladder cancer.  
5.3 Apaziquone 
Apaziquone, also referred commonly as EO9, is an indolequinone compound. Through an 
activation mechanism with NAD(P)H: Quinone oxidoreductase-1 (NQO1), Apaziquone, in 
an aerobic environment, has been shown to impact DNA-damaging species (Phillips et al., 
2004). Increase in cell kill is also achieved through alklyating byproducts through redox 
cycling leading to single-strand breaks and DNA cross-linking (Comer & Murphy, 2003). In 
vivo, it has demonstrated activity against colon, non-small cell lung, renal, melanoma and 
central nervous system tumor models (Hendricks et al., 1993). With early promising results, 
it has failed to show favorable phase II outcomes with Phillips et al. citing its rapid 
pharmacokinetic elimination and poor penetration in avascular tissues (Phillips et al., 1998). 
In humans, Apaziquone’s half-life is less than 10 minutes, via extra-hepatic metabolism by 
red blood cells, with its metabolites, EO5a, having decreased cytotoxicity (Schelens et al., 
1994; Vainchtein et al., 2007).  
Current research is aimed at finding adjunct compounds to improve its pharmokinetic 
properties. A quinone-based bioreductive drug, 2,3-bis(aziridinyl)-5-hydroxy-1,4-
naphthoquinone, through its selectivity for NQO1-rich cells under hypoxic conditions, has 
shown such potential (Phillips et al., 2004). 
5.4 Mycobacterium phlei 
This agent, has shown anti-tumor activity, is a cell wall extract, composed of carbohydrates, 
peptides, and lipids that is commonly found on the outer capsule of Mycobacterium phlei, a 
gram-positive microorganism that is located in soil, plants, and drinking water (Chin et al., 
1996; & Mallick et al., 1985). Commonly prepared as a mineral oil emulsion, it has 
demonstrated inhibitory effects on bladder cancer cell lines through inhibition of cellular 
proliferation via apoptosis, as well as by an increase in the production of interleukin-12 though 
stimulation of cancer-infiltrating monocytes and macrophages. Bladder cancer cell lines, in a 
study by Filion et al., that have been tested include: HT-1197 along with HT-1376 (which are 
derived from anaplastic transitional cell carcinomas of the bladder from humans, both grade 
IV and grade III respectively). Cytokine analysis and cellular apoptosis were detected using 
ELISA and cell death was determined by dimethylthiazoldiphenyltetrazolium bromide 
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(MTT), (Filion et al., 1999) . When tested in a murine model, mycobacterium phlei induced 
similar effects that are seen with BCG, namely a CD4+ T cell infiltrate when compared to 
control. Although the antitumor effect wasn’t as significant as that seen with BCG, treatment 
was better tolerated overall (Chin et al., 1996). 
5.5 Docetaxel 
Docetaxel, a member of the taxane family, works through microtubule depolymerization 
inhibition and is commonly used in treatment of prostate and breast cancer, among others. 
Barlow et al., originally showed a 56% response rate in 18 patients who initially failed BCG 
therapy and refused to undergo cystectomy. The treatment regimen consisted of 6 weekly 
bladder instillations on a dose-escalation protocol (McKiernan et al., 2006) They continued 
their protocol, with the addition of 15 patients, for a median follow up of 29 months and had 
a 1 and 2 year recurrence-free survival rates of 45 and 32%. Adverse reactions to docetaxel 
included: dysuria, hematuria, facial flushing, frequency, rash, urinary tract infection, and 
premature voiding during instillation of the medication. Overall, they concluded that the 
data is very promising and offers an alternative treatment to those that have failed BCG and 
do not undergo cystectomy, however, large, multi-institutional, prospective trials are 
needed to concur effectiveness (Barolw et al., 2009). 
Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, was studied 
by Kassouf et al., to determine its effect, in vitro, on enhancing the role of docetaxel on 
bladder cancer. Four bladder cancer cell lines were studied: 253J B-V, UM-UC-3, KU-7, and 
UM-UC-13. Through the use of flow cytometry and propidium iodide to determine cell 
cycle Analysis, along with Western Blot to establish EGFR downstream signaling, it was 
shown that when combined, gefitinib enhanced both the antiproliferative and apoptotic 
properties of docetaxel, but only when administered after the docetaxel (Kassouf et al., 
2006). 
5.6 Hyperthermia  
A novel approach of combining local microwave hyperthermia along with Mitomcyin C 
after undergoing transurethral resection was reported by Colombo et al., with 83 patients 
who were followed for 24 months. They take into account the detrimental effect that heat 
has on malignant cells (which are more sensitive to thermal changes in the environment 
than that of normal cells) such as inhibition of DNA synthesis, RNA, cellular protein, and 
DNA duplication in the cell cycle. In their study, 83 patients were randomly assigned (after 
undergoing transurethral resection of primary or recurrent noninvasive bladder cancer) to 
either receiving Mitomycin C alone or in conjunction with local microwave-induced 
hyperthermia. Hyperthermia was administered using the Synergo SB-TS:101-1, which 
consists of a 915 MHz intravesical microwave applicator, to reach a temperature of 42oC + 
2oC and maintained for 40 minutes.  
The patients were all followed with urine cytology as well as cystoscopy every 3 months for 
2 years, with biopsies taken if suspicious lesions were noted. Abdominal and pelvic 
ultrasound was also obtained on a bi-annual basis. Overall, 75 patients completed the 
protocol and those receiving the hyperthermia experienced more severe side effects: cystitis, 
suprapubic pain, and thermal reaction. Only six patients (17.1%) had recurrence with the 
combination therapy as compared to 23 patients (57.5%) receiving only Mitomycin C (P 
value = 0.0002). There was one patient with disease progression in the chemotherapy only 
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treatment group. Overall, the idea of combining intravesical chemotherapy along with 
hyperthermia is an attractive option for enhancing the effectiveness of chemotherapeutic 
agents especially for those that are not surgical candidates for radical cystectomy (Colombo 
et al., 2003).  
A more recent study was carried out by Nativ et al., to examine those patients that 
experience recurrence of papillary non-muscle invasive bladder cancer after undergoing 
BCG treatment. They looked at 111 patients and followed them for 2 years with urine 
cytology and cystoscopy every 3 months. All patients were treated with hyperthermia, 42oC 
+ 2oC, for two cycles of 30 minute instillations of 20mg of Mitomycin C, for 6 weekly 
treatments followed by 6 maintenance sessions at 4 to 6 week intervals.  
Adverse reactions were similar as compared to the earlier study with pain and bladder 
spasms being the most common (transient to mild at worse). Recurrence-free rates at one 
and two years were 85% and 56% respectively. There were 3 patients (3%) that progressed to 
muscle invasive bladder cancer during the follow up. Interestingly, those patients that 
received fewer than 10 maintenance treatments, had a tumor recurrence rate of 61% 
compared to 39% that completed the two year regimen (p value = 0.01) (Nativ et al., 2009). 
The combination of hyperthermia with intravesical treatment is very promising and should 
be considered very strongly for future trials in those patients that are considered BCG 
failures. 
5.7 Inositol Hexaphosphate  
Inositol Hexaphosphate (IP-6) is a naturally occurring polyphosphorylated carbohydrate 
that is found in foods that are high in fiber such as cereals, legumes, and grains (Fox & 
Eberl, 2002). It has already been shown to possess anti-tumor effects in numerous cancer cell 
lines: colon, hepatocellular, breast, lung, prostate, pancreas and melanoma among others 
while not being cytotoxic or cytostatic against normal cells (Shamsuddin et al., 1997). Zaslau 
et al., displayed its mechanism of action against bladder cancer cell lines (HTB9 [grade II], 
T24 [grade III], TCCSUP [grade IV]) via modulation of the cell cycle and induction of 
cellular apoptosis as well as necrosis (Zaslau et al., 2009).  
Already demonstrating reduction in cellular proliferation, they tested IP-6’s clinical 
efficacy with a 2-hour exposure time. All three cell lines (HTB9, T24, and TCCSUP) were 
plated and cultured with 2.5 and 4.5 mM of IP-6 for 2 hours and then had their 
supernatant incubated for an additional 24 and 48 hours. Cell viability was assessed 
though MTT colorimetric assay and cell cycle analysis though flow cytometry. All three 
cell lines, at all times tested, noted a significant reduction in cellular growth when treated 
with IP-6 with only a 2 hour incubation. Interestingly, when looking at cell cycle 
inhibition, IP-6 produced different results with the varying degrees of bladder cancer cell 
lines, which can be related to the different tumor grades replicating at different rates 
corresponding to diverse responses to the IP-6 treatments. There was an increase in cells 
in the G0/G1 phase, reduction in G2/M, while no change in the S phase with the TCCSUP 
cell line. The T24 cell line was determined to be accelerating and not dividing through 
observances of cell reduction with 4.5 mM IP-6 in the G0/G1 phase and no change in both 
the S and G2/M phases. Lastly, with the HTB9 cell line, as with the T24 cell line, no 
change was noted in G2/M, however, there was an induction in the arrest at G0/G1 while 
a decrease in S phase (Zaslau et al., 2009). 
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(MTT), (Filion et al., 1999) . When tested in a murine model, mycobacterium phlei induced 
similar effects that are seen with BCG, namely a CD4+ T cell infiltrate when compared to 
control. Although the antitumor effect wasn’t as significant as that seen with BCG, treatment 
was better tolerated overall (Chin et al., 1996). 
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inhibition and is commonly used in treatment of prostate and breast cancer, among others. 
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therapy and refused to undergo cystectomy. The treatment regimen consisted of 6 weekly 
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their protocol, with the addition of 15 patients, for a median follow up of 29 months and had 
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data is very promising and offers an alternative treatment to those that have failed BCG and 
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treatment group. Overall, the idea of combining intravesical chemotherapy along with 
hyperthermia is an attractive option for enhancing the effectiveness of chemotherapeutic 
agents especially for those that are not surgical candidates for radical cystectomy (Colombo 
et al., 2003).  
A more recent study was carried out by Nativ et al., to examine those patients that 
experience recurrence of papillary non-muscle invasive bladder cancer after undergoing 
BCG treatment. They looked at 111 patients and followed them for 2 years with urine 
cytology and cystoscopy every 3 months. All patients were treated with hyperthermia, 42oC 
+ 2oC, for two cycles of 30 minute instillations of 20mg of Mitomycin C, for 6 weekly 
treatments followed by 6 maintenance sessions at 4 to 6 week intervals.  
Adverse reactions were similar as compared to the earlier study with pain and bladder 
spasms being the most common (transient to mild at worse). Recurrence-free rates at one 
and two years were 85% and 56% respectively. There were 3 patients (3%) that progressed to 
muscle invasive bladder cancer during the follow up. Interestingly, those patients that 
received fewer than 10 maintenance treatments, had a tumor recurrence rate of 61% 
compared to 39% that completed the two year regimen (p value = 0.01) (Nativ et al., 2009). 
The combination of hyperthermia with intravesical treatment is very promising and should 
be considered very strongly for future trials in those patients that are considered BCG 
failures. 
5.7 Inositol Hexaphosphate  
Inositol Hexaphosphate (IP-6) is a naturally occurring polyphosphorylated carbohydrate 
that is found in foods that are high in fiber such as cereals, legumes, and grains (Fox & 
Eberl, 2002). It has already been shown to possess anti-tumor effects in numerous cancer cell 
lines: colon, hepatocellular, breast, lung, prostate, pancreas and melanoma among others 
while not being cytotoxic or cytostatic against normal cells (Shamsuddin et al., 1997). Zaslau 
et al., displayed its mechanism of action against bladder cancer cell lines (HTB9 [grade II], 
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efficacy with a 2-hour exposure time. All three cell lines (HTB9, T24, and TCCSUP) were 
plated and cultured with 2.5 and 4.5 mM of IP-6 for 2 hours and then had their 
supernatant incubated for an additional 24 and 48 hours. Cell viability was assessed 
though MTT colorimetric assay and cell cycle analysis though flow cytometry. All three 
cell lines, at all times tested, noted a significant reduction in cellular growth when treated 
with IP-6 with only a 2 hour incubation. Interestingly, when looking at cell cycle 
inhibition, IP-6 produced different results with the varying degrees of bladder cancer cell 
lines, which can be related to the different tumor grades replicating at different rates 
corresponding to diverse responses to the IP-6 treatments. There was an increase in cells 
in the G0/G1 phase, reduction in G2/M, while no change in the S phase with the TCCSUP 
cell line. The T24 cell line was determined to be accelerating and not dividing through 
observances of cell reduction with 4.5 mM IP-6 in the G0/G1 phase and no change in both 
the S and G2/M phases. Lastly, with the HTB9 cell line, as with the T24 cell line, no 
change was noted in G2/M, however, there was an induction in the arrest at G0/G1 while 
a decrease in S phase (Zaslau et al., 2009). 
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IP-6 was later tested, with the same bladder cancer cell lines, using Annexin V-Fluorescein 
Isothiocyanate (FITC) and Propidium Iodine along with flow cytometry to determine 
method of cell kill. Using the same concentrations, 2.5 and 4.5 mM, at 2 hour incubations, 
HTB9 was effected by necrotic mechanisms, and T24 and TCCSUP went through an 
induction of apoptosis (Zaslau et al., 2010). The authors, with promising results thus far, 
state the Phase II clinical trials are needed to evaluate the safety and clinical utility of IP-6 
for the intravesical use in bladder cancer. 
5.8 HTI-286 
HTI-286 is a synthetic analogue of the marine sponge product hemiasterlin. In a similar 
fashion to the taxanes, HTI-286 works through inhibition of tubulin polymerization with 
strong cytotoxic potential. In an in vitro study, HTI-286 was compared to MMC when tested 
in human bladder cancer cell lines RT4, MGH-U3, KU-7, as well as UM-UC3. In this study, it 
showed comparable cytotoxicity, inhibition of cell growth, and induction of apoptosis in all 
cell lines tested. An in vivo study using 8-week old nude mice demonstrated delayed cancer 
growth in a dose dependent manner (Hadaschik et al., 2008).  
5.9 Suramin 
Suramin, a polysulphonated naphthylurea, has anticancer functions that are comprised of 
growth factor antagonism and cellular DNA synthesis suppression (Walther et al., 1994; La 
Rocca et al., 1990). 
Serious side effects including neurologic, renal, and metabolic Have been caused by 
systemic administration of suramin (La Rocca et al, 1990; Figg et al, 1994; Bowden et al, 
1996) secondary to the compound having a 40-day plasma half-life in humans (Hawking, 
1978). Suramin possesses several structural advantages for use intravesically in bladder 
cancer: its’ high molecular mass (1429 Da) and negative ionic charge hamper systemic 
absorption (Ord et al, 2005); and its tendency to bind to protein favors growth factor 
antagonism in urine, which contains low protein levels (Ord et al, 2005). In particular, 
suramin inhibits the binding of epidermal growth factor (EGF) to its receptor, which are 
prevalent in high numbers in bladder cancer (Walther et al, 1996).  
A phase I clinical trial found that intravesical treatment with suramin for cases of recurrent 
superficial bladder cancer was safe up to a 153mg/ml dose (Uchio et al, 2003). However, 
suramin’s effects on bladder tumors has not yet been evaluated. Noted complications 
included bladder spasms and vesicoureteral reflux in a small percentage of the individual 
treatments, all of which completely abated within 48 hours (Uchio et al, 2003). Even at the 
highest dosages, plasma concentrations of suramin were minimal and further trials are 
warranted to decipher its usefulness. 
5.10 Gemcitabine  
Gemcitabine, as reported by Karak and Flechon, is a deoxycytidine analogue, a pyrimidine 
antimetabolite that is similar to cytarabine that works through inhibition of DNA synthesis 
(Karak & Flechon, 2007). Its effect on bladder cancer’s cell cycle is via a blockage of cells 
progressing through the G1/S phase and a cytotoxic effect in S-phase (Guchelaar et al., 
1996). It has already been approved through the Food and Drug Administration as a first 
line treatment for solid tumors of the pancreas as well as for inoperable, metastatic non-
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small cell lung and breast cancer (Karak & Flechon, 2007). Gemcitabine has been known to 
cause is myelosuppression (Aapro et al., 1998). 
Gemcitabine has also been used as single agent for those patients that were considered BCG 
failures. In a phase II trial Dalbagni et al. examined 30 patients that were refractory to BCG 
treatment. Treatment was given twice weekly for 3 weeks and surveillance was conducted at 8 
weeks and then every 3 months for one year. Although there was a complete response in 50% 
of patient at 3 months, this was reduced to only 10% at one year (Dalbagni et al., 2006). 
5.11 Mitomycin-C & Gemcitabine 
Gemcitabine, as described by Breyer et al., is 2’,2’-difluoro-2’-deoxycytidine, that has shown 
broad spectrum anti-tumor activity. In their study, 10 patients that were either BCG 
refractory or BCG intolerant were treated with Gemcitabine (1000mg in 50cc sterile water) 
then MMC (40mg in 20cc sterile water) once a week for 6 weeks as their induction treatment. 
This was then followed by maintenance treatment (same dosage) once a month for 12 
months. Median follow up for the patients (with median age of 67 years) was 26.5 months. 
Six out of ten patients were recurrence free at 14 months, with 4 patients having biopsy 
proven recurrence at a median of 6 months. Overall, the treatment was well tolerated with 
no major complications. Of note, 9 out of 10 patients had either high grade bladder cancer or 
carcinoma in situ before beginning treatment and had a median of five recurrences (Breyer 
et al, 2010). The same authors cited another study by Maymi and O’Donnell that compared 
Gemcitabine versus Gemicitabine in combination with MMC in 39 patients that have failed 
multiple, previous intravesical treatments. Alone, the median disease free survival was 6.5 
months compared to 20 months for the combination of Gemicitabine and MMC (Maymi et 
al.). In a comparison study, Malmstrom et al. found only 4 out of 21 patients disease free 
that were treated with MMC for noninvasive bladder cancer at 3 years (Malmostrom et al., 
1999). The literature that has been reviewed supports the use of MMC In combination with 
other intravesical agents to increase its effectiveness.  
5.12 Mitomycin-C and BCG 
The two leading intravescial treatments for non-muscle invasive bladder cancer are 
Mitomycin-C and BCG. There have been many studies that have looked to find an additive 
effect with the combination of the two agents (chemoimmunotherapy), but in whole, have 
not produced significant results. Witjes and colleagues examined 90 patients that underwent 
4 weekly instillations of 40 mg of MMC followed by 6 weekly instillations of BCG (group 1) 
and compared them to 92 patients that just underwent 10 weekly instillations of MMC 
(group 2). Surprisingly, there was no significant difference seen between the two groups in 
regards to bacterial cystitis, chemical cystitis, and other local side effects. Eleven patients 
had fever (>38.5C) in group 1 compared to only 3 patients in group 2. Median follow up was 
32 months. There were 35/90 patients with recurrence and 5/90 patients with progression in 
group 1 and 42/92 and 4/92 respectively, in group 2 (Witjes et al., 1998).  
A prospective, randomized comparison of BCG alone with that of BCG and electromotive 
MMC was carried out by Di Stasi and colleagues. After being diagnosed with pT1 bladder 
cancer, 212 patients were randomly assigned to induction of either 81 mg of BCG for 2 hours 
once a week for 6 weeks or 81 mg of BCG over 2 hours once a week for 2 weeks, then 40 mg 
of electromotive MMC (intravesical electric current 20 mA for 30 min) once a week for three 
weeks. Exclusion criteria included previous treatment with either BCG or electromotive 
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warranted to decipher its usefulness. 
5.10 Gemcitabine  
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small cell lung and breast cancer (Karak & Flechon, 2007). Gemcitabine has been known to 
cause is myelosuppression (Aapro et al., 1998). 
Gemcitabine has also been used as single agent for those patients that were considered BCG 
failures. In a phase II trial Dalbagni et al. examined 30 patients that were refractory to BCG 
treatment. Treatment was given twice weekly for 3 weeks and surveillance was conducted at 8 
weeks and then every 3 months for one year. Although there was a complete response in 50% 
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proven recurrence at a median of 6 months. Overall, the treatment was well tolerated with 
no major complications. Of note, 9 out of 10 patients had either high grade bladder cancer or 
carcinoma in situ before beginning treatment and had a median of five recurrences (Breyer 
et al, 2010). The same authors cited another study by Maymi and O’Donnell that compared 
Gemcitabine versus Gemicitabine in combination with MMC in 39 patients that have failed 
multiple, previous intravesical treatments. Alone, the median disease free survival was 6.5 
months compared to 20 months for the combination of Gemicitabine and MMC (Maymi et 
al.). In a comparison study, Malmstrom et al. found only 4 out of 21 patients disease free 
that were treated with MMC for noninvasive bladder cancer at 3 years (Malmostrom et al., 
1999). The literature that has been reviewed supports the use of MMC In combination with 
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effect with the combination of the two agents (chemoimmunotherapy), but in whole, have 
not produced significant results. Witjes and colleagues examined 90 patients that underwent 
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and compared them to 92 patients that just underwent 10 weekly instillations of MMC 
(group 2). Surprisingly, there was no significant difference seen between the two groups in 
regards to bacterial cystitis, chemical cystitis, and other local side effects. Eleven patients 
had fever (>38.5C) in group 1 compared to only 3 patients in group 2. Median follow up was 
32 months. There were 35/90 patients with recurrence and 5/90 patients with progression in 
group 1 and 42/92 and 4/92 respectively, in group 2 (Witjes et al., 1998).  
A prospective, randomized comparison of BCG alone with that of BCG and electromotive 
MMC was carried out by Di Stasi and colleagues. After being diagnosed with pT1 bladder 
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MMC, any intravesical agent in the last 6 months, upper tract disease, and previous 
radiotherapy to the pelvis or chemotherapy among others. Maintenance for the BCG alone 
group consisted of 81 mg BCG once a month for 10 months compared to the group being 
treated with BCG and electromotive MMC which received the combination once a month 
for 2 months, then 81 mg of BCG once a month for three months. Of critical importance is 
that the authors defined the primary endpoint being disease-free survival with secondary 
endpoints being time to progression, overall survival and disease specific survival. Median 
follow-up was an impressive 88 months.  
The patients that received the combination had a higher disease-free survival at 69 months 
compared to the patients that received only BCG, which was 21 months. Follow-up 
consisted of abdominal ultrasound, cystourethroscopy, and urine cytology every 3 months 
for the first three years and then every 6 months thereafter. If a patient was originally 
diagnosed with carcinoma in situ, the follow-up also included random bladder biopsies at 3 
and 6 months. The combination group also has a lower rate of progression at 9.3% 
compared to 21.9% of BCG alone group, with 10 and 23 patients progressing to muscle-
invasive bladder cancer respectively. Also, the BCG and electromotive MMC group only 
had 6 reported deaths due to bladder cancer compared to 23 in the BCG alone group. 
Adverse effects were similar between the two groups with each having 3 patients 
withdrawing from the trial. According to the authors, the benefit of the combination may be 
attributed to BCG-induced inflammation increasing the bladder mucosa permeability to the 
effects of the MMC, allowing it to reach the target tissue (Di Stasi et al., 2007).  
 
  T-cells Enhances immunotherapy by increasing MHC class I 
expression 
 Silibinin Induced G1 cell cycle arrest and reduces cyclin and 
cyclin-dependent kinases which decreases cell 
progression 
 KLH Possible mechanism of action could include an 
increase in humoral response in an association with 
an increase of natural killer cells 
 Apaziquone Needs to be combined with another agent or 
treatment modality to better its pharmokinetics to 
lengthen its half-life and therapeutic effect 
 Mycobacterium Phlei Increases production of IL-12, induces apoptosis, as 
well as promoting a CD4+ T cell response 
 Docetaxel Inhibits microtubule depolymerization 
 Hyperthermia Environmental/thermal changes which malignant 
cells are more sensitive to and causes inhibition of 
DNA and RNA synthesis among other cellular 
pathways 
 IP-6 Modulates cell cycle and induces cellular apoptosis 
and necrosis 
 HTI-286 Similar mechanism of action as the taxanes 
(Docetaxel) 
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 Suramin Growth factor antagonist and suppresses DNA 
synthesis 
 Gemcitabine Inhibits DNA synthesis and through a cystotoxic 
effect, inhibits malignant cells in G1/S and S-phase 
 MMC and Gemcitabine Overall, a well tolerated combination with beneficial 
results when compared to each agent alone. 
 MMC and BCG BCG may increase bladder mucosa permeability 
through an inflammatory response allowing MMC to 
reach its target at a more optimal level 
Table 3. Mechanism of action of Novel Treatments for Bladder Cancer 
6. Conclusion 
Further advancement in the treatment of non-muscle invasive bladder cancer will come in 
the understanding of the disease’s molecular/biochemical pathways and the effect on these 
pathways that chemopreventive and intravesical agents have on them. Certainly there are 
some areas that are more promising than others, especially with the combination of agents 
as well as the addition of hyperthermia to treatment regimens that are already producing 
significant positive results. As a review of the many agents discussed, table 2 provides the 
key features of potential chemopreventative agents for bladder cancer. Table 3 reviews the 
mechanism of action of Novel Treatments for Bladder Cancer. As always, it is not just the 
initial resection, or even the induction treatment that reduces recurrence and progression, 
but the role of maintenance therapy that is crucial for the patient to remain disease free. 
Again, with the new discoveries of cell signaling, cell cycle/death/apoptosis, interleukin, 
humoral and cell mediated responses, there will be more specific target treatments with the 
hopes of minimal side effects. 
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significant positive results. As a review of the many agents discussed, table 2 provides the 
key features of potential chemopreventative agents for bladder cancer. Table 3 reviews the 
mechanism of action of Novel Treatments for Bladder Cancer. As always, it is not just the 
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This book is an invaluable source of knowledge on bladder cancer biology, 
epidemiology, biomarkers, prognostic factors, and clinical presentation and 
diagnosis. It is also rich with plenty of up-to-date information, in a well-organized 
and easy to use format, focusing on the treatment of bladder cancer including 
surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy. 
These chapters, written by the experts in their fields, include many interesting, 
demonstrative and colorful pictures, figures, illustrations and tables. Due to its 
practicality, this book is recommended reading  to anyone interested in bladder cancer.
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